ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER

Abstract
The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
Description
SEQUENCE LISTING

This application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jan. 6, 2022 is named P32429-US-5_SL.txt and is 872,652 bytes in size.


FIELD OF THE INVENTION

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecules are characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof. The invention further relates to methods of producing these molecules and to methods of using the same.


BACKGROUND

Ligands interacting with molecules of the TNF (tumor necrosis factor) receptor superfamily have pivotal roles in the organization and function of the immune system. While regulating normal functions such as immune responses, hematopoiesis and morphogenesis, the TNF family ligands (also called cytokines) play a role in tumorgenesis, transplant rejection, septic shock, viral replication, bone resorption, rheumatoid arthritis and diabetes (Aggarwal, 2003). The TNF ligand family comprises 18 genes encoding 19 type II (i.e. intracellular N terminus and extracellular C-terminus) transmembrane proteins, characterized by the presence of a conserved C-terminal domain coined the ‘TNF homology domain’ (THD). This domain is responsible for receptor binding and is thus critical for the biological activity of the TNF ligand family members. The sequence identity between family members is ˜20-30% (Bodmer, 2002). Members of the TNF ligand family exert their biological function as self-assembling, noncovalent trimers (Banner et al, Cell 1993, 73, 431-445). Thus, the TNF family ligands form a trimer that is able to bind to and to activate the corresponding receptors of TNFR superfamily.


4-1BB (CD137), a member of the TNF receptor superfamily, has been first identified as a molecule whose expression is induced by T-cell activation (Kwon and Weissman, 1989). Subsequent studies demonstrated expression of 4-1BB in T- and B-lymphocytes (Snell et al., 2011; Zhang et al., 2010), NK-cells (Lin et al., 2008), NKT-cells (Kim et al., 2008), monocytes (Kienzle and von Kempis, 2000; Schwarz et al., 1995), neutrophils (Heinisch et al., 2000), mast (Nishimoto et al., 2005) and dendritic cells as well as cells of non-hematopoietic origin such as endothelial and smooth muscle cells (Broll et al., 2001; Olofsson et al., 2008). Expression of 4-1BB in different cell types is mostly inducible and driven by various stimulatory signals, such as T-cell receptor (TCR) or B-cell receptor triggering, as well as signaling induced through co-stimulatory molecules or receptors of pro-inflammatory cytokines (Diehl et al., 2002; von Kempis et al., 1997; Zhang et al., 2010).


Expression of 4-1BB ligand (4-1BBL or CD137L) is more restricted and is observed on professional antigen presenting cells (APC) such as B-cells, dendritic cells (DCs) and macrophages. Inducible expression of 4-1BBL is characteristic for T-cells, including both and γδ T-cell subsets, and endothelial cells (reviewed in Shao and Schwarz, 2011).


CD137 signaling is known to stimulate IFNγ secretion and proliferation of NK cells (Buechele et al., 2012; Lin et al., 2008; Melero et al., 1998) as well as to promote DC activation as indicated by their increased survival and capacity to secret cytokines and upregulate co-stimulatory molecules (Choi et al., 2009; Futagawa et al., 2002; Wilcox et al., 2002). However, CD137 is best characterized as a co-stimulatory molecule which modulates TCR-induced activation in both the CD4+ and CD8+ subsets of T-cells. In combination with TCR triggering, agonistic 4-1BB-specific antibodies enhance proliferation of T-cells, stimulate lymphokine secretion and decrease sensitivity of T-lymphocytes to activation-induced cells death (reviewed in (reviewed in Snell et al., 2011).


In line with these co-stimulatory effects of 4-1BB antibodies on T-cells in vitro, their administration to tumor bearing mice leads to potent anti-tumor effects in many experimental tumor models (Melero et al., 1997; Narazaki et al., 2010). However, 4-1BB usually exhibits its potency as an anti-tumor agent only when administered in combination with other immunomodulatory compounds (Curran et al., 2011; Guo et al., 2013; Morales-Kastresana et al., 2013; Teng et al., 2009; Wei et al., 2013), chemotherapeutic reagents (Ju et al., 2008; Kim et al., 2009), tumor-specific vaccination (Cuadros et al., 2005; Lee et al., 2011) or radiotherapy (Shi and Siemann, 2006). In vivo depletion experiments demonstrated that CD8+ T-cells play the most critical role in anti-tumoral effect of 4-1BB-specific antibodies. However, depending on the tumor model or combination therapy, which includes anti-4-1BB, contributions of other types of cells such as DCs, NK-cells or CD4+ T-cells have been reported (Melero et al., 1997; Murillo et al., 2009; Narazaki et al., 2010; Stagg et al., 2011).


In addition to their direct effects on different lymphocyte subsets, 4-1BB agonists can also induce infiltration and retention of activated T-cells in the tumor through 4-1BB-mediated upregulation of intercellular adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1) on tumor vascular endothelium (Palazon et al., 2011).


4-1BB triggering may also reverse the state of T-cell anergy induced by exposure to soluble antigen that may contribute to disruption of immunological tolerance in the tumor micro-environment or during chronic infections (Wilcox et al., 2004).


It appears that the immunomodulatory properties of 4-1BB agonistic antibodies in vivo require the presence of the wild type Fc-portion on the antibody molecule thereby implicating Fc-receptor binding as an important event required for the pharmacological activity of such reagents as has been described for agonistic antibodies specific to other apoptosis-inducing or immunomodulatory members of the TNFR-superfamily (Li and Ravetch, 2011; Teng et al., 2009). However, systemic administration of 4-1BB-specific agonistic antibodies with the functionally active Fc domain also induces expansion of CD8+ T-cells associated with liver toxicity (Dubrot et al., 2010) that is diminished or significantly ameliorated in the absence of functional Fc-receptors in mice. In human clinical trials (ClinicalTrials.gov, NCT00309023), Fc-competent 4-1BB agonistic antibodies (BMS-663513) administered once every three weeks for 12 weeks induced stabilization of the disease in patients with melanoma, ovarian or renal cell carcinoma. However, the same antibody given in another trial (NCT00612664) caused grade 4 hepatitis leading to termination of the trial (Simeone and Ascierto, 2012).


Collectively, the available pre-clinical and clinical data clearly demonstrate that there is a high clinical need for effective 4-1BB agonists. However, new generation drug candidates should not only effectively engage 4-1BB on the surface of hematopoietic and endothelial cells but also be capable of achieving that through mechanisms other than binding to Fc-receptors in order to avoid uncontrollable side effects. The latter may be accomplished through preferential binding to and oligomerization on tumor-specific or tumor-associated moieties.


Fusion proteins composed of one extracellular domain of a 4-1BB ligand and a single chain antibody fragment (Mueller et al., 2008; Hornig et al., 2012) or a single 4-1BB ligand fused to the C-terminus of a heavy chain (Zhang et al, 2007) have been made. WO 2010/010051 discloses the generation of fusion proteins that consist of three TNF ligand ectodomains linked to each other and fused to an antibody part.


However, there is still a need of new antigen binding molecules that combine a moiety capable of preferred binding to tumor-specific or tumor-associated targets with a moiety capable of forming a costimulatory TNF ligand trimer and that have sufficient stability to be pharmaceutically useful. The antigen binding molecules of the present invention comprise both and surprisingly they provide a trimeric and thus biologically active TNF ligand, although one of the trimerizing TNF ligand ectodomains is located on another polypeptide than the other two TNF ligand ectodomains of the molecule.


SUMMARY OF THE INVENTION

In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising


(a) at least one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.


In a particular aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising


(a) at least one moiety capable of specific binding to a target cell antigen,


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof, and


(c) an Fc domain composed of a first and a second subunit capable of stable association.


In a further aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, comprising


(a) at least one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that

    • (i) the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, respectively, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain, and wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the CH1 or CL domain by a peptide linker and wherein the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to the CL or CH1 domain of said polypeptide, or
    • (ii) the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, respectively, and wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the C-terminus of the CH3 domain by a peptide linker and wherein the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to C-terminus of the CH3 domain of said polypeptide, or
    • (iii) the first polypeptide contains a VH-CL or a VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, respectively, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain, and wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to to VH or VL by a peptide linker and wherein the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to VL or VH of said polypeptide.


In a particular aspect, the TNF ligand family member is one that costimulates human T-cell activation. Thus, the TNF family ligand trimer-containing antigen binding molecule comprises


(a) at least one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof, wherein the TNF ligand family member costimulates human T-cell activation. More particularly, the TNF ligand family member is selected from 4-1BBL and OX40L.


In one aspect, the TNF ligand family member is 4-1BBL.


In a further aspect, the ectodomain of a TNF ligand family member comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:96, SEQ ID NO: 373, SEQ ID NO:374 and SEQ ID NO:375, particularly the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:96.


In another aspect, the ectodomain of a TNF ligand family member or fragment thereof comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:96, particularly the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:96. More particularly, the ectodomain of a TNF ligand family member comprises the amino acid sequence of SEQ ID NO:96.


In a further aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99 and in that the second polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.


In one aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence of SEQ ID NO:5 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:6.


In a further aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence of SEQ ID NO:5 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:183.


In yet a further aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence of SEQ ID NO:97 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:184 or SEQ ID NO:185.


In another aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen,


(b) a first polypeptide containing a CH1 or CL domain and a second polypeptide containing a CL or CH1 domain, respectively, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain,


and wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other and to the CH1 or CL domain by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof connected by a peptide linker to the CL or CH1 domain of said polypeptide.


In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule comprising


(a) at least one moiety capable of specific binding to a target cell antigen,


(b) a first polypeptide containing a CH1 domain and a second polypeptide containing a CL domain, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain,


and wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the CH1 domain by a peptide linker and in that the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to the CL domain of said polypeptide.


In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule comprising


(a) at least one moiety capable of specific binding to a target cell antigen,


(b) a first polypeptide containing a CL domain and a second polypeptide containing a CH1 domain, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain,


and wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the CL domain by a peptide linker and in that the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to the CH1 domain of said polypeptide.


In a further aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule as defined herein before, wherein the moiety capable of specific binding to a target cell antigen is selected from the group consisting of an antibody, an antibody fragment and a scaffold antigen binding protein.


In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule as defined herein before, wherein the moiety capable of specific binding to a target cell antigen is an antibody fragment.


In particular, the moiety capable of specific binding to a target cell antigen is selected from the group consisting of an antibody fragment, a Fab molecule, a crossover Fab molecule, a single chain Fab molecule, a Fv molecule, a scFv molecule, a single domain antibody, an aVH and a scaffold antigen binding protein.


In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule as defined herein before, wherein the moiety capable of specific binding to a target cell antigen is a scaffold antigen binding protein.


In a particular aspect, the invention is concerned with a TNF family ligand trimer-containing antigen binding molecule as defined above, wherein the moiety capable of specific binding to a target cell antigen is a Fab molecule capable of specific binding to a target cell antigen.


The invention provides a TNF family ligand trimer-containing antigen binding molecule that comprises at least one moiety capable of specific binding to a target cell antigen. In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule comprises one moiety capable of specific binding to a target cell antigen. In another aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising two moieties capable of specific binding to a target cell antigen.


In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule of the invention, wherein the target cell antigen is selected from the group consisting of Fibroblast Activation Protein (FAP), Carcinoembryonic Antigen (CEA), Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), Epidermal Growth Factor Receptor (EGFR), CD19, CD20 and CD33.


In a particular aspect, the target cell antigen is Fibroblast Activation Protein (FAP).


In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to FAP comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:100, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:101, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:102, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:103, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11 or SEQ ID NO:104, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:105.


In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to FAP comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:7, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:8 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:9, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:10, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:12.


In a particular aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to FAP comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:100, (ii) CDR-H2 comprising the amino acid sequence SEQ ID NO:101, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:102, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:103, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:104, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:105.


In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule as defined herein before, wherein the moiety capable of specific binding to FAP comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:16 and a variable light chain comprising an amino acid sequence of SEQ ID NO:17 or wherein the moiety capable of specific binding to FAP comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:106 and a variable light chain comprising an amino acid sequence of SEQ ID NO:107.


In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule according to the invention, wherein a peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus to the CH1 or CL domain of a heavy chain by a second peptide linker and wherein one ectodomain of said TNF ligand family member or a fragment thereof is fused at the its C-terminus the CL or CH1 domain on a light chain by a third peptide linker.


In a particular aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule as defined above, wherein the peptide linker is (G4S)2, i.e. a peptide linker of SEQ ID NO:13. In one aspect, the first peptide linker is (G4S)2 (SEQ ID NO:13), the second peptide linker is GSPGSSSSGS (SEQ ID NO:57) and the third peptide linker is (G4S)2 (SEQ ID NO:13). In another aspect, the first, the second and the third peptide linker is (G4S)2 (SEQ ID NO:13).


The invention is further concerned with a TNF family ligand trimer-containing antigen binding molecule as defined herein before, comprising an Fc domain composed of a first and a second subunit capable of stable association.


In particular, the TNF family ligand trimer-containing antigen binding molecule of the invention comprising (c) an Fc domain composed of a first and a second subunit capable of stable association further comprises (a) a Fab molecule capable of specific binding to a target cell antigen, wherein the Fab heavy chain is fused at the C-terminus to the N-terminus of a CH2 domain in the Fc domain.


In a further aspect, the Fc domain is an IgG, particularly an IgG1 Fc domain or an IgG4 Fc domain. More particularly, the Fc domain is an IgG1 Fc domain. In a particular aspect, the Fc domain comprises a modification promoting the association of the first and second subunit of the Fc domain.


In another aspect, the invention is concerned with a TNF family ligand trimer-containing antigen binding molecule as defined herein before, comprising


(c) an Fc domain composed of a first and a second subunit capable of stable association, wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor, in particular towards Fcγ receptor.


In particular, the Fc domain comprises amino acid substitutions at positions 234 and 235 (EU numbering) and/or 329 (EU numbering) of the IgG heavy chains. More particularly, provided is a trimeric TNF family ligand-containing antigen binding molecule according to the invention which comprises an IgG1 Fc domain with the amino acid substitutions L234A, L235A and P329G (EU numbering).


In a further aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises


a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen,


a first peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker fused at its C-terminus by a second peptide linker to a second heavy or light chain,


and a second peptide comprising one ectodomain of said TNF ligand family member fused at its C-terminus by a third peptide linker to a second light or heavy chain, respectively.


In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the first peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a CH1 domain that is part of a heavy chain,


and the second peptide comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a CL domain that is part of a light chain.


In yet another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the first peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a CL domain that is part of a heavy chain,


and the second peptide comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a CH1 domain that is part of a light chain.


In a further aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the first peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a VH domain that is part of a heavy chain,


and the second peptide comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a VL domain that is part of a light chain.


Provided is further a TNF family ligand trimer-containing antigen binding molecule, wherein in the CL domain adjacent to the TNF ligand family member the amino acid at position 123 (EU numbering) has been replaced by arginine (R) and the amino acid at position 124 (EU numbering) has been substituted by lysine (K), and wherein in the CH1 domain adjacent to the TNF ligand family member the amino acids at position 147 (EU numbering) and at position 213 (EU numbering) have been substituted by glutamic acid (E).


In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule as described herein before, wherein the antigen binding molecule comprises


(a) a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen,


(b) a second heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99, and


a second light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.


In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises


(a) a Fab molecule capable of specific binding to FAP, and


(b) a second heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99, and


a second light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.


In a particular aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising a moiety capable of specific binding to FAP. In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises


(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:16 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:17 or


a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:106 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:107,


(ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:108, SEQ ID NO:111, SEQ ID NO:113, SEQ ID NO.115, SEQ ID NO:139 and SEQ ID NO:148, and


(iii) a second light chain comprising the amino acid sequence of SEQ ID NO:15, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114 and SEQ ID NO:115.


In another aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises


(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:16 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:17 or


a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:106 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:107,


(ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119 and SEQ ID NO:173, and


(iii) a second light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120 and SEQ ID NO:174.


In yet another aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, comprising


(a) at least one moiety capable of specific binding to a target cell antigen, and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, respectively, and wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the C-terminus of the CH3 domain by a peptide linker and wherein the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to C-terminus of the CH3 domain of said polypeptide.


In particular, such a TNF family ligand trimer-containing antigen binding molecule comprises two moieties capable of specific binding to a target cell antigen.


In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising two moieties capable of specific binding to FAP. In particular, provided is a TNF family ligand trimer-containing antigen binding molecule as described herein before comprises


(i) a first heavy chain comprising the amino acid sequence of SEQ ID NO:121, a second heavy chain comprising the amino acid sequence of SEQ ID NO:122, and two light chains comprising the amino acid sequence of SEQ ID NO:19, or


(ii) a first heavy chain comprising the amino acid sequence of SEQ ID NO:123, a second heavy chain comprising the amino acid sequence of SEQ ID NO:124, and two light chains comprising the amino acid sequence of SEQ ID NO:125, or


(iii) a first heavy chain comprising the amino acid sequence of SEQ ID NO:126, a second heavy chain comprising the amino acid sequence of SEQ ID NO:127, and two light chains comprising the amino acid sequence of SEQ ID NO:125.


In another particular aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule as described herein before, wherein the target cell antigen is CD19.


In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to CD19 comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:195 or SEQ ID NO:252, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:196 or SEQ ID NO:253, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:197 or SEQ ID NO:254, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:198 or SEQ ID NO:249, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:199 or SEQ ID NO:250, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:200 or SEQ ID NO:251.


In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to CD19 comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:201 and a variable light chain comprising an amino acid sequence of SEQ ID NO:202 or wherein the moiety capable of specific binding to FAP comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:357 and a variable light chain comprising an amino acid sequence of SEQ ID NO:358.


In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises


(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:201 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:202 or


a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:357 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:358,


(ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:108, SEQ ID NO:111 and SEQ ID NO:113, and


(iii) a second light chain comprising the amino acid sequence of SEQ ID NO:15, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:112 and SEQ ID NO:114.


In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises


(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:201 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:202 or


a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:357 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:358,


(ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119 and SEQ ID NO:173, and


(iii) a second light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120 and SEQ ID NO:174.


In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising two moieties capable of specific binding to CD19. In particular, provided is a TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 14, 29, 30 and 32 to 34, wherein the antigen binding molecule comprises


(i) a first heavy chain comprising the amino acid sequence of SEQ ID NO:209, a second heavy chain comprising the amino acid sequence of SEQ ID NO:210, and two light chains comprising the amino acid sequence of SEQ ID NO:206, or


(ii) a first heavy chain comprising the amino acid sequence of SEQ ID NO:213, a second heavy chain comprising the amino acid sequence of SEQ ID NO:214, and two light chains comprising the amino acid sequence of SEQ ID NO:206, or


(iii) a first heavy chain comprising the amino acid sequence of SEQ ID NO:309, a second heavy chain comprising the amino acid sequence of SEQ ID NO:310, and two light chains comprising the amino acid sequence of SEQ ID NO:279, or


(iv) a first heavy chain comprising the amino acid sequence of SEQ ID NO:313, a second heavy chain comprising the amino acid sequence of SEQ ID NO:314, and two light chains comprising the amino acid sequence of SEQ ID NO:279.


In another particular aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule as described herein before, wherein the target cell antigen is CEA.


In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to CEA comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:321, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:322, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:323, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:324, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:325, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:326.


In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to CEA comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:329 and a variable light chain comprising an amino acid sequence of SEQ ID NO:330.


In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule as described herein before, wherein the antigen binding molecule comprises


(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:329 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:330,


(ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:108, SEQ ID NO:111 and SEQ ID NO:113, and


(iii) a second light chain comprising the amino acid sequence of SEQ ID NO:15, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:112 and SEQ ID NO:114.


In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises


(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:329 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:330,


(ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119 and SEQ ID NO:173, and


(iii) a second light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120 and SEQ ID NO:174.


In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising two moieties capable of specific binding to CEA. Particularly, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises


(i) a first heavy chain comprising the amino acid sequence of SEQ ID NO:337, a second heavy chain comprising the amino acid sequence of SEQ ID NO:338, and two light chains comprising the amino acid sequence of SEQ ID NO:334, or


(ii) a first heavy chain comprising the amino acid sequence of SEQ ID NO:341, a second heavy chain comprising the amino acid sequence of SEQ ID NO:342, and two light chains comprising the amino acid sequence of SEQ ID NO:334.


In a further aspect, provided is aTNF family ligand trimer-containing antigen binding molecule as described herein before, wherein the TNF ligand family member is OX40L. In one aspect, provided is TNF family ligand trimer-containing antigen binding molecule, wherein the ectodomain of a TNF ligand family member comprises the amino acid sequence of SEQ ID NO:53 or SEQ ID NO:54, particularly the amino acid sequence of SEQ ID NO:53.


In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 5, 10 to 24, 29, 30, 32 to 34, 38 to 40, 44 and 45, comprising


(a) at least one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence of SEQ ID NO:371 or SEQ ID:372 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:53 or SEQ ID NO:54.


In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the target cell antigen is Fibroblast Activation Protein (FAP) and the moiety capable of specific binding to FAP comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:100, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:101, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:102, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:103, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11 or SEQ ID NO:104, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:105.


Particularly, provided is a TNF family ligand trimer-containing antigen binding molecule as described herein, wherein the antigen binding molecule comprises


(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:16 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:17 or


a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:106 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:107,


(ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:355, and


(iii) a second light chain comprising the amino acid sequence of SEQ ID NO:356.


According to another aspect of the invention, there is provided an isolated polynucleotide encoding a TNF family ligand trimer-containing antigen binding molecule as defined herein before. The invention further provides a vector, particularly an expression vector, comprising the isolated polynucleotide of the invention and a host cell comprising the isolated polynucleotide or the vector of the invention. In some embodiments the host cell is a eukaryotic cell, particularly a mammalian cell.


In another aspect, provided is a method for producing the TNF family ligand trimer-containing antigen binding molecule of the invention, comprising the steps of (i) culturing the host cell of the invention under conditions suitable for expression of the antigen binding molecule, and (ii) recovering the antigen binding molecule. The invention also encompasses a TNF family ligand trimer-containing antigen binding molecule produced by the method of the invention.


The invention further provides a pharmaceutical composition comprising the TNF family ligand trimer-containing antigen binding molecule of the invention and at least one pharmaceutically acceptable excipient.


Also encompassed by the invention is the TNF family ligand trimer-containing antigen binding molecule of the invention, or the pharmaceutical composition of the invention, for use as a medicament. In one aspect is provided the TNF family ligand trimer-containing antigen binding molecule of the invention, or the pharmaceutical composition of the invention, for use in the treatment of a disease in an individual in need thereof. In a specific embodiment, provided is the TNF family ligand trimer-containing antigen binding molecule of the invention, or the pharmaceutical composition of the invention, for use in the treatment of cancer.


Also provided is the use of the TNF family ligand trimer-containing antigen binding molecule of the invention for the manufacture of a medicament for the treatment of a disease in an individual in need thereof, in particular for the manufacture of a medicament for the treatment of cancer, as well as a method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the TNF family ligand trimer-containing antigen binding molecule of the invention in a pharmaceutically acceptable form. In a specific embodiment, the disease is cancer. In any of the above embodiments the individual is preferably a mammal, particularly a human.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A to 1D show the components for the assembly of split trimeric human 4-1BB ligands including linker GGGGSGGGGS (SEQ ID NO:13). FIG. 1A shows the dimeric ligand that is fused at the C-terminus to a human CH1 or CL domain or a VL or VH domain and FIG. 1B shows the monomeric ligand fused to human CL or CH1 domain or a VL or VH domain. FIG. 1C shows the dimeric ligand that is fused at the N-terminus to a human CH3 domain and FIG. 1D shows the monomeric ligand fused at the N-terminus to a human CH3 domain.



FIGS. 2A to 2J show the 4-1BBL-trimer-containing antigen binding molecules Constructs 1.1 to 1.10 of the invention. The preparation and production of these constructs is described in Example 1. The VH and VL domains are those of anti-FAP antibody 28H1, the thick black point stands for the knob-into-hole modification. * symbolizes amino acid modifications in the CH1 and CL domain (so-called charged residues).



FIGS. 3A to 3C show the components for the assembly of split trimeric murine 4-1BB ligands including linker GGGGSGGGGS (SEQ ID NO:13). FIG. 3A shows the dimeric ligand that is fused at the C-terminus to murine CL domain and FIG. 3B shows the monomeric ligand fused at the C-terminus to murine CH1 domain. Components for the assembly of FAP targeted split trimeric murine 4-1BB ligand. FIG. 3C shows the assembled murine 4-1BBL-trimer-containing antigen binding molecules as described in more detail in Example 1.3.



FIGS. 4A to 4F show the 4-1BBL-trimer-containing antigen binding molecules Constructs 2.1 to 2.6 of the invention. The preparation and production of these constructs is described in Example 2. The VH and VL domains are those of anti-FAP antibody 4B9, the thick black point stands for the knob-into-hole modification. * symbolizes amino acid modifications in the CH1 and CL domain (so-called charged residues).



FIGS. 5A and 5B show the “untargeted” variants of Constructs 1.1 and 1.2 comprising a DP47 Fab molecule instead of the anti-FAP Fab molecule. The molecules are named Control A and Control B, respectively. The preparation is described in Example 1.4. FIG. 5C is a drawing of the monomeric 4-1BB Fc(kih) construct as prepared in Example 3.



FIGS. 6A-1 to 6C-2 relate to the binding of FAP-targeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecule (FAP split 4-1BBL trimer, filled circles) or DP-47 untargeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecule (DP47 split 4-1BBL trimer, open circles) to resting (naïve) or activated human PMBCs. Specifically, the binding to resting (naïve) or activated human CD8+ T cells is shown in FIGS. 6A-1 and 6A-2, to resting (naïve) or activated human CD4+ T cells in FIGS. 6B-1 and 6B-2 and to resting (naïve) or activated human NK cells in FIGS. 6-C1 and 6-C2. Shown is the binding as Median of fluorescence intensity (MFI) of red macrophytic algae Phycoerythrin (R-PE)-labeled anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment which is used as secondary detection antibody. MFI was measured by flow cytometry and baseline corrected by subtracting the WI of the blank control.



FIGS. 7A-1 to 7B-4 show the binding of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs to human 4-1BB expressing T cells from PHA-L and Proleukin pre-activated and anti-human CD3/anti-human CD28 re-activated human PBMCs. Binding was detected with R-Phycoerythrin-fluorochrome conjugated anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested Constructs 1.1 to 1.10 of Example 1. For a better display the binding curves are split in four different blots with Construct 1.1 (monovalent FAP-targeted split trimeric human 4-1BB ligand Fc (kih)) and Control B (monovalent untargeted split trimeric human 4-1BB ligand Fc (kih) with CH-CL cross and charged residues) as comparison curves. Binding was monitored on CD3+CD8+ T cells (FIGS. 7A-1 to 7A-4) and CD3+CD4+ T cells (FIGS. 7B-1 to 7B-4). The 4-1BB expression level on CD8 T cells is normally higher than on CD4 T cells. All versions bind with a quite similar affinity to human 4-1BB.



FIGS. 8A-1 to 8B-4 show the binding of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs to CD4+ or CD8+ T cells from fresh PBMCs (FIGS. 8A-1 to 8A-4) or to human 4-1BB expressing PHA-L and Proleukin pre-activated and anti-human CD3/anti-human CD28 re-activated human PBMCs (FIGS. 8B-1 to 8B-4). Binding was detected with R-Phycoerythrin-fluorochrome conjugated anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested Constructs 2.1, 2.3, 2.4, 2.5 and 2.6 of Example 2 and control molecules Control B, Control C, Control E and Control F. For a better display the binding curves are split in two different blots with construct 2.1 (monovalent FAP-targeted split trimeric human 4-1BB ligand Fc (kih)) and control B (monovalent untargeted split trimeric human 4-1BB ligand Fc (kih) with CH-CL cross and charged residues) as comparison curves. Binding was monitored on CD45+CD3+CD8+ T cells (blots on the bottom) and CD45+CD3+CD4+ T cells (blots on the top). The 4-1BB expression level on CD8 T cells is normally higher than on CD4 T cells. All constructs bind with a quite similar affinity to human 4-1BB, whereas the bivalent construct 2.3 and its untargeted control C show a lower MFI. This can be due to sterical hindrance of 4-1BB-binding and/or less detection due to the 2nd detection antibody induced by the Fc-conjugated split 4-1BB ligand.



FIGS. 9A and 9B show the binding of FAP-targeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecules (FAP split 4-1BBL trimer, filled circles) or DP47 untargeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecules (DP47 split 4-1BBL trimer; open circles) to activated mouse splenocytes. In particular, the binding to activated mouse CD4+ T cells is shown in FIG. 9A and to activated mouse CD8+ T cells in FIG. 9B. An anti-mouse CD137-specific human IgG1 P329G LALA antibody (clone Lob12.3) was used as positive control (Triangles). The binding is characterized by plotting the MFI of R-PE-labeled anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment that is used as secondary detection antibody versus the concentration in nM of the tested split 4-1BBL trimer constructs. MFI was measured by flow cytometry and baseline corrected by subtracting the MFI of the blank control.



FIGS. 10A and 10B show the binding of 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecules (filled circles: FAP-targeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecule Construct 1.1, open circles: DP47 untargeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecule Control A to fibroblast activation protein (FAP)-expressing human melanoma (FIG. 10A) MV-3 cell line and (FIG. 10B) WM-266-4 cell line. The binding is characterized by plotting the MFI of R-PE-labeled anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment that is used as secondary detection antibody versus the concentration in nM of tested split 4-1BBL trimer constructs. MFI was measured by flow cytometry and baseline corrected by subtracting the MFI of the blank control.



FIGS. 11A-1 to 11B-2 show the binding of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs to human-FAP expressing human melanoma MV-3 cells (FIGS. 11A-1 to 11A-4) and/or NIH/3T3-huFAP clone 39 transfected mouse embryonic fibroblast cells (FIGS. 11B-1 and 11B-2). Binding was detected with R-Phycoerythrin-fluorochrome or fluorescein-fluorochrome conjugated anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragments. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested constructs. For a better display binding curves were distributed to four (FIGS. 11A-1 to 11A-4) or two blots (FIGS. 11B-1 and 11B-2), whereas construct 1.1 (monovalent FAP-targeted split trimeric human 4-1BB ligand Fc (kih)) is used a comparison curve. All constructs bind with a similar affinity to human FAP except the bivalent FAP-targeted constructs (constructs 1.5, 1.7 and 1.8). They showed a tendency to have lower EC50 values and lower median fluorescence intensity. This can be explained with their bivalent targeting (higher avidity, less molecules can bind at the same time due to occupancy of two epitopes resulting in a lower MFI). Structural differences may also explain the difference between Construct 1.8 (complete bivalent targeting) and Constructs 1.5 and 1.7 (only partial bivalent targeting).



FIGS. 12A-1 to 12B-2 show the binding of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) Constructs 2.1, 2.3, 2.4, 2.5 and 2.6 to human-FAP expressing human melanoma MV-3 cells (FIGS. 12A-1 and 12A-2) and WM-266-4 cells (FIGS. 12B-1 and 12B-2). Binding was detected with R-Phycoerythrin-fluorochrome conjugated anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragments. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested contructs. For a better display binding curves were distributed to two blots, whereas construct 2.1 (monovalent FAP-targeted split trimeric human 4-1BB ligand Fc (kih)) is used as comparison curve. All constructs bind with a similar affinity to human FAP except the bivalent FAP-targeted construct 2.3. It has a tendency to show lower EC50 values and lower median fluorescence intensity. This can be explained with its bivalent targeting, which results in higher avidity but less occupancy or FAP molecules on the cell surface resulting in a lower MFI.



FIGS. 13A-1 to 13B-2 show the binding of different FAP-targeted or untargeted split trimeric mouse 4-1BB ligand Fc (kih) constructs to CD4+ or CD8+ T cells from fresh splenocytes (FIGS. 13A-1 and 13A-2) or to mouse 4-1BB expressing anti-mouse CD3/anti-mouse CD28 monoclonal agonistic antibodies activated mouse splenocytes (FIGS. 13B-1 and 13B-2). Binding was detected with FITC-fluorochrome conjugated anti-mouse IgG Fcγ-specific goat IgG F(ab′)2 fragment. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested constructs. Binding was monitored on CD3+CD8+ T cells (left blot) and CD3+CD4+ T cells (right blot). The 4-1BB expression level on CD8 T cells is normally higher than on CD4 T cells. All constructs bind with a quite similar affinity to mouse 4-1BB.



FIGS. 14A and 14B show the binding of different FAP-targeted or untargeted split trimeric mouse 4-1BB ligand Fc (kih) constructs to human FAP expressing tumor cells. Binding was detected with FITC-fluorochrome conjugated anti-mouse IgG Fcγ-specific goat IgG F(ab′)2 fragment. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested constructs. Binding was monitored on MV-3 cells (FIG. 14A) and WM-266-4 cells (FIG. 14B). FAP-targeted split trimeric mouse 4-1BB ligand Fc (kih) constructs M.1 and M.2 bind with a quite similar affinity to FAP.



FIGS. 15A and 15B show a scheme that illustrates the general principal of the NFkB activity assay described in Example 6.1 using a reporter cell line. Shown is the activation assay set up with human 4-1BB expressing HeLa reporter cell line. A crosslinking of 4-1BB expressed on the reporter cells induces NFκB activation and NFκB-mediated Luciferase expression. After lysis of the cells Luciferase can catalyze the oxidation of Luciferin to Oxyluciferin. This chemical reaction correlates positively with the strength of NFκB-mediated luciferase expression and can be measured by the strength of light emission (units of released light). The ratio of FAP-expressing tumor cells to the reporter cell line HeLa-huCD137-NFkB-luc was 5 to 1.



FIGS. 16A to 16C show that the activation of the NFkB signaling pathway by FAP-targeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecule (Construct 1.1) is strictly dependent on its binding to FAP-expressing target cells. Human CD137 expressing NFkB reporter HeLa cells were co-cultured with the indicated tumor cells exhibiting different levels of cell surface FAP expression. Luciferase activity was assessed as described in Example 6.1 after culturing cells in the absence or presence of 4-1BBL-containing molecules at the indicated concentrations for 6 hours. Filled circles refer to Construct 1.1. Open circles refer to DP47 untargeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecule (Control A). Cell line NIH/3T3-human FAP clone 39 was used as target cells in 16A; 16B shows the activation with MV3 cell line as target cells and 16C with WM-266-4 cell line as target cells. Activity is characterized by blotting the units of released light (URL) measured during 0.5 s versus the concentration in nM of tested split 4-1BBL trimer constructs. URLs are emitted due to luciferase-mediated oxidation of luciferin to oxyluciferin.



FIGS. 17A-1 to 17C-4 shows the NFκB-activation-induced Luciferase expression and activity as measured with the assay described in Example 6.1. Counts of released light per seconds (CPS) are measured for 0.5 s/well and plotted against the used concentration of FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs. Human 4-1BB-expressing HeLa-reporter cells were incubated for 6 h in the absence (FIGS. 17A-1 to 17A-4) or presence of crosslinking human-FAP expressing human melanoma cell line MV-3 (FIGS. 17B-1 to 17B-4) or WM-266-4 (FIGS. 17C-1 to 17C-4). CPS were measured and blotted against the concentrations of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) Constructs. The cell ratio is one human 4-1BB-expressing HeLa reporter cell to five tumor cells. For better display, activation curves were split to four different display-blots with construct 1.1 (monovalent FAP-targeted split trimeric human 4-1BB ligand Fc (kih)) and control B (monovalent untargeted split trimeric human 4-1BB ligand Fc (kih) with CH-CL cross and charged residues) as comparison curves. FIGS. 17A-1 to 17D-4 show the activation without crosslinking FAP-expressing tumor cells, FIGS. 17B-1 to 17B-4 show the activation in the presence of crosslinking FAP-expressing MV-3 tumor cells and FIGS. 17C-1 to 17C-4 show the activation in the presence of crosslinking FAP-expressing WM-266-4 tumor cells.



FIGS. 18A to 18F show the NFκB-activation-induced Luciferase expression and activity as measured for the constructs of Example 2. Units of released light (URL) are measured for 0.5 s/well and plotted against the used concentration of FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs. Human 4-1BB-expressing HeLa-reporter cells were incubated for 6 h in the absence or presence of crosslinking human-FAP expressing human melanoma cell line MV-3 or WM-266-4. URLs were measured and blotted against the concentrations of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs 2.1, 2.3, 2.4, 2.5 and 2.6 and Controls B, C, E and F. The cell ratio is one 4-1BB-expressing HeLa reporter cell to five tumor cells. For better display activation curves were split to two different display-blots with construct 2.1 (monovalent FAP-targeted split trimeric human 4-1BB ligand Fc (kih)).



FIGS. 19A and 19B show the activation assay set up with cynomolgus monkey 4-1BB expressing T293-HEK reporter cell line. A crosslinking of cynomolgus monkey 4-1BB expressed on the reporter cells induces NFκB activation and NFκB-mediated Luciferase expression. After lysis of the cells Luciferase can catalyze the oxidation of Luciferin to Oxyluciferin. This chemical reaction correlates positively with the strength of NFκB-mediated luciferase expression and can be measured by the strength of light emission (units of released light).



FIGS. 20A to 20F show the NFκB-activation-induced Luciferase expression and activity. Units of released light (URL) are measured for 0.5 s/well and plotted against the used concentration of FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs. Cynomolgus monkey 4-1BB-expressing T293-HEK-reporter cells were incubated for 6 h in the absence or presence of crosslinking human-FAP expressing human melanoma cell line MV-3 or WM-266-4. URLs were measured and blotted against the concentrations of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs. The cell ratio is one 4-1BB-expressing T293-HEK reporter cell to five MV-3 or two WM-266-4 cells. For better display activation curves were split to two different blots with Construct 2.1 as comparison curve.



FIGS. 21A and 21B show a scheme illustrating the principal of the T-cell activation assay described in Example 6.3. Shown is the schematic assay activation set up with HLA-A2-NLV-specific CD8 T cells and NLV-pulsed HLA-A2+ FAP+ human melanoma cell line MV-3 in the presence of different titrated concentration of FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs. Cells were incubated for 28 h, the last 4 h in the presence of monesin-containing Golgi-Stop. The ratio of NLV-specific CD8 T cells to MV-3 tumor cells is 1:8.



FIGS. 22A-1 to 22E-3 and 23A-1 to 23E-3 relate to the Activation assay with HLA-A2-NLV-specific CD8 T cells and NLV-pulsed HLA-A2+ FAP+ human melanoma cell line MV-3 in the presence of different titrated concentration of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs as prepared in Example 1. For better display expression curves were split to several different display-blots with Construct 1.1 (monovalent FAP-targeted split trimeric human 4-1BB ligand Fc (kih)) and Control B (monovalent untargeted split trimeric human 4-1BB ligand Fc (kih)) as comparison curves. Results were obtained in four independent similar experiments and show that prolonged IFNγ secretion and CD137 expression of NLV-specific CD8+ T cells is strictly dependent on simultaneous activation of T-cells via recognition of NLV-HLA-A2 complexes (signal 1) and 4-1BB-triggering by FAP-targeted human split 4-1BBL (signal 2). The effect of 4-1BB upregulation is shown in graphs of FIGS. 22A-1 to 22E-3, whereas the effect of INFγ expression of CD8+ T cells is presented in graphs of FIGS. 23A-1 to 23E-3. Shown is always the frequency in percentage of positive cells in the total CD8+ T cell population. All FAP-targeted variants induced a similar activation improvement of NLV-peptide activated CD8 T cells shown in FIGS. 22A-1 to 22E-3 as 4-1BB-upregulation (positive feedback loop) and in FIGS. 23A-1 to 23E-3 as IFNγ expression after 24 h of stimulation. Differences of curves lie in the range of normal error deviation and are not significant.



FIGS. 24A-1 to 24B-3 and 25A-1 to 25B-3 refer to the Activation assay with HLA-A2-NLV-specific CD8 T cells and NLV-pulsed HLA-A2+ FAP+ human melanoma cell line MV-3 in the presence of titrated concentration of different FAP-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs of Example 2. For better display expression curves were split to two different display-blots with Construct 2.1 (monovalent FAP-targeted split trimeric human 4-1BB ligand Fc (kih)) and Control B as comparison curves. All FAP-targeted split trimeric human 4-1BB ligand Fc (kih) constructs show a similar activation improvement of HLA-A2-NLV-peptide specific CD8 T cells shown in FIGS. 24A-1 to 24B-3 as 4-1BB-upregulation (positive feedback loop) and in FIGS. 25A-1 to 25B-3 as IFNγ expression after 24 h of stimulation. Differences of curves lie in the range of normal error deviation and are not significant.



FIGS. 26A and 26B show a scheme illustrating the experiment as described in Example 6.4.



FIG. 27 shows the induction of CD8+ T cell proliferation. Shown is the frequency of proliferating CD8+ T cells versus the concentration of tested constructs.



FIG. 28A relates to the single dose PK experiment of Construct 1.2 and Control B in healthy NOG mice. Shown is the decline in Construct concentration over the time. FIG. 28B shows the results of the single dose PK experiment of Constructs 2.1, 2.3, Control B and Control C in tumor bearing NOG mice humaniced with stem cells. FIG. 28C relates to the single dose PK experiment comparing Construct 2.1 and 2.3 in healthy NOG mice.



FIGS. 29A to 29D show components for the assembly of split trimeric human 4-1BB ligands including linker GGGGSGGGGS (SEQ ID NO:13). FIG. 29A shows the dimeric ligand that is fused at the C-terminus to a human CL domain with mutations E123R and Q124K (charged residues) and FIG. 29B shows the monomeric 4-1BB ligand fused to human CH1 domain with mutations K147E and K213E (charged residues). Components for the assembly of bivalent CD19-targeted split trimeric human 4-1BB ligand (71-254) antigen binding molecule (construct 3.3). FIG. 29C shows the dimeric ligand being fused to the C-terminus of human IgG1 Fc hole chain. FIG. 29D shows the monomeric ligand being fused to the C-terminus of human IgG1 Fc knob chain.



FIGS. 30A to 30F show the CD19-targeted 4-1BBL-trimer-containing antigen binding molecules Constructs 3.1 to 3.6 of the invention. The preparation and production of these constructs is described in Example 3. The VH and VL domains are those of anti-CD19 antibody 8B8-018, the thick black point stands for the knob-into-hole modification. * symbolizes amino acid modifications in the CH1 and CL domain (so-called charged residues).



FIGS. 31A-1 to 31A-2 illustrate the randomization strategy for the CDR regions of the parental clone 8B8. Shown are the variable domains of the parental clone 8B8 and the CDR regions (boxed) according to the numbering of Kabat. (X) (SEQ ID NO:202; SEQ ID NO:201) represents the randomized positions. FIGS. 31B-1 to 31B-2 show the schematic description of the library generation strategies. Shown is the PCR amplification and cloning strategy used for the generation of the 8B8-based library with A) randomized CDR1 and CDR2 regions in the light and heavy chain or B) randomized CDR1 and CDR3 regions in the light and CDR3 region in the heavy chain. Respective enzymes used for cloning into the phagemide are indicated.



FIGS. 32A and 32B show the alignment of the parental anti-CD19 clone 8B8 (SEQ ID NO:202; SEQ ID NO:201) with the selected affinity-matured binders. Shown are the sequences of clone 8B8 and all selected affinity-matured binders. CDRs of both heavy and light chains are framed (SEQ ID NOs:231-272).



FIGS. 33A to 33H relate to the SPR analysis of the parental 8B8 clone and its affinity-matured variants. Shown are the sensorgrams of clone 8B8 and its affinity-matured derivatives that are devoid of the LCDR1 N27d and N28 hotspots.



FIG. 34 illustrates the setup of the assay measuring Simultaneous binding of CD19 targeted trimeric split 4-1BBL to hu4-1BB and huCD19 (Example 8.2).



FIGS. 35A-35F show simultaneous binding of the CD19 targeted trimeric 4-1BBL FC fusion antigen binding molecules Constructs 3.1, 3.3, 3.4, 3.5, 3.6 and 4.4 (Analyte 1) to immobilized human 4-1BB and human CD19 (Analyte 2).



FIGS. 36A-1 to 36B-3 show the binding of different CD19-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs to 4-1BB-expressing CD4 and CD8 T cells of PHA-L and Proleukin pre-activated and anti-human CD3/anti-human CD28 re-activated human PBMCs. Binding was detected with R-Phycoerythrin-fluorochrome conjugated anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested constructs. For a better display the binding curves are split in three different blots with construct 3.4 and control F (Isotype control huIgG1 P329G LALA) as comparison curves. Binding was monitored on CD45+CD3+CD8+ T cells (FIGS. 36A-1 to 36A-3) and CD45+CD3+CD4+ T cells (FIGS. 36B-1 to 36B-3). The 4-1BB expression level on CD8 T cells is normally higher than on CD4 T cells. All constructs bind with a quite similar affinity to human 4-1BB.



FIGS. 37A-1 to 37D-3 show the binding of CD19-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) antigen binding molecules to human-CD19 expressing B cell lymphoma cell lines: diffuse large non-Hodgkin B cell lymphoma SU-DHL-8 (37A-1 to 37A-3), acute B cell precursor lymphoid leukemia Nalm6 (37B-1 to 37B-3), diffuse large cell lymphoblast lymphoma Toledo (37C-1 to 37C-3) and diffuse large B cell lymphoma OCI-Ly18 (37D-1 to 37D-3). Binding was detected with R-Phycoerythrin-fluorochrome conjugated anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragments. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested constructs. For a better display the binding curves are split in three different blots with construct 3.4 and control F (Isotype control huIgG1 P329G LALA) as comparison curves. All constructs bind with a quite similar affinity to human CD19.



FIGS. 38A to 38C relate to NFκB-activation-induced Luciferase expression and activity of CD19-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) antigen binding molecules. Units of released light (URL) are measured for 0.5 s/well and plotted against the used concentration of CD19-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs 3.1 and 3.3 and control molecules B and C. Human 4-1BB-expressing HeLa-reporter cells were incubated for 7.5 h in the absence presence of crosslinking human-CD19 expressing SU-DHL-8 or Pfeiffer cells. URLs were measured and blotted against the concentrations of different CD19-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs. The cell ratio is one 4-1BB-expressing HeLa reporter cell to 2.5 or five tumor cells.



FIG. 39 shows the binding of different humanized variants of T84.66 IgG on CEA-expressing human gastric adenocarcinoma cells. Based on the data humanized variant 1 was selected for including it into CEA-targeted trimeric human 4-1BB ligand Fc (kih) antigen binding molecules.



FIGS. 40A to 40F show the CEA targeted 4-1BBL-trimer-containing antigen binding molecules Constructs 5.1 to 5.6 of the invention. The preparation and production of these constructs is described in Example 11. The VH and VL domains are those of anti-CEA antibody T84.66-LCHA, the thick black point stands for the knob-into-hole modification. * symbolizes amino acid modifications in the CH1 and CL domain (so-called charged residues).



FIG. 41A shows a schematic description of human NA3B3A2-avi His, the antigen used to assess binding of CEA-targeted trimeric split 4-1BBL Fc (kih) antigen binding molecules. FIG. 41B illustrates the setup of the assay measuring simultaneous binding of CEA-targeted trimeric split 4-1BBL to hu4-1BB and human NA3B3A2 (Example 12.1).



FIGS. 42A to 42D show simultaneous binding of the CEA targeted trimeric 4-1BBL Fc fusion antigen binding molecules Constructs 5.4, 5.6, 5.7 and 5.8 (Analyte 1) to immobilized human 4-1BB and human NA3B3A2 (Analyte 2).



FIGS. 43A to 43D show binding of different CEA-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs to 4-1BB-expressing CD4 and CD8 T cells of PHA-L and Proleukin pre-activated and anti-human CD3/anti-human CD28 re-activated human PBMCs. Binding was detected with R-Phycoerythrin-fluorochrome conjugated anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested constructs. For a better display the binding curves are split in two different blots with construct 5.4 and control F (Isotype control huIgG1 P329G LALA) as comparison curves. Binding was monitored on CD45+CD3+CD8+ T cells (blots on the bottom) and CD45+CD3+CD4+ T cells (blots on the top). The 4-1BB expression level on CD8 T cells is normally higher than on CD4 T cells. All constructs bind with quite similar affinity to human 4-1BB.



FIGS. 44A and 44B show the binding of CEA-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs to human-CEA expressing human gastric cell line MKN-45 (44A) and human colorectal adenocarcinoma cells line LS180 (right44B). Binding was detected with R-Phycoerythrin-fluorochrome conjugated anti-human IgG Fcγ-specific goat IgG F(ab′) 2 fragments. Shown is the median of fluorescence intensity (MFI) versus the concentration of tested constructs.



FIGS. 45A to 45D relate to NFκB-activation-induced Luciferase expression and activity of CEA-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) antigen binding molecules. Units of released light (URL) are measured for 0.5 s/well and blotted against the used concentration of CEA-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs 5.4, 5.6, 5.7 and 5.8 and control molecules. Human 4-1BB-expressing HeLa-reporter cells were incubated for 6 h in the absence or presence of crosslinking human-CEA expressing human gastric cancer cell line MKN-45. The cell ratio is one 4-1BB-expressing HeLa reporter cell to three tumor cells.



FIGS. 46A and 46B show the components for the assembly of monovalent FAP targeted split trimeric human OX40 ligand (construct 6.1) including linker GGGGSGGGGS (SEQ ID NO:13). FIG. 46A relates to dimeric ligand fused to human IgG1-CL domain, FIG. 46B relates to monomeric ligand fused to human IgG1-CH1 domain. FIG. 46C shows the FAP targeted OX40L-trimer-containing antigen binding molecule Construct 6.1. In FIG. 46D is shown the DP47 “untargeted” human IgG1 PGLALA (control F).



FIG. 47A shows the binding of FAP targeted split trimeric human OX40L to FAP positive WM-266-4 cells. WM-266-4 cells express high levels of human fibroblast activation protein (huFAP). Only FAP targeted OX40 ligand Fc (kih) constructs (filled square) but not control F (filled diamond) bound to WM-266-4 cells. Shown is the binding as median of fluorescence intensity (MFI) of Fluorescein isothiocyanate (FITC)-labeled anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment which is used as secondary detection antibody. MFI was measured by flow cytometry. The x-axis shows the concentration of antibody constructs. FIG. 47B shows the binding of FAP targeted OX40 ligand Fc (kih) construct to human FAP human OX40 negative A549 NucLight™ Red cells. FAP targeted OX40 ligand Fc (kih) construct showed no binding to OX40 negative FAP negative A549 tumor cells. Shown is the binding as median of fluorescence intensity (MFI) of FITC labeled anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment which is used as secondary detection antibody. MFI was measured by flow cytometry and baseline corrected by subtracting the MFI of the blank control.



FIGS. 48A-1 to 48A-2 show the binding of FAP-OX40L to resting and activated human CD4 T cells. OX40 is not expressed on resting human CD4 T cells (left side). In the absence of human OX40 expressing cells no binding was observed (48A-1). After activation of human PBMCs OX40 is up-regulated on CD4+ T cells (48A-2). FAP-OX40L bound to OX40+ activated CD4 T cells. Shown is the binding as median of fluorescence intensity (MFI) of FITC labeled anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment which is used as secondary detection antibody. MFI was measured by flow cytometry and baseline corrected by subtracting the MFI of the blank control. The x-axis shows the concentration of antibody constructs. FIGS. 48B-1 and 48B-2 show that OX40 is not expressed on resting human CD8 T cells (left side). In the absence of human OX40 expressing cells no binding was observed (left graphs). After activation of human PBMCs OX40 is up-regulated on CD8+ T cells (right side). OX40 expression on human CD8+ T cells is lower than on CD4+ T cells and varies between donors and time points. Expression of OX40 was low on the depicted CD8 T cells. FAP-OX40L bound to OX40+ activated CD8 T cells. Shown is the binding as median of fluorescence intensity (MFI) of FITC labeled anti-human IgG Fcγ-specific goat IgG F(ab′)2 fragment which is used as secondary detection antibody. MFI was measured by flow cytometry and baseline corrected by subtracting the MFI of the blank control. The x-axis shows the concentration of antibody constructs.


In FIGS. 49A and 49B, the activation of NFκB signaling pathway by the FAP targeted split trimeric human OX40L antigen binding molecule (FAP-OX40L) in HeLa_hOx40_NFkB_Luc1 reporter cells is demonstrated. Shown is the activation with (49B) or without (49A) crosslinking by secondary antibody. The reporter cells were cultured for 5 hours in the presence of FAP-OX40L at the indicated concentrations with or without crosslinking secondary poly-clonal anti-huIgG1 Fcγ-specific goat IgG F(ab)2 fragment in a 1:2 ratio. Luciferase activity was assessed as described in Example 6.1. Activity is characterized by blotting the units of released light (URL) measured during 0.5 s versus the concentration in nM of tested construct. URLs are emitted due to luciferase-mediated oxidation of luciferin to oxyluciferin.



FIG. 50A shows the activation of NFκB by FAP-OX40L in HeLa_hOx40_NFkB_Luc1 reporter cells in the presence of FAP positive cells. Shown is the activation of NFκB signaling pathway in the reporter cells by FAP-OX40L in the presence of low FAP expressing NIH-3T3 human FAP cells (ratio 3 FAP+ tumor cells to 1 reporter cell). The NFκB-mediated luciferase activity was characterized by blotting the units of released light (URL), measured during 0.5 s, versus the concentration in nM of tested compounds. URLs are emitted due to luciferase-mediated oxidation of luciferin to oxyluciferin. Values are baseline corrected by subtracting the URLs of the blank control. For a better comparison the area under the curve of the respective blotted dose-response curves were quantified as a marker for the agonistic capacity of each construct. The comparison is illustrated in FIG. 50B. The area was calculated using GraphPad Prism. Values are baseline corrected by subtracting the value of the blank control.



FIGS. 51A to 51D show the OX40 mediated costimulation of suboptimally TCR triggered resting human PBMC (Example 15.5). Hyper-crosslinking of FAP-OX40L by the present NIH/3T3-huFAP clone 39 cells strongly promoted survival and proliferation in human CD4 and CD8 T cells. Shown is the event count of vital CD4+(51A and 51C) and CD8+(51B and 51D) T cells. Baseline values of samples containing only the anti-human CD3 (clone V9, huIgG1), resting human PBMC and NIH/3T3-huFAP clone 39 were subtracted. Thus the enhancing effect of OX40 co-stimulation but not the effect of suboptimal anti-CD3 stimulation per se is shown here. In FIGS. 51A to 51D on the bottom the rescue of suboptimal TCR stimulation of resting human PBMC with cell surface immobilized FAP-OX40L—Proliferation is shown.





DETAILED DESCRIPTION OF THE INVENTION
Definitions

Unless defined otherwise, technical and scientific terms used herein have the same meaning as generally used in the art to which this invention belongs. For purposes of interpreting this specification, the following definitions will apply and whenever appropriate, terms used in the singular will also include the plural and vice versa.


As used herein, the term “antigen binding molecule” refers in its broadest sense to a molecule that specifically binds an antigenic determinant. Examples of antigen binding molecules are antibodies, antibody fragments and scaffold antigen binding proteins.


As used herein, the term “moiety capable of specific binding to a target cell antigen” refers to a polypeptide molecule that specifically binds to an antigenic determinant. In one aspect, the antigen binding moiety is able to activate signaling through its target cell antigen. In a particular aspect, the antigen binding moiety is able to direct the entity to which it is attached (e.g. the TNF family ligand trimer) to a target site, for example to a specific type of tumor cell or tumor stroma bearing the antigenic determinant. Moieties capable of specific binding to a target cell antigen include antibodies and fragments thereof as further defined herein. In addition, moieties capable of specific binding to a target cell antigen include scaffold antigen binding proteins as further defined herein, e.g. binding domains which are based on designed repeat proteins or designed repeat domains (see e.g. WO 2002/020565).


In relation to an antibody or fragment thereof, the term “moiety capable of specific binding to a target cell antigen” refers to the part of the molecule that comprises the area which specifically binds to and is complementary to part or all of an antigen. A moiety capable of specific antigen binding may be provided, for example, by one or more antibody variable domains (also called antibody variable regions). Particularly, a moiety capable of specific antigen binding comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).


The term “antibody” herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific and multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.


The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g. containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen.


The term “monospecific” antibody as used herein denotes an antibody that has one or more binding sites each of which bind to the same epitope of the same antigen. The term “bispecific” means that the antigen binding molecule is able to specifically bind to at least two distinct antigenic determinants. Typically, a bispecific antigen binding molecule comprises two antigen binding sites, each of which is specific for a different antigenic determinant. In certain embodiments the bispecific antigen binding molecule is capable of simultaneously binding two antigenic determinants, particularly two antigenic determinants expressed on two distinct cells.


The term “valent” as used within the current application denotes the presence of a specified number of binding sites in an antigen binding molecule. As such, the terms “bivalent”, “tetravalent”, and “hexavalent” denote the presence of two binding sites, four binding sites, and six binding sites, respectively, in an antigen binding molecule.


The terms “full length antibody”, “intact antibody”, and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure. “Native antibodies” refer to naturally occurring immunoglobulin molecules with varying structures. For example, native IgG-class antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two light chains and two heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3), also called a heavy chain constant region. Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a light chain constant domain (CL), also called a light chain constant region. The heavy chain of an antibody may be assigned to one of five types, called α (IgA), δ (IgD), ε (IgE), γ (IgG), or μ (IgM), some of which may be further divided into subtypes, e.g. γ1 (IgG1), γ2 (IgG2), γ3 (IgG3), γ4 (IgG4), α1 (IgA1) and α2 (IgA2). The light chain of an antibody may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.


An “antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab′, Fab′-SH, F(ab′)2; diabodies, triabodies, tetrabodies, cross-Fab fragments; linear antibodies; single-chain antibody molecules (e.g. scFv); and single domain antibodies. For a review of certain antibody fragments, see Hudson et al., Nat Med 9, 129-134 (2003). For a review of scFv fragments, see e.g. Plückthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); see also WO 93/16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For discussion of Fab and F(ab′)2 fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Pat. No. 5,869,046. Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific, see, for example, EP 404,097; WO 1993/01161; Hudson et al., Nat Med 9, 129-134 (2003); and Hollinger et al., Proc Natl Acad Sci USA 90, 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat Med 9, 129-134 (2003). Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, Mass.; see e.g. U.S. Pat. No. 6,248,516 B1). Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. E. coli or phage), as described herein.


Papain digestion of intact antibodies produces two identical antigen-binding fragments, called “Fab” fragments containing each the heavy- and light-chain variable domains and also the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. As used herein, Thus, the term “Fab fragment” refers to an antibody fragment comprising a light chain fragment comprising a VL domain and a constant domain of a light chain (CL), and a VH domain and a first constant domain (CH1) of a heavy chain. Fab′ fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteins from the antibody hinge region. Fab′-SH are Fab′ fragments in which the cysteine residue(s) of the constant domains bear a free thiol group. Pepsin treatment yields an F(ab′)2 fragment that has two antigen-combining sites (two Fab fragments) and a part of the Fc region.


The term “cross-Fab fragment” or “xFab fragment” or “crossover Fab fragment” refers to a Fab fragment, wherein either the variable regions or the constant regions of the heavy and light chain are exchanged. Two different chain compositions of a crossover Fab molecule are possible and comprised in the bispecific antibodies of the invention: On the one hand, the variable regions of the Fab heavy and light chain are exchanged, i.e. the crossover Fab molecule comprises a peptide chain composed of the light chain variable region (VL) and the heavy chain constant region (CH1), and a peptide chain composed of the heavy chain variable region (VH) and the light chain constant region (CL). This crossover Fab molecule is also referred to as CrossFab (VLVH). On the other hand, when the constant regions of the Fab heavy and light chain are exchanged, the crossover Fab molecule comprises a peptide chain composed of the heavy chain variable region (VH) and the light chain constant region (CL), and a peptide chain composed of the light chain variable region (VL) and the heavy chain constant region (CH1). This crossover Fab molecule is also referred to as CrossFab (CLCH1).


A “single chain Fab fragment” or “scFab” is a polypeptide consisting of an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, wherein said antibody domains and said linker have one of the following orders in N-terminal to C-terminal direction: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1 or d) VL-CH1-linker-VH-CL; and wherein said linker is a polypeptide of at least 30 amino acids, preferably between 32 and 50 amino acids. Said single chain Fab fragments are stabilized via the natural disulfide bond between the CL domain and the CH1 domain. In addition, these single chain Fab molecules might be further stabilized by generation of interchain disulfide bonds via insertion of cysteine residues (e.g. position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).


A “crossover single chain Fab fragment” or “x-scFab” is a is a polypeptide consisting of an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, wherein said antibody domains and said linker have one of the following orders in N-terminal to C-terminal direction: a) VH-CL-linker-VL-CH1 and b) VL-CH1-linker-VH-CL; wherein VH and VL form together an antigen-binding site which binds specifically to an antigen and wherein said linker is a polypeptide of at least 30 amino acids. In addition, these x-scFab molecules might be further stabilized by generation of interchain disulfide bonds via insertion of cysteine residues (e.g. position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).


A “single-chain variable fragment (scFv)” is a fusion protein of the variable regions of the heavy (VH) and light chains (VL) of an antibody, connected with a short linker peptide of ten to about 25 amino acids. The linker is usually rich in glycine for flexibility, as well as serine or threonine for solubility, and can either connect the N-terminus of the VH with the C-terminus of the VL, or vice versa. This protein retains the specificity of the original antibody, despite removal of the constant regions and the introduction of the linker. scFv antibodies are, e.g. described in Houston, J. S., Methods in Enzymol. 203 (1991) 46-96). In addition, antibody fragments comprise single chain polypeptides having the characteristics of a VH domain, namely being able to assemble together with a VL domain, or of a VL domain, namely being able to assemble together with a VH domain to a functional antigen binding site and thereby providing the antigen binding property of full length antibodies.


“Scaffold antigen binding proteins” are known in the art, for example, fibronectin and designed ankyrin repeat proteins (DARPINs®) have been used as alternative scaffolds for antigen-binding domains, see, e.g., Gebauer and Skerra, Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13:245-255 (2009) and Stumpp et al., Darpins: A new generation of protein therapeutics. Drug Discovery Today 13: 695-701 (2008). In one aspect of the invention, a scaffold antigen binding protein is selected from the group consisting of CTLA-4 (Evibody), Lipocalins (ANTICALIN®), a Protein A-derived molecule such as Z-domain of Protein A (AFFIBODY®), an A-domain (Avimer/Maxibody), a serum transferrin (trans-body); a designed ankyrin repeat protein (DARPIN®), a variable domain of antibody light chain or heavy chain (single-domain antibody, sdAb), a variable domain of antibody heavy chain (nanobody, aVH), VNAR fragments, a fibronectin (AdNectin), a C-type lectin domain (Tetranectin); a variable domain of a new antigen receptor beta-lactamase (VNAR fragments), a human gamma-crystallin or ubiquitin (AFFILIN® molecules); a kunitz type domain of human protease inhibitors, microbodies such as the proteins from the knottin family, peptide aptamers and fibronectin (adnectin).


CTLA-4 (Cytotoxic T Lymphocyte-associated Antigen 4) is a CD28-family receptor expressed on mainly CD4+ T-cells. Its extracellular domain has a variable domain-like Ig fold. Loops corresponding to CDRs of antibodies can be substituted with heterologous sequence to confer different binding properties. CTLA-4 molecules engineered to have different binding specificities are also known as Evibodies (e.g. U.S. Pat. No. 7,166,697B1). Evibodies are around the same size as the isolated variable region of an antibody (e.g. a domain antibody). For further details see Journal of Immunological Methods 248 (1-2), 31-45 (2001).


Lipocalins are a family of extracellular proteins which transport small hydrophobic molecules such as steroids, bilins, retinoids and lipids. They have a rigid beta-sheet secondary structure with a number of loops at the open end of the conical structure which can be engineered to bind to different target antigens. ANTICALINs® are between 160-180 amino acids in size, and are derived from lipocalins. For further details see Biochim Biophys Acta 1482: 337-350 (2000), U.S. Pat. No. 7,250,297B1 and US20070224633 (U.S. Pat. No. 7,585,940B2).


An AFFIBODY® is a scaffold derived from Protein A of Staphylococcus aureus which can be engineered to bind to antigen. The domain consists of a three-helical bundle of approximately 58 amino acids. Libraries have been generated by randomization of surface residues. For further details see Protein Eng. Des. Sel. 17, 455-462 (2004) and EP 1641818A1.


Avimers are multidomain proteins derived from the A-domain scaffold family. The native domains of approximately 35 amino acids adopt a defined disulfide bonded structure. Diversity is generated by shuffling of the natural variation exhibited by the family of A-domains. For further details see Nature Biotechnology 23(12), 1556-1561 (2005) and Expert Opinion on Investigational Drugs 16(6), 909-917 (June 2007).


A transferrin is a monomeric serum transport glycoprotein. Transferrins can be engineered to bind different target antigens by insertion of peptide sequences in a permissive surface loop. Examples of engineered transferrin scaffolds include the Trans-body. For further details see J. Biol. Chem 274, 24066-24073 (1999).


Designed Ankyrin Repeat Proteins (DARPINs®) are derived from Ankyrin which is a family of proteins that mediate attachment of integral membrane proteins to the cytoskeleton. A single ankyrin repeat is a 33 residue motif consisting of two alpha-helices and a beta-turn. They can be engineered to bind different target antigens by randomizing residues in the first alpha-helix and a beta-turn of each repeat. Their binding interface can be increased by increasing the number of modules (a method of affinity maturation). For further details see J. Mol. Biol. 332, 489-503 (2003), PNAS 100(4), 1700-1705 (2003) and J. Mol. Biol. 369, 1015-1028 (2007) and US20040132028A1 (U.S. Pat. No. 7,417,130B2).


A single-domain antibody is an antibody fragment consisting of a single monomeric variable antibody domain. The first single domain were derived from the variable domain of the antibody heavy chain from camelids (nanobodies or VHH fragments). Furthermore, the term single-domain antibody includes an autonomous human heavy chain variable domain (aVH) or VNAR fragments derived from sharks.


Fibronectin is a scaffold which can be engineered to bind to antigen. Adnectins consists of a backbone of the natural amino acid sequence of the 10th domain of the 15 repeating units of human fibronectin type III (FN3). Three loops at one end of the .beta.-sandwich can be engineered to enable an Adnectin to specifically recognize a therapeutic target of interest. For further details see Protein Eng. Des. Sel. 18, 435-444 (2005), US20080139791, WO2005056764 and U.S. Pat. No. 6,818,418B1.


Peptide aptamers are combinatorial recognition molecules that consist of a constant scaffold protein, typically thioredoxin (TrxA) which contains a constrained variable peptide loop inserted at the active site. For further details see Expert Opin. Biol. Ther. 5, 783-797 (2005).


Microbodies are derived from naturally occurring microproteins of 25-50 amino acids in length which contain 3-4 cysteine bridges—examples of microproteins include KalataBI and conotoxin and knottins. The microproteins have a loop which can beengineered to include upto 25 amino acids without affecting the overall fold of the microprotein. For further details of engineered knottin domains, see WO2008098796.


An “antigen binding molecule that binds to the same epitope” as a reference molecule refers to an antigen binding molecule that blocks binding of the reference molecule to its antigen in a competition assay by 50% or more, and conversely, the reference molecule blocks binding of the antigen binding molecule to its antigen in a competition assay by 50% or more.


The term “antigen binding domain” refers to the part of an antigen binding molecule that comprises the area which specifically binds to and is complementary to part or all of an antigen. Where an antigen is large, an antigen binding molecule may only bind to a particular part of the antigen, which part is termed an epitope. An antigen binding domain may be provided by, for example, one or more variable domains (also called variable regions). Preferably, an antigen binding domain comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).


As used herein, the term “antigenic determinant” is synonymous with “antigen” and “epitope,” and refers to a site (e.g. a contiguous stretch of amino acids or a conformational configuration made up of different regions of non-contiguous amino acids) on a polypeptide macromolecule to which an antigen binding moiety binds, forming an antigen binding moiety-antigen complex. Useful antigenic determinants can be found, for example, on the surfaces of tumor cells, on the surfaces of virus-infected cells, on the surfaces of other diseased cells, on the surface of immune cells, free in blood serum, and/or in the extracellular matrix (ECM). The proteins useful as antigens herein can be any native form the proteins from any vertebrate source, including mammals such as primates (e.g. humans) and rodents (e.g. mice and rats), unless otherwise indicated. In a particular embodiment the antigen is a human protein. Where reference is made to a specific protein herein, the term encompasses the “full-length”, unprocessed protein as well as any form of the protein that results from processing in the cell. The term also encompasses naturally occurring variants of the protein, e.g. splice variants or allelic variants.


By “specific binding” is meant that the binding is selective for the antigen and can be discriminated from unwanted or non-specific interactions. The ability of an antigen binding molecule to bind to a specific antigen can be measured either through an enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to one of skill in the art, e.g. Surface Plasmon Resonance (SPR) technique (analyzed on a BIACORE® instrument) (Liljeblad et al., Glyco J 17, 323-329 (2000)), and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). In one embodiment, the extent of binding of an antigen binding molecule to an unrelated protein is less than about 10% of the binding of the antigen binding molecule to the antigen as measured, e.g. by SPR. In certain embodiments, an molecule that binds to the antigen has a dissociation constant (Kd) of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g. 10−8M or less, e.g. from 10−8M to 10−13M, e.g. from 10′ M to 10−13 M).


“Affinity” or “binding affinity” refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g. an antibody) and its binding partner (e.g. an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g. antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd), which is the ratio of dissociation and association rate constants (koff and kon, respectively). Thus, equivalent affinities may comprise different rate constants, as long as the ratio of the rate constants remains the same. Affinity can be measured by common methods known in the art, including those described herein. A particular method for measuring affinity is Surface Plasmon Resonance (SPR).


A “target cell antigen” as used herein refers to an antigenic determinant presented on the surface of a target cell, for example a cell in a tumor such as a cancer cell or a cell of the tumor stroma. In certain embodiments, the target cell antigen is an antigen on the surface of a tumor cell. In one embodiment, target cell antigen is selected from the group consisting of Fibroblast Activation Protein (FAP), Carcinoembryonic Antigen (CEA), Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), Epidermal Growth Factor Receptor (EGFR), CD19, CD20 and CD33. In particular, the target cell antigen is Fibroblast Activation Protein (FAP).


The term “Fibroblast activation protein (FAP)”, also known as Prolyl endopeptidase FAP or Seprase (EC 3.4.21), refers to any native FAP from any vertebrate source, including mammals such as primates (e.g. humans) non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated. The term encompasses “full-length,” unprocessed FAP as well as any form of FAP which results from processing in the cell. The term also encompasses naturally occurring variants of FAP, e.g., splice variants or allelic variants. In one embodiment, the antigen binding molecule of the invention is capable of specific binding to human, mouse and/or cynomolgus FAP. The amino acid sequence of human FAP is shown in UniProt accession no. Q12884 (version 149, SEQ ID NO:20), or NCBI RefSeq NP_004451.2. The extracellular domain (ECD) of human FAP extends from amino acid position 26 to 760. The amino acid and nucleotide sequences of a His-tagged human FAP ECD is shown in SEQ ID NOs 15 and 16, respectively. The amino acid sequence of mouse FAP is shown in UniProt accession no. P97321 (version 126, SEQ ID NO:23), or NCBI RefSeq NP_032012.1. The extracellular domain (ECD) of mouse FAP extends from amino acid position 26 to 761. SEQ ID NOs 24 and 25 show the amino acid and nucleotide sequences, respectively, of a His-tagged mouse FAP ECD. SEQ ID NOs 26 and 27 show the amino acid and nucleotide sequences, respectively, of a His-tagged cynomolgus FAP ECD. Preferably, an anti-FAP binding molecule of the invention binds to the extracellular domain of FAP. Exemplary anti-FAP binding molecules are described in International Patent Application No. WO 2012/020006 A2.


The term “Carcinoembroynic antigen (CEA)”, also known as Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), refers to any native CEA from any vertebrate source, including mammals such as primates (e.g. humans) non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated. The amino acid sequence of human CEA is shown in UniProt accession no. P06731 (version 151, SEQ ID NO:28). CEA has long been identified as a tumor-associated antigen (Gold and Freedman, J Exp Med., 121:439-462, 1965; Berinstein N. L., J Clin Oncol., 20:2197-2207, 2002). Originally classified as a protein expressed only in fetal tissue, CEA has now been identified in several normal adult tissues. These tissues are primarily epithelial in origin, including cells of the gastrointestinal, respiratory, and urogential tracts, and cells of colon, cervix, sweat glands, and prostate (Nap et al., Tumour Biol., 9(2-3):145-53, 1988; Nap et al., Cancer Res., 52(8):2329-23339, 1992). Tumors of epithelial origin, as well as their metastases, contain CEA as a tumor associated antigen. While the presence of CEA itself does not indicate transformation to a cancerous cell, the distribution of CEA is indicative. In normal tissue, CEA is generally expressed on the apical surface of the cell (Hammarström S., Semin Cancer Biol. 9(2):67-81 (1999)), making it inaccessible to antibody in the blood stream. In contrast to normal tissue, CEA tends to be expressed over the entire surface of cancerous cells (Hammarström S., Semin Cancer Biol. 9(2):67-81 (1999)). This change of expression pattern makes CEA accessible to antibody binding in cancerous cells. In addition, CEA expression increases in cancerous cells. Furthermore, increased CEA expression promotes increased intercellular adhesions, which may lead to metastasis (Marshall J., Semin Oncol., 30 (a Suppl. 8):30-6, 2003). The prevalence of CEA expression in various tumor entities is generally very high. In concordance with published data, own analyses performed in tissue samples confirmed its high prevalence, with approximately 95% in colorectal carcinoma (CRC), 90% in pancreatic cancer, 80% in gastric cancer, 60% in non-small cell lung cancer (NSCLC, where it is co-expressed with HER3), and 40% in breast cancer; low expression was found in small cell lung cancer and glioblastoma.


CEA is readily cleaved from the cell surface and shed into the blood stream from tumors, either directly or via the lymphatics. Because of this property, the level of serum CEA has been used as a clinical marker for diagnosis of cancers and screening for recurrence of cancers, particularly colorectal cancer (Goldenberg D M., The International Journal of Biological Markers, 7:183-188, 1992; Chau I., et al., J Clin Oncol., 22:1420-1429, 2004; Flamini et al., Clin Cancer Res; 12(23):6985-6988, 2006).


The term “Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)”, also known as Chondroitin Sulfate Proteoglycan 4 (CSPG4) refers to any native MCSP from any vertebrate source, including mammals such as primates (e.g. humans) non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated. The amino acid sequence of human MCSP is shown in UniProt accession no. Q6UVK1 (version 103, SEQ ID NO:29). The term “Epidermal Growth Factor Receptor (EGFR)”, also named Proto-oncogene c-ErbB-1 or Receptor tyrosine-protein kinase erbB-1, refers to any native EGFR from any vertebrate source, including mammals such as primates (e.g. humans) non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated. The amino acid sequence of human EGFR is shown in UniProt accession no. P00533 (version 211, SEQ ID NO:30).


The term “CD19” refers to B-lymphocyte antigen CD19, also known as B-lymphocyte surface antigen B4 or T-cell surface antigen Leu-12 and includes any native CD19 from any vertebrate source, including mammals such as primates (e.g. humans) non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated. The amino acid sequence of human CD19 is shown in Uniprot accession no. P15391 (version 160, SEQ ID NO:31). The term encompasses “full-length” unprocessed human CD19 as well as any form of human CD19 that results from processing in the cell as long as the antibody as reported herein binds thereto. CD19 is a structurally distinct cell surface receptor expressed on the surface of human B cells, including, but not limited to, pre-B cells, B cells in early development {i.e., immature B cells), mature B cells through terminal differentiation into plasma cells, and malignant B cells. CD19 is expressed by most pre-B acute lymphoblastic leukemias (ALL), non-Hodgkin's lymphomas, B cell chronic lymphocytic leukemias (CLL), pro-lymphocytic leukemias, hairy cell leukemias, common acute lymphocytic leukemias, and some Null-acute lymphoblastic leukemias. The expression of CD19 on plasma cells further suggests it may be expressed on differentiated B cell tumors such as multiple myeloma. Therefore, the CD19 antigen is a target for immunotherapy in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.


“CD20” refers to B-lymphocyte antigen CD20, also known as membrane-spanning 4-domains subfamily A member 1 (MS4A1), B-lymphocyte surface antigen B1 or Leukocyte surface antigen Leu-16, and includes any native CD20 from any vertebrate source, including mammals such as primates (e.g. humans) non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated. The amino acid sequence of human CD20 is shown in Uniprot accession no. P11836 (version 149, SEQ ID NO:32). “CD33” refers to Myeloid cell surface antigen CD33, also known as SIGLEC3 or gp67, and includes any native CD33 from any vertebrate source, including mammals such as primates (e.g. humans) non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated. The amino acid sequence of human CD33 is shown in Uniprot accession no. P20138 (version 157, SEQ ID NO:33).


The term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antigen binding molecule to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). See, e.g., Kindt et al., Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity.


The term “hypervariable region” or “HVR,” as used herein refers to each of the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops (“hypervariable loops”). Generally, native four-chain antibodies comprise six HVRs; three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). HVRs generally comprise amino acid residues from the hypervariable loops and/or from the “complementarity determining regions” (CDRs), the latter being of highest sequence variability and/or involved in antigen recognition. Exemplary hypervariable loops occur at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3). (Chothia and Lesk, I Mol. Biol. 196:901-917 (1987).) Exemplary CDRs (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3) occur at amino acid residues 24-34 of L1, 50-56 of L2, 89-97 of L3, 31-35B of H1, 50-65 of H2, and 95-102 of H3. (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991).) Hypervariable regions (HVRs) are also referred to as complementarity determining regions (CDRs), and these terms are used herein interchangeably in reference to portions of the variable region that form the antigen binding regions. This particular region has been described by Kabat et al., U.S. Dept. of Health and Human Services, “Sequences of Proteins of Immunological Interest” (1983) and by Chothia et al., J. Mol. Biol. 196:901-917 (1987), where the definitions include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or variants thereof is intended to be within the scope of the term as defined and used herein. The appropriate amino acid residues which encompass the CDRs as defined by each of the above cited references are set forth below in Table A as a comparison. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid sequence of the antibody.









TABLE A







CDR Definitions1












CDR
Kabat
Chothia
AbM2







VH CDR1
31-35
26-32
26-35



VH CDR2
50-65
52-58
50-58



VH CDR3
 95-102
 95-102
 95-102



VL CDR1
24-34
26-32
24-34



VL CDR2
50-56
50-52
50-56



VL CDR3
89-97
91-96
89-97








1Numbering of all CDR definitions in Table A is according to the numbering conventions set forth by Kabat et al. (see below).





2“AbM” with a lowercase “b” as used in Table A refers to the CDRs as defined by Oxford Molecular's “AbM” antibody modeling software.







Kabat et al. also defined a numbering system for variable region sequences that is applicable to any antibody. One of ordinary skill in the art can unambiguously assign this system of “Kabat numbering” to any variable region sequence, without reliance on any experimental data beyond the sequence itself. As used herein, “Kabat numbering” refers to the numbering system set forth by Kabat et al., U.S. Dept. of Health and Human Services, “Sequence of Proteins of Immunological Interest” (1983). Unless otherwise specified, references to the numbering of specific amino acid residue positions in an antibody variable region are according to the Kabat numbering system.


With the exception of CDR1 in VH, CDRs generally comprise the amino acid residues that form the hypervariable loops. CDRs also comprise “specificity determining residues,” or “SDRs,” which are residues that contact antigen. SDRs are contained within regions of the CDRs called abbreviated-CDRs, or a-CDRs. Exemplary a-CDRs (a-CDR-L1, a-CDR-L2, a-CDR-L3, a-CDR-H1, a-CDR-H2, and a-CDR-H3) occur at amino acid residues 31-34 of L1, 50-55 of L2, 89-96 of L3, 31-35B of H1, 50-58 of H2, and 95-102 of H3. (See Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008).) Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., supra.


As used herein, the term “affinity matured” in the context of antigen binding molecules (e.g., antibodies) refers to an antigen binding molecule that is derived from a reference antigen binding molecule, e.g., by mutation, binds to the same antigen, preferably binds to the same epitope, as the reference antibody; and has a higher affinity for the antigen than that of the reference antigen binding molecule. Affinity maturation generally involves modification of one or more amino acid residues in one or more CDRs of the antigen binding molecule. Typically, the affinity matured antigen binding molecule binds to the same epitope as the initial reference antigen binding molecule.


“Framework” or “FR” refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.


An “acceptor human framework” for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework “derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.


The term “chimeric” antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.


The “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g. IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ respectively.


A “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A “humanized form” of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization. Other forms of “humanized antibodies” encompassed by the present invention are those in which the constant region has been additionally modified or changed from that of the original antibody to generate the properties according to the invention, especially in regard to C1q binding and/or Fc receptor (FcR) binding.


A “human” antibody is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.


The term “Fc domain” or “Fc region” herein is used to define a C-terminal region of an antibody heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. An IgG Fc region comprises an IgG CH2 and an IgG CH3 domain. The “CH2 domain” of a human IgG Fc region usually extends from an amino acid residue at about position 231 to an amino acid residue at about position 340. In one embodiment, a carbohydrate chain is attached to the CH2 domain. The CH2 domain herein may be a native sequence CH2 domain or variant CH2 domain. The “CH3 domain” comprises the stretch of residues C-terminal to a CH2 domain in an Fc region (i.e. from an amino acid residue at about position 341 to an amino acid residue at about position 447 of an IgG). The CH3 region herein may be a native sequence CH3 domain or a variant CH3 domain (e.g. a CH3 domain with an introduced “protuberance” (“knob”) in one chain thereof and a corresponding introduced “cavity” (“hole”) in the other chain thereof; see U.S. Pat. No. 5,821,333, expressly incorporated herein by reference). Such variant CH3 domains may be used to promote heterodimerization of two non-identical antibody heavy chains as herein described. In one embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.


The “knob-into-hole” technology is described e.g. in U.S. Pat. Nos. 5,731,168; 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001). Generally, the method involves introducing a protuberance (“knob”) at the interface of a first polypeptide and a corresponding cavity (“hole”) in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heterodimer formation and hinder homodimer formation. Protuberances are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory cavities of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by altering the nucleic acid encoding the polypeptides, e.g. by site-specific mutagenesis, or by peptide synthesis. In a specific embodiment a knob modification comprises the amino acid substitution T366W in one of the two subunits of the Fc domain, and the hole modification comprises the amino acid substitutions T366S, L368A and Y407V in the other one of the two subunits of the Fc domain. In a further specific embodiment, the subunit of the Fc domain comprising the knob modification additionally comprises the amino acid substitution S354C, and the subunit of the Fc domain comprising the hole modification additionally comprises the amino acid substitution Y349C. Introduction of these two cysteine residues results in the formation of a disulfide bridge between the two subunits of the Fc region, thus further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15 (2001)). The numbering is according to EU index of Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.


A “region equivalent to the Fc region of an immunoglobulin” is intended to include naturally occurring allelic variants of the Fc region of an immunoglobulin as well as variants having alterations which produce substitutions, additions, or deletions but which do not decrease substantially the ability of the immunoglobulin to mediate effector functions (such as antibody-dependent cellular cytotoxicity). For example, one or more amino acids can be deleted from the N-terminus or C-terminus of the Fc region of an immunoglobulin without substantial loss of biological function. Such variants can be selected according to general rules known in the art so as to have minimal effect on activity (see, e.g., Bowie, J. U. et al., Science 247:1306-10 (1990)).


The term “effector functions” refers to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), cytokine secretion, immune complex-mediated antigen uptake by antigen presenting cells, down regulation of cell surface receptors (e.g. B cell receptor), and B cell activation.


An “activating Fc receptor” is an Fc receptor that following engagement by an Fc region of an antibody elicits signaling events that stimulate the receptor-bearing cell to perform effector functions. Activating Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89). A particular activating Fc receptor is human FcγRIIIa (see UniProt accession no. P08637, version 141).


The term “TNF ligand family member” or “TNF family ligand” refers to a proinflammatory cytokine. Cytokines in general, and in particular the members of the TNF ligand family, play a crucial role in the stimulation and coordination of the immune system. At present, nineteen cyctokines have been identified as members of the TNF (tumour necrosis factor) ligand superfamily on the basis of sequence, functional, and structural similarities. All these ligands are type II transmembrane proteins with a C-terminal extracellular domain (ectodomain), N-terminal intracellular domain and a single transmembrane domain. The C-terminal extracellular domain, known as TNF homology domain (THD), has 20-30% amino acid identity between the superfamily members and is responsible for binding to the receptor. The TNF ectodomain is also responsible for the TNF ligands to form trimeric complexes that are recognized by their specific receptors.


Members of the TNF ligand family are selected from the group consisting of Lymphotoxin α (also known as LTA or TNFSF1), TNF (also known as TNFSF2), LTβ (also known as TNFSF3), OX40L (also known as TNFSF4), CD40L (also known as CD154 or TNFSF5), FasL (also known as CD95L, CD178 or TNFSF6), CD27L (also known as CD70 or TNFSF7), CD30L (also known as CD153 or TNFSF8), 4-1BBL (also known as TNFSF9), TRAIL (also known as APO2L, CD253 or TNFSF10), RANKL (also known as CD254 or TNFSF11), TWEAK (also known as TNFSF12), APRIL (also known as CD256 or TNFSF13), BAFF (also known as CD257 or TNFSF13B), LIGHT (also known as CD258 or TNFSF14), TL1A (also known as VEGI or TNFSF15), GITRL (also known as TNFSF18), EDA-A1 (also known as ectodysplasin A1) and EDA-A2 (also known as ectodysplasin A2). The term refers to any native TNF family ligand from any vertebrate source, including mammals such as primates (e.g. humans), non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated. In specific embodiments of the invention, the TNF ligand family member is selected from the group consisting of OX40L, FasL, CD27L, TRAIL, 4-1BBL, CD40L and GITRL. In a particular embodiment, the TNF ligand family member is selected from 4-1BBL and OX40L.


Further information, in particular sequences, of the TNF ligand family members may be obtained from publically accessible databases such as Uniprot. For instance, the human TNF ligands have the following amino acid sequences: human Lymphotoxin α (UniProt accession no. P01374, SEQ ID NO:34), human TNF (UniProt accession no. P01375, SEQ ID NO:35), human Lymphotoxin β (UniProt accession no. Q06643, SEQ ID NO:36), human OX40L (UniProt accession no. P23510, SEQ ID NO:37), human CD40L (UniProt accession no. P29965, SEQ ID NO:38), human FasL (UniProt accession no. P48023, SEQ ID NO:39), human CD27L (UniProt accession no. P32970, SEQ ID NO:40), human CD30L (UniProt accession no. P32971, SEQ ID NO:41), 4-1BBL (UniProt accession no. P41273, SEQ ID NO:42), TRAIL (UniProt accession no. P50591, SEQ ID NO:43), RANKL (UniProt accession no. 014788, SEQ ID NO:44), TWEAK (UniProt accession no. 043508, SEQ ID NO:45), APRIL (UniProt accession no. 075888, SEQ ID NO:46), BAFF (UniProt accession no. Q9Y275, SEQ ID NO:47), LIGHT (UniProt accession no. 043557, SEQ ID NO:48), TL1A (UniProt accession no. 095150, SEQ ID NO:49), GITRL (UniProt accession no. Q9UNG2, SEQ ID NO:50) and ectodysplasin A (UniProt accession no. Q92838, SEQ ID NO:51).


An “ectodomain” is the domain of a membrane protein that extends into the extracellular space (i.e. the space outside the target cell). Ectodomains are usually the parts of proteins that initiate contact with surfaces, which leads to signal transduction. The ectodomain of TNF ligand family member as defined herein thus refers to the part of the TNF ligand protein that extends into the extracellular space (the extracellular domain), but also includes shorter parts or fragments thereof that are responsible for the trimerization and for the binding to the corresponding TNF receptor. The term “ectodomain of a TNF ligand family member or a fragment thereof” thus refers to the extracellular domain of the TNF ligand family member that forms the extracellular domain or to parts thereof that are still able to bind to the receptor (receptor binding domain).


The term “costimulatory TNF ligand family member” or “costimulatory TNF family ligand” refers to a subgroup of TNF ligand family members, which are able to costimulate proliferation and cytokine production of T-cells. These TNF family ligands can costimulate TCR signals upon interaction with their corresponding TNF receptors and the interaction with their receptors leads to recruitment of TNFR-associated factors (TRAF), which initiate signalling cascades that result in T-cell activation. Costimulatory TNF family ligands are selected from the group consisting of 4-1BBL, OX40L, GITRL, CD70, CD30L and LIGHT, more particularly the costimulatory TNF ligand family member is selected from 4-1BBL and OX40L.


As described herein before, 4-1BBL is a type II transmembrane protein and one member of the TNF ligand family. Complete or full length 4-1BBL having the amino acid sequence of SEQ ID NO:42 has been described to form trimers on the surface of cells. The formation of trimers is enabled by specific motives of the ectodomain of 4-1BBL. Said motives are designated herein as “trimerization region”. The amino acids 50-254 of the human 4-1BBL sequence (SEQ ID NO:52) form the extracellular domain of 4-1BBL, but even fragments thereof are able to form the trimers. In specific embodiments of the invention, the term “ectodomain of 4-1BBL or a fragment thereof” refers to a polypeptide having an amino acid sequence selected from SEQ ID NO:4 (amino acids 52-254 of human 4-1BBL), SEQ ID NO:1 (amino acids 71-254 of human 4-1BBL), SEQ ID NO:3 (amino acids 80-254 of human 4-1BBL) and SEQ ID NO:2 (amino acids 85-254 of human 4-1BBL) or a polypeptide having an amino acid sequence selected from SEQ ID NO:96 (amino acids 71-248 of human 4-1BBL), SEQ ID NO:375 (amino acids 52-248 of human 4-1BBL), SEQ ID NO:374 (amino acids 80-248 of human 4-1BBL) and SEQ ID NO:373 (amino acids 85-248 of human 4-1BBL), but also other fragments of the ectodomain capable of trimerization are included herein.


As described herein before, OX40L is another type II transmembrane protein and a further member of the TNF ligand family. Complete or full length human OX40L has the amino acid sequence of SEQ ID NO:37. The amino acids 51-183 of the human OX40L sequence (SEQ ID NO:53) form the extracellular domain of OX40L, but even fragments thereof that are able to form the trimers. In specific embodiments of the invention, the term “ectodomain of OX40L or a fragment thereof” refers to a polypeptide having an amino acid sequence selected from SEQ ID NO:53 (amino acids 51-183 of human OX40L) or SEQ ID NO:54 (amino acids 52-183 of human OX40L), but also other fragments of the ectodomain capable of trimerization are included herein.


The term “peptide linker” refers to a peptide comprising one or more amino acids, typically about 2 to 20 amino acids. Peptide linkers are known in the art or are described herein. Suitable, non-immunogenic linker peptides are, for example, (G4S)n (SEQ ID NO: 390), (SG4)n (SEQ ID NO: 391) or G4(SG4)n (SEQ ID NO: 392) peptide linkers, wherein “n” is generally a number between 1 and 10, typically between 1 and 4, in particular 2, i.e. the peptides selected from the group consisting of GGGGS (SEQ ID NO:128), GGGGSGGGGS (SEQ ID NO:13), SGGGGSGGGG (SEQ ID NO:55) and GGGGSGGGGSGGGG (SEQ ID NO:56), but also include the sequences GSPGSSSSGS (SEQ ID NO:57), GSGSGSGS (SEQ ID NO:394), GSGSGNGS (SEQ ID NO:59), GGSGSGSG (SEQ ID NO:60), GGSGSG (SEQ ID NO:61), GGSG (SEQ ID NO:62), GGSGNGSG (SEQ ID NO:63), GGNGSGSG (SEQ ID NO:64) and GGNGSG (SEQ ID NO:65). Peptide linkers of particular interest are (G4S)1 or GGGGS (SEQ ID NO:128), (G4S)2 or GGGGSGGGGS (SEQ ID NO:13) and GSPGSSSSGS (SEQ ID NO:57), more particularly (G4S)2 or GGGGSGGGGS (SEQ ID NO:13) and GSPGSSSSGS (SEQ ID NO:57).


The term “amino acid” as used within this application denotes the group of naturally occurring carboxy α-amino acids comprising alanine (three letter code: ala, one letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine (cys, C), glutamine (gln, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y), and valine (val, V).


A “single chain fusion protein” as used herein refers to a single chain polypeptide composed of one or two ectodomains of said TNF ligand family member fused to a part of antigen binding moiety or Fc part. The fusion may occur by directly linking the N or C-terminal amino acid of the antigen binding moiety via a peptide linker to the C- or N-terminal amino acid of the ectodomain of said TNF ligand family member.


By “fused” or “connected” is meant that the components (e.g. a polypeptide and an ectodomain of said TNF ligand family member) are linked by peptide bonds, either directly or via one or more peptide linkers.


“Percent (%) amino acid sequence identity” with respect to a reference polypeptide (protein) sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN. SAWI or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, Calif., or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary. In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:





100times the fraction X/Y


where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.


In certain embodiments, amino acid sequence variants of the TNF ligand trimer-containing antigen binding molecules provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the TNF ligand trimer-containing antigen binding molecules. Amino acid sequence variants of the TNF ligand trimer-containing antigen binding molecules may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the molecules, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding. Sites of interest for substitutional mutagenesis include the HVRs and Framework (FRs). Conservative substitutions are provided in Table B under the heading “Preferred Substitutions” and further described below in reference to amino acid side chain classes (1) to (6). Amino acid substitutions may be introduced into the molecule of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.













TABLE B







Original
Exemplary
Preferred



Residue
Substitutions
Substitutions









Ala (A)
Val; Leu; Ile
Val



Arg (R)
Lys; Gln; Asn
Lys



Asn (N)
Gln; His; Asp, Lys; Arg
Gln



Asp (D)
Glu; Asn
Glu



Cys (C)
Ser; Ala
Ser



Gln (Q)
Asn; Glu
Asn



Glu (E)
Asp; Gln
Asp



Gly (G)
Ala
Ala



His (H)
Asn; Gln; Lys; Arg
Arg



Ile (I)
Leu; Val; Met; Ala; Phe; Norleucine
Leu



Leu (L)
Norleucine; Ile; Val; Met; Ala; Phe
Ile



Lys (K)
Arg; Gln; Asn
Arg



Met (M)
Leu; Phe; Ile
Leu



Phe (F)
Trp; Leu; Val; Ile; Ala; Tyr
Tyr



Pro (P)
Ala
Ala



Ser (S)
Thr
Thr



Thr (T)
Val; Ser
Ser



Trp (W)
Tyr; Phe
Tyr



Tyr (Y)
Trp; Phe; Thr; Ser
Phe



Val (V)
Ile; Leu; Met; Phe; Ala; Norleucine
Leu










Amino acids may be grouped according to common side-chain properties:

    • (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;
    • (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
    • (3) acidic: Asp, Glu;
    • (4) basic: His, Lys, Arg;
    • (5) residues that influence chain orientation: Gly, Pro;
    • (6) aromatic: Trp, Tyr, Phe.


Non-conservative substitutions will entail exchanging a member of one of these classes for another class.


The term “amino acid sequence variants” includes substantial variants wherein there are amino acid substitutions in one or more hypervariable region residues of a parent antigen binding molecule (e.g. a humanized or human antibody). Generally, the resulting variant(s) selected for further study will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antigen binding molecule and/or will have substantially retained certain biological properties of the parent antigen binding molecule. An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, e.g., using phage display-based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and the variant antigen binding molecules displayed on phage and screened for a particular biological activity (e.g. binding affinity). In certain embodiments, substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antigen binding molecule to bind antigen. For example, conservative alterations (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs. A useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called “alanine scanning mutagenesis” as described by Cunningham and Wells (1989) Science, 244:1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) are identified and replaced by a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with antigen is affected. Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions. Alternatively, or additionally, a crystal structure of an antigen-antigen binding molecule complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the desired properties.


Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include TNF family ligand trimer-containing antigen binding molecule with an N-terminal methionyl residue. Other insertional variants of the molecule include the fusion to the N- or C-terminus to a polypeptide which increases the serum half-life of the TNF ligand trimer-containing antigen binding molecules.


In certain embodiments, the TNF family ligand trimer-containing antigen binding molecules provided herein are altered to increase or decrease the extent to which the antibody is glycosylated. Glycosylation variants of the molecules may be conveniently obtained by altering the amino acid sequence such that one or more glycosylation sites is created or removed. Where the TNF ligand trimer-containing antigen binding molecule comprises an Fc region, the carbohydrate attached thereto may be altered. Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al. TIBTECH 15:26-32 (1997). The oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the “stem” of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharide in TNF family ligand trimer-containing antigen binding molecule may be made in order to create variants with certain improved properties. In one aspect, variants of TNF family ligand trimer-containing antigen binding molecules are provided having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region. Such fucosylation variants may have improved ADCC function, see e.g. US Patent Publication Nos. US 2003/0157108 (Presta, L.) or US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd). Further variants of the TNF family ligand trimer-containing antigen binding molecules of the invention include those with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region is bisected by GlcNAc. Such variants may have reduced fucosylation and/or improved ADCC function, see for example WO 2003/011878 (Jean-Mairet et al.); U.S. Pat. No. 6,602,684 (Umana et al.); and US 2005/0123546 (Umana et al., U.S. Pat. No. 9,296,820B2). Variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function and are described, e.g., in WO 1997/30087 (Patel et al.); WO 1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.).


In certain embodiments, it may be desirable to create cysteine engineered variants of the TNF family ligand trimer-containing antigen binding molecule of the invention, e.g., “thioMAbs,” in which one or more residues of the molecule are substituted with cysteine residues. In particular embodiments, the substituted residues occur at accessible sites of the molecule. By substituting those residues with cysteine, reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate. In certain embodiments, any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and 5400 (EU numbering) of the heavy chain Fc region. Cysteine engineered antigen binding molecules may be generated as described, e.g., in U.S. Pat. No. 7,521,541.


In certain aspects, the TNF family ligand trimer-containing antigen binding molecules provided herein may be further modified to contain additional non-proteinaceous moieties that are known in the art and readily available. The moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers. Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, prolypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight, and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the bispecific antibody derivative will be used in a therapy under defined conditions, etc. In another aspect, conjugates of an antibody and non-proteinaceous moiety that may be selectively heated by exposure to radiation are provided. In one embodiment, the non-proteinaceous moiety is a carbon nanotube (Kam, N. W. et al., Proc. Natl. Acad. Sci. USA 102 (2005) 11600-11605). The radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the non-proteinaceous moiety to a temperature at which cells proximal to the antibody-non-proteinaceous moiety are killed.


In another aspect, immunoconjugates of the TNF family ligand trimer-containing antigen binding molecules provided herein maybe obtained. An “immunoconjugate” is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.


The term “polynucleotide” refers to an isolated nucleic acid molecule or construct, e.g. messenger RNA (mRNA), virally-derived RNA, or plasmid DNA (pDNA). A polynucleotide may comprise a conventional phosphodiester bond or a non-conventional bond (e.g. an amide bond, such as found in peptide nucleic acids (PNA). The term “nucleic acid molecule” refers to any one or more nucleic acid segments, e.g. DNA or RNA fragments, present in a polynucleotide.


By “isolated” nucleic acid molecule or polynucleotide is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, a recombinant polynucleotide encoding a polypeptide contained in a vector is considered isolated for the purposes of the present invention. Further examples of an isolated polynucleotide include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution. An isolated polynucleotide includes a polynucleotide molecule contained in cells that ordinarily contain the polynucleotide molecule, but the polynucleotide molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the present invention, as well as positive and negative strand forms, and double-stranded forms. Isolated polynucleotides or nucleic acids according to the present invention further include such molecules produced synthetically. In addition, a polynucleotide or a nucleic acid may be or may include a regulatory element such as a promoter, ribosome binding site, or a transcription terminator.


By a nucleic acid or polynucleotide having a nucleotide sequence at least, for example, 95% “identical” to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the 5′ or 3′ terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence. As a practical matter, whether any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs, such as the ones discussed above for polypeptides (e.g. ALIGN-2).


The term “expression cassette” refers to a polynucleotide generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a target cell. The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid sequence to be transcribed and a promoter. In certain embodiments, the expression cassette of the invention comprises polynucleotide sequences that encode bispecific antigen binding molecules of the invention or fragments thereof.


The term “vector” or “expression vector” is synonymous with “expression construct” and refers to a DNA molecule that is used to introduce and direct the expression of a specific gene to which it is operably associated in a target cell. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. The expression vector of the present invention comprises an expression cassette. Expression vectors allow transcription of large amounts of stable mRNA. Once the expression vector is inside the target cell, the ribonucleic acid molecule or protein that is encoded by the gene is produced by the cellular transcription and/or translation machinery. In one embodiment, the expression vector of the invention comprises an expression cassette that comprises polynucleotide sequences that encode bispecific antigen binding molecules of the invention or fragments thereof.


The terms “host cell”, “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein. A host cell is any type of cellular system that can be used to generate the bispecific antigen binding molecules of the present invention. Host cells include cultured cells, e.g. mammalian cultured cells, such as CHO cells, BHK cells, NS0 cells, SP2/0 cells, Y0 myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, yeast cells, insect cells, and plant cells, to name only a few, but also cells comprised within a transgenic animal, transgenic plant or cultured plant or animal tissue.


An “effective amount” of an agent refers to the amount that is necessary to result in a physiological change in the cell or tissue to which it is administered.


A “therapeutically effective amount” of an agent, e.g. a pharmaceutical composition, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result. A therapeutically effective amount of an agent for example eliminates, decreases, delays, minimizes or prevents adverse effects of a disease.


An “individual” or “subject” is a mammal. Mammals include, but are not limited to, domesticated animals (e.g. cows, sheep, cats, dogs, and horses), primates (e.g. humans and non-human primates such as monkeys), rabbits, and rodents (e.g. mice and rats). Particularly, the individual or subject is a human.


The term “pharmaceutical composition” refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.


A “pharmaceutically acceptable excipient” refers to an ingredient in a pharmaceutical composition, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable excipient includes, but is not limited to, a buffer, a stabilizer, or a preservative.


The term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.


As used herein, “treatment” (and grammatical variations thereof such as “treat” or “treating”) refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, the molecules of the invention are used to delay development of a disease or to slow the progression of a disease.


The term “cancer” as used herein refers to proliferative diseases, such as lymphomas, carcinoma, lymphoma, blastoma, sarcoma, leukemia, lymphocytic leukemias, lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colorectal cancer (CRC), pancreatic cancer, breast cancer, triple-negative breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, mesothelioma, hepatocellular cancer, biliary cancer, neoplasms of the central nervous system (CNS), spinal axis tumors, brain stem glioma, glioblastoma multiforme, astrocytomas, schwanomas, ependymonas, medulloblastomas, meningiomas, squamous cell carcinomas, pituitary adenoma and Ewings sarcoma, melanoma, multiple myeloma, B-cell cancer (lymphoma), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, chronic myeloblastic leukemia, including refractory versions of any of the above cancers, or a combination of one or more of the above cancers.


TNF Family Ligand Trimer-Containing Antigen Binding Molecules of the Invention


The invention provides novel TNF family ligand trimer-containing antigen binding molecules with particularly advantageous properties such as producibility, stability, binding affinity, biological activity, targeting efficiency and reduced toxicity.


In a first aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising


(a) at least one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.


In a particular aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising


(a) at least one moiety capable of specific binding to a target cell antigen,


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof, and


(c) an Fc domain composed of a first and a second subunit capable of stable association.


In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule comprises (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof, wherein the TNF ligand family member is costimulates human T-cell activation.


In another particular aspect, the TNF family ligand trimer-containing antigen binding molecule comprises (a) at least one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof, wherein the ectodomains of a TNF ligand family member are identical in all instances.


In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule of claim 1, comprising


(a) at least one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that

    • (i) the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, respectively, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain, and wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the CH1 or CL domain by a peptide linker and wherein the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to the CL or CH1 domain of said polypeptide, or
    • (ii) the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, respectively, and wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the C-terminus of the CH3 domain by a peptide linker and wherein the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to C-terminus of the CH3 domain of said polypeptide, or
    • (iii) the first polypeptide contains a VH-CL or a VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, respectively, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain, and wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to to VH or VL by a peptide linker and wherein the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to VL or VH of said polypeptide.
    • In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule comprises a TNF ligand family member that costimulates human T-cell activation which is selected from 4-1BBL and OX40L. More particularly, the TNF ligand family member is 4-1BBL.
    • In another aspect, wherein the ectodomain of a TNF ligand family member comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:96, SEQ ID NO: 373, SEQ ID NO:374 and SEQ ID NO:375, particularly the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:96. In one aspect, the ectodomain of a TNF ligand family member or fragment thereof comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:96, particularly the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:96. In a particular aspect, the ectodomain of a TNF ligand family member or fragment thereof comprises the amino acid sequence of SEQ ID NO:96.


In a further aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99 and in that the second polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4. In a particular aspect, the first polypeptide comprises the amino acid sequence of SEQ ID NO:97 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:96.


In one aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence of SEQ ID NO:5 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:6.


In a further aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence of SEQ ID NO:5 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:183.


In yet a further aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence of SEQ ID NO:97 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:184 or SEQ ID NO:185.


In another aspect, the TNF ligand family member is OX40L. In a particular aspect, provided is TNF family ligand trimer-containing antigen binding molecule, wherein the ectodomain of a TNF ligand family member comprises the amino acid sequence of SEQ ID NO:53 or SEQ ID NO:54, particularly the amino acid sequence of SEQ ID NO:53.


In one aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule comprising


(a) at least one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence of SEQ ID NO:371 or SEQ ID:372 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:53 or SEQ ID NO:54, respectively.


In one aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen,


(b) a first polypeptide containing a CH1 or CL domain and a second polypeptide containing a CL or CH1 domain, respectively, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain,


and wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the CH1 or CL domain by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to the CL or CH1 domain of said polypeptide.


In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule comprising


(a) at least one moiety capable of specific binding to a target cell antigen,


(b) a first polypeptide containing a CH1 domain and a second polypeptide containing a CL domain, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain,


and wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the CH1 domain by a peptide linker and in that the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to the CL domain of said polypeptide.


In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule comprising


(a) at least one moiety capable of specific binding to a target cell antigen,


(b) a first polypeptide containing a CL domain and a second polypeptide containing a CH1 domain, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 and CL domain,


and wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the CL domain by a peptide linker and in that the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to the CH1 domain of said polypeptide.


In another aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising


(a) one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.


In yet another aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising


(a) more than one moiety capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to said polypeptide.


In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising


(a) two moities capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.


In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, comprising


(a) at least one moiety capable of specific binding to a target cell antigen, and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, respectively, and wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the C-terminus of the CH3 domain by a peptide linker and wherein the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to C-terminus of the CH3 domain of said polypeptide. Particularly, such TNF family ligand trimer-containing antigen binding molecule comprises two moieties capable of specific binding to a target cell antigen.


In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising


(a) two moities capable of specific binding to a target cell antigen and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof,


wherein the two moieties capable of specific binding to a target cell antigen bind to two different target cell antigens.


In a further aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule as defined herein before, wherein the moiety capable of specific binding to a target cell antigen is selected from the group consisting of an antibody, an antibody fragment and a scaffold antigen binding protein.


In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule as described herein before, wherein the moiety capable of specific binding to a target cell antigen is selected from the group consisting of an antibody fragment, a Fab molecule, a crossover Fab molecule, a single chain Fab molecule, a Fv molecule, a scFv molecule, a single domain antibody, an aVH and a scaffold antigen binding protein. In one aspect, the moiety capable of specific binding to a target cell antigen is an aVH or a scaffold antigen binding protein. In one aspect, the moiety capable of specific binding to a target cell antigen is a scaffold antigen binding protein capable of specific binding to a target cell antigen.


In particular, the TNF family ligand trimer-containing antigen binding molecule comprises one or two moieties capable of specific binding to a target cell antigen.


In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to a target cell antigen is a Fab molecule or a crossover Fab molecule capable of specific binding to a target cell antigen. In particular, the moiety capable of specific binding to a target cell antigen is a Fab capable of specific binding to a target cell antigen.


Furthermore, provided is TNF family ligand trimer-containing antigen binding molecule as described herein, wherein the target cell antigen is selected from the group consisting of Fibroblast Activation Protein (FAP), Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), Epidermal Growth Factor Receptor (EGFR), Carcinoembryonic Antigen (CEA), CD19, CD20 and CD33.


In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule according to the invention, wherein a peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus to the CH1 domain of a heavy chain by a second peptide linker and wherein one ectodomain of said TNF ligand family member or a fragment thereof is fused at the its C-terminus to the CL domain on a light chain by a third peptide linker.


In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule according to the invention, wherein a peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus to the CL domain of a heavy chain by a second peptide linker and wherein one ectodomain of said TNF ligand family member or a fragment thereof is fused at the its C-terminus to the CH1 domain on a light chain by a third peptide linker.


In a further aspect, the invention is concerned with a TNF family ligand trimer-containing antigen binding molecule according to the invention, wherein a peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus to the CL domain of a light chain by a second peptide linker and wherein one ectodomain of said TNF ligand family member or a fragment thereof is fused at the its C-terminus to the CH1 domain of the heavy chain by a third peptide linker.


In a particular aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule as defined above, wherein the peptide linker is (G4S)2 (SEQ ID NO:13). In one aspect, the first peptide linker is (G4S)2 (SEQ ID NO:13), the second peptide linker is GSPGSSSSGS (SEQ ID NO:57) and the third peptide linker is (G4S)2 (SEQ ID NO:13). In particular, the invention relates to a TNF ligand trimer-containing antigen binding molecule as defined above, wherein the first peptide linker is (G4S)2 (SEQ ID NO:13), the second peptide linker is (G4S)2 (SEQ ID NO:13), and the third peptide linker is (G4S)2 (SEQ ID NO:13).


In another aspect, the TNF family ligand trimer-containing antigen binding molecule as defined herein before comprises an Fc domain composed of a first and a second subunit capable of stable association.


In particular, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises (a) a Fab molecule capable of specific binding to a target cell antigen, wherein the Fab heavy chain is fused at the C-terminus to the N-terminus of a CH2 domain in the Fc domain and (c) an Fc domain composed of a first and a second subunit capable of stable association.


In a further aspect, the Fc domain is an IgG, particularly an IgG1 Fc domain or an IgG4 Fc domain. More particularly, the Fc domain is an IgG1 Fc domain. In a particular aspect, the Fc domain comprises a modification promoting the association of the first and second subunit of the Fc domain.


Fc Domain Modifications Reducing Fc Receptor Binding and/or Effector Function


The Fc domain of the TNF family ligand trimer-containing antigen binding molecules of the invention consists of a pair of polypeptide chains comprising heavy chain domains of an immunoglobulin molecule. For example, the Fc domain of an immunoglobulin G (IgG) molecule is a dimer, each subunit of which comprises the CH2 and CH3 IgG heavy chain constant domains. The two subunits of the Fc domain are capable of stable association with each other.


The Fc domain confers favorable pharmacokinetic properties to the antigen binding molecules of the invention, including a long serum half-life which contributes to good accumulation in the target tissue and a favorable tissue-blood distribution ratio. At the same time it may, however, lead to undesirable targeting of the bispecific antibodies of the invention to cells expressing Fc receptors rather than to the preferred antigen-bearing cells. Accordingly, in particular aspects, the Fc domain of the TNF family ligand trimer-containing antigen binding molecule of the invention exhibits reduced binding affinity to an Fc receptor and/or reduced effector function, as compared to a native IgG1 Fc domain. In one aspect, the Fc does not substantially bind to an Fc receptor and/or does not induce effector function. In a particular aspect the Fc receptor is an Fcγ receptor. In one aspect, the Fc receptor is a human Fc receptor.


In a specific aspect, the Fc receptor is an activating human Fcγ receptor, more specifically human FcγRIIIa, FcγRI or FcγRIIa, most specifically human FcγRIIIa. In one aspect, the Fc domain does not induce effector function. The reduced effector function can include, but is not limited to, one or more of the following: reduced complement dependent cytotoxicity (CDC), reduced antibody-dependent cell-mediated cytotoxicity (ADCC), reduced antibody-dependent cellular phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex-mediated antigen uptake by antigen-presenting cells, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling inducing apoptosis, reduced dendritic cell maturation, or reduced T cell priming.


In certain aspects, one or more amino acid modifications may be introduced into the Fc region of a TNF family ligand trimer-containing antigen binding molecule provided herein, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g. a substitution) at one or more amino acid positions.


In a particular aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising


(a) at least one moiety capable of specific binding to a target cell antigen,


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof, and


(c) an Fc domain composed of a first and a second subunit capable of stable association, wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor, in particular towards Fcγ receptor.


In one aspect, the Fc domain of the TNF family ligand trimer-containing antigen binding molecule of the invention comprises one or more amino acid mutation that reduces the binding affinity of the Fc domain to an Fc receptor and/or effector function. Typically, the same one or more amino acid mutation is present in each of the two subunits of the Fc domain. In particular, the Fc domain comprises an amino acid substitution at a position of E233, L234, L235, N297, P331 and P329 (EU numbering). In particular, the Fc domain comprises amino acid substitutions at positions 234 and 235 (EU numbering) and/or 329 (EU numbering) of the IgG heavy chains. More particularly, provided is a trimeric TNF family ligand-containing antigen binding molecule according to the invention which comprises an Fc domain with the amino acid substitutions L234A, L235A and P329G (“P329G LALA”, EU numbering) in the IgG heavy chains. The amino acid substitutions L234A and L235A refer to the so-called LALA mutation. The “P329G LALA” combination of amino acid substitutions almost completely abolishes Fcγ receptor binding of a human IgG1 Fc domain and is described in International Patent Appl. Publ. No. WO 2012/130831 A1 which also describes methods of preparing such mutant Fc domains and methods for determining its properties such as Fc receptor binding or effector functions. “EU numbering” refers to the numbering according to EU index of Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.


Fc domains with reduced Fc receptor binding and/or effector function also include those with substitution of one or more of Fc domain residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Pat. No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called “DANA” Fc mutant with substitution of residues 265 and 297 to alanine (U.S. Pat. No. 7,332,581).


In another aspect, the Fc domain is an IgG4 Fc domain. IgG4 antibodies exhibit reduced binding affinity to Fc receptors and reduced effector functions as compared to IgG1 antibodies. In a more specific aspect, the Fc domain is an IgG4 Fc domain comprising an amino acid substitution at position 5228 (Kabat numbering), particularly the amino acid substitution S228P. In a more specific aspect, the Fc domain is an IgG4 Fc domain comprising amino acid substitutions L235E and S228P and P329G (EU numbering). Such IgG4 Fc domain mutants and their Fcγ receptor binding properties are also described in WO 2012/130831.


Mutant Fc domains can be prepared by amino acid deletion, substitution, insertion or modification using genetic or chemical methods well known in the art. Genetic methods may include site-specific mutagenesis of the encoding DNA sequence, PCR, gene synthesis, and the like. The correct nucleotide changes can be verified for example by sequencing.


Binding to Fc receptors can be easily determined e.g. by ELISA, or by Surface Plasmon Resonance (SPR) using standard instrumentation such as a BIACORE® instrument (GE Healthcare), and Fc receptors such as may be obtained by recombinant expression. A suitable such binding assay is described herein. Alternatively, binding affinity of Fc domains or cell activating bispecific antigen binding molecules comprising an Fc domain for Fc receptors may be evaluated using cell lines known to express particular Fc receptors, such as human NK cells expressing FcγIIIa receptor.


Effector function of an Fc domain, or bispecific antibodies of the invention comprising an Fc domain, can be measured by methods known in the art. A suitable assay for measuring ADCC is described herein. Other examples of in vitro assays to assess ADCC activity of a molecule of interest are described in U.S. Pat. No. 5,500,362; Hellstrom et al. Proc Natl Acad Sci USA 83, 7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA 82, 1499-1502 (1985); U.S. Pat. No. 5,821,337; Bruggemann et al., J Exp Med 166, 1351-1361 (1987). Alternatively, non-radioactive assays methods may be employed (see, for example, ACTI™ non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, Calif.); and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, Wis.)). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g. in a animal model such as that disclosed in Clynes et al., Proc Natl Acad Sci USA 95, 652-656 (1998).


In some embodiments, binding of the Fc domain to a complement component, specifically to C1q, is reduced. Accordingly, in some embodiments wherein the Fc domain is engineered to have reduced effector function, said reduced effector function includes reduced CDC. C1q binding assays may be carried out to determine whether the bispecific antibodies of the invention is able to bind C1q and hence has CDC activity. See e.g., C1q and C3c binding ELISA in WO 2006/029879 and WO 2005/100402. To assess complement activation, a CDC assay may be performed (see, for example, Gazzano-Santoro et al., J Immunol Methods 202, 163 (1996); Cragg et al., Blood 101, 1045-1052 (2003); and Cragg and Glennie, Blood 103, 2738-2743 (2004)).


In a particular aspect, the Fc domain comprises a modification promoting the association of the first and second subunit of the Fc domain.


Fc Domain Modifications Promoting Heterodimerization


In one aspect, the TNF family ligand trimer-containing antigen binding molecules of the invention comprise (a) at least one moiety capable of specific binding to a target cell antigen, (b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof, and (c) an Fc domain composed of a first and a second subunit capable of stable association, wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor, in particular towards Fcγ receptor. Thus, they comprise different moieties, fused to one or the other of the two subunits of the Fc domain that are typically comprised in two non-identical polypetide chains (“heavy chains”). Recombinant co-expression of these polypeptides and subsequent dimerization leads to several possible combinations of the two polypeptides. To improve the yield and purity of the TNF family ligand trimer-containing antigen binding molecules in recombinant production, it will thus be advantageous to introduce in the Fc domain of the TNF family ligand trimer-containing antigen binding molecules of the invention a modification promoting the association of the desired polypeptides.


Accordingly, the Fc domain of the TNF family ligand trimer-containing antigen binding molecules of the invention comprises a modification promoting the association of the first and the second subunit of the Fc domain. The site of most extensive protein-protein interaction between the two subunits of a human IgG Fc domain is in the CH3 domain of the Fc domain. Thus, said modification is particularly in the CH3 domain of the Fc domain.


In a specific aspect, said modification is a so-called “knob-into-hole” modification, comprising a “knob” modification in one of the two subunits of the Fc domain and a “hole” modification in the other one of the two subunits of the Fc domain. Thus, in a particular aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule as described herein before which comprises an IgG molecule, wherein the Fc part of the first heavy chain comprises a first dimerization module and the Fc part of the second heavy chain comprises a second dimerization module allowing a heterodimerization of the two heavy chains of the IgG molecule and the first dimerization module comprises knobs and the second dimerization module comprises holes according to the knob into hole technology.


The knob-into-hole technology is described e.g. in U.S. Pat. Nos. 5,731,168; 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001). Generally, the method involves introducing a protuberance (“knob”) at the interface of a first polypeptide and a corresponding cavity (“hole”) in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heterodimer formation and hinder homodimer formation. Protuberances are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory cavities of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine).


Accordingly, in a particular aspect, in the CH3 domain of the first subunit of the Fc domain of the TNF family ligand trimer-containing antigen binding molecules of the invention an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the CH3 domain of the first subunit which is positionable in a cavity within the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the CH3 domain of the second subunit within which the protuberance within the CH3 domain of the first subunit is positionable.


The protuberance and cavity can be made by altering the nucleic acid encoding the polypeptides, e.g. by site-specific mutagenesis, or by peptide synthesis.


In a specific aspect, in the CH3 domain of the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W), and in the CH3 domain of the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V). More particularly, in the second subunit of the Fc domain additionally the threonine residue at position 366 is replaced with a serine residue (T366S) and the leucine residue at position 368 is replaced with an alanine residue (L368A). More particularly, in the first subunit of the Fc domain additionally the serine residue at position 354 is replaced with a cysteine residue (S354C), and in the second subunit of the Fc domain additionally the tyrosine residue at position 349 is replaced by a cysteine residue (Y349C). The introduction of these two cysteine residues results in the formation of a disulfide bridge between the two subunits of the Fc domain. The disulfide bridge further stabilizes the dimer (Carter, J Immunol Methods 248, 7-15 (2001)).


In an alternative aspect, a modification promoting association of the first and the second subunit of the Fc domain comprises a modification mediating electrostatic steering effects, e.g. as described in PCT publication WO 2009/089004. Generally, this method involves replacement of one or more amino acid residues at the interface of the two Fc domain subunits by charged amino acid residues so that homodimer formation becomes electrostatically unfavorable but heterodimerization electrostatically favorable.


Modifications in the CH1/CL Domains


To further improve correct pairing, the TNF family ligand trimer-containing antigen binding molecules can contain different charged amino acid substitutions (so-called “charged residues”). These modifications are introduced in the crossed or non-crossed CH1 and CL domains. In a particular aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule, wherein in one of CL domains the amino acid at position 123 (EU numbering) has been replaced by arginine (R) and the amino acid at position 124 (EU numbering) has been substituted by lysine (K) and wherein in one of the CH1 domains the the amino acids at position 147 (EU numbering) and at position 213 (EU numbering) have been substituted by glutamic acid (E).


More particularly, the invention relates to a TNF family ligand trimer-containing antigen binding molecule, wherein in the CL domain adjacent to the TNF ligand family member the amino acid at position 123 (EU numbering) has been replaced by arginine (R) and the amino acid at position 124 (EU numbering) has been substituted by lysine (K), and wherein in the CH1 domain adjacent to the TNF ligand family member the amino acids at position 147 (EU numbering) and at position 213 (EU numbering) have been substituted by glutamic acid (E).


Particular TNF Family Ligand Trimer-Containing Antigen Binding Molecules


In another aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises


a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen,


a first peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker fused at its C-terminus by a second peptide linker to a second heavy or light chain,


and a second peptide comprising one ectodomain of said TNF ligand family member fused at its C-terminus by a third peptide linker to a second light or heavy chain, respectively.


In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the first peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a CH1 domain that is part of a heavy chain, and the second peptide comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a CL domain that is part of a light chain.


In yet another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the first peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a CL domain that is part of a heavy chain, and the second peptide comprising one ectodomain of said TNF ligand family member or a fragment thereof that is fused at its C-terminus by a third peptide linker to a CH1 domain that is part of a light chain.


In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the first peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a VH domain that is part of a heavy chain, and the second peptide comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a VL domain that is part of a light chain.


In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule of claims 21 to 23, wherein in the CL domain adjacent to the TNF ligand family member the amino acid at position 123 (EU numbering) has been replaced by arginine (R) and the amino acid at position 124 (EU numbering) has been substituted by lysine (K), and wherein in the CH1 domain adjacent to the TNF ligand family member the amino acids at position 147 (EU numbering) and at position 213 (EU numbering) have been substituted by glutamic acid (E). These modifications lead to so-called charged residues with advantageous properties that avoid undesired effects such as for example mispairing.


Furthermore, provided is TNF family ligand trimer-containing antigen binding molecule as described herein, wherein the target cell antigen is selected from the group consisting of Fibroblast Activation Protein (FAP), Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), Epidermal Growth Factor Receptor (EGFR), Carcinoembryonic Antigen (CEA), CD19, CD20 and CD33.


TNF Family Ligand Trimer-Containing Antigen Binding Molecules, Wherein the Target Cell Antigen is FAP


In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the target cell antigen is Fibroblast Activation Protein (FAP).


In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to FAP comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:100, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:101, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:102, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:103, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11 or SEQ ID NO:104, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:105.


In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule of the invention, wherein the moiety capable of specific binding to a target cell antigen is a Fab molecule capable of specific binding to FAP and comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:7, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:8 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:9, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:10, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:12.


In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule of the invention, wherein the moiety capable of specific binding to a target cell antigen is a Fab molecule capable of specific binding to FAP and comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:100, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:101 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:102, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:103, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:104 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:105.


In a further aspect, the moiety capable of specific binding to FAP comprises a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:16 and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:17.


In another aspect, the moiety capable of specific binding to FAP comprises a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:106 and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:107.


In one aspect, the moiety capable of specific binding to FAP comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:16 and a variable light chain comprising an amino acid sequence of SEQ ID NO:17 or a variable heavy chain comprising an amino acid sequence of SEQ ID NO:106 and a variable light chain comprising an amino acid sequence of SEQ ID NO:107.


In a particular aspect, the moiety capable of specific binding to FAP comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:16 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:17. In another particular aspect, the moiety capable of specific binding to FAP comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:106 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:107. In a specific aspect, the moiety capable of specific binding to FAP comprises a VH domain consisting of amino acid sequence of SEQ ID NO:106 and a VL domain consisting of the amino acid sequence of SEQ ID NO:107.


In a further aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:16 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:17, and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99 and in that the second polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.


In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:16 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:17, and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the the amino acid sequence of SEQ ID NO:97 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:96.


In another aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:106 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:107, and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99 and in that the second polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.


In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:106 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:107, and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the the amino acid sequence of SEQ ID NO:97 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:96.


In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises


a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen,


a second heavy chain comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker that is fused at its C-terminus by a second peptide linker to a CH1 domain, and a second light chain comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a CL domain, and wherein the antigen binding molecule comprises


(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:16 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:17 or


a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:106 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:107,


(ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:108, SEQ ID NO:111 and SEQ ID NO:113, and


(iii) a second light chain comprising the amino acid sequence of SEQ ID NO:15, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:112 and SEQ ID NO:114.


In a further particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, and wherein the antigen binding molecule comprises


a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen,


a second heavy chain comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a CL domain, and a second light chain comprising one ectodomain of said TNF ligand family member or a fragment thereof that is fused at its C-terminus by a third peptide linker to a CH1 domain, and wherein the molecule comprises


(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:16 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:17 or


a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:106 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:107,


(ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119 and SEQ ID NO:173, and


(iii) a second light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120 and SEQ ID NO:174.


More particularly, provided is a TNF family ligand trimer-containing antigen binding molecule comprising


(a) a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen, wherein the first heavy chain comprises the VH domain comprising the amino acid sequence of SEQ ID NO:106 and the first light chain comprises the VL domain comprising the amino acid sequence of SEQ ID NO:107, and


(b) a second heavy chain comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a CL domain, and a second light chain comprising one ectodomain of said TNF ligand family member or a fragment thereof that is fused at its C-terminus by a third peptide linker to a CH1 domain, wherein the second heavy chain comprises the amino acid sequence of SEQ ID NO:119 or SEQ ID NO:173, and the second light chain comprises the amino acid sequence of SEQ ID NO:120 or SEQ ID NO:174. In particular, the second heavy chain comprises the amino acid sequence of SEQ ID NO:119 and the second light chain comprises the amino acid sequence of SEQ ID NO:120.


Furthermore, the invention provides a TNF family ligand trimer-containing antigen binding molecule, comprising


(a) at least one moiety capable of specific binding to a target cell antigen, and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, respectively, and wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the C-terminus of the CH3 domain by a peptide linker and wherein the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to C-terminus of the CH3 domain of said polypeptide.


In a particular aspect, such a TNF family ligand trimer-containing antigen binding molecule comprises two moieties capable of specific binding to a target cell antigen.


More particular, such TNF family ligand trimer-containing antigen binding molecule comprises


(i) a first heavy chain comprising the amino acid sequence of SEQ ID NO:121, a second heavy chain comprising the amino acid sequence of SEQ ID NO:122, and two light chains comprising the amino acid sequence of SEQ ID NO:19, or


(ii) a first heavy chain comprising the amino acid sequence of SEQ ID NO:123, a second heavy chain comprising the amino acid sequence of SEQ ID NO:124, and two light chains comprising the amino acid sequence of SEQ ID NO:125, or


(iii) a first heavy chain comprising the amino acid sequence of SEQ ID NO:126, a second heavy chain comprising the amino acid sequence of SEQ ID NO:127, and two light chains comprising the amino acid sequence of SEQ ID NO:125.


In a further aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule, selected from the group consisting of:


a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:18, a first light chain comprising the amino acid sequence of SEQ ID NO:19, a second heavy chain comprising the amino acid sequence of SEQ ID NO:14 and a second light chain comprising the amino acid sequence of SEQ ID NO:15;


b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:18, a first light chain comprising the amino acid sequence of SEQ ID NO:19, a second heavy chain comprising the amino acid sequence of SEQ ID NO:115 and a second light chain comprising the amino acid sequence of SEQ ID NO:116;


c) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:135, a first light chain comprising the amino acid sequence of SEQ ID NO:136, a second heavy chain comprising the amino acid sequence of SEQ ID NO:108 and a second light chain comprising the amino acid sequence of SEQ ID NO:109;


d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:18, a first light chain comprising the amino acid sequence of SEQ ID NO:19, a second heavy chain comprising the amino acid sequence of SEQ ID NO:139 and a second light chain comprising the amino acid sequence of SEQ ID NO:140;


e) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:19, a first heavy chain comprising the amino acid sequence of SEQ ID NO:121 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:122;


f) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:18, a first light chain comprising the amino acid sequence of SEQ ID NO:19, a second heavy chain comprising the amino acid sequence of SEQ ID NO:108 and a second light chain comprising the amino acid sequence of SEQ ID NO:110;


g) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:145, a first light chain comprising the amino acid sequence of SEQ ID NO:19, a second heavy chain comprising the amino acid sequence of SEQ ID NO:115 and a second light chain comprising the amino acid sequence of SEQ ID NO:116;


h) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:18, a first light chain comprising the amino acid sequence of SEQ ID NO:19, a second heavy chain comprising the amino acid sequence of SEQ ID NO:148 and a second light chain comprising the amino acid sequence of SEQ ID NO:149;


i) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:18, a first light chain comprising the amino acid sequence of SEQ ID NO:19, a second heavy chain comprising the amino acid sequence of SEQ ID NO:111 and a second light chain comprising the amino acid sequence of SEQ ID NO:112; and


j) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:18, a first light chain comprising the amino acid sequence of SEQ ID NO:19, a second heavy chain comprising the amino acid sequence of SEQ ID NO:113 and a second light chain comprising the amino acid sequence of SEQ ID NO:114.


In another aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule, selected from the group consisting of:


a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:164, a first light chain comprising the amino acid sequence of SEQ ID NO:125, a second heavy chain comprising the amino acid sequence of SEQ ID NO:115 and a second light chain comprising the amino acid sequence of SEQ ID NO:116;


b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:164, a first light chain comprising the amino acid sequence of SEQ ID NO:125, a second heavy chain comprising the amino acid sequence of SEQ ID NO:117 and a second light chain comprising the amino acid sequence of SEQ ID NO:118;


c) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:125, a first heavy chain comprising the amino acid sequence of SEQ ID NO:123 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:124;


d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:164, a first light chain comprising the amino acid sequence of SEQ ID NO:125, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119 and a second light chain comprising the amino acid sequence of SEQ ID NO:120;


e) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:164, a first light chain comprising the amino acid sequence of SEQ ID NO:125, a second heavy chain comprising the amino acid sequence of SEQ ID NO:173 and a second light chain comprising the amino acid sequence of SEQ ID NO:174; and


f) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:125, a first heavy chain comprising the amino acid sequence of SEQ ID NO:126 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:127.


In particular, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:164, a first light chain comprising the amino acid sequence of SEQ ID NO:125, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119 and a second light chain comprising the amino acid sequence of SEQ ID NO:120.


In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the TNF ligand family member is OX40L and wherein the target cell antigen is Fibroblast Activation Protein (FAP) and the moiety capable of specific binding to FAP comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:100, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:101, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:102, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:103, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:11 or SEQ ID NO:104, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:105.


In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule of comprises


(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:16 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:17 or


a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:106 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:107,


(ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:355, and


(iii) a second light chain comprising the amino acid sequence of SEQ ID NO:356.


TNF Family Ligand Trimer-Containing Antigen Binding Molecules, Wherein the Target Cell Antigen is CD19


In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the target cell antigen is CD19.


In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to CD19 comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:195 or SEQ ID NO:252, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:196 or SEQ ID NO:253, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:197 or SEQ ID NO:254, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:198 or SEQ ID NO:249, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:199 or SEQ ID NO:250, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:200 or SEQ ID NO:251.


In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule of the invention, wherein the moiety capable of specific binding to a target cell antigen is a Fab molecule capable of specific binding to CD19 and comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:195, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:196 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:197, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:198, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:199 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:200.


In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule of the invention, wherein the moiety capable of specific binding to a target cell antigen is a Fab molecule capable of specific binding to CD19 and comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:252, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:253 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:254, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:249, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:250 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:251.


In another aspect, the moiety capable of specific binding to CD19 comprises a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:201 and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:202.


In a further aspect, the moiety capable of specific binding to CD19 comprises a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:357 and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:358.


In one aspect, the moiety capable of specific binding to CD19 comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:201 and a variable light chain comprising an amino acid sequence of SEQ ID NO:202 or wherein the moiety capable of specific binding to CD19 comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:357 and a variable light chain comprising an amino acid sequence of SEQ ID NO:358.


In a particular aspect, the moiety capable of specific binding to CD19 comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:201 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:202. In another particular aspect, the moiety capable of specific binding to CD19 comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:357 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:358.


In another aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:201 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:202, and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99 and in that the second polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.


In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:201 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:202, and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the the amino acid sequence of SEQ ID NO:97 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:96.


In another aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:357 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:358, and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99 and in that the second polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.


In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:357 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:358, and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the the amino acid sequence of SEQ ID NO:97 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:96.


In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises


a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen,


a second heavy chain comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker that is fused at its C-terminus by a second peptide linker to a CH1 domain, and a second light chain comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a CL domain, and wherein the antigen binding molecule comprises


(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:201 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:202 or


a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:357 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:358,


(ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:108, SEQ ID NO:111 and SEQ ID NO:113, and


(iii) a second light chain comprising the amino acid sequence of SEQ ID NO:15, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:112 and SEQ ID NO:114.


In a further particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, and wherein the antigen binding molecule comprises


a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen,


a second heavy chain comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a CL domain, and a second light chain comprising one ectodomain of said TNF ligand family member or a fragment thereof that is fused at its C-terminus by a third peptide linker to a CH1 domain, and wherein the molecule comprises


(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:201 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:202 or


a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:357 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:358,


(ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119 and SEQ ID NO:173, and


(iii) a second light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120 and SEQ ID NO:174.


Furthermore, the invention provides a TNF family ligand trimer-containing antigen binding molecule, comprising


(a) at least one moiety capable of specific binding to a target cell antigen, and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, respectively, and wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the C-terminus of the CH3 domain by a peptide linker and wherein the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to C-terminus of the CH3 domain of said polypeptide.


In a particular aspect, such a TNF family ligand trimer-containing antigen binding molecule comprises two moieties capable of specific binding to a target cell antigen.


More particular, such TNF family ligand trimer-containing antigen binding molecule comprises


(i) a first heavy chain comprising the amino acid sequence of SEQ ID NO:209, a second heavy chain comprising the amino acid sequence of SEQ ID NO:210, and two light chains comprising the amino acid sequence of SEQ ID NO:206, or


(ii) a first heavy chain comprising the amino acid sequence of SEQ ID NO:213, a second heavy chain comprising the amino acid sequence of SEQ ID NO:214, and two light chains comprising the amino acid sequence of SEQ ID NO:206, or


(iii) a first heavy chain comprising the amino acid sequence of SEQ ID NO:309, a second heavy chain comprising the amino acid sequence of SEQ ID NO:310, and two light chains comprising the amino acid sequence of SEQ ID NO:279, or


(iv) a first heavy chain comprising the amino acid sequence of SEQ ID NO:313, a second heavy chain comprising the amino acid sequence of SEQ ID NO:314, and two light chains comprising the amino acid sequence of SEQ ID NO:279.


In a further aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule, selected from the group consisting of:


a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:205, a first light chain comprising the amino acid sequence of SEQ ID NO:206, a second heavy chain comprising the amino acid sequence of SEQ ID NO:115 and a second light chain comprising the amino acid sequence of SEQ ID NO:116;


b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:205, a first light chain comprising the amino acid sequence of SEQ ID NO:206, a second heavy chain comprising the amino acid sequence of SEQ ID NO:117 and a second light chain comprising the amino acid sequence of SEQ ID NO:118;


c) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:206, a first heavy chain comprising the amino acid sequence of SEQ ID NO:209 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:210;


d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:205, a first light chain comprising the amino acid sequence of SEQ ID NO:206, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119 and a second light chain comprising the amino acid sequence of SEQ ID NO:120;


e) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:205, a first light chain comprising the amino acid sequence of SEQ ID NO:206, a second heavy chain comprising the amino acid sequence of SEQ ID NO:173 and a second light chain comprising the amino acid sequence of SEQ ID NO:174; and


f) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:206, a first heavy chain comprising the amino acid sequence of SEQ ID NO:213 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:214.


In particular, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:205, a first light chain comprising the amino acid sequence of SEQ ID NO:206, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119 and a second light chain comprising the amino acid sequence of SEQ ID NO:120.


In another aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule, selected from the group consisting of:


a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:357, a first light chain comprising the amino acid sequence of SEQ ID NO:358, a second heavy chain comprising the amino acid sequence of SEQ ID NO:115 and a second light chain comprising the amino acid sequence of SEQ ID NO:116;


b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:357, a first light chain comprising the amino acid sequence of SEQ ID NO:358, a second heavy chain comprising the amino acid sequence of SEQ ID NO:117 and a second light chain comprising the amino acid sequence of SEQ ID NO:118;


c) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:358, a first heavy chain comprising the amino acid sequence of SEQ ID NO:209 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:210;


d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:357, a first light chain comprising the amino acid sequence of SEQ ID NO:358, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119 and a second light chain comprising the amino acid sequence of SEQ ID NO:120;


e) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:357, a first light chain comprising the amino acid sequence of SEQ ID NO:358, a second heavy chain comprising the amino acid sequence of SEQ ID NO:173 and a second light chain comprising the amino acid sequence of SEQ ID NO:174; and


f) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:358, a first heavy chain comprising the amino acid sequence of SEQ ID NO:213 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:214.


In particular, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:357, a first light chain comprising the amino acid sequence of SEQ ID NO:358, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119 and a second light chain comprising the amino acid sequence of SEQ ID NO:120.


TNF family ligand trimer-containing antigen binding molecules, wherein the target cell antigen is CEA.


In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the target cell antigen is CEA.


In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule, wherein the moiety capable of specific binding to CD19 comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:321, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:322, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:323, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:324, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:325, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:326.


In a particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule of the invention, wherein the moiety capable of specific binding to a target cell antigen is a Fab molecule capable of specific binding to CEA and comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:321, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:322 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:323, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:324, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:325 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:326.


In a further aspect, the moiety capable of specific binding to CEA comprises a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:327 and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:328.


In one aspect, the moiety capable of specific binding to CEA comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:327 and a variable light chain comprising an amino acid sequence of SEQ ID NO:328.


In a further aspect, the moiety capable of specific binding to CEA comprises a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:329 and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:330.


In one aspect, the moiety capable of specific binding to CEA comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO:329 and a variable light chain comprising an amino acid sequence of SEQ ID NO:330.


In another aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:329 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:330, and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99 and in that the second polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4.


In a particular aspect, the TNF family ligand trimer-containing antigen binding molecule of the invention comprises


(a) at least one moiety capable of specific binding to a target cell antigen comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:329 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:330, and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide comprises the the amino acid sequence of SEQ ID NO:97 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:96.


In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, wherein the antigen binding molecule comprises


a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen,


a second heavy chain comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker that is fused at its C-terminus by a second peptide linker to a CH1 domain, and a second light chain comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a CL domain, and wherein the antigen binding molecule comprises


(i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:329 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:330,


(ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:108, SEQ ID NO:111 and SEQ ID NO:113, and


(iii) a second light chain comprising the amino acid sequence of SEQ ID NO:15, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:112 and SEQ ID NO:114.


In a further particular aspect, provided is a TNF family ligand trimer-containing antigen binding molecule, and wherein the antigen binding molecule comprises


a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to a target cell antigen,


a second heavy chain comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a CL domain, and a second light chain comprising one ectodomain of said TNF ligand family member or a fragment thereof that is fused at its C-terminus by a third peptide linker to a CH1 domain, and wherein the molecule comprises


i) a first heavy chain comprising the VH domain comprising the amino acid sequence of SEQ ID NO:329 and a first light chain comprising the VL domain comprising the amino acid sequence of SEQ ID NO:330,


(ii) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119 and SEQ ID NO:173, and


(iii) a second light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120 and SEQ ID NO:174.


Furthermore, the invention provides a TNF family ligand trimer-containing antigen binding molecule, comprising


(a) at least one moiety capable of specific binding to a target cell antigen, and


(b) a first and a second polypeptide that are linked to each other by a disulfide bond,


wherein the antigen binding molecule is characterized in that the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, respectively, and wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other and to the C-terminus of the CH3 domain by a peptide linker and wherein the second polypeptide comprises one ectodomain of said TNF ligand family member or a fragment thereof connected via a peptide linker to C-terminus of the CH3 domain of said polypeptide.


In a particular aspect, such a TNF family ligand trimer-containing antigen binding molecule comprises two moieties capable of specific binding to a target cell antigen.


More particular, such TNF family ligand trimer-containing antigen binding molecule comprises


(i) a first heavy chain comprising the amino acid sequence of SEQ ID NO:337, a second heavy chain comprising the amino acid sequence of SEQ ID NO:338, and two light chains comprising the amino acid sequence of SEQ ID NO:334, or


(ii) a first heavy chain comprising the amino acid sequence of SEQ ID NO:341, a second heavy chain comprising the amino acid sequence of SEQ ID NO:342, and two light chains comprising the amino acid sequence of SEQ ID NO:334.


In a further aspect, the invention relates to a TNF family ligand trimer-containing antigen binding molecule, selected from the group consisting of:


a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:333, a first light chain comprising the amino acid sequence of SEQ ID NO:334, a second heavy chain comprising the amino acid sequence of SEQ ID NO:115 and a second light chain comprising the amino acid sequence of SEQ ID NO:116;


b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:333, a first light chain comprising the amino acid sequence of SEQ ID NO:334, a second heavy chain comprising the amino acid sequence of SEQ ID NO:117 and a second light chain comprising the amino acid sequence of SEQ ID NO:118;


c) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:334, a first heavy chain comprising the amino acid sequence of SEQ ID NO:337 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:338;


d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:333, a first light chain comprising the amino acid sequence of SEQ ID NO:334, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119 and a second light chain comprising the amino acid sequence of SEQ ID NO:120;


e) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:333, a first light chain comprising the amino acid sequence of SEQ ID NO:334, a second heavy chain comprising the amino acid sequence of SEQ ID NO:173 and a second light chain comprising the amino acid sequence of SEQ ID NO:174; and


f) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:334, a first heavy chain comprising the amino acid sequence of SEQ ID NO:341 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:342.


In particular, the invention provides a TNF family ligand trimer-containing antigen binding molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:333, a first light chain comprising the amino acid sequence of SEQ ID NO:334, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119 and a second light chain comprising the amino acid sequence of SEQ ID NO:120.


Polynucleotides


The invention further provides isolated polynucleotides encoding a TNF family ligand trimer-containing antigen binding molecule as described herein or a fragment thereof.


The isolated polynucleotides encoding TNF ligand trimer-containing antigen binding molecules of the invention may be expressed as a single polynucleotide that encodes the entire antigen binding molecule or as multiple (e.g., two or more) polynucleotides that are co-expressed. Polypeptides encoded by polynucleotides that are co-expressed may associate through, e.g., disulfide bonds or other means to form a functional antigen binding molecule. For example, the light chain portion of an immunoglobulin may be encoded by a separate polynucleotide from the heavy chain portion of the immunoglobulin. When co-expressed, the heavy chain polypeptides will associate with the light chain polypeptides to form the immunoglobulin.


In some aspects, the isolated polynucleotide encodes the entire TNF family ligand trimer-containing antigen binding molecule according to the invention as described herein. In particular, the isolated polynucleotide encodes a polypeptide comprised in the TNF family ligand trimer-containing antigen binding molecule according to the invention as described herein.


In one aspect, the present invention is directed to an isolated polynucleotide encoding a TNF family ligand trimer-containing antigen binding molecule, wherein the polynucleotide comprises (a) a sequence that encodes a moiety capable of specific binding to a target cell antigen, (b) a sequence that encodes a polypeptide comprising two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and (c) a sequence that encodes a polypeptide comprising one ectodomain of said TNF ligand family member or a fragment thereof.


In another aspect, provided is an isolated polynucleotide encoding a 4-1BB ligand trimer-containing antigen binding molecule, wherein the polynucleotide comprises (a) a sequence that encodes a moiety capable of specific binding to a target cell antigen, (b) a sequence that encodes a polypeptide comprising two ectodomains of 4-1BBL or two fragments thereof that are connected to each other by a peptide linker and (c) a sequence that encodes a polypeptide comprising one ectodomain of 4-1BBL or a fragment thereof.


In a further aspect, the invention is directed to an isolated polynucleotide comprising a sequence that encodes a polypeptide comprising two 4-1BBL fragments comprising an amino acid sequence that is at least about 90%, 95%, 98% or 100% identical to an amino acid sequence shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:96, and to a polynucleotide comprising a sequence that encodes a polypeptide comprising one 4-1BBL fragment comprising an amino acid sequence that is at least about 90%, 95%, 98% or 100% identical to an amino acid sequence shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:96.


Furthermore, provided is an isolated polynucleotide encoding a OX40 ligand trimer-containing antigen binding molecule, wherein the polynucleotide comprises (a) a sequence that encodes a moiety capable of specific binding to a target cell antigen, (b) a sequence that encodes a polypeptide comprising two ectodomains of OX40L or two fragments thereof that are connected to each other by a peptide linker and (c) a sequence that encodes a polypeptide comprising one ectodomain of OX40L or a fragment thereof.


In another aspect, the invention is directed to an isolated polynucleotide comprising a sequence that encodes a polypeptide comprising two 4-1BBL fragments comprising an amino acid sequence that is at least about 90%, 95%, 98% or 100% identical to an amino acid sequence shown in SEQ ID NO:53 or SEQ ID NO:54, and to a polynucleotide comprising a sequence that encodes a polypeptide comprising one 4-1BBL fragment comprising an amino acid sequence that is at least about 90%, 95%, 98% or 100% identical to an amino acid sequence shown in SEQ ID NO:53 or SEQ ID NO:54.


In further aspects, the invention relates to the polynucleotides comprising a sequence that is at least about 90%, 95%, 98% or 100% identical to the specific cDNA sequences disclosed herein. In a particular aspect, the invention relates to a polynucleotide comprising a sequence that is identical to one of the specific cDNA sequences disclosed herein.


In other aspects, the nucleic acid molecule comprises or consists of a nucleotide sequence that encodes an amino acid sequence as set forth in any one of SEQ ID NOs: 5, 6, 97, 98, 99, 183, 184 or 185. In a further aspect, the nucleic acid molecule comprises or consists of a nucleotide sequence that encodes an amino acid sequence as set forth in any one of SEQ ID NOs:14, 15, 108, 109, 110, 111, 112, 113, 114, 115,116, 117, 118, 119, 120, 173 or 174.


In still other aspects, the nucleic acid molecule comprises or consists of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 66, 67, 68, 69, 129, 130, 131, 132, 133, 134, 137, 138, 141, 142, 143, 144, 146, 147, 150, 151, 152, 153, 162, 163, 165, 166, 167, 168, 169, 170, 171, 172, 175, 176, 177, 178, 203, 204, 207, 208, 211, 212, 215, 216, 273, 274, 277, 278, 281, 282, 285, 286, 289, 290, 293, 294, 297, 298, 301, 302, 305, 307, 308, 311, 312, 315, 316, 331, 332, 335, 336, 339, 340, 343, 344, 347, 348, 353 or 354.


In certain aspects, the polynucleotide or nucleic acid is DNA. In other embodiments, a polynucleotide of the present invention is RNA, for example, in the form of messenger RNA (mRNA). RNA of the present invention may be single stranded or double stranded.


Recombinant Methods


TNF family ligand trimer-containing antigen binding molecules of the invention may be obtained, for example, by solid-state peptide synthesis (e.g. Merrifield solid phase synthesis) or recombinant production. For recombinant production one or more polynucleotide encoding the TNF family ligand trimer-containing antigen binding molecule or polypeptide fragments thereof, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such polynucleotide may be readily isolated and sequenced using conventional procedures. In one aspect of the invention, a vector, preferably an expression vector, comprising one or more of the polynucleotides of the invention is provided. Methods which are well known to those skilled in the art can be used to construct expression vectors containing the coding sequence of the TNF family ligand trimer-containing antigen binding molecule (fragment) along with appropriate transcriptional/translational control signals. These methods include in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. See, for example, the techniques described in Maniatis et al., MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory, N.Y. (1989); and Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Associates and Wiley Interscience, N.Y. (1989). The expression vector can be part of a plasmid, virus, or may be a nucleic acid fragment. The expression vector includes an expression cassette into which the polynucleotide encoding the TNF family ligand trimer-containing antigen binding molecule or polypeptide fragments thereof (i.e. the coding region) is cloned in operable association with a promoter and/or other transcription or translation control elements. As used herein, a “coding region” is a portion of nucleic acid which consists of codons translated into amino acids. Although a “stop codon” (TAG, TGA, or TAA) is not translated into an amino acid, it may be considered to be part of a coding region, if present, but any flanking sequences, for example promoters, ribosome binding sites, transcriptional terminators, introns, 5′ and 3′ untranslated regions, and the like, are not part of a coding region. Two or more coding regions can be present in a single polynucleotide construct, e.g. on a single vector, or in separate polynucleotide constructs, e.g. on separate (different) vectors. Furthermore, any vector may contain a single coding region, or may comprise two or more coding regions, e.g. a vector of the present invention may encode one or more polypeptides, which are post- or co-translationally separated into the final proteins via proteolytic cleavage. In addition, a vector, polynucleotide, or nucleic acid of the invention may encode heterologous coding regions, either fused or unfused to a polynucleotide encoding the TNF family ligand trimer-containing antigen binding molecule of the invention or polypeptide fragments thereof, or variants or derivatives thereof. Heterologous coding regions include without limitation specialized elements or motifs, such as a secretory signal peptide or a heterologous functional domain. An operable association is when a coding region for a gene product, e.g. a polypeptide, is associated with one or more regulatory sequences in such a way as to place expression of the gene product under the influence or control of the regulatory sequence(s). Two DNA fragments (such as a polypeptide coding region and a promoter associated therewith) are “operably associated” if induction of promoter function results in the transcription of mRNA encoding the desired gene product and if the nature of the linkage between the two DNA fragments does not interfere with the ability of the expression regulatory sequences to direct the expression of the gene product or interfere with the ability of the DNA template to be transcribed. Thus, a promoter region would be operably associated with a nucleic acid encoding a polypeptide if the promoter was capable of effecting transcription of that nucleic acid. The promoter may be a cell-specific promoter that directs substantial transcription of the DNA only in predetermined cells. Other transcription control elements, besides a promoter, for example enhancers, operators, repressors, and transcription termination signals, can be operably associated with the polynucleotide to direct cell-specific transcription.


Suitable promoters and other transcription control regions are disclosed herein. A variety of transcription control regions are known to those skilled in the art. These include, without limitation, transcription control regions, which function in vertebrate cells, such as, but not limited to, promoter and enhancer segments from cytomegaloviruses (e.g. the immediate early promoter, in conjunction with intron-A), simian virus 40 (e.g. the early promoter), and retroviruses (such as, e.g. Rous sarcoma virus). Other transcription control regions include those derived from vertebrate genes such as actin, heat shock protein, bovine growth hormone and rabbit à-globin, as well as other sequences capable of controlling gene expression in eukaryotic cells. Additional suitable transcription control regions include tissue-specific promoters and enhancers as well as inducible promoters (e.g. promoters inducible tetracyclins). Similarly, a variety of translation control elements are known to those of ordinary skill in the art. These include, but are not limited to ribosome binding sites, translation initiation and termination codons, and elements derived from viral systems (particularly an internal ribosome entry site, or IRES, also referred to as a CITE sequence). The expression cassette may also include other features such as an origin of replication, and/or chromosome integration elements such as retroviral long terminal repeats (LTRs), or adeno-associated viral (AAV) inverted terminal repeats (ITRs).


Polynucleotide and nucleic acid coding regions of the present invention may be associated with additional coding regions which encode secretory or signal peptides, which direct the secretion of a polypeptide encoded by a polynucleotide of the present invention. For example, if secretion of the TNF family ligand trimer-containing antigen binding molecule or polypeptide fragments thereof is desired, DNA encoding a signal sequence may be placed upstream of the nucleic acid encoding a TNF family ligand trimer-containing antigen binding molecule of the invention or polypeptide fragments thereof. According to the signal hypothesis, proteins secreted by mammalian cells have a signal peptide or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Those of ordinary skill in the art are aware that polypeptides secreted by vertebrate cells generally have a signal peptide fused to the N-terminus of the polypeptide, which is cleaved from the translated polypeptide to produce a secreted or “mature” form of the polypeptide. In certain embodiments, the native signal peptide, e.g. an immunoglobulin heavy chain or light chain signal peptide is used, or a functional derivative of that sequence that retains the ability to direct the secretion of the polypeptide that is operably associated with it. Alternatively, a heterologous mammalian signal peptide, or a functional derivative thereof, may be used. For example, the wild-type leader sequence may be substituted with the leader sequence of human tissue plasminogen activator (TPA) or mouse β-glucuronidase.


DNA encoding a short protein sequence that could be used to facilitate later purification (e.g. a histidine tag) or assist in labeling the fusion protein may be included within or at the ends of the polynucleotide encoding a TNF family ligand trimer-containing antigen binding molecule of the invention or polypeptide fragments thereof.


In a further aspect of the invention, a host cell comprising one or more polynucleotides of the invention is provided. In certain embodiments a host cell comprising one or more vectors of the invention is provided. The polynucleotides and vectors may incorporate any of the features, singly or in combination, described herein in relation to polynucleotides and vectors, respectively. In one aspect, a host cell comprises (e.g. has been transformed or transfected with) a vector comprising a polynucleotide that encodes (part of) a TNF family ligand trimer-containing antigen binding molecule of the invention of the invention. As used herein, the term “host cell” refers to any kind of cellular system which can be engineered to generate the fusion proteins of the invention or fragments thereof. Host cells suitable for replicating and for supporting expression of antigen binding molecules are well known in the art. Such cells may be transfected or transduced as appropriate with the particular expression vector and large quantities of vector containing cells can be grown for seeding large scale fermenters to obtain sufficient quantities of the antigen binding molecule for clinical applications. Suitable host cells include prokaryotic microorganisms, such as E. coli, or various eukaryotic cells, such as Chinese hamster ovary cells (CHO), insect cells, or the like. For example, polypeptides may be produced in bacteria in particular when glycosylation is not needed. After expression, the polypeptide may be isolated from the bacterial cell paste in a soluble fraction and can be further purified. In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for polypeptide-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized”, resulting in the production of a polypeptide with a partially or fully human glycosylation pattern. See Gerngross, Nat Biotech 22, 1409-1414 (2004), and Li et al., Nat Biotech 24, 210-215 (2006).


Suitable host cells for the expression of (glycosylated) polypeptides are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells. Plant cell cultures can also be utilized as hosts. See e.g. U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES™ technology for producing antibodies in transgenic plants). Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293T cells as described, e.g., in Graham et al., J Gen Virol 36, 59 (1977)), baby hamster kidney cells (BHK), mouse sertoli cells (TM4 cells as described, e.g., in Mather, Biol Reprod 23, 243-251 (1980)), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical carcinoma cells (HELA), canine kidney cells (MDCK), buffalo rat liver cells (BRL 3A), human lung cells (W138), human liver cells (Hep G2), mouse mammary tumor cells (MMT 060562), TRI cells (as described, e.g., in Mather et al., Annals N.Y. Acad Sci 383, 44-68 (1982)), MRC 5 cells, and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including dhfr-CHO cells (Urlaub et al., Proc Natl Acad Sci USA 77, 4216 (1980)); and myeloma cell lines such as Y0, NS0, P3X63 and Sp2/0. For a review of certain mammalian host cell lines suitable for protein production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003). Host cells include cultured cells, e.g., mammalian cultured cells, yeast cells, insect cells, bacterial cells and plant cells, to name only a few, but also cells comprised within a transgenic animal, transgenic plant or cultured plant or animal tissue. In one embodiment, the host cell is a eukaryotic cell, preferably a mammalian cell, such as a Chinese Hamster Ovary (CHO) cell, a human embryonic kidney (HEK) cell or a lymphoid cell (e.g., Y0, NS0, Sp20 cell). Standard technologies are known in the art to express foreign genes in these systems. Cells expressing a polypeptide comprising either the heavy or the light chain of an immunoglobulin, may be engineered so as to also express the other of the immunoglobulin chains such that the expressed product is an immunoglobulin that has both a heavy and a light chain.


In one aspect, a method of producing a TNF family ligand trimer-containing antigen binding molecule of the invention or polypeptide fragments thereof is provided, wherein the method comprises culturing a host cell comprising polynucleotides encoding the TNF family ligand trimer-containing antigen binding molecule of the invention or polypeptide fragments thereof, as provided herein, under conditions suitable for expression of the TNF family ligand trimer-containing antigen binding molecule of the invention or polypeptide fragments thereof, and recovering the TNF family ligand trimer-containing antigen binding molecule of the invention or polypeptide fragments thereof from the host cell (or host cell culture medium).


In the TNF family ligand trimer-containing antigen binding molecule of the invention, the components (at least one moiety capable of specific binding to a target cell antigen, one polypeptide comprising two ectodomains of a TNF ligand family member or fragments thereof and a polypeptide comprising one ectodomain of said TNF family ligand family member or a fragment thereof) are not genetically fused to each other. The polypeptides are designed such that its components (two ectodomains of a TNF ligand family member or fragments thereof and other components such as CH or CL) are fused to each other directly or through a linker sequence. The composition and length of the linker may be determined in accordance with methods well known in the art and may be tested for efficacy. Examples of linker sequences between different components of the antigen binding molecules of the invention are found in the sequences provided herein. Additional sequences may also be included to incorporate a cleavage site to separate the individual components of the fusion protein if desired, for example an endopeptidase recognition sequence.


In certain embodiments the moieties capable of specific binding to a target cell antigen (e.g. Fab fragments) forming part of the antigen binding molecule comprise at least an immunoglobulin variable region capable of binding to an antigen. Variable regions can form part of and be derived from naturally or non-naturally occurring antibodies and fragments thereof. Methods to produce polyclonal antibodies and monoclonal antibodies are well known in the art (see e.g. Harlow and Lane, “Antibodies, a laboratory manual”, Cold Spring Harbor Laboratory, 1988). Non-naturally occurring antibodies can be constructed using solid phase-peptide synthesis, can be produced recombinantly (e.g. as described in U.S. Pat. No. 4,186,567) or can be obtained, for example, by screening combinatorial libraries comprising variable heavy chains and variable light chains (see e.g. U.S. Pat. No. 5,969,108 to McCafferty).


Any animal species of immunoglobulin can be used in the invention. Non-limiting immunoglobulins useful in the present invention can be of murine, primate, or human origin. If the fusion protein is intended for human use, a chimeric form of immunoglobulin may be used wherein the constant regions of the immunoglobulin are from a human. A humanized or fully human form of the immunoglobulin can also be prepared in accordance with methods well known in the art (see e. g. U.S. Pat. No. 5,565,332 to Winter). Humanization may be achieved by various methods including, but not limited to (a) grafting the non-human (e.g., donor antibody) CDRs onto human (e.g. recipient antibody) framework and constant regions with or without retention of critical framework residues (e.g. those that are important for retaining good antigen binding affinity or antibody functions), (b) grafting only the non-human specificity-determining regions (SDRs or a-CDRs; the residues critical for the antibody-antigen interaction) onto human framework and constant regions, or (c) transplanting the entire non-human variable domains, but “cloaking” them with a human-like section by replacement of surface residues. Humanized antibodies and methods of making them are reviewed, e.g., in Almagro and Fransson, Front Biosci 13, 1619-1633 (2008), and are further described, e.g., in Riechmann et al., Nature 332, 323-329 (1988); Queen et al., Proc Natl Acad Sci USA 86, 10029-10033 (1989); U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Jones et al., Nature 321, 522-525 (1986); Morrison et al., Proc Natl Acad Sci 81, 6851-6855 (1984); Morrison and Oi, Adv Immunol 44, 65-92 (1988); Verhoeyen et al., Science 239, 1534-1536 (1988); Padlan, Molec Immun 31(3), 169-217 (1994); Kashmiri et al., Methods 36, 25-34 (2005) (describing SDR (a-CDR) grafting); Padlan, Mol Immunol 28, 489-498 (1991) (describing “resurfacing”); Dall'Acqua et al., Methods 36, 43-60 (2005) (describing “FR shuffling”); and Osbourn et al., Methods 36, 61-68 (2005) and Klimka et al., Br J Cancer 83, 252-260 (2000) (describing the “guided selection” approach to FR shuffling). Particular immunoglobulins according to the invention are human immunoglobulins. Human antibodies and human variable regions can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk and van de Winkel, Curr Opin Pharmacol 5, 368-74 (2001) and Lonberg, Curr Opin Immunol 20, 450-459 (2008). Human variable regions can form part of and be derived from human monoclonal antibodies made by the hybridoma method (see e.g. Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)). Human antibodies and human variable regions may also be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge (see e.g. Lonberg, Nat Biotech 23, 1117-1125 (2005). Human antibodies and human variable regions may also be generated by isolating Fv clone variable region sequences selected from human-derived phage display libraries (see e.g., Hoogenboom et al. in Methods in Molecular Biology 178, 1-37 (O'Brien et al., ed., Human Press, Totowa, N.J., 2001); and McCafferty et al., Nature 348, 552-554; Clackson et al., Nature 352, 624-628 (1991)). Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments.


In certain aspects, the moieties capable of specific binding to a target cell antigen (e.g. Fab fragments) comprised in the antigen binding molecules of the present invention are engineered to have enhanced binding affinity according to, for example, the methods disclosed in PCT publication WO 2012/020006 (see Examples relating to affinity maturation) or U.S. Pat. Appl. Publ. No. 2004/0132066 (U.S. Pat. No. 7,432,063B2). The ability of the antigen binding molecules of the invention to bind to a specific antigenic determinant can be measured either through an enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to one of skill in the art, e.g. surface plasmon resonance technique (Liljeblad, et al., Glyco J 17, 323-329 (2000)), and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). Competition assays may be used to identify an antigen binding molecule that competes with a reference antibody for binding to a particular antigen. In certain embodiments, such a competing antigen binding molecule binds to the same epitope (e.g. a linear or a conformational epitope) that is bound by the reference antigen binding molecule. Detailed exemplary methods for mapping an epitope to which an antigen binding molecule binds are provided in Morris (1996) “Epitope Mapping Protocols”, in Methods in Molecular Biology vol. 66 (Humana Press, Totowa, N.J.). In an exemplary competition assay, immobilized antigen is incubated in a solution comprising a first labeled antigen binding molecule that binds to the antigen and a second unlabeled antigen binding molecule that is being tested for its ability to compete with the first antigen binding molecule for binding to the antigen. The second antigen binding molecule may be present in a hybridoma supernatant. As a control, immobilized antigen is incubated in a solution comprising the first labeled antigen binding molecule but not the second unlabeled antigen binding molecule. After incubation under conditions permissive for binding of the first antibody to the antigen, excess unbound antibody is removed, and the amount of label associated with immobilized antigen is measured. If the amount of label associated with immobilized antigen is substantially reduced in the test sample relative to the control sample, then that indicates that the second antigen binding molecule is competing with the first antigen binding molecule for binding to the antigen. See Harlow and Lane (1988) Antibodies: A Laboratory Manual ch.14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).


TNF ligand trimer-containing antigen binding molecules of the invention prepared as described herein may be purified by art-known techniques such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, and the like. The actual conditions used to purify a particular protein will depend, in part, on factors such as net charge, hydrophobicity, hydrophilicity etc., and will be apparent to those having skill in the art. For affinity chromatography purification an antibody, ligand, receptor or antigen can be used to which the TNF ligand trimer-containing antigen binding molecule binds. For example, for affinity chromatography purification of fusion proteins of the invention, a matrix with protein A or protein G may be used. Sequential Protein A or G affinity chromatography and size exclusion chromatography can be used to isolate an antigen binding molecule essentially as described in the Examples. The purity of the TNF ligand trimer-containing antigen binding molecule or fragments thereof can be determined by any of a variety of well-known analytical methods including gel electrophoresis, high pressure liquid chromatography, and the like. For example, the TNF ligand trimer-containing antigen binding molecules expressed as described in the Examples were shown to be intact and properly assembled as demonstrated by reducing and non-reducing SDS-PAGE.


Assays


The antigen binding molecules provided herein may be identified, screened for, or characterized for their physical/chemical properties and/or biological activities by various assays known in the art.


1. Affinity Assays


The affinity of the TNF family ligand trimer-containing antigen binding molecule provided herein for the corresponding TNF receptor can be determined in accordance with the methods set forth in the Examples by surface plasmon resonance (SPR), using standard instrumentation such as a BIACORE® instrument (GE Healthcare), and receptors or target proteins such as may be obtained by recombinant expression. The affinity of the TNF family ligand trimer-containing antigen binding molecule for the target cell antigen can also be determined by surface plasmon resonance (SPR), using standard instrumentation such as a BIACORE® instrument (GE Healthcare), and receptors or target proteins such as may be obtained by recombinant expression. A specific illustrative and exemplary embodiment for measuring binding affinity is described in Example 4. According to one aspect, KD is measured by surface plasmon resonance using a BIACORE® T100 machine (GE Healthcare) at 25° C.


2. Binding Assays and Other Assays


Binding of the TNF family ligand trimer-containing antigen binding molecule provided herein to the corresponding receptor expressing cells may be evaluated using cell lines expressing the particular receptor or target antigen, for example by flow cytometry (FACS). In one aspect, fresh peripheral blood mononuclear cells (PBMCs) expressing the TNF receptor are used in the binding assay. These cells are used directly after isolation (naïve PMBCs) or after stimulation (activated PMBCs). In another aspect, activated mouse splenocytes (expressing the TNF receptor molecule) were used to demonstrate the binding of the TNF family ligand trimer-containing antigen binding molecule of the invention to the corresponding TNF receptor expressing cells.


In a further aspect, cancer cell lines expressing the target cell antigen, for example FAP, were used to demonstrate the binding of the antigen binding molecules to the target cell antigen.


In another aspect, competition assays may be used to identify an antigen binding molecule that competes with a specific antibody or antigen binding molecule for binding to the target or TNF receptor, respectively. In certain embodiments, such a competing antigen binding molecule binds to the same epitope (e.g., a linear or a conformational epitope) that is bound by a specific anti-target antibody or a specific anti-TNF receptor antibody. Detailed exemplary methods for mapping an epitope to which an antibody binds are provided in Morris (1996) “Epitope Mapping Protocols,” in Methods in Molecular Biology vol. 66 (Humana Press, Totowa, N.J.).


3. Activity Assays


In one aspect, assays are provided for identifying TNF family ligand trimer-containing antigen binding molecules that bind to a specific target cell antigen and to a specific TNF receptor having biological activity. Biological activity may include, e.g., agonistic signalling through the TNF receptor on cells expressing the target cell antigen. TNF family ligand trimer-containing antigen binding molecules identified by the assays as having such biological activity in vitro are also provided.


In certain aspects, a TNF family ligand trimer-containing antigen binding molecule of the invention is tested for such biological activity. Assays for detecting the biological activity of the molecules of the invention are those described in Example 6. Furthermore, assays for detecting cell lysis (e.g. by measurement of LDH release), induced apoptosis kinetics (e.g. by measurement of Caspase 3/7 activity) or apoptosis (e.g. using the TUNEL assay) are well known in the art. In addition the biological activity of such complexes can be assessed by evaluating their effects on survival, proliferation and lymphokine secretion of various lymphocyte subsets such as NK cells, NKT-cells or γδ T-cells or assessing their capacity to modulate phenotype and function of antigen presenting cells such as dendritic cells, monocytes/macrophages or B-cells.


Pharmaceutical Compositions, Formulations and Routes of Administration


In a further aspect, the invention provides pharmaceutical compositions comprising any of the TNF family ligand trimer-containing antigen binding molecules provided herein, e.g., for use in any of the below therapeutic methods. In one embodiment, a pharmaceutical composition comprises any of the TNF family ligand trimer-containing antigen binding molecules provided herein and at least one pharmaceutically acceptable excipient. In another embodiment, a pharmaceutical composition comprises any of the TNF family ligand trimer-containing antigen binding molecules provided herein and at least one additional therapeutic agent, e.g., as described below.


Pharmaceutical compositions of the present invention comprise a therapeutically effective amount of one or more TNF family ligand trimer-containing antigen binding molecules dissolved or dispersed in a pharmaceutically acceptable excipient. The phrases “pharmaceutical or pharmacologically acceptable” refers to molecular entities and compositions that are generally non-toxic to recipients at the dosages and concentrations employed, i.e. do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate. The preparation of a pharmaceutical composition that contains at least one TNF family ligand trimer-containing antigen binding molecule and optionally an additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated herein by reference. In particular, the compositions are lyophilized formulations or aqueous solutions. As used herein, “pharmaceutically acceptable excipient” includes any and all solvents, buffers, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g. antibacterial agents, antifungal agents), isotonic agents, salts, stabilizers and combinations thereof, as would be known to one of ordinary skill in the art.


Parenteral compositions include those designed for administration by injection, e.g. subcutaneous, intradermal, intralesional, intravenous, intraarterial intramuscular, intrathecal or intraperitoneal injection. For injection, the TNF family ligand trimer-containing antigen binding molecules of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the fusion proteins may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. Sterile injectable solutions are prepared by incorporating the fusion proteins of the invention in the required amount in the appropriate solvent with various of the other ingredients enumerated below, as required. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and/or the other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, suspensions or emulsion, the preferred methods of preparation are vacuum-drying or freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered liquid medium thereof. The liquid medium should be suitably buffered if necessary and the liquid diluent first rendered isotonic prior to injection with sufficient saline or glucose. The composition must be stable under the conditions of manufacture and storage, and preserved against the contaminating action of microorganisms, such as bacteria and fungi. It will be appreciated that endotoxin contamination should be kept minimally at a safe level, for example, less that 0.5 ng/mg protein. Suitable pharmaceutically acceptable excipients include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). Aqueous injection suspensions may contain compounds which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, dextran, or the like. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl cleats or triglycerides, or liposomes.


Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (18th Ed. Mack Printing Company, 1990). Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, e.g. films, or microcapsules. In particular embodiments, prolonged absorption of an injectable composition can be brought about by the use in the compositions of agents delaying absorption, such as, for example, aluminum monostearate, gelatin or combinations thereof.


Exemplary pharmaceutically acceptable excipients herein further include interstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in US Patent Publication Nos. 2005/0260186 (U.S. Pat. No. 7,871,607B2) and 2006/0104968. In one aspect, a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.


Exemplary lyophilized antibody formulations are described in U.S. Pat. No. 6,267,958. Aqueous antibody formulations include those described in U.S. Pat. No. 6,171,586 and WO2006/044908, the latter formulations including a histidine-acetate buffer.


In addition to the compositions described previously, the fusion proteins may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the fusion proteins may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.


Pharmaceutical compositions comprising the fusion proteins of the invention may be manufactured by means of conventional mixing, dissolving, emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the proteins into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.


The TNF family ligand trimer-containing antigen binding molecules may be formulated into a composition in a free acid or base, neutral or salt form. Pharmaceutically acceptable salts are salts that substantially retain the biological activity of the free acid or base. These include the acid addition salts, e.g. those formed with the free amino groups of a proteinaceous composition, or which are formed with inorganic acids such as for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric or mandelic acid. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine. Pharmaceutical salts tend to be more soluble in aqueous and other protic solvents than are the corresponding free base forms.


The composition herein may also contain more than one active ingredients as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended.


The formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.


Therapeutic Methods and Compositions


Any of the TNF family ligand trimer-containing antigen binding molecules provided herein may be used in therapeutic methods.


For use in therapeutic methods, TNF family ligand trimer-containing antigen binding molecules of the invention can be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.


In one aspect, TNF family ligand trimer-containing antigen binding molecules of the invention for use as a medicament are provided. In further aspects, TNF family ligand trimer-containing antigen binding molecules of the invention for use in treating a disease, in particular for use in the treatment of cancer, are provided. In certain aspects, TNF family ligand trimer-containing antigen binding molecules of the invention for use in a method of treatment are provided. In one aspect, the invention provides a TNF family ligand trimer-containing antigen binding molecule as described herein for use in the treatment of a disease in an individual in need thereof. In certain aspects, the invention provides a TNF family ligand trimer-containing antigen binding molecule for use in a method of treating an individual having a disease comprising administering to the individual a therapeutically effective amount of the fusion protein. In certain aspects, the disease to be treated is cancer. Examples of cancers include solid tumors, bladder cancer, renal cell carcinoma, brain cancer, head and neck cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, esophageal cancer, colon cancer, colorectal cancer, rectal cancer, gastric cancer, prostate cancer, blood cancer, skin cancer, squamous cell carcinoma, bone cancer, and kidney cancer, melanoma, B-cell lymphoma, B-cell leukemia, non-Hodgkin lymphoma and acute lymphoblastic leukemia. Thus, a TNF family ligand trimer-containing antigen binding molecule as described herein for use in the treatment of cancer is provided. The subject, patient, or “individual” in need of treatment is typically a mammal, more specifically a human.


In another aspect, provided is a TNF family ligand trimer-containing antigen binding molecule as described herein for use in the treatment of infectious diseases, in particular for the treatment of viral infections. In a further aspect, provided is a TNF family ligand trimer-containing antigen binding molecule as described herein for use in the treatment of autoimmune diseases such as for example Lupus disease.


In one aspect, provided is a TNF family ligand trimer-containing antigen binding molecule according to the invention for use in treating head and neck squamous cell carcinoma (HNSCC), breast cancer, colorectal cancer (CRC), pancreatic cancer (PAC), gastric cancer, non-small-cell lung carcinoma (NSCLC) and Mesothelioma, wherein the target cell antigen is FAP.


In a further aspect, the invention relates to the use of a TNF family ligand trimer-containing antigen binding molecule in the manufacture or preparation of a medicament for the treatment of a disease in an individual in need thereof. In one aspect, the medicament is for use in a method of treating a disease comprising administering to an individual having the disease a therapeutically effective amount of the medicament. In certain embodiments the disease to be treated is a proliferative disorder, particularly cancer. Thus, in one aspect, the invention relates to the use of a TNF family ligand trimer-containing antigen binding molecule of the invention in the manufacture or preparation of a medicament for the treatment of cancer. Examples of cancers include solid tumors, bladder cancer, renal cell carcinoma, brain cancer, head and neck cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, esophageal cancer, colon cancer, colorectal cancer, rectal cancer, gastric cancer, prostate cancer, blood cancer, skin cancer, squamous cell carcinoma, bone cancer, and kidney cancer, melanoma, B-cell lymphoma, B-cell leukemia, non-Hodgkin lymphoma and acute lymphoblastic leukemia. Other cell proliferation disorders that can be treated using a TNF family ligand trimer-containing antigen binding molecule of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous system (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic region, and urogenital system. Also included are pre-cancerous conditions or lesions and cancer metastases. In certain embodiments the cancer is chosen from the group consisting of renal cell cancer, skin cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, head and neck cancer. A skilled artisan may recognize that in some cases the TNF family ligand trimer-containing antigen binding molecule may not provide a cure but may only provide partial benefit. In some aspects, a physiological change having some benefit is also considered therapeutically beneficial. Thus, in some aspects, an amount of TNF family ligand trimer-containing antigen binding molecule that provides a physiological change is considered an “effective amount” or a “therapeutically effective amount”.


In a further aspect, the invention relates to the use of a TNF family ligand trimer-containing antigen binding molecule as described herein in the manufacture or preparation of a medicament for the treatment of infectious diseases, in particular for the treatment of viral infections or for the treatment of autoimmune diseases, for example Lupus disease.


In a further aspect, the invention provides a method for treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a TNF family ligand trimer-containing antigen binding molecule of the invention. In one aspect a composition is administered to said individual, comprising a fusion protein of the invention in a pharmaceutically acceptable form. In certain aspects, the disease to be treated is a proliferative disorder. In a particular aspect, the disease is cancer. In another aspect, the disease is an infectious disease or an autoimmune disease. In certain aspects, the method further comprises administering to the individual a therapeutically effective amount of at least one additional therapeutic agent, e.g. an anti-cancer agent if the disease to be treated is cancer. An “individual” according to any of the above embodiments may be a mammal, preferably a human.


For the prevention or treatment of disease, the appropriate dosage of a TNF family ligand trimer-containing antigen binding molecule of the invention (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the route of administration, the body weight of the patient, the type of fusion protein, the severity and course of the disease, whether the fusion protein is administered for preventive or therapeutic purposes, previous or concurrent therapeutic interventions, the patient's clinical history and response to the fusion protein, and the discretion of the attending physician. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject. Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.


The TNF family ligand trimer-containing antigen binding molecule is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 μg/kg to 15 mg/kg (e.g. 0.1 mg/kg-10 mg/kg) of TNF family ligand trimer-containing antigen binding molecule can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. One typical daily dosage might range from about 1 μg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs. One exemplary dosage of the fusion protein would be in the range from about 0.005 mg/kg to about 10 mg/kg. In other examples, a dose may also comprise from about 1 μg/kg body weight, about 5 μg/kg body weight, about 10 μg/kg body weight, about 50 μg/kg body weight, about 100 μg/kg body weight, about 200 μg/kg body weight, about 350 μg/kg body weight, about 500 μg/kg body weight, about 1 mg/kg body weight, about 5 mg/kg body weight, about 10 mg/kg body weight, about 50 mg/kg body weight, about 100 mg/kg body weight, about 200 mg/kg body weight, about 350 mg/kg body weight, about 500 mg/kg body weight, to about 1000 mg/kg body weight or more per administration, and any range derivable therein. In examples of a derivable range from the numbers listed herein, a range of about 5 mg/kg body weight to about 100 mg/kg body weight, about 5 μg/kg body weight to about 500 mg/kg body weight etc., can be administered, based on the numbers described above. Thus, one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 5.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, or e.g. about six doses of the fusion protein). An initial higher loading dose, followed by one or more lower doses may be administered. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.


The TNF family ligand trimer-containing antigen binding molecules of the invention will generally be used in an amount effective to achieve the intended purpose. For use to treat or prevent a disease condition, the TNF family ligand trimer-containing antigen binding molecules of the invention, or pharmaceutical compositions thereof, are administered or applied in a therapeutically effective amount. Determination of a therapeutically effective amount is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein.


For systemic administration, a therapeutically effective dose can be estimated initially from in vitro assays, such as cell culture assays. A dose can then be formulated in animal models to achieve a circulating concentration range that includes the IC50 as determined in cell culture. Such information can be used to more accurately determine useful doses in humans.


Initial dosages can also be estimated from in vivo data, e.g., animal models, using techniques that are well known in the art. One having ordinary skill in the art could readily optimize administration to humans based on animal data.


Dosage amount and interval may be adjusted individually to provide plasma levels of the TNF family ligand trimer-containing antigen binding molecules which are sufficient to maintain therapeutic effect. Usual patient dosages for administration by injection range from about 0.1 to 50 mg/kg/day, typically from about 0.5 to 1 mg/kg/day. Therapeutically effective plasma levels may be achieved by administering multiple doses each day. Levels in plasma may be measured, for example, by HPLC.


In cases of local administration or selective uptake, the effective local concentration of the TNF family ligand trimer-containing antigen binding molecule may not be related to plasma concentration. One skilled in the art will be able to optimize therapeutically effective local dosages without undue experimentation.


A therapeutically effective dose of the TNF family ligand trimer-containing antigen binding molecules described herein will generally provide therapeutic benefit without causing substantial toxicity. Toxicity and therapeutic efficacy of a fusion protein can be determined by standard pharmaceutical procedures in cell culture or experimental animals. Cell culture assays and animal studies can be used to determine the LD50 (the dose lethal to 50% of a population) and the ED50 (the dose therapeutically effective in 50% of a population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio LD50/ED50. TNF family ligand trimer-containing antigen binding molecules that exhibit large therapeutic indices are preferred. In one embodiment, the TNF family ligand trimer-containing antigen binding molecule according to the present invention exhibits a high therapeutic index. The data obtained from cell culture assays and animal studies can be used in formulating a range of dosages suitable for use in humans. The dosage lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon a variety of factors, e.g., the dosage form employed, the route of administration utilized, the condition of the subject, and the like. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition (see, e.g., Fingl et al., 1975, in: The Pharmacological Basis of Therapeutics, Ch. 1, p. 1, incorporated herein by reference in its entirety).


The attending physician for patients treated with fusion proteins of the invention would know how and when to terminate, interrupt, or adjust administration due to toxicity, organ dysfunction, and the like. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administered dose in the management of the disorder of interest will vary with the severity of the condition to be treated, with the route of administration, and the like. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency will also vary according to the age, body weight, and response of the individual patient.


Other Agents and Treatments


The TNF family ligand trimer-containing antigen binding molecules of the invention may be administered in combination with one or more other agents in therapy. For instance, a fusion protein of the invention may be co-administered with at least one additional therapeutic agent. The term “therapeutic agent” encompasses any agent that can be administered for treating a symptom or disease in an individual in need of such treatment. Such additional therapeutic agent may comprise any active ingredients suitable for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. In certain embodiments, an additional therapeutic agent is another anti-cancer agent.


Such other agents are suitably present in combination in amounts that are effective for the purpose intended. The effective amount of such other agents depends on the amount of fusion protein used, the type of disorder or treatment, and other factors discussed above. The TNF family ligand trimer-containing antigen binding molecules are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.


Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate compositions), and separate administration, in which case, administration of the TNF family ligand trimer-containing antigen binding molecule of the invention can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent and/or adjuvant.


Articles of Manufacture


In another aspect of the invention, an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper that is pierceable by a hypodermic injection needle). At least one active agent in the composition is a TNF ligand trimer-containing antigen binding molecule of the invention.


The label or package insert indicates that the composition is used for treating the condition of choice. Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises a TNF ligand trimer-containing antigen binding molecule of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition.


Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.









TABLE C







(Sequences):









SEQ




ID NO:
Name
Sequence





  1
Human (hu) 4-1BBL (71-
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP



254)
LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY




YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA




ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG




VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLP




SPRSE





  2
hu 4-1BBL (85-254)
LDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSL




TGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAG




EGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEA




RNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQ




LTQGATVLGLFRVTPEIPAGLPSPRSE





  3
hu 4-1BBL (80-254)
DPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGL




AGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRR




VVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPP




ASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARAR




HAWQLTQGATVLGLFRVTPEIPAGLPSPRSE





  4
hu 4-1BBL (52-254)
PWAVSGARASPGSAASPRLREGPELSPDDPAGLLDLR




QGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGL




SYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSG




SVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSA




FGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQG




ATVLGLFRVTPEIPAGLPSPRSE





  5
dimeric hu 4-1BBL (71-254)
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP



connected by (G4S)2 linker
LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY




YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA




ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG




VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLP




SPRSEGGGGSGGGGSREGPELSPDDPAGLLDLRQGM




FAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYK




EDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSL




ALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGF




QGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATV




LGLFRVTPEIPAGLPSPRSE





  6
monomeric hu 4-1BBL (71-
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP



254) plus (G4S)2 linker
LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY




YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA




ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG




VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLP




SPRSEGGGGSGGGGS





  7
FAP(28H1) CDR-H1
SHAMS





  8
FAP(28H1) CDR-H2
AIWASGEQYYADSVKG





  9
FAP(28H1) CDR-H3
GWLGNFDY





 10
FAP(28H1) CDR-L1
RASQSVSRSYLA





 11
FAP(28H1) CDR-L2
GASTRAT





 12
FAP(28H1) CDR-L3
QQGQVIPPT





 13
(G4S)2
GGGGSGGGGS





 14
dimeric hu 4-1BBL (71-
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP



254)-CH1 Fc knob chain
LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY




YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA




ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG




VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLP




SPRSEGGGGSGGGGSREGPELSPDDPAGLLDLRQGM




FAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYK




EDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSL




ALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGF




QGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATV




LGLFRVTPEIPAGLPSPRSEGGGGSGGGGSASTKGPS




VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG




ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI




CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAA




GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE




VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT




VLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQP




REPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAV




EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS




RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK





 15
monomeric hu 4-1BBL (71-
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP



254)-CL
LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY




YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA




ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG




VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLP




SPRSEGGGGSGGGGSRTVAAPSVFIFPPSDEQLKSGT




ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT




EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG




LSSPVTKSFNRGEC





 16
FAP(28H1) VH
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSHA




MSWVRQAPGKGLEWVSAIWASGEQYYADSVK




GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK




GWLGNFDYWGQGTLVTVSS





 17
FAP(28H1) VL
EIVLTQSPGTLSLSPGERATLSCRASQSVSRSYLA




WYQQKPGQAPRLLIIGASTRATGIPDRFSGSGSG




TDFTLTISRLEPEDFAVYYCQQGQVIPPTFGQGT




KVEIK





 18
anti-FAP(28H1) Fc hole
see Table 2



chain






 19
anti-FAP(28H1) light chain
see Table 2





 20
Human (hu) FAP
UniProt no. Q12884





 21
hu FAP ectodomain+poly-
RPSRVHNSEENTMRALTLKDILNGTFSYKTFFPNWIS



lys−tag+his6−tag
GQEYLHQSADNNIVLYNIETGQSYTILSNRTMKSVNA




SNYGLSPDRQFVYLESDYSKLWRYSYTATYYIYDLS




NGEFVRGNELPRPIQYLCWSPVGSKLAYVYQNNIYL




KQRPGDPPFQITFNGRENKIFNGIPDWVYEEEMLATK




YALWWSPNGKFLAYAEFNDTDIPVIAYSYYGDEQYP




RTINIPYPKAGAKNPVVRIFIIDTTYPAYVGPQEVPVP




AMIASSDYYFSWLTWVTDERVCLQWLKRVQNVSVL




SICDFREDWQTWDCPKTQEHIEESRTGWAGGFFVST




PVFSYDAISYYKIFSDKDGYKHIHYIKDTVENAIQITS




GKWEAINIFRVTQDSLFYSSNEFEEYPGRRNIYRISIGS




YPPSKKCVTCHLRKERCQYYTASFSDYAKYYALVCY




GPGIPISTLHDGRTDQEIKILEENKELENALKNIQLPKE




EIKKLEVDEITLWYKMILPPQFDRSKKYPLLIQVYGG




PCSQSVRSVFAVNWISYLASKEGMVIALVDGRGTAF




QGDKLLYAVYRKLGVYEVEDQITAVRKFIEMGFIDE




KRIAIWGWSYGGYVSSLALASGTGLFKCGIAVAPVSS




WEYYASVYTERFMGLPTKDDNLEHYKNSTVMARAE




YFRNVDYLLIHGTADDNVHFQNSAQIAKALVNAQV




DFQAMWYSDQNHGLSGLSTNHLYTHMTHFLKQCFS




LSDGKKKKKKGHHHHHH





 22
nucleotide sequence
CGCCCTTCAAGAGTTCATAACTCTGAAGAAAATAC



hu FAP ectodomain+poly-
AATGAGAGCACTCACACTGAAGGATATTTTAAATG



lys−tag+his6−tag
GAACATTTTCTTATAAAACATTTTTTCCAAACTGGA




TTTCAGGACAAGAATATCTTCATCAATCTGCAGAT




AACAATATAGTACTTTATAATATTGAAACAGGACA




ATCATATACCATTTTGAGTAATAGAACCATGAAAA




GTGTGAATGCTTCAAATTACGGCTTATCACCTGAT




CGGCAATTTGTATATCTAGAAAGTGATTATTCAAA




GCTTTGGAGATACTCTTACACAGCAACATATTACA




TCTATGACCTTAGCAATGGAGAATTTGTAAGAGGA




AATGAGCTTCCTCGTCCAATTCAGTATTTATGCTGG




TCGCCTGTTGGGAGTAAATTAGCATATGTCTATCA




AAACAATATCTATTTGAAACAAAGACCAGGAGAT




CCACCTTTTCAAATAACATTTAATGGAAGAGAAAA




TAAAATATTTAATGGAATCCCAGACTGGGTTTATG




AAGAGGAAATGCTTGCTACAAAATATGCTCTCTGG




TGGTCTCCTAATGGAAAATTTTTGGCATATGCGGA




ATTTAATGATACGGATATACCAGTTATTGCCTATTC




CTATTATGGCGATGAACAATATCCTAGAACAATAA




ATATTCCATACCCAAAGGCTGGAGCTAAGAATCCC




GTTGTTCGGATATTTATTATCGATACCACTTACCCT




GCGTATGTAGGTCCCCAGGAAGTGCCTGTTCCAGC




AATGATAGCCTCAAGTGATTATTATTTCAGTTGGC




TCACGTGGGTTACTGATGAACGAGTATGTTTGCAG




TGGCTAAAAAGAGTCCAGAATGTTTCGGTCCTGTC




TATATGTGACTTCAGGGAAGACTGGCAGACATGGG




ATTGTCCAAAGACCCAGGAGCATATAGAAGAAAG




CAGAACTGGATGGGCTGGTGGATTCTTTGTTTCAA




CACCAGTTTTCAGCTATGATGCCATTTCGTACTACA




AAATATTTAGTGACAAGGATGGCTACAAACATATT




CACTATATCAAAGACACTGTGGAAAATGCTATTCA




AATTACAAGTGGCAAGTGGGAGGCCATAAATATA




TTCAGAGTAACACAGGATTCACTGTTTTATTCTAG




CAATGAATTTGAAGAATACCCTGGAAGAAGAAAC




ATCTACAGAATTAGCATTGGAAGCTATCCTCCAAG




CAAGAAGTGTGTTACTTGCCATCTAAGGAAAGAAA




GGTGCCAATATTACACAGCAAGTTTCAGCGACTAC




GCCAAGTACTATGCACTTGTCTGCTACGGCCCAGG




CATCCCCATTTCCACCCTTCATGATGGACGCACTG




ATCAAGAAATTAAAATCCTGGAAGAAAACAAGGA




ATTGGAAAATGCTTTGAAAAATATCCAGCTGCCTA




AAGAGGAAATTAAGAAACTTGAAGTAGATGAAAT




TACTTTATGGTACAAGATGATTCTTCCTCCTCAATT




TGACAGATCAAAGAAGTATCCCTTGCTAATTCAAG




TGTATGGTGGTCCCTGCAGTCAGAGTGTAAGGTCT




GTATTTGCTGTTAATTGGATATCTTATCTTGCAAGT




AAGGAAGGGATGGTCATTGCCTTGGTGGATGGTCG




AGGAACAGCTTTCCAAGGTGACAAACTCCTCTATG




CAGTGTATCGAAAGCTGGGTGTTTATGAAGTTGAA




GACCAGATTACAGCTGTCAGAAAATTCATAGAAAT




GGGTTTCATTGATGAAAAAAGAATAGCCATATGGG




GCTGGTCCTATGGAGGATACGTTTCATCACTGGCC




CTTGCATCTGGAACTGGTCTTTTCAAATGTGGTATA




GCAGTGGCTCCAGTCTCCAGCTGGGAATATTACGC




GTCTGTCTACACAGAGAGATTCATGGGTCTCCCAA




CAAAGGATGATAATCTTGAGCACTATAAGAATTCA




ACTGTGATGGCAAGAGCAGAATATTTCAGAAATGT




AGACTATCTTCTCATCCACGGAACAGCAGATGATA




ATGTGCACTTTCAAAACTCAGCACAGATTGCTAAA




GCTCTGGTTAATGCACAAGTGGATTTCCAGGCAAT




GTGGTACTCTGACCAGAACCACGGCTTATCCGGCC




TGTCCACGAACCACTTATACACCCACATGACCCAC




TTCCTAAAGCAGTGTTTCTCTTTGTCAGACGGCAA




AAAGAAAAAGAAAAAGGGCCACCACCATCACCAT




CAC





 23
mouse FAP
UniProt no. P97321





 24
Murine FAP
RPSRVYKPEGNTKRALTLKDILNGTFSYKTYFPNWIS



ectodomain+poly−lys−
EQEYLHQSEDDNIVFYNIETRESYIILSNSTMKSVNAT



tag+his6−tag
DYGLSPDRQFVYLESDYSKLWRYSYTATYYIYDLQN




GEFVRGYELPRPIQYLCWSPVGSKLAYVYQNNIYLK




QRPGDPPFQITYTGRENRIFNGIPDWVYEEEMLATKY




ALWWSPDGKFLAYVEFNDSDIPIIAYSYYGDGQYPR




TINIPYPKAGAKNPVVRVFIVDTTYPHHVGPMEVPVP




EMIASSDYYFSWLTWVSSERVCLQWLKRVQNVSVL




SICDFREDWHAWECPKNQEHVEESRTGWAGGFFVST




PAFSQDATSYYKIFSDKDGYKHIHYIKDTVENAIQITS




GKWEAIYIFRVTQDSLFYSSNEFEGYPGRRNIYRISIG




NSPPSKKCVTCHLRKERCQYYTASFSYKAKYYALVC




YGPGLPISTLHDGRTDQEIQVLEENKELENSLRNIQLP




KVEIKKLKDGGLTFWYKMILPPQFDRSKKYPLLIQVY




GGPCSQSVKSVFAVNWITYLASKEGIVIALVDGRGTA




FQGDKFLHAVYRKLGVYEVEDQLTAVRKFIEMGFID




EERIAIWGWSYGGYVSSLALASGTGLFKCGIAVAPVS




SWEYYASIYSERFMGLPTKDDNLEHYKNSTVMARA




EYFRNVDYLLIHGTADDNVHFQNSAQIAKALVNAQV




DFQAMWYSDQNHGILSGRSQNHLYTHMTHFLKQCF




SLSDGKKKKKKGHHHHHH





 25
nucleotide sequence
CGTCCCTCAAGAGTTTACAAACCTGAAGGAAACAC



Murine FAP
AAAGAGAGCTCTTACCTTGAAGGATATTTTAAATG



ectodomain+poly−lys−
GAACATTCTCATATAAAACATATTTTCCCAACTGG



tag+his6−tag
ATTTCAGAACAAGAATATCTTCATCAATCTGAGGA




TGATAACATAGTATTTTATAATATTGAAACAAGAG




AATCATATATCATTTTGAGTAATAGCACCATGAAA




AGTGTGAATGCTACAGATTATGGTTTGTCACCTGA




TCGGCAATTTGTGTATCTAGAAAGTGATTATTCAA




AGCTCTGGCGATATTCATACACAGCGACATACTAC




ATCTACGACCTTCAGAATGGGGAATTTGTAAGAGG




ATACGAGCTCCCTCGTCCAATTCAGTATCTATGCT




GGTCGCCTGTTGGGAGTAAATTAGCATATGTATAT




CAAAACAATATTTATTTGAAACAAAGACCAGGAG




ATCCACCTTTTCAAATAACTTATACTGGAAGAGAA




AATAGAATATTTAATGGAATACCAGACTGGGTTTA




TGAAGAGGAAATGCTTGCCACAAAATATGCTCTTT




GGTGGTCTCCAGATGGAAAATTTTTGGCATATGTA




GAATTTAATGATTCAGATATACCAATTATTGCCTA




TTCTTATTATGGTGATGGACAGTATCCTAGAACTA




TAAATATTCCATATCCAAAGGCTGGGGCTAAGAAT




CCGGTTGTTCGTGTTTTTATTGTTGACACCACCTAC




CCTCACCACGTGGGCCCAATGGAAGTGCCAGTTCC




AGAAATGATAGCCTCAAGTGACTATTATTTCAGCT




GGCTCACATGGGTGTCCAGTGAACGAGTATGCTTG




CAGTGGCTAAAAAGAGTGCAGAATGTCTCAGTCCT




GTCTATATGTGATTTCAGGGAAGACTGGCATGCAT




GGGAATGTCCAAAGAACCAGGAGCATGTAGAAGA




AAGCAGAACAGGATGGGCTGGTGGATTCTTTGTTT




CGACACCAGCTTTTAGCCAGGATGCCACTTCTTAC




TACAAAATATTTAGCGACAAGGATGGTTACAAACA




TATTCACTACATCAAAGACACTGTGGAAAATGCTA




TTCAAATTACAAGTGGCAAGTGGGAGGCCATATAT




ATATTCCGCGTAACACAGGATTCACTGTTTTATTCT




AGCAATGAATTTGAAGGTTACCCTGGAAGAAGAA




ACATCTACAGAATTAGCATTGGAAACTCTCCTCCG




AGCAAGAAGTGTGTTACTTGCCATCTAAGGAAAGA




AAGGTGCCAATATTACACAGCAAGTTTCAGCTACA




AAGCCAAGTACTATGCACTCGTCTGCTATGGCCCT




GGCCTCCCCATTTCCACCCTCCATGATGGCCGCAC




AGACCAAGAAATACAAGTATTAGAAGAAAACAAA




GAACTGGAAAATTCTCTGAGAAATATCCAGCTGCC




TAAAGTGGAGATTAAGAAGCTCAAAGACGGGGGA




CTGACTTTCTGGTACAAGATGATTCTGCCTCCTCAG




TTTGACAGATCAAAGAAGTACCCTTTGCTAATTCA




AGTGTATGGTGGTCCTTGTAGCCAGAGTGTTAAGT




CTGTGTTTGCTGTTAATTGGATAACTTATCTCGCAA




GTAAGGAGGGGATAGTCATTGCCCTGGTAGATGGT




CGGGGCACTGCTTTCCAAGGTGACAAATTCCTGCA




TGCCGTGTATCGAAAACTGGGTGTATATGAAGTTG




AGGACCAGCTCACAGCTGTCAGAAAATTCATAGA




AATGGGTTTCATTGATGAAGAAAGAATAGCCATAT




GGGGCTGGTCCTACGGAGGTTATGTTTCATCCCTG




GCCCTTGCATCTGGAACTGGTCTTTTCAAATGTGG




CATAGCAGTGGCTCCAGTCTCCAGCTGGGAATATT




ACGCATCTATCTACTCAGAGAGATTCATGGGCCTC




CCAACAAAGGACGACAATCTCGAACACTATAAAA




ATTCAACTGTGATGGCAAGAGCAGAATATTTCAGA




AATGTAGACTATCTTCTCATCCACGGAACAGCAGA




TGATAATGTGCACTTTCAGAACTCAGCACAGATTG




CTAAAGCTTTGGTTAATGCACAAGTGGATTTCCAG




GCGATGTGGTACTCTGACCAGAACCATGGTATATT




ATCTGGGCGCTCCCAGAATCATTTATATACCCACA




TGACGCACTTCCTCAAGCAATGCTTTTCTTTATCAG




ACGGCAAAAAGAAAAAGAAAAAGGGCCACCACCA




TCACCATCAC





 26
Cynomolgus FAP
RPPRVHNSEENTMRALTLKDILNGTFSYKTFFPNWIS



ectodomain+poly−lys−
GQEYLHQSADNNIVLYNIETGQSYTILSNRTMKSVNA



tag+his6−tag
SNYGLSPDRQFVYLESDYSKLWRYSYTATYYIYDLS




NGEFVRGNELPRPIQYLCWSPVGSKLAYVYQNNIYL




KQRPGDPPFQITFNGRENKIFNGIPDWVYEEEMLATK




YALWWSPNGKFLAYAEFNDTDIPVIAYSYYGDEQYP




RTINIPYPKAGAKNPFVRIFIIDTTYPAYVGPQEVPVP




AMIASSDYYFSWLTWVTDERVCLQWLKRVQNVSVL




SICDFREDWQTWDCPKTQEHIEESRTGWAGGFFVST




PVFSYDAISYYKIFSDKDGYKHIHYIKDTVENAIQITS




GKWEAINIFRVTQDSLFYSSNEFEDYPGRRNIYRISIG




SYPPSKKCVTCHLRKERCQYYTASFSDYAKYYALVC




YGPGIPISTLHDGRTDQEIKILEENKELENALKNIQLP




KEEIKKLEVDEITLWYKMILPPQFDRSKKYPLLIQVY




GGPCSQSVRSVFAVNWISYLASKEGMVIALVDGRGT




AFQGDKLLYAVYRKLGVYEVEDQITAVRKFIEMGFI




DEKRIAIWGWSYGGYVSSLALASGTGLFKCGIAVAP




VSSWEYYASVYTERFMGLPTKDDNLEHYKNSTVMA




RAEYFRNVDYLLIHGTADDNVHFQNSAQIAKALVNA




QVDFQAMWYSDQNHGLSGLSTNHLYTHMTHFLKQ




CFSLSDGKKKKKKGHHHHHH





 27
nucleotide sequence
CGCCCTCCAAGAGTTCATAACTCTGAAGAAAATAC



Cynomolgus FAP
AATGAGAGCACTCACACTGAAGGATATTTTAAATG



ectodomain+poly−lys−
GGACATTTTCTTATAAAACATTTTTTCCAAACTGGA



tag+his6−tag
TTTCAGGACAAGAATATCTTCATCAATCTGCAGAT




AACAATATAGTACTTTATAATATTGAAACAGGACA




ATCATATACCATTTTGAGTAACAGAACCATGAAAA




GTGTGAATGCTTCAAATTATGGCTTATCACCTGAT




CGGCAATTTGTATATCTAGAAAGTGATTATTCAAA




GCTTTGGAGATACTCTTACACAGCAACATATTACA




TCTATGACCTTAGCAATGGAGAATTTGTAAGAGGA




AATGAGCTTCCTCGTCCAATTCAGTATTTATGCTGG




TCGCCTGTTGGGAGTAAATTAGCATATGTCTATCA




AAACAATATCTATTTGAAACAAAGACCAGGAGAT




CCACCTTTTCAAATAACATTTAATGGAAGAGAAAA




TAAAATATTTAATGGAATCCCAGACTGGGTTTATG




AAGAGGAAATGCTTGCTACAAAATATGCTCTCTGG




TGGTCTCCTAATGGAAAATTTTTGGCATATGCGGA




ATTTAATGATACAGATATACCAGTTATTGCCTATTC




CTATTATGGCGATGAACAATATCCCAGAACAATAA




ATATTCCATACCCAAAGGCCGGAGCTAAGAATCCT




TTTGTTCGGATATTTATTATCGATACCACTTACCCT




GCGTATGTAGGTCCCCAGGAAGTGCCTGTTCCAGC




AATGATAGCCTCAAGTGATTATTATTTCAGTTGGC




TCACGTGGGTTACTGATGAACGAGTATGTTTGCAG




TGGCTAAAAAGAGTCCAGAATGTTTCGGTCTTGTC




TATATGTGATTTCAGGGAAGACTGGCAGACATGGG




ATTGTCCAAAGACCCAGGAGCATATAGAAGAAAG




CAGAACTGGATGGGCTGGTGGATTCTTTGTTTCAA




CACCAGTTTTCAGCTATGATGCCATTTCATACTACA




AAATATTTAGTGACAAGGATGGCTACAAACATATT




CACTATATCAAAGACACTGTGGAAAATGCTATTCA




AATTACAAGTGGCAAGTGGGAGGCCATAAATATA




TTCAGAGTAACACAGGATTCACTGTTTTATTCTAG




CAATGAATTTGAAGATTACCCTGGAAGAAGAAAC




ATCTACAGAATTAGCATTGGAAGCTATCCTCCAAG




CAAGAAGTGTGTTACTTGCCATCTAAGGAAAGAAA




GGTGCCAATATTACACAGCAAGTTTCAGCGACTAC




GCCAAGTACTATGCACTTGTCTGCTATGGCCCAGG




CATCCCCATTTCCACCCTTCATGACGGACGCACTG




ATCAAGAAATTAAAATCCTGGAAGAAAACAAGGA




ATTGGAAAATGCTTTGAAAAATATCCAGCTGCCTA




AAGAGGAAATTAAGAAACTTGAAGTAGATGAAAT




TACTTTATGGTACAAGATGATTCTTCCTCCTCAATT




TGACAGATCAAAGAAGTATCCCTTGCTAATTCAAG




TGTATGGTGGTCCCTGCAGTCAGAGTGTAAGGTCT




GTATTTGCTGTTAATTGGATATCTTATCTTGCAAGT




AAGGAAGGGATGGTCATTGCCTTGGTGGATGGTCG




GGGAACAGCTTTCCAAGGTGACAAACTCCTGTATG




CAGTGTATCGAAAGCTGGGTGTTTATGAAGTTGAA




GACCAGATTACAGCTGTCAGAAAATTCATAGAAAT




GGGTTTCATTGATGAAAAAAGAATAGCCATATGGG




GCTGGTCCTATGGAGGATATGTTTCATCACTGGCC




CTTGCATCTGGAACTGGTCTTTTCAAATGTGGGAT




AGCAGTGGCTCCAGTCTCCAGCTGGGAATATTACG




CGTCTGTCTACACAGAGAGATTCATGGGTCTCCCA




ACAAAGGATGATAATCTTGAGCACTATAAGAATTC




AACTGTGATGGCAAGAGCAGAATATTTCAGAAAT




GTAGACTATCTTCTCATCCACGGAACAGCAGATGA




TAATGTGCACTTTCAAAACTCAGCACAGATTGCTA




AAGCTCTGGTTAATGCACAAGTGGATTTCCAGGCA




ATGTGGTACTCTGACCAGAACCACGGCTTATCCGG




CCTGTCCACGAACCACTTATACACCCACATGACCC




ACTTCCTAAAGCAGTGTTTCTCTTTGTCAGACGGC




AAAAAGAAAAAGAAAAAGGGCCACCACCATCACC




ATCAC





 28
human CEA
UniProt no. P06731





 29
human MCSP
UniProt no. Q6UVK1





 30
human EGFR
UniProt no. P00533





 31
human CD19
UniProt no. P15391





 32
human CD20
Uniprot no. P11836





 33
human CD33
UniProt no. P20138





 34
human Lymphotoxin α
UniProt no. P01374





 35
human TNF
UniProt no. P01375





 36
human Lymphotoxin β
UniProt no. Q06643





 37
human OX40L
UniProt no. P23510





 38
human CD40L
UniProt no. P29965





 39
human FasL
UniProt no. P48023





 40
human CD27L
UniProt no. P32970





 41
human CD30L
UniProt no. P32971





 42
human 4-1BBL
UniProt no. P41273





 43
human TRAIL
UniProt no. P50591





 44
human RANKL
UniProt no. O14788





 45
human TWEAK
UniProt no. O43508





 46
human APRIL
UniProt no. O75888





 47
human BAFF
UniProt no. Q9Y275





 48
human LIGHT
UniProt no. O43557





 49
human TL1A
UniProt no. O95150





 50
human GITRL
UniProt no. Q9UNG2





 51
human ectodysplasin A
UniProt no. Q92838





 52
hu 4-1BBL (50-254)
ACPWAVSGARASPGSAASPRLREGPELSPDDPAGLL




DLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLT




GGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGE




GSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEAR




NSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQL




TQGATVLGLFRVTPEIPAGLPSPRSE





 53
hu OX40L (51-183)
QVSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMK




VQNNSVIINCDGFYLISLKGYFSQEVNISLHYQKDEEP




LFQLKKVRSVNSLMVASLTYKDKVYLNVTTDNTSL




DDFHVNGGELILIHQNPGEFCVL





 54
hu OX40L (52-183)
VSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKV




QNNSVIINCDGFYLISLKGYFSQEVNISLHYQKDEEPL




FQLKKVRSVNSLMVASLTYKDKVYLNVTTDNTSLD




DFHVNGGELILIHQNPGEFCVL





 55
Peptide linker (SG4)2
SGGGGSGGGG





 56
Peptide linker G4(SG4)2
GGGGSGGGGSGGGG





 57
Peptide linker
GSPGSSSSGS





 58
Peptide linker (G4S)4
GGGGSGGGGSGGGGSGGGGS





 59
Peptide linker
GSGSGNGS





 60
Peptide linker
GGSGSGSG





 61
Peptide linker
GGSGSG





 62
Peptide linker
GGSG





 63
Peptide linker
GGSGNGSG





 64
Peptide linker
GGNGSGSG





 65
Peptide linker
GGNGSG





 66
nucleotide sequence
See Table 2



dimeric hu 4-1BBL (71-




254)-CH1 Fc knob chain






 67
nucleotide sequence
See Table 2



monomeric hu 4-1BBL (71-




254)-CL1






 68
nucleotide sequence
See Table 2



anti-FAP (28H1) Fc hole




chain






 69
nucleotide sequence
See Table 2



anti-FAP (28H1) light chain






 70
Murine (mu) 4-1BBL
UniProt no. Q3U1Z9-1





 71
nucleotide sequence
See Table 13



dimeric mu 4-1BBL (104-




309, C137, 160, 246S)-CH1




Fc knob chain






 72
nucleotide sequence
See Table 13



monomeric mu 4-1BBL




(104-309, C137, 160, 246S)-




CL






 73
nucleotide sequence
See Table 13



anti-FAP Fc KK chain






 74
nucleotide sequence
See Table 13



anti-FAP light chain






 75
dimeric mu 4-1BBL (104-
See Table 13



309, C137, 160, 246S) - CL




Fc DD chain






 76
monomeric mu 4-1BBL
See Table 13



(104-309, C137, 160, 246S)-




CL1






 77
anti-FAP Fc KK chain
See Table 13





 78
anti-FAP light chain
See Table 13





 79
nucleotide sequence DP47
See Table 18



Fc-hole chain






 80
nucleotide sequence DP47
See Table 18



light chain






 81
DP47 Fc-hole chain
See Table 18





 82
DP47 light chain
See Table 18





 83
Human 4-1BB Fc(kih)
See Table 31





 84
Cynomolgus 4-1BB Fc(kih)
See Table 31





 85
Murine 4-1BB Fc(kih)
See Table 31





 86
nucleotide sequence
See Table 32



Fc hole chain






 87
nucleotide sequence
See Table 32



Human 4-1BB Fc(kih)






 88
nucleotide sequence
See Table 32



Cynomolgus 4-1BB Fc(kih)






 89
nucleotide sequence
See Table 32



Murine 4-1BB Fc(kih)






 90
Fc hole chain
See Table 32





 91
Human 4-1BB Fc(kih)
See Table 32





 92
Cynomolgus 4-1BB Fc(kih)
See Table 32





 93
Murine 4-1BB Fc(kih)
See Table 32





 94
nucleotide sequence
See Table 33



Human 4-1BB His






 95
Human 4-1BB His
See Table 33





 96
Human (hu) 4-1BBL (71-
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP



248)
LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY




YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA




ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG




VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGL





 97
dimeric hu 4-1BBL (71-248)
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP



connected by (G4S)2 linker
LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY




YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA




ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG




VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLG




GGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQLVA




QNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKEL




VVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQP




LRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLH




LSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRV




TPEIPAGL





 98
dimeric hu 4-1BBL (80-254)
DPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGL



connected by (G4S)2 linker
AGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRR




VVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPP




ASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARAR




HAWQLTQGATVLGLFRVTPEIPAGLPSPRSEGGGGSG




GGGSDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY




SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQ




LELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALT




VDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHT




EARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE





 99
dimeric hu 4-1BBL (52-254)
PWAVSGARASPGSAASPRLREGPELSPDDPAGLLDLR



connected by (G4S)2 linker
QGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGL




SYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSG




SVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSA




FGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQG




ATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSPWAV




SGARASPGSAASPRLREGPELSPDDPAGLLDLRQGMF




AQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKE




DTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSL




ALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGF




QGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATV




LGLFRVTPEIPAGLPSPRSE





100
FAP(4B9) CDR-H1
SYAMS





101
FAP(4B9) CDR-H2
AIIGSGASTYYADSVKG





102
FAP(4B9) CDR-H3
GWFGGFNY





103
FAP(4B9) CDR-L1
RASQSVTSSYLA





104
FAP(4B9) CDR-L2
VGSRRAT





105
FAP(4B9) CDR-L3
QQGIMLPPT





106
FAP(4B9) VH
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA




MSWVRQAPGKGLEWVSAIIGSGASTYYADSVK




GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK




GWFGGFNYWGQGTLVTVSS





107
FAP(4B9) VL
EIVLTQSPGTLSLSPGERATLSCRASQSVTSSYLA




WYQQKPGQAPRLLINVGSRRATGIPDRFSGSGSG




TDFTLTISRLEPEDFAVYYCQQGIMLPPTFGQGT




KVEIK





108
dimeric hu 4-1BBL (71-
see Table 4



254)-CH1* Fc knob chain






109
monomeric hu 4-1BBL (71-
see Table 4



254)-CL*






110
monomeric hu 4-1BBL (71-
see Table 7



254)-(G4S)1-CL*






111
dimeric hu 4-1BBL (52-
see Table 10



254)-CH1* Fc knob chain






112
monomeric hu 4-1BBL (52-
see Table 10



254)-CL*






113
dimeric hu 4-1BBL (80-
see Table 11



254)-CH1* Fc knob chain






114
monomeric hu 4-1BBL (80-
see Table 11



254)-CL*






115
dimeric hu 4-1BBL (71-
see Table 3



254)-CL* Fc knob chain






116
monomeric hu 4-1BBL (71-
see Table 3



254)-CH1*






117
dimeric hu 4-1BBL (71-
see Table 22



254)-CL Fc knob chain






118
monomeric hu 4-1BBL (71-
see Table 22



254)-CH1






119
dimeric hu 4-1BBL (71-
see Table 24



248)-CL* Fc knob chain






120
monomeric hu 4-1BBL (71-
see Table 24



248)-CH1*






121
anti-FAP (28H1) Fc hole
see Table 6



chain fused to dimeric 4-




1BBL (71-254)






122
anti-FAP (28H1) Fc knob
see Table 6



chain fused to monomeric 4-




1BBL (71-254)






123
anti-FAP (4B9) Fc hole
see Table 23



chain fused to dimeric 4-




1BBL (71-254)






124
anti-FAP (4B9) Fc knob
see Table 23



chain fused to monomeric 4-




1BBL (71-254)






125
anti-FAP (4B9) light chain
see Table 21





126
anti-FAP (4B9) Fc hole
see Table 26



chain fused to dimeric 4-




1BBL (71-248)






127
anti-FAP (4B9) Fc knob
see Table 26



chain fused to monomeric 4-




1BBL (71-248)






128
Peptide linker
GGGGS





129
nucleotide sequence dimeric
see Table 3



hu 4-1BBL (71-254) - CL*




Fc knob chain






130
nucleotide sequence
see Table 3



monomeric hu 4-1BBL (71-




254) - CH1*






131
nucleotide sequence dimeric
see Table 4



hu 4-1BBL (71-254) -




CH1* Fc knob chain






132
nucleotide sequence
see Table 4



monomeric hu 4-1BBL (71-




254) - CL*






133
nucleotide sequence anti-
see Table 4



FAP (28H1) (VHCL) Fc




hole chain






134
nucleotide sequence anti-
see Table 4



FAP (28H1) (VLCH1) light




chain






135
anti-FAP (VHCL) (28H1)
see Table 4



Fc hole chain






136
anti-FAP (VLCH1) (28H1)
see Table 4



light chain






137
nucleotide sequence
see Table 5



monomeric hu 4-1BBL (71-




254) - CH1* Fc knob chain






138
nucleotide sequence dimeric
see Table 5



hu 4-1BBL (71-254) - CL*






139
monomeric hu 4-1BBL (71-
see Table 5



254) - CL* Fc knob chain






140
dimeric hu 4-1BBL (71-254) -
see Table 5



CL*






141
nucleotide sequence anti-
see Table 6



FAP (28H1) Fc hole chain




fused to dimeric hu 4-1BBL




(71-254)






142
nucleotide sequence anti-
see Table 6



FAP (28H1) Fc knob chain




fused to monomeric hu 4-




1BBL (71-254)






143
nucleotide sequence
see Table 7



monomeric hu 4-1BBL (71-




254) -(G4S)1 - CL*






144
nucleotide sequence [anti-
see Table 8



FAP (28H1)]2 Fc hole chain






145
[anti-FAP (28H1)]2 Fc hole
see Table 8



chain






146
nucleotide sequence dimeric
see Table 9



hu 4-1BBL (71-254) - FAP




(VHCL*) Fc knob chain






147
nucleotide sequence
see Table 9



monomeric hu 4-1BBL (71-




254) - FAP (VLCH1*)






148
dimeric hu 4-1BBL (71-254) -
see Table 9



FAP (VHCL*) Fc knob




chain






149
monomeric hu 4-1BBL (71-
see Table 9



254) - FAP (VLCH1*)






150
nucleotide sequence dimeric
see Table 10



hu 4-1BBL (52-254) -




CH1* Fc knob chain






151
nucleotide sequence
see Table 10



Monomeric hu 4-1BBL (52-




254) -CL*






152
nucleotide sequence dimeric
see Table 11



hu 4-1BBL (80-254) -




CH1* Fc knob chain






153
nucleotide sequence
see Table 11



Monomeric hu 4-1BBL (80-




254) -CL*






154
nucleotide sequence DP47
see Table 14



FC KK chain






155
nucleotide sequence DP47
see Table 14



light chain






156
DP47 FC KK chain
see Table 14





157
DP47 light chain
see Table 14





158
nucleotide sequence dimeric
see Table 15



mu 4-1BBL (104-309,




C160S) - CL Fc DD chain






159
nucleotide sequence
see Table 15



monomeric murine 4-1BBL




(104-309, C160S) - CH1






160
dimeric mu 4-1BBL (104-
see Table 15



309, C160S) - CL Fc DD




chain






161
monomeric murine 4-1BBL
see Table 15



(104-309, C160S) - CH1






162
nucleotide sequence
see Table 21



anti-FAP (4B9) Fc hole




chain






163
nucleotide sequence
see Table 21



anti-FAP (4B9) light chain






164
anti-FAP (4B9) Fc hole
see Table 21



chain






165
nucleotide sequence dimeric
see Table 22



hu 4-1BBL (71-254) - CL




Fc knob chain






166
nucleotide sequence
see Table 22



monomeric hu 4-1BBL (71-




254) - CH1






167
nucleotide sequence anti-
see Table 23



FAP (4B9) Fc hole chain




fused to dimeric hu 4-1BBL




(71-254)






168
nucleotide sequence anti-
see Table 23



FAP (4B9) Fc knob chain




fused to monomeric hu 4-




1BBL (71-254)






169
nucleotide sequence dimeric
see Table 24



hu 4-1BBL (71-248) - CL*




Fc knob chain






170
nucleotide sequence
see Table 24



monomeric hu




4-1BBL (71-248) - CH1*






171
nucleotide sequence dimeric
see Table 25



hu 4-1BBL (71-248) - CL




Fc knob chain






172
nucleotide sequence
see Table 25



monomeric hu




4-1BBL (71-248) - CH1






173
Dimeric hu 4-1BBL (71-
see Table 25



248) - CL Fc knob chain






174
Monomeric hu
see Table 25



4-1BBL (71-248) - CH1






175
nucleotide sequence anti-
see Table 26



FAP (4B9) Fc hole chain




fused to dimeric hu 4-1BBL




(71-248)






176
nucleotide sequence anti-
see Table 26



FAP (4B9) Fc knob chain




fused to monomeric hu 4-




1BBL (71-248)






177
nucleotide sequence DP47
see Table 27



Fc hole chain fused to




dimeric hu 4-1BBL (71-254)






178
nucleotide sequence DP47
see Table 27



Fc knob chain fused to




monomeric hu 4-1BBL (71-




254)






179
DP47 Fc hole chain fused to
see Table 27



dimeric hu 4-1BBL (71-254)






180
DP47 Fc knob chain fused
see Table 27



to monomeric hu 4-1BBL




(71-254)






181
nucleotide sequence DP47
see Table 29



heavy chain (hu IgG1




PGLALA)






182
DP47 heavy chain (hu IgG1
see Table 29



PGLALA)






183
monomeric hu 4-1BBL (71-
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP



254) plus (G4S)1 linker
LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY




YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA




ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG




VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLP




SPRSEGGGGS





184
monomeric hu 4-1BBL (71-
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP



248) plus (G4S)2 linker
LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY




YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA




ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG




VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLG




GGGSGGGGS





185
monomeric hu 4-1BBL (71-
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP



248) plus (G4S)1 linker
LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVY




YVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA




ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLG




VHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLG




GGGS





186
Nucleotide sequence
see Table 43



human CD19 antigen Fc




knob chain avi tag






187
Polypeptide sequence
see Table 43



human CD19 antigen Fc




knob chain avi tag






188
Nucleotide sequence
see Table 43



cynomolgus CD19 antigen




Fc knob chain avi tag






189
Polypeptide sequence
see Table 43



cynomolgus CD19 antigen




Fc knob chain avi tag






190
humanized CD19 (8B8)
NSNGNT



HVR-L1






191
humanized CD19 (8B8)
KFNG



HVR-H2






192
humanized CD19 (8B8)
TEKFQGRVTM



var. 1 to 9 HVR-H2






193
humanized CD19 (8B8)
LENPNGNT



var. 5 HVR-L1






194
humanized CD19 (8B8)
LENPSGNT



var. 9 HVR-L1






195
CD19 (8B8-018) CDR-H1
DYIMH





196
CD19 (8B8-018) CDR-H2
YINPYNDGSKYTEKFQG





197
CD19 (8B8-018) CDR-H3
GTYYYGSALFDY





198
CD19 (8B8-018) CDR-L1
KSSQSLENPNGNTYLN





199
CD19 (8B8-018) CDR-L2
RVSKRFS





200
CD19 (8B8-018) CDR-L3
LQLTHVPYT





201
CD19 (8B8-018) VH
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMH




WVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVT




MTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGS




ALFDYWGQGTTVTVSS





202
CD19 (8B8-018) VL
DIVMTQTPLSLSVTPGQPASISCKSSQSLENPNGNTYL




NWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTD




FTLKISRVEAEDVGVYYCLQLTHVPYTFGQGTKLEIK





203
Nucleotide sequence anti-
see Table 47



CD19(8B8-018)




Fc hole chain






204
Nucleotide sequence anti-
see Table 47



CD19(8B8-018) light chain






205
anti-CD19(8B8-018) Fc hole
see Table 47



chain






206
anti-CD19(8B8-018) light
see Table 47



chain






207
Nucleotide sequence anti-
see Table 49



CD19(8B8-018)Fc hole




dimeric ligand chain






208
Nucleotide sequence anti-
see Table 49



CD19(8B8-018) Fc knob




monomeric ligand






209
anti-CD19(8B8-018) Fc hole
see Table 49



dimeric ligand chain






210
anti-CD19(8B8-018) Fc
see Table 49



knob monomeric ligand






211
Nucleotide sequence anti-
see Table 52



CD19(8B8-018) Fc hole




dimeric ligand (71-248)




chain






212
Nucleotide sequence anti-
see Table 52



CD19(8B8-018) Fc knob




monomeric (71-248) ligand






213
anti-CD19(8B8-018) Fc hole
see Table 52



dimeric ligand (71-248)




chain






214
anti-CD19(8B8-018) Fc
see Table 52



knob monomeric (71-248)




ligand






215
Nucleotide sequence CD19
GAGGTCCAGCTGCAGCAGTCTGGACCTGAGCTGGT



(8B8) VH Parental clone
AAAGCCTGGGGCTTCAGTGAAGATGGCCTGCAAG




GCTTCTGGATACACATTCACTGACTATATTATGCA




CTGGGTGAAGCAGAAGACTGGGCAGGGCCTTGAG




TGGATTGGATATATTAATCCTTACAATGATGGTTCT




AAGTACACTGAGAAGTTCAACGGCAAGGCCACAC




TGACTTCAGACAAATCTTCCATCACAGCCTACATG




GAGCTCAGCAGCCTGACCTCTGAGGACTCTGCGGT




CTATTACTGTGCAAGAGGGACCTATTATTATGGTA




GCGCCCTCTTTGACTACTGGGGCCAAGGCACCACT




CTCACAGTCTCCTCG





216
Nucleotide sequence CD19
GATGCTGTGATGACCCAAACTCCACTCTCCCTGCC



(8B8) VL Parental clone
TGTCAGTCTTGGAGATCAAGCCTCCATCTCTTGCA




GGTCTAGTCAGAGCCTTGAAAACAGTAATGGAAA




CACCTATTTGAACTGGTACCTCCAGAAACCAGGCC




AGTCTCCACAACTCCTGATCTACAGGGTTTCCAAA




CGATTTTCTGGGGTCCTAGACAGGTTCAGTGGTAG




TGGATCAGGGACAGATTTCACACTGAAAATCAGCA




GAGTGGAGGCTGAGGATTTGGGAGTTTATTTCTGC




CTACAACTTACACATGTCCCGTACACGTTCGGAGG




GGGGACCAAGCTGGAAATAAAA





217
CD19 L1 reverse random
see Table 53





218
CD19 L2 forward random
see Table 53





219
CD19 H1 reverse random
see Table 53





220
CD19 H2 forward random
see Table 53





221
CD19 H3 reverse constant
see Table 53





222
LMB3
see Table 53





223
D19 L1 forward constant
see Table 54





224
CD19 L3 reverse random
see Table 54





225
CD19 L3 forward constant
see Table 54





226
CD19 H3 reverse random
see Table 54





227
Nucleotide sequence SNAP
GGCCGCCGCTAGCGGCATCGACTACAAGGACGAC



tag human CD19 ECD-
GATGACAAGGCCGGCATCGATGCCATCATGGACA



PDGFR
AAGACTGCGAAATGAAGCGCACCACCCTGGATAG




CCCTCTGGGCAAGCTGGAACTGTCTGGGTGCGAAC




AGGGCCTGCACGAGATCAAGCTGCTGGGCAAAGG




AACATCTGCCGCCGACGCCGTGGAAGTGCCTGCCC




CAGCCGCCGTGCTGGGCGGACCAGAGCCACTGAT




GCAGGCCACCGCCTGGCTCAACGCCTACTTTCACC




AGCCTGAGGCCATCGAGGAGTTCCCTGTGCCAGCC




CTGCACCACCCAGTGTTCCAGCAGGAGAGCTTTAC




CCGCCAGGTGCTGTGGAAACTGCTGAAAGTGGTGA




AGTTCGGAGAGGTCATCAGCTACCAGCAGCTGGCC




GCCCTGGCCGGCAATCCCGCCGCCACCGCCGCCGT




GAAAACCGCCCTGAGCGGAAATCCCGTGCCCATTC




TGATCCCCTGCCACCGGGTGGTGTCTAGCTCTGGC




GCCGTGGGGGGCTACGAGGGCGGGCTCGCCGTGA




AAGAGTGGCTGCTGGCCCACGAGGGCCACAGACT




GGGCAAGCCTGGGCTGGGTGATATCCCCGAGGAA




CCCCTGGTCGTGAAGGTGGAAGAGGGCGACAATG




CCGTGCTGCAGTGCCTGAAGGGCACCTCCGATGGC




CCTACCCAGCAGCTGACCTGGTCCAGAGAGAGCCC




CCTGAAGCCCTTCCTGAAGCTGTCTCTGGGCCTGC




CTGGCCTGGGCATCCATATGAGGCCTCTGGCCATC




TGGCTGTTCATCTTCAACGTGTCCCAGCAGATGGG




CGGCTTCTACCTGTGTCAGCCTGGCCCCCCATCTG




AGAAGGCTTGGCAGCCTGGCTGGACCGTGAACGT




GGAAGGATCCGGCGAGCTGTTCCGGTGGAACGTGT




CCGATCTGGGCGGCCTGGGATGCGGCCTGAAGAA




CAGATCTAGCGAGGGCCCCAGCAGCCCCAGCGGC




AAACTGATGAGCCCCAAGCTGTACGTGTGGGCCAA




GGACAGACCCGAGATCTGGGAGGGCGAGCCTCCT




TGCCTGCCCCCTAGAGACAGCCTGAACCAGAGCCT




GAGCCAGGACCTGACAATGGCCCCTGGCAGCACA




CTGTGGCTGAGCTGTGGCGTGCCACCCGACTCTGT




GTCTAGAGGCCCTCTGAGCTGGACCCACGTGCACC




CTAAGGGCCCTAAGAGCCTGCTGAGCCTGGAACTG




AAGGACGACAGGCCCGCCAGAGATATGTGGGTCA




TGGAAACCGGCCTGCTGCTGCCTAGAGCCACAGCC




CAGGATGCCGGCAAGTACTACTGCCACAGAGGCA




ACCTGACCATGAGCTTCCACCTGGAAATCACCGCC




AGACCCGTGCTGTGGCACTGGCTGCTGAGAACAGG




CGGCTGGAAGGTCGACGAACAAAAACTCATCTCA




GAAGAGGATCTGAATGCTGTGGGCCAGGACACGC




AGGAGGTCATCGTGGTGCCACACTCCTTGCCCTTT




AAGGTGGTGGTGATCTCAGCCATCCTGGCCCTGGT




GGTGCTCACCATCATCTCCCTTATCATCCTCATCAT




GCTTTGGCAGAAGAAGCCACGT





228
Nucleotide sequence SNAP
CCGGCCGCCGCTAGCGGCATCGACTACAAGGACG



tag cynomolgus CD19
ACGATGACAAGGCCGGCATCGATGCCATCATGGA



ECD- PDGFR
CAAAGACTGCGAAATGAAGCGCACCACCCTGGAT




AGCCCTCTGGGCAAGCTGGAACTGTCTGGGTGCGA




ACAGGGCCTGCACGAGATCAAGCTGCTGGGCAAA




GGAACATCTGCCGCCGACGCCGTGGAAGTGCCTGC




CCCAGCCGCCGTGCTGGGCGGACCAGAGCCACTG




ATGCAGGCCACCGCCTGGCTCAACGCCTACTTTCA




CCAGCCTGAGGCCATCGAGGAGTTCCCTGTGCCAG




CCCTGCACCACCCAGTGTTCCAGCAGGAGAGCTTT




ACCCGCCAGGTGCTGTGGAAACTGCTGAAAGTGGT




GAAGTTCGGAGAGGTCATCAGCTACCAGCAGCTG




GCCGCCCTGGCCGGCAATCCCGCCGCCACCGCCGC




CGTGAAAACCGCCCTGAGCGGAAATCCCGTGCCCA




TTCTGATCCCCTGCCACCGGGTGGTGTCTAGCTCTG




GCGCCGTGGGGGGCTACGAGGGCGGGCTCGCCGT




GAAAGAGTGGCTGCTGGCCCACGAGGGCCACAGA




CTGGGCAAGCCTGGGCTGGGTGATATCCCCCAGGA




ACCCCTGGTCGTGAAGGTGGAAGAGGGCGACAAT




GCCGTGCTCCAGTGTCTCGAGGGCACCTCCGATGG




CCCTACACAGCAGCTCGTGTGGTGCAGAGACAGCC




CCTTCGAGCCCTTCCTGAACCTGTCTCTGGGCCTGC




CTGGCATGGGCATCAGAATGGGCCCTCTGGGCATC




TGGCTGCTGATCTTCAACGTGTCCAACCAGACCGG




CGGCTTCTACCTGTGTCAGCCTGGCCTGCCAAGCG




AGAAGGCTTGGCAGCCTGGATGGACCGTGTCCGTG




GAAGGATCTGGCGAGCTGTTCCGGTGGAACGTGTC




CGATCTGGGCGGCCTGGGATGCGGCCTGAAGAAC




AGAAGCAGCGAGGGCCCTAGCAGCCCCAGCGGCA




AGCTGAATAGCAGCCAGCTGTACGTGTGGGCCAA




GGACAGACCCGAGATGTGGGAGGGCGAGCCTGTG




TGTGGCCCCCCTAGAGATAGCCTGAACCAGAGCCT




GAGCCAGGACCTGACAATGGCCCCTGGCAGCACA




CTGTGGCTGAGCTGTGGCGTGCCACCCGACTCTGT




GTCCAGAGGCCCTCTGAGCTGGACACACGTGCGGC




CTAAGGGCCCTAAGAGCAGCCTGCTGAGCCTGGA




ACTGAAGGACGACCGGCCCGACCGGGATATGTGG




GTGGTGGATACAGGCCTGCTGCTGACCAGAGCCAC




AGCCCAGGATGCCGGCAAGTACTACTGCCACAGA




GGCAACTGGACCAAGAGCTTTTACCTGGAAATCAC




CGCCAGACCCGCCCTGTGGCACTGGCTGCTGAGAA




TCGGAGGCTGGAAGGTCGACGAGCAGAAGCTGAT




CTCCGAAGAGGACCTGAACGCCGTGGGCCAGGAT




ACCCAGGAAGTGATCGTGGTGCCCCACAGCCTGCC




CTTCAAGGTGGTCGTGATCAGCGCCATTCTGGCCC




TGGTGGTGCTGACCATCATCAGCCTGATCATCCTG




ATTATGCTGTGGCAGAAAAAGCCCCGC





229
Polypeptide sequence SNAP
PAAASGIDYKDDDDKAGIDAIMDKDCEMKRTTLDSP



tag human CD19 ECD-
LGKLELSGCEQGLHEIKLLGKGTSAADAVEVPAPAA



PDGFR
VLGGPEPLMQATAWLNAYFHQPEAIEEFPVPALHHP




VFQQESFTRQVLWKLLKVVKFGEVISYQQLAALAGN




PAATAAVKTALSGNPVPILIPCHRVVSSSGAVGGYEG




GLAVKEWLLAHEGHRLGKPGLGDIPEEPLVVKVEEG




DNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKLSLG




LPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSE




KAWQPGWTVNVEGSGELFRWNVSDLGGLGCGLKN




RSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLP




PRDSLNQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPL




SWTHVHPKGPKSLLSLELKDDRPARDMWVMETGLL




LPRATAQDAGKYYCHRGNLTMSFHLEITARPVLWH




WLLRTGGWKVDEQKLISEEDLNAVGQDTQEVIVVP




HSLPFKVVVISAILALVVLTIISLIILIMLWQKKPR





230
Polypeptide sequence SNAP
PAAASGIDYKDDDDKAGIDAIMDKDCEMKRTTLDSP



tag cynomolgus CD19
LGKLELSGCEQGLHEIKLLGKGTSAADAVEVPAPAA



ECD-PDGFR
VLGGPEPLMQATAWLNAYFHQPEAIEEFPVPALHHP




VFQQESFTRQVLWKLLKVVKFGEVISYQQLAALAGN




PAATAAVKTALSGNPVPILIPCHRVVSSSGAVGGYEG




GLAVKEWLLAHEGHRLGKPGLGDIPQEPLVVKVEEG




DNAVLQCLEGTSDGPTQQLVWCRDSPFEPFLNLSLG




LPGMGIRMGPLGIWLLIFNVSNQTGGFYLCQPGLPSE




KAWQPGWTVSVEGSGELFRWNVSDLGGLGCGLKN




RSSEGPSSPSGKLNSSQLYVWAKDRPEMWEGEPVCG




PPRDSLNQSLSQDLTMAPGSTLWLSCGVPPDSVSRGP




LSWTHVRPKGPKSSLLSLELKDDRPDRDMWVVDTG




LLLTRATAQDAGKYYCHRGNWTKSFYLEITARPAL




WHWLLRIGGWKVDEQKLISEEDLNAVGQDTQEVIV




VPHSLPFKVVVISAILALVVLTIISLIILIMLWQKKPR





231
CD19 (8B8-5H09) CDR-L1
see Table 56





232
CD19 (8B8-5H09) CDR-L2
see Table 56





233
CD19 (8B8-5H09) CDR-L3
see Table 56





234
CD19 (8B8-5H09) CDR-H1
see Table 57





235
CD19 (8B8-5H09) CDR-H2
see Table 57





236
CD19 (8B8-5H09) CDR-H3
see Table 57





237
CD19 (8B8-7H07) CDR-L1
see Table 56





238
CD19 (8B8-7H07) CDR-L2
see Table 56





239
CD19 (8B8-7H07) CDR-L3
see Table 56





240
CD19 (8B8-7H07) CDR-H1
see Table 57





241
CD19 (8B8-7H07) CDR-H2
see Table 57





242
CD19 (8B8-7H07) CDR-H3
see Table 57





243
CD19 (8B8-2B03) CDR-L1
see Table 56





244
CD19 (8B8-2B03) CDR-L2
see Table 56





245
CD19 (8B8-2B03) CDR-L3
see Table 56





246
CD19 (8B8-2B03) CDR-H1
see Table 57





247
CD19 (8B8-2B03) CDR-H2
see Table 57





248
CD19 (8B8-2B03) CDR-H3
see Table 57





249
CD19 (8B8-2B11) CDR-L1
see Table 56





250
CD19 (8B8-2B11) CDR-L2
see Table 56





251
CD19 (8B8-2B11) CDR-L3
see Table 56





252
CD19 (8B8-2B11) CDR-H1
see Table 57





253
CD19 (8B8-2B11) CDR-H2
see Table 57





254
CD19 (8B8-2B11) CDR-H3
see Table 57





255
CD19 (8B8-5A07) CDR-L1
see Table 56





256
CD19 (8B8-5A07) CDR-L2
see Table 56





257
CD19 (8B8-5A07) CDR-L3
see Table 56





258
CD19 (8B8-5A07) CDR-H1
see Table 57





259
CD19 (8B8-5A07) CDR-H2
see Table 57





260
CD19 (8B8-5A07) CDR-H3
see Table 57





261
CD19 (8B8-5B08) CDR-L1
see Table 56





262
CD19 (8B8-5B08) CDR-L2
see Table 56





263
CD19 (8B8-5B08) CDR-L3
see Table 56





264
CD19 (8B8-5B08) CDR-H1
see Table 57





265
CD19 (8B8-5B08) CDR-H2
see Table 57





266
CD19 (8B8-5B08) CDR-H3
see Table 57





267
CD19 (8B8-5D08) CDR-L1
see Table 56





268
CD19 (8B8-5D08) CDR-L2
see Table 56





269
CD19 (8B8-5D08) CDR-L3
see Table 56





270
CD19 (8B8-5D08) CDR-H1
see Table 57





271
CD19 (8B8-5D08) CDR-H2
see Table 57





272
CD19 (8B8-5D08) CDR-H3
see Table 57





273
nucleotide sequence CD19
see Table 58



(8B8) parental light chain






274
nucleotide sequence CD19
see Table 58



(8B8) parental heavy chain






275
CD19 (8B8) parental light
see Table 58



chain






276
CD19 (8B8) parental heavy
see Table 58



chain






277
nucleotide sequence CD19
see Table 59



(8B8-2B11) light chain






278
nucleotide sequence CD19
see Table 59



(8B8-2B11) heavy chain






279
CD19 (8B8-2B11) light
see Table 59



chain






280
CD19 (8B8-2B11) heavy
see Table 59



chain






281
nucleotide sequence CD19
see Table 59



(8B8-7H07) light chain






282
nucleotide sequence CD19
see Table 59



(8B8-7H07) heavy chain






283
CD19 (8B8-7H07) light
see Table 59



chain






284
CD19 (8B8-7H07) heavy
see Table 59



chain






285
nucleotide sequence CD19
see Table 59



(8B8-2B03) light chain






286
nucleotide sequence CD19
see Table 59



(8B8-2B03) heavy chain






287
CD19 (8B8-2B03) light
see Table 59



chain






288
CD19 (8B8-2B03) heavy
see Table 59



chain






289
nucleotide sequence CD19
see Table 59



(8B8-5A07) light chain






290
nucleotide sequence CD19
see Table 59



(8B8-5A07) heavy chain






291
CD19 (8B8-5A07) light
see Table 59



chain






292
CD19 (8B8-5A07) heavy
see Table 59



chain






293
nucleotide sequence CD19
see Table 59



(8B8-5D08) light chain






294
nucleotide sequence CD19
see Table 59



(8B8-5D08) heavy chain






295
CD19 (8B8-5D08) light
see Table 59



chain






296
CD19 (8B8-5D08) heavy
see Table 59



chain






297
nucleotide sequence CD19
see Table 59



(8B8-5B08) light chain






298
nucleotide sequence CD19
see Table 59



(8B8-5B08) heavy chain






299
CD19 (8B8-5B08) light
see Table 59



chain






300
CD19 (8B8-5B08) heavy
see Table 59



chain






301
nucleotide sequence CD19
see Table 59



(8B8-5H09) light chain






302
nucleotide sequence CD19
see Table 59



(8B8-5H09) heavy chain






303
CD19 (8B8-5H09) light
see Table 59



chain






304
CD19 (8B8-5H09) heavy
see Table 59



chain






305
Nucleotide sequence anti-
see Table 62



CD19 (8B8-2B11)




Fc hole chain






306
anti-CD19 (8B8-2B11) Fc
see Table 62



hole chain






307
Nucleotide sequence anti-
see Table 64



CD19 (8B8-2B11) Fc hole




dimeric ligand chain






308
Nucleotide sequence anti-
see Table 64



CD19 (8B8-2B11) Fc knob




monomeric ligand






309
anti-CD19 (8B8-2B11) Fc
see Table 64



hole dimeric ligand chain






310
anti-CD19 (8B8-2B11) Fc
see Table 64



knob monomeric ligand






311
Nucleotide sequence anti-
see Table 67



CD19 (8B8-2B11) Fc hole




dimeric ligand (71-248)




chain






312
Nucleotide sequence anti-
see Table 67



CD19 (8B8-2B11) Fc knob




monomeric (71-248) ligand






313
anti-CD19 (8B8-2B11) Fc
see Table 67



hole dimeric ligand (71-248)




chain






314
anti-CD19 (8B8-2B11) Fc
see Table 67



knob monomeric (71-248)




ligand






315
nucleotide sequence
see Table 72



CD19 (8B8-018) heavy chain




(huIgG1 PGLALA)






316
CD19 (8B8-018) heavy chain
see Table 72



(huIgG1 PGLALA)






317
anti-mu CEA T84.66
MKCSWVIFFL MAVVTGVNSE VQLQQSGAEL



VH
VEPGASVKLS CTASGFNIKD TYMHWVKQRP




EQGLEWIGRI DPANGNSKYV PKFQGKATIT




ADTSSNTAYL QLTSLTSEDT AVYYCAPFGY




YVSDYAMAYW GQGTSVTVSS





318
anti-mu CEA T84.66
METDTLLLWV LLLWVPGSTG DIVLTQSPAS



VL
LAVSLGQRAT MSCRAGESVD IFGVGFLHWY




QQKPGQPPKL LIYRASNLES GIPVRFSGTG




SRTDFTLIID PVEADDVATY YCQQTNEDPY




TFGGGTKLEI K





319
IGHV1-69*08
TAAGGGGCTT CCTAGTCCTA AGGCTGAGGA



IMGT Acc No. Z14309
AGGGATCCTG GTTTAGTTAA AGAGGATTTT




ATTCACCCCT GTGTCCTCTC CACAGGTGTC




CAGTCCCAGG TCCAGCTGGT GCAATCTGGG




GCTGAGGTGA AGAAGCCTGG GTCCTCGGTG




AAGGTCTCCT GCAAGGCTTC TGGAGGCACC




TTCAGCAGCT ATACTATCAG CTGGGTGCGA




CAGGCCCCTG GACAAGGGCT TGAGTGGATG




GGAAGGATCA TCCCTATCCT TGGTACAGCA




AACTACGCAC AGAAGTTCCA GGGCAGAGTC




ACGATTACCG CGGACAAATC CACGAGCACA




GCCTACATGG AGCTGAGCAG CCTGAGATCT




GAGGACACGG CCGTGTATTA CTGTGCGAGA GA





320
IGKV3-11*01
CTGCAGCTGG AAGCTCAGCT CCCACCCAGC



IMGT Acc No.
TGCTTTGCAT GTCCCTCCCA GCTGCCCTAC




CTTCCAGAGC CCATATCAAT GCCTGTGTCA




GAGCCCTGGG GAGGAACTGC TCAGTTAGGA




CCCAGAGGGA ACCATGGAAG CCCCAGCTCA




GCTTCTCTTC CTCCTGCTAC TCTGGCTCCC




AGGTGAGGGG AACATGAGGT GGTTTTGCAC




ATTAGTGAAA ACTCTTGCCA CCTCTGCTCA




GCAAGAAATA TAATTAAAAT TCAAAGTATA




TCAACAATTT TGGCTCTACT CAAAGACAGT




TGGTTTGATC TTGATTACAT GAGTGCATTT




CTGTTTTATT TCCAATTTCA GATACCACCG




GAGAAATTGT GTTGACACAG TCTCCAGCCA




CCCTGTCTTT GTCTCCAGGG GAAAGAGCCA




CCCTCTCCTG CAGGGCCAGT CAGAGTGTTA




GCAGCTACTT AGCCTGGTAC CAACAGAAAC




CTGGCCAGGC TCCCAGGCTC CTCATCTATG




ATGCATCCAA CAGGGCCACT GGCATCCCAG




CCAGGTTCAG TGGCAGTGGG TCTGGGACAG




ACTTCACTCT CACCATCAGC AGCCTAGAGC




CTGAAGATTT TGCAGTTTAT TACTGTCAGC




AGCGTAGCAA CTGGCCTCCC ACAGTGATTC




CACATGAAAC AAAAACCCCA ACAAGACCAT




CAGTGTTTAC TAGATTATTA TACCAGCTGC




TTCCTTTACA GACAGCTAGT GGGGTGGCCA




CTCAGTGTTA GCATCTCAGC TCTATTTGGC




CATTTTGGAG TTCAAGT





321
CEA CDR-H1
see Table 81





322
CEA CDR-H2
see Table 81





323
CEA CDR-H3
see Table 81





324
CEA CDR-L1
see Table 81





325
CEA CDR-L2
see Table 81





326
CEA CDR-L3
see Table 81





327
Parental CEA binder VH
see Table 81





328
Parental CEA binder VL
see Table 81





329
Humanized CEA binder VH
see Table 81





330
Humanized CEA binder VL
see Table 81





331
Nucleotide sequence anti-
see Table 82



CEA (T84.66-LCHA) Fc




hole chain






332
Nucleotide sequence anti-
see Table 82



CEA (T84.66-LCHA) light




chain






333
anti-CEA (T84.66-LCHA)
see Table 82



Fc hole chain






334
anti-CEA (T84.66-LCHA)
see Table 82



light chain






335
Nucleotide sequence anti-
see Table 84



CEA (T84.66-LCHA) Fc




hole dimeric ligand chain






336
Nucleotide sequence anti-
see Table 84



CEA (T84.66-LCHA) Fc




knob monomeric ligand






337
anti-CEA (T84.66-LCHA)
see Table 84



Fc hole dimeric ligand chain






338
anti-CEA (T84.66-LCHA)
see Table 84



Fc knob monomeric ligand






339
Nucleotide sequence anti-
see Table 87



CEA (T84.66-LCHA) Fc




hole dimeric ligand (71-248)




chain






340
Nucleotide sequence anti-
see Table 87



CEA (T84.66-LCHA) Fc




knob monomeric (71-248)




ligand






341
anti-CEA (T84.66-LCHA)
see Table 87



Fc hole dimeric ligand (71-




248) chain






342
anti-CEA (T84.66-LCHA)
see Table 87



Fc knob monomeric (71-




248) ligand






343
Nucleotide sequence anti-
see Table 88



CEA (T84.66) Fc hole chain






344
Nucleotide sequence anti-
see Table 88



CEA (T84.66) light chain






345
anti-CEA (T84.66) Fc hole
see Table 88



chain






346
anti-CEA (T84.66) light
see Table 88



chain






347
Nucleotide sequence anti-
see Table 89



CEA (T84.66) Fc hole




dimeric ligand chain






348
Nucleotide sequence anti-
see Table 89



CEA (T84.66) Fc knob




monomeric ligand






349
anti-CEA (T84.66) Fc hole
see Table 89



dimeric ligand chain






350
anti-CEA (T84.66) Fc knob
see Table 89



monomeric ligand






351
nucleotide sequence hu
see Table 92



NA3B3A2-avi His






352
human NA3B3A2-avi-His
see Table 92





353
Nucleotide sequence
see Table 97



Dimeric hu OX40L (51-183) -




CL* Fc knob chain






354
Nucleotide sequence
see Table 97



Monomeric hu




OX40L (51-183) - CH1*






355
Dimeric hu OX40L (51-183) -
see Table 97



CL* Fc knob chain






356
Monomeric hu
see Table 97



OX40L (51-183) - CH1*






357
CD19 (8B8-2B11) VH
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMH




WVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVT




MTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGP




QLFDYWGQGTTVTVSS





358
CD19 (8B8-2B11) VL
DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGTTYL




NWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTD




FTLKISRVEAEDVGVYYCLQLLEDPYTFGQGTKLEIK





359
CD19 (8B8-7H07) VH
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMH




WVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVT




MTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGS




ELFDYWGQGTTVTVSS





360
CD19 (8B8-7H07) VL
DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYL




NWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTD




FTLKISRVEAEDVGVYYCLQATHIPYTFGQGTKLEIK





361
CD19 (8B8-2B03) VH
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYITH




WVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVT




MTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGP




DLFDYWGQGTTVTVSS





362
CD19 (8B8-2B03) VL
DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYL




NWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTD




FTLKISRVEAEDVGVYYCLQLTHVPYTFGQGXKLEIK





363
CD19 (8B8-5A07) VH
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMH




WVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVT




MTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGS




ALFDYWGQGTTVTVSS





364
CD19 (8B8-5A07) VL
DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYL




NWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTD




FTLKISRVEAEDVGVYYCLQPGHYPGTFGQGTKLEIK





365
CD19 (8B8-5D08) VH
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMH




WVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVT




MTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGS




ELFDYWGQGTTVTVSS





366
CD19 (8B8-5D08) VL
DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYL




NWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTD




FTLKISRVEAEDVGVYYCLQLTHEPYTFGQGTKLEIK





367
CD19 (8B8-5B08) VH
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMH




WVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVT




MTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGP




QLFDYWGQGTTVTVSS





368
CD19 (8B8-5B08) VL
DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYL




NWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTD




FTLKISRVEAEDVGVYYCLQLDSYPNTFGQGTKLEIK





369
CD19 (8B8-5H09) VH
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMH




WVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVT




MTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGS




ALFDYWGQGTTVTVSS





370
CD19 (8B8-5H09) VL
DIVMTQTPLSLSVTPGQPASISCKSSQSLESSTGNTYL




NWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTD




FTLKISRVEAEDVGVYYCLQLIDYPVTFGQGTKLEIK





371
dimeric huOX40L (51-183)
QVSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMK



connected by (G4S)2 linker
VQNNSVIINCDGFYLISLKGYFSQEVNISLHYQKDEEP




LFQLKKVRSVNSLMVASLTYKDKVYLNVTTDNTSL




DDFHVNGGELILIHQNPGEFCVLGGGGSGGGGSQVS




HRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKVQN




NSVIINCDGFYLISLKGYFSQEVNISLHYQKDEEPLFQ




LKKVRSVNSLMVASLTYKDKVYLNVTTDNTSLDDF




HVNGGELILIHQNPGEFCVL





372
dimeric huOX40L (52-183)
VSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKV



connected by (G4S)2 linker
QNNSVIINCDGFYLISLKGYFSQEVNISLHYQKDEEPL




FQLKKVRSVNSLMVASLTYKDKVYLNVTTDNTSLD




DFHVNGGELILIHQNPGEFCVLGGGGSGGGGSVSHR




YPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKVQNNS




VIINCDGFYLISLKGYFSQEVNISLHYQKDEEPLFQLK




KVRSVNSLMVASLTYKDKVYLNVTTDNTSLDDFHV




NGGELILIHQNPGEFCVL





373
hu 4-1BBL (85-248)
LDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSL




TGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAG




EGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEA




RNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQ




LTQGATVLGLFRVTPEIPAGL





374
hu 4-1BBL (80-248)
DPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGL




AGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRR




VVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPP




ASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARAR




HAWQLTQGATVLGLFRVTPEIPAGL





375
hu 4-1BBL (52-248)
PWAVSGARASPGSAASPRLREGPELSPDDPAGLLDLR




QGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGL




SYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSG




SVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSA




FGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQG




ATVLGLFRVTPEIPAGL









General information regarding the nucleotide sequences of human immunoglobulins light and heavy chains is given in: Kabat, E. A., et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991). Amino acids of antibody chains are numbered and referred to according to the EU numbering systems according to Kabat (Kabat, E. A., et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991)) as defined above.


EXAMPLES

The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided above.


Recombinant DNA Techniques


Standard methods were used to manipulate DNA as described in Sambrook et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989. The molecular biological reagents were used according to the manufacturer's instructions. General information regarding the nucleotide sequences of human immunoglobulin light and heavy chains is given in: Kabat, E. A. et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Ed., NIH Publication No 91-3242.


DNA Sequencing


DNA sequences were determined by double strand sequencing.


Gene Synthesis


Desired gene segments were either generated by PCR using appropriate templates or were synthesized by Geneart AG (Regensburg, Germany) from synthetic oligonucleotides and PCR products by automated gene synthesis. In cases where no exact gene sequence was available, oligonucleotide primers were designed based on sequences from closest homologues and the genes were isolated by RT-PCR from RNA originating from the appropriate tissue. The gene segments flanked by singular restriction endonuclease cleavage sites were cloned into standard cloning/sequencing vectors. The plasmid DNA was purified from transformed bacteria and concentration determined by UV spectroscopy. The DNA sequence of the subcloned gene fragments was confirmed by DNA sequencing. Gene segments were designed with suitable restriction sites to allow sub-cloning into the respective expression vectors. All constructs were designed with a 5′-end DNA sequence coding for a leader peptide which targets proteins for secretion in eukaryotic cells.


Cell Culture Techniques


Standard cell culture techniques were used as described in Current Protocols in Cell Biology (2000), Bonifacino, J. S., Dasso, M., Harford, J. B., Lippincott-Schwartz, J. and Yamada, K. M. (eds.), John Wiley & Sons, Inc.


Protein Purification


Proteins were purified from filtered cell culture supernatants referring to standard protocols. In brief, antibodies were applied to a Protein A Sepharose column (GE healthcare) and washed with PBS. Elution of antibodies was achieved at pH 2.8 followed by immediate neutralization of the sample. Aggregated protein was separated from monomeric antibodies by size exclusion chromatography (Superdex 200, GE Healthcare) in PBS or in 20 mM Histidine, 150 mM NaCl pH 6.0. Monomeric antibody fractions were pooled, concentrated (if required) using e.g., a MILLIPORE Amicon Ultra (30 MWCO) centrifugal concentrator, frozen and stored at −20° C. or −80° C. Part of the samples were provided for subsequent protein analytics and analytical characterization e.g. by SDS-PAGE, size exclusion chromatography (SEC) or mass spectrometry.


SDS-PAGE


The NuPAGE® Pre-Cast gel system (Invitrogen) was used according to the manufacturer's instruction. In particular, 10% or 4-12% NuPAGE® Novex® Bis-TRIS Pre-Cast gels (pH 6.4) and a NuPAGE® MES (reduced gels, with NuPAGE® Antioxidant running buffer additive) or MOPS (non-reduced gels) running buffer was used.


Analytical Size Exclusion Chromatography


Size exclusion chromatography (SEC) for the determination of the aggregation and oligomeric state of antibodies was performed by HPLC chromatography. Briefly, Protein A purified antibodies were applied to a Tosoh TSKGEL® G3000SW column in 300 mM NaCl, 50 mM KH2PO4/K2HPO4, pH 7.5 on an Agilent HPLC 1100 system or to a Superdex 200 column (GE Healthcare) in 2×PBS on a Dionex HPLC-System. The eluted protein was quantified by UV absorbance and integration of peak areas. BioRad Gel Filtration Standard 151-1901 served as a standard.


Mass Spectrometry


This section describes the characterization of the multispecific antibodies with VH/VL exchange (VH/VL CrossMabs) with emphasis on their correct assembly. The expected primary structures were analyzed by electrospray ionization mass spectrometry (ESI-MS) of the deglycosylated intact CrossMabs and deglycosylated/plasmin digested or alternatively deglycosylated/limited LysC digested CrossMabs.


The VH/VL CrossMabs were deglycosylated with N-Glycosidase F in a phosphate or Tris buffer at 37° C. for up to 17 h at a protein concentration of 1 mg/ml. The plasmin or limited LysC (Roche) digestions were performed with 100 μs deglycosylated VH/VL CrossMabs in a Tris buffer pH 8 at room temperature for 120 hours and at 37° C. for 40 min, respectively. Prior to mass spectrometry the samples were desalted via HPLC on a Sephadex G25 column (GE Healthcare). The total mass was determined via ESI-MS on a maXis 4G UHR-QTOF MS system (Bruker Daltonik) equipped with a TriVersa NanoMate source (Advion).


Determination of Binding and Binding Affinity of Multispecific Antibodies to the Respective Antigens Using Surface Plasmon Resonance (SPR) (BIACORE®)


Binding of the generated antibodies to the respective antigens is investigated by surface plasmon resonance using a BIACORE® instrument (GE Healthcare Biosciences AB, Uppsala, Sweden). Briefly, for affinity measurements Goat-Anti-Human IgG, JIR 109-005-098 antibodies are immobilized on a CM5 chip via amine coupling for presentation of the antibodies against the respective antigen. Binding is measured in HBS buffer (HBS-P (10 mM HEPES, 150 mM NaCl, 0.005% Tween 20, ph 7.4), 25° C. (or alternatively at 37° C.). Antigen (R&D Systems or in house purified) was added in various concentrations in solution. Association was measured by an antigen injection of 80 seconds to 3 minutes; dissociation was measured by washing the chip surface with HBS buffer for 3-10 minutes and a KD value was estimated using a 1:1 Langmuir binding model. Negative control data (e.g. buffer curves) are subtracted from sample curves for correction of system intrinsic baseline drift and for noise signal reduction. The respective Biacore Evaluation Software is used for analysis of sensorgrams and for calculation of affinity data.


Example 1

1.1 Preparation of Targeted Human 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules


Different fragments of the DNA sequence encoding part of the ectodomain (amino acids 71-254, 52-254 and 80-254) of human 4-1BB ligand were synthetized according to the P41273 sequence of Uniprot database (SEQ ID NO:42).


As components for the assembly of a TNF ligand trimer-containing antigen binding molecule a polypeptide comprising two ectodomains of 4-1BB ligand, separated by (G4S)2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CH1 or CL domain, was cloned as depicted in FIG. 1A (human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CH1 or CL) or as depicted in FIG. 1C (human CH3, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand).


A polypeptide comprising one ectodomain of 4-1BB ligand and fused to the human IgG1-CL or CH1 domain, was cloned as described in FIG. 1B (human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CL or CH1) or as depicted in FIG. 1D (human CH3, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand).


The polypeptides were subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains with optional peptide linkers, for example for construct 1 the polypeptide encoding the dimeric 4-1BB ligand fused to a human CH1 domain was subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant, Zhu et al. 1998) using a linker (G4S)2 of SEQ ID NO:13 or GSPGSSSSGS of SEQ ID NO:57.


The variable region of heavy and light chain DNA sequences encoding a binder specific for fibroblast activation protein (FAP), i.e. 28H1, were subcloned in frame with either the constant heavy chain of the hole (Carter, J. Immunol. Methods (2001), 248, 7-15) or the constant light chain of human IgG1. The generation and preparation of the FAP binders is described in WO 2012/020006 A2, which is incorporated herein by reference.


Table 1 summarizes the characteristics of the constructs produced. The constructs 1 to 10 differ in their geometry, valency for FAP, 4-1BB ligand ectodomain, crossover of the CH1 and CL domain (CrossMab technology), mutations in the CH1 and CL domains and different peptide linkers in the polypeptide comprising one ectodomain of 4-1BB ligand (monomeric 4-1BBL chain).









TABLE 1







Characteristics of produced TNF ligand trimer-containing antigen binding molecules


(FAP split 4-1BBL trimers)

















Crossed

Linker to 4-



Valency for
FAP
4-1BBL
CH1-CL
Charged
1BBL in


Construct
FAP
binder
ectodomain
domains
residues
light chain





1.1
monovalent
28H1
71-254
no
no
(G4S)2








(SEQ ID








NO: 13)


1.2
monovalent
28H1
71-254
yes (Ligand)
yes
(G4S)2







(Ligand)
(SEQ ID








NO: 13)


1.3
monovalent
28H1
71-254
yes (FAP
yes
(G4S)2






Fab)
(Ligand)
(SEQ ID








NO: 13)


1.4
monovalent
28H1
71-254
no
yes
(G4S)2







(Ligand)
(SEQ ID








NO: 13)


1.5
bivalent
28H1
71-254
no
no
(G4S)2








(SEQ ID








NO: 13)


1.6
monovalent
28H1
71-254
no
yes
(G4S)1







(Ligand)
(SEQ ID








NO: 128)


1.7
bivalent
28H1
71-254
yes (Ligand)
yes
(G4S)2







(Ligand)
(SEQ ID








NO: 13)


1.8
bivalent
28H1
71-254
yes (FAP
yes
(G4S)2






Fab fused to
(Ligand)
(SEQ ID






Ligand)

NO: 13)


1.9
monovalent
28H1
52-254
no
yes
(G4S)2







(Ligand)
(SEQ ID








NO: 13)


1.10
monovalent
28H1
80-254
no
yes
(G4S)2







(Ligand)
(SEQ ID








NO: 13)









In order to avoid mispairing, in most of the constructs one pair of CH1 and CL domains was replaced by each other (domain crossover) as described in WO 2009/080253 A1.


To further improve correct pairing, different charged amino acid substitutions were introduced in the crossed or non-crossed CH1 and CL domains as charged residues in constructs 2 to 4 and 6 to 10. In the human CL domain the mutations E123R and Q124K were introduced, whereas the mutations K147E and K213E were cloned into the human CH1 domain.


For all constructs the knobs into holes heterodimerization technology was used with the S354C/T366W mutations in the CH3 domain of the knob chain and the corresponding Y349C/T366S/L368A/Y407V mutations in the CH3 domain of the hole chain (Carter, J Immunol Methods 248, 7-15 (2001)).


The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in International Patent Appl. Publ. No. WO 2012/130831 A1.


For example, in construct 1 the combination of the ligand-Fc knob chain containing the S354C/T366W mutations in the first CH3 domain, with the targeted anti-FAP-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations in the second CH3 domain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a FAP binding Fab (FIG. 2A, Construct 1.1).


Table 2 shows the cDNA and amino acid sequences of the monovalent FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecule (Construct 1.1).









TABLE 2







Sequences of FAP-targeted human


4-1BB ligand trimer containing


Fc (kih) fusion molecule


Construct 1.1











SEQ





ID





NO:
Description
Sequence







66
Dimeric hu 4-
AGAGAGGGCCCTGAGCTGAGCCCCG




1BBL (71-254)-
ATGATCCTGCTGGACTGCTGGACCT




CH1 Fc knob
GCGGCAGGGCATGTTTGCTCAGCTG




chain
GTGGCCCAGAACGTGCTGCTGATCG





ATGGCCCCCTGTCCTGGTACAGCGA





TCCTGGACTGGCTGGCGTGTCACTG





ACAGGCGGCCTGAGCTACAAAGAGG





ACACCAAAGAACTGGTGGTGGCCAA





GGCCGGCGTGTACTACGTGTTCTTT





CAGCTGGAACTGCGGAGAGTGGTGG





CCGGCGAAGGATCTGGCTCTGTGTC





TCTGGCCCTGCATCTGCAGCCTCTG





AGAAGCGCTGCTGGCGCTGCAGCTC





TGGCACTGACAGTGGATCTGCCTCC





TGCCAGCTCCGAGGCCCGGAATAGC





GCATTTGGGTTTCAAGGCAGGCTGC





TGCACCTGTCTGCCGGCCAGAGGCT





GGGAGTGCATCTGCACACAGAGGCC





AGGGCTAGACACGCCTGGCAGCTGA





CACAGGGCGCTACAGTGCTGGGCCT





GTTCAGAGTGACCCCCGAGATTCCA





GCCGGCCTGCCTTCTCCAAGAAGCG





AAGGCGGAGGCGGATCTGGCGGCGG





AGGATCTAGAGAGGGACCCGAACTG





TCCCCTGACGATCCAGCCGGGCTGC





TGGATCTGAGACAGGGAATGTTCGC





CCAGCTGGTGGCTCAGAATGTGCTG





CTGATTGACGGACCTCTGAGCTGGT





ACTCCGACCCAGGGCTGGCAGGGGT





GTCCCTGACTGGGGGACTGTCCTAC





AAAGAAGATACAAAAGAACAGCTGG





AACTGAGGCGGGTGGTGGCTGGGGA





GGGCTCAGGATCTGTGTCCCTGGCT





CTGCATCTGCAGCCACTGCGCTCTG





CTGCTGGCGCAGCTGCACTGGCTCT





GACTGTGGACCTGCCACCAGCCTCT





AGCGAGGCCAGAAACAGCGCCTTCG





GGTTCCAAGGACGCCTGCTGCATCT





GAGCGCCGGACAGCGCCTGGGAGTG





CATCTGCATACTGAAGCCAGAGCCC





GGCATGCTTGGCAGCTGACTCAGGG





GGCAACTGTGCTGGGACTGTTTCGC





GTGACACCTGAGATCCCTGCCGGAC





TGCCAAGCCCTAGATCAGAAGGGGG





CGGAGGAAGCGGAGGGGGAGGAAGT





GCTAGCACCAAGGGCCCTAGCGTGT





TCCCTCTGGCCCCTAGCAGCAAGAG





CACAAGTGGAGGAACAGCCGCCCTG





GGCTGCCTGGTCAAGGACTACTTCC





CCGAGCCCGTGACCGTGTCCTGGAA





TTCTGGCGCCCTGACAAGCGGCGTG





CACACATTTCCAGCCGTGCTGCAGA





GCAGCGGCCTGTACTCTCTGAGCAG





CGTCGTGACCGTGCCCTCTAGCTCT





CTGGGCACCCAGACCTACATCTGCA





ACGTGAACCACAAGCCCAGCAACAC





CAAAGTGGACAAGAAGGTGGAACCC





AAGAGCTGCGACAAGACCCACACCT





GTCCCCCTTGCCCTGCCCCTGAAGC





TGCTGGTGGCCCTTCCGTGTTCCTG





TTCCCCCCAAAGCCCAAGGACACCC





TGATGATCAGCCGGACCCCCGAAGT





GACCTGCGTGGTGGTCGATGTGTCC





CACGAGGACCCTGAAGTGAAGTTCA





ATTGGTACGTGGACGGCGTGGAAGT





GCACAATGCCAAGACCAAGCCGCGG





GAGGAGCAGTACAACAGCACGTACC





GTGTGGTCAGCGTCCTCACCGTCCT





GCACCAGGACTGGCTGAATGGCAAG





GAGTACAAGTGCAAGGTCTCCAACA





AAGCCCTCGGCGCCCCCATCGAGAA





AACCATCTCCAAAGCCAAAGGGCAG





CCCCGAGAACCACAGGTGTACACCC





TGCCCCCATGCCGGGATGAGCTGAC





CAAGAACCAGGTCAGCCTGTGGTGC





CTGGTCAAAGGCTTCTATCCCAGCG





ACATCGCCGTGGAGTGGGAGAGCAA





TGGGCAGCCGGAGAACAACTACAAG





ACCACGCCTCCCGTGCTGGACTCCG





ACGGCTCCTTCTTCCTCTACAGCAA





GCTCACCGTGGACAAGAGCAGGTGG





CAGCAGGGGAACGTCTTCTCATGCT





CCGTGATGCATGAGGCTCTGCACAA





CCACTACACGCAGAAGAGCCTCTCC





CTGTCTCCGGGTAAA







67
Monomeric hu 4-
AGAGAGGGCCCTGAGCTGAGCCCCG




1BBL (71-254)-
ATGATCCTGCTGGACTGCTGGACCT




CL
GCGGCAGGGCATGTTTGCTCAGCTG





GTGGCCCAGAACGTGCTGCTGATCG





ATGGCCCCCTGTCCTGGTACAGCGA





TCCTGGACTGGCTGGCGTGTCACTG





ACAGGCGGCCTGAGCTACAAAGAGG





ACACCAAAGAACTGGTGGTGGCCAA





GGCCGGCGTGTACTACGTGTTCTTT





CAGCTGGAACTGCGGAGAGTGGTGG





CCGGCGAAGGATCTGGCTCTGTGTC





TCTGGCCCTGCATCTGCAGCCTCTG





AGAAGCGCTGCTGGCGCTGCAGCTC





TGGCACTGACAGTGGATCTGCCTCC





TGCCAGCTCCGAGGCCCGGAATAGC





GCATTTGGGTTTCAAGGCAGGCTGC





TGCACCTGTCTGCCGGCCAGAGGCT





GGGAGTGCATCTGCACACAGAGGCC





AGGGCTAGACACGCCTGGCAGCTGA





CACAGGGCGCTACAGTGCTGGGCCT





GTTCAGAGTGACCCCCGAGATTCCA





GCCGGCCTGCCTTCTCCAAGAAGCG





AAGGCGGAGGCGGATCTGGCGGCGG





AGGATCTCGTACGGTGGCTGCACCA





TCTGTCTTCATCTTCCCGCCATCTG





ATGAGCAGTTGAAATCTGGAACTGC





CTCTGTTGTGTGCCTGCTGAATAAC





TTCTATCCCAGAGAGGCCAAAGTAC





AGTGGAAGGTGGATAACGCCCTCCA





ATCGGGTAACTCCCAGGAGAGTGTC





ACAGAGCAGGACAGCAAGGACAGCA





CCTACAGCCTCAGCAGCACCCTGAC





GCTGAGCAAAGCAGACTACGAGAAA





CACAAAGTCTACGCCTGCGAAGTCA





CCCATCAGGGCCTGAGCTCGCCCGT





CACAAAGAGCTTCAACAGGGGAGAG





TGT







68
anti-FAP
GAAGTGCAGCTGCTGGAATCCGGCG




Fc hole
GAGGCCTGGTGCAGCCTGGCGGATC




chain
TCTGAGACTGTCCTGCGCCGCCTCC





GGCTTCACCTTCTCCTCCCACGCCA





TGTCCTGGGTCCGACAGGCTCCTGG





CAAAGGCCTGGAATGGGTGTCCGCC





ATCTGGGCCTCCGGCGAGCAGTACT





ACGCCGACTCTGTGAAGGGCCGGTT





CACCATCTCCCGGGACAACTCCAAG





AACACCCTGTACCTGCAGATGAACT





CCCTGCGGGCCGAGGACACCGCCGT





GTACTACTGTGCCAAGGGCTGGCTG





GGCAACTTCGACTACTGGGGACAGG





GCACCCTGGTCACCGTGTCCAGCGC





TAGCACCAAGGGCCCCTCCGTGTTC





CCCCTGGCCCCCAGCAGCAAGAGCA





CCAGCGGCGGCACAGCCGCTCTGGG





CTGCCTGGTCAAGGACTACTTCCCC





GAGCCCGTGACCGTGTCCTGGAACA





GCGGAGCCCTGACCTCCGGCGTGCA





CACCTTCCCCGCCGTGCTGCAGAGT





TCTGGCCTGTATAGCCTGAGCAGCG





TGGTCACCGTGCCTTCTAGCAGCCT





GGGCACCCAGACCTACATCTGCAAC





GTGAACCACAAGCCCAGCAACACCA





AGGTGGACAAGAAGGTGGAGCCCAA





GAGCTGCGACAAAACTCACACATGC





CCACCGTGCCCAGCACCTGAAGCTG





CAGGGGGACCGTCAGTCTTCCTCTT





CCCCCCA





AAACCCAAGGACACCCTCATGATCT





CCCGGACCCCTGAGGTCACATGCGT





GGTGGTGGACGTGAGCCACGAAGAC





CCTGAGGTCAAGTTCAACTGGTACG





TGGACGGCGTGGAGGTGCATAATGC





CAAGACAAAGCCGCGGGAGGAGCAG





TACAACAGCACGTACCGTGTGGTCA





GCGTCCTCACCGTCCTGCACCAGGA





CTGGCTGAATGGCAAGGAGTACAAG





TGCAAGGTCTCCAACAAAGCCCTCG





GCGCCCCCATCGAGAAAACCATCTC





CAAAGCCAAAGGGCAGCCCCGAGAA





CCACAGGTGTGCACCCTGCCCCCAT





CCCGGGATGAGCTGACCAAGAACCA





GGTCAGCCTCTCGTGCGCAGTCAAA





GGCTTCTATCCCAGCGACATCGCCG





TGGAGTGGGAGAGCAATGGGCAGCC





GGAGAACAACTACAAGACCACGCCT





CCCGTGCTGGACTCCGACGGCTCCT





TCTTCCTCGTGAGCAAGCTCACCGT





GGACAAGAGCAGGTGGCAGCAGGGG





AACGTCTTCTCATGCTCCGTGATGC





ATGAGGCTCTGCACAACCACTACAC





GCAGAAGAGCCTCTCCCTGTCTCCG





GGTAAA







69
anti-FAP light
GAGATCGTGCTGACCCAGTCCCCCG




chain
GCACCCTGTCTCTGAGCCCTGGCGA





GAGAGCCACCCTGTCCTGCAGAGCC





TCCCAGTCCGTGTCCCGGTCCTACC





TCGCCTGGTATCAGCAGAAGCCCGG





CCAGGCCCCTCGGCTGCTGATCATC





GGCGCCTCTACCAGAGCCACCGGCA





TCCCTGACCGGTTCTCCGGCTCTGG





CTCCGGCACCGACTTCACCCTGACC





ATCTCCCGGCTGGAACCCGAGGACT





TCGCCGTGTACTACTGCCAGCAGGG





CCAGGTCATCCCTCCCACCTTTGGC





CAGGGCACCAAGGTGGAAATCAAGC





GTACGGTGGCTGCACCATCTGTCTT





CATCTTCCCGCCATCTGATGAGCAG





TTGAAATCTGGAACTGCCTCTGTTG





TGTGCCTGCTGAATAACTTCTATCC





CAGAGAGGCCAAAGTACAGTGGAAG





GTGGATAACGCCCTCCAATCGGGTA





ACTCCCAGGAGAGTGTCACAGAGCA





GGACAGCAAGGACAGCACCTACAGC





CTCAGCAGCACCCTGACGCTGAGCA





AAGCAGACTACGAGAAACACAAAGT





CTACGCCTGCGAAGTCACCCATCAG





GGCCTGAGCTCGCCCGTCACAAAGA





GCTTCAACAGGGGAGAGTGT







14
Dimeric hu 4-
REGPELSPDDPAGLLDLRQGMFAQL




1BBL (71-254)-
VAQNVLLIDGPLSWYSDPGLAGVSL




CH1 Fc knob
TGGLSYKEDTKELVVAKAGVYYVFF




chain
QLELRRVVAGEGSGSVSLALHLQPL





RSAAGAAALALTVDLPPASSEARNS





AFGFQGRLLHLSAGQRLGVHLHTEA





RARHAWQLTQGATVLGLFRVTPEIP





AGLPSPRSEGGGGSGGGGSREGPEL





SPDDPAGLLDLRQGMFAQLVAQNVL





LIDGPLSWYSDPGLAGVSLTGGLSY





KEDTKELVVAKAGVYYVFFQLELRR





VVAGEGSGSVSLALHLQPLRSAAGA





AALALTVDLPPASSEARNSAFGFQG





RLLHLSAGQRLGVHLHTEARARHAW





QLTQGATVLGLFRVTPEIPAGLPSP





RSEGGGGSGGGGSASTKGPSVFPLA





PSSKSTSGGTAALGCLVKDYFPEPV





TVSWNSGALTSGVHTFPAVLQSSGL





YSLSSVVTVPSSSLGTQTYICNVNH





KPSNTKVDKKVEPKSCDKTHTCPPC





PAPEAAGGPSVFLFPPKPKDTLMIS





RTPEVTCVVVDVSHEDPEVKFNWYV





DGVEVHNAKTKPREEQYNSTYRVVS





VLTVLHQDWLNGKEYKCKVSNKALG





APIEKTISKAKGQPREPQVYTLPPC





RDELTKNQVSLWCLVKGFYPSDIAV





EWESNGQPENNYKTTPPVLDSDGSF





FLYSKLTVDKSRWQQGNVFSCSVMH





EALHNHYTQKSLSLSPGK







15
Monomeric hu 4-
REGPELSPDDPAGLLDLRQGMFAQL




1BBL (71-254)-
VAQNVLLIDGPLSWYSDPGLAGVSL




CL1
TGGLSYKEDTKELVVAKAGVYYVFF





QLELRRVVAGEGSGSVSLALHLQPL





RSAAGAAALALTVDLPPASSEARNS





AFGFQGRLLHLSAGQRLGVHLHTEA





RARHAWQLTOGATVLGLFRVTPEIP





AGLPSPRSEGGGGSGGGGSRTVAAP





SVFIFPPSDEQLKSGTASVVCLLNN





FYPREAKVQWKVDNALQSGNSQESV





TEQDSKDSTYSLSSTLTLSKADYEK





HKVYACEVTHQGLSSPVTKSFNRGE





C







18
anti-FAP(28Hl)
EVQLLESGGGLVQPGGSLRLSCAAS




Fc hole chain
GFTFSSHAMSWVRQAPGKGLEWVSA





IWASGEQYYADSVKGRFTISRDNSK





NTLYLQMNSLRAEDTAVYYCAKGWL





GNFDYWGQGTLVTVSSASTKGPSVF





PLAPSSKSTSGGTAALGCLVKDYFP





EPVTVSWNSGALTSGVHTFPAVLQS





SGLYSLSSVVTVPSSSLGTQTYICN





VNHKPSNTKVDKKVEPKSCDKTHTC





PPCPAPEAAGGPSVFLFPPKPKDTL





MISRTPEVTCVVVDVSHEDPEVKFN





WYVDGVEVHNAKTKPREEQYNSTYR





VVSVLTVLHQDWLNGKEYKCKVSNK





ALGAPIEKTISKAKGQPREPQVCTL





PPSRDELTKNQVSLSCAVKGFYPSD





IAVEWESNGQPENNYKTTPPVLDSD





GSFFLVSKLTVDKSRWQQGNVFSCS





VMHEALHNHYTQKSLSLSPGK







19
anti-FAP (28H1)
EIVLTQSPGTLSLSPGERATLSCRA




light chain
SQSVSRSYLAWYQQKPGQAPRLLII





GASTRATGIPDRFSGSGSGTDFTLT





ISRLEPEDFAVYYCQQGQVIPPTFG





QGTKVEIKRTVAAPSVFIFPPSDEQ





LKSGTASVVCLLNNFYPREAKVQWK





VDNALQSGNSQESVTEQDSKDSTYS





LSSTLTLSKADYEKHKVYACEVTHQ





GLSSPVTKSFNRGEC










Table 3 shows the cDNA and amino acid sequences of acid sequences of the monovalent FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecule (FIG. 2B, Construct 1.2) with CH1-CL crossover and charged residues.









TBALE 3







Sequences of FAP-targeted human 4-1BB ligand


trimer containing Fc (kih) fusion molecule


Construct 1.2









SEQ ID




NO:
Description
Sequence












129
Dimeric hu 4-
AGAGAGGGCCCTGAGCTGAGCCCCG



1BBL (71-254)-
ATGATCCTGCTGGACTGCTGGACCT



CL* Fc knob
GCGGCAGGGCATGTTTGCTCAGCTG



chain
GTGGCCCAGAACGTGCTGCTGATCG




ATGGCCCCCTGTCCTGGTACAGCGA




TCCTGGACTGGCTGGCGTGTCACTG




ACAGGCGGCCTGAGCTACAAAGAGG




ACACCAAAGAACTGGTGGTGGCCAA




GGCCGGCGTGTACTACGTGTTCTTT




CAGCTGGAACTGCGGAGAGTGGTGG




CCGGCGAAGGATCTGGCTCTGTGTC




TCTGGCCCTGCATCTGCAGCCTCTG




AGAAGCGCTGCTGGCGCTGCAGCTC




TGGCACTGACAGTGGATCTGCCTCC




TGCCAGCTCCGAGGCCCGGAATAGC




GCATTTGGGTTTCAAGGCAGGCTGC




TGCACCTGTCTGCCGGCCAGAGGCT




GGGAGTGCATCTGCACACAGAGGCC




AGGGCTAGACACGCCTGGCAGCTGA




CACAGGGCGCTACAGTGCTGGGCCT




GTTCAGAGTGACCCCCGAGATTCCA




GCCGGCCTGCCTTCTCCAAGAAGCG




AAGGCGGAGGCGGATCTGGCGGCGG




AGGATCTAGAGAGGGACCCGAACTG




TCCCCTGACGATCCAGCCGGGCTGC




TGGATCTGAGACAGGGAATGTTCGC




CCAGCTGGTGGCTCAGAATGTGCTG




CTGATTGACGGACCTCTGAGCTGGT




ACTCCGACCCAGGGCTGGCAGGGGT




GTCCCTGACTGGGGGACTGTCCTAC




AAAGAAGATACAAAAGAACTGGTGG




TGGCTAAAGCTGGGGTGTACTATGT




GTTTTTTCAGCTGGAACTGAGGCGG




GTGGTGGCTGGGGAGGGCTCAGGAT




CTGTGTCCCTGGCTCTGCATCTGCA




GCCACTGCGCTCTGCTGCTGGCGCA




GCTGCACTGGCTCTGACTGTGGACC




TGCCACCAGCCTCTAGCGAGGCCAG




AAACAGCGCCTTCGGGTTCCAAGGA




CGCCTGCTGCATCTGAGCGCCGGAC




AGCGCCTGGGAGTGCATCTGCATAC




TGAAGCCAGAGCCCGGCATGCTTGG




CAGCTGACTCAGGGGGCAACTGTGC




TGGGACTGTTTCGCGTGACACCTGA




GATCCCTGCCGGACTGCCAAGCCCT




AGATCAGAAGGGGGCGGAGGTTCCG




GAGGGGGAGGATCTCGTACGGTGGC




TGCACCATCTGTCTTTATCTTCCCA




CCCAGCGACCGGAAGCTGAAGTCTG




GCACAGCCAGCGTCGTGTGCCTGCT




GAATAACTTCTACCCCCGCGAGGCC




AAGGTGCAGTGGAAGGTGGACAATG




CCCTGCAGAGCGGCAACAGCCAGGA




AAGCGTGACCGAGCAGGACAGCAAG




GACTCCACCTACAGCCTGAGCAGCA




CCCTGACCCTGAGCAAGGCCGACTA




CGAGAAGCACAAGGTGTACGCCTGC




GAAGTGACCCACCAGGGCCTGTCTA




GCCCCGTGACCAAGAGCTTCAACCG




GGGCGAGTGCGACAAGACCCACACC




TGTCCTCCATGCCCTGCCCCTGAAG




CTGCTGGCGGCCCTAGCGTGTTCCT




GTTCCCCCCAAAGCCCAAGGACACC




CTGATGATCAGCCGGACCCCTGAAG




TGACCTGCGTGGTGGTGGATGTGTC




CCACGAGGACCCTGAAGTGAAGTTC




AATTGGTACGTGGACGGCGTGGAAG




TGCACAATGCCAAGACCAAGCCGCG




GGAGGAGCAGTACAACAGCACGTAC




CGTGTGGTCAGCGTCCTCACCGTCC




TGCACCAGGACTGGCTGAATGGCAA




GGAGTACAAGTGCAAGGTCTCCAAC




AAAGCCCTCGGCGCCCCCATCGAGA




AAACCATCTCCAAAGCCAAAGGGCA




GCCCCGAGAACCACAGGTGTACACC




CTGCCCCCATGCCGGGATGAGCTGA




CCAAGAACCAGGTCAGCCTGTGGTG




CCTGGTCAAAGGCTTCTATCCCAGC




GACATCGCCGTGGAGTGGGAGAGCA




ATGGGCAGCCGGAGAACAACTACAA




GACCACGCCTCCCGTGCTGGACTCC




GACGGCTCCTTCTTCCTCTACAGCA




AGCTCACCGTGGACAAGAGCAGGTG




GCAGCAGGGGAACGTCTTCTCATGC




TCCGTGATGCATGAGGCTCTGCACA




ACCACTACACGCAGAAGAGCCTCTC




CCTGTCTCCGGGTAAA





130
Monomeric hu 4-
AGAGAGGGCCCTGAGCTGAGCCCCG



1BBL (71-254)-
ATGATCCTGCTGGACTGCTGGACCT



CH1*
GCGGCAGGGCATGTTTGCTCAGCTG




GTGGCCCAGAACGTGCTGCTGATCG




ATGGCCCCCTGTCCTGGTACAGCGA




TCCTGGACTGGCTGGCGTGTCACTG




ACAGGCGGCCTGAGCTACAAAGAGG




ACACCAAAGAACTGGTGGTGGCCAA




GGCCGGCGTGTACTACGTGTTCTTT




CAGCTGGAACTGCGGAGAGTGGTGG




CCGGCGAAGGATCTGGCTCTGTGTC




TCTGGCCCTGCATCTGCAGCCTCTG




AGAAGCGCTGCTGGCGCTGCAGCTC




TGGCTCTGACAGTGGATCTGCCTCC




TGCCAGCTCCGAGGCCCGGAATAGC




GCATTTGGGTTTCAAGGCCGGCTGC




TGCACCTGTCTGCCGGCCAGAGACT




GGGAGTGCATCTGCACACAGAGGCC




AGAGCCAGGCACGCCTGGCAGCTGA




CACAGGGCGCTACAGTGCTGGGCCT




GTTCAGAGTGACCCCCGAGATTCCT




GCCGGCCTGCCTAGCCCTAGATCTG




AAGGCGGCGGAGGTTCCGGAGGCGG




AGGATCTGCTAGCACAAAGGGCCCC




AGCGTGTTCCCTCTGGCCCCTAGCA




GCAAGAGCACATCTGGCGGAACAGC




CGCCCTGGGCTGCCTGGTGGAAGAT




TACTTCCCCGAGCCCGTGACCGTGT




CCTGGAATTCTGGCGCCCTGACAAG




CGGCGTGCACACCTTTCCAGCCGTG




CTGCAGAGCAGCGGCCTGTACTCTC




TGAGCAGCGTCGTGACAGTGCCCAG




CAGCTCTCTGGGCACCCAGACCTAC




ATCTGCAACGTGAACCACAAGCCCA




GCAACACCAAGGTGGACGAGAAGGT




GGAACCCAAGTCCTGC





68
anti-FAP Fc hole
See Table 2



chain






69
anti-FAP light
See Table 2



chain






115
Dimeric hu 4-
REGPELSPDDPAGLLDLRQGMFAQL



1BBL (71-254)-
VAQNVLLIDGPLSWYSDPGLAGVSL



CL* Fc knob
TGGLSYKEDTKELVVAKAGVYYVFF



chain
QLELRRVVAGEGSGSVSLALHLQPL




RSAAGAAALALTVDLPPASSEARNS




AFGFQGRLLHLSAGQRLGVHLHTEA




RARHAWQLTQGATVLGLFRVTPEIP




AGLPSPRSEGGGGSGGGGSREGPEL




SPDDPAGLLDLRQGMFAQLVAQNVL




LIDGPLSWYSDPGLAGVSLTGGLSY




KEDTKELVVAKAGVYYVFFQLELRR




VVAGEGSGSVSLALHLQPLRSAAGA




AALALTVDLPPASSEARNSAFGFQG




RLLHLSAGQRLGVHLHTEARARHAW




QLTQGATVLGLFRVTPEIPAGLPSP




RSEGGGGSGGGGSRTVAAPSVFIFP




PSDRKLKSGTASVVCLLNNFYPREA




KVQWKVDNALQSGNSQESVTEQDSK




DSTYSLSSTLTLSKADYEKHKVYAC




EVTHQGLSSPVTKSFNRGECDKTHT




CPPCPAPEAAGGPSVFLFPPKPKDT




LMISRTPEVTCVVVDVSHEDPEVKF




NWYVDGVEVHNAKTKPREEQYNSTY




RVVSVLTVLHQDWLNGKEYKCKVSN




KALGAPIEKTISKAKGQPREPQVYT




LPPCRDELTKNQVSLWCLVKGFYPS




DIAVEWESNGQPENNYKTTPPVLDS




DGSFFLYSKLTVDKSRWQQGNVFSC




SVMHEALHNHYTQKSLSLSPGK





116
Monomeric hu 4-
REGPELSPDDPAGLLDLRQGMFAQL



1BBL (71-254)-
VAQNVLLIDGPLSWYSDPGLAGVSL



CH1*
TGGLSYKEDTKELVVAKAGVYYVFF




QLELRRVVAGEGSGSVSLALHLQPL




RSAAGAAALALTVDLPPASSEARNS




AFGFQGRLLHLSAGQRLGVHLHTEA




RARHAWQLTQGATVLGLFRVTPEIP




AGLPSPRSEGGGGSGGGGSASTKGP




SVFPLAPSSKSTSGGTAALGCLVED




YFPEPVTVSWNSGALTSGVHTFPAV




LQSSGLYSLSSVVTVPSSSLGTQTY




ICNVNHKPSNTKVDEKVEPKSC





18
anti-FAP(28H1)
See Table 2



Fc hole chain






19
anti-FAP (28H1)
See Table 2



light chain









Table 4 shows the cDNA and amino acid sequences of the monovalent FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion molecule Construct 1.3 (FIG. 2C) (FAP split trimer with CH1-CL crossover in anti-FAP Fab and charged residues on the 4-1BBL containing chains).









TABLE 4







Sequences of FAP-targeted human 4-1BB ligand


trimer containing Fc (kih) fusion


molecule Construct 1.3









SEQ ID




NO:
Description
Sequence












131
Dimeric hu 4-
AGAGAGGGCCCTGAGCTGAGCCCCG



1BBL (71-254)-
ATGATCCTGCTGGACTGCTGGACCT



CH1* Fc knob
GCGGCAGGGCATGTTTGCTCAGCTG



chain
GTGGCCCAGAACGTGCTGCTGATCG




ATGGCCCCCTGTCCTGGTACAGCGA




TCCTGGACTGGCTGGCGTGTCACTG




ACAGGCGGCCTGAGCTACAAAGAGG




ACACCAAAGAACTGGTGGTGGCCAA




GGCCGGCGTGTACTACGTGTTCTTT




CAGCTGGAACTGCGGAGAGTGGTGG




CCGGCGAAGGATCTGGCTCTGTGTC




TCTGGCCCTGCATCTGCAGCCTCTG




AGAAGCGCTGCTGGCGCTGCAGCTC




TGGCACTGACAGTGGATCTGCCTCC




TGCCAGCTCCGAGGCCCGGAATAGC




GCATTTGGGTTTCAAGGCAGGCTGC




TGCACCTGTCTGCCGGCCAGAGGCT




GGGAGTGCATCTGCACACAGAGGCC




AGGGCTAGACACGCCTGGCAGCTGA




CACAGGGCGCTACAGTGCTGGGCCT




GTTCAGAGTGACCCCCGAGATTCCA




GCCGGCCTGCCTTCTCCAAGAAGCG




AAGGCGGAGGCGGATCTGGCGGCGG




AGGATCTAGAGAGGGACCCGAACTG




TCCCCTGACGATCCAGCCGGGCTGC




TGGATCTGAGACAGGGAATGTTCGC




CCAGCTGGTGGCTCAGAATGTGCTG




CTGATTGACGGACCTCTGAGCTGGT




ACTCCGACCCAGGGCTGGCAGGGGT




GTCCCTGACTGGGGGACTGTCCTAC




AAAGAAGATACAAAAGAACTGGTGG




TGGCTAAAGCTGGGGTGTACTATGT




GTTTTTTCAGCTGGAACTGAGGCGG




GTGGTGGCTGGGGAGGGCTCAGGAT




CTGTGTCCCTGGCTCTGCATCTGCA




GCCACTGCGCTCTGCTGCTGGCGCA




GCTGCACTGGCTCTGACTGTGGACC




TGCCACCAGCCTCTAGCGAGGCCAG




AAACAGCGCCTTCGGGTTCCAAGGA




CGCCTGCTGCATCTGAGCGCCGGAC




AGCGCCTGGGAGTGCATCTGCATAC




TGAAGCCAGAGCCCGGCATGCTTGG




CAGCTGACTCAGGGGGCAACTGTGC




TGGGACTGTTTCGCGTGACACCTGA




GATCCCTGCCGGACTGCCAAGCCCT




AGATCAGAAGGGGGCGGAGGAAGCG




GAGGGGGAGGAAGTGCTAGCACCAA




GGGCCCCTCCGTGTTCCCCCTGGCC




CCCAGCAGCAAGAGCACCAGCGGCG




GCACAGCCGCTCTGGGCTGCCTGGT




CGAGGACTACTTCCCCGAGCCCGTG




ACCGTGTCCTGGAACAGCGGAGCCC




TGACCTCCGGCGTGCACACCTTCCC




CGCCGTGCTGCAGAGTTCTGGCCTG




TATAGCCTGAGCAGCGTGGTCACCG




TGCCTTCTAGCAGCCTGGGCACCCA




GACCTACATCTGCAACGTGAACCAC




AAGCCCAGCAACACCAAGGTGGACG




AGAAGGTGGAGCCCAAGAGCTGCGA




CAAAACTCACACATGCCCACCGTGC




CCAGCACCTGAAGCTGCAGGGGGAC




CGTCAGTCTTCCTCTTCCCCCCAAA




ACCCAAGGACACCCTCATGATCTCC




CGGACCCCTGAGGTCACATGCGTGG




TGGTGGACGTGAGCCACGAAGACCC




TGAGGTCAAGTTCAACTGGTACGTG




GACGGCGTGGAGGTGCATAATGCCA




AGACAAAGCCGCGGGAGGAGCAGTA




CAACAGCACGTACCGTGTGGTCAGC




GTCCTCACCGTCCTGCACCAGGACT




GGCTGAATGGCAAGGAGTACAAGTG




CAAGGTCTCCAACAAAGCCCTCGGC




GCCCCCATCGAGAAAACCATCTCCA




AAGCCAAAGGGCAGCCCCGAGAACC




ACAGGTGTACACCCTGCCCCCATGC




CGGGATGAGCTGACCAAGAACCAGG




TCAGCCTGTGGTGCCTGGTCAAAGG




CTTCTATCCCAGCGACATCGCCGTG




GAGTGGGAGAGCAATGGGCAGCCGG




AGAACAACTACAAGACCACGCCTCC




CGTGCTGGACTCCGACGGCTCCTTC




TTCCTCTACAGCAAGCTCACCGTGG




ACAAGAGCAGGTGGCAGCAGGGGAA




CGTCTTCTCATGCTCCGTGATGCAT




GAGGCTCTGCACAACCACTACACGC




AGAAGAGCCTCTCCCTGTCTCCGGG




TAAA





132
Monomeric hu 4-
AGAGAGGGCCCTGAGCTGAGCCCCG



1BBL (71-254)-
ATGATCCTGCTGGACTGCTGGACCT



CL*
GCGGCAGGGCATGTTTGCTCAGCTG




GTGGCCCAGAACGTGCTGCTGATCG




ATGGCCCCCTGTCCTGGTACAGCGA




TCCTGGACTGGCTGGCGTGTCACTG




ACAGGCGGCCTGAGCTACAAAGAGG




ACACCAAAGAACTGGTGGTGGCCAA




GGCCGGCGTGTACTACGTGTTCTTT




CAGCTGGAACTGCGGAGAGTGGTGG




CCGGCGAAGGATCTGGCTCTGTGTC




TCTGGCCCTGCATCTGCAGCCTCTG




AGAAGCGCTGCTGGCGCTGCAGCTC




TGGCACTGACAGTGGATCTGCCTCC




TGCCAGCTCCGAGGCCCGGAATAGC




GCATTTGGGTTTCAAGGCAGGCTGC




TGCACCTGTCTGCCGGCCAGAGGCT




GGGAGTGCATCTGCACACAGAGGCC




AGGGCTAGACACGCCTGGCAGCTGA




CACAGGGCGCTACAGTGCTGGGCCT




GTTCAGAGTGACCCCCGAGATTCCA




GCCGGCCTGCCTTCTCCAAGAAGCG




AAGGCGGAGGCGGATCTGGCGGCGG




AGGATCTCGTACGGTGGCTGCACCA




TCTGTCTTCATCTTCCCGCCATCTG




ATCGGAAGTTGAAATCTGGAACTGC




CTCTGTTGTGTGCCTGCTGAATAAC




TTCTATCCCAGAGAGGCCAAAGTAC




AGTGGAAGGTGGATAACGCCCTCCA




ATCGGGTAACTCCCAGGAGAGTGTC




ACAGAGCAGGACAGCAAGGACAGCA




CCTACAGCCTCAGCAGCACCCTGAC




GCTGAGCAAAGCAGACTACGAGAAA




CACAAAGTCTACGCCTGCGAAGTCA




CCCATCAGGGCCTGAGCTCGCCCGT




CACAAAGAGCTTCAACAGGGGAGAG




TGT





133
anti-FAP (VHCL)
GAAGTGCAGCTGCTGGAATCCGGCG



(28H1) Fc hole
GAGGCCTGGTGCAGCCTGGCGGATC



chain
TCTGAGACTGTCCTGCGCCGCCTCC




GGCTTCACCTTCTCCTCCCACGCCA




TGTCCTGGGTCCGACAGGCTCCTGG




CAAAGGCCTGGAATGGGTGTCCGCC




ATCTGGGCCTCCGGCGAGCAGTACT




ACGCCGACTCTGTGAAGGGCCGGTT




CACCATCTCCCGGGACAACTCCAAG




AACACCCTGTACCTGCAGATGAACT




CCCTGCGGGCCGAGGACACCGCCGT




GTACTACTGTGCCAAGGGCTGGCTG




GGCAACTTCGACTACTGGGGACAGG




GCACCCTGGTCACCGTGTCCAGCGC




TAGCGTGGCCGCTCCCAGCGTGTTC




ATCTTCCCACCCAGCGACGAGCAGC




TGAAGTCCGGCACAGCCAGCGTGGT




GTGCCTGCTGAACAACTTCTACCCC




CGCGAGGCCAAGGTGCAGTGGAAGG




TGGACAACGCCCTGCAGAGCGGCAA




CAGCCAGGAATCCGTGACCGAGCAG




GACAGCAAGGACTCCACCTACAGCC




TGAGCAGCACCCTGACCCTGAGCAA




GGCCGACTACGAGAAGCACAAGGTG




TACGCCTGCGAAGTGACCCACCAGG




GCCTGTCCAGCCCCGTGACCAAGAG




CTTCAACCGGGGCGAGTGCGACAAG




ACCCACACCTGTCCCCCTTGCCCTG




CCCCTGAAGCTGCTGGTGGCCCTTC




CGTGTTCCTGTTCCCCCCAAAGCCC




AAGGACACCCTGATGATCAGCCGGA




CCCCCGAAGTGACCTGCGTGGTGGT




CGATGTGTCCCACGAGGACCCTGAA




GTGAAGTTCAATTGGTACGTGGACG




GCGTGGAAGTGCACAATGCCAAGAC




CAAGCCGCGGGAGGAGCAGTACAAC




AGCACGTACCGTGTGGTCAGCGTCC




TCACCGTCCTGCACCAGGACTGGCT




GAATGGCAAGGAGTACAAGTGCAAG




GTCTCCAACAAAGCCCTCGGCGCCC




CCATCGAGAAAACCATCTCCAAAGC




CAAAGGGCAGCCCCGAGAACCACAG




GTGTGCACCCTGCCCCCATCCCGGG




ATGAGCTGACCAAGAACCAGGTCAG




CCTCTCGTGCGCAGTCAAAGGCTTC




TATCCCAGCGACATCGCCGTGGAGT




GGGAGAGCAATGGGCAGCCGGAGAA




CAACTACAAGACCACGCCTCCCGTG




CTGGACTCCGACGGCTCCTTCTTCC




TCGTGAGCAAGCTCACCGTGGACAA




GAGCAGGTGGCAGCAGGGGAACGTC




TTCTCATGCTCCGTGATGCATGAGG




CTCTGCACAACCACTACACGCAGAA




GAGCCTCTCCCTGTCTCCGGGTAAA





134
anti-FAP
GAGATCGTGCTGACCCAGTCTCCCG



(VLCH1) (28H1)
GCACCCTGAGCCTGAGCCCTGGCGA



light chain
GAGAGCCACCCTGAGCTGCAGAGCC




AGCCAGAGCGTGAGCCGGAGCTACC




TGGCCTGGTATCAGCAGAAGCCCGG




CCAGGCCCCCAGACTGCTGATCATC




GGCGCCAGCACCCGGGCCACCGGCA




TCCCCGATAGATTCAGCGGCAGCGG




CTCCGGCACCGACTTCACCCTGACC




ATCAGCCGGCTGGAACCCGAGGACT




TCGCCGTGTACTACTGCCAGCAGGG




CCAGGTGATCCCCCCCACCTTCGGC




CAGGGCACCAAGGTGGAAATCAAGA




GCAGCGCTTCCACCAAAGGCCCTTC




CGTGTTTCCTCTGGCTCCTAGCTCC




AAGTCCACCTCTGGAGGCACCGCTG




CTCTCGGATGCCTCGTGAAGGATTA




TTTTCCTGAGCCTGTGACAGTGTCC




TGGAATAGCGGAGCACTGACCTCTG




GAGTGCATACTTTCCCCGCTGTGCT




GCAGTCCTCTGGACTGTACAGCCTG




AGCAGCGTGGTGACAGTGCCCAGCA




GCAGCCTGGGCACCCAGACCTACAT




CTGCAACGTGAACCACAAGCCCAGC




AACACCAAGGTGGACAAGAAGGTGG




AACCCAAGTCTTGT





108
Dimeric hu 4-
REGPELSPDDPAGLLDLRQGMFAQL



1BBL (71-254)-
VAQNVLLIDGPLSWYSDPGLAGVSL



CH1* Fc knob
TGGLSYKEDTKELVVAKAGVYYVFF



chain
QLELRRVVAGEGSGSVSLALHLQPL




RSAAGAAALALTVDLPPASSEARNS




AFGFQGRLLHLSAGQRLGVHLHTEA




RARHAWQLTQGATVLGLFRVTPEIP




AGLPSPRSEGGGGSGGGGSREGPEL




SPDDPAGLLDLRQGMFAQLVAQNVL




LIDGPLSWYSDPGLAGVSLTGGLSY




KEDTKELVVAKAGVYYVFFQLELRR




VVAGEGSGSVSLALHLQPLRSAAGA




AALALTVDLPPASSEARNSAFGFQG




RLLHLSAGQRLGVHLHTEARARHAW




QLTQGATVLGLFRVTPEIPAGLPSP




RSEGGGGSGGGGSASTKGPSVFPLA




PSSKSTSGGTAALGCLVEDYFPEPV




TVSWNSGALTSGVHTFPAVLQSSGL




YSLSSVVTVPSSSLGTQTYICNVNH




KPSNTKVDEKVEPKSCDKTHTCPPC




PAPEAAGGPSVFLFPPKPKDTLMIS




RTPEVTCVVVDVSHEDPEVKFNWYV




DGVEVHNAKTKPREEQYNSTYRVVS




VLTVLHQDWLNGKEYKCKVSNKALG




APIEKTISKAKGQPREPQVYTLPPC




RDELTKNQVSLWCLVKGFYPSDIAV




EWESNGQPENNYKTTPPVLDSDGSF




FLYSKLTVDKSRWQQGNVFSCSVMH




EALHNHYTQKSLSLSPGK





109
Monomeric hu 4-
REGPELSPDDPAGLLDLRQGMFAQL



1BBL (71-254)-
VAQNVLLIDGPLSWYSDPGLAGVSL



CL*
TGGLSYKEDTKELVVAKAGVYYVFF




QLELRRVVAGEGSGSVSLALHLQPL




RSAAGAAALALTVDLPPASSEARNS




AFGFQGRLLHLSAGQRLGVHLHTEA




RARHAWQLTQGATVLGLFRVTPEIP




AGLPSPRSEGGGGSGGGGSRTVAAP




SVFIFPPSDRKLKSGTASVVCLLNN




FYPREAKVQWKVDNALQSGNSQESV




TEQDSKDSTYSLSSTLTLSKADYEK




HKVYACEVTHQGLSSPVTKSFNRGE




C





135
anti-FAP (VHCL)
EVQLLESGGGLVQPGGSLRLSCAAS



(28H1) Fc hole
GFTFSSHAMSWVRQAPGKGLEWVSA



chain
IWASGEQYYADSVKGRFTISRDNSK




NTLYLQMNSLRAEDTAVYYCAKGWL




GNFDYWGQGTLVTVSSASVAAPSVF




IFPPSDEQLKSGTASVVCLLNNFYP




REAKVQWKVDNALQSGNSQESVTEQ




DSKDSTYSLSSTLTLSKADYEKHKV




YACEVTHQGLSSPVTKSFNRGECDK




THTCPPCPAPEAAGGPSVFLFPPKP




KDTLMISRTPEVTCVVVDVSHEDPE




VKFNWYVDGVEVHNAKTKPREEQYN




STYRVVSVLTVLHQDWLNGKEYKCK




VSNKALGAPIEKTISKAKGQPREPQ




VCTLPPSRDELTKNQVSLSCAVKGF




YPSDIAVEWESNGQPENNYKTTPPV




LDSDGSFFLVSKLTVDKSRWQQGNV




FSCSVMHEALHNHYTOKSLSLSPGK





136
anti-FAP
EIVLTQSPGTLSLSPGERATLSCRA



(VLCH1) (28H1)
SQSVSRSYLAWYQQKPGQAPRLLII



light chain
GASTRATGIPDRFSGSGSGTDFTLT




ISRLEPEDFAVYYCQQGQVIPPTFG




QGTKVEIKSSASTKGPSVFPLAPSS




KSTSGGTAALGCLVKDYFPEPVTVS




WNSGALTSGVHTFPAVLQSSGLYSL




SSVVTVPSSSLGTQTYICNVNHKPS




NTKVDKKVEPKSC









Table 5 shows the cDNA and amino acid sequences of the monovalent FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion molecule Construct 1.4 (FIG. 2D) (FAP split trimer with anti-FAP Fab, monomeric 4-1BB ligand fused to CH1-knob chain and charged residues on the 4-1BBL containing chains).









TABLE 5







Sequences of FAP-targeted human 4-1BB ligand


trimer containing Fc (kih) fusion


molecule Construct 1.4









SEQ ID




NO:
Description
Sequence












137
Monomeric hu 4-
AGAGAGGGCCCTGAGCTGAGCCCCG



1BBL (71-254)-
ATGATCCTGCTGGACTGCTGGACCT



CH1* Fc knob
GCGGCAGGGCATGTTTGCTCAGCTG



chain
GTGGCCCAGAACGTGCTGCTGATCG




ATGGCCCCCTGTCCTGGTACAGCGA




TCCTGGACTGGCTGGCGTGTCACTG




ACAGGCGGCCTGAGCTACAAAGAGG




ACACCAAAGAACTGGTGGTGGCCAA




GGCCGGCGTGTACTACGTGTTCTTT




CAGCTGGAACTGCGGAGAGTGGTGG




CCGGCGAAGGATCTGGCTCTGTGTC




TCTGGCCCTGCATCTGCAGCCTCTG




AGAAGCGCTGCTGGCGCTGCAGCTC




TGGCTCTGACAGTGGATCTGCCTCC




TGCCAGCTCCGAGGCCCGGAATAGC




GCATTTGGGTTTCAAGGCCGGCTGC




TGCACCTGTCTGCCGGCCAGAGACT




GGGAGTGCATCTGCACACAGAGGCC




AGAGCCAGGCACGCCTGGCAGCTGA




CACAGGGCGCTACAGTGCTGGGCCT




GTTCAGAGTGACCCCCGAGATTCCT




GCCGGCCTGCCTAGCCCTAGATCTG




AAGGCGGCGGAGGTTCCGGAGGCGG




AGGATCTGCTAGCACCAAGGGCCCC




TCCGTGTTCCCCCTGGCCCCCAGCA




GCAAGAGCACCAGCGGCGGCACAGC




CGCTCTGGGCTGCCTGGTCGAGGAC




TACTTCCCCGAGCCCGTGACCGTGT




CCTGGAACAGCGGAGCCCTGACCTC




CGGCGTGCACACCTTCCCCGCCGTG




CTGCAGAGTTCTGGCCTGTATAGCC




TGAGCAGCGTGGTCACCGTGCCTTC




TAGCAGCCTGGGCACCCAGACCTAC




ATCTGCAACGTGAACCACAAGCCCA




GCAACACCAAGGTGGACGAGAAGGT




GGAGCCCAAGAGCTGCGACAAAACT




CACACATGCCCACCGTGCCCAGCAC




CTGAAGCTGCAGGGGGACCGTCAGT




CTTCCTCTTCCCCCCAAAACCCAAG




GACACCCTCATGATCTCCCGGACCC




CTGAGGTCACATGCGTGGTGGTGGA




CGTGAGCCACGAAGACCCTGAGGTC




AAGTTCAACTGGTACGTGGACGGCG




TGGAGGTGCATAATGCCAAGACAAA




GCCGCGGGAGGAGCAGTACAACAGC




ACGTACCGTGTGGTCAGCGTCCTCA




CCGTCCTGCACCAGGACTGGCTGAA




TGGCAAGGAGTACAAGTGCAAGGTC




TCCAACAAAGCCCTCGGCGCCCCCA




TCGAGAAAACCATCTCCAAAGCCAA




AGGGCAGCCCCGAGAACCACAGGTG




TACACCCTGCCCCCATGCCGGGATG




AGCTGACCAAGAACCAGGTCAGCCT




GTGGTGCCTGGTCAAAGGCTTCTAT




CCCAGCGACATCGCCGTGGAGTGGG




AGAGCAATGGGCAGCCGGAGAACAA




CTACAAGACCACGCCTCCCGTGCTG




GACTCCGACGGCTCCTTCTTCCTCT




ACAGCAAGCTCACCGTGGACAAGAG




CAGGTGGCAGCAGGGGAACGTCTTC




TCATGCTCCGTGATGCATGAGGCTC




TGCACAACCACTACACGCAGAAGAG




CCTCTCCCTGTCTCCGGGTAAA





138
Dimeric hu 4-
AGAGAGGGCCCTGAGCTGAGCCCCG



1BBL (71-254)-
ATGATCCTGCTGGACTGCTGGACCT



CL*
GCGGCAGGGCATGTTTGCTCAGCTG




GTGGCCCAGAACGTGCTGCTGATCG




ATGGCCCCCTGTCCTGGTACAGCGA




TCCTGGACTGGCTGGCGTGTCACTG




ACAGGCGGCCTGAGCTACAAAGAGG




ACACCAAAGAACTGGTGGTGGCCAA




GGCCGGCGTGTACTACGTGTTCTTT




CAGCTGGAACTGCGGAGAGTGGTGG




CCGGCGAAGGATCTGGCTCTGTGTC




TCTGGCCCTGCATCTGCAGCCTCTG




AGAAGCGCTGCTGGCGCTGCAGCTC




TGGCACTGACAGTGGATCTGCCTCC




TGCCAGCTCCGAGGCCCGGAATAGC




GCATTTGGGTTTCAAGGCAGGCTGC




TGCACCTGTCTGCCGGCCAGAGGCT




GGGAGTGCATCTGCACACAGAGGCC




AGGGCTAGACACGCCTGGCAGCTGA




CACAGGGCGCTACAGTGCTGGGCCT




GTTCAGAGTGACCCCCGAGATTCCA




GCCGGCCTGCCTTCTCCAAGAAGCG




AAGGCGGAGGCGGATCTGGCGGCGG




AGGATCTAGAGAGGGACCCGAACTG




TCCCCTGACGATCCAGCCGGGCTGC




TGGATCTGAGACAGGGAATGTTCGC




CCAGCTGGTGGCTCAGAATGTGCTG




CTGATTGACGGACCTCTGAGCTGGT




ACTCCGACCCAGGGCTGGCAGGGGT




GTCCCTGACTGGGGGACTGTCCTAC




AAAGAAGATACAAAAGAACTGGTGG




TGGCTAAAGCTGGGGTGTACTATGT




GTTTTTTCAGCTGGAACTGAGGCGG




GTGGTGGCTGGGGAGGGCTCAGGAT




CTGTGTCCCTGGCTCTGCATCTGCA




GCCACTGCGCTCTGCTGCTGGCGCA




GCTGCACTGGCTCTGACTGTGGACC




TGCCACCAGCCTCTAGCGAGGCCAG




AAACAGCGCCTTCGGGTTCCAAGGA




CGCCTGCTGCATCTGAGCGCCGGAC




AGCGCCTGGGAGTGCATCTGCATAC




TGAAGCCAGAGCCCGGCATGCTTGG




CAGCTGACTCAGGGGGCAACTGTGC




TGGGACTGTTTCGCGTGACACCTGA




GATCCCTGCCGGACTGCCAAGCCCT




AGATCAGAAGGGGGCGGAGGTTCCG




GAGGGGGAGGATCTCGTACGGTGGC




TGCACCATCTGTCTTCATCTTCCCG




CCATCTGATCGGAAGTTGAAATCTG




GAACTGCCTCTGTTGTGTGCCTGCT




GAATAACTTCTATCCCAGAGAGGCC




AAAGTACAGTGGAAGGTGGATAACG




CCCTCCAATCGGGTAACTCCCAGGA




GAGTGTCACAGAGCAGGACAGCAAG




GACAGCACCTACAGCCTCAGCAGCA




CCCTGACGCTGAGCAAAGCAGACTA




CGAGAAACACAAAGTCTACGCCTGC




GAAGTCACCCATCAGGGCCTGAGCT




CGCCCGTCACAAAGAGCTTCAACAG




GGGAGAGTGT





68
anti-FAP (28H1)
see Table 2



Fc hole chain






69
anti-FAP (28H1)
See Table 2



light chain






139
Monomeric hu 4-
REGPELSPDDPAGLLDLRQGMFAQL



1BBL (71-254)-
VAQNVLLIDGPLSWYSDPGLAGVSL



CL* Fc knob
TGGLSYKEDTKELVVAKAGVYYVFF



chain
QLELRRVVAGEGSGSVSLALHLQPL




RSAAGAAALALTVDLPPASSEARNS




AFGFQGRLLHLSAGQRLGVHLHTEA




RARHAWQLTQGATVLGLFRVTPEIP




AGLPSPRSEGGGGSGGGGSREGPEL




SPDDPAGLLDLRQGMFAQLVAQNVL




LIDGPLSWYSDPGLAGVSLTGGLSY




KEDTKELVVAKAGVYYVFFQLELRR




VVAGEGSGSVSLALHLQPLRSAAGA




AALALTVDLPPASSEARNSAFGFQG




RLLHLSAGQRLGVHLHTEARARHAW




QLTQGATVLGLFRVTPEIPAGLPSP




RSEGGGGSGGGGSASTKGPSVFPLA




PSSKSTSGGTAALGCLVEDYFPEPV




TVSWNSGALTSGVHTFPAVLQSSGL




YSLSSVVTVPSSSLGTQTYICNVNH




KPSNTKVDEKVEPKSCDKTHTCPPC




PAPEAAGGPSVFLFPPKPKDTLMI




SRTPEVTCVVVDVSHEDPEV




KFNWYVDGVEVHNAKTKPREEQYNS




TYRWSVLTVLHQDWLNGKEYKCKVS




NKALGAPIEKTISKAKGQPREPQVY




TLPPCRDELTKNQVSLWCLVKGFYP




SDLAVEWESNGQPENNYKTTPPVLD




SDGSFFLYSKLTVDKSRWQQGNVFS




CSVMHEALHNHYTQKSLSLSPGK





140
Dimeric hu 4-
REGPELSPDDPAGLLDLRQGMFAQL



1BBL (71-254)-
VAQNVLLIDGPLSWYSDPGLAGVSL



CL*
TGGLSYKEDTKELVVAKAGVYYVFF




QLELRRVVAGEGSGSVSLALHLQPL




RSAAGAAALALTVDLPPASSEARNS




AFGFQGRLLHLSAGQRLGVHLHTEA




RARHAWQLTQGATVLGLFRVTPEIP




AGLPSPRSEGGGGSGGGGSREGPEL




SPDDPAGLLDLRQGMFAQLVAQNVL




LIDGPLSWYSDPGLAGVSLTGGLSY




KEDTKELWAKAGVYYVFFQLELRRW




AGEGSGSVSLALHLQPLRSAAGAAA




LALTVDLPPASSEARNSAFGFQGRL




LHLSAGQRLGVHLHTEARARHAWQL




TQGATVLGLFRVTPEIPAGLPSPRS




EGGGGSGGGGSRTVAAPSVFIFPPS




DRKLKSGTASWCLLNNFYPREAKVQ




WKVDNALQSGNSQESVTEQDSKDST




YSLSSTLTLSKADYEKHKVYACEVT




HQGLSSPVTKSFNRGEC





18
anti-FAP (28H1)
see Table 2



Fc hole chain






19
anti-FAP (28H1)
see Table 2



light chain









Table 6 shows the cDNA and amino acid sequences of the bivalent FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion molecule Construct 1.5 (FIG. 2E) (FAP split trimer with 2 anti-FAP Fabs, dimeric and monomeric 4-1BB ligand fused at the C-terminus of each heavy chain, respectively).









TABLE 6







Sequences of FAP-targeted human 4-1BB ligand 


trimer containing Fc (kih) fusion molecule Construct 1.5









SEQ




ID NO:
Description
Sequence





141
anti-FAP (28H1)
GAAGTGCAGCTGCTGGAATCCGGCGGAGGCCTGGTGCA



Fc hole chain
GCCTGGCGGATCTCTGAGACTGTCCTGCGCCGCCTCCG



fused to 
GCTTCACCTTCTCCTCCCACGCCATGTCCTGGGTCCGA



dimeric hu 
CAGGCTCCTGGCAAAGGCCTGGAATGGGTGTCCGCCAT



4-1BBL (71-254)
CTGGGCCTCCGGCGAGCAGTACTACGCCGACTCTGTGA




AGGGCCGGTTCACCATCTCCCGGGACAACTCCAAGAAC




ACCCTGTACCTGCAGATGAACTCCCTGCGGGCCGAGGA




CACCGCCGTGTACTACTGTGCCAAGGGCTGGCTGGGCA




ACTTCGACTACTGGGGACAGGGCACCCTGGTCACCGTG




TCCAGCGCTAGCACCAAGGGCCCCTCCGTGTTCCCCCT




GGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCG




CTCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAGCCC




GTGACCGTGTCCTGGAACAGCGGAGCCCTGACCTCCGG




CGTGCACACCTTCCCCGCCGTGCTGCAGAGTTCTGGCC




TGTATAGCCTGAGCAGCGTGGTCACCGTGCCTTCTAGC




AGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCA




CAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGC




CCAAGAGCTGCGACAAAACTCACACATGCCCACCGTGC




CCAGCACCTGAAGCTGCAGGGGGACCGTCAGTCTTCCT




CTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCC




GGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGC




CACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGA




CGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGG




AGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC




CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGA




GTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGCCC




CCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCC




CGAGAACCACAGGTGTGCACCCTGCCCCCATCCCGGGA




TGAGCTGACCAAGAACCAGGTCAGCCTCTCGTGCGCAG




TCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGG




GAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCAC




GCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCG




TGAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAG




GGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCT




GCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTC




CGGGTGGAGGCGGCGGAAGCGGAGGAGGAGGATCCAGA




GAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGGACT




GCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGTGG




CCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTGG




TACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG




CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG




TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTG




GAACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTC




TGTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCG




CTGCTGGCGCTGCAGCTCTGGCACTGACAGTGGATCTG




CCTCCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGG




GTTTCAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGA




GGCTGGGAGTGCATCTGCACACAGAGGCCAGGGCTAGA




CACGCCTGGCAGCTGACACAGGGCGCTACAGTGCTGGG




CCTGTTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGC




CTTCTCCAAGAAGCGAAGGCGGAGGCGGATCTGGCGGC




GGAGGATCTAGAGAGGGACCCGAACTGTCCCCTGACGA




TCCAGCCGGGCTGCTGGATCTGAGACAGGGAATGTTCG




CCCAGCTGGTGGCTCAGAATGTGCTGCTGATTGACGGA




CCTCTGAGCTGGTACTCCGACCCAGGGCTGGCAGGGGT




GTCCCTGACTGGGGGACTGTCCTACAAAGAAGATACAA




AAGAACTGGTGGTGGCTAAAGCTGGGGTGTACTATGTG




TTTTTTCAGCTGGAACTGAGGCGGGTGGTGGCTGGGGA




GGGCTCAGGATCTGTGTCCCTGGCTCTGCATCTGCAGC




CACTGCGCTCTGCTGCTGGCGCAGCTGCACTGGCTCTG




ACTGTGGACCTGCCACCAGCCTCTAGCGAGGCCAGAAA




CAGCGCCTTCGGGTTCCAAGGACGCCTGCTGCATCTGA




GCGCCGGACAGCGCCTGGGAGTGCATCTGCATACTGAA




GCCAGAGCCCGGCATGCTTGGCAGCTGACTCAGGGGGC




AACTGTGCTGGGACTGTTTCGCGTGACACCTGAGATCC




CTGCCGGACTGCCAAGCCCTAGATCAGAA





142
anti-FAP (28H1)
GAAGTGCAGCTGCTGGAATCCGGCGGAGGCCTGGTGCA



Fc knob chain
GCCTGGCGGATCTCTGAGACTGTCCTGCGCCGCCTCCG



fused to
GCTTCACCTTCTCCTCCCACGCCATGTCCTGGGTCCGA



monomeric hu 
CAGGCTCCTGGCAAAGGCCTGGAATGGGTGTCCGCCAT



4-1BBL (71-254)
CTGGGCCTCCGGCGAGCAGTACTACGCCGACTCTGTGA




AGGGCCGGTTCACCATCTCCCGGGACAACTCCAAGAAC




ACCCTGTACCTGCAGATGAACTCCCTGCGGGCCGAGGA




CACCGCCGTGTACTACTGTGCCAAGGGCTGGCTGGGCA




ACTTCGACTACTGGGGACAGGGCACCCTGGTCACCGTG




TCCAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCT




GGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGG




CCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCG




GTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGG




CGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGAC




TCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGC




AGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCA




CAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGC




CCAAATCTTGTGACAAAACTCACACATGCCCACCGTGC




CCAGCACCTGAAGCTGCAGGGGGACCGTCAGTCTTCCT




CTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCC




GGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGC




CACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGA




CGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGG




AGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC




CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGA




GTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGCCC




CCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCC




CGAGAACCACAGGTGTACACCCTGCCCCCCTGCAGAGA




TGAGCTGACCAAGAACCAGGTGTCCCTGTGGTGTCTGG




TCAAGGGCTTCTACCCCAGCGATATCGCCGTGGAGTGG




GAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCAC




CCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGT




ACTCCAAACTGACCGTGGACAAGAGCCGGTGGCAGCAG




GGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCT




GCACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCC




CCGGCGGAGGCGGCGGAAGCGGAGGAGGAGGATCCAGA




GAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGGACT




GCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGTGG




CCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTGG




TACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG




CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG




TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTG




GAACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTC




TGTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCG




CTGCTGGCGCTGCAGCTCTGGCACTGACAGTGGATCTG




CCTCCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGG




GTTTCAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGA




GGCTGGGAGTGCATCTGCACACAGAGGCCAGGGCTAGA




CACGCCTGGCAGCTGACACAGGGCGCTACAGTGCTGGG




CCTGTTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGC




CTTCTCCAAGAAGCGAA





 69
anti-FAP (28H1)
see Table 2



light chain






121
anti-FAP (28H1)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSHAMSWVR



Fc hole chain
QAPGKGLEWVSAIWASGEQYYADSVKGRFTISRDNSKN



fused to 
TLYLQMNSLRAEDTAVYYCAKGWLGNFDYWGQGTLVTV



dimeric hu  
SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP



4-1BBL (71-254)
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS




SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC




PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS




HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV




LTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQP




REPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEW




ESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQ




GNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSR




EGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSW




YSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQL




ELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDL




PPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARAR




HAWQLTQGATVLGLFRVTPEIPAGLPSPRSEGGGGSGG




GGSREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDG




PLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYV




FFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALAL




TVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTE




ARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE





122
anti-FAP (28H1)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSHAMSWVR



Fc knob chain
QAPGKGLEWVSAIWASGEQYYADSVKGRFTISRDNSKN



fused to
TLYLQMNSLRAEDTAVYYCAKGWLGNFDYWGQGTLVTV



monomeric hu 
SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP



4-1BBL (71-254)
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS




SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC




PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS




HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV




LTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQP




REPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEW




ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ




GNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSR




EGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSW




YSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQL




ELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDL




PPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARAR




HAWQLTQGATVLGLFRVTPEIPAGLPSPRSE





 19
anti-FAP (28H1)
see Table 2



light chain









Table 7 shows the cDNA and amino acid sequences of the monovalent FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion molecule Construct 1.6 (FIG. 2F) (FAP split trimer with anti-FAP Fab, monomeric 4-1BB ligand fused to CL* via a (G4S)-linker).









TABLE 7







Sequences of FAP-targeted


human 4-1BB ligand trimer containing


Fc (kih) fusion molecule Construct 1.6









SEQ




ID NO:
Description
Sequence





131
Dimeric hu 
see Table 4



4-1BBL 




(71-254)-




CH1* Fc 




knob chain






143
Monomeric 
AGAGAGGGCCCTGAGCTGAGCCCCGATG



hu 4-1BBL 
ATCCTGCTGGACTGCTGGACCTGCGGCA



(71-254)-
GGGCATGTTTGCTCAGCTGGTGGCCCAG



(G4S)1- CL*
AACGTGCTGCTGATCGATGGCCCCCTGT




CCTGGTACAGCGATCCTGGACTGGCTGG




CGTGTCACTGACAGGCGGCCTGAGCTAC




AAAGAGGACACCAAAGAACTGGTGGTGG




CCAAGGCCGGCGTGTACTACGTGTTCTT




TCAGCTGGAACTGCGGAGAGTGGTGGCC




GGCGAAGGATCTGGCTCTGTGTCTCTGG




CCCTGCATCTGCAGCCTCTGAGAAGCGC




TGCTGGCGCTGCAGCTCTGGCACTGACA




GTGGATCTGCCTCCTGCCAGCTCCGAGG




CCCGGAATAGCGCATTTGGGTTTCAAGG




CAGGCTGCTGCACCTGTCTGCCGGCCAG




AGGCTGGGAGTGCATCTGCACACAGAGG




CCAGGGCTAGACACGCCTGGCAGCTGAC




ACAGGGCGCTACAGTGCTGGGCCTGTTC




AGAGTGACCCCCGAGATTCCAGCCGGCC




TGCCTTCTCCAAGAAGCGAAGGCGGAGG




CGGATCTCGTACGGTGGCTGCACCATCT




GTCTTCATCTTCCCGCCATCTGATCGGA




AGTTGAAATCTGGAACTGCCTCTGTTGT




GTGCCTGCTGAATAACTTCTATCCCAGA




GAGGCCAAAGTACAGTGGAAGGTGGATA




ACGCCCTCCAATCGGGTAACTCCCAGGA




GAGTGTCACAGAGCAGGACAGCAAGGAC




AGCACCTACAGCCTCAGCAGCACCCTGA




CGCTGAGCAAAGCAGACTACGAGAAACA




CAAAGTCTACGCCTGCGAAGTCACCCAT




CAGGGCCTGAGCTCGCCCGTCACAAAGA




GCTTCAACAGGGGAGAGTGT





 68
anti-FAP 
see Table 2



(28H1) Fc




hole chain






 69
anti-FAP 
see Table 2



(28H1)




light chain






108
Dimeric hu 
see Table 4



4-1BBL 




(71-254)-




CH1* Fc 




knob chain






110
Monomeric 
REGPELSPDDPAGLLDLRQGMFAQLVAQ



hu 4-1BBL 
NVLLIDGPLSWYSDPGLAGVSLTGGLSY



(71-254)-
KEDTKELVVAKAGVYYVFFQLELRRVVA



(G4S)1- CL*
GEGSGSVSLALHLQPLRSAAGAAALALT




VDLPPASSEARNSAFGFQGRLLHLSAGQ




RLGVHLHTEARARHAWQLTQGATVLGLF




RVTPEIPAGLPSPRSEGGGGSRTVAAPS




VFIFPPSDRKLKSGTASVVCLLNNFYPR




EAKVQWKVDNALQSGNSQESVTEQDSKD




STYSLSSTLTLSKADYEKHKVYACEVTH




QGLSSPVTKSFNRGEC





 18
anti-FAP 
see Table 2



(28H1) Fc




hole chain






 19
anti-FAP 
see Table 2



(28H1)




light chain









Table 8 shows the cDNA and amino acid sequences of the bivalent FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion molecule Construct 1.7 (FIG. 2G) (FAP split trimer with double anti-FAP on the N-terminus of Fc hole chain and charged residues on crossed CH1 and CL fused to 4-1BB ligands).









TABLE 8







Sequences of FAP-targeted


human 4-1BB ligand trimer containing


Fc (kih) fusion molecule Construct 1.7









SEQ




ID NO:
Description
Sequence





129
Dimeric 
see Table 3



hu 4-1BBL 




(71-254)-




CL* Fc 




knob chain






130
Monomeric 
see Table 3



hu 4-1BBL 




(71-254)-




CH1*






144
[anti-FAP
GAAGTGCAGCTGCTGGAATCCGGCGGAG



(28H1)]2
GCCTGGTGCAGCCTGGCGGATCTCTGAG



Fc hole
ACTGTCCTGCGCCGCCTCCGGCTTCACC



chain
TTCTCCTCCCACGCCATGTCCTGGGTCC




GACAGGCTCCTGGCAAAGGCCTGGAATG




GGTGTCCGCCATCTGGGCCTCCGGCGAG




CAGTACTACGCCGACTCTGTGAAGGGCC




GGTTCACCATCTCCCGGGACAACTCCAA




GAACACCCTGTACCTGCAGATGAACTCC




CTGCGGGCCGAGGACACCGCCGTGTACT




ACTGTGCCAAGGGCTGGCTGGGCAACTT




CGACTACTGGGGACAGGGCACCCTGGTC




ACCGTGTCCAGCGCTAGCACAAAGGGAC




CTAGCGTGTTCCCCCTGGCCCCCAGCAG




CAAGTCTACATCTGGCGGAACAGCCGCC




CTGGGCTGCCTCGTGAAGGACTACTTTC




CCGAGCCCGTGACCGTGTCCTGGAACTC




TGGCGCTCTGACAAGCGGCGTGCACACC




TTTCCAGCCGTGCTGCAGAGCAGCGGCC




TGTACTCTCTGAGCAGCGTCGTGACAGT




GCCCAGCAGCTCTCTGGGCACCCAGACC




TACATCTGCAACGTGAACCACAAGCCCA




GCAACACCAAGGTGGACAAGAAGGTGGA




ACCCAAGAGCTGCGACGGCGGAGGGGGA




TCTGGCGGCGGAGGATCCGAAGTGCAGC




TGCTGGAATCCGGCGGAGGCCTGGTGCA




GCCTGGCGGATCTCTGAGACTGTCCTGC




GCCGCCTCCGGCTTCACCTTCTCCTCCC




ACGCCATGTCCTGGGTCCGACAGGCTCC




TGGCAAAGGCCTGGAATGGGTGTCCGCC




ATCTGGGCCTCCGGCGAGCAGTACTACG




CCGACTCTGTGAAGGGCCGGTTCACCAT




CTCCCGGGACAACTCCAAGAACACCCTG




TACCTGCAGATGAACTCCCTGCGGGCCG




AGGACACCGCCGTGTACTACTGTGCCAA




GGGCTGGCTGGGCAACTTCGACTACTGG




GGACAGGGCACCCTGGTCACCGTGTCCA




GCGCTAGCACCAAGGGCCCCTCCGTGTT




CCCCCTGGCCCCCAGCAGCAAGAGCACC




AGCGGCGGCACAGCCGCTCTGGGCTGCC




TGGTCAAGGACTACTTCCCCGAGCCCGT




GACCGTGTCCTGGAACAGCGGAGCCCTG




ACCTCCGGCGTGCACACCTTCCCCGCCG




TGCTGCAGAGTTCTGGCCTGTATAGCCT




GAGCAGCGTGGTCACCGTGCCTTCTAGC




AGCCTGGGCACCCAGACCTACATCTGCA




ACGTGAACCACAAGCCCAGCAACACCAA




GGTGGACAAGAAGGTGGAGCCCAAGAGC




TGCGACAAAACTCACACATGCCCACCGT




GCCCAGCACCTGAAGCTGCAGGGGGACC




GTCAGTCTTCCTCTTCCCCCCAAAACCC




AAGGACACCCTCATGATCTCCCGGACCC




CTGAGGTCACATGCGTGGTGGTGGACGT




GAGCCACGAAGACCCTGAGGTCAAGTTC




AACTGGTACGTGGACGGCGTGGAGGTGC




ATAATGCCAAGACAAAGCCGCGGGAGGA




GCAGTACAACAGCACGTACCGTGTGGTC




AGCGTCCTCACCGTCCTGCACCAGGACT




GGCTGAATGGCAAGGAGTACAAGTGCAA




GGTCTCCAACAAAGCCCTCGGCGCCCCC




ATCGAGAAAACCATCTCCAAAGCCAAAG




GGCAGCCCCGAGAACCACAGGTGTGCAC




CCTGCCCCCATCCCGGGATGAGCTGACC




AAGAACCAGGTCAGCCTCTCGTGCGCAG




TCAAAGGCTTCTATCCCAGCGACATCGC




CGTGGAGTGGGAGAGCAATGGGCAGCCG




GAGAACAACTACAAGACCACGCCTCCCG




TGCTGGACTCCGACGGCTCCTTCTTCCT




CGTGAGCAAGCTCACCGTGGACAAGAGC




AGGTGGCAGCAGGGGAACGTCTTCTCAT




GCTCCGTGATGCATGAGGCTCTGCACAA




CCACTACACGCAGAAGAGCCTCTCCCTG




TCTCCGGGTAAA





 69
anti-FAP 
see Table 2



(28H1)




light chain






115
Dimeric 
see Table 3



hu 4-1BBL 




(71-254)-




CL* Fc 




knob chain






116
Monomeric 
see Table 3



hu 4-1BBL 




(71-254)-




CH1*






145
[anti-FAP
EVQLLESGGGLVQPGGSLRLSCAASGFT



(28H1)]2
FSSHAMSWVRQAPGKGLEWVSAIWASGE



Fc hole
QYYADSVKGRFTISRDNSKNTLYLQMNS



chain
LRAEDTAVYYCAKGWLGNFDYWGQGTLV




TVSSASTKGPSVFPLAPSSKSTSGGTAA




LGCLVKDYFPEPVTVSWNSGALTSGVHT




FPAVLQSSGLYSLSSVVTVPSSSLGTQT




YICNVNHKPSNTKVDKKVEPKSCDGGGG




SGGGGSEVQLLESGGGLVQPGGSLRLSC




AASGFTFSSHAMSWVRQAPGKGLEWVSA




IWASGEQYYADSVKGRFTISRDNSKNTL




YLQMNSLRAEDTAVYYCAKGWLGNFDYW




GQGTLVTVSSASTKGPSVFPLAPSSKST




SGGTAALGCLVKDYFPEPVTVSWNSGAL




TSGVHTFPAVLQSSGLYSLSSVVTVPSS




SLGTQTYICNVNHKPSNTKVDKKVEPKS




CDKTHTCPPCPAPEAAGGPSVFLFPPKP




KDTLMISRTPEVTCVVVDVSHEDPEVKF




NWYVDGVEVHNAKTKPREEQYNSTYRVV




SVLTVLHQDWLNGKEYKCKVSNKALGAP




IEKTISKAKGQPREPQVCTLPPSRDELT




KNQVSLSCAVKGFYPSDIAVEWESNGQP




ENNYKTTPPVLDSDGSFFLVSKLTVDKS




RWQQGNVFSCSVMHEALHNHYTQKSLSL




SPGK





 19
anti-FAP 
see Table 2



(28H1)




light chain









Table 9 shows the cDNA and amino acid sequences of the bivalent FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion molecule Construct 1.8 (FIG. 2H) (FAP split trimer with 4-1BB ligands fused to anti-FAP CrossFab, with charged residues, on knob chain).









TABLE 9







Sequences of FAP-targeted human 4-1BB ligand


trimer containing Fc (kih) fusion molecule Construct 1.8









SEQ




ID NO:
Description
Sequence





146
Dimeric hu 4-
AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG



1BBL (71-254)-
ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGG



FAP (VHCL*) Fc
TGGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCC



knob chain
TGGTACAGCGATCCTGGACTGGCTGGCGTGTCACTGAC




AGGCGGCCTGAGCTACAAAGAGGACACCAAAGAACTGG




TGGTGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAG




CTGGAACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGG




CTCTGTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAA




GCGCTGCTGGCGCTGCAGCTCTGGCACTGACAGTGGAT




CTGCCTCCTGCCAGCTCCGAGGCCCGGAATAGCGCATT




TGGGTTTCAAGGCAGGCTGCTGCACCTGTCTGCCGGCC




AGAGGCTGGGAGTGCATCTGCACACAGAGGCCAGGGCT




AGACACGCCTGGCAGCTGACACAGGGCGCTACAGTGCT




GGGCCTGTTCAGAGTGACCCCCGAGATTCCAGCCGGCC




TGCCTTCTCCAAGAAGCGAAGGCGGAGGCGGATCTGGC




GGCGGAGGATCTAGAGAGGGACCCGAACTGTCCCCTGA




CGATCCAGCCGGGCTGCTGGATCTGAGACAGGGAATGT




TCGCCCAGCTGGTGGCTCAGAATGTGCTGCTGATTGAC




GGACCTCTGAGCTGGTACTCCGACCCAGGGCTGGCAGG




GGTGTCCCTGACTGGGGGACTGTCCTACAAAGAAGATA




CAAAAGAACTGGTGGTGGCTAAAGCTGGGGTGTACTAT




GTGTTTTTTCAGCTGGAACTGAGGCGGGTGGTGGCTGG




GGAGGGCTCAGGATCTGTGTCCCTGGCTCTGCATCTGC




AGCCACTGCGCTCTGCTGCTGGCGCAGCTGCACTGGCT




CTGACTGTGGACCTGCCACCAGCCTCTAGCGAGGCCAG




AAACAGCGCCTTCGGGTTCCAAGGACGCCTGCTGCATC




TGAGCGCCGGACAGCGCCTGGGAGTGCATCTGCATACT




GAAGCCAGAGCCCGGCATGCTTGGCAGCTGACTCAGGG




GGCAACTGTGCTGGGACTGTTTCGCGTGACACCTGAGA




TCCCTGCCGGACTGCCAAGCCCTAGATCAGAAGGGGGC




GGAGGTTCCGGAGGCGGAGGATCTGAGGTGCAGCTGCT




GGAATCCGGCGGAGGCCTGGTGCAGCCTGGCGGATCTC




TGAGACTGTCCTGCGCCGCCTCCGGCTTCACCTTCTCC




TCCCACGCCATGTCCTGGGTCCGACAGGCTCCTGGCAA




AGGCCTGGAATGGGTGTCCGCCATCTGGGCCTCCGGCG




AGCAGTACTACGCCGACTCTGTGAAGGGCCGGTTCACC




ATCTCCCGGGACAACTCCAAGAACACCCTGTACCTGCA




GATGAACTCCCTGCGGGCCGAGGACACCGCCGTGTACT




ACTGTGCCAAGGGCTGGCTGGGCAACTTCGACTACTGG




GGCCAGGGCACCCTGGTCACCGTGTCCAGCGCTAGCGT




GGCTGCACCATCTGTCTTTATCTTCCCACCCAGCGACC




GGAAGCTGAAGTCTGGCACAGCCAGCGTCGTGTGCCTG




CTGAATAACTTCTACCCCCGCGAGGCCAAGGTGCAGTG




GAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGG




AAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTAC




AGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTA




CGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACC




AGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCAACCGG




GGCGAGTGCGACAAGACCCACACCTGTCCTCCATGCCC




TGCCCCTGAAGCTGCTGGCGGCCCTAGCGTGTTCCTGT




TCCCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGG




ACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCCCA




CGAGGACCCTGAAGTGAAGTTCAATTGGTACGTGGACG




GCGTGGAAGTGCACAATGCCAAGACCAAGCCGCGGGAG




GAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCT




CACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGT




ACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGCCCCC




ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCG




AGAACCACAGGTGTACACCCTGCCCCCATGCCGGGATG




AGCTGACCAAGAACCAGGTCAGCCTGTGGTGCCTGGTC




AAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGA




GAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGC




CTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTAC




AGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGG




GAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGC




ACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCG




GGTAAA





147
Monomeric hu 4-
AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG



1BBL (71-254)-
ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGG



FAP (VLCH1*)
TGGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCC




TGGTACAGCGATCCTGGACTGGCTGGCGTGTCACTGAC




AGGCGGCCTGAGCTACAAAGAGGACACCAAAGAACTGG




TGGTGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAG




CTGGAACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGG




CTCTGTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAA




GCGCTGCTGGCGCTGCAGCTCTGGCTCTGACAGTGGAT




CTGCCTCCTGCCAGCTCCGAGGCCCGGAATAGCGCATT




TGGGTTTCAAGGCCGGCTGCTGCACCTGTCTGCCGGCC




AGAGACTGGGAGTGCATCTGCACACAGAGGCCAGAGCC




AGGCACGCCTGGCAGCTGACACAGGGCGCTACAGTGCT




GGGCCTGTTCAGAGTGACCCCCGAGATTCCTGCCGGCC




TGCCTAGCCCTAGATCTGAAGGCGGCGGAGGTTCCGGA




GGCGGAGGATCTGAGATCGTGCTGACCCAGTCTCCCGG




CACCCTGAGCCTGAGCCCTGGCGAGAGAGCCACCCTGA




GCTGCAGAGCCAGCCAGAGCGTGAGCCGGAGCTACCTG




GCCTGGTATCAGCAGAAGCCCGGCCAGGCCCCCAGACT




GCTGATCATCGGCGCCAGCACCCGGGCCACCGGCATCC




CCGATAGATTCAGCGGCAGCGGCTCCGGCACCGACTTC




ACCCTGACCATCAGCCGGCTGGAACCCGAGGACTTCGC




CGTGTACTACTGCCAGCAGGGCCAGGTGATCCCCCCCA




CCTTCGGCCAGGGCACCAAGGTGGAAATCAAGTCCTCT




GCTAGCACAAAGGGCCCCAGCGTGTTCCCTCTGGCCCC




TAGCAGCAAGAGCACATCTGGCGGAACAGCCGCCCTGG




GCTGCCTGGTGGAAGATTACTTCCCCGAGCCCGTGACC




GTGTCCTGGAATTCTGGCGCCCTGACAAGCGGCGTGCA




CACCTTTCCAGCCGTGCTGCAGAGCAGCGGCCTGTACT




CTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCTCTCTG




GGCACCCAGACCTACATCTGCAACGTGAACCACAAGCC




CAGCAACACCAAGGTGGACGAGAAGGTGGAACCCAAGT




CCTGC





 68
anti-FAP (28H1)
see Table 2



Fc hole chain






 69
anti-FAP (28H1)
see Table 2



light chain






148
Dimeric hu 4-
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLS



1BBL (71-254)-
WYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQ



FAP (VHCL*) 
LELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVD



Fc knob chain
LPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARA




RHAWQLTQGATVLGLFRVTPEIPAGLPSPRSEGGGGSG




GGGSREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLID




GPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYY




VFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALA




LTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHT




EARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSEGG




GGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFS




SHAMSWVRQAPGKGLEWVSAIWASGEQYYADSVKGRFT




ISRDNSKNTLYLQMNSLRAEDTAVYYCAKGWLGNFDYW




GQGTLVTVSSASVAAPSVFIFPPSDRKLKSGTASVVCL




LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY




SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR




GECDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR




TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE




EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAP




IEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLV




KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY




SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP




GK





149
Monomeric hu 4-
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLS



1BBL (71-254)-
WYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQ



FAP (VLCH1*)
LELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVD




LPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARA




RHAWQLTQGATVLGLFRVTPEIPAGLPSPRSEGGGGSG




GGGSEIVLTQSPGTLSLSPGERATLSCRASQSVSRSYL




AWYQQKPGQAPRLLIIGASTRATGIPDRFSGSGSGTDF




TLTISRLEPEDFAVYYCQQGQVIPPTFGQGTKVEIKSS




ASTKGPSVFPLAPSSKSTSGGTAALGCLVEDYFPEPVT




VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL




GTQTYICNVNHKPSNTKVDEKVEPKSC





 18
anti-FAP (28H1)
see Table 2



Fc hole chain






 19
anti-FAP (28H1)
see Table 2



light chain









Table 10 shows the cDNA and amino acid sequences of the monovalent FAP-targeted 4-1BB ligand (52-254) trimer-containing Fc (kih) fusion molecule Construct 1.9 (FIG. 2I) (FAP split trimer with 4-1BBL ectodomain amino acids 52-254 and charged residues on ligand chains).









TABLE 10







Sequences of FAP-targeted human 4-1BB ligand


trimer containing Fc (kih) fusion molecule Construct 1.9









SEQ




ID NO:
Description
Sequence





150
Dimeric hu 4-
CCTTGGGCTGTGTCTGGCGCTAGAGCCTCTCCTGGATC



1BBL (52-254)-
TGCCGCCAGCCCCAGACTGAGAGAGGGACCTGAGCTGA



CH1* Fc knob
GCCCCGATGATCCTGCCGGACTGCTGGATCTGAGACAG



chain
GGCATGTTCGCCCAGCTGGTGGCCCAGAACGTGCTGCT




GATCGATGGCCCCCTGTCCTGGTACAGCGATCCTGGAC




TGGCTGGCGTGTCACTGACAGGCGGCCTGAGCTACAAA




GAGGACACCAAAGAACTGGTGGTGGCCAAGGCCGGCGT




GTACTACGTGTTCTTTCAGCTGGAACTGCGGAGAGTGG




TGGCCGGCGAGGGATCTGGATCTGTGTCTCTGGCCCTG




CATCTGCAGCCCCTGAGAAGCGCTGCTGGCGCTGCAGC




TCTGGCACTGACAGTGGATCTGCCTCCTGCCAGCTCCG




AGGCCCGGAATAGCGCATTTGGGTTTCAAGGCAGACTG




CTGCACCTGTCTGCCGGCCAGAGGCTGGGAGTGCATCT




GCACACAGAGGCCAGGGCTAGACACGCCTGGCAGCTGA




CACAGGGCGCTACAGTGCTGGGCCTGTTCAGAGTGACC




CCCGAGATTCCAGCCGGACTGCCCAGCCCTAGATCTGA




AGGCGGCGGAGGAAGCGGAGGCGGAGGATCCCCTTGGG




CTGTGTCTGGCGCTAGAGCCTCTCCTGGATCTGCCGCC




AGCCCCAGACTGAGAGAGGGACCTGAGCTGAGCCCCGA




TGATCCTGCCGGACTGCTGGACCTGCGGCAGGGAATGT




TCGCTCAGCTGGTGGCTCAGAATGTGCTGCTGATTGAC




GGACCTCTGTCCTGGTACTCCGACCCTGGCCTGGCAGG




GGTGTCCCTGACTGGGGGACTGTCCTACAAAGAAGATA




CAAAAGAACTGGTGGTGGCTAAAGCTGGGGTGTACTAT




GTGTTTTTTCAGCTGGAACTGAGGCGGGTGGTGGCTGG




GGAGGGCTCAGGATCTGTGTCCCTGGCTCTGCATCTGC




AGCCTCTGCGCTCTGCTGCTGGCGCAGCTGCACTGGCT




CTGACTGTGGACCTGCCACCAGCCTCTAGCGAGGCCAG




AAACAGCGCCTTCGGGTTCCAAGGACGGCTGCTGCATC




TGAGCGCCGGACAGCGCCTGGGAGTGCATCTGCATACT




GAAGCCAGAGCCCGGCATGCTTGGCAGCTGACCCAGGG




GGCAACTGTGCTGGGACTGTTTCGCGTGACACCTGAGA




TCCCCGCTGGCCTGCCTAGCCCAAGAAGTGAAGGGGGA




GGCGGATCTGGCGGAGGGGGATCTGCTAGCACCAAGGG




CCCCTCCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCA




CCAGCGGCGGCACAGCCGCTCTGGGCTGCCTGGTCGAG




GACTACTTCCCCGAGCCCGTGACCGTGTCCTGGAACAG




CGGAGCCCTGACCTCCGGCGTGCACACCTTCCCCGCCG




TGCTGCAGAGTTCTGGCCTGTATAGCCTGAGCAGCGTG




GTCACCGTGCCTTCTAGCAGCCTGGGCACCCAGACCTA




CATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGG




TGGACGAGAAGGTGGAGCCCAAGAGCTGCGACAAAACT




CACACATGCCCACCGTGCCCAGCACCTGAAGCTGCAGG




GGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGG




ACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC




GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAA




GTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATG




CCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACG




TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGA




CTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCA




ACAAAGCCCTCGGCGCCCCCATCGAGAAAACCATCTCC




AAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACAC




CCTGCCCCCATGCCGGGATGAGCTGACCAAGAACCAGG




TCAGCCTGTGGTGCCTGGTCAAAGGCTTCTATCCCAGC




GACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGA




GAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCG




ACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGAC




AAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTC




CGTGATGCATGAGGCTCTGCACAACCACTACACGCAGA




AGAGCCTCTCCCTGTCTCCGGGTAAA





151
Monomeric hu 4-
CCTTGGGCTGTGTCTGGCGCTAGAGCCTCTCCTGGATC



1BBL (52-254)-
TGCCGCCAGCCCCAGACTGAGAGAGGGACCTGAGCTGA



CL*
GCCCCGATGATCCTGCCGGACTGCTGGATCTGAGACAG




GGCATGTTCGCCCAGCTGGTGGCCCAGAACGTGCTGCT




GATCGATGGCCCCCTGTCCTGGTACAGCGATCCTGGAC




TGGCTGGCGTGTCACTGACAGGCGGCCTGAGCTACAAA




GAGGACACCAAAGAACTGGTGGTGGCCAAGGCCGGCGT




GTACTACGTGTTCTTTCAGCTGGAACTGCGGAGAGTGG




TGGCCGGCGAGGGATCTGGATCTGTGTCTCTGGCCCTG




CATCTGCAGCCCCTGAGAAGCGCTGCTGGCGCTGCAGC




TCTGGCACTGACAGTGGATCTGCCTCCTGCCAGCTCCG




AGGCCCGGAATAGCGCATTTGGGTTTCAAGGCAGGCTG




CTGCACCTGTCTGCCGGCCAGAGGCTGGGAGTGCATCT




GCACACAGAGGCCAGGGCTAGACACGCCTGGCAGCTGA




CACAGGGCGCTACAGTGCTGGGCCTGTTCAGAGTGACC




CCCGAGATTCCAGCCGGCCTGCCTTCTCCAAGAAGCGA




AGGCGGAGGCGGATCTGGCGGCGGAGGATCTCGTACGG




TGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGAT




CGGAAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCT




GCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGT




GGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAG




GAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTA




CAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACT




ACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCAT




CAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAG




GGGAGAGTGT





 68
anti-FAP (28H1)
see Table 2



Fc hole chain






 69
anti-FAP (28H1)
see Table 2



light chain






111
Dimeric hu 4-
PWAVSGARASPGSAASPRLREGPELSPDDPAGLLDLRQ



1BBL (52-254)-
GMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYK



CH1* Fc knob
EDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLAL



chain
HLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRL




LHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVT




PEIPAGLPSPRSEGGGGSGGGGSPWAVSGARASPGSAA




SPRLREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLID




GPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYY




VFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALA




LTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHT




EARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSEGG




GGSGGGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVE




DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV




VTVPSSSLGTQTYICNVNHKPSNTKVDEKVEPKSCDKT




HTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTC




VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST




YRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTIS




KAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPS




DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD




KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK





112
Monomeric hu 4-
PWAVSGARASPGSAASPRLREGPELSPDDPAGLLDLRQ



1BBL (52-254)-
GMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYK



CL*
EDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLAL




HLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRL




LHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVT




PEIPAGLPSPRSEGGGGSGGGGSRTVAAPSVFIFPPSD




RKLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ




ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH




QGLSSPVTKSFNRGEC





 18
anti-FAP (28H1)
see Table 2



Fc hole chain






 19
anti-FAP (28H1)
see Table 2



light chain









Table 11 shows the cDNA and amino acid sequences of the monovalent FAP-targeted 4-1BB ligand (80-254) trimer-containing Fc (kih) fusion molecule Construct 1.10 (FIG. 2J) (FAP split trimer with 4-1BBL ectodomain amino acids 80-254 and charged residues on ligand chains).









TABLE 11







Sequences of FAP-targeted human 4-1BB ligand


trimer containing Fc (kih) fusion molecule Construct 10









SEQ




ID NO:
Description
Sequence





152
Dimeric hu 4-
GATCCTGCCGGCCTGCTGGATCTGCGGCAGGGAATGTT



1BBL (80-254)-
TGCCCAGCTGGTGGCCCAGAACGTGCTGCTGATCGATG



CH1* Fc knob
GCCCCCTGAGCTGGTACAGCGATCCTGGACTGGCTGGC



chain
GTGTCACTGACAGGCGGCCTGAGCTACAAAGAGGACAC




CAAAGAACTGGTGGTGGCCAAGGCCGGCGTGTACTACG




TGTTCTTTCAGCTGGAACTGCGGAGAGTGGTGGCCGGC




GAAGGATCTGGCTCTGTGTCTCTGGCCCTGCATCTGCA




GCCCCTGAGAAGCGCTGCTGGCGCTGCAGCTCTGGCAC




TGACAGTGGATCTGCCTCCTGCCAGCTCCGAGGCCCGG




AATAGCGCATTTGGGTTTCAAGGCAGACTGCTGCACCT




GTCTGCCGGCCAGAGGCTGGGAGTGCATCTGCACACAG




AGGCCAGGGCTAGACACGCCTGGCAGCTGACACAGGGC




GCTACAGTGCTGGGCCTGTTCAGAGTGACCCCCGAGAT




TCCAGCCGGACTGCCCAGCCCTAGATCTGAAGGCGGCG




GAGGAAGCGGAGGCGGAGGATCCGACCCAGCTGGACTG




CTGGACCTGCGGCAGGGAATGTTCGCTCAGCTGGTGGC




TCAGAATGTGCTGCTGATTGACGGACCTCTGTCCTGGT




ACTCCGACCCTGGCCTGGCAGGGGTGTCCCTGACTGGG




GGACTGTCCTACAAAGAAGATACAAAAGAACTGGTGGT




GGCTAAAGCTGGGGTGTACTATGTGTTTTTTCAGCTGG




AACTGAGGCGGGTGGTGGCTGGGGAGGGCTCAGGATCT




GTGTCCCTGGCTCTGCATCTGCAGCCTCTGCGCTCTGC




TGCTGGCGCAGCTGCACTGGCTCTGACTGTGGACCTGC




CACCAGCCTCTAGCGAGGCCAGAAACAGCGCCTTCGGG




TTCCAAGGACGGCTGCTGCATCTGAGCGCCGGACAGCG




CCTGGGAGTGCATCTGCATACTGAAGCCAGAGCCCGGC




ATGCTTGGCAGCTGACCCAGGGGGCAACTGTGCTGGGA




CTGTTTCGCGTGACACCTGAGATCCCCGCTGGCCTGCC




TAGCCCAAGAAGTGAAGGGGGAGGCGGATCTGGCGGAG




GGGGATCTGCTAGCACCAAGGGCCCCTCCGTGTTCCCC




CTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGC




CGCTCTGGGCTGCCTGGTCGAGGACTACTTCCCCGAGC




CCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCTCC




GGCGTGCACACCTTCCCCGCCGTGCTGCAGAGTTCTGG




CCTGTATAGCCTGAGCAGCGTGGTCACCGTGCCTTCTA




GCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAAC




CACAAGCCCAGCAACACCAAGGTGGACGAGAAGGTGGA




GCCCAAGAGCTGCGACAAAACTCACACATGCCCACCGT




GCCCAGCACCTGAAGCTGCAGGGGGACCGTCAGTCTTC




CTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTC




CCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGA




GCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTG




GACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCG




GGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCG




TCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAG




GAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGC




CCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGC




CCCGAGAACCACAGGTGTACACCCTGCCCCCATGCCGG




GATGAGCTGACCAAGAACCAGGTCAGCCTGTGGTGCCT




GGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGT




GGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC




ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT




CTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGC




AGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCT




CTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTC




TCCGGGTAAA





153
Monomeric hu 4-
GATCCTGCCGGCCTGCTGGATCTGCGGCAGGGAATGTT



1BBL (80-254)-
TGCCCAGCTGGTGGCCCAGAACGTGCTGCTGATCGATG



CL*
GCCCCCTGAGCTGGTACAGCGATCCTGGACTGGCTGGC




GTGTCACTGACAGGCGGCCTGAGCTACAAAGAGGACAC




CAAAGAACTGGTGGTGGCCAAGGCCGGCGTGTACTACG




TGTTCTTTCAGCTGGAACTGCGGAGAGTGGTGGCCGGC




GAAGGATCTGGCTCTGTGTCTCTGGCCCTGCATCTGCA




GCCCCTGAGAAGCGCTGCTGGCGCTGCAGCTCTGGCAC




TGACAGTGGATCTGCCTCCTGCCAGCTCCGAGGCCCGG




AATAGCGCATTTGGGTTTCAAGGCAGGCTGCTGCACCT




GTCTGCCGGCCAGAGGCTGGGAGTGCATCTGCACACAG




AGGCCAGGGCTAGACACGCCTGGCAGCTGACACAGGGC




GCTACAGTGCTGGGCCTGTTCAGAGTGACCCCCGAGAT




TCCAGCCGGCCTGCCTTCTCCAAGAAGCGAAGGCGGAG




GCGGATCTGGCGGCGGAGGATCTCGTACGGTGGCTGCA




CCATCTGTCTTCATCTTCCCGCCATCTGATCGGAAGTT




GAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATA




ACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTG




GATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGT




CACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCA




GCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAA




CACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCT




GAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGT




GT





 68
anti-FAP (28H1)
see Table 2



Fc hole chain






 69
anti-FAP (28H1)
see Table 2



light chain






113
Dimeric hu 4-
DPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAG



1BBL (80-254)-
VSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAG



CH1* Fc knob
EGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEAR



chain
NSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQG




ATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSDPAGL




LDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTG




GLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGS




VSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFG




FQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLG




LFRVTPEIPAGLPSPRSEGGGGSGGGGSASTKGPSVFP




LAPSSKSTSGGTAALGCLVEDYFPEPVTVSWNSGALTS




GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN




HKPSNTKVDEKVEPKSCDKTHTCPPCPAPEAAGGPSVF




LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV




DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK




EYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCR




DELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKT




TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA




LHNHYTQKSLSLSPGK





114
Monomeric hu 4-
DPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAG



1BBL (80-254)-
VSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAG



CL*
EGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEAR




NSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQG




ATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSRTVAA




PSVFIFPPSDRKLKSGTASVVCLLNNFYPREAKVQWKV




DNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEK




HKVYACEVTHQGLSSPVTKSFNRGEC





 18
anti-FAP (28H1)
see Table 2



Fc hole chain






 19
anti-FAP (28H1)
see Table 2



light chain









1.2 Production of FAP (28H1) Targeted Split Trimeric 4-1BB Ligand Fc Fusion Constructs


The targeted TNF ligand trimer-containing Fc (kih) fusion antigen binding molecule encoding sequences were cloned into a plasmid vector, which drives expression of the insert from an MPSV promoter and contains a synthetic polyA sequence located at the 3′ end of the CDS. In addition, the vector contains an EBV OriP sequence for episomal maintenance of the plasmid.


The targeted TNF ligand trimer-containing Fc (kih) fusion antigen binding molecule was produced by co-transfecting HEK293-EBNA cells with the mammalian expression vectors using polyethylenimine. The cells were transfected with the corresponding expression vectors at a 1:1:1:1 ratio (e.g. “vector dimeric ligand-(CH1 or CL)-knob chain”: “vector monomeric ligand fusion-(CL or CH1)”: “vector anti-FAP Fab-hole heavy chain”: “vector anti-FAP light chain”) for the Constructs 1, 2, 3, 4, 6, 7, 8, 9, 10. For the bivalent Construct 5, a 1:1:1 ratio (“vector hole heavy chain”: “vector knob heavy chain”: “vector anti-FAP light chain”) was used.


For production in 500 mL shake flasks, 300 million HEK293 EBNA cells were seeded 24 hours before transfection. For transfection cells were centrifuged for 10 minutes at 210×g, and the supernatant was replaced by 20 mL pre-warmed CD CHO medium. Expression vectors (200 μg of total DNA) were mixed in 20 mL CD CHO medium. After addition of 540 μL PEI, the solution was vortexed for 15 seconds and incubated for 10 minutes at room temperature. Afterwards, cells were mixed with the DNA/PEI solution, transferred to a 500 mL shake flask and incubated for 3 hours at 37° C. in an incubator with a 5% CO2 atmosphere. After the incubation, 160 mL of Excell medium supplemented with 6 mM L-Glutamine, 5 g/L PEPSOY and 1.2 mM valproic acid was added and cells were cultured for 24 hours. One day after transfection 12% Feed 7 and Glucose (final concentration 3 g/L) were added. After culturing for 7 days, the supernatant was collected by centrifugation for 30-40 minutes at 400× g. The solution was sterile filtered (0.22 μm filter), supplemented with sodium azide to a final concentration of 0.01% (w/v), and kept at 4° C.


The targeted TNF ligand trimer-containing Fc (kih) fusion antigen binding molecule was purified from cell culture supernatants by affinity chromatography using Protein A, followed by size exclusion chromatography. For affinity chromatography, the supernatant was loaded on a MABSELECT SURE® column (CV=5-15 mL, resin from GE Healthcare) equilibrated with 20 mM sodium phosphate, 20 mM sodium citrate buffer (pH 7.5). Unbound protein was removed by washing with at least 6 column volumes of the same buffer. The bound protein was eluted using either a linear gradient (20 CV) or a step elution (8 CV) with 20 mM sodium citrate, 100 mM Sodium chloride, 100 mM Glycine buffer (pH 3.0). For the linear gradient an additional 4 column volumes step elution was applied.


The pH of collected fractions was adjusted by adding 1/10 (v/v) of 0.5M sodium phosphate, pH 8.0. The protein was concentrated prior to loading on a HILOAD® Superdex 200 column (GE Healthcare) equilibrated with 20 mM Histidine, 140 mM sodium chloride, 0.01% (v/v) TWEEN® 20 (polysorbate 20) solution of pH 6.0.


The protein concentration was determined by measuring the optical density (OD) at 280 nm, using a molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the targeted TNF ligand trimer-containing Fc (kih) fusion antigen binding molecule was analyzed by SDS-PAGE in the presence and absence of a reducing agent (5 mM 1,4-dithiotreitol) and staining with Coomassie SIMPLYBLUE™ SafeStain (Invitrogen USA) or CE-SDS using Caliper LabChip GXII (Perkin Elmer). The aggregate content of samples was analyzed using a TSKGEL® G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in 25 mM K2HPO4, 125 mM NaCl, 200 mM L-Arginine Monohydrocloride, 0.02% (w/v) NaN3, pH 6.7 running buffer at 25° C.


Table 12 summarizes the yield and final monomer content of the FAP-targeted 4-1BBL trimer-containing Fc (kih) fusion antigen binding molecules.









TABLE 12







Biochemical Analysis of the FAP (28H1)-targeted 4-1BBL


trimer-containing Fc (kih) fusion antigen binding molecules










Yield
Monomer


Construct
[mg/l]
[%] (SEC)












Construct 1.1 
12.7
95


Construct 1.2 
25.2
97


Construct 1.3 
22
92


Construct 1.4 
14.2
99


Construct 1.5 
14
99


Construct 1.6 
12
98


Construct 1.7 
3.4
99


Construct 1.8 
5.4
98


Construct 1.9 
11.2
98


Construct 1.10
19.8
99









1.3 Preparation of Targeted Murine 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules


Similarly to targeted human 4-1BB ligand trimer-containing Fc fusion antigen binding molecules, murine FAP-targeted 4-1BBL trimer-containing Fc fusion antigen binding molecules were prepared.


The DNA sequence encoding part of the ectodomain (amino acids 104-309) of murine 4-1BB ligand was synthetized according to the Q3U1Z9-1 sequence of Uniprot database (SEQ ID NO:70). For Construct M.1 the cysteines at positions 137, 160 and 246 were mutated to Serine by standard PCR methods, whereas for Construct M.2 the cysteine at position 160 was mutated to Serine (C160S).


The murine ligand was assembled as described for the human 4-1BBL and as depicted in FIGS. 3A and 3B. The dimeric 4-1BBL, separated by (G4S)2 (SEQ ID NO:13) linkers, was fused to the murine IgG1-CL domain (FIG. 3A) and the monomeric 4-1BBL was fused to murine IgG1-CH domain (FIG. 3B). The polypeptide encoding the dimeric 4-1BB ligand fused to murine CL domain was subcloned in frame with the murine IgG1 heavy chain CH2 and CH3 domains to build the Constructs as depicted in FIG. 3C.


For the murine constructs, mutations Lys392Asp and Lys409Asp (DD) were introduced in the heavy chain containing the murine 4-1BBL and mutations Glu356Lys and Asp399Lys (KK) were introduced in the heavy chain containing the anti-FAP Fab to obtain asymmetric molecules (Gunasekaran K. et al, J Biol. Chem., 2010, Jun. 18; 285(25):19637-46).


Mutations Asp265Ala and Pro329Gly (DAPG) were introduced in the constant region of the heavy chains to abrogate binding to Fc gamma receptors.


Table 13 shows, respectively, the cDNA and amino acid sequences of the FAP-targeted murine 4-1BB ligand trimer-containing Fc fusion antigen binding molecule Construct M.1.









TABLE 13







Sequences of FAP-targeted murine Construct M.1









SEQ




ID NO:
Description
Sequence





71
Dimeric murine
AGAACCGAGCCCAGACCCGCCCTGACCATCACCACCAG



4-1BBL (104-
CCCTAACCTGGGCACCAGAGAGAACAACGCCGACCAAG



309, C137, 160,
TGACCCCCGTGTCCCACATCGGCAGCCCCAATACCACA



246S)-CL Fc DD 
CAGCAGGGCAGCCCTGTGTTCGCCAAGCTGCTGGCCAA



chain
GAACCAGGCCAGCCTGAGCAACACCACCCTGAACTGGC




ACAGCCAGGATGGCGCCGGAAGCAGCTATCTGAGCCAG




GGCCTGAGATACGAAGAGGACAAGAAAGAACTGGTGGT




GGACAGCCCTGGCCTGTACTACGTGTTCCTGGAACTGA




AGCTGAGCCCCACCTTCACCAACACCGGCCACAAGGTG




CAGGGCTGGGTGTCACTGGTGCTGCAGGCCAAACCCCA




GGTGGACGACTTCGACAACCTGGCCCTGACCGTGGAAC




TGTTCCCCAGCAGCATGGAAAACAAGCTGGTGGATCGG




AGCTGGTCCCAGCTTCTGCTGCTGAAGGCCGGACACAG




ACTGAGCGTGGGCCTGAGGGCTTATCTGCACGGCGCCC




AGGACGCCTACAGAGACTGGGAGCTGAGCTACCCCAAC




ACAACCAGCTTCGGCCTGTTCCTCGTGAAGCCCGACAA




CCCTTGGGAAGGCGGCGGAGGATCTGGCGGAGGCGGAT




CTAGAACAGAGCCTCGGCCTGCCCTGACAATTACCACA




TCCCCCAATCTGGGCACCCGGGAAAACAATGCAGATCA




AGTGACACCTGTGTCTCATATTGGCTCCCCAAACACTA




CCCAGCAGGGCTCCCCCGTGTTTGCTAAACTGCTGGCT




AAAAATCAGGCCTCCCTGTCTAACACAACACTGAACTG




GCACTCCCAGGACGGCGCTGGCAGCTCTTACCTGAGTC




AGGGACTGCGCTATGAGGAAGATAAGAAAGAACTGGTG




GTGGATTCCCCCGGACTGTACTATGTGTTTCTGGAACT




GAAACTGTCCCCTACCTTTACAAATACCGGGCACAAAG




TGCAGGGATGGGTGTCCCTGGTGCTGCAGGCTAAGCCT




CAGGTGGACGATTTTGATAATCTGGCTCTGACAGTGGA




ACTGTTTCCTAGCAGCATGGAAAACAAGCTGGTGGACA




GAAGCTGGTCCCAGCTCCTGCTGCTGAAGGCCGGACAC




AGACTGAGCGTGGGCCTGAGAGCCTATCTGCACGGCGC




CCAGGACGCCTACAGAGACTGGGAGCTGAGCTACCCCA




ACACAACCAGCTTCGGCCTGTTCCTCGTGAAGCCCGAC




AACCCTTGGGAAGGCGGCGGAGGATCTGGCGGAGGCGG




ATCCAGAGCTGATGCTGCCCCTACCGTGTCCATCTTCC




CACCCAGCAGCGAGCAGCTGACATCTGGGGGAGCTAGC




GTCGTGTGCTTCCTGAACAACTTCTACCCCAAGGACAT




CAACGTGAAGTGGAAGATCGACGGCAGCGAGCGGCAGA




ACGGCGTGCTGAATAGCTGGACCGACCAGGACAGCAAG




GACTCCACCTACAGCATGAGCAGCACCCTGACCCTGAC




CAAGGACGAGTACGAGCGGCACAACAGCTACACATGCG




AGGCCACCCACAAGACCAGCACCAGCCCCATCGTGAAG




TCCTTCAACCGGAACGAGTGCGTGCCCAGAGACTGCGG




CTGCAAGCCTTGCATCTGCACCGTGCCTGAGGTGTCCA




GCGTGTTCATCTTCCCACCCAAGCCCAAGGACGTGCTG




ACCATCACCCTGACACCCAAAGTGACCTGCGTGGTGGT




GGCCATCAGCAAGGATGACCCCGAGGTGCAGTTCAGTT




GGTTCGTGGACGACGTGGAAGTGCACACCGCTCAGACC




AAGCCCAGAGAGGAACAGATCAACAGCACCTTCAGAAG




CGTGTCCGAGCTGCCCATCATGCACCAGGACTGGCTGA




ACGGCAAAGAATTCAAGTGCAGAGTGAACAGCGCCGCC




TTTGGCGCCCCTATCGAGAAAACCATCTCCAAGACCAA




GGGCAGACCCAAGGCCCCCCAGGTGTACACAATCCCCC




CACCCAAAGAACAGATGGCCAAGGACAAGGTGTCCCTG




ACCTGCATGATCACCAATTTCTTCCCAGAGGATATCAC




CGTGGAATGGCAGTGGAACGGCCAGCCCGCCGAGAACT




ACGACAACACCCAGCCTATCATGGACACCGACGGCTCC




TACTTCGTGTACAGCGACCTGAACGTGCAGAAGTCCAA




CTGGGAGGCCGGCAACACCTTCACCTGTAGCGTGCTGC




ACGAGGGCCTGCACAACCACCACACCGAGAAGTCCCTG




TCCCACAGCCCTGGCAAG





72
Monomeric
AGAACCGAGCCCAGACCCGCCCTGACCATCACCACCAG



murine 4-1BBL
CCCTAACCTGGGCACCAGAGAGAACAACGCCGACCAAG



(104-309, C137,
TGACCCCCGTGTCCCACATCGGCAGCCCCAATACCACA



160,246S)-CL
CAGCAGGGCAGCCCTGTGTTCGCCAAGCTGCTGGCCAA




GAACCAGGCCAGCCTGAGCAACACCACCCTGAACTGGC




ACAGCCAGGATGGCGCCGGAAGCAGCTATCTGAGCCAG




GGCCTGAGATACGAAGAGGACAAGAAAGAACTGGTGGT




GGACAGCCCTGGCCTGTACTACGTGTTCCTGGAACTGA




AGCTGAGCCCCACCTTCACCAACACCGGCCACAAGGTG




CAGGGCTGGGTGTCACTGGTGCTGCAGGCCAAACCCCA




GGTGGACGACTTCGACAACCTGGCCCTGACCGTGGAAC




TGTTCCCCAGCAGCATGGAAAACAAGCTGGTGGATCGG




AGCTGGTCCCAGCTTCTGCTGCTGAAGGCCGGACACAG




ACTGAGCGTGGGCCTGAGGGCCTATCTGCATGGCGCCC




AGGACGCCTACAGAGACTGGGAGCTGAGCTACCCCAAC




ACAACCAGCTTCGGCCTGTTCCTCGTGAAGCCCGACAA




CCCTTGGGAAGGCGGCGGAGGCTCCGGAGGAGGCGGAA




GCGCTAAGACCACCCCCCCCAGCGTGTACCCTCTGGCC




CCTGGATCTGCCGCCCAGACCAACAGCATGGTGACCCT




GGGCTGCCTGGTGAAGGGCTACTTCCCCGAGCCTGTGA




CCGTGACCTGGAACAGCGGCAGCCTGAGCAGCGGCGTG




CACACCTTTCCAGCCGTGCTGCAGAGCGACCTGTACAC




CCTGAGCAGCTCCGTGACCGTGCCTAGCAGCACCTGGC




CCAGCCAGACAGTGACCTGCAACGTGGCCCACCCTGCC




AGCAGCACCAAGGTGGACAAGAAAATCGTGCCCCGGGA




CTGC





73
anti-FAP (28H1)
GAAGTGCAGCTGCTGGAATCCGGCGGAGGCCTGGTGCA



Fc KK heavy
GCCTGGCGGATCTCTGAGACTGTCCTGCGCCGCCTCCG



chain
GCTTCACCTTCTCCTCCCACGCCATGTCCTGGGTCCGA




CAGGCTCCTGGCAAAGGCCTGGAATGGGTGTCCGCCAT




CTGGGCCTCCGGCGAGCAGTACTACGCCGACTCTGTGA




AGGGCCGGTTCACCATCTCCCGGGACAACTCCAAGAAC




ACCCTGTACCTGCAGATGAACTCCCTGCGGGCCGAGGA




CACCGCCGTGTACTACTGTGCCAAGGGCTGGCTGGGCA




ACTTCGACTACTGGGGACAGGGCACCCTGGTCACCGTG




TCCAGCGCTAAGACCACCCCCCCTAGCGTGTACCCTCT




GGCCCCTGGATCTGCCGCCCAGACCAACAGCATGGTGA




CCCTGGGCTGCCTGGTGAAGGGCTACTTCCCCGAGCCT




GTGACCGTGACCTGGAACAGCGGCAGCCTGAGCAGCGG




CGTGCACACCTTTCCAGCCGTGCTGCAGAGCGACCTGT




ACACCCTGAGCAGCTCCGTGACCGTGCCTAGCAGCACC




TGGCCCAGCCAGACAGTGACCTGCAACGTGGCCCACCC




TGCCAGCAGCACCAAGGTGGACAAGAAAATCGTGCCCC




GGGACTGCGGCTGCAAGCCCTGCATCTGCACCGTGCCC




GAGGTGTCCAGCGTGTTCATCTTCCCACCCAAGCCCAA




GGACGTGCTGACCATCACCCTGACCCCCAAAGTGACCT




GCGTGGTGGTGGCCATCAGCAAGGACGACCCCGAGGTG




CAGTTCTCTTGGTTTGTGGACGACGTGGAGGTGCACAC




AGCCCAGACAAAGCCCCGGGAGGAACAGATCAACAGCA




CCTTCAGAAGCGTGTCCGAGCTGCCCATCATGCACCAG




GACTGGCTGAACGGCAAAGAATTCAAGTGCAGAGTGAA




CAGCGCCGCCTTCGGCGCCCCCATCGAGAAAACCATCA




GCAAGACCAAGGGCAGACCCAAGGCCCCCCAGGTGTAC




ACCATCCCCCCACCCAAAAAACAGATGGCCAAGGACAA




GGTGTCCCTGACCTGCATGATCACCAACTTTTTCCCCG




AGGACATCACCGTGGAGTGGCAGTGGAATGGCCAGCCC




GCCGAGAACTACAAGAACACCCAGCCCATCATGAAGAC




CGACGGCAGCTACTTCGTGTACAGCAAGCTGAACGTGC




AGAAGTCCAACTGGGAGGCCGGCAACACCTTCACCTGT




AGCGTGCTGCACGAGGGCCTGCACAACCACCACACCGA




GAAGTCCCTGAGCCACTCCCCCGGCAAG





74
anti-FAP (28H1)
GAGATCGTGCTGACCCAGTCCCCCGGCACCCTGTCTCT



light chain
GAGCCCTGGCGAGAGAGCCACCCTGTCCTGCAGAGCCT




CCCAGTCCGTGTCCCGGTCCTACCTCGCCTGGTATCAG




CAGAAGCCCGGCCAGGCCCCTCGGCTGCTGATCATCGG




CGCCTCTACCAGAGCCACCGGCATCCCTGACCGGTTCT




CCGGCTCTGGCTCCGGCACCGACTTCACCCTGACCATC




TCCCGGCTGGAACCCGAGGACTTCGCCGTGTACTACTG




CCAGCAGGGCCAGGTCATCCCTCCCACCTTTGGCCAGG




GCACCAAGGTGGAAATCAAGCGTGCCGATGCTGCACCA




ACTGTATCGATTTTCCCACCATCCAGTGAGCAGTTAAC




ATCTGGAGGTGCCTCAGTCGTGTGCTTCTTGAACAACT




TCTACCCCAAAGACATCAATGTCAAGTGGAAGATTGAT




GGCAGTGAACGACAAAATGGCGTCCTGAACAGTTGGAC




TGATCAGGACAGCAAAGACAGCACCTACAGCATGAGCA




GCACCCTCACGTTGACCAAGGACGAGTATGAACGACAT




AACAGCTATACCTGTGAGGCCACTCACAAGACATCAAC




TTCACCCATTGTCAAGAGCTTCAACAGGAATGAGTGT





75
Dimeric murine
RTEPRPALTITTSPNLGTRENNADQVTPVSHIGSPNTT



4-1BBL (104-
QQGSPVFAKLLAKNQASLSNTTLNWHSQDGAGSSYLSQ



309, C137, 160,
GLRYEEDKKELVVDSPGLYYVFLELKLSPTFTNTGHKV



246S)-CL Fc 
QGWVSLVLQAKPQVDDFDNLALTVELFPSSMENKLVDR



DD chain
SWSQLLLLKAGHRLSVGLRAYLHGAQDAYRDWELSYPN




TTSFGLFLVKPDNPWEGGGGSGGGGSRTEPRPALTITT




SPNLGTRENNADQVTPVSHIGSPNTTQQGSPVFAKLLA




KNQASLSNTTLNWHSQDGAGSSYLSQGLRYEEDKKELV




VDSPGLYYVFLELKLSPTFTNTGHKVQGWVSLVLQAKP




QVDDFDNLALTVELFPSSMENKLVDRSWSQLLLLKAGH




RLSVGLRAYLHGAQDAYRDWELSYPNTTSFGLFLVKPD




NPWEGGGGSGGGGSRADAAPTVSIFPPSSEQLTSGGAS




VVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSK




DSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVK




SFNRNECVPRDCGCKPCICTVPEVSSVFIFPPKPKDVL




TITLTPKVTCVVVAISKDDPEVQFSWFVDDVEVHTAQT




KPREEQINSTFRSVSELPIMHQDWLNGKEFKCRVNSAA




FGAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSL




TCMITNFFPEDITVEWQWNGQPAENYDNTQPIMDTDGS




YFVYSDLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSL




SHSPGK





76
Monomeric
RTEPRPALTITTSPNLGTRENNADQVTPVSHIGSPNTT



murine 4-1BBL
QQGSPVFAKLLAKNQASLSNTTLNWHSQDGAGSSYLSQ



(104-309, C137,
GLRYEEDKKELVVDSPGLYYVFLELKLSPTFTNTGHKV



160, 246S)-CL
QGWVSLVLQAKPQVDDFDNLALTVELFPSSMENKLVDR




SWSQLLLLKAGHRLSVGLRAYLHGAQDAYRDWELSYPN




TTSFGLFLVKPDNPWEGGGGSGGGGSAKTTPPSVYPLA




PGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGV




HTFPAVLQSDLYTLSSSVTVPSSTWPSQTVTCNVAHPA




SSTKVDKKIVPRDC





77
anti-FAP (28H1)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSHAMSWVR



Fc KK chain
QAPGKGLEWVSAIWASGEQYYADSVKGRFTISRDNSKN




TLYLQMNSLRAEDTAVYYCAKGWLGNFDYWGQGTLVTV




SSAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEP




VTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSST




WPSQTVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVP




EVSSVFIFPPKPKDVLTITLTPKVTCVVVAISKDDPEV




QFSWFVDDVEVHTAQTKPREEQINSTFRSVSELPIMHQ




DWLNGKEFKCRVNSAAFGAPIEKTISKTKGRPKAPQVY




TIPPPKKQMAKDKVSLTCMITNFFPEDITVEWQWNGQP




AENYKNTQPIMKTDGSYFVYSKLNVQKSNWEAGNTFTC




SVLHEGLHNHHTEKSLSHSPGK





78
anti-FAP (28H1)
EIVLTQSPGTLSLSPGERATLSCRASQSVSRSYLAWYQ



light chain
QKPGQAPRLLIIGASTRATGIPDRFSGSGSGTDFTLTI




SRLEPEDFAVYYCQQGQVIPPTFGQGTKVEIKRADAAP




TVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKID




GSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERH




NSYTCEATHKTSTSPIVKSFNRNEC









Table 14 shows, respectively, the cDNA and amino acid sequences of the untargeted (DP47) murine 4-1BB ligand trimer-containing Fc fusion antigen binding molecule Control M.1.









TABLE 14







Sequences of untargeted murine Control M.1









SEQ




ID NO:
Description
Sequence





 71
Dimeric murine
See Table 13



4-1BBL (104-




309, C137, 160,




246S)-CL Fc DD 




chain






 72
Monomeric
See Table 13



murine 4-1BBL




(104-309, C137,




160, 246S)-CH1






154
DP47 Fc KK
GAGGTGCAATTGTTGGAGTCTGGGGGAGGCTTGGTACA



chain
GCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCCG




GATTCACCTTTAGCAGTTATGCCATGAGCTGGGTCCGC




CAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTAT




TAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCG




TGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAG




AACACGCTGTATCTGCAGATGAACAGCCTGAGAGCCGA




GGACACGGCCGTATATTACTGTGCGAAAGGCAGCGGAT




TTGACTACTGGGGCCAAGGAACCCTGGTCACCGTCTCG




AGCGCTAAGACCACCCCCCCTAGCGTGTACCCTCTGGC




CCCTGGATCTGCCGCCCAGACCAACAGCATGGTGACCC




TGGGCTGCCTGGTGAAGGGCTACTTCCCCGAGCCTGTG




ACCGTGACCTGGAACAGCGGCAGCCTGAGCAGCGGCGT




GCACACCTTTCCAGCCGTGCTGCAGAGCGACCTGTACA




CCCTGAGCAGCTCCGTGACCGTGCCTAGCAGCACCTGG




CCCAGCCAGACAGTGACCTGCAACGTGGCCCACCCTGC




CAGCAGCACCAAGGTGGACAAGAAAATCGTGCCCCGGG




ACTGCGGCTGCAAGCCCTGCATCTGCACCGTGCCCGAG




GTGTCCAGCGTGTTCATCTTCCCACCCAAGCCCAAGGA




CGTGCTGACCATCACCCTGACCCCCAAAGTGACCTGCG




TGGTGGTGGCCATCAGCAAGGACGACCCCGAGGTGCAG




TTCTCTTGGTTTGTGGACGACGTGGAGGTGCACACAGC




CCAGACAAAGCCCCGGGAGGAACAGATCAACAGCACCT




TCAGAAGCGTGTCCGAGCTGCCCATCATGCACCAGGAC




TGGCTGAACGGCAAAGAATTCAAGTGCAGAGTGAACAG




CGCCGCCTTCGGCGCCCCCATCGAGAAAACCATCAGCA




AGACCAAGGGCAGACCCAAGGCCCCCCAGGTGTACACC




ATCCCCCCACCCAAAAAACAGATGGCCAAGGACAAGGT




GTCCCTGACCTGCATGATCACCAACTTTTTCCCCGAGG




ACATCACCGTGGAGTGGCAGTGGAATGGCCAGCCCGCC




GAGAACTACAAGAACACCCAGCCCATCATGAAGACCGA




CGGCAGCTACTTCGTGTACAGCAAGCTGAACGTGCAGA




AGTCCAACTGGGAGGCCGGCAACACCTTCACCTGTAGC




GTGCTGCACGAGGGCCTGCACAACCACCACACCGAGAA




GTCCCTGAGCCACTCCCCCGGCAAG





155
DP47 light 
GAAATCGTGTTAACGCAGTCTCCAGGCACCCTGTCTTT



chain
GTCTCCAGGGGAAAGAGCCACCCTCTCTTGCAGGGCCA




GTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAG




CAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGG




AGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCA




GTGGCAGTGGATCCGGGACAGACTTCACTCTCACCATC




AGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTG




TCAGCAGTATGGTAGCTCACCGCTGACGTTCGGCCAGG




GGACCAAAGTGGAAATCAAACGTGCCGATGCTGCACCA




ACTGTATCGATTTTCCCACCATCCAGTGAGCAGTTAAC




ATCTGGAGGTGCCTCAGTCGTGTGCTTCTTGAACAACT




TCTACCCCAAAGACATCAATGTCAAGTGGAAGATTGAT




GGCAGTGAACGACAAAATGGCGTCCTGAACAGTTGGAC




TGATCAGGACAGCAAAGACAGCACCTACAGCATGAGCA




GCACCCTCACGTTGACCAAGGACGAGTATGAACGACAT




AACAGCTATACCTGTGAGGCCACTCACAAGACATCAAC




TTCACCCATTGTCAAGAGCTTCAACAGGAATGAGTGT





 75
Dimeric murine
see Table 13



4-1BBL (104-




309, C137, 160,




246S)-CL Fc DD 




chain






 76
Monomeric
See Table 13



murine 4-1BBL




(104-309, C137,




160, 246S)-CH1






156
DP47 Fc KK
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVR



chain
QAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSK




NTLYLQMNSLRAEDTAVYYCAKGSGFDYWGQGTLVTVS




SAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPV




TVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTW




PSQTVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPE




VSSVFIFPPKPKDVLTITLTPKVTCVVVAISKDDPEVQ




FSWFVDDVEVHTAQTKPREEQINSTFRSVSELPIMHQD




WLNGKEFKCRVNSAAFGAPIEKTISKTKGRPKAPQVYT




IPPPKKQMAKDKVSLTCMITNFFPEDITVEWQWNGQPA




ENYKNTQPIMKTDGSYFVYSKLNVQKSNWEAGNTFTCS




VLHEGLHNHHTEKSLSHSPGK





157
DP47 light 
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQ



chain
QKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTI




SRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIKRADAAP




TVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKID




GSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERH




NSYTCEATHKTSTSPIVKSFNRNEC









Table 15 shows the cDNA and amino acid sequences of the FAP-targeted murine 4-1BB ligand trimer-containing Fc fusion antigen binding molecule Construct M.2.









TABLE 15







Sequences of FAP-targeted murine Construct M.2









SEQ ID




NO:
Description
Sequence












158
Dimeric murine
AGAACCGAGCCCAGACCCGCCCTGACCATCACCACCAG



4-1BBL
CCCTAACCTGGGCACCAGAGAGAACAACGCCGACCAAG



(104-309, C160S)-
TGACCCCCGTGTCCCACATCGGCTGCCCCAATACCACAC



CL Fc DD chain
AGCAGGGCAGCCCTGTGTTCGCCAAGCTGCTGGCCAAG




AACCAGGCCAGCCTGAGCAACACCACCCTGAACTGGCA




CAGCCAGGATGGCGCCGGAAGCAGCTATCTGAGCCAGG




GCCTGAGATACGAAGAGGACAAGAAAGAACTGGTGGTG




GACAGCCCTGGCCTGTACTACGTGTTCCTGGAACTGAAG




CTGAGCCCCACCTTCACCAACACCGGCCACAAGGTGCA




GGGCTGGGTGTCACTGGTGCTGCAGGCCAAACCCCAGG




TGGACGACTTCGACAACCTGGCCCTGACCGTGGAACTGT




TCCCCTGCAGCATGGAAAACAAGCTGGTGGATCGGAGC




TGGTCCCAGCTTCTGCTGCTGAAGGCCGGACACAGACTG




AGCGTGGGCCTGAGGGCTTATCTGCACGGCGCCCAGGA




CGCCTACAGAGACTGGGAGCTGAGCTACCCCAACACAA




CCAGCTTCGGCCTGTTCCTCGTGAAGCCCGACAACCCTT




GGGAAGGCGGCGGAGGCTCCGGAGGAGGCGGATCTAGA




ACAGAGCCTCGGCCTGCCCTGACAATTACCACATCCCCC




AATCTGGGCACCCGGGAAAACAATGCAGATCAAGTGAC




ACCTGTGTCTCATATTGGGTGCCCCAACACTACCCAGCA




GGGGTCCCCAGTGTTTGCTAAACTGCTGGCTAAAAATCA




GGCCTCCCTGTCTAACACAACACTGAATTGGCATAGTCA




GGACGGGGCTGGCAGCAGCTACCTGTCTCAGGGACTGC




GCTATGAGGAAGATAAGAAAGAACTGGTGGTGGATTCC




CCCGGACTGTACTATGTGTTTCTGGAACTGAAACTGTCC




CCTACCTTTACAAATACCGGGCACAAAGTGCAGGGATG




GGTGTCCCTGGTGCTGCAGGCTAAGCCTCAGGTGGACGA




TTTTGATAATCTGGCTCTGACAGTGGAACTGTTTCCTTGC




TCTATGGAAAACAAACTGGTGGACCGCTCTTGGAGCCA




GTTGCTGCTGCTGAAAGCTGGCCACCGGCTGTCTGTGGG




ACTGAGAGCATACCTGCATGGGGCACAGGATGCCTACC




GGGATTGGGAACTGTCCTACCCTAACACTACTTCCTTCG




GACTGTTCCTCGTGAAACCTGATAATCCCTGGGAGGGCG




GAGGCGGAAGTGGCGGAGGGGGATCCAGAGCTGATGCT




GCCCCTACCGTGTCCATCTTCCCACCCAGCAGCGAGCAG




CTGACATCTGGGGGAGCTAGCGTCGTGTGCTTCCTGAAC




AACTTCTACCCCAAGGACATCAACGTGAAGTGGAAGAT




CGACGGCAGCGAGCGGCAGAACGGCGTGCTGAATAGCT




GGACCGACCAGGACAGCAAGGACTCCACCTACAGCATG




AGCAGCACCCTGACCCTGACCAAGGACGAGTACGAGCG




GCACAACAGCTACACATGCGAGGCCACCCACAAGACCA




GCACCAGCCCCATCGTGAAGTCCTTCAACCGGAACGAG




TGCGTGCCCAGAGACTGCGGCTGCAAGCCTTGCATCTGC




ACCGTGCCTGAGGTGTCCAGCGTGTTCATCTTCCCACCC




AAGCCCAAGGACGTGCTGACCATCACCCTGACACCCAA




AGTGACCTGCGTGGTGGTGGCCATCAGCAAGGATGACC




CCGAGGTGCAGTTCAGTTGGTTCGTGGACGACGTGGAA




GTGCACACCGCTCAGACCAAGCCCAGAGAGGAACAGAT




CAACAGCACCTTCAGAAGCGTGTCCGAGCTGCCCATCAT




GCACCAGGACTGGCTGAACGGCAAAGAATTCAAGTGCA




GAGTGAACAGCGCCGCCTTTGGCGCCCCTATCGAGAAA




ACCATCTCCAAGACCAAGGGCAGACCCAAGGCCCCCCA




GGTGTACACAATCCCCCCACCCAAAGAACAGATGGCCA




AGGACAAGGTGTCCCTGACCTGCATGATCACCAATTTCT




TCCCAGAGGATATCACCGTGGAATGGCAGTGGAACGGC




CAGCCCGCCGAGAACTACGACAACACCCAGCCTATCAT




GGACACCGACGGCTCCTACTTCGTGTACAGCGACCTGAA




CGTGCAGAAGTCCAACTGGGAGGCCGGCAACACCTTCA




CCTGTAGCGTGCTGCACGAGGGCCTGCACAACCACCAC




ACCGAGAAGTCCCTGTCCCACAGCCCTGGCAAG





159
Monomeric
AGAACCGAGCCCAGACCCGCCCTGACCATCACCACCAG



murine 4-1BBL
CCCTAACCTGGGCACCAGAGAGAACAACGCCGACCAAG



(104-309, C160S)-
TGACCCCCGTGTCCCACATCGGCTGCCCCAATACCACAC



CH1
AGCAGGGCAGCCCTGTGTTCGCCAAGCTGCTGGCCAAG




AACCAGGCCAGCCTGAGCAACACCACCCTGAACTGGCA




CAGCCAGGATGGCGCCGGAAGCAGCTATCTGAGCCAGG




GCCTGAGATACGAAGAGGACAAGAAAGAACTGGTGGTG




GACAGCCCTGGCCTGTACTACGTGTTCCTGGAACTGAAG




CTGAGCCCCACCTTCACCAACACCGGCCACAAGGTGCA




GGGCTGGGTGTCACTGGTGCTGCAGGCCAAACCCCAGG




TGGACGACTTCGACAACCTGGCCCTGACCGTGGAACTGT




TCCCCTGCAGCATGGAAAACAAGCTGGTGGATCGGAGC




TGGTCCCAGCTTCTGCTGCTGAAGGCCGGACACAGACTG




AGCGTGGGCCTGAGGGCTTATCTGCACGGCGCCCAGGA




CGCCTACAGAGACTGGGAGCTGAGCTACCCCAACACAA




CCAGCTTCGGCCTGTTCCTCGTGAAGCCCGACAACCCTT




GGGAAGGCGGCGGAGGCTCCGGAGGAGGCGGAAGCGC




TAAGACCACCCCCCCCAGCGTGTACCCTCTGGCCCCTGG




ATCTGCCGCCCAGACCAACAGCATGGTGACCCTGGGCT




GCCTGGTGAAGGGCTACTTCCCCGAGCCTGTGACCGTGA




CCTGGAACAGCGGCAGCCTGAGCAGCGGCGTGCACACC




TTTCCAGCCGTGCTGCAGAGCGACCTGTACACCCTGAGC




AGCTCCGTGACCGTGCCTAGCAGCACCTGGCCCAGCCA




GACAGTGACCTGCAACGTGGCCCACCCTGCCAGCAGCA




CCAAGGTGGACAAGAAAATCGTGCCCCGGGACTGC





73
anti-FAP (28H1)
see Table 13



Fc KK chain






74
anti-FAP (28H1)
see Table 13



light chain






160
Dimeric murine
RTEPRPALTITTSPNLGTRENNADQVTPVSHIGCPNTTQQGS



4-1BBL
PVFAKLLAKNQASLSNTTLNWHSQDGAGSSYLSQGLRYEE



(104-309, C160S)-
DKKELVVDSPGLYYVFLELKLSPTFTNTGHKVQGWVSLVL



CL Fc DD chain
QAKPQVDDFDNLALTVELFPCSMENKLVDRSWSQLLLLK




AGHRLSVGLRAYLHGAQDAYRDWELSYPNTTSFGLFLVK




PDNPWEGGGGSGGGGSRTEPRPALTITTSPNLGTRENNAD




QVTPVSHIGCPNTTQQGSPVFAKLLAKNQASLSNTTLNWH




SQDGAGSSYLSQGLRYEEDKKELVVDSPGLYYVFLELKLS




PTFTNTGHKVQGWVSLVLQAKPQVDDFDNLALTVELFPCS




MENKLVDRSWSQLLLLKAGHRLSVGLRAYLHGAQDAYR




DWELSYPNTTSFGLFLVKPDNPWEGGGGSGGGGSRADAA




PTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSE




RQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYT




CEATHKTSTSPIVKSFNRNECVPRDCGCKPCICTVPEVSSVF




IFPPKPKDVLTITLTPKVTCVVVAISKDDPEVQFSWFVDDV




EVHTAQTKPREEQINSTFRSVSELPIMHQDWLNGKEFKCR




VNSAAFGAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKV




SLTCMITNFFPEDITVEWQWNGQPAENYDNTQPIMDTDGS




YFVYSDLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLS




HSPGK





161
Monomeric
RTEPRPALTITTSPNLGTRENNADQVTPVSHIGCPNTTQQGS



murine 4-1BBL
PVFAKLLAKNQASLSNTTLNWHSQDGAGSSYLSQGLRYEE



(104-309, C160S)-
DKKELVVDSPGLYYVFLELKLSPTFTNTGHKVQGWVSLVL



CH1
QAKPQVDDFDNLALTVELFPCSMENKLVDRSWSQLLLLK




AGHRLSVGLRAYLHGAQDAYRDWELSYPNTTSFGLFLVK




PDNPWEGGGGSGGGGSAKTTPPSVYPLAPGSAAQTNSMV




TLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYT




LSSSVTVPSSTWPSQTVTCNVAHPASSTKVDKKIVPRDC





77
anti-FAP (28H1)
see Table 13



Fc KK chain






78
anti-FAP (28H1)
see Table 13



light chain









Table 16 shows the cDNA and amino acid sequences of the DP47-untargeted murine 4-1BB ligand trimer-containing Fc fusion antigen binding molecule Construct Control M.2.









TABLE 16







Sequences of FAP-targeted murine Control M.2









SEQ ID




NO:
Description
Sequence





158
Dimeric mu 4-
see Table 15



1BBL (104-309,




C160S) — CL Fc




DD chain



159
Monomeric mu 4-
see Table 15



1BBL (104-309,




C160S) — CH1



154
DP47 Fc KK
see Table 14



chain



155
DP47 light chain
see Table 14


160
Dimeric mu 4-
see Table 15



1BBL (104-309,




C160S) — CL Fc




DD chain



161
Monomeric mu 4-
see Table 15



1BBL (104-309,




C160S) — CH1



156
DP47 Fc KK
see Table 14



chain



157
DP47 light chain
see Table 14









The murine 4-1BB ligand trimer-containing Fc fusion antigen binding molecules were produced and purified as described herein before for the human 4-1BBL constructs.


Table 17 summarizes the yield and final monomer content of the FAP-targeted and untargeted murine 4-1BBL trimer-containing Fc fusion antigen binding molecule.









TABLE 17







Summary of the production of the FAP-targeted and untargeted


murine 4-1BBL trimer-containing Fc fusion antigen binding molecules










Yield
Monomer


Construct
[mg/l]
[%] (SEC)





Construct M.1
2.6
95


Control M.2
2.3
96


Construct M.2
8.5
98


Control M.2
8.1
97









1.4 Preparation and Purification of Untargeted Human 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules (Control Molecules)


The control molecules were prepared as described above for the FAP-targeted Constructs 1 and 2, with the only difference that the anti-FAP binder (VH-VL) was replaced by a germline control, termed DP47, not binding to the antigen. The control is an untargeted monovalent split trimeric human 4-1BB ligand Fc (kih) (Control A, FIG. 5A) and for Control B, the construct also contains a CH-CL crossover with charged residues (FIG. 5B). The variable region of heavy and light chain DNA sequences of the FAP binder were replaced with those of the germline control (DP47) and subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1.


The untargeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules were produced as described above for the FAP-targeted constructs. The cells were transfected with the corresponding expression vectors at a 1:1:1:1 ratio (“vector dimeric ligand-CH1 or CL*-knob chain”: “vector monomeric ligand fusion-CL or CH1*”: “vector DP47 Fab-hole chain”: “vector DP47 light chain”).


Table 18 shows, respectively, the cDNA and amino acid sequences of the DP47-untargeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecule Control A.









TABLE 18







Sequences of DP47 untargeted 4-1BB ligand trimer-containing Fc (kih)


fusion antigen binding molecule (DP47 split 4-1BBL trimer) Control A









SEQ ID




NO:
Description
Sequence





66
Dimeric hu 4-
See Table 2



1BBL (71-254)-




CH1 Fc knob




chain






67
Monomeric hu
see Table 2



4-1BBL (71-254)-




CL






79
DP47 Fc hole
GAGGTGCAATTGTTGGAGTCTGGGGGAGGCTTGGTACA



chain
GCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCCGG




ATTCACCTTTAGCAGTTATGCCATGAGCTGGGTCCGCCA




GGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTA




GTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGA




AGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAAC




ACGCTGTATCTGCAGATGAACAGCCTGAGAGCCGAGGA




CACGGCCGTATATTACTGTGCGAAAGGCAGCGGATTTGA




CTACTGGGGCCAAGGAACCCTGGTCACCGTCTCGAGTGC




TAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTC




CTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCT




GCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGT




CGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACC




TTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTC




AGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCAC




CCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCA




ACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGT




GACAAAACTCACACATGCCCACCGTGCCCAGCACCTGA




AGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAA




ACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGT




CACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTG




AGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG




CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAA




CAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCA




CCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGG




TCTCCAACAAAGCCCTCGGCGCCCCCATCGAGAAAACC




ATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGT




GTGCACCCTGCCCCCATCCCGGGATGAGCTGACCAAGA




ACCAGGTCAGCCTCTCGTGCGCAGTCAAAGGCTTCTATC




CCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAG




CCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGA




CTCCGACGGCTCCTTCTTCCTCGTGAGCAAGCTCACCGT




GGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCAT




GCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGC




AGAAGAGCCTCTCCCTGTCTCCGGGTAAA





80
DP47 light chain
GAAATCGTGTTAACGCAGTCTCCAGGCACCCTGTCTTTG




TCTCCAGGGGAAAGAGCCACCCTCTCTTGCAGGGCCAGT




CAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAG




AAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGAGCA




TCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGG




CAGTGGATCCGGGACAGACTTCACTCTCACCATCAGCAG




ACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCA




GTATGGTAGCTCACCGCTGACGTTCGGCCAGGGGACCA




AAGTGGAAATCAAACGTACGGTGGCTGCACCATCTGTCT




TCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAA




CTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG




AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCC




AATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGAC




AGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGAC




GCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACG




CCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCA




CAAAGAGCTTCAACAGGGGAGAGTGT





14
Dimeric hu 4-
See Table 2



1BBL (71-254)-




CH1 Fc knob




chain






15
Monomeric hu 4-
See Table 2



1BBL (71-254)-




CL






81
DP47 Fc hole
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQA



chain
PGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYL




QMNSLRAEDTAVYYCAKGSGFDYWGQGTLVTVSSASTKG




PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL




TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH




KPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPP




KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV




HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV




SNKALGAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVS




LSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF




LVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS




PGK





82
DP47 light chain
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKP




GQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDF




AVYYCQQYGSSPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQ




LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV




TEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS




PVTKSFNRGEC









Table 19 shows the cDNA and amino acid sequences of the DP47-untargeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecule with CH1-CL crossover and charged residues in the 4-1BB ligand containing arms (Control B).









TABLE 19







Sequences of DP47 untargeted 4-1BB ligand trimer-containing Fc (kih)


fusion antigen binding molecule (DP47 split 4-1BBL trimer) Control B









SEQ ID




NO:
Description
Sequence





96
Dimeric hu 4-1BBL
see Table 3 



(71-254) — CL*




Fc knob chain



97
Monomeric hu 4-1BBL
see Table 3 



(71-254) — CH1*



79
DP47 Fc hole chain
see Table 18


80
DP47 light chain
see Table 18


98
Dimeric hu 4-1BBL
see Table 3 



(71-254) — CL*




Fc knob chain



99
Monomeric hu 4-1BBL
see Table 3 



(71-254) — CH1*



81
DP47 Fc hole chain
see Table 18


82
DP47 light chain
see Table 18









Table 20 summarizes the yield and final monomer content of the DP47 untargeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules.









TABLE 20







Production Characteristics of DP47 untargeted 4-1BBL trimer-containing


Fc (kih) fusion antigen binding molecules (Control molecules)











Monomer
Yield
LC/MS


Construct
[%] (SEC)
[mg/l]
(non red)













Control A
97
3.7
Theoretical*:





179069.7 Da





Experimental:





179116.2 Da





* without





terminal lysines


Control B
99
15.4









Example 2

2.1 Preparation of FAP (4B9) Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules


Different fragments of the DNA sequence encoding part of the ectodomain (amino acid 71-254 and 71-248) of human 4-1BB ligand were synthetized according to the P41273 sequence of Uniprot database (SEQ ID NO:42).


2.1.1 Preparation of Monovalent FAP (4B9) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 2.1)


A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G4S)2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned as depicted in FIG. 1A: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CL.


A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the human IgG1-CH1 domain, was cloned as described in FIG. 1B: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CH.


The polypeptide encoding the dimeric 4-1BB ligand fused to human CL domain was subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant, Zhu et al. 1998) using a linker (G4S)2 (SEQ ID NO:13), or alternatively, GSPGSSSSGS (SEQ ID NO:57).


To improve correct pairing the following mutations have been introduced in the crossed CH-CL. In the dimeric 4-1BB ligand fused to human CL the mutations E123R and Q124K were introduced. In the monomeric 4-1BB ligand fused to human CH1, the mutations K147E and K213E were cloned into the human CH1 domain.


The variable region of heavy and light chain DNA sequences encoding a binder specific for fibroblast activation protein (FAP), clone 4B9, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1.


The generation and preparation of the FAP binders is described in WO 2012/020006 A2, which is incorporated herein by reference.


The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in International Patent Appl. Publ. No. WO 2012/130831.


For all constructs the knobs into hole heterodimerization technology was used with the the S354C/T366W mutations in the knob chain and the corresponding Y349C/T366S/L368A/Y407V mutations in the hole chain.


Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-FAP-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-FAP light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a FAP binding Fab (FIG. 4A, Construct 2.1).


Table 21 shows the cDNA and amino acid sequences of the monovalent FAP (4B9)-human 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule containing CH1-CL crossover and charged residues (Construct 2.1).









TABLE 21







Sequences of monovalent FAP(4B9)-targeted human 4-1BB ligand (71-254)


containing Fc (kih) fusion molecule Construct 2.1









SEQ ID




NO:
Description
Sequence





129
Dimeric hu 4-
see Table 3



1BBL (71-254)-




CL* Fc knob




chain






130
Monomeric hu
see Table 3



4-1BBL (71-254)




CH1*






162
anti-FAP (4B9)
GAGGTGCAGCTGCTCGAAAGCGGCGGAGGACTGGTGCA



Fc hole chain
GCCTGGCGGCAGCCTGAGACTGTCTTGCGCCGCCAGCG




GCTTCACCTTCAGCAGCTACGCCATGAGCTGGGTCCGCC




AGGCCCCTGGCAAGGGACTGGAATGGGTGTCCGCCATC




ATCGGCTCTGGCGCCAGCACCTACTACGCCGACAGCGTG




AAGGGCCGGTTCACCATCAGCCGGGACAACAGCAAGAA




CACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGG




ACACCGCCGTGTACTACTGCGCCAAGGGATGGTTCGGC




GGCTTCAACTACTGGGGACAGGGCACCCTGGTCACAGT




GTCCAGCGCTAGCACCAAGGGCCCCTCCGTGTTCCCCCT




GGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCG




CTCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAGCCCG




TGACCGTGTCCTGGAACAGCGGAGCCCTGACCTCCGGC




GTGCACACCTTCCCCGCCGTGCTGCAGAGTTCTGGCCTG




TATAGCCTGAGCAGCGTGGTCACCGTGCCTTCTAGCAGC




CTGGGCACCCAGACCTACATCTGCAACGTGAACCACAA




GCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCA




AGAGCTGCGACAAAACTCACACATGCCCACCGTGCCCA




GCACCTGAAGCTGCAGGGGGACCGTCAGTCTTCCTCTTC




CCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACC




CCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGA




AGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCG




TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG




CAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACC




GTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA




GTGCAAGGTCTCCAACAAAGCCCTCGGCGCCCCCATCG




AGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAA




CCACAGGTGTGCACCCTGCCCCCATCCCGGGATGAGCTG




ACCAAGAACCAGGTCAGCCTCTCGTGCGCAGTCAAAGG




CTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCA




ATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCC




GTGCTGGACTCCGACGGCTCCTTCTTCCTCGTGAGCAAG




CTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGT




CTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCA




CTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA





163
anti-FAP (4B9)
GAGATCGTGCTGACCCAGTCCCCCGGCACCCTGTCTCTG



light chain
AGCCCTGGCGAGAGAGCCACCCTGTCCTGCAGAGCCTC




CCAGTCCGTGACCTCCTCCTACCTCGCCTGGTATCAGCA




GAAGCCCGGCCAGGCCCCTCGGCTGCTGATCAACGTGG




GCAGTCGGAGAGCCACCGGCATCCCTGACCGGTTCTCCG




GCTCTGGCTCCGGCACCGACTTCACCCTGACCATCTCCC




GGCTGGAACCCGAGGACTTCGCCGTGTACTACTGCCAGC




AGGGCATCATGCTGCCCCCCACCTTTGGCCAGGGCACCA




AGGTGGAAATCAAGCGTACGGTGGCTGCACCATCTGTCT




TCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAA




CTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG




AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCC




AATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGAC




AGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGAC




GCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACG




CCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCA




CAAAGAGCTTCAACAGGGGAGAGTGT





115
Dimeric hu 4-
see Table 3



1BBL (71-254)-




CL* Fc knob




chain






116
Monomeric hu
see Table 3



4-1BBL (71-254)-




CH1*






164
anti-FAP (4B9)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQA



Fc hole chain
PGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYL




QMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSSAS




TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS




GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN




VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF




LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG




VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK




CKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDELTKN




QVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD




GSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS




LSLSPGK





125
anti-FAP (4B9)
EIVLTQSPGTLSLSPGERATLSCRASQSVTSSYLAWYQQKP



light chain
GQAPRLLINVGSRRATGIPDRFSGSGSGTDFTLTISRLEPEDF




AVYYCQQGIMLPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQ




LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV




TEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS




PVTKSFNRGEC









2.1.2 Preparation of Monovalent FAP (4B9) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains without Charged Residues (Construct 2.2)


A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G4S)2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned as depicted in FIG. 1A: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CL.


A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the human IgG1-CH1 domain, was cloned as described in FIG. 1B: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CH1.


The polypeptide encoding the dimeric 4-1BB ligand fused to human CL domain was subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant, Zhu et al. 1998) using a linker (G4S)2 (SEQ ID NO:13) or, alternatively, GSPGSSSSGS (SEQ ID NO:57).


The variable region of heavy and light chain DNA sequences encoding a binder specific for fibroblast activation protein (FAP), clone 4B9, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1.


The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors (WO 2012/130831).


Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-FAP-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-FAP light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a FAP binding Fab (FIG. 4B, Construct 2.2).


Table 22 shows the cDNA and amino acid sequences of the monovalent FAP (4B9)-human 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule containing CH1-CL crossover without charged residues (Construct 2.2).









TABLE 22







Sequences of monovalent FAP(4B9)-targeted human 4-1BB ligand (71-254)


containing Fc (kih) fusion molecule Construct 2.2









SEQ ID




NO:
Description
Sequence





165
Dimeric hu 4-
AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG



1BBL (71-254)-
ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT



CL Fc knob chain
GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG




GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG




CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG




TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG




AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT




GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCT




GCTGGCGCTGCAGCTCTGGCACTGACAGTGGATCTGCCT




CCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTT




CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT




GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG




CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG




TTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCT




CCAAGAAGCGAAGGCGGAGGCGGATCTGGCGGCGGAG




GATCTAGAGAGGGACCCGAACTGTCCCCTGACGATCCA




GCCGGGCTGCTGGATCTGAGACAGGGAATGTTCGCCCA




GCTGGTGGCTCAGAATGTGCTGCTGATTGACGGACCTCT




GAGCTGGTACTCCGACCCAGGGCTGGCAGGGGTGTCCC




TGACTGGGGGACTGTCCTACAAAGAAGATACAAAAGAA




CTGGTGGTGGCTAAAGCTGGGGTGTACTATGTGTTTTTT




CAGCTGGAACTGAGGCGGGTGGTGGCTGGGGAGGGCTC




AGGATCTGTGTCCCTGGCTCTGCATCTGCAGCCACTGCG




CTCTGCTGCTGGCGCAGCTGCACTGGCTCTGACTGTGGA




CCTGCCACCAGCCTCTAGCGAGGCCAGAAACAGCGCCT




TCGGGTTCCAAGGACGCCTGCTGCATCTGAGCGCCGGAC




AGCGCCTGGGAGTGCATCTGCATACTGAAGCCAGAGCC




CGGCATGCTTGGCAGCTGACTCAGGGGGCAACTGTGCTG




GGACTGTTTCGCGTGACACCTGAGATCCCTGCCGGACTG




CCAAGCCCTAGATCAGAAGGGGGCGGAGGTTCCGGAGG




GGGAGGATCTCGTACGGTGGCCGCTCCCTCCGTGTTTAT




CTTTCCCCCATCCGATGAACAGCTGAAAAGCGGCACCGC




CTCCGTCGTGTGTCTGCTGAACAATTTTTACCCTAGGGA




AGCTAAAGTGCAGTGGAAAGTGGATAACGCACTGCAGT




CCGGCAACTCCCAGGAATCTGTGACAGAACAGGACTCC




AAGGACAGCACCTACTCCCTGTCCTCCACCCTGACACTG




TCTAAGGCTGATTATGAGAAACACAAAGTCTACGCCTGC




GAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAA




GAGCTTCAACAGGGGAGAGTGTGACAAGACCCACACCT




GTCCCCCTTGTCCTGCCCCTGAAGCTGCTGGCGGCCCTT




CTGTGTTCCTGTTCCCCCCAAAGCCCAAGGACACCCTGA




TGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTG




GATGTGTCCCACGAGGACCCTGAAGTGAAGTTCAATTGG




TACGTGGACGGCGTGGAAGTGCACAATGCCAAGACCAA




GCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGG




TCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATG




GCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTC




GGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG




GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCAT




GCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGTGG




TGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTG




GAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAA




GACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTT




CCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGC




AGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGG




CTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGT




CTCCGGGTAAA





166
Monomeric hu 4-
AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG



1BBL (71-254)-
ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT



CH1
GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG




GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG




CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG




TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG




AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT




GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCT




GCTGGCGCTGCAGCTCTGGCTCTGACAGTGGATCTGCCT




CCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTT




CAAGGCCGGCTGCTGCACCTGTCTGCCGGCCAGAGACT




GGGAGTGCATCTGCACACAGAGGCCAGAGCCAGGCACG




CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG




TTCAGAGTGACCCCCGAGATTCCTGCCGGCCTGCCTAGC




CCTAGATCTGAAGGCGGCGGAGGTTCCGGAGGCGGAGG




ATCTGCTAGCACCAAAGGCCCTTCCGTGTTTCCTCTGGC




TCCTAGCTCCAAGTCCACCTCTGGAGGCACCGCTGCTCT




CGGATGCCTCGTGAAGGATTATTTTCCTGAGCCTGTGAC




AGTGTCCTGGAATAGCGGAGCACTGACCTCTGGAGTGC




ATACTTTCCCCGCTGTGCTGCAGTCCTCTGGACTGTACA




GCCTGAGCAGCGTGGTGACAGTGCCCAGCAGCAGCCTG




GGCACCCAGACCTACATCTGCAACGTGAACCACAAGCC




CAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGT




CTTGT





162
anti-FAP (4B9)
see Table 21



Fc hole chain






163
anti-FAP (4B9)
see Table 21



light chain






117
Dimeric hu 4-
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY



1BBL (71-254)-
SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR



CL Fc knob chain
RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS




EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT




QGATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSREGPEL




SPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLA




GVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAG




EGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNS




AFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATV




LGLFRVTPEIPAGLPSPRSEGGGGSGGGGSRTVAAPSVFIFP




PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN




SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH




QGLSSPVTKSFNRGECDKTHTCPPCPAPEAAGGPSVFLFPP




KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV




HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV




SNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVS




LWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF




FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL




SPGK





118
Monomeric hu 4-
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY



1BBL (71-254)-
SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR



CH1
RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS




EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT




QGATVLGLFRVTPEIPAGLPSPRSEGGGGSGGGGSASTKGP




SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT




SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK




PSNTKVDKKVEPKSC





164
anti-FAP (4B9)
see Table 21



Fc hole chain






125
anti-FAP (4B9)
see Table 21



light chain









2.1.3 Preparation of Bivalent FAP (4B9) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with the Dimeric and Monomeric 4-1BB Ligands Fused at the C-Terminus of Each Heavy Chain (Construct 2.3)


A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G4S)2 (SEQ ID NO:13) linkers was fused to the C-terminus of human IgG1 Fc hole chain, as depicted in FIG. 1C: human IgG1 Fc hole, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the C-terminus of human IgG1 Fc knob chain as described in FIG. 1D: human IgG1 Fc knob, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand.


The polypeptide encoding the dimeric 4-1BB ligand was subcloned in frame at the C-terminus of human IgG1 heavy chain CH2 and CH3 domains on the hole (Merchant, Zhu et al. 1998) using a (G4S)2 (SEQ ID NO:13) connector. The polypeptide encoding the monomeric 4-1BB ligand was subcloned in frame at the C-terminus of human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant, Zhu et al. 1998) using a (G4S)2 (SEQ ID NO:13) connector.


The variable region of heavy and light chain DNA sequences encoding a binder specific for fibroblast activation protein (FAP), clone 4B9, were subcloned in frame with either the constant heavy chain of the hole, the knob or the constant light chain of human IgG1.


The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831.


Combination of the anti-FAP huIgG1 hole dimeric ligand chain containing the Y349C/T366S/L368A/Y407V mutations, the anti-FAP huIgG1 knob monomeric ligand chain containing the S354C/T366W mutations and the anti-FAP light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and two FAP binding Fabs (FIG. 4C, Construct 2.3)


Table 23 shows the cDNA and amino acid sequences of the bivalent FAP (4B9)-targeted 4-1BB ligand trimer-containing Fc (kih) fusion molecule Construct 2.3 (FAP split trimer with 2 anti-FAP Fabs, dimeric and monomeric 4-1BB ligand fused at the C-terminus of each heavy chain, respectively).









TABLE 23







Sequences of bivalent FAP(4B9)-targeted human 4-1BB ligand (71-254)


containing Fc (kih) fusion molecule Construct 2.3









SEQ ID




NO:
Description
Sequence





167
anti-FAP (4B9)
GAGGTGCAGCTGCTCGAAAGCGGCGGAGGACTGGTGCA



Fc hole chain
GCCTGGCGGCAGCCTGAGACTGTCTTGCGCCGCCAGCG



fused to dimeric
GCTTCACCTTCAGCAGCTACGCCATGAGCTGGGTCCGCC



hu 4-1BBL (71-254)
AGGCCCCTGGCAAGGGACTGGAATGGGTGTCCGCCATC




ATCGGCTCTGGCGCCAGCACCTACTACGCCGACAGCGTG




AAGGGCCGGTTCACCATCAGCCGGGACAACAGCAAGAA




CACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGG




ACACCGCCGTGTACTACTGCGCCAAGGGATGGTTCGGC




GGCTTCAACTACTGGGGACAGGGCACCCTGGTCACAGT




GTCCAGCGCTAGCACCAAGGGCCCCTCCGTGTTCCCCCT




GGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCG




CTCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAGCCCG




TGACCGTGTCCTGGAACAGCGGAGCCCTGACCTCCGGC




GTGCACACCTTCCCCGCCGTGCTGCAGAGTTCTGGCCTG




TATAGCCTGAGCAGCGTGGTCACCGTGCCTTCTAGCAGC




CTGGGCACCCAGACCTACATCTGCAACGTGAACCACAA




GCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCA




AGAGCTGCGACAAAACTCACACATGCCCACCGTGCCCA




GCACCTGAAGCTGCAGGGGGACCGTCAGTCTTCCTCTTC




CCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACC




CCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGA




AGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCG




TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG




CAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACC




GTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA




GTGCAAGGTCTCCAACAAAGCCCTCGGCGCCCCCATCG




AGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAA




CCACAGGTGTGCACCCTGCCCCCATCCCGGGATGAGCTG




ACCAAGAACCAGGTCAGCCTCTCGTGCGCAGTCAAAGG




CTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCA




ATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCC




GTGCTGGACTCCGACGGCTCCTTCTTCCTCGTGAGCAAG




CTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGT




CTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCA




CTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGAGG




CGGCGGAAGCGGAGGAGGAGGATCCAGAGAGGGCCCT




GAGCTGAGCCCCGATGATCCTGCTGGACTGCTGGACCTG




CGGCAGGGCATGTTTGCTCAGCTGGTGGCCCAGAACGTG




CTGCTGATCGATGGCCCCCTGTCCTGGTACAGCGATCCT




GGACTGGCTGGCGTGTCACTGACAGGCGGCCTGAGCTA




CAAAGAGGACACCAAAGAACTGGTGGTGGCCAAGGCCG




GCGTGTACTACGTGTTCTTTCAGCTGGAACTGCGGAGAG




TGGTGGCCGGCGAAGGATCTGGCTCTGTGTCTCTGGCCC




TGCATCTGCAGCCTCTGAGAAGCGCTGCTGGCGCTGCAG




CTCTGGCACTGACAGTGGATCTGCCTCCTGCCAGCTCCG




AGGCCCGGAATAGCGCATTTGGGTTTCAAGGCAGGCTG




CTGCACCTGTCTGCCGGCCAGAGGCTGGGAGTGCATCTG




CACACAGAGGCCAGGGCTAGACACGCCTGGCAGCTGAC




ACAGGGCGCTACAGTGCTGGGCCTGTTCAGAGTGACCC




CCGAGATTCCAGCCGGCCTGCCTTCTCCAAGAAGCGAA




GGCGGAGGCGGATCTGGCGGCGGAGGATCTAGAGAGGG




ACCCGAACTGTCCCCTGACGATCCAGCCGGGCTGCTGGA




TCTGAGACAGGGAATGTTCGCCCAGCTGGTGGCTCAGA




ATGTGCTGCTGATTGACGGACCTCTGAGCTGGTACTCCG




ACCCAGGGCTGGCAGGGGTGTCCCTGACTGGGGGACTG




TCCTACAAAGAAGATACAAAAGAACTGGTGGTGGCTAA




AGCTGGGGTGTACTATGTGTTTTTTCAGCTGGAACTGAG




GCGGGTGGTGGCTGGGGAGGGCTCAGGATCTGTGTCCCT




GGCTCTGCATCTGCAGCCACTGCGCTCTGCTGCTGGCGC




AGCTGCACTGGCTCTGACTGTGGACCTGCCACCAGCCTC




TAGCGAGGCCAGAAACAGCGCCTTCGGGTTCCAAGGAC




GCCTGCTGCATCTGAGCGCCGGACAGCGCCTGGGAGTG




CATCTGCATACTGAAGCCAGAGCCCGGCATGCTTGGCA




GCTGACTCAGGGGGCAACTGTGCTGGGACTGTTTCGCGT




GACACCTGAGATCCCTGCCGGACTGCCAAGCCCTAGATC




AGAA





168
anti-FAP (4B9)
GAGGTGCAGCTGCTCGAAAGCGGCGGAGGACTGGTGCA



Fc knob chain
GCCTGGCGGCAGCCTGAGACTGTCTTGCGCCGCCAGCG



fused to
GCTTCACCTTCAGCAGCTACGCCATGAGCTGGGTCCGCC



monomeric hu 4-
AGGCCCCTGGCAAGGGACTGGAATGGGTGTCCGCCATC



1BBL (71-254)
ATCGGCTCTGGCGCCAGCACCTACTACGCCGACAGCGTG




AAGGGCCGGTTCACCATCAGCCGGGACAACAGCAAGAA




CACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGG




ACACCGCCGTGTACTACTGCGCCAAGGGATGGTTCGGC




GGCTTCAACTACTGGGGACAGGGCACCCTGGTCACAGT




GTCCAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCT




GGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGG




CCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGG




TGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGC




GTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTC




TACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC




TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAA




GCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCA




AATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAG




CACCTGAAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCC




CCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCC




CTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAA




GACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGT




GGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGC




AGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCG




TCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAG




TGCAAGGTCTCCAACAAAGCCCTCGGCGCCCCCATCGA




GAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC




CACAGGTGTACACCCTGCCCCCCTGCAGAGATGAGCTG




ACCAAGAACCAGGTGTCCCTGTGGTGTCTGGTCAAGGGC




TTCTACCCCAGCGATATCGCCGTGGAGTGGGAGAGCAA




CGGCCAGCCTGAGAACAACTACAAGACCACCCCCCCTG




TGCTGGACAGCGACGGCAGCTTCTTCCTGTACTCCAAAC




TGACCGTGGACAAGAGCCGGTGGCAGCAGGGCAACGTG




TTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCA




CTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGCGGAG




GCGGCGGAAGCGGAGGAGGAGGATCCAGAGAGGGCCC




TGAGCTGAGCCCCGATGATCCTGCTGGACTGCTGGACCT




GCGGCAGGGCATGTTTGCTCAGCTGGTGGCCCAGAACGT




GCTGCTGATCGATGGCCCCCTGTCCTGGTACAGCGATCC




TGGACTGGCTGGCGTGTCACTGACAGGCGGCCTGAGCTA




CAAAGAGGACACCAAAGAACTGGTGGTGGCCAAGGCCG




GCGTGTACTACGTGTTCTTTCAGCTGGAACTGCGGAGAG




TGGTGGCCGGCGAAGGATCTGGCTCTGTGTCTCTGGCCC




TGCATCTGCAGCCTCTGAGAAGCGCTGCTGGCGCTGCAG




CTCTGGCACTGACAGTGGATCTGCCTCCTGCCAGCTCCG




AGGCCCGGAATAGCGCATTTGGGTTTCAAGGCAGGCTG




CTGCACCTGTCTGCCGGCCAGAGGCTGGGAGTGCATCTG




CACACAGAGGCCAGGGCTAGACACGCCTGGCAGCTGAC




ACAGGGCGCTACAGTGCTGGGCCTGTTCAGAGTGACCC




CCGAGATTCCAGCCGGCCTGCCTTCTCCAAGAAGCGAA





163
anti-FAP (4B9)
see Table 21



light chain






123
anti-FAP (4B9)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQA



Fc hole chain
PGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYL



fused to dimeric
QMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSSAS



hu 4-1BBL
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS



(71-254)
GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN




VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF




LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG




VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK




CKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDELTKN




QVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD




GSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS




LSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQ




LVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELV




VAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAA




GAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGV




HLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSEG




GGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQLVAQNV




LLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGV




YYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALA




LTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEA




RARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE





124
anti-FAP (4B9)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQA



Fc knob chain
PGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYL



fused to
QMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSSAS



monomeric hu 4-
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS



1BBL (71-254)
GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN




VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF




LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG




VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK




CKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKN




QVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD




GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS




LSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQ




LVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELV




VAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAA




GAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGV




HLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE





125
anti-FAP (4B9)
see Table 21



light chain









2.1.4 Preparation of Monovalent FAP (4B9) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 2.4)


A polypeptide containing two ectodomains of 4-1BB ligand (71-248), separated by (G4S)2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned as depicted in FIG. 1A: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-248) and fused to the human IgG1-CH domain, was cloned as described in FIG. 1B: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CH.


The polypeptide encoding the dimeric 4-1BB ligand fused to human CL domain was subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant, Zhu et al. 1998) using a linker (G4S)2 (SEQ ID NO:13) or, alternatively, GSPGSSSSGS (SEQ ID NO:57). To improve correct pairing the following mutations have been introduced in the crossed CH-CL. In the dimeric 4-1BB ligand fused to human CL, E123R and Q124K. In the monomeric 4-1BB ligand fused to human CH1, K147E and K213E.


The variable region of heavy and light chain DNA sequences encoding a binder specific for fibroblast activation protein (FAP), clone 4B9, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1.


The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831.


Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-FAP-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-FAP light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a FAP binding Fab (FIG. 4D, Construct 2.4).


Table 24 shows the cDNA and amino acid sequences of the monovalent FAP (4B9)-human 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule containing CH1-CL crossover with charged residues (Construct 2.4).









TABLE 24







Sequences of monovalent FAP(4B9)-targeted human 4-1BB ligand (71-248)


containing Fc (kih) fusion molecule Construct 2.4









SEQ ID




NO:
Description
Sequence





169
Dimeric hu 4-
AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG



1BBL (71-248)-
ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT



CL* Fc knob
GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG



chain
GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG




CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG




TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG




AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT




GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGATCTGCT




GCTGGCGCCGCTGCTCTGGCACTGACAGTGGATCTGCCT




CCTGCCAGCAGCGAGGCCCGGAATAGCGCATTTGGGTTT




CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT




GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG




CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG




TTCAGAGTGACCCCCGAGATTCCAGCCGGACTGGGAGG




CGGCGGATCTGGCGGCGGAGGATCTAGAGAAGGACCCG




AGCTGTCCCCTGACGATCCAGCCGGGCTGCTGGATCTGA




GACAGGGAATGTTCGCCCAGCTGGTGGCTCAGAATGTG




CTGCTGATTGACGGACCTCTGAGCTGGTACTCCGACCCA




GGGCTGGCAGGGGTGTCCCTGACTGGGGGACTGTCCTAC




AAAGAAGATACAAAAGAACTGGTGGTGGCTAAAGCTGG




GGTGTACTATGTGTTTTTTCAGCTGGAACTGAGGCGGGT




GGTGGCTGGGGAGGGCTCAGGATCTGTGTCCCTGGCTCT




GCATCTGCAGCCACTGCGCTCTGCAGCAGGGGCTGCAG




CACTGGCCCTGACTGTGGACCTGCCCCCAGCTTCTTCCG




AGGCCAGAAACAGCGCCTTCGGGTTCCAAGGACGCCTG




CTGCATCTGAGCGCCGGACAGCGCCTGGGAGTGCATCT




GCATACTGAAGCCAGAGCCCGGCATGCTTGGCAGCTGA




CTCAGGGGGCAACTGTGCTGGGACTGTTTCGCGTGACAC




CTGAGATCCCCGCTGGACTGGGCGGAGGCGGTTCCGGA




GGGGGAGGATCTCGTACGGTGGCTGCACCATCTGTCTTT




ATCTTCCCACCCAGCGACCGGAAGCTGAAGTCTGGCAC




AGCCAGCGTCGTGTGCCTGCTGAATAACTTCTACCCCCG




CGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGC




AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGA




CAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGA




CCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTAC




GCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTG




ACCAAGAGCTTCAACCGGGGCGAGTGCGACAAGACCCA




CACCTGTCCTCCATGCCCTGCCCCTGAAGCTGCTGGCGG




CCCTAGCGTGTTCCTGTTCCCCCCAAAGCCCAAGGACAC




CCTGATGATCAGCCGGACCCCTGAAGTGACCTGCGTGGT




GGTGGATGTGTCCCACGAGGACCCTGAAGTGAAGTTCA




ATTGGTACGTGGACGGCGTGGAAGTGCACAATGCCAAG




ACCAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCG




TGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCT




GAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAG




CCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCC




AAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCC




CCCATGCCGGGATGAGCTGACCAAGAACCAGGTCAGCC




TGTGGTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCG




CCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAC




TACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCC




TTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGG




TGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCAT




GAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTC




CCTGTCTCCGGGTAAA





170
Monomeric hu 4-
AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG



1BBL (71-248)-
ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT



CH1*
GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG




GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG




CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG




TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG




AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT




GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGATCTGCT




GCTGGCGCCGCTGCTCTGGCACTGACAGTGGATCTGCCT




CCTGCCAGCAGCGAGGCCCGGAATAGCGCATTTGGGTTT




CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT




GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG




CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG




TTCAGAGTGACCCCCGAGATTCCAGCCGGACTGGGAGG




CGGAGGTTCCGGAGGCGGAGGATCTGCTAGCACAAAGG




GCCCCAGCGTGTTCCCTCTGGCCCCTAGCAGCAAGAGCA




CATCTGGCGGAACAGCCGCCCTGGGCTGCCTGGTGGAA




GATTACTTCCCCGAGCCCGTGACCGTGTCCTGGAATTCT




GGCGCCCTGACAAGCGGCGTGCACACCTTTCCAGCCGTG




CTGCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTG




ACAGTGCCCAGCAGCTCTCTGGGCACCCAGACCTACATC




TGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGA




CGAGAAGGTGGAACCCAAGTCCTGC





162
anti-FAP (4B9)
see Table 21



Fc hole chain






163
anti-FAP (4B9)
see Table 21



light chain






119
Dimeric hu 4-
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY



1BBL (71-248)-
SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR



CL* Fc knob
RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS



chain
EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT




QGATVLGLFRVTPEIPAGLGGGGSGGGGSREGPELSPDDPA




GLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTG




GLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSV




SLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQG




RLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRV




TPEIPAGLGGGGSGGGGSRTVAAPSVFIFPPSDRKLKSGTAS




VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD




STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR




GECDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE




VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY




NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTI




SKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSD




IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR




WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK





120
Monomeric hu 4-
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY



1BBL (71-248)-
SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR



CH1*
RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS




EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT




QGATVLGLFRVTPEIPAGLGGGGSGGGGSASTKGPSVFPLA




PSSKSTSGGTAALGCLVEDYFPEPVTVSWNSGALTSGVHTF




PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV




DEKVEPKSC





164
anti-FAP (4B9)
see Table 21



Fc hole chain






125
anti-FAP (4B9)
see Table 21



light chain









2.1.5 Preparation of Monovalent FAP (4B9) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains without Charged Residues (Construct 2.5)


A polypeptide containing two ectodomains of 4-1BB ligand (71-248), separated by (G4S)2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned as depicted in FIG. 1A: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-248) and fused to the human IgG1-CH domain, was cloned as described in FIG. 1B: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CH.


The polypeptide encoding the dimeric 4-1BB ligand fused to human CL domain was subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant, Zhu et al. 1998) using a linker (G4S)2 (SEQ ID NO:13) or, alternatively, GSPGSSSSGS (SEQ ID NO:57).


The variable region of heavy and light chain DNA sequences encoding a binder specific for fibroblast activation protein (FAP), clone 4B9, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1.


The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831.


Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-FAP-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-FAP light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a FAP binding Fab (FIG. 4E, Construct 2.5)


Table 25 shows the cDNA and amino acid sequences of the monovalent FAP (4B9)-human 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule containing CH1-CL crossover without charged residues (Construct 2.5).









TABLE 25







Sequences of monovalent FAP(4B9)-targeted human 4-1BB ligand (71-248)


containing Fc (kih) fusion molecule Construct 2.5









SEQ ID




NO:
Description
Sequence





171
nucleotide
AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG



sequence dimeric
ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT



hu 4-1BBL (71-248)-
GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG



CL Fc knob chain
GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG




CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG




TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG




AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT




GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGATCTGCT




GCTGGCGCCGCTGCTCTGGCACTGACAGTGGATCTGCCT




CCTGCCAGCAGCGAGGCCCGGAATAGCGCATTTGGGTTT




CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT




GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG




CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG




TTCAGAGTGACCCCCGAGATTCCAGCCGGACTGGGAGG




CGGCGGATCTGGCGGCGGAGGATCTAGAGAAGGACCCG




AGCTGTCCCCTGACGATCCAGCCGGGCTGCTGGATCTGA




GACAGGGAATGTTCGCCCAGCTGGTGGCTCAGAATGTG




CTGCTGATTGACGGACCTCTGAGCTGGTACTCCGACCCA




GGGCTGGCAGGGGTGTCCCTGACTGGGGGACTGTCCTAC




AAAGAAGATACAAAAGAACTGGTGGTGGCTAAAGCTGG




GGTGTACTATGTGTTTTTTCAGCTGGAACTGAGGCGGGT




GGTGGCTGGGGAGGGCTCAGGATCTGTGTCCCTGGCTCT




GCATCTGCAGCCACTGCGCTCTGCAGCAGGGGCTGCAG




CACTGGCCCTGACTGTGGACCTGCCCCCAGCTTCTTCCG




AGGCCAGAAACAGCGCCTTCGGGTTCCAAGGACGCCTG




CTGCATCTGAGCGCCGGACAGCGCCTGGGAGTGCATCT




GCATACTGAAGCCAGAGCCCGGCATGCTTGGCAGCTGA




CTCAGGGGGCAACTGTGCTGGGACTGTTTCGCGTGACAC




CTGAGATCCCCGCTGGACTGGGCGGAGGCGGTTCCGGA




GGGGGAGGATCTCGTACGGTGGCCGCTCCCTCCGTGTTT




ATCTTTCCCCCATCCGATGAACAGCTGAAAAGCGGCACC




GCCTCCGTCGTGTGTCTGCTGAACAATTTTTACCCTAGG




GAAGCTAAAGTGCAGTGGAAAGTGGATAACGCACTGCA




GTCCGGCAACTCCCAGGAATCTGTGACAGAACAGGACT




CCAAGGACAGCACCTACTCCCTGTCCTCCACCCTGACAC




TGTCTAAGGCTGATTATGAGAAACACAAAGTCTACGCCT




GCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACA




AAGAGCTTCAACAGGGGAGAGTGTGACAAGACCCACAC




CTGTCCCCCTTGTCCTGCCCCTGAAGCTGCTGGCGGCCC




TTCTGTGTTCCTGTTCCCCCCAAAGCCCAAGGACACCCT




GATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGG




TGGATGTGTCCCACGAGGACCCTGAAGTGAAGTTCAATT




GGTACGTGGACGGCGTGGAAGTGCACAATGCCAAGACC




AAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGT




GGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAA




TGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCC




TCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAA




GGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCC




ATGCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGT




GGTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG




TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTAC




AAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTC




TTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTG




GCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGA




GGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCT




GTCTCCGGGTAAA





172
Monomeric hu 4-
AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG



1BBL (71-248)-
ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT



CH1
GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG




GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG




CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG




TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG




AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT




GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGATCTGCT




GCTGGCGCCGCTGCTCTGGCACTGACAGTGGATCTGCCT




CCTGCCAGCAGCGAGGCCCGGAATAGCGCATTTGGGTTT




CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT




GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG




CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG




TTCAGAGTGACCCCCGAGATTCCAGCCGGACTGGGAGG




CGGAGGTTCCGGAGGCGGAGGATCTGCTAGCACCAAAG




GCCCTTCCGTGTTTCCTCTGGCTCCTAGCTCCAAGTCCAC




CTCTGGAGGCACCGCTGCTCTCGGATGCCTCGTGAAGGA




TTATTTTCCTGAGCCTGTGACAGTGTCCTGGAATAGCGG




AGCACTGACCTCTGGAGTGCATACTTTCCCCGCTGTGCT




GCAGTCCTCTGGACTGTACAGCCTGAGCAGCGTGGTGAC




AGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCT




GCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGAC




AAGAAGGTGGAACCCAAGTCTTGT





162
anti-FAP (4B9)
see Table 21



Fc hole chain






163
anti-FAP (4B9)
see Table 21



light chain






173
Dimeric hu 4-
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY



1BBL (71-248)-
SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR



CL Fc knob chain
RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS




EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT




QGATVLGLFRVTPEIPAGLGGGGSGGGGSREGPELSPDDPA




GLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTG




GLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSV




SLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQG




RLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRV




TPEIPAGLGGGGSGGGGSRTVAAPSVFIFPPSDEQLKSGTAS




VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD




STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR




GECDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE




VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY




NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTI




SKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSD




IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR




WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK





174
Monomeric hu 4-
REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY



1BBL (71-248)-
SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELR



CH1
RVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASS




EARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLT




QGATVLGLFRVTPEIPAGLGGGGSGGGGSASTKGPSVFPLA




PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT




FPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK




VDKKVEPKSC





164
anti-FAP (4B9)
see Table 21



Fc hole chain






125
anti-FAP (4B9)
see Table 21



light chain









2.1.6 Preparation of Bivalent FAP (4B9) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with the Dimeric and Monomeric 4-1BB Ligands Fused at the C-Terminus of Each Heavy Chain (Construct 2.6)


A polypeptide containing two ectodomains of 4-1BB ligand (71-248), separated by (G4S)2 (SEQ ID NO:13) linkers was fused to the C-terminus of human IgG1 Fc hole chain, as depicted in FIG. 1C: human IgG1 Fc hole, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand. A polypeptide containing one ectodomain of 4-1BB ligand (71-248) and fused to the C-terminus of human IgG1 Fc knob chain as described in FIG. 1D: human IgG1 Fc knob, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand.


The polypeptide encoding the dimeric 4-1BB ligand was subcloned in frame at the C-terminus of human IgG1 heavy chain CH2 and CH3 domains on the hole (Merchant, Zhu et al. 1998) using a (G4S)2 (SEQ ID NO:13) connector. The polypeptide encoding the monomeric 4-1BB ligand was subcloned in frame at the C-terminus of human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant, Zhu et al. 1998) using a (G4S)2 (SEQ ID NO:13) connector.


The variable region of heavy and light chain DNA sequences encoding a binder specific for fibroblast activation protein (FAP), clone 4B9, were subcloned in frame with either the constant heavy chain of the hole, the knob or the constant light chain of human IgG1.


The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831.


Combination of the anti-FAP huIgG1 hole dimeric ligand chain containing the Y349C/T366S/L368A/Y407V mutations, the anti-FAP huIgG1 knob monomeric ligand chain containing the S354C/T366W mutations and the anti-FAP light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and two FAP binding Fabs (FIG. 4F, Construct 2.6).


Table 26 shows the cDNA and amino acid sequences of the bivalent FAP (4B9)-targeted 4-1BB ligand trimer-containing Fc (kih) fusion molecule Construct 2.6 (FAP split trimer with 2 anti-FAP Fabs, dimeric and monomeric 4-1BB ligand fused at the C-terminus of each heavy chain, respectively).









TABLE 26







Sequences of bivalent FAP(4B9)-targeted human 4-1BB ligand (71-248)


containing Fc (kih) fusion molecule Construct 2.6









SEQ ID




NO:
Description
Sequence





175
nucleotide
GAGGTGCAGCTGCTCGAAAGCGGCGGAGGACTGGTGCA



sequence of anti-
GCCTGGCGGCAGCCTGAGACTGTCTTGCGCCGCCAGCG



FAP (4B9) Fc
GCTTCACCTTCAGCAGCTACGCCATGAGCTGGGTCCGCC



hole chain fused
AGGCCCCTGGCAAGGGACTGGAATGGGTGTCCGCCATC



to dimeric hu 4-
ATCGGCTCTGGCGCCAGCACCTACTACGCCGACAGCGTG



1BBL (71-248)
AAGGGCCGGTTCACCATCAGCCGGGACAACAGCAAGAA




CACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGG




ACACCGCCGTGTACTACTGCGCCAAGGGATGGTTCGGC




GGCTTCAACTACTGGGGACAGGGCACCCTGGTCACAGT




GTCCAGCGCTAGCACCAAGGGCCCCTCCGTGTTCCCCCT




GGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCG




CTCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAGCCCG




TGACCGTGTCCTGGAACAGCGGAGCCCTGACCTCCGGC




GTGCACACCTTCCCCGCCGTGCTGCAGAGTTCTGGCCTG




TATAGCCTGAGCAGCGTGGTCACCGTGCCTTCTAGCAGC




CTGGGCACCCAGACCTACATCTGCAACGTGAACCACAA




GCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCA




AGAGCTGCGACAAAACTCACACATGCCCACCGTGCCCA




GCACCTGAAGCTGCAGGGGGACCGTCAGTCTTCCTCTTC




CCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACC




CCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGA




AGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCG




TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG




CAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACC




GTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA




GTGCAAGGTCTCCAACAAAGCCCTCGGCGCCCCCATCG




AGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAA




CCACAGGTGTGCACCCTGCCCCCATCCCGGGATGAGCTG




ACCAAGAACCAGGTCAGCCTCTCGTGCGCAGTCAAAGG




CTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCA




ATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCC




GTGCTGGACTCCGACGGCTCCTTCTTCCTCGTGAGCAAG




CTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGT




CTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCA




CTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGAGG




CGGCGGAAGCGGAGGAGGAGGATCCAGAGAGGGCCCT




GAGCTGAGCCCCGATGATCCTGCTGGACTGCTGGACCTG




CGGCAGGGCATGTTTGCTCAGCTGGTGGCCCAGAACGTG




CTGCTGATCGATGGCCCCCTGTCCTGGTACAGCGATCCT




GGACTGGCTGGCGTGTCACTGACAGGCGGCCTGAGCTA




CAAAGAGGACACCAAAGAACTGGTGGTGGCCAAGGCCG




GCGTGTACTACGTGTTCTTTCAGCTGGAACTGCGGAGAG




TGGTGGCCGGCGAAGGATCTGGCTCTGTGTCTCTGGCCC




TGCATCTGCAGCCTCTGAGAAGCGCTGCTGGCGCTGCAG




CTCTGGCACTGACAGTGGATCTGCCTCCTGCCAGCTCCG




AGGCCCGGAATAGCGCATTTGGGTTTCAAGGCAGGCTG




CTGCACCTGTCTGCCGGCCAGAGGCTGGGAGTGCATCTG




CACACAGAGGCCAGGGCTAGACACGCCTGGCAGCTGAC




ACAGGGCGCTACAGTGCTGGGCCTGTTCAGAGTGACCC




CCGAGATTCCAGCCGGCCTGGGCGGAGGCGGATCTGGC




GGCGGAGGATCTAGAGAGGGACCCGAACTGTCCCCTGA




CGATCCAGCCGGGCTGCTGGATCTGAGACAGGGAATGT




TCGCCCAGCTGGTGGCTCAGAATGTGCTGCTGATTGACG




GACCTCTGAGCTGGTACTCCGACCCAGGGCTGGCAGGG




GTGTCCCTGACTGGGGGACTGTCCTACAAAGAAGATAC




AAAAGAACTGGTGGTGGCTAAAGCTGGGGTGTACTATG




TGTTTTTTCAGCTGGAACTGAGGCGGGTGGTGGCTGGGG




AGGGCTCAGGATCTGTGTCCCTGGCTCTGCATCTGCAGC




CACTGCGCTCTGCTGCTGGCGCAGCTGCACTGGCTCTGA




CTGTGGACCTGCCACCAGCCTCTAGCGAGGCCAGAAAC




AGCGCCTTCGGGTTCCAAGGACGCCTGCTGCATCTGAGC




GCCGGACAGCGCCTGGGAGTGCATCTGCATACTGAAGC




CAGAGCCCGGCATGCTTGGCAGCTGACTCAGGGGGCAA




CTGTGCTGGGACTGTTTCGCGTGACACCTGAGATCCCTG




CCGGACTG





176
nucleotide
GAGGTGCAGCTGCTCGAAAGCGGCGGAGGACTGGTGCA



sequence anti-
GCCTGGCGGCAGCCTGAGACTGTCTTGCGCCGCCAGCG



FAP (4B9) Fc
GCTTCACCTTCAGCAGCTACGCCATGAGCTGGGTCCGCC



knob chain fused
AGGCCCCTGGCAAGGGACTGGAATGGGTGTCCGCCATC



to monomeric hu
ATCGGCTCTGGCGCCAGCACCTACTACGCCGACAGCGTG



4-1BBL (71-248)
AAGGGCCGGTTCACCATCAGCCGGGACAACAGCAAGAA




CACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGG




ACACCGCCGTGTACTACTGCGCCAAGGGATGGTTCGGC




GGCTTCAACTACTGGGGACAGGGCACCCTGGTCACAGT




GTCCAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCT




GGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGG




CCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGG




TGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGC




GTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTC




TACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC




TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAA




GCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCA




AATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAG




CACCTGAAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCC




CCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCC




CTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAA




GACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGT




GGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGC




AGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCG




TCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAG




TGCAAGGTCTCCAACAAAGCCCTCGGCGCCCCCATCGA




GAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC




CACAGGTGTACACCCTGCCCCCCTGCAGAGATGAGCTG




ACCAAGAACCAGGTGTCCCTGTGGTGTCTGGTCAAGGGC




TTCTACCCCAGCGATATCGCCGTGGAGTGGGAGAGCAA




CGGCCAGCCTGAGAACAACTACAAGACCACCCCCCCTG




TGCTGGACAGCGACGGCAGCTTCTTCCTGTACTCCAAAC




TGACCGTGGACAAGAGCCGGTGGCAGCAGGGCAACGTG




TTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCA




CTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGCGGAG




GCGGCGGAAGCGGAGGAGGAGGATCCAGAGAGGGCCC




TGAGCTGAGCCCCGATGATCCTGCTGGACTGCTGGACCT




GCGGCAGGGCATGTTTGCTCAGCTGGTGGCCCAGAACGT




GCTGCTGATCGATGGCCCCCTGTCCTGGTACAGCGATCC




TGGACTGGCTGGCGTGTCACTGACAGGCGGCCTGAGCTA




CAAAGAGGACACCAAAGAACTGGTGGTGGCCAAGGCCG




GCGTGTACTACGTGTTCTTTCAGCTGGAACTGCGGAGAG




TGGTGGCCGGCGAAGGATCTGGCTCTGTGTCTCTGGCCC




TGCATCTGCAGCCTCTGAGAAGCGCTGCTGGCGCTGCAG




CTCTGGCACTGACAGTGGATCTGCCTCCTGCCAGCTCCG




AGGCCCGGAATAGCGCATTTGGGTTTCAAGGCAGGCTG




CTGCACCTGTCTGCCGGCCAGAGGCTGGGAGTGCATCTG




CACACAGAGGCCAGGGCTAGACACGCCTGGCAGCTGAC




ACAGGGCGCTACAGTGCTGGGCCTGTTCAGAGTGACCC




CCGAGATTCCAGCCGGCCTG





163
anti-FAP (4B9)
see Table 21



light chain






126
anti-FAP (4B9)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQA



Fc hole chain
PGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYL



fused to dimeric
QMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSSAS



hu 4-1BBL (71-248)
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS




GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN




VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF




LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG




VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK




CKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDELTKN




QVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD




GSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS




LSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQ




LVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELV




VAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAA




GAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGV




HLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLGGGGSG




GGGSREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGP




LSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFF




QLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDL




PPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHA




WQLTQGATVLGLFRVTPEIPAGL





127
anti-FAP (4B9)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQA



Fc knob chain
PGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYL



fused to
QMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSSAS



monomeric hu 4-
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS



1BBL (71-248)
GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN




VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF




LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG




VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK




CKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKN




QVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD




GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS




LSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQ




LVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELV




VAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAA




GAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGV




HLHTEARARHAWQLTQGATVLGLFRVTPEIPAGL





125
anti-FAP (4B9)
see Table 21



light chain









2.2 Preparation of Untargeted Human 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules (Control Molecules)


Further control molecules were prepared as described in Example 1.4 above for Control A and B. A bivalent variant Control C was prepared in analogy to the bivalent Construct 2.3 and 2.6 and a monovalent variant Control E was prepared in analogy to Construct 2.5 (containing a 4-1BB ligand (71-248) trimer), with the only difference that the anti-FAP binder (VH-VL) was replaced by a germline control, termed DP47, not binding to the antigen.


Table 27 shows the cDNA and amino acid sequences of the bivalent DP47-untargeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion molecule Control C. Table 28 shows the cDNA and amino acid sequences of the monovalent DP47-untargeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion molecule Control E.









TABLE 27







Sequences of bivalent DP47-untargeted human


4-1BB ligand (71-254) containing Fc


(kih) fusion molecule Control C









SEQ ID




NO:
Description
Sequence












177
nucleotide
GAGGTGCAATTGTTGGAGTCTGGGG



sequence DP47
GAGGCTTGGTACAGCCTGGGGGGTC



Fc hole chain
CCTGAGACTCTCCTGTGCAGCCTCC



fused to dimeric
GGATTCACCTTTAGCAGTTATGCCA



hu 4-1BBL
TGAGCTGGGTCCGCCAGGCTCCAGG



(71-254)
GAAGGGGCTGGAGTGGGTCTCAGCT




ATTAGTGGTAGTGGTGGTAGCACAT




ACTACGCAGACTCCGTGAAGGGCCG




GTTCACCATCTCCAGAGACAATTCC




AAGAACACGCTGTATCTGCAGATGA




ACAGCCTGAGAGCCGAGGACACGGC




CGTATATTACTGTGCGAAAGGCAGC




GGATTTGACTACTGGGGCCAAGGAA




CCCTGGTCACCGTCTCGAGTGCTAG




CACCAAGGGCCCCTCCGTGTTCCCC




CTGGCCCCCAGCAGCAAGAGCACCA




GCGGCGGCACAGCCGCTCTGGGCTG




CCTGGTCAAGGACTACTTCCCCGAG




CCCGTGACCGTGTCCTGGAACAGCG




GAGCCCTGACCTCCGGCGTGCACAC




CTTCCCCGCCGTGCTGCAGAGTTCT




GGCCTGTATAGCCTGAGCAGCGTGG




TCACCGTGCCTTCTAGCAGCCTGGG




CACCCAGACCTACATCTGCAACGTG




AACCACAAGCCCAGCAACACCAAGG




TGGACAAGAAGGTGGAGCCCAAGAG




CTGCGACAAAACTCACACATGCCCA




CCGTGCCCAGCACCTGAAGCTGCAG




GGGGACCGTCAGTCTTCCTCTTCCC




CCCAAAACCCAAGGACACCCTCATG




ATCTCCCGGACCCCTGAGGTCACAT




GCGTGGTGGTGGACGTGAGCCACGA




AGACCCTGAGGTCAAGTTCAACTGG




TACGTGGACGGCGTGGAGGTGCATA




ATGCCAAGACAAAGCCGCGGGAGGA




GCAGTACAACAGCACGTACCGTGTG




GTCAGCGTCCTCACCGTCCTGCACC




AGGACTGGCTGAATGGCAAGGAGTA




CAAGTGCAAGGTCTCCAACAAAGCC




CTCGGCGCCCCCATCGAGAAAACCA




TCTCCAAAGCCAAAGGGCAGCCCCG




AGAACCACAGGTGTGCACCCTGCCC




CCATCCCGGGATGAGCTGACCAAGA




ACCAGGTCAGCCTCTCGTGCGCAGT




CAAAGGCTTCTATCCCAGCGACATC




GCCGTGGAGTGGGAGAGCAATGGGC




AGCCGGAGAACAACTACAAGACCAC




GCCTCCCGTGCTGGACTCCGACGGC




TCCTTCTTCCTCGTGAGCAAGCTCA




CCGTGGACAAGAGCAGGTGGCAGCA




GGGGAACGTCTTCTCATGCTCCGTG




ATGCATGAGGCTCTGCACAACCACT




ACACGCAGAAGAGCCTCTCCCTGTC




TCCGGGTGGAGGCGGCGGAAGCGGA




GGAGGAGGATCCAGAGAGGGCCCTG




AGCTGAGCCCCGATGATCCTGCTGG




ACTGCTGGACCTGCGGCAGGGCATG




TTTGCTCAGCTGGTGGCCCAGAACG




TGCTGCTGATCGATGGCCCCCTGTC




CTGGTACAGCGATCCTGGACTGGCT




GGCGTGTCACTGACAGGCGGCCTGA




GCTACAAAGAGGACACCAAAGAACT




GGTGGTGGCCAAGGCCGGCGTGTAC




TACGTGTTCTTTCAGCTGGAACTGC




GGAGAGTGGTGGCCGGCGAAGGATC




TGGCTCTGTGTCTCTGGCCCTGCAT




CTGCAGCCTCTGAGAAGCGCTGCTG




GCGCTGCAGCTCTGGCACTGACAGT




GGATCTGCCTCCTGCCAGCTCCGAG




GCCCGGAATAGCGCATTTGGGTTTC




AAGGCAGGCTGCTGCACCTGTCTGC




CGGCCAGAGGCTGGGAGTGCATCTG




CACACAGAGGCCAGGGCTAGACACG




CCTGGCAGCTGACACAGGGCGCTAC




AGTGCTGGGCCTGTTCAGAGTGACC




CCCGAGATTCCAGCCGGCCTGCCTT




CTCCAAGAAGCGAAGGCGGAGGCGG




ATCTGGCGGCGGAGGATCTAGAGAG




GGACCCGAACTGTCCCCTGACGATC




CAGCCGGGCTGCTGGATCTGAGACA




GGGAATGTTCGCCCAGCTGGTGGCT




CAGAATGTGCTGCTGATTGACGGAC




CTCTGAGCTGGTACTCCGACCCAGG




GCTGGCAGGGGTGTCCCTGACTGGG




GGACTGTCCTACAAAGAAGATACAA




AAGAACTGGTGGTGGCTAAAGCTGG




GGTGTACTATGTGTTTTTTCAGCTG




GAACTGAGGCGGGTGGTGGCTGGGG




AGGGCTCAGGATCTGTGTCCCTGGC




TCTGCATCTGCAGCCACTGCGCTCT




GCTGCTGGCGCAGCTGCACTGGCTC




TGACTGTGGACCTGCCACCAGCCTC




TAGCGAGGCCAGAAACAGCGCCTTC




GGGTTCCAAGGACGCCTGCTGCATC




TGAGCGCCGGACAGCGCCTGGGAGT




GCATCTGCATACTGAAGCCAGAGCC




CGGCATGCTTGGCAGCTGACTCAGG




GGGCAACTGTGCTGGGACTGTTTCG




CGTGACACCTGAGATCCCTGCCGGA




CTGCCAAGCCCTAGATCAGAA





178
nucleotide
GAGGTGCAATTGTTGGAGTCTGGGG



sequence DP47
GAGGCTTGGTACAGCCTGGGGGGTC



Fc knob chain
CCTGAGACTCTCCTGTGCAGCCTCC



fused to
GGATTCACCTTTAGCAGTTATGCCA



monomeric hu 4-
TGAGCTGGGTCCGCCAGGCTCCAGG



1BBL (71-254)
GAAGGGGCTGGAGTGGGTCTCAGCT




ATTAGTGGTAGTGGTGGTAGCACAT




ACTACGCAGACTCCGTGAAGGGCCG




GTTCACCATCTCCAGAGACAATTCC




AAGAACACGCTGTATCTGCAGATGA




ACAGCCTGAGAGCCGAGGACACGGC




CGTATATTACTGTGCGAAAGGCAGC




GGATTTGACTACTGGGGCCAAGGAA




CCCTGGTCACCGTCTCGAGTGCTAG




CACCAAGGGCCCATCGGTCTTCCCC




CTGGCACCCTCCTCCAAGAGCACCT




CTGGGGGCACAGCGGCCCTGGGCTG




CCTGGTCAAGGACTACTTCCCCGAA




CCGGTGACGGTGTCGTGGAACTCAG




GCGCCCTGACCAGCGGCGTGCACAC




CTTCCCGGCTGTCCTACAGTCCTCA




GGACTCTACTCCCTCAGCAGCGTGG




TGACCGTGCCCTCCAGCAGCTTGGG




CACCCAGACCTACATCTGCAACGTG




AATCACAAGCCCAGCAACACCAAGG




TGGACAAGAAAGTTGAGCCCAAATC




TTGTGACAAAACTCACACATGCCCA




CCGTGCCCAGCACCTGAAGCTGCAG




GGGGACCGTCAGTCTTCCTCTTCCC




CCCAAAACCCAAGGACACCCTCATG




ATCTCCCGGACCCCTGAGGTCACAT




GCGTGGTGGTGGACGTGAGCCACGA




AGACCCTGAGGTCAAGTTCAACTGG




TACGTGGACGGCGTGGAGGTGCATA




ATGCCAAGACAAAGCCGCGGGAGGA




GCAGTACAACAGCACGTACCGTGTG




GTCAGCGTCCTCACCGTCCTGCACC




AGGACTGGCTGAATGGCAAGGAGTA




CAAGTGCAAGGTCTCCAACAAAGCC




CTCGGCGCCCCCATCGAGAAAACCA




TCTCCAAAGCCAAAGGGCAGCCCCG




AGAACCACAGGTGTACACCCTGCCC




CCCTGCAGAGATGAGCTGACCAAGA




ACCAGGTGTCCCTGTGGTGTCTGGT




CAAGGGCTTCTACCCCAGCGATATC




GCCGTGGAGTGGGAGAGCAACGGCC




AGCCTGAGAACAACTACAAGACCAC




CCCCCCTGTGCTGGACAGCGACGGC




AGCTTCTTCCTGTACTCCAAACTGA




CCGTGGACAAGAGCCGGTGGCAGCA




GGGCAACGTGTTCAGCTGCAGCGTG




ATGCACGAGGCCCTGCACAACCACT




ACACCCAGAAGTCCCTGAGCCTGAG




CCCCGGCGGAGGCGGCGGAAGCGGA




GGAGGAGGATCCAGAGAGGGCCCTG




AGCTGAGCCCCGATGATCCTGCTGG




ACTGCTGGACCTGCGGCAGGGCATG




TTTGCTCAGCTGGTGGCCCAGAACG




TGCTGCTGATCGATGGCCCCCTGTC




CTGGTACAGCGATCCTGGACTGGCT




GGCGTGTCACTGACAGGCGGCCTGA




GCTACAAAGAGGACACCAAAGAACT




GGTGGTGGCCAAGGCCGGCGTGTAC




TACGTGTTCTTTCAGCTGGAACTGC




GGAGAGTGGTGGCCGGCGAAGGATC




TGGCTCTGTGTCTCTGGCCCTGCAT




CTGCAGCCTCTGAGAAGCGCTGCTG




GCGCTGCAGCTCTGGCACTGACAGT




GGATCTGCCTCCTGCCAGCTCCGAG




GCCCGGAATAGCGCATTTGGGTTTC




AAGGCAGGCTGCTGCACCTGTCTGC




CGGCCAGAGGCTGGGAGTGCATCTG




CACACAGAGGCCAGGGCTAGACACG




CCTGGCAGCTGACACAGGGCGCTAC




AGTGCTGGGCCTGTTCAGAGTGACC




CCCGAGATTCCAGCCGGCCTGCCTT




CTCCAAGAAGCGAA





80
nucleotide
see Table 18



sequence DP47




light chain






179
DP47 Fc hole
EVQLLESGGGLVQPGGSLRLSCAAS



chain fused to
GFTFSSYAMSWVRQAPGKGLEWVSA



dimeric hu 4-
IIGSGASTYYADSVKGRFTISRDNS



1BBL (71-254)
KNTLYLQMNSLRAEDTAVYYCAKGW




FGGFNYWGQGTLVTVSSASTKGPSV




FPLAPSSKSTSGGTAALGCLVKDYF




PEPVTVSWNSGALTSGVHTFPAVLQ




SSGLYSLSSVVTVPSSSLGTQTYIC




NVNHKPSNTKVDKKVEPKSCDKTHT




CPPCPAPEAAGGPSVFLFPPKPKDT




LMISRTPEVTCVVVDVSHEDPEVKF




NWYVDGVEVHNAKTKPREEQYNSTY




RVVSVLTVLHQDWLNGKEYKCKVSN




KALGAPIEKTISKAKGQPREPQVCT




LPPSRDELTKNQVSLSCAVKGFYPS




DIAVEWESNGQPENNYKTTPPVLDS




DGSFFLVSKLTVDKSRWQQGNVFSC




SVMHEALHNHYTQKSLSLSPGGGGG




SGGGGSREGPELSPDDPAGLLDLRQ




GMFAQLVAQNVLLIDGPLSWYSDPG




LAGVSLTGGLSYKEDTKELVVAKAG




VYYVFFQLELRRVVAGEGSGSVSLA




LHLQPLRSAAGAAALALTVDLPPAS




SEARNSAFGFQGRLLHLSAGQRLGV




HLHTEARARHAWQLTQGATVLGLFR




VTPEIPAGLPSPRSEGGGGSGGGGS




REGPELSPDDPAGLLDLRQGMFAQL




VAQNVLLIDGPLSWYSDPGLAGVSL




TGGLSYKEDTKELVVAKAGVYYVFF




QLELRRVVAGEGSGSVSLALHLQPL




RSAAGAAATALTVDLPPASSEARNS




AFGFQGRLLHLSAGQRLGVHLHTEA




RARHAWQLTQGATVLGLFRVTPEIP




AGLPSPRSE





180
DP47 Fc knob
EVQLLESGGGLVQPGGSLRLSCAAS



chain fused to
GFTFSSYAMSWVRQAPGKGLEWVSA



monomeric hu 4-
IIGSGASTYYADSVKGRFTISRDNS



1BBL (71-254)
KNTLYLQMNSLRAEDTAVYYCAKGW




FGGFNYWGQGTLVTVSSASTKGPSV




FPLAPSSKSTSGGTAALGCLVKDYF




PEPVTVSWNSGALTSGVHTFPAVLQ




SSGLYSLSSVVTVPSSSLGTQTYIC




NVNHKPSNTKVDRKVEPKSCDKTHT




CPPCPAPEAAGGPSVFLFPPKPKDT




LMISRTPEVTCVVVDVSHEDPEVKF




NWYVDGVEVHNAKTKPREEQYNSTY




RVVSVLTVLHQDWLNGKEYKCKVSN




KALGAPIEKTISKAKGQPREPQVYT




LPPCRDELTKNQVSLWCLVKGFYPS




DIAVEWESNGQPENNYKTTPPVLDS




DGSFFLYSKLTVDKSRWQQGNVFSC




SVMHEALHNHYTQKSLSLSPGGGGG




SGGGGSREGPELSPDDPAGLLDLRQ




GMFAQLVAQNVLLIDGPLSWYSDPG




LAGVSLTGGLSYKEDTKELVVAKAG




VYYVFFQLELRRVVAGEGSGSVSLA




LHLQPLRSAAGAAALALTVDLPPAS




SEARNSAFGFQGRLLHLSAGQRLGV




HLHTEARARHAWQLTQGATVLGLFR




VTPEIPAGLPSPRSE





82
DP47 light chain
see Table 18
















TABLE 28







Sequences of monovalent untargeted human 4-1BB ligand


(71-248) containing Fc (kih) fusion molecule Control E









SEQ ID




NO:
Description
Sequence












171
Dimeric hu 4-
see Table 25



1BBL (71-248)-




CL Fc knob chain



172
Monomeric hu
see Table 25



4-1BBL (71-248)-




CH1



79
DP47 Fc hole
see Table 18



chain



80
DP47 light chain
see Table 18


173
Dimeric hu 4-
see Table 25



1BBL (71-248)-




CL Fc knob chain



174
Monomeric hu
see Table 25



4-1BBL (71-248)-




CH1



81
DP47 Fc hole
see Table 18



chain



82
DP47 light chain
see Table 18









2.3 Preparation of Untargeted Human IgG1 as Control F


An additional control molecule used in the assays was an untargeted DP47, germline control, human IgG1, containing the Pro329Gly, Leu234Ala and Leu235Ala mutations, to abrogate binding to Fc gamma receptors according to the method described in International Patent Appl. Publ. No. WO 2012/130831).


Table 29 shows the cDNA and amino acid sequences of the cDNA and amino acid sequences of the untargeted DP47 huIgG1 PGLALA (Control F).









TABLE 29







Sequences of untargeted DP47 huIgG1 (Control F)









SEQ ID




NO:
Description
Sequence












181
nucleotide
GAGGTGCAATTGTTGGAGTCTGGGG



sequence DP47
GAGGCTTGGTACAGCCTGGGGGGTC



heavy chain (hu
CCTGAGACTCTCCTGTGCAGCCTCC



IgG1 PGLALA)
GGATTCACCTTTAGCAGTTATGCCA




TGAGCTGGGTCCGCCAGGCTCCAGG




GAAGGGGCTGGAGTGGGTCTCAGCT




ATTAGTGGTAGTGGTGGTAGCACAT




ACTACGCAGACTCCGTGAAGGGCCG




GTTCACCATCTCCAGAGACAATTCC




AAGAACACGCTGTATCTGCAGATGA




ACAGCCTGAGAGCCGAGGACACGGC




CGTATATTACTGTGCGAAAGGCAGC




GGATTTGACTACTGGGGCCAAGGAA




CCCTGGTCACCGTCTCGAGTGCTAG




CACCAAGGGCCCATCGGTCTTCCCC




CTGGCACCCTCCTCCAAGAGCACCT




CTGGGGGCACAGCGGCCCTGGGCTG




CCTGGTCAAGGACTACTTCCCCGAA




CCGGTGACGGTGTCGTGGAACTCAG




GCGCCCTGACCAGCGGCGTGCACAC




CTTCCCGGCTGTCCTACAGTCCTCA




GGACTCTACTCCCTCAGCAGCGTGG




TGACCGTGCCCTCCAGCAGCTTGGG




CACCCAGACCTACATCTGCAACGTG




AATCACAAGCCCAGCAACACCAAGG




TGGACAAGAAAGTTGAGCCCAAATC




TTGTGACAAAACTCACACATGCCCA




CCGTGCCCAGCACCTGAAGCTGCAG




GGGGACCGTCAGTCTTCCTCTTCCC




CCCAAAACCCAAGGACACCCTCATG




ATCTCCCGGACCCCTGAGGTCACAT




GCGTGGTGGTGGACGTGAGCCACGA




AGACCCTGAGGTCAAGTTCAACTGG




TACGTGGACGGCGTGGAGGTGCATA




ATGCCAAGACAAAGCCGCGGGAGGA




GCAGTACAACAGCACGTACCGTGTG




GTCAGCGTCCTCACCGTCCTGCACC




AGGACTGGCTGAATGGCAAGGAGTA




CAAGTGCAAGGTCTCCAACAAAGCC




CTCGGCGCCCCCATCGAGAAAACCA




TCTCCAAAGCCAAAGGGCAGCCCCG




AGAACCACAGGTGTACACCCTGCCC




CCATCCCGGGATGAGCTGACCAAGA




ACCAGGTCAGCCTGACCTGCCTGGT




CAAAGGCTTCTATCCCAGCGACATC




GCCGTGGAGTGGGAGAGCAATGGGC




AGCCGGAGAACAACTACAAGACCAC




GCCTCCCGTGCTGGACTCCGACGGC




TCCTTCTTCCTCTACAGCAAGCTCA




CCGTGGACAAGAGCAGGTGGCAGCA




GGGGAACGTCTTCTCATGCTCCGTG




ATGCATGAGGCTCTGCACAACCACT




ACACGCAGAAGAGCCTCTCCCTGTC




TCCGGGTAAA





80
DP47 light chain
See Table 18





182
DP47 heavy chain
EVQLLESGGGLVQPGGSLRLSCAAS



(hu IgG1
GFTFSSYAMSWVRQAPGKGLEWVSA



PGLALA)
ISGSGGSTYYADSVKGRFTISRDNS




KNTLYLQMNSLRAEDTAVYYCAKGS




GFDYWGQGTLVTVSSASTKGPSVFP




LAPSSKSTSGGTAALGCLVKDYFPE




PVTVSWNSGALTSGVHTFPAVLQSS




GLYSLSSVVTVPSSSLGTQTYICNV




NHKPSNTKVDKKVEPKSCDKTHTCP




PCPAPEAAGGPSVFLFPPKPKDTLM




ISRTPEVTCVVVDVSHEDPEVKFNW




YVDGVEVHNAKTKPREEQYNSTYRV




VSVLTVLHQDWLNGKEYKCKVSNKA




LGAPIEKTISKAKGQPREPQVYTLP




PSRDELTKNQVSLTCLVKGFYPSDI




AVEWESNGQPENNYKTTPPVLDSDG




SFFLYSKLTVDKSRWQQGNVFSCSV




MHEALHNHYTQKSLSLSPGK





82
DP47 light chain
See Table 18









2.4 Production of Monovalent and Bivalent FAP (4B9) Targeted Split Trimeric 4-1BB Ligand Fc Fusion Constructs and Control Molecules


The targeted and untargeted split trimeric 4-1BB ligand Fc (kih) fusion encoding sequences were cloned into a plasmid vector, which drives expression of the insert from an MPSV promoter and contains a synthetic polyA sequence located at the 3′ end of the CDS. In addition, the vector contains an EBV OriP sequence for episomal maintenance of the plasmid.


The split trimeric 4-1BB ligand Fc (kih) fusion was produced by co-transfecting HEK293-EBNA cells with the mammalian expression vectors using polyethylenimine. The cells were transfected with the corresponding expression vectors. For Constructs 2.1, 2.2, 2.4 and 2.5 and corresponding control molecules, a 1:1:1:1 ratio (e.g.“vector dimeric ligand-CL- knob chain”: “vector monomeric ligand fusion-CH1”: “vector anti-FAP Fab-hole chain”: “vector anti-FAP light chain”) was used. For Constructs 2.3 and 2.6 and its control moelcule, a 1:1:1 ratio (“vector huIgG1 Fc hole dimeric ligand chain”: “vector huIgG1 Fc knob monomeric ligand chain”: “vector anti-FAP light chain”) was taken. Human IgGs, used as control in the assay, were produced as for the bispecific constructs (for transfection only a vector for light and a vector for heavy chain were used.


For production in 500 mL shake flasks, 300 million HEK293 EBNA cells were seeded 24 hours before transfection. For transfection cells were centrifuged for 10 minutes at 210× g, and the supernatant was replaced by 20 mL pre-warmed CD CHO medium. Expression vectors (200 μg of total DNA) were mixed in 20 mL CD CHO medium. After addition of 540 μL PEI, the solution was vortexed for 15 seconds and incubated for 10 minutes at room temperature. Afterwards, cells were mixed with the DNA/PEI solution, transferred to a 500 mL shake flask and incubated for 3 hours at 37° C. in an incubator with a 5% CO2 atmosphere. After the incubation, 160 mL of Excell medium supplemented with 6 mM L-Glutamine, 5 g/L PEPSOY and 1.2 mM valproic acid was added and cells were cultured for 24 hours. One day after transfection 12% Feed 7 and Glucose (final conc. 3 g/L) were added. After culturing for 7 days, the supernatant was collected by centrifugation for 30-40 minutes at least 400× g. The solution was sterile filtered (0.22 μm filter), supplemented with sodium azide to a final concentration of 0.01% (w/v), and kept at 4° C.


The targeted and untargeted TNF ligand trimer-containing Fc (kih) fusion antigen binding molecules and the human IgG1 were purified from cell culture supernatants by affinity chromatography using Protein A, followed by size exclusion chromatography. For affinity chromatography, the supernatant was loaded on a MAB SELECT SURE® column (CV=5-15 mL, resin from GE Healthcare) equilibrated with Sodium Phosphate (20 mM), Sodium Citrate (20 mM) buffer (pH 7.5). Unbound protein was removed by washing with at least 6 column volumes of the same buffer. The bound protein was eluted using either a linear gradient (20 CV) or a step elution (8 CV) with 20 mM sodium citrate, 100 mM Sodium chloride, 100 mM Glycine buffer (pH 3.0). For the linear gradient an additional 4 column volumes step elution was applied.


The pH of collected fractions was adjusted by adding 1/10 (v/v) of 0.5M sodium phosphate, pH8.0. The protein was concentrated prior to loading on a HILOAD® Superdex 200 column (GE Healthcare) equilibrated with 20 mM Histidine, 140 mM sodium chloride, 0.01% (v/v) TWEEN® 20 (polysorbate 20) solution of pH 6.0.


The protein concentration was determined by measuring the optical density (OD) at 280 nm, using a molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the targeted trimeric 4-1BB ligand Fc (kih) fusion was analyzed by SDS-PAGE in the presence and absence of a reducing agent (5 mM 1,4-dithiotreitol) and staining with Coomassie SIMPLYBLUE™ SafeStain (Invitrogen USA) or CE-SDS using Caliper LabChip GXII (Perkin Elmer). The aggregate content of samples was analyzed using a TSKGEL® G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in 25 mM K2HPO4, 125 mM NaCl, 200 mM L-Arginine Monohydrocloride, 0.02% (w/v) NaN3, pH 6.7 running buffer at 25° C.


Table 30 summarizes the yield and final monomer content of the FAP (4B9) targeted and untargeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules and control molecules.









TABLE 30







Biochemical analysis of FAP(4B9) targeted and -


untargeted 4-1BB ligand trimer containing Fc


(kih) fusion antigen binding molecules and control molecules












Monomer





[%]
Yield



Construct
(SEC)
[mg/1]















Construct 2.1
95
15.8



Construct 2.3
97
11.5



Construct 2.4
97
14.1



Construct 2.5
100
16.5



Control C (bivalent)
98
12.6



Control E (monovalent)
93
4.1



Control F (germline DP47 human IgG1
100
50



PGLALA












Example 3
Preparation, Purification and Characterization of 4-1BB

DNA sequences encoding the ectodomains of human, mouse or cynomolgus 4-1BB (Table 31) were subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant et al., 1998). An AcTEV protease cleavage site was introduced between an antigen ectodomain and the Fc of human IgG1. An Avi tag for directed biotinylation was introduced at the C-terminus of the antigen-Fc knob. Combination of the antigen-Fc knob chain containing the S354C/T366W mutations, with a Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations allows generation of a heterodimer which includes a single copy of 4-1BB ectodomain containing chain, thus creating a monomeric form of Fc-linked antigen (FIG. 5C). Table 32 shows the cDNA and amino acid sequences of the antigen Fc-fusion constructs.









TABLE 31







Amino acid numbering of antigen


ectodomains (ECD) and their origin










SEQ ID NO:
Construct
Origin
ECD





83
human 4-1BB ECD
Synthetized according
aa 24-186




to Q07011



84
cynomolgus 4-1BB ECD
isolated from
aa 24-186




cynomolgus blood



85
murine 4-1BB ECD
Synthetized according
aa 24-187




to P20334
















TABLE 32







cDNA and Amino acid sequences of monomeric


antigen Fc(kih) fusion molecules









SEQ ID




NO:
Antigen
Sequence





86
Nucleotide
GACAAAACTCACACATGCCCACCGT



sequence
GCCCAGCACCTGAACTCCTGGGGGG



Fc hole chain
ACCGTCAGTCTTCCTCTTCCCCCCA




AAACCCAAGGACACCCTCATGATCT




CCCGGACCCCTGAGGTCACATGCGT




GGTGGTGGACGTGAGCCACGAAGAC




CCTGAGGTCAAGTTCAACTGGTACG




TGGACGGCGTGGAGGTGCATAATGC




CAAGACAAAGCCGCGGGAGGAGCAG




TACAACAGCACGTACCGTGTGGTCA




GCGTCCTCACCGTCCTGCACCAGGA




CTGGCTGAATGGCAAGGAGTACAAG




TGCAAGGTCTCCAACAAAGCCCTCC




CAGCCCCCATCGAGAAAACCATCTC




CAAAGCCAAAGGGCAGCCCCGAGAA




CCACAGGTGTGCACCCTGCCCCCAT




CCCGGGATGAGCTGACCAAGAACCA




GGTCAGCCTCTCGTGCGCAGTCAAA




GGCTTCTATCCCAGCGACATCGCCG




TGGAGTGGGAGAGCAATGGGCAGCC




GGAGAACAACTACAAGACCACGCCT




CCCGTGCTGGACTCCGACGGCTCCT




TCTTCCTCGTGAGCAAGCTCACCGT




GGACAAGAGCAGGTGGCAGCAGGGG




AACGTCTTCTCATGCTCCGTGATGC




ATGAGGCTCTGCACAACCACTACAC




GCAGAAGAGCCTCTCCCTGTCTCCG




GGTAAA





87
Nucleotide
CTGCAGGACCCCTGCAGCAACTGCC



sequence
CTGCCGGCACCTTCTGCGACAACAA



human 4-1BB
CCGGAACCAGATCTGCAGCCCCTGC



antigen
CCCCCCAACAGCTTCAGCTCTGCCG



Fc knob
GCGGACAGCGGACCTGCGACATCTG



chain
CAGACAGTGCAAGGGCGTGTTCAGA




ACCCGGAAAGAGTGCAGCAGCACCA




GCAACGCCGAGTGCGACTGCACCCC




CGGCTTCCATTGTCTGGGAGCCGGC




TGCAGCATGTGCGAGCAGGACTGCA




AGCAGGGCCAGGAACTGACCAAGAA




GGGCTGCAAGGACTGCTGCTTCGGC




ACCTTCAACGACCAGAAGCGGGGCA




TCTGCCGGCCCTGGACCAACTGTAG




CCTGGACGGCAAGAGCGTGCTGGTC




AACGGCACCAAAGAACGGGACGTCG




TGTGCGGCCCCAGCCCTGCTGATCT




GTCTCCTGGGGCCAGCAGCGTGACC




CCTCCTGCCCCTGCCAGAGAGCCTG




GCCACTCTCCTCAGGTCGACGAACA




GTTATATTTTCAGGGCGGCTCACCC




AAATCTGCAGACAAAACTCACACAT




GCCCACCGTGCCCAGCACCTGAACT




CCTGGGGGGACCGTCAGTCTTCCTC




TTCCCCCCAAAACCCAAGGACACCC




TCATGATCTCCCGGACCCCTGAGGT




CACATGCGTGGTGGTGGACGTGAGC




CACGAAGACCCTGAGGTCAAGTTCA




ACTGGTACGTGGACGGCGTGGAGGT




GCATAATGCCAAGACAAAGCCGCGG




GAGGAGCAGTACAACAGCACGTACC




GTGTGGTCAGCGTCCTCACCGTCCT




GCACCAGGACTGGCTGAATGGCAAG




GAGTACAAGTGCAAGGTCTCCAACA




AAGCCCTCCCAGCCCCCATCGAGAA




AACCATCTCCAAAGCCAAAGGGCAG




CCCCGAGAACCACAGGTGTACACCC




TGCCCCCATGCCGGGATGAGCTGAC




CAAGAACCAGGTCAGCCTGTGGTGC




CTGGTCAAAGGCTTCTATCCCAGCG




ACATCGCCGTGGAGTGGGAGAGCAA




TGGGCAGCCGGAGAACAACTACAAG




ACCACGCCTCCCGTGCTGGACTCCG




ACGGCTCCTTCTTCCTCTACAGCAA




GCTCACCGTGGACAAGAGCAGGTGG




CAGCAGGGGAACGTCTTCTCATGCT




CCGTGATGCATGAGGCTCTGCACAA




CCACTACACGCAGAAGAGCCTCTCC




CTGTCTCCGGGTAAATCCGGAGGCC




TGAACGACATCTTCGAGGCCCAGAA




GATTGAATGGCACGAG





88
Nucleotide
TTGCAGGATCTGTGTAGTAACTGCC



sequence
CAGCTGGTACATTCTGTGATAATAA



cynomolgus 4-
CAGGAGTCAGATTTGCAGTCCCTGT



1BB antigen
CCTCCAAATAGTTTCTCCAGCGCAG



Fc knob chain
GTGGACAAAGGACCTGTGACATATG




CAGGCAGTGTAAAGGTGTTTTCAAG




ACCAGGAAGGAGTGTTCCTCCACCA




GCAATGCAGAGTGTGACTGCATTTC




AGGGTATCACTGCCTGGGGGCAGAG




TGCAGCATGTGTGAACAGGATTGTA




AACAAGGTCAAGAATTGACAAAAAA




AGGTTGTAAAGACTGTTGCTTTGGG




ACATTTAATGACCAGAAACGTGGCA




TCTGTCGCCCCTGGACAAACTGTTC




TTTGGATGGAAAGTCTGTGCTTGTG




AATGGGACGAAGGAGAGGGACGTGG




TCTGCGGACCATCTCCAGCCGACCT




CTCTCCAGGAGCATCCTCTGCGACC




CCGCCTGCCCCTGCGAGAGAGCCAG




GACACTCTCCGCAGGTCGACGAACA




GTTATATTTTCAGGGCGGCTCACCC




AAATCTGCAGACAAAACTCACACAT




GCCCACCGTGCCCAGCACCTGAACT




CCTGGGGGGACCGTCAGTCTTCCTC




TTCCCCCCAAAACCCAAGGACACCC




TCATGATCTCCCGGACCCCTGAGGT




CACATG




CGTGGTGGTGGACGTGAGCCACGAA




GACCCTGAGGTCAAGTTCAACTGGT




ACGTGGACGGCGTGGAGGTGCATAA




TGCCAAGACAAAGCCGCGGGAGGAG




CAGTACAACAGCACGTACCGTGTGG




TCAGCGTCCTCACCGTCCTGCACCA




GGACTGGCTGAATGGCAAGGAGTAC




AAGTGCAAGGTCTCCAACAAAGCCC




TCCCAGCCCCCATCGAGAAAACCAT




CTCCAAAGCCAAAGGGCAGCCCCGA




GAACCACAGGTGTACACCCTGCCCC




CATGCCGGGATGAGCTGACCAAGAA




CCAGGTCAGCCTGTGGTGCCTGGTC




AAAGGCTTCTATCCCAGCGACATCG




CCGTGGAGTGGGAGAGCAATGGGCA




GCCGGAGAACAACTACAAGACCACG




CCTCCCGTGCTGGACTCCGACGGCT




CCTTCTTCCTCTACAGCAAGCTCAC




CGTGGACAAGAGCAGGTGGCAGCAG




GGGAACGTCTTCTCATGCTCCGTGA




TGCATGAGGCTCTGCACAACCACTA




CACGCAGAAGAGCCTCTCCCTGTCT




CCGGGTAAATCCGGAGGCCTGAACG




ACATCTTCGAGGCCCAGAAGATTGA




ATGGCACGAG





89
murine 4-1BB
GTGCAGAACAGCTGCGACAACTGCC



antigen Fc knob
AGCCCGGCACCTTCTGCCGGAAGTA



chain
CAACCCCGTGTGCAAGAGCTGCCCC




CCCAGCACCTTCAGCAGCATCGGCG




GCCAGCCCAACTGCAACATCTGCAG




AGTGTGCGCCGGCTACTTCCGGTTC




AAGAAGTTCTGCAGCAGCACCCACA




ACGCCGAGTGCGAGTGCATCGAGGG




CTTCCACTGCCTGGGCCCCCAGTGC




ACCAGATGCGAGAAGGACTGCAGAC




CCGGCCAGGAACTGACCAAGCAGGG




CTGTAAGACCTGCAGCCTGGGCACC




TTCAACGACCAGAACGGGACCGGCG




TGTGCCGGCCTTGGACCAATTGCAG




CCTGGACGGGAGAAGCGTGCTGAAA




ACCGGCACCACCGAGAAGGACGTCG




TGTGCGGCCCTCCCGTGGTGTCCTT




CAGCCCTAGCACCACCATCAGCGTG




ACCCCTGAAGGCGGCCCTGGCGGAC




ACTCTCTGCAGGTCCTGGTCGACGA




ACAGTTATATTTTCAGGGCGGCTCA




CCCAAATCTGCAGACAAAACTCACA




CATGCCCACCGTGCCCAGCACCTGA




ACTCCTGGGGGGACCGTCAGTCTTC




CTCTTCCCCCCAAAACCCAAGGAC




ACCCTCATGATCTCCCGGACCCCTG




AGGTCACATGCGTGGTGGTGGACGT




GAGCCACGAAGACCCTGAGGTCAAG




TTCAACTGGTACGTGGACGGCGTGG




AGGTGCATAATGCCAAGACAAAGCC




GCGGGAGGAGCAGTACAACAGCACG




TACCGTGTGGTCAGCGTCCTCACCG




TCCTGCACCAGGACTGGCTGAATGG




CAAGGAGTACAAGTGCAAGGTCTCC




AACAAAGCCCTCCCAGCCCCCATCG




AGAAAACCATCTCCAAAGCCAAAGG




GCAGCCCCGAGAACCACAGGTGTAC




ACCCTGCCCCCATGCCGGGATGAGC




TGACCAAGAACCAGGTCAGCCTGTG




GTGCCTGGTCAAAGGCTTCTATCCC




AGCGACATCGCCGTGGAGTGGGAGA




GCAATGGGCAGCCGGAGAACAACTA




CAAGACCACGCCTCCCGTGCTGGAC




TCCGACGGCTCCTTCTTCCTCTACA




GCAAGCTCACCGTGGACAAGAGCAG




GTGGCAGCAGGGGAACGTCTTCTCA




TGCTCCGTGATGCATGAGGCTCTGC




ACAACCACTACACGCAGAAGAGCCT




CTCCCTGTCTCCGGGTAAATCCGGA




GGCCTGAACGACATCTTCGAGGCCC




AGAAGATTGAATGGCACGAG





90
Fc hole chain
DKTHTCPPCPAPELLGGPSVFLFPP




kPKDTLMISRTPEVTCVVVDVSHEDP




EVKFNWYVDGVEVHNAKTKPREEQY




NSTYRVVSVLTVLHQDWLNGKEYKC




KVSNKALPAPIEKTISKAKGQPREP




QVCTLPPSRDELTKNQVSLSCAVKG




FYPSDIAVEWESNGQPENNYKTTPP




VLDSDGSFFLVSKLTVDKSRWQQGN




VFSCSVMHEALHNHYTQKSLSLSPG




K





91
human 4-1BB
LQDPCSNCPAGTFCDNNRNQICSPC



antigen Fc knob
PPNSFSSAGGQRTCDICRQCKGVFR



chain
TRKECSSTSNAECDCTPGFHCLGAG




CSMCEQDCKQGQELTKKGCKDCCFG




TFNDQKRGICRPWTNCSLDGKSVLV




NGTKERDVVCGPSPADLSPGASSVT




PPAPAREPGHSPQVDEQLYFQGGSP




KSADKTHTCPPCPAPELLGGPSVFL




FPPKPKDTLMISRTPEVTCVVVDVS




HEDPEVKFNWYVDGVEVHNAKTKPR




EEQYNSTYRVVSVLTVLHQDWLNGK




EYKCKVSNKALPAPIEKTISKAKGQ




PREPQVYTLPPCRDELTKNQVSLWC




LVKGFYPSDIAVEWESNGQPENNYK




TTPPVLDSDGSFFLYSKLTVDKSRW




QQGNVFSCSVMHEALHNHYTQKSLS




LSPGKSGGLNDIFEAQKIEWHE





92
cynomolgus 4-
LQDLCSNCPAGTFCDNNRSQICSPC



1BB antigen
PPNSFSSAGGQRTCDICRQCKGVFK



Fc knob chain
TRKECSSTSNAECDCISGYHCLGAE




CSMCEQDCKQGQELTKKGCKDCCFG




TFNDQKRGICRPWTNCSLDGKSVLV




NGTKERDVVCGPSPADLSPGASSAT




PPAPAREPGHSPQVDEQLYFQGGSP




KSADKTHTCPPCPAPELLGGPSVFL




FPPKPKDTLMISRTPEVTCVVVDVS




HEDPEVKFNWYVDGVEVHNAKTKPR




EEQYNSTYRVVSVLTVLHQDWLNGK




EYKCKVSNKALPAPIEKTISKAKGQ




PREPQVYTLPPCRDELTKNQVSLWC




LVKGFYPSDIAVEWESNGQPENNYK




TTPPVLDSDGSFFLYSKLTVDKSRW




QQGNVFSCSVMHEALHNHYTQKSLS




LSPGKSGGLNDIFEAQKIEWHE





93
murine 4-1BB
VQNSCDNCQPGTFCRKYNPVCKSCP



antigen Fc knob
PSTFSSIGGQPNCNICRVCAGYFRF



chain
KKFCSSTHNAECECIEGFHCLGPQC




TRCEKDCRPGQELTKQGCKTCSLGT




FNDQNGTGVCRPWTNCSLDGRSVLK




TGTTEKDVVCGPPVVSFSPSTTISV




TPEGGPGGHSLQVLVDEQLYFQGGS




PKSADKTHTCPPCPAPELLGGPSVF




LFPPKPKDTLMISRTPEVTCVVVDV




SHEDPEVKFNWYVDGVEVHNAKTKP




REEQYNSTYRVVSVLTVLHQDWLNG




KEYKCKVSNKALPAPIEKTISKAKG




QPREPQVYTLPPCRDELTKNQVSLW




CLVKGFYPSDIAVEWESNGQPENNY




KTTPPVLDSDGSFFLYSKLTVDKSR




WQQGNVFSCSVMHEALHNHYTQKSL




SLSPGKSGGLNDIFEAQKIEWHE









All 4-1BB-Fc-fusion molecule encoding sequences were cloned into a plasmid vector, which drives expression of the insert from an MPSV promoter and contains a synthetic polyA signal sequence located at the 3′ end of the CDS. In addition, the vector contains an EBV OriP sequence for episomal maintenance of the plasmid.


For preparation of the biotinylated monomeric antigen/Fc fusion molecules, exponentially growing suspension HEK293 EBNA cells were co-transfected with three vectors encoding the two components of fusion protein (knob and hole chains) as well as BirA, an enzyme necessary for the biotinylation reaction. The corresponding vectors were used at a 2:1:0.05 ratio (“antigen ECD-AcTEV- Fc knob”: “Fc hole”: “BirA”).


For protein production in 500 ml shake flasks, 400 million HEK293 EBNA cells were seeded 24 hours before transfection. For transfection cells were centrifuged for 5 minutes at 210 g, and the supernatant was replaced by pre-warmed CD CHO medium. Expression vectors were resuspended in 20 mL of CD CHO medium containing 200 μg of vector DNA. After addition of 540 μL of polyethylenimine (PEI), the solution was vortexed for 15 seconds and incubated for 10 minutes at room temperature. Afterwards, cells were mixed with the DNA/PEI solution, transferred to a 500 mL shake flask and incubated for 3 hours at 37° C. in an incubator with a 5% CO2 atmosphere. After the incubation, 160 mL of F17 medium was added and cells were cultured for 24 hours. The production medium was supplemented with 5 μM kifunensine. One day after transfection, 1 mM valproic acid and 7% Feed 1 with supplements were added to the culture. After 7 days of culturing, the cell supernatant was collected by spinning down cells for 15 min at 210 g. The solution was sterile filtered (0.22 μm filter), supplemented with sodium azide to a final concentration of 0.01% (w/v), and kept at 4° C.


Secreted proteins were purified from cell culture supernatants by affinity chromatography using Protein A, followed by size exclusion chromatography. For affinity chromatography, the supernatant was loaded on a HITRAP® ProteinA HP column (CV=5 mL, GE Healthcare) equilibrated with 40 mL 20 mM sodium phosphate, 20 mM sodium citrate pH 7.5. Unbound protein was removed by washing with at least 10 column volumes of 20 mM sodium phosphate, 20 mM sodium citrate, 0.5 M sodium chloride containing buffer (pH 7.5). The bound protein was eluted using a linear pH-gradient of sodium chloride (from 0 to 500 mM) created over 20 column volumes of 20 mM sodium citrate, 0.01% (v/v) TWEEN® 20 (polysorbate 20), pH 3.0. The column was then washed with 10 column volumes of 20 mM sodium citrate, 500 mM sodium chloride, 0.01% (v/v) TWEEN® 20 (polysorbate 20), pH 3.0.


The pH of collected fractions was adjusted by adding 1/40 (v/v) of 2M Tris, pH8.0. The protein was concentrated and filtered prior to loading on a HILOAD® Superdex 200 column (GE Healthcare) equilibrated with 2 mM MOPS, 150 mM sodium chloride, 0.02% (w/v) sodium azide solution of pH 7.4.


For affinity determination to the human receptor, the ectodomain of human 4-1BB was also subcloned in frame with an avi (SEQ ID NO: 376; GLNDIFEAQKIEWHE) and a hexahistidine tag (SEQ ID NO: 393).


Protein production was performed as described above for the Fc-fusion protein. Secreted proteins were purified from cell culture supernatants by chelating chromatography, followed by size exclusion chromatography. The first chromatographic step was performed on a Ni-NTA SUPERFLOW™ Cartridge (5 ml, Qiagen) equilibrated in 20 mM sodium phosphate, 500 nM sodium chloride, pH7.4. Elution was performed by applying a gradient over 12 column volume from 5% to 45% of elution buffer (20 mM sodium phosphate, 500 nM sodium chloride, 500 mM Imidazole, pH7.4). The protein was concentrated and filtered prior to loading on a HILOAD® Superdex 75 column (GE Healthcare) equilibrated with 2 mM MOPS, 150 mM sodium chloride, 0.02% (w/v) sodium azide solution of pH 7.4 (Table 33).









TABLE 33







Sequences of monomeric human


4-1BB His molecule











SEQ ID





NO:
antigen
Sequence







94
nucleotide
CTGCAGGACCCCTGCAGCAACTGCC




sequence
CTGCCGGCACCTTCTGCGACAACAA




human
CCGGAACCAGATCTGCAGCCCCTGC




4-1BB His
CCCCCCAACAGCTTCAGCTCTGCCG





GCGGACAGCGGACCTGCGACATCTG





CAGACAGTGCAAGGGCGTGTTCAGA





ACCCGGAAAGAGTGCAGCAGCACCA





GCAACGCCGAGTGCGACTGCACCCC





CGGCTTCCATTGTCTGGGAGCCGGC





TGCAGCATGTGCGAGCAGGACTGCA





AGCAGGGCCAGGAACTGACCAAGAA





GGGCTGCAAGGACTGCTGCTTCGGC





ACCTTCAACGACCAGAAGCGGGGCA





TCTGCCGGCCCTGGACCAACTGTAG





CCTGGACGGCAAGAGCGTGCTGGTC





AACGGCACCAAAGAACGGGACGTCG





TGTGCGGCCCCAGCCCTGCTGATCT





GTCTCCTGGGGCCAGCAGCGTGACC





CCTCCTGCCCCTGCCAGAGAGCCTG





GCCACTCTCCTCAGGTCGACGAACA





GTTATATTTTCAGGGCGGCTCAGGC





CTGAACGACATCTTCGAGGCCCAGA





AGATCGAGTGGCACGAGGCTCGAGC





TCACCACCATCACCATCAC







95
human
LQDPCSNCPAGTFCDNNRNQICSPC




4-1BB His
PPNSFSSAGGQRTCDICRQCKGVFR





TRKECSSTSNAECDCTPGFHCLGAG





CSMCEQDCKQGQELTKKGCKDCCFG





TFNDQKRGICRPWTNCSLDGKSVLV





NGTKERDVVCGPSPADLSPGASSVT





PPAPAREPGHSPQVDEQLYFQGGSG





LNDIFEAQKIEWHEARAHHHHHH










Example 4
Biochemical Characterization of FAP-Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecule by Surface Plasmon Resonance

The binding of FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules to recombinant 4-1BB was assessed by surface plasmon resonance (SPR). All SPR experiments were performed on a BIACORE® instrument T100 at 25° C. with HBS-EP as a running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20, Biacore, Freiburg/Germany).


The avidity of the interaction between the FAP-targeted or untargeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules and recombinant 4-1BB (human, cyno and murine) was determined as described below. The data demonstrated that both targeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules as well as untargeted DP47 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules bind with comparable avidities to human and cynomolgus 4-1BB but negligibly to the mouse homolog.


Recombinant biotinylated human, cynomolgus and murine 4-1BB Fc(kih) fusion molecules were directly coupled on a SA chip using the standard coupling instruction (Biacore, Freiburg/Germany). The immobilization level was about 30 RU. FAP-targeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules, or the DP47 untargeted controls, were passed at a concentration range from 0.39 to 200 nM with a flow of 30 μL/minutes through the flow cells over 120 seconds. The dissociation was monitored for 180 seconds. Bulk refractive index differences were corrected for by subtracting the response obtained on a reference empty flow cell.


For affinity measurement, direct coupling of around 7200 resonance units (RU) of an anti-human Fc specific antibody was performed on a CM5 chip at pH 5.0 using the standard amine coupling kit (GE Healthcare). FAP-targeted or untargeted 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules, at 50 nM were captured with a flow rate of 30 μl/min for 60 sec on flow cell 2. A dilution series (1.95 to 1000 nM) of human 4-1BB-avi-His was passed on both flow cells at 30 μl/min for 180 sec to record the association phase. The dissociation phase was monitored for 180 s and triggered by switching from the sample solution to HBS-EP. The chip surface was regenerated after every cycle using a double injection of 60 sec 10 mM Glycine-HCl pH 2.1. Bulk refractive index differences were corrected for by subtracting the response obtained on reference flow cell 1. For the interaction between the 4-1BB ligand trimer-containing Fc (kih) fusion antigen binding molecules and hu4-1BB avi His, the affinity constants were derived from the rate constants by fitting to a 1:1 Langmuir binding curve using the Biaeval software (GE Healthcare).









TABLE 34







Fittings to 1:1 Langmuir binding and Affinity constants











Ligand
Analyte
ka (1/Ms)
kd (1/s)
KD (M)














FAP split 4-1BBL
hu4-1BB
4.8E+04
2.6E-02
5.5E-07


trimer






(Construct 1.1)






DP47 split 4-1BBL
hu4-1BB
6.2E+04
3.3E-02
5.2E-07


trimer






(Control A)









Example 5
Functional Characterization of the Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

5.1. Binding on Naïve Versus Activated Human PMBCs of the FAP-Targeted 4-1BB Ligand Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecules


Buffy coats were obtained from the Zurich blood donation center. To isolate fresh peripheral blood mononuclear cells (PBMCs) the buffy coat was diluted with the same volume of DPBS (Gibco by Life Technologies, Cat. No. 14190 326). 50 mL polypropylene centrifuge tubes (TPP, Cat.-No. 91050) were supplied with 15 mL HISTOPAQUE® reagent 1077 (SIGMA Life Science, Cat.-No. 10771, polysucrose and sodium diatrizoate, adjusted to a density of 1.077 g/mL) and the diluted buffy coat solution was layered above the HISTOPAQUE® reagent 1077. The tubes were centrifuged for 30 min at 400× g. PBMCs were then collected from the interface, washed three times with DPBS and resuspended in T cell medium consisting of RPMI 1640 medium (Gibco by Life Technology, Cat. No. 42401-042) supplied with 10% Fetal Bovine Serum (FBS, Gibco by Life Technology, Cat. No. 16000-044, Lot 941273, gamma-irradiated, mycoplasma-free and heat inactivated at 56° C. for 35 min), 1% (v/v) GlutaMAX-I (GIBCO by Life Technologies, Cat. No. 35050 038), 1 mM Sodium Pyruvate (SIGMA, Cat. No. S8636), 1% (v/v) MEM non-essential amino acids (SIGMA, Cat.-No. M7145) and 50 μM β-Mercaptoethanol (SIGMA, M3148).


PBMCs were used directly after isolation or stimulated to induce 4-1BB expression at the cell surface of T and NK cells by culturing for 4 days in T cell medium supplemented with 200 U/mL Proleukin (Novartis Pharma Schweiz AG, CHCLB-P-476-700-10340) and 2 μg/mL PHA-L (SIGMA Cat.-No. L2769) in a 6-well tissue culture plate and then 1 day in a 6-well tissue culture plate coated with 10 ug/mL anti-human CD3 (clone OKT3, BioLegend, Cat.-No. 317315) and 2 μg/mL anti-human CD28 (clone CD28.2, BioLegend, Cat.-No.: 302928) in T cell medium at 37° C. and 5% CO2.


To determine binding of 4-1BBL trimer-containing Fc fusion antigen binding molecules to human PBMCs, 0.1×106 naïve or activated PBMCs were added to each well of a round-bottom suspension cell 96-well plates (Greiner bio-one, cellstar, Cat. No. 650185). Plates were centrifuged 4 minutes with 400× g and at 4° C. Supernatant was discarded. Afterwards cells were stained in 100 μL/well DPBS containing 1:1000 diluted LIVE/DEAD® Fixable Blue Dead Cell Stain Kit, for UV excitation (Life Technologies, Molecular Probes, L-23105) or Fixable Viability Dye eF660 (eBioscience 65-0864-18) or LIVE/DEAD® Fixable Green Dead Cell Stain Kit (Life Technologies, Molecular Probes, L-23101) for 30 minutes at 4° C. in the dark. If DAPI was used as Live/Death stain, this staining step was skipped. Cells were washed once with 200 μL cold FACS buffer (DPBS supplied with 2% (v/v) FBS, 5 mM EDTA pH8 (Amresco, Cat. No. E177) and 7.5 mM sodium azide (Sigma-Aldrich S2002).


Next, 50 μL/well of 4° C. cold FACS buffer containing different titrated concentrations of 4-1BBL trimer-containing Fc fusion antigen binding molecules were added and cells were incubated for 120 minutes at 4° C., washed four times with 200 μL/well 4° C. FACS buffer and resuspended. Cells were further stained with 50 μL/well of 4° C. cold FACS buffer containing 0.67 μg/mL anti-human CD3-PerCP-Cy5.5 (clone UCHT1, mouse IgG1κ, BioLegend, Cat.-No. 300430) or 0.16 μl anti-human CD3-PE/Cy7 (clone SP34-2, mouse IgG1κ, BD Pharmingen, Cat.-No. 557749, Lot 33324597), 0.67 μg/mL anti-human CD45-AF488 (clone HI30, mouse IgG1κ, BioLegend, Cat.-No. 304017) or 0.12 μg/mL anti-human CD56-FITC (clone NCAM16.2, mouse IgG2bκ, BD Pharmingen, Cat.-No. 345811) or 1 μL anti-human CD56-APC (clone B159, mouse IgG1 κ, BD Pharmingen, Cat.-No. 555518, Lot 3098894), 0.25 μg/mL anti-human CD4-BV421 (clone RPA-T4, mouse IgG1κ, BioLegend, Cat.-No. 300532) or 0.23 μg/mL anti-human CD4-BV421 (clone OKT4, mouse IgG2bκ, BioLegend, Cat.-No. 317434), 0.25 μL anti-human CD8a-APC (clone RPA-T8, mouse IgG1κ, BD Pharmingen, Cat.-No. 555369) or 0.67 μL anti-human CD8a-APC/Cy7 (clone RPA-T8, mouse IgG1κ, BioLegend, Cat.-No. 301016) or 0.83 ng/mL anti-human CD8a-BV711 (clone RPA-T8, mouse IgG1κ, BD Pharmingen, Cat.-No. 301044) and 5 μg/mL PE-conjugated AffiniPure anti-human IgG Fcγ-fragment-specific goat IgG F(ab′)2 fragment (Jackson ImmunoResearch, Cat. No. 109 116 098 or 109 116 170). Cells were washed twice with FACS-buffer. If cells were stained with fixable viability dyes, they were fixed with 50 μL/well DPBS containing 1% formaldehyde (Sigma, HT501320-9.5L). Cells were resuspended in FACS buffer and acquired the next or the same day using a 5-laser LSR-FORTESSA® (BD Bioscience with DIVA software) or 3-laser Miltenyi Quant Analyzer 10 (Mitenyi Biotec) and Flow Jo (FlowJo X 10.0.7). If DAPI staining was used to detect dead cells, they were resuspended in 80 μL/well FACS buffer containing 0.2 μg/mL DAPI (Santa Cruz Biotec, Cat. No. Sc-3598) and acquired the same day using a 5-laser LSR-FORTESSA® (BD Bioscience with DIVA software).


As shown in FIGS. 6A-1 to 6C-2, both FAP-targeted or untargeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules did not bind to resting human CD4+ T cells and showed no detectable binding to resting CD8+ T cells and NK cells. In contrast, both constructs bound strongly to activated NK, CD8+ or CD4+ T cells, although the latter showed approximately 10 fold lower intensity of specific fluorescence as compared to the NK cells and 20 fold decreased intensity of specific fluorescence as compared to CD8+ T cells.



FIGS. 7A-1 to 7A-4 and 7B-1 to 7B-4 show the binding of Constructs 1.1 to 1.10 as prepared in Example 1 on 4-1BB-expressing activated human CD3+ CD8+ T cells and 4-1BB-expressing activated human CD3+CD4+ T cells, respectively. Table 35 shows the EC50 values as measured for Constructs 1.1 to 1.10.









TABLE 35







Binding on activated human CD3+CD8+ T cells and CD3+ CD4












EC50[nM]
EC50[nM]



Construct
4-1BB+CD8+
4-1BB+CD4+















Control B
0.11
16.21



1.1
0.43
4.99



1.2
0.18
20.79



1.3
0.07
2.82



1.4
0.19
0.34



1.5
0.17
2.67



1.6
0.19
0.95



1.7
0.26
16.47



1.8
0.14
2.77



1.9
0.18
12.92



1.10
0.12
0.3











FIGS. 8A-1 to 8A-4 and 8B-1 to 8B-4 show the binding of Constructs 2.1, 2.3, 2.4, 2.5 and 2.6 as prepared in Example 2 on CD4+ and CD8+ from fresh human blood and on activated 4-1BB-expressing CD4+ T cells and CD8+ T cells, respectively. Gates were set on living CD45+CD3+CD4+ or CD45+CD3+CD8+ T cells and MFI of PE-conjugated AffiniPure anti-human IgG IgG Fcγ-fragment-specific goat F(ab′)2 fragment were blotted against the titrated concentration of targeted split trimeric 4-1BB ligand Fc fusion variants. Table 36 shows the EC50 values as measured for Constructs 2.1, 2.3, 2.4, 2.5 and 2.6.









TABLE 36







Binding on activated 4-1BB-expressing CD4+ T cells and CD8+ T cells










EC50[nM]
EC50[nM]


Construct
4-1BB+CD8+
4-1BB+CD4+












Control B
0.36
0.42


Control C
0.39
0.41


Control E
0.57
0.76


2.1
0.21
0.24


2.3
0.44
0.3


2.4
0.3
0.38


2.5
0.35
0.68


2.6
0.33
0.24









5.2 Binding of FAP-Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecule to Activated Mouse Splenocytes


Mouse spleens were collected in 3 mL PBS and a single cell suspension was generated using gentle MACS tubes (Miltenyi Biotec Cat.-No. 130-096-334) and gentleMACS Octo Dissociator (Miltenyi Biotec). Afterwards splenocytes were filtered through a 30 μm Pre-Separation Filters (Miltenyi Biotec Cat.-No. 130-041-407) and centrifuged for 7 min at 350× g and 4° C. Supernatant was aspirated and cells were resuspended in RPMI 1640 medium supplied with 10% (v/v) FBS, 1% (v/v) GlutaMAX-I, 1 mM Sodium-Pyruvate, 1% (v/v) MEM non-essential amino acids, 50 μM β-Mercaptoethanol and 10% Penicillin-Streptomycin (SIGMA, Cat.-No. P4333). 106 cells/mL were cultured for 2 days in a 6-well tissue culture plate coated with 10 μg/mL anti-mouse CD3c Armenian Hamster IgG (clone 145-2C11, BioLegend, Cat.-No. 100331) and 2 μg/mL anti-mouse CD28 Syrian Hamster IgG (clone 37.51, BioLegend, Cat.-No. 102102).


Activated mouse splenocytes were harvested, washed in DPBS, counted and 0.1×106 cells were transferred to each well of a 96 U-bottom non-tissue culture treated well plate. Supernatant was removed and cells were stained in 100 uL/well DPBS containing 1:5000 diluted Fixable Viability Dye eF660 (Bioscience, Cat-No. 65-0864-18) for 30 min at 4° C. Cells were washed with PBS and stained in 50 uL FACS buffer containing different concentration of FAP-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules (FAP split 4-1BBL trimer), untargeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules (DP47 split 4-1BBL trimer) or anti-mouse CD137 human IgG1 P329G LALA mAb (clone Lob.12.3, BioXcell Catalog #: BE0169). Cells were incubated for 120 min at 4° C. Cells were washed four times with FACS buffer and stained in 50 FACS buffer containing 10 μg/mL purified anti-mouse CD16/CD32 rat IgG-Fc-Block (BD Pharmingen, Cat.-No. 553142 clone 2.4G2), 5 μg/mL anti-mouse CD8b rat IgG2bκ-FITC (BioLegend, Cat.-No. 126606, clone YTS156.7.7), 0.67 μg/mL anti-mouse CD3 rat IgG2bκ-APC-Cy7 (BioLegend, Cat.-No. 100222, clone 17A2), 0.67 μg/mL anti-mouse CD4 rat IgG2bκ-PE-Cy7 (BioLegend, Cat.-No. 100422, clone GK1.5), 2 μg/mL anti-mouse NK1.1 Mouse (C3H×BALB/c) IgG2aκ-PerCp-Cy5.5 (BioLegend, Cat.-No. 108728, clone PK136) and 10 μg/mL PE-conjugated AffiniPure polyclonal F(ab′)2 Fragment goat anti-human IgG, Fey fragment specific, minimal cross-reactive to bovine mouse and rabbit serum proteins (Jackson ImmunoResearch, Cat.-No. 109-116-170) for 30 min at 4° C. Cells were washed twice with 200 μL/well cold FACS buffer. Cells were fixed with 50 DPBS containing 1% formaldehyde. Cells were resuspended in FACS-buffer and acquired the next day using a 5-laser LSR-FORTESSA® (BD Bioscience with DIVA software).


As shown in FIGS. 9A and 9B, FAP-targeted hu4-1BB ligand trimer-containing Fc fusion antigen binding molecules (FAP split hu4-1BBL trimer) and untargeted hu4-1BB ligand trimer-containing Fc fusion antigen binding molecules (DP47 split hu4-1BBL trimer) do not bind to mouse 4-1BB. Therefore activity cannot be tested in immune competent mice. For in vivo mode of action studies either humanized mouse models in immune incompetent mice or surrogates containing mouse 4-1BBL trimers as shown in FIGS. 3A to 3C have to be used.


5.3 Binding to FAP-Expressing Tumor Cells


For binding assays on FAP expressing cells, the human melanoma cell line MV-3 (see Ruiter et al., Int. J. Cancer 1991, 48(1), 85-91), WM-266-4 (ATTC CRL-1676) or NIH/3T3-huFAP clone 39 cell line were used. To generate the latter cell line, NIH/3T3 cells were transfected with human FAP (NIH/3T3-huFAP clone 39). The cells were generated by transfection of mouse embryonic fibroblast NIH/3T3 cells (ATCC CRL-1658) with the expression pETR4921 plasmid encoding human FAP under a CMV promoter. Cells were maintained in the presence of 1.5 μg/mL puromycin (InvivoGen, Cat.-No.: ant-pr-5). 0.1×106 of FAP expressing tumor cells were added to each well of a round-bottom suspension cell 96-well plates (Greiner bio-one, cellstar, Cat.-No. 650185). Cells were washed once with 200 μL DPBS and pellets were resuspended. 100 μL/well of 4° C. cold DPBS buffer containing 1:5000 diluted Fixable Viability Dye EFLUOR® 450 (eBioscience, Cat.-No. 65-0863-18) or Fixable Viability Dye EFLUOR® 660 (eBioscience, Cat.-No. 65-0864-18) were added and plates were incubated for 30 minutes at 4° C. Cells were washed once with 200 μL 4° C. cold DPBS buffer and resuspended in 50 μL/well of 4° C. cold FACS buffer (DPBS supplied with 2% (v/v) FBS, 5 mM EDTA pH 8 (Amresco, Cat.-No. E177) and 7.5 mM Sodium azide (Sigma-Aldrich 52002) containing different concentrations of titrated 4-1BBL trimer-containing Fc fusion antigen binding molecules, followed by incubation for 1 hour at 4° C. After washing four times with with 200 μL/well, cells were stained with 50 μL/well of 4° C. cold FACS buffer containing 30 μg/mL FITC-conjugated AffiniPure anti-human IgG Fcγ-fragment-specific goat F(ab′) 2 fragment (Jackson ImmunoResearch, Cat.-No. 109-096-098) or 5 μg/mL PE-conjugated AffiniPure anti-human IgG Fgγ-fragment-specific goat F(ab′)2 fragment (Jackson ImmunoResearch, Cat. No. 109-116-098 or 109-116-170) for 30 minutes at 4° C. Cells were washed twice with 200 μL 4° C. FACS buffer and then resuspended in 50 μL/well DPBS containing 1% formaldehyde. The same or the next day cells were resuspended in 100 μL FACS-buffer and acquired using 5-laser LSR-FORTESSA® (BD Bioscience with DIVA software) or 3-laser Miltenyi Quant Analyzer 10 (Mitenyi Biotec) and Flow Jo (FlowJo X 10.0.7).


As shown in FIGS. 10A and 10B, the FAP-targeted 4-1BB ligand trimer-containing Fc(kih) fusion antigen binding molecule (FAP split 4-1BBL trimer) Construct 1.1, but not the untargeted, DP47-Fab-containing construct (DP47 split 4-1BBL trimer) Control A, efficiently bound to human fibroblast activation protein (FAP)-expressing melanoma (10A) MV-3 cells or (10B) WM-266-4 cells.



FIGS. 11A-1 to 11A-4 shows the binding of Constructs 1.1 to 1.10 as prepared in Example 1 to human-FAP expressing human melanoma MV-3 cells and in FIGS. 11B-1 and 11B-2 the binding of Construct 1.1, 1.2, 1.3 and 1.5 to human FAP expressing NIH/3T3-huFAP clone 39 transfected mouse embryonic fibroblast cells is presented. Table 37 shows the EC50 values as measured for Constructs 1.1 to 1.10.









TABLE 37







Binding to human FAP-expressing tumor cells










EC50[nM]
EC50[nM]


Construct
FAP+MV-3
NIH/3T3-hu FAP












1.1
4.14
12.2


1.2
5.36
9.35


1.3

14.97


1.4
5.13



1.5
0.53
10.06


1.6
8.16



1.7
4.09



1.8
2.79



1.9
4.22



1.10
4.31











FIGS. 12A-1 to 12B-2 shows the binding of different FAP (4B9)-targeted or untargeted split trimeric human 4-1BB ligand Fc (kih) constructs to human-FAP expressing human melanoma MV-3 cells (FIGS. 12A-1 and 12A-2) and WM-266-4 cells (FIGS. 12B-1 and 12B-2). The constructs 2.1, 2.3, 2.4, 2.5 and 2.6 were prepared as described in Example 2 and Controls were prepared as described herein before. Gates were set on living tumor cells and MFI of PE-conjugated AffiniPure anti-human IgG Fcγ-fragment-specific goat F(ab′) 2 fragment were blotted against the titrated concentration of targeted split trimeric 4-1BB ligand Fc fusion constructs. Table 38 shows the EC50 values as measured.









TABLE 38







Binding to human FAP-expressing tumor cells










EC50[nM]
EC50[nM]


Construct
FAP+ MV-3
FAP+ WM-266-4












2.1
1.66
0.99


2.3
0.53
0.42


2.4
0.83
0.59


2.5
1.66
1.2









5.4 Functional Characterization of the Murine Targeted 4-1BB Ligand Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecules


5.4.1 Binding to Activated Mouse Splenocytes


Mouse spleens were collected in 3 mL PBS and a single cell suspension was generated using gentle MACS tubes (Miltenyi Biotec Cat.-No. 130-096-334) and gentleMACS Octo Dissociator (Miltenyi Biotec). Afterwards splenocytes were filtered through 30 μm Pre-Separation Filters (Miltenyi Biotec Cat.-No. 130-041-407) and centrifuged for 7 min at 350× g and 4° C. Supernatant was aspirated and cells were resuspended in RPMI 1640 medium supplied with 10% (v/v) FBS, 1% (v/v) GlutaMAX-I, 1 mM Sodium-Pyruvate, 1% (v/v) MEM non-essential amino acids, 50 μM β-Mercaptoethanol.


For binding on fresh mouse splenocytes cells were used directly. To induce mouse 4-1BB expression on T cells, mouse splenocytes were activated as following: 106 cells/mL were cultured for 2 days in a 6-well tissue culture plate coated with 10 μg/mL anti-mouse CD3c Armenian Hamster IgG (clone 145-2C11, BioLegend, Cat.-No. 100331) and 2 μg/mL anti-mouse CD28 Syrian Hamster IgG (clone 37.51, BioLegend, Cat.-No. 102102).


Fresh mouse splenocytes or activated mouse splenocytes were collected, washed in DPBS (Gibco life technologies, Cat.-No. 14190-136), counted and 0.1×106 cells were transferred to each well of a 96 U-bottom non-tissue culture treated well plate (Greiner bio-one, cell star, Cat.-No. 650185). Supernatant was removed and cells were stained in 100 uL/well 4° C. cold DPBS containing 1:1000 diluted LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit (Life Technologies, L34957) for 30 min at 4° C. Cells were washed with cold DPBS and stained in 50 uL/well cold FACS buffer (DPBS supplied with 2% (v/v) FBS, 5 mM EDTA pH8 (Amresco, Cat. No. E177) and 7.5 mM Sodium azide (Sigma-Aldrich S2002)) containing different concentration of mouse 4-1BB ligand trimer-containing Fc(kih) fusion molecules or mouse IgG1 Isotype control (BioLegend, Cat.-No. 400153, clone MOPC-21). Cells were incubated for 120 min at 4° C., washed four times with cold DPBS and stained in 50 μL/well cold FACS buffer containing 30 μg/mL FITC-conjugated anti-mouse IgG Fc-gamma-specific goat IgG F(ab′)2 (Jackson Immunoresearch, Cat.-No. 115-096-071) for 30 min at 4° C. Afterwards cells were washed twice with cold DPBS and stained with 50 μL/well FACS buffer supplied with 10 μg/mL purified anti-mouse CD16/CD32 rat IgG-Fc-Block (BD Pharmingen, Cat.-No. 553142 clone 2.4G2), 0.67 μg/mL anti-mouse CD8a-APC-Cy7 (BioLegend, Cat.-No. 100714, clone 53-6.7), 0.67 μg/mL anti-mouse CD3c-PerCP-Cy5.5 (BioLegend, Cat.-No. 100328, clone 145-2C11), 0.67 μg/mL anti-mouse CD4 rat IgG2bκ-PE-Cy7 (BioLegend, Cat.-No. 100422, clone GK1.5) for 30 min at 4° C. Cells were washed twice with 200 μL/well cold DPBS, fixed with 50 μL/well DPBS containing 1% Formaldehyde and resuspended in FACS-buffer. Cells were acquired using 3-laser MACSQuant Analyzer 10 (Miltenyi Biotech) and Flow Jo v10.0.7 (FlowJo LLC). Gates were set on CD3+ CD8+ or CD3+ CD4+ T cells and the median florescence intensity (MFI) of FITC-conjugated anti-mouse IgG Fc-gamma-specific goat IgG F(ab′)2 was analyzed and normalized by the subtraction of the MFI of the blank control (no addition of mouse 4-1BB ligand trimer-containing Fc(kih) fusion molecule). The MFI was blotted against the concentration of used mouse 4-1BB ligand trimer-containing Fc(kih) fusion molecules to display the binding to mouse 4-1BB cell-bound molecule.


As can be seen in FIGS. 13A-1 to 13B-2, the murine 4-1BBL Constructs M.1 and M.2 as well as corresponding control molecules Control M.1 and Control M.2 bind with a quite similar affinity to mouse 4-1BB. Table 39 shows the EC50 values as measured for Constructs M.1 and M.2 and the control molecules.









TABLE 39







Binding on activated 4-1BB-expressing


CD4+ T cells and CD8+ T cells










EC50[nM]
EC50[nM]


Construct
4-1BB+CD8+
4-1BB+CD4+












Control M.1
0.95
0.74


M.1
0.87
0.52


Control M.2
0.78
0.6


M.2
0.54
0.42









5.4.2 Binding on FAP-Expressing Tumor Cells


For binding assays on FAP expressing cells, the human melanoma cell line MV-3 (see Ruiter et al., Int. J. Cancer 1991, 48(1), 85-91) and WM-266-4 (ATTC CRL-1676) were used (anti-FAP specific clone 28H1 is mouse/human-crossreactive). 0.1×106 of FAP expressing tumor cells were added to each well of a round-bottom suspension cell 96-well plates (Greiner bio-one, cellstar, Cat.-No. 650185). Cells were washed once with 200 μL cold DPBS and pellets were resuspended in 100 μL/well of 4° C. cold DPBS buffer containing 1:1000 diluted LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit (Life Technologies, L34957) and incubated for 30 min at 4° C. Cells were washed once with 200 μL cold DPBS buffer and resuspended in 50 μL/well of cold FACS buffer (DPBS supplied with 2% (v/v) FBS, 5 mM EDTA pH8 (Amresco, Cat. No. E177) and 7.5 mM Sodium azide (Sigma-Aldrich S2002)) containing murine 4-1BB ligand trimer-containing Fc(kih) fusion molecules at a series of concentrations followed by incubation for 1 hour at 4° C. After washing four times with 200 μL DPBS/well, cells were stained with 50 μL/well of 4° C. cold FACS buffer containing 30 μg/mL FITC-conjugated anti-mouse IgG Fc-gamma-specific goat IgG F(ab′)2 (Jackson Immunoresearch, Cat.-No. 115-096-071) for 30 min at 4° C. Cells were washed twice with 200 μL/well cold DPBS buffer, fixed with 50 μL/well DPBS containing 1% Formaldehyde and resuspended in FACS-buffer. Cells were acquired using 3-laser MACSQuant Analyzer 10 (Miltenyi Biotech) and Flow Jo v10.0.7 (FlowJo LLC). Gates were set on living cells and the median florescence intensity (MFI) of FITC-conjugated anti-mouse IgG Fc-gamma-specific goat IgG F(ab′)2 was analyzed and normalized by the subtraction of the MFI of the blank control (no addition of mouse 4-1BB ligand trimer-containing Fc(kih) fusion molecule). The MFI was blotted against the concentration of used murine 4-1BB ligand trimer-containing Fc(kih) fusion molecules to display the binding to murine 4-1BB cell-bound molecule. As expected, the murine 4-1BBL constructs M.1 and M.2 bind with a quite similar affinity to FAP whereas the control molecules do not bind.



FIGS. 14 and 14B shows the binding of the FAP-targeted or untargeted split trimeric murine 4-1BB ligand Fc (kih) Constructs M.1 and M.2 to human-FAP expressing human melanoma MV-3 cells (FIG. 14A) and WM-266-4 cells (FIG. 14B). Table 40 shows the EC50 values as measured.









TABLE 40







Binding to human FAP-expressing tumor cells










EC50[nM]
EC50[nM]


Construct
FAP+ MV-3
FAP+ WM-266-4












M.1
7.26
5.14


M.2
6.9
5.63









Example 6
Biological Activity of the Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

6.1. NF-κB Activation in HeLa Cells Expressing Human 4-1BB


Generation of HeLa Cells Expressing Human 4-1BB and NF-κB-Luciferase


The cervix carcinoma cell line HeLa (ATCC CCL-2) was transduced with a plasmid based on the expression vector pETR10829, which contains the sequence of human 4-1BB (Uniprot accession Q07011) under control of a CMV-promoter and a puromycin resistance gene. Cells were cultured in DMEM medium supplemented with 10% (v/v) FBS, 1% (v/v) GlutaMAX-I and 3 μg/mL Puromycin.


4-1BB-transduced HeLa cells were tested for 4-1BB expression by flow cytometry: 0.2×106 living cells were resuspended in 100 μL FACS buffer containing 0.1 μs PerCP/Cy5.5 conjugated anti-human 4-1BB mouse IgG1K clone 4B4-1 (BioLegend Cat.-No. 309814) or its isotype control (PerCP/Cy5.5 conjugated mouse IgG1K isotype control antibody clone MOPC-21, BioLegend Cat.-No. 400150) and incubated for 30 minutes at 4° C. Cells were washed twice with FACS buffer, resuspended in 300 μL FACS buffer containing 0.06 μg DAPI (Santa Cruz Biotec, Cat. No. Sc-3598) and acquired using a 5-laser LSR-FORTESSA® (BD Bioscience, DIVA software). Limited dilutions were performed to generate single clones as described: human-4-1BB-transduced HeLa cells were resuspended in medium to a density of 10, 5 and 2.5 cells/ml and 200 μl of cell suspensions were transferred to round bottom tissue-culture treated 96-well plates (6 plates/cell concentration, TPP Cat.-No. 92697). Single clones were harvested, expanded and tested for 4-1BB expression as described above. The clone with the highest expression of 4-1BB (clone 5) was chosen for subsequent transfection with the NF-κB-luciferase expression-vector 5495p Tranlucent HygB. The vector confers transfected cells both with resistance to Hygromycin B and capacity to express luciferase under control of NF-kB-response element (back bone vector Panomics, Cat.-No. LR0051 with introduced HyB resistence). Human-4-1BB HeLa clone 5 cells were cultured to 70% confluence. 50 μg (40 μL) linearized (restriction enzymes AseI and SalI) 5495p Tranlucent HygB expression vector were added to a sterile 0.4 cm Gene Pulser/MicroPulser Cuvette (Biorad, Cat.-No, 165-2081). 2.5×106 human-4-1BB HeLa clone 5 cells in 400 μl supplement-free DMEM medium were added and mixed carefully with the plasmid solution. Transfection of cells was performed using a Gene Pulser Xcell total system (Biorad, Cat-No. 165-2660) under the following settings: exponential pulse, capacitance 500 μF, voltage 160 V, resistance ∞. Immediately after the pulse transfected cells were transferred to a 75 cm2 tissue culture flask (TPP, Cat.-No. 90075) with 15 mL 37° C. warm DMEM medium supplied with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I. Next day, culture medium containing 3 μg/mL Puromycin and 200 μg/mL Hygromycin B (Roche, Cat.-No. 10843555001) was added. Surviving cells were expanded and limited dilution was performed as described above to generate single clones.


Clones were tested for 4-1BB expression as described above and for NF-κB-Luciferase activity as following: Clones were harvested in selection medium and counted using a Cell Counter Vi-cell xr 2.03 (Beckman Coulter, Cat.-No. 731050). Cells were set to a cell density of 0.33×106 cells/mL and 150 μL of this cell suspension were transferred to each well of a sterile white 96-well flat bottom tissue culture plate with lid (greiner bio-one, Cat.-No. 655083) and—as a control—to normal 96-well flat bottom tissue culture plate (TPP Cat.-No. 92096) to test survival and cell density the next day. Cells were incubated at 37° C. and 5% CO2 overnight. The next day 50 μL of medium containing different concentrations of recombinant human tumor necrosis factor alpha (rhTNF-α, PeproTech, Cat.-No. 300-01A) were added to each well of a 96-well plate resulting in final concentration of rhTNF-α of 100, 50, 25, 12.5, 6.25 and 0 ng/well. Cells were incubated for 6 hours at 37° C. and 5% CO2 and then washed three times with 200 μL/well DPBS. Reporter Lysis Buffer (Promega, Cat-No: E3971) was added to each well (40 μl) and the plates were stored over night at −20° C. The next day frozen cell plates and Detection Buffer (Luciferase 1000 Assay System, Promega, Cat.-No. E4550) were thawed to room temperature. 100 uL of detection buffer were added to each well and the plate was measured as fast as possible using a SpectraMax M5/M5e microplate reader and the SoftMax Pro Software (Molecular Devices). Measured units of released light for 500 ms/well (URLs) above control (no rhTNF-α added) were taken as luciferase activity. The NF-κB-luc-4-1BB-HeLa clone 26 exhibiting the highest luciferase activity and a considerable level of 4-1BB-expression and was chosen for further use.


NF-κB Activation in Hela Cells Expressing Human 4-1BB Co-Cultured with FAP-Expressing Tumor Cells


NF-κB-luciferase human-4-1BB HeLa cells were harvested and resuspended in DMEM medium supplied with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I to a concentration of 0.2×106 cells/ml. 100 μl (2×104 cells) of this cell suspension were transferred to each well of a sterile white 96-well flat bottom tissue culture plate with lid (greiner bio-one, Cat. No. 655083) and the plate were incubated at 37° C. and 5% CO2 overnight. The next day 50 μL of medium containing titrated concentrations of FAP-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules (FAP split 4-1BBL trimer) or DP47-untargeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules (DP47 split 4-1BBL trimer) were added. FAP-expressing tumor cells (MV3, WM-266-4 or NIH/3T3-huFAP clone 39) were resuspended in DMEM medium supplied with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I to a concentration of 2×106 cells/ml.


Suspension of FAP-expressing tumor cell (50 final ratio 1:5) or only medium were added to each well and plates were incubated for 6 hours at 37° C. and 5% CO2. Cells were washed two times with 200 μL/well DPBS. 40 μl freshly prepared Reporter Lysis Buffer (Promega, Cat-No: E3971) were added to each well and the plate were stored over night at −20° C. The next day frozen cell plate and Detection Buffer (Luciferase 1000 Assay System, Promega, Cat. No. E4550) were thawed at room temperature. 100 μL of detection buffer were added to each well and luciferase activity was measured as fast as possible using a SpectraMax M5/M5e microplate reader and a SoftMax Pro Software (Molecular Devices) counting light emission in URL (units of released light for 0.5s/well) or Victor3 1420 multilabel counter plate reader (Perkin Elmer) and the Perkin Elmer 2030 Manager Software counting light emission as counts per seconds (CPS) and blotted against the concentration of tested constructs.


FAP-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecule (FAP split 4-1BBL trimer) triggered activation of the NFκB signaling pathway in the reporter cell line in the presence of FAP-expressing tumor cells. In contrast, the untargeted variant of the same molecule failed to trigger such an effect at any of the tested concentrations (FIGS. 16A to 16C). This activity of targeted 4-1BBL was strictly dependent on the expression of FAP at the cell surface of tumor cells as no NF-kB activation could be detected upon culturing of the NF-kB reporter cell line with FAP-negative tumor cells even in the presence of FAP-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecule. The activities as measured for Constructs 1.1 to 1.10 are shown in FIGS. 17A-1 to 17C-4 and the data as measured for Constructs 2.1, 2.4 and 2.5 are presented in FIGS. 18A to 18F.


6.2. NFκB Activation in HEK T293 Cells Expressing Cynomolgus Monkey 4-1BB


Generation of HEK T293 Cells Expressing Cynomolgus Monkey 4-1BB and NFκB-Luciferase


For the production of viral-like particles (VLP) the Human Embryonic Kidney (HEK) T293/17 (ATCC CRL-11268) was transfected using Lipofectamine® LTX Reagent with PLUS™ Reagent (Life Technologies, Cat.-No. 15338100) with the vector pETR14372 encoding a NFκB-luciferase-IRIS-GFP reporter gene cassette (NFκB-luc-GFP) accordingly to the manufacture's protocol. 6 hours later DMEM supplied with 10% FBS medium replacement was performed and VLP were harvested 4 days later. Fresh HEK 293T cells were transduced at a confluency of 70-80% with the produced pETR14372-VLP and 4 μg/mL polybrene. Cells were cultured for 24 h and a medium exchange was performed. The transduced HEK T293/17 cells were harvested and a limited dilution of 1 cell/well was performed to screen for stable single clones. The single clones were stimulated with 25 ng/mL TNF-α (PeproTech Inc. Cat.-No. 300-01A) in the medium and were screened for a positive GFP signal over time using the Incuyte Zoom Fluorescence Microscope System (Essen Bioscience). After GFP signal recording cells were tested for luciferase activity using the NANO GLO® Luciferase Kit (Promega, N1120) accordingly to the manufacture's protocol. Luciferase activity was measured using Victor3 1420 multilabel counter plate reader (Perkin Elmer) and the Perkin Elmer 2030 Manager Software. Light emission was counted in counts per seconds (CPS) for 0.5 sec/well. The clone 61 showed the highest expression of GFP and Luciferase after TNF-α activation and was further used for the reporter cell line generation.


As described above, new VLP were produced using the vector pETR14879 encoding cynomolgus monkey 4-1BB and a puromycine resistance and the HEK 293T NFκB-fluc-GFP clone 61 cell line was transduced at a confluency of 70-80% with the produced pETR14879-VLP and 4 μg/mL polybrene. Cells were cultured for 24 h and a medium exchange was performed. Four days after transduction the cells were stained with PE-conjugated anti-human cynomolgus-crossreactive 4-1BB antibody (mouse IgG1κ, clone MOPC-21, BioLegend, Cat.-No. 309804) in DPBS containing 1% FBS, were sorted by FACS (ARIA, BD) and seeded with 5 cells/well in DMEM supplied with 10% FBS medium containing 1 μg/mL Puromycine (InvivoGen, Cat.-No. ant-pr). Growing clones were tested as described for GFP and Luciferase activity after TNF-α stimulation and for high cynomolgus monkey 4-1BB expression by flow cytometry. Double positive clones were chosen and tested for Luficerase activity in the presence of monovalent FAP-targeted Construct 2.1 or Control B and FAP-expressing MV-3 or WM-266-4 cells. HEK T293/17-NF-κB-luc-GFP-cy4-1BB expressing Clone 61-13 was chosen to be used for all further experiments.


NFκB Activation of HEK T293/17 Reporter Cells Expressing Cynomolgus Monkey 4-1BB Co-Cultured with FAP-Expressing Tumor Cells


HEK T293/17-NFκB-luc-GFP-cy4-1BB expressing Clone 61-13 cells were harvested and resuspended in DMEM medium supplied with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I to a concentration of 0.2×106 cells/mL. 100 μl (2×104 cells) of this cell suspension were transferred to each well of a sterile white 96-well flat bottom tissue culture plate with lid (greiner bio-one, Cat. No. 655083) and the plate were incubated at 37° C. and 5% CO2 overnight. The next day 50 μL of medium containing different titrated concentrations of FAP-targeted or untargeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules were added. FAP-expressing tumor cells (MV3 and WM-266-4) were resuspended in medium to a concentration of 2×106 cells/ml. Suspension of FAP-expressing tumor cell (50 μl) was added to each well and plates were incubated for 6 hours at 37° C. and 5% CO2. The principle of the assay is shown in FIGS. 19A and 19B. After incubation cells were washed three times with 200 μL/well DPBS. 40 μfreshly prepared Reporter Lysis Buffer (Promega, Cat-No: E3971) were added to each well and plates were stored over night at −20° C. The next day frozen cell plates and detection buffer (Luciferase 1000 Assay System, Promega, Cat. No. E4550) were thawed to room temperature. 100 μL of detection buffer were added to each well and luciferase activity was measured as fast as possible using SpectraMax M5/M5e (Molecular Devices) microplate reader (500 ms integration time, no filter collecting all wavelength). Light emission was counted in units of released light (URL) for 0.5 sec/well and blotted against the concentration of tested FAP-targeted or untargeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules. The results for Constructs of Example 2 are shown in FIGS. 20A to 20F.


6.3 Antigen-Specific CD8+ T Cell-Based Assay


Isolation and Culture of Antigen-Specific CD8 T Cells


Fresh blood was obtained from a HLA-A2+ CMV-infected volunteer. PBMCs were isolated as described above. CD8 T cells were purified from PBMCs using a negative selection human CD8 T cell isolation Kit according to manufacturer's recommendations (Miltenyi Biotec, Cat. No. 130-094-156). Ten million of isolated CD8 T cells were resuspended in 1 mL sterile DPBS supplemented with 1% (v/v) FBS along with 50 μL of PE-labeled HLA-A2-pentamer containing the CMV-derived NLVPMVATV peptide (SEQ ID NO: 377) (ProImmune, Cat. No. F008-2B) and incubated for 10 min at room temperature. Cells were washed twice with 3 mL sterile DPBS supplied with 1% (v/v) FBS. Cells were resuspended in 1 mL cells DPBS supplied with 1% (v/v) FBS containing 1 μg/mL anti-human CD8-FITC (clone LT8, Abcam, Cat. No. Ab28010) and incubated for 30 minutes at 4° C. Cells were washed twice, resuspended to a concentration of 5×106 cells/mL in DPBS supplied with 1% (v/v) FBS, and filtrated through a 30 μm pre-separation nylon-net cell strainer (Miltenyi Biotec, Cat. No. 130-041-407). NLV-peptide-specific CD8+ T cells were isolated by FACS sorting using an ARIA cell sorter (BD Bioscience with DIVA software) with the following settings: 100 μm nozzle and purity sort mask. Sorted cells were collected in a 15 ml polypropylene centrifuge tube (TPP, Cat. No. 91015) containing 5 ml RPMI 1640 medium supplied with 10% (v/v) FBS, 1% (v/v) GlutaMAX-I and 400 U/mL Proleukin. Sorted cells were centrifuged for 7 minutes at 350× g at room temperature and resuspended in same medium to a concentration of 0.53×106 cells/mL. 100 μL/well of this cell suspension were added to each well of a previously prepared feeder plate.


PHA-L-activated irradiated allogeneic feeder cells were prepared from PBMCs as previously described (Levitsky et al., 1998) and distributed to 96 well culture plates at 2×105 feeder cells per well.


After one day of culturing 100 μL medium/well were removed from well containing sorted CD8+ T-cells and replaced by new RPMI 1640 medium supplemented with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I and 400 U/mL Proleukin, this was repeated during culture on a regular basis (every 2-4 days). As soon as cells start to proliferate, they were transferred to 24-well flat-bottom tissue culture plate (TPP, 92024). Cells were expanded/split and reactivated with new feeder cell preparation on a regular basis.


Activation Assay of Antigen-Specific CD8+ T Cells


MV3 cells were harvested and washed with DPBS and 2×107 cells were resuspended in 250 μL C diluent of the PKH-26 Red Fluorescence Cell linker Kit (Sigma, Cat.-No. PKH26GL). 1 μL PKH26-Red-stain solution was diluted with 250 μL C diluent and added to the suspension of MV3 cells which were then incubated for 5 min at room temperature in the dark. This was followed by addition of 0.5 mL FBS and cells were incubated for 1 minute and washed once with T cell medium consisting of RPMI 1640 medium supplemented with 10% (v/v) FBS, 1% (v/v) GlutaMAX-I, 1 mM Sodium-Pyruvate, 1% (v/v) MEM non-essential amino acids and 50 μM β-Mercaptoethanol. 1×106 MV3 cells/mL were resuspended in T cell medium and separated into three tubes. Synthetic NLVPMVATV peptide (SEQ ID NO: 377) (obtained from thinkpeptides) was added to a final concentration of 1×10−9 M or 1×10−8M and cells were incubated for 90 min. MV3 cells were washed once with T cell medium and resuspended to a density of 0.5×106 cells/mL, distributed (100 μL/well) to a 96-well round bottom cell-suspension plate (Greiner bio-one, cellstar, Cat.-No. 650185) and incubated over night at 37° C. and 5% CO2. The principle of the assay is shown in FIGS. 21A and 21B.


The next day, 50 μL/well T cell medium containing different titrated concentrations of targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules were added. NLV-specific CD8 T cells were harvested, CFDA-SE (5(6)-Carboxyfluoresceindiacetate-N-succinimidylester, SIGMA-Aldrich, Cat.-No. 21888-25MG-F) was added to a final concentration of 40 nM and cells were incubated under rotation for 15 min at 37° C. Labeling was stopped by adding FBS, cells were washed and resuspended in T cell medium to a final concentration of 0.125×106 cells/mL. 50 μL of this CFSE-labeled CD8 T cell suspension were added to each well (final E:T ratio=1:8). Cell plates were incubated for 24 h, 50 μL/well were removed and 50 μL T cell medium containing 2.64 μL/mL Golgi stop (Protein Transport Inhibitor containing Monesin, BD Bioscience, Cat.-No. 554724) were added to each well (final concentration 0.66 μL/mL). Cells were incubated for 4 h and then plates were washed with 200 μL/well DPBS and stained with 100 μL/well 4° C. DPBS containing 1:5000 diluted Fixable Viability Dye-eF450 (eBioscience, Cat.-No. 65-0864) for 30 minutes at 4° C. Cell plates were washed with 200 μL/well DPBS followed by staining with fluorescent dye-conjugated antibodies: anti-human CD137-PerCP/Cy5.5 (clone 4B4-1, mouse IgG1κ, BioLegend, Cat.-No. 309814), anti-human CD8-BV605 (clone RPA-T8, mouse IgG1κ, BioLegend, Cat.-No. 301012) or 0.67 μg/mL anti-human CD8a-APC/Cy7 (clone RPA-T8, mouse IgG1κ, BioLegend, Cat.-No. 301016) and anti-human CD25 PE/Cy7 (clone BC96, mouse IgG1κ, BioLegend, Cat.-No. 302612). After incubation for 30 min at 4° C., cells were washed twice with 200 μL/well FACS buffer, resuspended in 50 μL/well freshly prepared FoxP3 Fix/Perm buffer (eBioscience Cat.-No. 00-5123 and 00-5223) and incubated for 30 min at 4° C. Plates were washed twice with 200 μL/well Perm-Buffer (DPBS supplied with 2% (v/v) FBS, 1% (w/v) saponin (Sigma Life Science, 57900) and 1% (w/v) sodium azide (Sigma-Aldrich, 52002) and stained with 50 μL/well Perm-Buffer (eBioscience, Cat.-No. 00-8333-56) containing 0.25 μg/mL anti-human IFNγ-APC (clone B27, mouse IgG1κ, BioLegend, Cat.-No. 506510) or 0.33 μg/mL anti-human IFNγ-BV510 (clone 4S.B3, mouse IgG1κ, BioLegend, Cat.-No. 502543). Plates were incubated for 1 h at 4° C. and washed twice with 200 μL/well Perm-Buffer. For fixation, 50 μL/well DPBS containing 1% formaldehyde were added. The same or the next day, cells were resuspended in 100 μL/well FACS buffer and acquired using a 5-laser FORTESSA® flow cytometer (BD Bioscience with DIVA software) or 3-laser Miltenyi Quant Analyzer 10 (Miltenyi Biotec) and Flow Jo (FlowJo X 10.0.7).


As shown in FIGS. 22A-1 to 22E-3 and FIGS. 23A-1 to 23E-3 for Constructs 1.1 to 1.10 and in FIGS. 24A-1 to 24B-3 and 25A-1 to 25B-3 for Constructs 2.1, 2.3 and 2.4, antigen-specific CD8+ T cells, but not unstimulated controls, exhibited increased levels of surface 4-1BB expression in the presence of FAP-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecule (FAP split 4-1BBL trimer). This effect of 4-1BBL was dose dependent and required FAP-targeting as addition of the untargeted control molecule did not affect the level of 4-1BB expression. Furthermore, T-cells activated at the higher peptide concentration (1×10−8M) showed sustained secretion of INFγ in the presence of FAP-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecule (FAP split 4-1BBL trimer). Collectively, these data demonstrate that the antigen-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecule modulates the surface phenotype and responsiveness of antigen specific T-cells in a targeting dependent manner.


6.4 Comparison of Cell-Targeted and Untargeted Mouse 4-1BBL Fc Fusion Antigen Binding Molecules


Targeted and untargeted mouse 4-1BB ligand trimer-containing Fc fusion antigen binding molecules (FAP split mouse 4-1BBL trimer and DP47 split mouse 4-1BBL trimer) were prepared as described in Example 1.3.


To compare the bioactivity of cell-targeted and untargeted mouse 4-1BB ligand trimer-containing Fc fusion antigen binding molecules, Proliferation Dye EFLUOR® 670-labeled (eBioscience, Cat.-No. 65-0840-90) or CellTrace Violet Cell Proliferation dye-labeled (Cell tracer, Cat.-No. C34557) fresh mouse splenocytes were cocultured for 3-4 days in 96 well tissue culture U-bottom plates (TTP, Cat.-No. 92097) with adherent 50 Gy irradiated NIH/3T3-huFAP clone 39 cells (generation see 5.3) in RPMI 1640 medium (Gibco, Cat.-No. 42401-042) supplied with 10% (v/v) FBS, 1% (v/v) GlutaMAX-I, 1 mM Sodium-Pyruvate, 1% (v/v) MEM non-essential amino acids and 50 μM β-Mercaptoethanolin the presence of 0.5 μg/mL anti-mouse CD3 Syrian hamster IgG (clone 145-2C11, BD, Cat.-No. 553057) and the indicated drug candidate molecule added at a range of concentrations (FIGS. 26A and 26B). After three or four days, cells were washed with FACS buffer and stained for 30 min at 4° C. in 25 uL FACS buffer/well containing anti-mouse CD8 ratIgG2a-BV711 (BioLegend, Cat.-No. 100747, clone 53-6.7) and anti-mouse CD4 ratIgG2a-BV421 (BioLegend, Cat.-No. 100544, clone RM4-5) and 0.67 μg/mL anti-mouse CD137 (4-1BB) Syrian hamster IgG-PE (BioLegend, Cat.-No. 106106, clone 17B5) and anti-mouse CD25-PErCP-Cy5.5 ratIgG2b (BioLegend, Cat.-No. 1019112). Cells were washed and incubated for 1 h at room temperature in prepared Fix/Perm Buffer (Foxp3/Transcription Factor Staining Buffer Set, eBioscience, Cat.-Ni. 00-5523-00). Cells were washed twice with freshly prepared Perm buffer and co-stained with 25 μL/well Perm-buffer containing fluorescently-labeled antibodies against the cytotoxic lineage transcription factor Eomes, i.e. anti-mouse Eomes ratIgG2a-ALEXA FLUOR® 488 (eBioscience, Cat.-No. 534875, clone Dan11mag) and—if CD137 was not stained—against the cytotoxic effector molecule granzyme B, i.e. anti-mouse ratIgG2a granzyme B-PE (eBioscience, Cat.-No. 128822, clone 16G6) for 1 h at room temperature. Cells were then washed twice, resuspended in FACS buffer and acquired using laser FORTESSA® flow cytometer (BD Bioscience with DIVA software) or the 3-laser MACSQuant Analyzer 10 (Miltenyi Biotech) and Flow Jo v10.0.7 (FlowJo LLC). Gates were set on living CD8+ T cells and CD4+ T cells and the frequency of proliferating cells was determined as well as the expression levels of CD25, Eomes and granzyme B or CD137. The proliferation frequency and frequencys and MFIs of activation markers were blotted against the concentration of used mouse 4-1BB ligand trimer-containing Fc(kih) fusion molecules to display the functional activity. As can be seen in FIG. 27, an increase in proliferating CD8+ T cells could be observed for Constructs M.1 and M.2.


6.5 Liver Changes in Mice Treated with Anti-Murine 4-1BB Antibody Lob 12.3 (muIgG1 Wt) or with Construct M.2


C57BL/6 mice bearing MC38-muFAP (murine colorectal cancer model) s.c. were treated once per week for 3 weeks with agonistic anti-murine 4-1BB antibodies targeted to FAP (Efficacy Study 020-GA1401: “Experiment to show efficacy of 4-1BB targeted therapy in combination with a-PD-L1 in MC38-muFAP s.c. model in C57B6 mice.”). Antibodies used were Lob 12.3 muIgG1 Wt (with “wildtype” Fc, clone Lob 12.3 from BioXcell Catalog #: BE0169) or Construct M.2 with DAPG mutation (inactive Fc). The two antibodies were administered once weekly for three consecutive weeks. Four animals/group were sacrificed 7 days after last treatment and livers examined microscopically.


Liver changes were observed only in animals receiving Lob 12.3 muIgG1 Wt, consisting in foci of hepatocellular degeneration with accumulation of F4/80 positive macrophages and a lower amount of mixed population of inflammatory cells (mainly lymphocytes) frequently showing a vasocentric distribution. Occasionally single cell necrosis of hepatocytes, and perivascular mononuclear cell infiltrates in portal spaces were noted. No treatment related findings were observed in the liver of animals receiving Construct M.2 (Table 41).









TABLE 41







Incidence of Histopathogical Findings (n=4/group)












Lob 12.3
Construct


Treatment
Vehicle
muIgG1 Wt
M.2













Foci of hepatocellular degeneration with

4



macrophages and inflammatory cells





Perivascular inflammatory cells infiltrates

4



Single cell necrosis

4










Hepatitis, attributed to crosslinking by FcγRs in the liver, has been observed in patients treated with Urelumab BMS-663513 (Ascierto P. A. et al. 2010) and in mouse using the mouse surrogate. The absence of liver findings in animals treated with an antibody with inactive Fc support this hypothesis.


6.6 Determination of Pharmacokinetic Parameters of Human 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules


In order to test if the human 4-1BB ligand trimer-containing Fc fusion antigen binding molecules of the invention are suitable for pharmaceutical use, the pharmacokinetic parameters (PK data) such as clearance, volume of distribution or elimination half-time (t1/2) in mice were determined. Thus, the following experiments were carried out:


Experiment A: Single Dose PK of Construct 1.2 and Control B in Healthy NOG Mice


NOG female mice at an average age of 8 to 10 weeks at start of experiment (purchased from Taconic, SOPF facility) were maintained under specific-pathogen-free condition with daily cycles of 12 h light/12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). Experimental study protocol was reviewed and approved by local government (P 2011128). After arrival animals were maintained for one week to get accustomed to new environment and for observation. Continuous health monitoring was carried out on regular basis.


A single dose pharmacokinetic study (SDPK) was performed to evaluate exposure of Construct 1.2 and Control B. An i.v. bolus administration of 2.5 mg/kg was administered to NOG mice and blood samples were taken at selected time points for pharmacokinetic evaluation. Mouse serum samples were analyzed by ELISA. Biotinylated human 4-1BB, test samples, Digoxygenin labelled anti-huCH1 antibody and anti-Digoxygenin detection antibody (POD) were added stepwise to a 96-well streptavidin-coated microtiter plate and incubated after every step for 1 h at room temperature. The plate was washed three times after each step to remove unbound substances. Finally, the peroxidase-bound complex was visualized by adding ABTS substrate solution to form a colored reaction product. The reaction product intensity which was photometrically determined at 405 nm (with reference wavelength at 490 nm) is proportional to the analyte concentration in the serum sample. The calibration range of the standard curve for the constructs was 0.156 to 10 ng/ml, where 3 ng/ml is the lower limit of quantification (LLOQ). FIG. 28A shows the decrease in concentration over the time as observed in this experiment.


Experiment B: Single Dose PK of Constructs 2.1, 2.3, Control B and Control C in Tumor Bearing NOG Mice Humaniced with Stem Cells


A single dose pharmacokinetic study (SDPK) was performed to evaluate exposure of Construct 2.1, 2.3, Control B and Control C. NSG female mice transferred with human stem cells were delivered by Jackson Laboratories. Mice were maintained under specific-pathogen-free condition with daily cycles of 12 h light/12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). Experimental study protocol was reviewed and approved by local government (ZH193-2014). After arrival animals were maintained for one week to get accustomed to new environment and for observation. Continuous health monitoring was carried out on regular basis.


Human MKN45 cells (human gastric carcinoma) were originally obtained from ATCC and after expansion deposited in the Glycart internal cell bank. Cells were cultured in DMEM containing 10% FCS. Cells were cultured at 37° C. in a water-saturated atmosphere at 5% CO2. In vitro passage 9 was used for subcutaneous injection, at a viability of 97%. Human fibroblasts NIH-3T3 were engineered at Roche Nutley to express human FAP. Clone 39 was used at an in vitro passage number 12 and at a viability of 98%. 50 microliters cell suspension (1×106 MKN45 cells+1×106 3T3-huFAP) mixed with 50 microliters Matrigel were injected subcutaneously in the flank of anaesthetized mice. An i.v. bolus administration of 10 mg/kg was administered to humaniced mice when tumor reached an average size of 190 mm3. Blood samples were taken at selected time points for pharmacokinetic evaluation. Mouse serum samples were analyzed by ELISA. Biotinylated human 4-1BB, test samples, Digoxygenin labelled anti-huCH1 antibody and anti-Digoxygenin detection antibody (POD) were added stepwise to a 96-well streptavidin-coated microtiter plate and incubated after every step for 1 h at room temperature. The plate was washed three times after each step to remove unbound substances. Finally, the peroxidase-bound complex is visualized by adding ABTS substrate solution to form a colored reaction product. The reaction product intensity which was photometrically determined at 405 nm (with reference wavelength at 490 nm) is proportional to the analyte concentration in the serum sample. The calibration range of the standard curve for the constructs was 0.156 to 10 ng/ml, where 3 ng/ml is the lower limit of quantification (LLOQ). FIG. 28B shows the decrease in concentration of the constructs over the time as observed in this experiment.


Experiment C: Single Dose PK of Construct 2.1 and 2.3 in Healthy NOG Mice


NOG female mice at an average ager of 8-10 weeks at start of experiment (purchased from Taconic, SOPF facility) were maintained under specific-pathogen-free condition with daily cycles of 12 h light/12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). Experimental study protocol was reviewed and approved by local government (P 2011128). After arrival animals were maintained for one week to get accustomed to new environment and for observation. Continuous health monitoring was carried out on regular basis.


A single dose pharmacokinetic study (SDPK) was performed to evaluate exposure of Construct 2.1 and 2.3. An i.v. bolus administration of 2.5 mg/kg was administered to NOG mice and blood samples were taken at selected time points for pharmacokinetic evaluation. Mouse serum samples were analyzed by ELISA. Biotinylated human 4-1BB, test samples, Digoxygenin labelled anti-huCH1 antibody and anti-Digoxygenin detection antibody (POD) were added stepwise to a 96-well streptavidin-coated microtiter plate and incubated after every step for 1 h at room temperature. The plate is washed three times after each step to remove unbound substances. Finally, the peroxidase-bound complex is visualized by adding ABTS substrate solution to form a colored reaction product. The reaction product intensity, which is photometrically determined at 405 nm (with reference wavelength at 490 nm), is proportional to the analyte concentration in the serum sample. The calibration range of the standard curve for the constructs was 0.156 to 10 ng/ml, where 3 ng/ml is the lower limit of quantification (LLOQ). FIG. 28C shows the observed decrease in concentration over the time.


The tested constructs 2.1 and 2.3 are stable enough in the body and possess PK parameters in a suitable range for pharmaceutical development. It can also be concluded from the results that construct 2.1 is slightly more stable.


6.7 FAP Prevalence in Human Tumors


The prevalence of FAP in human tumors was evaluated as described in WO 2014/161845 to get an understanding on possible clinical use of FAP-targeted constructs.


Rat anti-human Seprase antibody (IgG2a, clone D8) from Vitatex (MABS1001) was used to immunostain 2,5 μm FFPET sections from various tumour indications on the Ventana Benchmark XT. Sections were subjected to standard CC1 treatment followed by antibody incubation for 60′ at 37° C. at a concentration of 5 μg/mL in Dako antibody diluent (S3022) and positive staining was detected using the Ultraview DAB detection system (Ventana #760-4456). Matched isotype antibody from Abcam (ab18450) was used as the negative control. FAP+ stromal infiltrate was present in human tumors of different indications including head and neck squamous cell carcinoma (HNSCC), breast cancer, colorectal cancer (CRC), pancreatic cancer (PAC), gastric cancer, non-small-cell lung carcinoma (NSCLC) and Mesothelioma marking potentially interesting clinical indications for a FAP-targeted constructs (Table 42).









TABLE 42







FAP prevalence in human tumors










% cases with moderate




to high grade of FAP
No. of samples


Tumor Type
infiltrate
investigated












HNSCC
90
10


Breast Cancer
77
105


triple negative BC
80
7


CRC
77
90


PAC
74
19


Gastric Cancer
68
28


NSCLC
66
90


Mesothelioma
60
10









Example 7

7.1 Preparation of CD19 (8B8-018) Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules


7.1.1 Preparation, Purification and Characterization of CD19 Antigen Fc Fusion for Phage Display Campaign


In order to express and purify the human and cynomolgus CD19 ectodomain in a monomeric state (human CD19 see SEQ ID NO:31), the respective DNA fragment was fused to a human IgG1 Fc gene segment containing the “knob” mutations (human: SEQ ID NO: 186; cynomolgus: SEQ ID NO: 188) and was transfected with an “Fc-hole” (SEQ ID NO: 86) counterpart (Merchant et al., 1998). An IgA cleavage site (PTPPTP; SEQ ID NO: 378) was introduced between an antigen ectodomain and the Fc knob chain. An Avi tag for directed biotinylation was introduced at the C-terminus of the antigen-Fc knob chain and mutations H435R and Y436F were introduced in the Fc hole for purification purposes (Jendeberg L. et al, J. Immunological methods, 1997). Combination of the antigen-Fc knob chain containing the S354C/T366W mutations (human: SEQ ID NO: 187; cynomolgus: SEQ ID NO: 189), with a Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations (SEQ ID NO: 90) allows generation of a heterodimeric Fc fusion fragment which includes a single copy of the CD19 ectodomain (in analogy to the 4-1BB construct in FIG. 5C). Table 43 lists the cDNA and amino acid sequences of the antigen Fc-fusion construct.









Table 43







cDNA and Amino acid sequences of monomeric


human and cynomolgus CD19 antigen


Fc(kih) fusion molecule









SEQ ID
Antigen
Sequence


NO:












86
Nucleotide
see Table 32



sequence




Fc hole chain






186
Nucleotide
CCCGAGGAACCCCTGGTCGTGAAGG



sequence
TGGAAGAGGGCGACAATGCCGTGCT



human CD19
GCAGTGCCTGAAGGGCACCTCCGAT



antigen Fc
GGCCCTACCCAGCAGCTGACCTGGT



knob chain
CCAGAGAGAGCCCCCTGAAGCCCTT



avi tag
CCTGAAGCTGTCTCTGGGCCTGCCT




GGCCTGGGCATCCATATGAGGCCTC




TGGCCATCTGGCTGTTCATCTTCAA




CGTGTCCCAGCAGATGGGCGGCTTC




TACCTGTGTCAGCCTGGCCCCCCAT




CTGAGAAGGCTTGGCAGCCTGGCTG




GACCGTGAACGTGGAAGGATCCGGC




GAGCTGTTCCGGTGGAACGTGTCCG




ATCTGGGCGGCCTGGGATGCGGCCT




GAAGAACAGATCTAGCGAGGGCCCC




AGCAGCCCCAGCGGCAAACTGATGA




GCCCCAAGCTGTACGTGTGGGCCAA




GGACAGACCCGAGATCTGGGAGGGC




GAGCCTCCTTGCCTGCCCCCTAGAG




ACAGCCTGAACCAGAGCCTGAGCCA




GGAC




CTGACAATGGCCCCTGGCAGCACAC




TGTGGCTGAGCTGTGGCGTGCCACC




CGACTCTGTGTCTAGAGGCCCTCTG




AGCTGGACCCACGTGCACCCTAAGG




GCCCTAAGAGCCTGCTGAGCCTGGA




ACTGAAGGACGACAGGCCCGCCAGA




GATATGTGGGTCATGGAAACCGGCC




TGCTGCTGCCTAGAGCCACAGCCCA




GGATGCCGGCAAGTACTACTGCCAC




AGAGGCAACCTGACCATGAGCTTCC




ACCTGGAAATCACCGCCAGACCCGT




GCTGTGGCACTGGCTGCTGAGAACA




GGCGGCTGGAAGGTCGACGCTAGCG




GTGGTAGTCCGACACCTCCGACACC




CGGGGGTGGTTCTGCAGACAAAACT




CACACATGCCCACCGTGCCCAGCAC




CTGAAGCCGCAGGGGGACCGTCAGT




CTTCCTCTTCCCCCCAAAACCCAAG




GACACCCTCATGATCTCCCGGACCC




CTGAGGTCACATGCGTGGTGGTGGA




CGTGAGCCACGAAGACCCTGAGGTC




AAGTTCAACTGGTACGTGGACGGCG




TGGAGGTGCATAATGCCAAGACAAA




GCCGCGGGAGGAGCAGTACAACAGC




ACGTACCGTGTGGTCAGCGTCCTCA




CCGTCCTGCACCAGGACTGGCTGAA




TGGCAAGGAGTACAAGTGCAAGGTC




TCCAACAAAGCCCTCGGAGCCCCCA




TCGAGAAAACCATCTCCAAAGCCAA




AGGGCAGCCCCGAGAACCACAGGTG




TACACCCTGCCCCCATGCCGGGATG




AGCTGACCAAGAACCAGGTCAGCCT




GTGGTGCCTGGTCAAAGGCTTCTAT




CCCAGCGACATCGCCGTGGAGTGGG




AGAGCAATGGGCAGCCGGAGAACAA




CTACAAGACCACGCCTCCCGTGCTG




GACTCCGACGGCTCCTTCTTCCTCT




ACAGCAAGCTCACCGTGGACAAGAG




CAGGTGGCAGCAGGGGAACGTCTTC




TCATGCTCCGTGATGCATGAGGCTC




TGCACAACCACTAGACGCAGAAGAG




CCTCTCCCTGTCTCCGGGTAAATCC




GGAGGCCTGAACGACATCTTCGAGG




CCCAGAAGATTGAATGGCACGAG





90
Polypeptide
see Table 32



sequence Fc




hole chain






187
Polypeptide
PEEPLVVKVEEGDNAVLQCLKGTSD



sequence
GPTQQLTWSRESPLKPFLKLSLGLP



human CD19
GLGIHMRPLAIWLFIFNVSQQMGGF



antigen Fc
YLCQPGPPSEKAWQPGWTVNVEGSG



knob chain
ELFRWNVSDLGGLGCGLKNRSSEGP



avi tag
SSPSGKLMSPKLYVWAKDRPEIWEG




EPPCLPPRDSLNQSLSQDLTMAPGS




TLWLSCGVPPDSVSRGPLSWTHVHP




KGPKSLLSLELKDDRPARDMWVMET




GLLLPRATAQDAGKYYCHRGNLTMS




FHLEITARPVLWHWLLRTGGWKVDA




SGGSPTPPTPGGGSADKTHTCPPCP




APEAAGGPSVFLFPPKPKDTLMISR




TPEVTCVVVDVSHEDPEVKFNWYVD




GVEVHNAKTKPREEQYNSTYRVVSV




LTVLHQDWLNGKEYKCKVSNKALGA




PIEKTISKAKGQPREPQVYTLPPCR




DELTKNQVSLWCLVKGFYPSDIAVE




WESNGQPENNYKTTPPVLDSDGSFF




LYSKLTVDKSRWQQGNVFSCSVMHE




ALHNHYTQKSLSLSPGKSGGLNDIF




EAQKIEWHE





188
Nucleotide
CCCCAGGAACCCCTGGTCGTGAAGG



sequence
TGGAAGAGGGCGACAATGCCGTGCT



cynomolgus
CCAGTGCCTGGAAGGCACCTCCGAT



CD19 antigen
GGCCCTACACAGCAGCTCGTGTGGT



Fc knob
GCAGAGACAGCCCCTTCGAGCCCTT



chain avi tag
CCTGAACCTGTCTCTGGGCCTGCCT




GGCATGGGCATCAGAATGGGCCCTC




TGGGCATCTGGCTGCTGATCTTCAA




CGTGTCCAACCAGACCGGCGGCTTC




TACCTGTGTCAGCCTGGCCTGCCAA




GCGAGAAGGCTTGGCAGCCTGGATG




GACCGTGTCCGTGGAAGGATCTGGC




GAGCTGTTCCGGTGGAACGTGTCCG




ATCTGGGCGGCCTGGGATGCGGCCT




GAAGAACAGAAGCAGCGAGGGCCCT




AGCAGCCCCAGCGGCAAGCTGAATA




GCAGCCAGCTGTACGTGTGGGCCAA




GGACAGACCCGAGATGTGGGAGGGC




GAGCCTGTGTGTGGCCCCCCTAGAG




ATAGCCTGAACCAGAGCCTGAGCCA




GGACCTGACAATGGCCCCTGGCAGC




ACACTGTGGCTGAGCTGTGGCGTGC




CACCCGACTCTGTGTCCAGAGGCCC




TCTGAGCTGGACACACGTGCGGCCA




AAGGGCCCTAAGAGCAGCCTGCTGA




GCCTGGAACTGAAGGACGACCGGCC




CGACCGGGATATGTGGGTGGTGGAT




ACAGGCCTGCTGCTGACCAGAGCCA




CAGCCCAGGATGCCGGCAAGTACTA




CTGCCACAGAGGCAACTGGACCAAG




AGCTTTTACCTGGAAATCACCGCCA




GACCCGCCCTGTGGCACTGGCTGCT




GAGAATCGGAGGCTGGAAGGTCGAC




GCTAGCGGTGGTAGTCCGACACCTC




CGACACCCGGGGGTGGTTCTGCAGA




CAAAACTCACACATGCCCACCGTGC




CCAGCACCTGAAGCCGCAGGGGGAC




CGTCAGTCTTCCTCTTCCCCCCAAA




ACCCAAGGACACCCTCATGATCTCC




CGGACCCCTGAGGTCACATGCGTGG




TGGTGGACGTGAGCCACGAAGACCC




TGAGGTCAAGTTCAACTGGTACGTG




GACGGCGTGGAGGTGCATAATGCCA




AGACAAAGCCGCGGGAGGAGCAGTA




CAACAGCACGTACCGTGTGGTCAGC




GTCCTCACCGTCCTGCACCAGGACT




GGCTGAATGGCAAGGAGTACAAGTG




CAAGGTCTCCAACAAAGCCCTCGGA




GCCCCCATCGAGAAAACCATCTCCA




AAGCCAAAGGGCAGCCCCGAGAACC




ACAGGTGTACACCCTGCCCCCATGC




CGGGATGAGCTGACCAAGAACCAGG




TCAGCCTGTGGTGCCTGGTCAAAGG




CTTCTATCCCAGCGACATCGCCGTG




GAGTGGGAGAGCAATGGGCAGCCGG




AGAACAACTACAAGACCACGCCTCC




CGTGCTGGACTCCGACGGCTCCTTC




TTCCTCTACAGCAAGCTCACCGTGG




ACAAGAGCAGGTGGCAGCAGGGGAA




CGTCTTCTCATGCTCCGTGATGCAT




GAGGCTCTGCACAACCACTACACGC




AGAAGAGCCTCTCCCTGTCTCCGGG




TAAATCCGGAGGCCTGAACGACATC




TTCGAGGCCCAGAAGATTGAATGGC




ACGAG





189
Polypeptide
PQEPLVVKVEEGDNAVLQCLEGTSD



sequence
GPTQQLVWCRDSPFEPFLNLSLGLP



cynomolgus
GMGIRMGPLGIWLLIFNVSNQTGGF



CD19 antigen
YLCQPGLPSEKAWQPGWTVSVEGSG



Fc knob
ELFRWNVSDLGGLGCGLKNRSSEGP



chain avi tag
SSPSGKLNSSQLYVWAKDRPEMWEG




EPVCGPPRDSLNQSLSQDLTMAPGS




TLWLSCGVPPDSVSRGPLSWTHVRP




KGPKSSLLSLELKDDRPDRDMWVVD




TGLLLTRATAQDAGKYYCHRGNWTK




SFYLEITARPALWHWLLRIGGWKVD




ASGGSPTPPTPGGGSADKTHTCPPC




PAPEAAGGPSVFLFPPKPKDTLMIS




RTPEVTCVVVDVSHEDPEVKFNWYV




DGVEVHNAKTKPREEQYNSTYRVVS




VLTVLHQDWLNGKEYKCKVSNKALG




APIEKTISKAKGQPREPQVYTLPPC




RDELTKNQVSLWCLVKGFYPSDIAV




EWESNGQPENNYKTTPPVLDSDGSF




FLYSKLTVDKSRWQQGNVFSCSVMH




EALHNHYTQKSLSLSPGKSGGLNDI




FEAQKIEWHE









For the production of the monomeric antigen/Fc fusion molecules, exponentially growing suspension CHO cells were co-transfected with two plasmids encoding the two components of fusion protein (knob and hole chains) using standard methods.


Secreted protein was purified from cell culture supernatant by affinity chromatography using Protein A, followed by size exclusion chromatography. For affinity chromatography, the supernatant was loaded on a MABSELECT SURE® column volume (CV)=5-15 mL, resin from GE Healthcare) equilibrated with Sodium Phosphate (20 mM), Sodium Citrate (20 mM), 0.5M sodium chloride buffer (pH 7.5). Unbound protein was removed by washing with at least 6 column volumes of the same buffer. The bound protein was eluted using a linear gradient; step 1, 10 CV from 0 to 60% elution buffer (20 mM sodium citrate, 500 mM Sodium chloride buffer (pH 2.5)); step 2, 2 CV from 60 to 100% elution buffer. For the linear gradient an additional 2 column volumes step elution with 100% elution buffer was applied.


The pH of collected fractions was adjusted by adding 1/40 (v/v) of 2M Tris, pH8.0. The protein was concentrated and filtered prior to loading on a HILOAD® Superdex 200 column (GE Healthcare) equilibrated with 2 mM MOPS, 150 mM sodium chloride, 0.02% (w/v) sodium azide solution of pH 7.4.


Table 44 summarizes the yield and final monomer content of monomeric human and cynomolgus CD19 antigen Fc(kih) fusion protein.









TABLE 44







Biochemical analysis of monomeric human and


cynomolgus CD19 antigen Fc(kih) fusion protein










Monomer [%]
Yield


Construct
(SEC)
[mg/l]












monomeric human CD19 Fc(kih) fusion protein
91
0.2


monomeric cynomolgus CD19 Fc(kih) fusion
95
3.56


protein











Part of the purified antigen was in vitro biotinylated using the BirA biotin-protein ligase standard reaction kit (Avidity, Cat. #BirA500) according to the manufacturer's instructions. The biotinylation degree for the human CD19-containing fusion was 94%, for the respective cynomolgus CD19 construct 100%. The biotinylated protein was then used for selection, screening and characterization of affinity-matured 8B8-derived clones devoid of the de-amidation hotspots N27d and N28.


7.1.2 Generation of Anti-CD19 Clone 8B8-018


7.1.2.1 Immunization and Generation of Mouse Anti-Human CD19 Antibodies (Hybridomas)


Balb/c mice were immunized six times and boosted with CD19-transfected HEK293 cells (mean receptor density 35,000 per cell). The immune response was monitored by testing serum samples with a CD19-cell-ELISA on human CD19-transfected NIH-3T3 cells. Spleen cells from mice with sufficient titers of anti-human CD19 antibody were used for immortalization by fusion with mouse myeloma cell line P3X63 Ag8.653. Three fusions were carried out and hybridoma supernatants screened by cell-ELISA on human CD19-transfected NIH-3T3 cells and FACS binding assay using Daudi (CD19+) and CD19− cells for anti-human CD19 specific antibodies (see Example 1 of WO 2011/147834).


7.1.2.2 Hybridoma Screening and Cell Biological Functional Evaluation of Anti-CD19 Antibody


Cell-ELISA for Screening Antibodies Against Human CD19

A cell ELISA was applied for screening of hybridomas, and to identify those hybridomas that secrete antibodies against human-CD19. NIH3T3 cells transfected with human-CD19 were used as positive cells; non-transfected NIH3T3 cells were used as negative control cells. For the assessment of the positive hybridomas the OD ratio between transfected and non-transfected NIH3T3 cells was quantified.

    • Culture Medium: DMEM high glucose (4.5 mg/ml), 10% FCS, Na-Pyruvate, NEAA, Glutamine
    • Antibodies positive control: anti CD19 monoclonal antibody (IgG1) Pharmingen Cat #555409 c=1 mg/ml
    • Detection antibody: Goat anti-Mouse IgG (H+L) HRP Conjugate Bio-Rad Cat #170-06516
    • Dilution 1: 2000 in 1×ELISA Blocking Reagent
    • Other reagents: Fibronectin Roche Cat #838039 c=1 mg/ml
    • Glutardialdehyde: 25% stock solution//Grade Agar Scientific #R102 final concentration: 0.05% in PBS
    • ELISA Blocking Reagent: 10× stock solution//Roche Cat #1112589
    • TMB substrate: Roche Cat #11432559
    • Stop Solution: 1 M H2SO4
    • BioRad Cat #170-6516 Dilution 1: 2000 in 1×ELISA Blocking Reagent


Day 1:





    • Fibronectin coating: 5 μg/cm2 in PBS; 96well plate=32 cm2; 160 μg/plate in 6 ml

    • PBS, 50 μl/well

    • incubate 45 min at RT, aspirate coating solution

    • Seed 1.25×104 cells/well in 50 μl culture medium in a 96well plate

    • incubate 40 hours at 37° C.

    • add to upper half of the plate: NIH3T3 cells expressing CD19

    • add to lower half of the plate: non-transfected NIH3T3 cells





Day 3:





    • Addition of positive control antibody or samples (supernatant or mouse serum) in 50 μl culture medium

    • incubate for 2 h at 4° C.

    • Remove medium, fix cells with 100 μl Glutardialdehyde (0.05% in PBS)

    • Wash two times with 200 μl PBS

    • Addition of detection antibody 1:2000, 50 μl/well

    • incubate 2 h at RT

    • wash three times with 200 μl PBS

    • add 50 μl TMB, incubate for 30 min. at RT,

    • stop by addition of 25 μl 1 M H2SO4; read extinction at 450 nm/620 nm

    • Calculation of results: ratio OD NIH3T3 CD19: OD NIH3T3 non-transfected


      The selected antibody demonstrated specific binding to CD19 transfected NIH3T3 cells as compared to untransfected NIH3T3 cells (see Example 2 of WO 2011/147834).





7.1.2.3 Humanization of Anti-CD19 Antibody


The CD19 binding specificity of the murine antibody was transferred onto a human acceptor framework to eliminate potential immunogenicity issues arising from sequence stretches that the human body will recognize as foreign. This was done by engrafting the entire complementary determining regions (CDR) of the murine (donor) antibody onto a human (acceptor) antibody framework, and is called CDR-grafting or antibody humanization.


The murine amino acid sequence was aligned with a collection of human germ-line antibody V genes, and sorted according to sequence identity and homology. Before selecting one particular acceptor sequence, the so-called canonical loop structures of the donor antibody have to be determined (Morea, V., et al., Methods, Vol 20, Issue 3 (2000) 267-279). These canonical loop structures are determined by the type of residues present at the so-called canonical positions. These positions lie (partially) outside of the CDR regions, and have to be kept functionally equivalent in the final construct in order to retain the CDR conformation of the parental (donor) antibody. The human germ-line sequence VBASE_VH1_1 was chosen as the acceptor for the heavy chain and sequence VBASE_VK2_5 was chosen for the light chain.


7.1.2.4 Removal of Deamidation Hotspots


It has been found that the wild-type humanized anti-human CD19 antibody has three deamidation hotspots in the HVR-L1: NSNGNT (SEQ ID NO: 190). Additionally it has been found that in the HVR-H2 a further deamidation hotspot is present: KFNG (SEQ ID NO: 191). To address the deamidation hotspot in the HVR-H2 an N (Asn) to Q (Gln) point mutation at position 64 (numbering according to Kabat) has been introduced. Thus, the antibody as reported herein has a HVR-H2 comprising the amino acid sequence TEKFQGRVTM (SEQ ID NO: 192).


To address the deamidation hotspots in the light chain and to obtain a humanized anti-human CD19 antibody with improved deamidation stability individual mutations at Kabat position 27d, 27e, 28 and 29 and a double mutation at positions 27e and 28 (numbering according to Kabat) were introduced. In total 9 variants (var.1 to var.9) of the wild-type humanized antibody (var.0) have been generated (see Table 45A and Table 45B).









TABLE 45A







Variants of humanized wild-type CD19 antibody














Kabat




Kabat

position:



Variant
position
LC:
6, 4
HC:
















var.0:
wt
SEQ ID
QSLE
wt
SEQ ID
TEKF




NO: 379
NSNG

NO: 389
NGKA





NTYL


TM





NW








var.1:
N27dH
SEQ ID
QSLE

SEQ ID
TEKF




NO: 380
HSNG

NO: 192
QGRV





NTYL


TM





NW








var.2:
N27dO
SEQ ID
QSLE

SEQ ID
TEKF




NO: 381
QSNG

NO: 192
QGRV





NTYL


TM





NW








var.3:
S27eA
SEQ ID
QSLE

SEQ ID
TEKF




NO: 382
NANG

NO: 192
QGRV





NTYL


TM





NW








var.4:
S27cV
SEQ ID
QSLE

SEQ ID
TEKF




NO: 383
NVNG

NO: 192
QGRV





NTYL


TM





NW








var.5:
S27eP
SEQ ID
QSLE

SEQ ID
TEKF




NO: 384
NPNG

NO: 192
QGRV





NTYL


TM





NW








var.6:
N28Q
SEQ ID
QSLE

SEQ ID
TEKF




NO: 385
NSQG

NO: 192
QGRV





NTYL


TM





NW








var.7:
G29A
SEQ ID
QSLE

SEQ ID
TEKF




NO: 386
NSNA

NO: 192
QGRV





NTYL


TM





NW








var. 8:
G29V
SEQ ID
QSLE

SEQ ID
TEKF




NO: 387
NSNV

NO: 192
QGRV





NTYL


TM





NW








var.9:
S27eP/
SEQ ID
QSLE

SEQ ID
TEKF



N28S
NO: 388
NPSG

NO: 192
QGRV





NTYL


TM





NW

















TABLE 45B








variant

















parameter
0
1
2
3
4
5
6
7
8
9




















KD
5
250
136
2
1
6
54
4
16
45


(BIACORE ®)












[nM]














0.1
1.1
105.2
191.5
43.6
4.4
51.5
17.6
4


[min]












human CD19
46
0
75
84
85
95
91
72
83
83


binding after pH












7.4 incubation












[%]












human CD19
90
0
95
95
97
99
97
86
91
87


binding after pH












6.0 incubation












[%]












SEC main peak
>95
>95
>95
>95
>95
>95
>95
>95
>95



after incubation












[%]









It has been found that with a single mutation at position 27e according to Kabat from S (serine) to P (proline) all deamidation hotspots in the HVR-L1 can be addressed. This is a mutation not of the deamidation prone N (asparagine) residue but of a neighboring residue.


Thus, the antibody as reported herein has a HVR-L1 comprising the amino acid sequence LENPNGNT (SEQ ID NO: 193). In one embodiment the humanized anti-human CD19 antibody comprises a HVR-L1 that has the amino acid sequence LENPSGNT (SEQ ID NO: 194).


Additionally these antibodies maintain the cross-reactivity to cynomolgus CD19 as shown in the following Table 46.


















EC50 [μg/ml]
var.0
var.5
var.9





















huCD19 ECD
0.087
0.084
0.089



cyCD19 ECD
0.313
0.255
0.435










The wild-type humanized anti-human CD19 antibody (var.0) shows after purification approx. 7.5% deamidation. After storage for two weeks at pH 7.4 the amount of deamidated antibody is increased to approx. 18.5%. The variant antibody with an S27eP mutation (var.5) shows approx. 2% deamidation and 2% succinimide formation after purification. During storage at pH 7.4 for two weeks only approx. 7.5% deamidated antibody is present. Var. 5 is named clone 8B8-018 and was elected for the preparation of CD19-targeted TNF family ligand trimer-containing antigen binding molecules.


7.1.3 Preparation of Monovalent CD19(8B8-018) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 3.1)


A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G4S)2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned as depicted in FIG. 29A: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the human IgG1-CH domain, was cloned as described in FIG. 29B: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CH.


The polypeptide encoding the dimeric 4-1BB ligand fused to human CL domain was subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant, Zhu et al. 1998). To improve correct pairing the following mutations have been introduced in the crossed CH-CL. In the dimeric 4-1BB ligand fused to human CL, E123R and Q124K. In the monomeric 4-1BB ligand fused to human CH1, K147E and K213E.


The variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-018, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831.


Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CD19-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CD19 light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CD19 binding Fab (FIG. 30A, Construct 3.1).


Table 47 shows the cDNA and amino acid sequences of the monovalent CD19(8B8-018) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule with crossed CH-CL and charged residues (construct 3.1).









TABLE 47







cDNA and amino acid sequences of monovalent


CD19 (8B8-018) targeted split trimeric 4-1BB


ligand (71-254) Fc (kih) fusion containing


CH-CL cross with charged residues


(construct 3.1). * for charged residues









SEQ ID




NO:
Description
Sequence





129
Nucleotide
see Table 3



sequence Dimeric




hu 4-1BBL (71-




254)-CL* Fc




knob chain






130
Nucleotide
see Table 3



sequence




Monomeric hu




4-1BBL




(71-254)-CH1*






203
Nucleotide
CAGGTCCAGCTGGTGCAGTCCGGCG



sequence anti-
CCGAGGTCAAGAAACCCGGGGCTTC



CD 19(8B8-018)
TGTGAAGGTTTCATGCAAGGCAAGC



Fc hole chain
GGATACACCTTCACCGACTATATCA




TGCATTGGGTCAGGCAGGCCCCTGG




CCAAGGTCTCGAATGGATGGGCTAC




ATTAACCCATATAATGATGGCTCCA




AATACACCGAGAAGTTTCAGGGAAG




AGTCACTATGACATCTGACACCAGT




ATCAGCACTGCTTACATGGAGCTGT




CCCGCCTTCGGTCTGATGACACCGC




AGTGTATTACTGTGCCAGGGGCACA




TATTACTACGGCTCAGCTCTGTTCG




ACTATTGGGGGCAGGGAACCACAGT




AACCGTGAGCTCCGCTAGCACCAAG




GGCCCCTCCGTGTTCCCCCTGGCCC




CCAGCAGCAAGAGCACCAGCGGCGG




CACAGCCGCTCTGGGCTGCCTGGTC




AAGGACTACTTCCCCGAGCCCGTGA




CCGTGTCCTGGAACAGCGGAGCCCT




GACCTCCGGCGTGCACACCTTCCCC




GCCGTGCTGCAGAGTTCTGGCCTGT




ATAGCCTGAGCAGCGTGGTCACCGT




GCCTTCTAGCAGCCTGGGCACCCAG




ACCTACATCTGCAACGTGAACCACA




AGCCCAGCAACACCAAGGTGGACAA




GAAGGTGGAGCCCAAGAGCTGCGAC




AAAACTCACACATGCCCACCGTGCC




CAGCACCTGAAGCTGCAGGGGGACC




GTCAGTCTTCCTCTTCCCCCCAAAA




CCCAAGGACACCCTCATGATCTCCC




GGACCCCTGAGGTCACATGCGTGGT




GGTGGACGTGAGCCACGAAGACCCT




GAGGTCAAGTTCAACTGGTACGTGG




ACGGCGTGGAGGTGCATAATGCCAA




GACAAAGCCGCGGGAGGAGCAGTAC




AACAGCACGTACCGTGTGGTCAGCG




TCCTCACCGTCCTGCACCAGGACTG




GCTGAATGGCAAGGAGTACAAGTGC




AAGGTCTCCAACAAAGCCCTCGGCG




CCCCCATCGAGAAAACCATCTCCAA




AGCCAAAGGGCAGCCCCGAGAACCA




CAGGTGTGCACCCTGCCCCCATCCC




GGGATGAGCTGACCAAGAACCAGGT




CAGCCTCTCGTGCGCAGTCAAAGGC




TTCTATCCCAGCGACATCGCCGTGG




AGTGGGAGAGCAATGGGCAGCCGGA




GAACAACTACAAGACCACGCCTCCC




GTGCTGGACTCCGACGGCTCCTTCT




TCCTCGTGAGCAAGCTCACCGTGGA




CAAGAGCAGGTGGCAGCAGGGGAAC




GTCTTCTCATGCTCCGTGATGCATG




AGGCTCT




GCACAACCACTACACGCAGAAGAGC




CTCTCCCTGTCTCCGGGTAAA





204
Nucleotide
GACATCGTCATGACCCAGACACCCC



sequence anti-
TGTCCCTCTCTGTGACCCCTGGCCA



CD19(8B8-018)
GCCAGCCTCAATTAGCTGCAAGTCC



light chain
TCTCAAAGTCTGGAGAACCCCAATG




GGAACACTTACCTTAATTGGTATCT




GCAGAAACCCGGACAATCCCCTCAA




CTCCTGATCTACAGGGTCTCTAAGA




GATTCTCAGGCGTGCCAGATCGCTT




TAGCGGTTCCGGGTCTGGCACAGAC




TTCACCTTGAAGATTAGTCGGGTTG




AAGCTGAGGATGTGGGAGTCTATTA




CTGTCTGCAGCTCACTCATGTGCCC




TACACCTTTGGTCAGGGCACAAAAC




TGGAGATCAAGCGGACCGTGGCCGC




TCCCTCCGTGTTCATCTTCCCACCC




TCCGACGAGCAGCTGAAGTCCGGCA




CCGCCAGCGTGGTGTGCCTGCTGAA




CAACTTCTACCCCCGCGAGGCCAAG




GTGCAGTGGAAGGTGGACAACGCCC




TGCAGTCCGGCAACTCCCAGGAATC




CGTGACCGAGCAGGACTCCAAGGAC




AGCACCTACTCCCTGTCCTCCACCC




TGACCCTGTCCAAGGCCGACTACGA




GAAGCACAAGGTGTACGCCTGCGAA




GTGACCCACCAGGGCCTGTCCAGCC




CCGTGACCAAGTCCTTCAACCGGGG




CGAGTGC





115
Dimeric hu 4-
see Table 3



1BBL (71-254)-




CL* Fc knob




chain






116
Monomeric hu
see Table 3



4-1BBL (71-254)




-CHI*






205
anti-CD19(8B8-
QVQLVQSGAEVKKPGASVKVSCKAS



018) Fc hole
GYTFTDYIMHWVRQAPGQGLEWMGY



chain
INPYNDGSKYTEKFQGRVTMTSDTS




ISTAYMELSRLRSDDTAVYYCARGT




YYYGSALFDYWGQGTTVTVSSASTK




GPSVFPLAPSSKSTSGGTAALGCLV




KDYFPEPVTVSWNSGALTSGVHTFP




AVLQSSGLYSLSSVVTVPSSSLGTQ




TYICNVNHKPSNTKVDKKVEPKSCD




KTHTCPPCPAPEAAGGPSVFLFPPK




PKDTLM1SRTPEVTCVVVDVSHEDP




EVKFNWYVDGVEVHNAKTKPREEQY




NSTYRVVSVLTVLHQDWLNGKEYKC




KVSNKALGAPIEKTISKAKGQPREP




QVCTLPPSRDELTKNQVSLSCAVKG




FYPSDIAVEWESNGQPENNYKTTPP




VLDSDGSFFLVSKLTVDKSRWQQGN




VFSCSVMHEALHNHYTQKSLSLSPG




K





206
anti-CD19(8B8-
DIVMTQTPLSLSVTPGQPASISCKS



018) light chain
SQSLENPNGNTYLNWYLQKPGQSPQ




LLIYRVSKRFSGVPDRFSGSGSGTD




FTLKISRVEAEDVGVYYCLQLTHVP




YTFGQGTKLEIKRTVAAPSVFIFPP




SDEQLKSGTASVVCLLNNFYPREAK




VQWKVDNALQSGNSQESVTEQDSKD




STYSLSSTLTLSKADYEKHKVYACE




VTHQGLSSPVTKSFNRGEC









7.1.4 Preparation of Monovalent CD19(8B8-018) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains without Charged Residues (Construct 3.2)


A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G4S)2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned in analogy as depicted in FIG. 29A, but without amino acid mutations in the CL domain: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the human IgG1-CH1 domain, was cloned in analogy as depicted in FIG. 29B, but without amino acid mutations in the CH1 domain: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CH1.


The variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-018, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1.


The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CD19-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CD19 light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CD19-binding Fab (FIG. 30B, Construct 3.2).


Table 48 shows the cDNA and amino acid sequences of the monovalent CD19(8B8-018) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule containing crossed CH-CL cross without charged residues (construct 3.2).









TABLE 48







cDNA and amino acid sequences of monovalent CD19(8B8-018)


targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion


containing CH-CLcross without charged residues (construct 3.2).











SEQ ID





NO:
Description
Sequence















165
Nucleotide
see Table 22




sequence dimeric





ligand (71-254)-





CL Fc knob chain




166
Nucleotide
see Table 22




sequence





monomeric hu





4-1BBL (71-254)-





CH1




203
Nucleotide
see Table 47




sequence anti-





CD19(8B8-018)





Fc hole chain




204
Nucleotide
see Table 47




sequence anti-





CD19(8B8-018)





light chain




117
Dimeric ligand
see Table 22




(71-254) - CL Fc





knob chain




118
Monomeric
see Table 22




ligand (71-254) -





CH1




205
anti-CD19(8B8-
see Table 47




018) Fc hole





chain




206
anti-CD19(8B8-
see Table 47




018) light chain











7.1.5 Preparation of Bivalent CD19(8B8-018) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding (Construct 3.3)


A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G4S)2 (SEQ ID NO:13) linkers was fused to the C-terminus of human IgG1 Fc hole chain, as depicted in FIG. 29C: human IgG1 Fc hole, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the C-terminus of human IgG1 Fc knob chain as described in FIG. 29D: human IgG1 Fc knob, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand.


The variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-018, were subcloned in frame with either the constant heavy chain of the hole, the knob or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the anti-CD19 huIgG1 hole dimeric ligand chain containing the Y349C/T366S/L368A/Y407V mutations, the anti-CD19 huIgG1 knob monomeric ligand chain containing the S354C/T366W mutations and the anti-CD19 light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and two CD19 binding Fabs (FIG. 30C, construct 3.3).


Table 49 shows the cDNA and amino acid sequences of the bivalent CD19(8B8-018) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule (construct 3.3).









TABLE 49







Base pair sequences of bivalent CD19(8B8-018)


targeted split trimeric 4-1BB ligand


Fc (kih) PGLALA fusion (construct 3.3)









SEQ ID




NO:
Description
Sequence





207
Nucleotide
CAGGTCCAGCTGGTGCAGTCCGGCG



sequence anti-
CCGAGGTCAAGAAACCCGGGGCTTC



CD19(8B8-018)
TGTGAAGGTTTCATGCAAGGCAAGC



Fc hole dimeric
GGATACACCTTCACCGACTATATCA



ligand chain
TGCATTGGGTCAGGCAGGCCCCTGG




CCAAGGTCTCGAATGGATGGGCTAC




ATTAACCCATATAATGATGGCTCCA




AATACACCGAGAAGTTTCAGGGAAG




AGTCACTATGACATCTGACACCAGT




ATCAGCACTGCTTACATGGAGCTGT




CCCGCCTTCGGTCTGATGACACCGC




AGTGTATTACTGTGCCAGGGGCACA




TATTACTACGGCTCAGCTCTGTTCG




ACTATTGGGGGCAGGGAACCACAGT




AACCGTGAGCTCCGCTAGCACCAAG




GGCCCCTCCGTGTTCCCCCTGGCCC




CCAGCAGCAAGAGCACCAGCGGCGG




CACAGCCGCTCTGGGCTGCCTGGTC




AAGGACTACTTCCCCGAGCCCGTGA




CCGTGTCCTGGAACAGCGGAGCCCT




GACCTCCGGCGTGCACACCTTCCCC




GCCGTGCTGCAGAGTTCTGGCCTGT




ATAGCCTGAGCAGCGTGGTCACCGT




GCCTTCTAGCAGCCTGGGCACCCAG




ACCTACATCTGCAACGTGAACCACA




AGCCCAGCAACACCAAGGTGGACAA




GAAGGTGGAGCCCAAGAGCTGCGAC




AAAACTCACACATGCCCACCGTGCC




CAGCACCTGAAGCTGCAGGGGGACC




GTCAGTCTTCCTCTTCCCCCCAAAA




CCCAAGGACACCCTCATGATCTCCC




GGACCCCTGAGGTCACATGCGTGGT




GGTGGACGTGAGCCACGAAGACCCT




GAGGTCAAGTTCAACTGGTACGTGG




ACGGCGTGGAGGTGCATAATGCCAA




GACAAAGCCGCGGGAGGAGCAGTAC




AACAGCACGTACCGTGTGGTCAGCG




TCCTCACCGTCCTGCACCAGGACTG




GCTGAATGGCAAGGAGTACAAGTGC




AAGGTCTCCAACAAAGCCCTCGGCG




CCCCCATCGAGAAAACCATCTCCAA




AGCCAAAGGGCAGCCCCGAGAACCA




CAGGTGTGCACCCTGCCCCCATCCC




GGGATGAGCTGACCAAGAACCAGGT




CAGCCTCTCGTGCGCAGTCAAAGGC




TTCTATCCCAGCGACATCGCCGTGG




AGTGGGAGAGCAATGGGCAGCCGGA




GAACAACTACAAGACCACGCCTCCC




GTGCTGGACTCCGACGGCTCCTTCT




TCCTCGTGAGCAAGCTCACCGTGGA




CAAGAGCAGGTGGCAGCAGGGGAAC




GTCTTCTCATGCTCCGTGATGCATG




AGGCTCTGCACAACCACTACACGCA




GAAGAGCCTCTCCCTGTCTCCGGGT




GGAGGCGGCGGAAGCGGAGGAGGAG




GATCCAGAGAGGGCCCTGAGCTGAG




CCCCGATGATCCTGCTGGACTGCTG




GACCTGCGGCAGGGCATGTTTGCTC




AGCTGGTGGCCCAGAACGTGCTGCT




GATCGATGGCCCCCTGTCCTGGTAC




AGCGATCCTGGACTGGCTGGCGTGT




CACTGACAGGCGGCCTGAGCTACAA




AGAGGACACCAAAGAACTGGTGGTG




GCCAAGGCCGGCGTGTACTACGTGT




TCTTTCAGCTGGAACTGCGGAGAGT




GGTGGCCGGCGAAGGATCTGGCTCT




GTGTCTCTGGCCCTGCATCTGCAGC




CTCTGAGAAGCGCTGCTGGCGCTGC




AGCTCTGGCACTGACAGTGGATCTG




CCTCCTGCCAGCTCCGAGGCCCGGA




ATAGCGCATTTGGGTTTCAAGGCAG




GCTGCTGCACCTGTCTGCCGGCCAG




AGGCTGGGAGTGCATCTGCACACAG




AGGCCAGGGCTAGACACGCCTGGCA




GCTGACACAGGGCGCTACAGTGCTG




GGCCTGTTCAGAGTGACCCCCGAGA




TTCCAGCCGGCCTGCCTTCTCCAAG




AAGCGAAGGCGGAGGCGGATCTGGC




GGCGGAGGATCTAGAGAGGGACCCG




AACTGTCCCCTGACGATCCAGCCGG




GCTGCTGGATCTGAGACAGGGAATG




TTCGCCCAGCTGGTGGCTCAGAATG




TGCTGCTGATTGACGGACCTCTGAG




CTGGTACTCCGACCCAGGGCTGGCA




GGGGTGTCCCTGACTGGGGGACTGT




CCTACAAAGAAGATACAAAAGAACT




GGTGGTGGCTAAAGCTGGGGTGTAC




TATGTGTTTTTTCAGCTGGAACTGA




GGCGGGTGGTGGCTGGGGAGGGCTC




AGGATCTGTGTCCCTGGCTCTGCAT




CTGCAGCCACTGCGCTCTGCTGCTG




GCGCAGCTGCACTGGCTCTGACTGT




GGACCTGCCACCAGCCTCTAGCGAG




GCCAGAAACAGCGCCTTCGGGTTCC




AAGGACGCCTGCTGCATCTGAGCGC




CGGACAGCGCCTGGGAGTGCATCTG




CATACTGAAGCCAGAGCCCGGCATG




CTTGGCAGCTGACTCAGGGGGCAAC




TGTGCTGGGACTGTTTCGCGTGACA




CCTGAGATCCCTGCCGGACTGCCAA




GCCCTAGATCAGAA





208
Nucleotide
CAGGTCCAGCTGGTGCAGTCCGGCG



sequence anti-
CCGAGGTCAAGAAACCCGGGGCTTC



CD19(8B8-0I8)
TGTGAAGGTTTCATGCAAGGCAAGC



Fc knob
GGATACACCTTCACCGACTATATCA



monomeric ligand
TGCATTGGGTCAGGCAGGCCCCTGG




CCAAGGTCTCGAATGGATGGGCTAC




ATTAACCCATATAATGATGGCTCCA




AATACACCGAGAAGTTTCAGGGAAG




AGTCACTATGACATCTGACACCAGT




ATCAGCACTGCTTACATGGAGCTGT




CCCGCCTTCGGTCTGATGACACCGC




AGTGTATTACTGTGCCAGGGGCACA




TATTACTACGGCTCAGCTCTGTTCG




ACTATTGGGGGCAGGGAACCACAGT




AACCGTGAGCTCCGCTAGCACCAAG




GGCCCATCGGTCTTCCCCCTGGCAC




CCTCCTCCAAGAGCACCTCTGGGGG




CACAGCGGCCCTGGGCTGCCTGGTC




AAGGACTACTTCCCCGAACCGGTGA




CGGTGTCGTGGAACTCAGGCGCCCT




GACCAGCGGCGTGCACACCTTCCCG




GCTGTCCTACAGTCCTCAGGACTCT




ACTCCCTCAGCAGCGTGGTGACCGT




GCCCTCCAGCAGCTTGGGCACCCAG




ACCTACATCTGCAACGTGAATCACA




AGCCCAGCAACACCAAGGTGGACAA




GAAAGTTGAGCCCAAATCTTGTGAC




AAAACTCACACATGCCCACCGTGCC




CAGCACCTGAAGCTGCAGGGGGACC




GTCAGTCTTCCTCTTCCCCCCAAAA




CCCAAGGACACCCTCATGATCTCCC




GGACCCCTGAGGTCACATGCGTGGT




GGTGGACGTGAGCCACGAAGACCCT




GAGGTCAAGTTCAACTGGTACGTGG




ACGGCGTGGAGGTGCATAATGCCAA




GACAAAGCCGCGGGAGGAGCAGTAC




AACAGCACGTACCGTGTGGTCAGCG




TCCTCACCGTCCTGCACCAGGACTG




GCTGAATGGCAAGGAGTACAAGTGC




AAGGTCTCCAACAAAGCCCTCGGCG




CCCCCATCGAGAAAACCATCTCCAA




AGCCAAAGGGCAGCCCCGAGAACCA




CAGGTGTACACCCTGCCCCCCTGCA




GAGATGAGCTGACCAAGAACCAGGT




GTCCCTGTGGTGTCTGGTCAAGGGC




TTCTACCCCAGCGATATCGCCGTGG




AGTGGGAGAGCAACGGCCAGCCTGA




GAACAACTACAAGACCACCCCCCCT




GTGCTGGACAGCGACGGCAGCTTCT




TCCTGTACTCCAAACTGACCGTGGA




CAAGAGCCGGTGGCAGCAGGGCAAC




GTGTTCAGCTGCAGCGTGATGCACG




AGGCCCTGCACAACCACTACACCCA




GAAGTCCCTGAGCCTGAGCCCCGGC




GGAGGCGGCGGAAGCGGAGGAGGAG




GATCCAGAGAGGGCCCTGAGCTGAG




CCCCGATGATCCTGCTGGACTGCTG




GACCTGCGGCAGGGCATGTTTGCTC




AGCTGGTGGCCCAGAACGTGCTGCT




GATCGATGGCCCCCTGTCCTGGTAC




AGCGATCCTGGACTGGCTGGCGTGT




CACTGACAGGCGGCCTGAGCTACAA




AGAGGACACCAAAGAACTGGTGGTG




GCCAAGGCCGGCGTGTACTACGTGT




TCTTTCAGCTGGAACTGCGGAGAGT




GGTGGCCGGCGAAGGATCTGGCTCT




GTGTCTCTGGCCCTGCATCTGCAGC




CTCTGAGAAGCGCTGCTGGCGCTGC




AGCTCTGGCACTGACAGTGGATCTG




CCTCCTGCCAGCTCCGAGGCCCGGA




ATAGCGCATTTGGGTTTCAAGGCAG




GCTGCTGCACCTGTCTGCCGGCCAG




AGGCTGGGAGTGCATCTGCACACAG




AGGCCAGGGCTAGACACGCCTGGCA




GCTGACACAGGGCGCTACAGTGCTG




GGCCTGTTCAGAGTGACCCCCGAGA




TTCCAGCCGGCCTGCCTTCTCCAAG




AAGCGAA





204
Nucleotide
see Table 47



sequence anti-




CD19(8B8-018)




light chain






209
anti-CD19(8B8-
QVQLVQSGAEVKKPGASVKVSCKAS



018) Fc hole
GYTFTDYIMHWVRQAPGQGLEWMGY



dimeric ligand
INPYNDGSKYTEKFQGRVTMTSDTS



chain
ISTAYMELSRLRSDDTAVYYCARGT




YYYGSALFDYWGQGTTVTVSSASTK




GPSVFPLAPSSKSTSGGTAALGCLV




KDYFPEPVTVSWNSGALTSGVHTFP




AVLQSSGLYSLSSVVTVPSSSLGTQ




TYICNVNHKPSNTKVDKKVEPKSCD




KTHTCPPCPAPEAAGGPSVFLFPPK




PKDTLMISRTPEVTCVVVDVSHEDP




EVKFNWYVDGVEVHNAKTKPREEQY




NSTYRVVSVLTVLHQDWLNGKEYKC




KVSNKALGAPIEKTISKAKGQPREP




QVCTLPPSRDELTKNQVSLSCAVKG




FYPSDIAVEWESNGQPENNYKTTPP




VLDSDGSFFLVSKLTVDKSRWQQGN




VFSCSVMHEALHNHYTQKSLSLSPG




GGGGSGGGGSREGPELSPDDPAGLL




DLRQGMFAQLVAQNVLLIDGPLSWY




SDPGLAGVSLTGGLSYKEDTKELVV




AKAGVYYVFFQLELRRVVAGEGSGS




VSLALHLQPLRSAAGAAALALTVDL




PPASSEARNSAFGFQGRLLHLSAGQ




RLGVHLHTEARARHAWQLTQGATVL




GLFRVTPEIPAGLPSPRSEGGGGSG




GGGSREGPELSPDDPAGLLDLRQGM




FAQLVAQNVLLIDGPLSWYSDPGLA




GVSLTGGLSYKEDTKELVVAKAGVY




YVFFQLELRRVVAGEGSGSVSLALH




LQPLRSAAGAAALALTVDLPPASSE




ARNSAFGFQGRLLHLSAGQRLGVHL




HTEARARHAWQLTQGATVLGLFRVT




PEIPAGLPSPRSE





210
anti-CD 19(8B8-
QVQLVQSGAEVKKPGASVKVSCKAS



018) Fc knob
GYTFTDYIMHWVRQAPGQGLEWMGY



monomeric ligand
INPYNDGSKYTEKFQGRVTMTSDTS




ISTAYMELSRLRSDDTAVYYCARGT




YYYGSALFDYWGQGTTVTVSSASTK




GPSVFPLAPSSKSTSGGTAALGCLV




KDYFPEPVTVSWNSGALTSGVHTFP




AVLQSSGLYSLSSVVTVPSSSLGTQ




TYICNVNHKPSNTKVDKKVEPKSCD




KTHTCPPCPAPEAAGGPSVFLFPPK




PKDTLMISRTPEVTCVVVDVSHEDP




EVKFNWYVDGVEVHNAKTKPREEQY




NSTYRVVSVLTVLHQDWLNGKEYKC




KVSNKALGAPIEKTISKAKGQPREP




QVYTLPPCRDELTKNQVSLWCLVKG




FYPSDIAVEWESNGQPENNYKTTPP




VLDSDGSFFLYSKLTVDKSRWQQGN




VFSCSVMHEALHNHYTQKSLSLSPG




GGGGSGGGGSREGPELSPDDPAGLL




DLRQGMFAQLVAQNVLLIDGPLSWY




SDPGLAGVSLTGGLSYKEDTKELVV




AKAGVYYVFFQLELRRVVAGEGSGS




VSLALHLQPLRSAAGAAALALTVDL




PPASSEARNSAFGFQGRLLHLSAGQ




RLGVHLHTEARARHAWQLTQGATVL




GLFRVTPEIPAGLPSPRSE





206
anti-CD 19(8B8-
see Table 47



018) light chain









7.1.6 Preparation of Monovalent CD19 (8B8-018) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 3.4)


A polypeptide containing two ectodomains of 4-1BB ligand (71-248), separated by (G4S)2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned in analogy to the one depicted in FIG. 29A: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-248) and fused to the human IgG1-CH domain, was cloned in nalogy to the one described in FIG. 29B: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CH.


The polypeptide encoding the dimeric 4-1BB ligand fused to human CL domain was subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant, Zhu et al. 1998). To improve correct pairing the following mutations have been introduced in the crossed CH-CL. In the dimeric 4-1BB ligand fused to human CL, E123R and Q124K. In the monomeric 4-1BB ligand fused to human CH1, K147E and K213E.


The variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-018, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831.Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CD19-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CD19 light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CD19 binding Fab (FIG. 30D, construct 3.4).


Table 50 shows the cDNA and amino acid sequences of the monovalent CD19(8B8-018) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule with crossed CH-CL and charged residues (construct 3.4).









TABLE 50







cDNA and amino acid sequences of monovalent CD19(8B8-018)


targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion


containing CH-CL cross with charged residues (construct 3.4).









SEQ ID NO:
Description
Sequence





169
Nucleotide sequence dimeric
see Table 24



ligand (71-248) - CL* Fc knob



170
Nucleotide sequence monomeric
see Table 24



hu 4-1BBL (71-248) - CH1*



203
Nucleotide sequence anti-
see Table 47



CD19(8B8-018) Fc hole chain



204
Nucleotide sequence anti-
see Table 47



CD19(8B8-018) light chain



119
Dimeric ligand (71-248) - CL*
see Table 24



Fc knob chain



120
Monomeric ligand (71-248) - CH1*
see Table 24


205
anti-CD19(8B8-018) Fc hole chain
see Table 47


206
anti-CD19(8B8-018) light chain
see Table 47





*charged residues






7.1.7 Preparation of Monovalent CD19(8B8-018) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains without Charged Residues (Construct 3.5)


A polypeptide containing two ectodomains of 4-1BB ligand (71-248), separated by (G4S)2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned in analogy as depicted in FIG. 29A, but without amino acid mutations in the CL domain: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-248) and fused to the human IgG1-CH1 domain, was cloned in analogy as depicted in FIG. 29B, but without amino acid mutations in the CH1 domain: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CH1.


The variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-018, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CD19-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CD19 light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CD19-binding Fab (FIG. 30E, Construct 3.5).


Table 51 shows the cDNA and amino acid sequences of the monovalent CD19(8B8-018) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule containing crossed CH-CL cross without charged residues (construct 3.5).









TABLE 51







cDNA and amino acid sequences of monovalent CD19(8B8-018)


targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion


containing CH-CL cross without charged residues (construct 3.5).









SEQ ID NO:
Description
Sequence





171
Nucleotide sequence dimeric
see Table 25



ligand (71-248) - CL Fc knob chain



172
Nucleotide sequence monomeric
see Table 25



ligand (71-248)-CH1



203
Nucleotide sequence anti-
see Table 47



CD19(8B8-018) Fc hole chain



204
Nucleotide sequence anti-
see Table 47



CD19(8B8-018) light chain



173
Dimeric ligand (71-248) - CL Fc
see Table 25



knob chain



174
Monomeric ligand (71-248) - CH1
see Table 25


205
anti-CD19(8B8-018) Fc hole chain
see Table 47


206
anti-CD19(8B8-018) light chain
see Table 47









7.1.8 Preparation of Bivalent CD19(8B8-018) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding (Construct 3.6)


A polypeptide containing two ectodomains of 4-1BB ligand (71-248), separated by (G4S)2 (SEQ ID NO:13) linkers was fused to the C-terminus of human IgG1 Fc hole chain, as depicted in FIG. 29C: human IgG1 Fc hole, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the C-terminus of human IgG1 Fc knob chain as described in FIG. 29D: human IgG1 Fc knob, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand.


The variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-018, were subcloned in frame with either the constant heavy chain of the hole, the knob or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the anti-CD19 huIgG1 hole dimeric ligand chain containing the Y349C/T366S/L368A/Y407V mutations, the anti-CD19 huIgG1 knob monomeric ligand chain containing the S354C/T366W mutations and the anti-CD19 light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and two CD19 binding Fabs (FIG. 30F, construct 3.6).


Table 52 shows the cDNA and amino acid sequences of the bivalent CD19(8B8-018) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule (construct 3.6).









TABLE 52







cDNA and amino acid sequences of bivalent


CD19(8B8-018) targeted split trimeric 4-


1BB ligand (71-248) Fc (kih) fusion


(construct 3.6)









SEQ ID




NO:
Description
Sequence





211
Nucleotide
CAGGTCCAGCTGGTGCAGTCCGGCG



sequence anti-
CCGAGGTCAAGAAACCCGGGGCTTC



CD19(8B8-018)
TGTGAAGGTTTCATGCAAGGCAAGC



Fc hole dimeric
GGATACACCTTCACCGACTATATCA



ligand (71-248)
TGCATTGGGTCAGGCAGGCCCCTGG



chain
CCAAGGTCTCGAATGGATGGGCTAC




ATTAACCCATATAATGATGGCTCCA




AATACACCGAGAAGTTTCAGGGAAG




AGTCACTATGACATCTGACACCAGT




ATCAGCACTGCTTACATGGAGCTGT




CCCGCCTTCGGTCTGATGACACCGC




AGTGTATTACTGTGCCAGGGGCACA




TATTACTACGGCTCAGCTCTGTTCG




ACTATTGGGGGCAGGGAACCACAGT




AACCGTGAGCTCCGCTAGCACCAAG




GGCCCCTCCGTGTTCCCCCTGGCCC




CCAGCAGCAAGAGCACCAGCGGCGG




CACAGCCGCTCTGGGCTGCCTGGTC




AAGGACTACTTCCCCGAGCCCGTGA




CCGTGTCCTGGAACAGCGGAGCCCT




GACCTCCGGCGTGCACACCTTCCCC




GCCGTGCTGCAGAGTTCTGGCCTGT




ATAGCCTGAGCAGCGTGGTCACCGT




GCCTTCTAGCAGCCTGGGCACCCAG




ACCTACATCTGCAACGTGAACCACA




AGCCCAGCAACACCAAGGTGGACAA




GAAGGTGGAGCCCAAGAGCTGCGAC




AAAACTCACACATGCCCACCGTGCC




CAGCACCTGAAGCTGCAGGGGGACC




GTCAGTCTTCCTCTTCCCCCCAAAA




CCCAAGGACACCCTCATGATCTCCC




GGACCCCTGAGGTCACATGCGTGGT




GGTGGACGTGAGCCACGAAGACCCT




GAGGTCAAGTTCAACTGGTACGTGG




ACGGCGTGGAGGTGCATAATGCCAA




GACAAAGCCGCGGGAGGAGCAGTAC




AACAGCACGTACCGTGTGGTCAGCG




TCCTCACCGTCCTGCACCAGGACTG




GCTGAATGGCAAGGAGTACAAGTGC




AAGGTCTCCAACAAAGCCCTCGGCG




CCCCCATCGAGAAAACCATCTCCAA




AGCCAAAGGGCAGCCCCGAGAACCA




CAGGTGTGCACCCTGCCCCCATCCC




GGGATGAGCTGACCAAGAACCAGGT




CAGCCTCTCGTGCGCAGTCAAAGGC




TTCTATCCCAGCGACATCGCCGTGG




AGTGGGAGAGCAATGGGCAGCCGGA




GAACAACTACAAGACCACGCCTCCC




GTGCTGGACTCCGACGGCTCCTTCT




TCCTCGTGAGCAAGCTCACCGTGGA




CAAGAGCAGGTGGCAGCAGGGGAAC




GTCTTCTCATGCTCCGTGATGCATG




AGGCTCTGCACAACCACTACACGCA




GAAGAGCCTCTCCCTGTCTCCGGGT




GGAGGCGGCGGAAGCGGAGGAGGAG




GATCCAGAGAGGGCCCTGAGCTGAG




CCCTGATGATCCTGCCGGACTGCTG




GACCTGCGGCAGGGAATGTTTGCCC




AGCTGGTGGCCCAGAACGTGCTGCT




GATCGATGGCCCCCTGTCCTGGTAC




AGCGATCCTGGACTGGCTGGCGTGT




CACTGACAGGCGGCCTGAGCTACAA




AGAGGACACCAAAGAACTGGTGGTG




GCCAAGGCCGGCGTGTACTACGTGT




TCTTTCAGCTGGAACTGCGGAGAGT




GGTGGCCGGCGAAGGATCTGGCTCT




GTGTCTCTGGCCCTGCATCTGCAGC




CTCTGAGATCTGCTGCTGGCGCCGC




TGCTCTGGCACTGACAGTGGATCTG




CCTCCTGCCAGCAGCGAGGCCCGGA




ATAGCGCATTTGGGTTTCAAGGCAG




GCTGCTGCACCTGTCTGCCGGCCAG




AGGCTGGGAGTGCATCTGCACACAG




AGGCCAGGGCTAGACACGCCTGGCA




GCTGACACAGGGCGCTACAGTGCTG




GGCCTGTTCAGAGTGACCCCCGAGA




TTCCAGCAGGCCTGGGAGGCGGCGG




ATCTGGCGGCGGAGGATCTAGAGAA




GGACCCGAGCTGTCCCCCGACGATC




CCGCTGGGCTGCTGGATCTGAGACA




GGGCATGTTCGCTCAGCTGGTGGCT




CAGAATGTGCTGCTGATTGACGGAC




CTCTGAGCTGGTACTCCGACCCAGG




GCTGGCAGGGGTGTCCCTGACTGGG




GGACTGTCCTACAAAGAAGATACAA




AAGAACTGGTGGTGGCTAAAGCTGG




GGTGTACTATGTGTTTTTTCAGCTG




GAACTGAGGCGGGTGGTGGCTGGGG




AGGGCTCAGGATCTGTGTCCCTGGC




TCTGCATCTGCAGCCACTGCGCTCT




GCAGCAGGGGCTGCAGCACTGGCCC




TGACTGTGGACCTGCCCCCAGCTTC




TTCCGAGGCCAGAAACAGCGCCTTC




GGGTTCCAAGGACGCCTGCTGCATC




TGAGCGCCGGACAGCGCCTGGGAGT




GCATCTGCATACTGAAGCCAGAGCC




CGGCATGCTTGGCAGCTGACTCAGG




GGGCAACTGTGCTGGGACTGTTTCG




CGTGACACCTGAGATCCCAGCCGGG




CTC





212
Nucleotide
CAGGTCCAGCTGGTGCAGTCCGGCG



sequence anti-
CCGAGGTCAAGAAACCCGGGGCTTC



CD 19(8B8-018)
TGTGAAGGTTTCATGCAAGGCAAGC



Fc knob
GGATACACCTTCACCGACTATATCA



monomeric (71-
TGCATTGGGTCAGGCAGGCCCCTGG



248) ligand
CCAAGGTCTCGAATGGATGGGCTAC




ATTAACCCATATAATGATGGCTCCA




AATACACCGAGAAGTTTCAGGGAAG




AGTCACTATGACATCTGACACCAGT




ATCAGCACTGCTTACATGGAGCTGT




CCCGCCTTCGGTCTGATGACACCGC




AGTGTATTACTGTGCCAGGGGCACA




TATTACTACGGCTCAGCTCTGTTCG




ACTATTGGGGGCAGGGAACCACAGT




AACCGTGAGCTCCGCTAGCACCAAG




GGCCCATCGGTCTTCCCCCTGGCAC




CCTCCTCCAAGAGCACCTCTGGGGG




CACAGCGGCCCTGGGCTGCCTGGTC




AAGGACTACTTCCCCGAACCGGTGA




CGGTGTCGTGGAACTCAGGCGCCCT




GACCAGCGGCGTGCACACCTTCCCG




GCTGTCCTACAGTCCTCAGGACTCT




ACTCCCTCAGCAGCGTGGTGACCGT




GCCCTCCAGCAGCTTGGGCACCCAG




ACCTACATCTGCAACGTGAATCACA




AGCCCAGCAACACCAAGGTGGACAA




GAAAGTTGAGCCCAAATCTTGTGAC




AAAACTCACACATGCCCACCGTGCC




CAGCACCTGAAGCTGCAGGGGGACC




GTCAGTCTTCCTCTTCCCCCCAAAA




CCCAAGGACACCCTCATGATCTCCC




GGACCCCTGAGGTCACATGCGTGGT




GGTGGACGTGAGCCACGAAGACCCT




GAGGTCAAGTTCAACTGGTACGTGG




ACGGCGTGGAGGTGCATAATGCCAA




GACAAAGCCGCGGGAGGAGCAGTAC




AACAGCACGTACCGTGTGGTCAGCG




TCCTCACCGTCCTGCACCAGGACTG




GCTGAATGGCAAGGAGTACAAGTGC




AAGGTCTCCAACAAAGCCCTCGGCG




CCCCCATCGAGAAAACCATCTCCAA




AGCCAAAGGGCAGCCCCGAGAACCA




CAGGTGTACACCCTGCCCCCCTGCA




GA




GATGAGCTGACCAAGAACCAGGTGT




CCCTGTGGTGTCTGGTCAAGGGCTT




CTACCCCAGCGATATCGCCGTGGAG




TGGGAGAGCAACGGCCAGCCTGAGA




ACAACTACAAGACCACCCCCCCTGT




GCTGGACAGCGACGGCAGCTTCTTC




CTGTACTCCAAACTGACCGTGGACA




AGAGCCGGTGGCAGCAGGGCAACGT




GTTCAGCTGCAGCGTGATGCACGAG




GCCCTGCACAACCACTACACCCAGA




AGTCCCTGAGCCTGAGCCCCGGCGG




AGGCGGCGGAAGCGGAGGAGGAGGA




TCCAGAGAGGGCCCTGAGCTGAGCC




CTGATGATCCTGCCGGACTGCTGGA




CCTGCGGCAGGGAATGTTTGCCCAG




CTGGTGGCCCAGAACGTGCTGCTGA




TCGATGGCCCCCTGTCCTGGTACAG




CGATCCTGGACTGGCTGGCGTGTCA




CTGACAGGCGGCCTGAGCTACAAAG




AGGACACCAAAGAACTGGTGGTGGC




CAAGGCCGGCGTGTACTACGTGTTC




TTTCAGCTGGAACTGCGGAGAGTGG




TGGCCGGCGAAGGATCTGGCTCTGT




GTCTCTGGCCCTGCATCTGCAGCCT




CTGAGATCTGCTGCTGGCGCCGCTG




CTCTGGCACTGACAGTGGATCTGCC




TCCTGCCAGCAGCGAGGCCCGGAAT




AGCGCATTTGGGTTTCAAGGCAGGC




TGCTGCACCTGTCTGCCGGCCAGAG




GCTGGGAGTGCATCTGCACACAGAG




GCCAGGGCTAGACACGCCTGGCAGC




TGACACAGGGCGCTACAGTGCTGGG




CCTGTTCAGAGTGACCCCCGAGATT




CCTGCCGGGCTC





204
Nucleotide
see Table 47



sequence anti-




CD19(8B8-018)




light chain






213
anti-CD19(8B8-
QVQLVQSGAEVKKPGASVKVSCKAS



018) Fc hole
GYTFTDYIMHWVRQAPGQGLEWMGY



dimeric ligand
INPYNDGSKYTEKFQGRVTMTSDTS



(71-248) chain
ISTAYMELSRLRSDDTAVYYCARGT




YYYGSALFDYWGQGTTVTVSSASTK




GPSVFPLAPSSKSTSGGTAALGCLV




KDYFPEPVTVSWNSGALTSGVHTFP




AVLQSSGLYSLSSVVTVPSSSLGTQ




TYICNVNHKPSNTKVDKKVEPKSCD




KTHTCPPCPAPEAAGGPSVFLFPPK




PKDTLMISRTPEVTCVVVDVSHEDP




EVKFNWYVDGVEVHNAKTKPREEQY




NSTYRVVSVLTVLHQDWLNGKEYKC




KVSNKALGAPIEKTISKAKGQPREP




QVCTLPPSRDELTKNQVSLSCAVKG




FYPSDIAVEWESNGQPENNYKTTPP




VLDSDGSFFLVSKLTVDKSRWQQGN




VFSCSVMHEALHNHYTQKSLSLSPG




GGGGSGGGGSREGPELSPDDPAGLL




DLRQGMFAQLVAQNVLLIDGPLSWY




SDPGLAGVSLTGGLSYKEDTKELVV




AKAGVYYVFFQLELRRVVAGEGSGS




VSLALHLQPLRSAAGAAALALTVDL




PPASSEARNSAFGFQGRLLHLSAGQ




RLGVHLHTEARARHAWQLTQGATVL




GLFRVTPEIPAGLGGGGSGGGGSRE




GPELSPDDPAGLLDLRQGMFAQLVA




QNVLLIDGPLSWYSDPGLAGVSLTG




GLSYKEDTKELVVAKAGVYYVFFQL




ELRRVVAGEGSGSVSLALHLQPLRS




AAGAAALALTVDLPPASSEARNSAF




GFQGRLLHLSAGQRLGVHLHTEARA




RHAWQLTQGATVLGLFRVTPEIPAG




L





214
anti-CD19(8B8-
QVQLVQSGAEVKKPGASVKVSCKAS



018) Fc knob
GYTFTDYIMHWVRQAPGQGLEWMGY



monomeric (71-
INPYNDGSKYTEKFQGRVTMTSDTS



248) ligand
ISTAYMELSRLRSDDTAVYYCARGT




YYYGSALFDYWGQGTTVTVSSASTK




GPSVFPLAPSSKSTSGGTAALGCLV




KDYFPEPVTVSWNSGALTSGVHTFP




AVLQSSGLYSLSSVVTVPSSSLGTQ




TYICNVNHKPSNTKVDKKVEPKSCD




KTHTCPPCPAPEAAGGPSVFLFPPK




PKDTLMISRTPEVTCVVVDVSHEDP




EVKFNWYVDGVEVHNAKTKPREEQY




NSTYRVVSVLTVLHQDWLNGKEYKC




KVSNKALGAPIEKTISKAKGQPREP




QVYTLPPCRDELTKNQVSLWCLVKG




FYPSDIAVEWESNGQPENNYKTTPP




VLDSDGSFFLYSKLTVDKSRWQQGN




VFSCSVMHEALHNHYTQKSLSLSPG




GGGGSGGGGSREGPELSPDDPAGLL




DLRQGMFAQLVAQNVLLIDGPLSWY




SDPGLAGVSLTGGLSYKEDTKELWA




KAGVYYVFFQLELRRWAGEGSGSVS




LALHLQPLRSAAGAAALALTVDLPP




ASSEARNSAFGFQGRLLHLSAGQRL




GVHLHTEARARHAWQLTQGATVLGL




FRVTPEIPAGL





206
anti-CD 19(8B8-
see Table 47



018) light chain









7.2 Preparation of CD19 (8B8-Derived Affinity Matured) Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules and Corresponding Control Molecules


7.2.1 Generation of 8B8-Derived Affinity-Matured Anti-CD19 Binders Devoid of Hotspots


7.2.1.1 Selection of Affinity Matured CD19-Specific Antibodies


De-amidation of the asparagine residues at positions 27d and 28, located in CDR1 of the light chain of the humanized clone 8B8, leads to a significant reduction in the biological activity. Therefore, 2 phage display libraries were generated in which a) both asparagine residues at positions 27d and 28 were eliminated and b) additional CDRs of heavy and light chain were randomized in order to select for 8B8 variants with an improved affinity.


7.2.1.2 Generation of 8B8 Affinity Maturation Libraries Devoid of LCDR1 Hotspots


Generation of affinity-matured 8B8-derived antibodies without the de-amidation sites N27d and N28, located in LCDR1, was carried out by phage display using standard protocols (Silacci et al, 2005). In a first step, the VL and VH DNA sequences of the humanized parental clone 8B8 (SEQ ID NO: 215 and SEQ ID NO: 216) were cloned into our phagemid which was then used as a template for randomization. In a next step, two libraries were generated for the selection of favourable clones by phage display. In order to eliminate the above-mentioned hotspot positions, a LCDR1 randomization primer (SEQ ID NO: 217) that only allowed amino acids S T Q E at positions 27d and 28 was used for both libraries. Maturation library 1 was randomized in CDR1 and 2 of both the light and the heavy chain, while maturation library 2 was randomized in CDR1 and 3 of the light chain and in CDR3 of the heavy chain. The randomized positions in the respective CDR regions are shown in FIGS. 31A-1 to 31A-2. For the generation of the maturation library 1, randomized in CDR1 and 2 of both the light and the heavy chain, three fragments were assembled by “splicing by overlapping extension” (SOE) PCR and cloned into the phage vector (FIGS. 31B-1 to 31B-2). The following primer combinations were used to generate the library fragments: fragment 1 (LMB3 (SEQ ID NO: 222) and CD19 L1 reverse random (SEQ ID NO: 217), fragment 2 (CD19 L2 forward random (SEQ ID NO: 218) and CD19 HI reverse random (SEQ ID NO: 219), and fragment 3 (CD19 H2 forward random (SEQ ID NO: 220) and CD19 H3 reverse constant (SEQ ID NO: 221) (Table 53). After assembly of sufficient amounts of full length randomized fragment, it was digested with NcoI/NheI alongside with identically treated acceptor phagemid vector. A 3-fold molar excess of library insert was ligated with 10 μg of phagemid vector. Purified ligations were used for 20 transformations resulting in 2×10 exp9 transformants. Phagemid particles displaying the 8B8 affinity maturation library were rescued and purified by PEG/NaCl purification to be used for selections.


The generation of the second library, randomized in CDR1 and 3 of the light chain and in CDR3 of the heavy chain, was done similarly. The following primer combinations were used to generate the library fragments: fragment 1 (LMB3 (SEQ ID NO: 222) and CD19 L1 reverse random (SEQ ID NO: 217), fragment 2 (CD19 L1 forward constant (SEQ ID NO 223) and CD19 L3 reverse random (SEQ ID NO 224), and fragment 3 (CD19 L3 forward constant (SEQ ID NO: 225) and CD19 H3 reverse random (SEQ ID NO: 226) (Table 54). After assembly of sufficient amounts of full length randomized fragment, it was digested with NcoI/KpnI alongside with identically treated acceptor phagemid vector. A 3-fold molar excess of library insert was ligated with 20 ug of phagemid vector. Purified ligations were used for 40 transformations resulting in 2×10 exp9 transformants. Phagemid particles displaying the 8B8 affinity maturation library were rescued and purified by PEG/NaCl purification to be used for selections.









TABLE 53







Primers for 8B8 affinity maturation and hotspot removal library L1_L2/H1_H2









SEQ ID
Name
Sequence





217
CD19 L1
CAG CTG CGG GCT CTG ACC CGG TTT CTG GAG ATA



reverse
CCA GTT CAG 1 CGT 2 GCC 3 GGA 4 TTC CAG AGA TTG



random
GCT GGA TTT GCA AGA AAT G




1: 40% Y, 6% A/S/T/G/P/D/N/E/Q/V, 2: 40% N, 6%




A/S/T/Y/G/P/D/E/Q/V, 3: 25% S/T/Q/E, 4: 25% S/T/Q/E





218
CD19 L2
CTC CAG AAA CCG GGT CAGAGC CCG CAG CTG CTG



forward
ATC TAC 5 GTA TCT 6 CGC 7 8 GGC GTT 9 GAT CGT TTC



random
AGC GGT TCT GGA TCC GGC ACC




5: 30% R, 20% E, 5% A/S/T/Y/G/P/D/N/Q/V. 6: 30% K, 20%




S, 5% A/N/T/Y/G/P/D/E/Q/V, 7: 40% F, 5%




A/S/T/Y/G/P/D/E/Q/V/I/L, 8: 40% S, 6.6%




A/T/Y/G/P/D/E/Q/V, 9: 50% P, 50% L





219
CD19 H1
CAT CCA CTC CAG ACC CTG GCC CGG GGC CTGACG



reverse
AAC CCA 10 CAT 11 12 13 14 GAA 15 GTA ACC AGA TGC



random
TTT GCA GCT CAC TTT AAC GGAAGC




10: 52% H, 4% G/A/S/P/T/N/Y/D/E/Q/V/I, 11: 30% I, 15% Y,




5% G/A/S/T/P/N/H/D/E/Q/V, 12: 52% Y, 4%




G/A/S/P/T/N/H/D/E/Q/V/I, 13: 30% D, 15% G, 5%




A/S/P/Y/N/H/D/E/Q/V/I, 14: 52% T, 4%




G/A/S/P/Y/N/H/D/E/Q/V/I, 15: 52% T, 4%




G/A/S/P/Y/N/H/D/E/Q/V/I





220
CD19 H2
CAG GCC CCG GGC CAG GGT CTG GAG TGGATG GGC



forward
16 ATT 17 CCA 18 19 20 21 TCC 22 TAT ACC 23 AAA TTC



random
CAG GGC CGC GTC ACG ATG ACC




16: 45% Y, 5% A/S/P/TN/H/D/E/Q/V/I, 17: 52% N, 4%




G/A/S/P/Y/T/H/D/E/Q/V/I, 18: 40% Y, 5%




G/A/S/P/T/N/H/D/E/Q/V/I, 19: 30% N, 15% S, 5%




G/A/T/P/Y/H/D/E/Q/V/I, 20: 30% D, 15% G, 5%




A/S/T/P/Y/N/H/E/Q/V/I, 21: 52% G, 4%




N/A/S/P/Y/T/H/D/E/Q/V/I, 22: 30% K, 15% N, 4%




G/A/S/P/Y/T/H/D/E/Q/V/I, 23: 30% E, 15% Q, 5%




G/A/S/T/P/Y/N/H/D/V/I





221
CD19 H3
CGTCACCGGTTCGGGGAAGTAGTCCTTGACCAG



reverse




constant






222
LMB3
CAGGAAACAGCTATGACCATGATTAC
















TABLE 54







Primers for 8B8 affinity maturation and hotspot removal library L1_L3/H3









SEQ ID
Name
Sequence





223
CD19 L1
TGGTATCTCCAGAAACCGGGTCAGAGCCCGCAG



forward




constant






217
CD19 L1
See Table 53



reverse




random






224
CD19 L3
TTT AAT TTC CAG TTT AGT TCC TTG ACC GAA GGT 24



reverse
25 26 27 28 29 CTG CAG ACA ATA GTA GAC GCC AAC



random
GTC TTC AGC




24: 52% Y, 4% G/A/S/T/N/P/D/E/Q/V/L/I, 25: 52% P, 4%




G/A/S/T/Y/N/H/D/E/QN/I, 26: 42% V, 10% L, 4%




G/A/S/T/Y/N/P/D/E/Q/V/I, 27: 52% H, 4%




G/A/S/T/Y/N/P/D/E/Q/V/I, 28: 42% T, 10% I, 4%




G/A/S/T/Y/N/P/D/E/Q/V/L, 29: 45% L, 11% G, 4%




A/S/T/Y/N/P/D/E/Q/V/I





225
CD19 L3
ACCTTCGGTCAAGGAACTAAACTGGAAATTAAACG



forward




constant






226
CD19 H3
TT GGT GCT AGC AGA GCT TAC GGT CAC CGT GGT



reverse
ACC TTG GCC CCA GTA ATC AAA 30 31 32 33 34 35 36 37



random
38 GCG TGC ACA ATA GTA AAC AGC GGT GTC




30: 50% L, 3.8% G/A/S/T/P/H/Y/N/D/E/Q/V/I, 31: 50% A,




4.2% G/S/T/P/H/Y/N/D/E/Q/V/I, 32: 50% S, 4.2%




G/A/T/P/H/Y/N/D/E/QN/I, 33: 50% G, 4.2%




S/A/T/P/H/Y/N/D/E/Q/V/I, 34: 50% Y, 4.2%




G/A/T/P/H/S/N/D/E/Q/V/I, 35: 50% Y, 4.2%




G/A/T/P/H/S/N/D/E/Q/V/I, 36: 50% Y, 4.2%




G/A/T/P/H/S/N/D/E/Q/V/I, 37: 50% T, 4.2%




G/A/Y/P/H/S/N/D/E/Q/V/I, 38: 50% G, 4.2%




Y/A/T/P/H/S/N/D/E/Q/V/I





222
LMB3
See Table 53









7.2.1.3 Selection of Affinity Matured 8B8-Derived Clones Devoid of LCDR1 Hotspots N27d and N28


For the selection of affinity-matured clones devoid of the LCDR1hotspots N27d and N28, two selection approaches by phage display were performed:


In the first approach, the selection was executed on human CD19-Fc fusion protein using both phage display libraries. Panning rounds were performed in solution according to the following pattern: 1. binding of ˜1012 phagemid particles to 30 nM biotinylated CD19-Fc protein for 0.5 h in a total volume of 1 ml, 2. capture of biotinylated CD19-Fc protein and specifically bound phage particles by addition of 5.4×107 streptavidin-coated magnetic beads for 10 min, 3. washing of beads using 5×1 ml PBS/TWEEN® 20 (polysorbate 20) and 5×1 ml PBS, 4. elution of phage particles by addition of 1 ml 100 mM TEA for 10 min and neutralization by adding 500 ul 1M Tris/HCl pH 7.4, 5. re-infection of exponentially growing E. coli TG1 bacteria, and 6.infection with helperphage VCSM13 and subsequent PEG/NaCl precipitation of phagemid particles to be used in subsequent selection rounds. Selections were carried out over 3 rounds using decreasing antigen concentrations (30×10−9M, 10×10−9M, and 3×10−9M). In round 2 and 3, capture of antigen:phage complexes was performed using neutravidin plates instead of streptavidin beads. Neutravidin plates were washed with 5×PBS/TWEEN® 20 (polysorbate 20) and 5×PBS. In round 3, the neutravidin plate was incubated overnight in 2 liters PBS for an “off-rate” selection before phage was eluted from the plate. Furthermore, cynomolgus CD19-Fc protein was used in round 2 in order to enrich cross-reactive binders.


In the second selection approach, the phage panning was executed on cells transiently expressing either the human or cynomolgus CD19 ECD on the cell surface. For the transient transfection of HEK cells, expression plasmids were generated that harbor the DNA sequences (from 5′ to 3′) for the following protein segments: A Flag tag, a SNAP tag, the CD19 ECD of either human or cynomolgus origin, and the transmembrane region of the Platelet-derived growth factor receptor (PDGFR) (SEQ ID NOs: 227 and 228). The expression of the respective proteins (SEQ ID NOs: 229 and 230) on the cell surface was confirmed by flow cytometry using an anti-Flag antibody for detection. Both libraries were exposed in the first selection round to cells either expressing the human or cynomolgus CD19 ECD-containing protein fusion. For the subsequent panning rounds, the species of the CD19 ECD was alternated accordingly. Cells transiently transfected with an irrelevant membrane protein were used for pre-clearing.


Panning rounds were performed according to the following pattern:


1. Transfection of HEK cells with constructs expressing either CD19 ECD or an irrelevant transmembrane protein according to the standard procedure described before,


2. Incubation of the cells for total 48h at 37° C. in an incubator with a 5% CO2 atmosphere, 3. Isolation of cells by centrifugation (3 min at 250×g) and re-suspension of 1×10E7 CD19 ECD-positive cells and 1×10E7 negative cells in PBS/5% BSA, respectively,


3. Pre-clearing of unspecific phage by incubating the phage library with 1×107 CD19-negative cells for 60 min at 4° C. using a gently rotating tube rotator,


4. Centrifugation of cells at 250×g for 3 min and transfer of supernatant into a fresh tube and addition of 1×10E7 CD19-positive cells and incubation for 60 min at 4° C. by gentle rotation on a tube rotator,


5. Washing of cells by centrifugation for 1 min at 250×g, aspiration of the supernatant, and re-suspension in 1 ml PBS (8 times),


6. Phage elution with 1 ml 100 mM TEA, incubation for 5 min at RT, and neutralization of the eluate with 500 ul 1M Tris-HCl, pH7.6,


7. re-infection of exponentially growing E. coli TG1 bacteria, and


8.infection with helperphage VCSM13 and subsequent PEG/NaCl precipitation of phagemid particles to be used in subsequent selection rounds. Selections were carried out over 3 rounds.


For both selection approaches, specific binders were identified by ELISA as follows: 100 ul of 30 nM biotinylated CD19-Fc protein per well were coated on neutravidin plates. Fab-containing bacterial supernatants were added and binding Fabs were detected via their Flag-tags using an anti-Flag/HRP secondary antibody.


Clones that were ELISA-positive on recombinant human CD19 were further tested in a cell-based ELISA using cells that were transiently transfected with the human CD19 ECD-containing expression plasmid (SEQ ID NO: 227). This analysis was performed as follows: 48 h after transfection, HEK cells were harvested and centrifuged at 250×g for 5 min. Cells were then re suspended in ice-cold PBS BSA 2% to 4×106 cells/ml and incubated for 20 min on ice to block unspecific binding sites. 4×105 cells in 100 ul were distributed to each well of a 96 well plate and centrifuged at 250×g and 4° C. for 3 min. Supernatant was aspirated off and 50u1 bacterial supernatant containing soluble Fab fragments was diluted with 50 ul ice-cold PBS/BSA 2%, added to the plate, mixed with the cells and incubated for 1 h at 4° C. Afterwards, cells were washed 3 times with ice cold PBS before 100 ul PBS BSA 2% per well containing a 1:2000 dilution of anti-Fab-HRP antibody were added. After an incubation time of 1 h, cells were washed again 3 times with ice-cold PBS. For the development, 100 ul “1-step ultra TMB-ELISA” substrate was added per well. After an incubation time of 10 minutes, supernatant was transferred to a new 96-well plate containing 40 ul H2SO4 1M per well and absorbance was measured 450 nM. Clones exhibiting significant signals over background were subjected to a kinetic screening experiment by SPR-analysis using ProteOn XPR36.


7.2.1.4 Identification of Affinity-Matured 8B8-Derived Variants by SPR


In order to further characterize the ELISA-positive clones, the off-rate was measured by surface plasmon resonance and compared with the parental humanized clone 8B8.


For this experiment, 7000 RU of polyclonal anti-human Fab antibody were immobilized on all 6 channels of a GLM chip by Amine coupling (NaAcetate pH4.5, 25 μl/min, 240s) (vertical orientation). Each antibody-containing bacterial supernatant was filtered and 2-fold diluted with PBS, and then injected for 360s at 25 μl/minute to achieve immobilization levels of between 100 and 400 response units (RU) in vertical orientation. Injection of monomeric CD19-Fc: For one-shot kinetics measurements, injection direction was changed to horizontal orientation, three-fold dilution series of purified monomeric CD19-Fc (varying concentration ranges between 150 and 6 nM) were injected simultaneously at 50 μl/min along separate channels 1-4, with association times of 180 s, and dissociation times of 300 s. A human IgG Fc fragment (150 nM) was injected in channel 5 as a negative control for specific binding to monomeric CD19-Fc Buffer (PBST) was injected along the sixth channel to provide an “in-line” blank for referencing. Regeneration was performed by two pulses of 10 mM glycine pH 1.5 and 50 mM NaOH for 30s at 90 ul/min (horizontal orientation). Dissociation rate constants (koff) were calculated using a simple one-to-one Langmuir binding model in ProteOn Manager v3.1 software by simultaneously fitting the sensorgrams. Clones expressing Fabs with the slowest dissociation rate constants were identified (Table 55). Of note, the dissociation rate constants of clones 5A07 and 5B08 could not be determined due to inadequate fitting. Nevertheless, both clones were selected because results obtained suggested a very slow dissociation. The variable domains of the corresponding phagemids were sequenced. Importantly, both asparagine residue in LCDR1 (position 27d and 28) were replaced by a serine or a threonine, demonstrating that both de-amidation sites were removed. An alignment is shown in FIGS. 32A and 32B. The CDRs of the best clones are listed in Table 56 (variable regions of the light chain) and Table 57 (variable regions of the heavy chain) (clone 5H09: (SEQ ID NO:231-236); clone 7H07: (SEQ ID NO:237-242); clone 2B03: (SEQ ID NO: 243-248); clone 2B11: (SEQ ID NO:249-254); clone 5A07: (SEQ ID NO:255-260); clone 5B08: (SEQ ID NO:261-266); clone 5D08: (SEQ ID NO:267-272).









TABLE 55







Dissociation constants of selected clones obtained in


screening analysis with bacterial supernatant










clone
Dissociation constant kd (1/s)







Parental 8B8
3.01E−4



5H09
2.58E−4



7H07
5.75E−5



2B03
3.24E−5



2B11
4.37E−6



5A07
n.d.



5B08
n.d.



5D08
1.95E−4

















TABLE 56







CDR sequences of the selected 8B8 light chains














SEQ

SEQ

SEQ




ID

ID

ID



clone
NO
CDR-L1
NO
CDR-L2
NO
CDR-L3





5H09
231
KSSQSLESSTGNTYLN
232
RVSKRFS
233
LQLIDYPVT





7H07
237
KSSQSLETSTGNTYLN
238
RVSKRFS
239
LQATHIPYT





2B03
243
KSSQSLETSTGNTYLN
244
RVSKRFS
245
LQLTHVPYT





2B11
249
KSSQSLETSTGTTYLN
250
RVSKRFS
251
LQLLEDPYT





5A07
255
KSSQSLETSTGNTYLN
256
RVSKRFS
257
LQPGHYPGT





5B08
261
KSSQSLETSTGNTYLN
262
RVSKRFS
263
LQLDSYPNT





5D08
267
KSSQSLETSTGNTYLN
268
RVSKRFS
269
LQLTHEPYT
















TABLE 57







CDR sequences of the selected 8B8 heavy chains














SEQ

SEQ

SEQ




ID
CDR-
ID

ID



clone
NO
H1
NO
CDR-H2
NO
CDR-H3





5H09
234
DYIMH
235
YINPYNDGSKYTEKFQG
236
GTYYYGSALFDY





7H07
240
DYIMH
241
YINPYNDGSKYTEKFQG
242
GTYYYGSELFDY





2B03
246
DYITH
247
YINPYNDGSKYTEKFQG
248
GTYYYGPDLFDY





2B11
252
DYIMH
253
YINPYNDGSKYTEKFQG
254
GTYYYGPQLFDY





5A07
258
DYIMH
259
YINPYNDGSKYTEKFQG
260
GTYYYGSALFDY





5B08
264
DYIMH
265
YINPYNDGSKYTEKFQG
266
GTYYYGPQLFDY





5D08
270
DYIMH
271
YINPYNDGSKYTEKFQG
272
GTYYYGSELFDY









7.2.2 Characterization of Affinity-Matured 8B8-Derived Antibodies


7.2.2.1 Cloning of Variable Antibody Domains into Expression Vectors


The variable regions of heavy and light chain DNA sequences of the selected anti-CD19 binders were subcloned in frame with either the constant heavy chain or the constant light chain of human IgG1. In the heavy chain, Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in order to abrogate binding to Fc gamma receptors according to the method described in International Patent Appl. Publ. No. WO 2012/130831 A1.


The cDNA and amino acid sequences of the anti-CD19 IgGs are shown in Table 58 and Table 59, respectively. All antibody-encoding sequences were cloned into an expression vector, which drives transcription of the insert with a chimeric MPSV promoter and contains a synthetic polyA signal sequence located at the 3′ end of the CDS. In addition, the vector contains an EBV OriP sequence for episomal maintenance of the plasmid.









TABLE 58







cDNA and amino acid sequences of anti-CD19 clone 8B8


in P329GLALA human IgG1 format









SEQ
Clone



ID
and



NO:
Chain
Sequence





273
8B8
GATGCTGTGATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGA



Parental
GATCAAGCCTCCATCTCTTGCAGGTCTAGTCAGAGCCTTGAAAACAGT



light
AATGGAAACACCTATTTGAACTGGTACCTCCAGAAACCAGGCCAGTC



chain
TCCACAACTCCTGATCTACAGGGTTTCCAAACGATTTTCTGGGGTCCT




AGACAGGTTCAGTGGTAGTGGATCAGGGACAGATTTCACACTGAAAA




TCAGCAGAGTGGAGGCTGAGGATTTGGGAGTTTATTTCTGCCTACAA




CTTACACATGTCCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAAT





AAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATG






AGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCT






ATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCG






GGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCT






ACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACAC






AAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCAC






AAAGAGCTTCAACAGGGGAGAGTGT






274
8B8
GAGGTCCAGCTGCAGCAGTCTGGACCTGAGCTGGTAAAGCCTGGGGC



parental
TTCAGTGAAGATGGCCTGCAAGGCTTCTGGATACACATTCACTGACTA



heavy
TATTATGCACTGGGTGAAGCAGAAGACTGGGCAGGGCCTTGAGTGGA



chain
TTGGATATATTAATCCTTACAATGATGGTTCTAAGTACACTGAGAAGT




TCAACGGCAAGGCCACACTGACTTCAGACAAATCTTCCATCACAGCC




TACATGGAGCTCAGCAGCCTGACCTCTGAGGACTCTGCGGTCTATTAC




TGTGCAAGAGGGACCTATTATTATGGTAGCGCCCTCTTTGACTACTGG




GGCCAAGGCACCACTCTCACAGTCTCCTCGGCTAGCACCAAGGGCCCA





TCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGC






GGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTG






TCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTG






TCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC






TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCC






CAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAA






CTCACACATGCCCACCGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTC






AGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGAC






CCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAG






GTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGAC






AAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC






CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAA






GGTCTCCAACAAAGCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAG






CCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCG






GGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCT






TCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGA






GAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCT






TCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAA






CGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCA






GAAGAGCCTCTCCCTGTCTCCGGGTAAA






275
8B8
DAVMTQTPLSLPVSLGDQASISCRSSQSLENSNGNTYLNWYLQKPGQSP



Parental
QLLIYRVSKRFSGVLDRFSGSGSGTDFTLKISRVEAEDLGVYFCLQLTHVP



light
YTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLIVNFYPREAKVQW



chain

KVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGL






SSPVTKSFNRGEC






276
8B8
EVQLQQSGPELVKPGASVKMACKASGYTFTDYIMHWVKQKTGQGLEWI



parental
GYINPYNDGSKYTEKFNGKATLTSDKSSITAYMELSSLTSEDSAVYYCAR



heavy
GTYYYGSALFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL



chain

VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC






NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTL






MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV






SVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPSRD






ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK






LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

















TABLE 59







cDNA and amino acid sequences of affinity matured


anti-CD19 clones in P329GLALA human IgG1 format









SEQ
Clone



ID
and



NO:
Chain
Sequence





277
2B11
GATATTGTCATGACTCAAACTCCACTGTCTCTGTCCGTGACCCCGGGT



light
CAGCCAGCGAGCATTTCTTGCAAATCCAGCCAATCTCTGGAAACCTCC



chain
ACCGGCACCACGTACCTGAACTGGTATCTCCAGAAACCGGGTCAGAG




CCCGCAGCTGCTGATCTACCGTGTATCTAAGCGCTTCTCCGGCGTTCC




TGATCGTTTCAGCGGTTCTGGATCCGGCACCGACTTTACTCTGAAAAT




CAGCCGTGTGGAAGCTGAAGACGTTGGCGTCTACTATTGTCTGCAGCT




GCTGGAAGATCCATACACCTTCGGTCAAGGAACGAAACTGGAAATTA




AACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATG




AGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACT




TCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTC




CAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGG




ACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGAC




TACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCT




GAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT





278
2B11
CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCGC



heavy
TTCCGTTAAAGTGAGCTGCAAAGCATCTGGTTACACCTTCACTGACTA



chain
TATCATGCACTGGGTTCGTCAGGCCCCGGGCCAGGGTCTGGAGTGGA




TGGGCTACATTAACCCATACAACGACGGTTCCAAATATACCGAGAAA




TTCCAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCCACCGCG




TACATGGAACTGTCTAGACTGCGTTCTGACGACACCGCTGTTTACTAT




TGTGCACGCGGTACCTACTACTACGGTCCACAGCTGTTTGATTACTGG




GGCCAAGGTACCACGGTGACCGTAAGCTCTGCTAGCACCAAGGGCCC




ATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCAC




AGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGA




CGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTC




CCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTG




ACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGT




GAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC




AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGA




AGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGG




ACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTG




GACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGA




CGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAG




TACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCA




GGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAA




GCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA




GCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGC




TGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTAT




CCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGA




ACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCT




TCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGG




AACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC




ACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA





279
2B11
DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGTTYLNWYLQKPGQSPQL



light
LIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQLLEDPY



chain
TFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV




QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC




EVTHQGLSSPVTKSFNRGEC





280
2B11
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQAPGQGLEW



heavy
MGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYC



chain
ARGTYYYGPQLFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAA




LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS




SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF




LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT




KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISK




AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE




NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY




TQKSLSLSPGK





281
7H07
GATATTGTTATGACTCAAACTCCACTGTCTCTGTCCGTGACCCCGGGT



light
CAGCCAGCGAGCATTTCTTGCAAATCCAGCCAATCTCTGGAAACCTCC



chain
ACCGGCAACACGTACCTGAACTGGTATCTCCAGAAACCGGGTCAGAG




CCCGCAGCTGCTGATCTACCGTGTATCTAAGCGCTTCTCCGGCGTTCC




TGATCGTTTCAGCGGTTCTGGATCCGGCACCGACTTTACTCTGAAAAT




CAGCCGTGTGGAAGCTGAAGACGTTGGCGTCTACTATTGTCTGCAGG




CAACCCATATCCCATACACCTTCGGTCAAGGAACTAAACTGGAAATT




AAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGAT




GAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAAC




TTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCT




CCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAG




GACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGA




CTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC




TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT





282
7H07
CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCGC



heavy
TTCCGTTAAAGTGAGCTGCAAAGCATCTGGTTACACCTTCACTGACTA



chain
TATCATGCACTGGGTTCGTCAGGCCCCGGGCCAGGGTCTGGAGTGGA




TGGGCTACATTAACCCATACAACGACGGTTCCAAATATACCGAGAAA




TTCCAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCCACCGCG




TACATGGAACTGTCTAGACTGCGTTCTGACGACACCGCTGTTTACTAT




TGTGCACGCGGTACCTACTACTACGGTTCTGAACTGTTTGATTACTGG




GGCCAAGGTACCACGGTGACCGTAAGCTCTGCTAGCACCAAGGGCCC




ATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCAC




AGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGA




CGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTC




CCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTG




ACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGT




GAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC




AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGA




AGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGG




ACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTG




GACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGA




CGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAG




TACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCA




GGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAA




GCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA




GCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGC




TGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTAT




CCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGA




ACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCT




TCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGG




AACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC




ACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA





283
7H07
DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYLNWYLQKPGQSPQL



light
LIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQATHIPYT



chain
FGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ




WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE




VTHQGLSSPVTKSFNRGEC





284
7H07
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQAPGQGLEW



heavy
MGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYC



chain
ARGTYYYGSELFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAA




LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS




SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF




LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT




KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISK




AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE




NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY




TQKSLSLSPGK





285
2B03
GATATTGTTATGACTCAAACTCCACTGTCTCTGTCCGTGACCCCGGGT



light
CAGCCAGCGAGCATTTCTTGCAAATCCAGCCAATCTCTGGAAACCTC



chain
CACCGGCAACACGTACCTGAACTGGTATCTCCAGAAACCGGGTCAGA




GCCCGCAGCTGCTGATCTACCGTGTATCTAAGCGCTTCTCCGGCGTTC




CTGATCGTTTCAGCGGTTCTGGATCCGGCACCGACTTTACTCTGAAAA




TCAGCCGTGTGGAAGCTGAAGACGTTGGCGTCTACTATTGTCTGCAG




TTGACCCACGTTCCGTACACCTTCGGTCAAGGAANNAAACTGGAAAT




TAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGA




TGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAA




CTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCC




TCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAA




GGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCA




GACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG




CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT





286
2B03
CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCGC



heavy
TTCCGTTAAAGTGAGCTGCAAAGCATCTGGTTACACCTTCACTGACTA



chain
TATCACGCACTGGGTTCGTCAGGCCCCGGGCCAGGGTCTGGAGTGGA




TGGGCTACATTAACCCATACAACGACGGTTCCAAATATACCGAGAAA




TTCCAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCCACCGC




GTACATGGAACTGTCTAGACTGCGTTCTGACGACACCGCTGTTTACTA




TTGTGCACGCGGTACCTACTACTACGGTCCAGATCTGTTTGATTACTG




GGGCCAAGGTACCACGGTGACCGTAAGCTCTGCTAGCACCAAGGGCC




CATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCA




CAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTG




ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTT




CCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGT




GACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACG




TGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCC




CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG




AAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG




GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGT




GGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG




ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA




GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACC




AGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA




AGCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC




AGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG




CTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTA




TCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG




AACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTT




CTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGG




GGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACT




ACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA





287
2B03
DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYLNWYLQKPGQSPQ



light
LLIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQLTHVP



chain
YTFGQGXKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK




VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA




CEVTHQGLSSPVTKSFNRGEC





288
2B03
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYITHWVRQAPGQGLEW



heavy
MGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYC



chain
ARGTYYYGPDLFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAA




LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS




SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSV




FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT




KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISK




AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP




ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH




YTQKSLSLSPGK





289
5A07
GATATTGTTATGACTCAAACTCCACTGTCTCTGTCCGTGACCCCGGGT



light
CAGCCAGCGAGCATTTCTTGCAAATCCAGCCAATCTCTGGAAACCTC



chain
CACCGGCAACACGTACCTGAACTGGTATCTCCAGAAACCGGGTCAGA




GCCCGCAGCTGCTGATCTACCGTGTATCTAAGCGCTTCTCCGGCGTTC




CTGATCGTTTCAGCGGTTCTGGATCCGGCACCGACTTTACTCTGAAAA




TCAGCCGTGTGGAAGCTGAAGACGTTGGCGTCTACTATTGTCTGCAG




CCAGGTCATTACCCAGGTACCTTCGGTCAAGGAACTAAACTGGAAAT




TAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGA




TGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAA




CTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCC




TCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAA




GGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCA




GACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG




CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT





290
5A07
CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCGC



heavy
TTCCGTTAAAGTGAGCTGCAAAGCATCTGGTTACACCTTCACTGACTA



chain
TATCATGCACTGGGTTCGTCAGGCCCCGGGCCAGGGTCTGGAGTGGA




TGGGCTACATTAACCCATACAACGACGGTTCCAAATATACCGAGAAA




TTCCAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCCACCGC




GTACATGGAACTGTCTAGACTGCGTTCTGACGACACCGCTGTTTACTA




TTGTGCACGCGGTACTTACTACTACGGTTCCGCCCTCTTTGATTACTG




GGGCCAAGGTACCACGGTGACCGTAAGCTCTGCTAGCACCAAGGGCC




CATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCA




CAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTG




ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTT




CCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGT




GACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACG




TGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCC




CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG




AAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG




GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGT




GGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG




ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA




GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACC




AGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA




AGCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC




AGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG




CTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTA




TCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG




AACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTT




CTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGG




GGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACT




ACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA





291
5A07
DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYLNWYLQKPGQSPQ



light
LLIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQPGHYP



chain
GTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK




VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA




CEVTHQGLSSPVTKSFNRGEC





292
5A07
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQAPGQGLEW



heavy
MGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYC



chain
ARGTYYYGSALFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAA




LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS




SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSV




FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT




KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISK




AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP




ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH




YTQKSLSLSPGK





293
5D08
GATATTGTTATGACTCAAACTCCACTGTCTCTGTCCGTGACCCCGGGT



light
CAGCCAGCGAGCATTTCTTGCAAATCCAGCCAATCTCTGGAAACCTC



chain
CACCGGCAACACGTACCTGAACTGGTATCTCCAGAAACCGGGTCAGA




GCCCGCAGCTGCTGATCTACCGTGTATCTAAGCGCTTCTCCGGCGTTC




CTGATCGTTTCAGCGGTTCTGGATCCGGCACCGACTTTACTCTGAAAA




TCAGCCGTGTGGAAGCTGAAGACGTTGGCGTCTACTATTGTCTGCAG




CTGACCCATGAACCATACACCTTCGGTCAAGGAACTAAACTGGAAAT




TAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGA




TGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAA




CTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCC




TCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAA




GGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCA




GACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG




CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT





294
5D08
CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCGC



heavy
TTCCGTTAAAGTGAGCTGCAAAGCATCTGGTTACACCTTCACTGACTA



chain
TATCATGCACTGGGTTCGTCAGGCCCCGGGCCAGGGTCTGGAGTGGA




TGGGCTACATTAACCCATACAACGACGGTTCCAAATATACCGAGAAA




TTCCAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCCACCGC




GTACATGGAACTGTCTAGACTGCGTTCTGACGACACCGCTGTTTACTA




TTGTGCACGCGGTACCTACTACTACGGTTCTGAACTGTTTGATTACTG




GGGCCAAGGTACCACGGTGACCGTAAGCTCTGCTAGCACCAAGGGCC




CATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCA




CAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTG




ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTT




CCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGT




GACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACG




TGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCC




CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG




AAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG




GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGT




GGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG




ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA




GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACC




AGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA




AGCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC




AGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG




CTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTA




TCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG




AACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTT




CTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGG




GGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACT




ACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA





295
5D08
DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYLNWYLQKPGQSPQ



light
LLIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQLTHEP



chain
YTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK




VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA




CEVTHQGLSSPVTKSFNRGEC





296
5D08
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQAPGQGLEW



heavy
MGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYC



chain
ARGTYYYGSELFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAA




LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS




SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSV




FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT




KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISK




AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP




ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH




YTQKSLSLSPGK





297
5B08
GATATTGTTATGACTCAAACTCCACTGTCTCTGTCCGTGACCCCGGGT



light
CAGCCAGCGAGCATTTCTTGCAAATCCAGCCAATCTCTGGAAACCTC



chain
CACCGGCAACACGTACCTGAACTGGTATCTCCAGAAACCGGGTCAGA




GCCCGCAGCTGCTGATCTACCGTGTATCTAAGCGCTTCTCCGGCGTTC




CTGATCGTTTCAGCGGTTCTGGATCCGGCACCGACTTTACTCTGAAAA




TCAGCCGTGTGGAAGCTGAAGACGTTGGCGTCTACTATTGTCTGCAG




CTGGATTCTTACCCAAACACCTTCGGTCAAGGAACTAAACTGGAAAT




TAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGA




TGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAA




CTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCC




TCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAA




GGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCA




GACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG




CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT





298
5B08
CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCGC



heavy
TTCCGTTAAAGTGAGCTGCAAAGCATCTGGTTACACCTTCACTGACTA



chain
TATCATGCACTGGGTTCGTCAGGCCCCGGGCCAGGGTCTGGAGTGGA




TGGGCTACATTAACCCATACAACGACGGTTCCAAATATACCGAGAAA




TTCCAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCCACCGC




GTACATGGAACTGTCTAGACTGCGTTCTGACGACACCGCTGTTTACTA




TTGTGCACGCGGTACCTACTACTACGGTCCACAGCTGTTTGATTACTG




GGGCCAAGGTACCACGGTGACCGTAAGCTCTGCTAGCACCAAGGGCC




CATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCA




CAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTG




ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTT




CCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGT




GACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACG




TGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCC




CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG




AAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG




GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGT




GGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG




ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA




GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACC




AGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA




AGCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC




AGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG




CTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTA




TCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG




AACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTT




CTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGG




GGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACT




ACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA





299
5B08
DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGNTYLNWYLQKPGQSPQ



light
LLIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQLDSYP



chain
NTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK




VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA




CEVTHQGLSSPVTKSFNRGEC





300
5B08
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQAPGQGLEW



heavy
MGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYC



chain
ARGTYYYGPQLFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAA




LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS




SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSV




FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT




KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISK




AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP




ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH




YTQKSLSLSPGK





301
5H09
GATATTGTTATGACTCAAACTCCACTGTCTCTGTCCGTGACCCCGGGT



light
CAGCCAGCGAGCATTTCTTGCAAATCCAGCCAATCTCTGGAATCTTCC



chain
ACCGGCAACACGTACCTGAACTGGTATCTCCAGAAACCGGGTCAGAG




CCCGCAGCTGCTGATCTACCGTGTATCTAAGCGCTTCTCCGGCGTTCC




TGATCGTTTCAGCGGTTCTGGATCCGGCACCGACTTTACTCTGAAAAT




CAGCCGTGTGGAAGCTGAAGACGTTGGCGTCTACTATTGTCTGCAGC




TGATCGATTACCCAGTTACCTTCGGTCAAGGAACTAAACTGGAAATT




AAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGAT




GAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAA




CTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCC




TCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAA




GGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCA




GACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG




CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT





302
5H09
CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCGC



heavy
TTCCGTTAAAGTGAGCTGCAAAGCATCTGGTTACACCTTCACTGACTA



chain
TATCATGCACTGGGTTCGTCAGGCCCCGGGCCAGGGTCTGGAGTGGA




TGGGCTACATTAACCCATACAACGACGGTTCCAAATATACCGAGAAA




TTCCAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCCACCGC




GTACATGGAACTGTCTAGACTGCGTTCTGACGACACCGCTGTTTACTA




TTGTGCACGCGGTACCTACTACTACGGTTCTGCACTGTTTGATTACTG




GGGCCAAGGTACCACGGTGACCGTAAGCTCTGCTAGCACCAAGGGCC




CATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCA




CAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTG




ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTT




CCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGT




GACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACG




TGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCC




CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG




AAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG




GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGT




GGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG




ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA




GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACC




AGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA




AGCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC




AGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG




CTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTA




TCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG




AACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTT




CTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGG




GGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACT




ACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA





303
5H09
DIVMTQTPLSLSVTPGQPASISCKSSQSLESSTGNTYLNWYLQKPGQSPQ



light
LLIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQLIDYP



chain
VTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK




VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA




CEVTHQGLSSPVTKSFNRGEC





304
5H09
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQAPGQGLEW



heavy
MGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYC



chain
ARGTYYYGSALFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAA




LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS




SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSV




FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT




KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISK




AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP




ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH




YTQKSLSLSPGK









7.2.2.2 Affinity Determination of Selected Antibodies by SPR


For the exact determination of the affinities by SPR, the selected anti-CD19 antibodies were produced by co-transfecting HEK293-EBNA cells with the mammalian expression vectors using polyethylenimine. The cells were transfected with the corresponding expression vectors in a 1:1 ratio (“vector heavy chain”: “vector light chain”) according to the standard procedure. 7 days after transfection, the antibody titer in the supernatant was measured and all titers were equilibrated to 10 μg/ml.


The Affinity (KD) of the parental antibody 8B8 as well as it derivatives was measured by SPR using a ProteOn XPR36 instrument (Biorad) at 25° C. 7000 RU of polyclonal anti-human Fab antibody were immobilized on all 6 channels of a GLM chip by Amine coupling (NaAcetate pH4.5, 25 ul/min, 240s) (vertical orientation). Each antibody-containing HEK supernatant was filtered, diluted with PBST (10 mM phosphate, 150 mM sodium chloride pH 7.4, 0.005% Tween 20) to a concentration of 10 ug/ml, and then injected at a for 360s at 25 μl/minute to achieve immobilization levels between 500 and 800 response units (RU) in vertical orientation. Injection of monomeric CD19-Fc: For one-shot kinetics measurements, injection direction was changed to horizontal orientation, three-fold dilution series of purified monomeric CD19-Fc (varying concentration ranges between 150 and 6 nM) were injected simultaneously at 50μl/min along separate channels 1-4, with association times of 180s, and dissociation times of 300s. A human IgG Fc fragment (150 nM) was injected in channel 5 as a negative control for specific binding to monomeric CD19-Fc. Buffer (PBST) was injected along the sixth channel to provide an “in-line” blank for referencing. An overview of the respective sensorgrams is shown in FIGS. 33A-33H. Regeneration was performed by two pulses of 10 mM glycine pH 1.5 and 50 mM NaOH for 30s at 90 ul/min (vertical orientation). Association rate constants (kon) and dissociation rate constants (koff) were calculated using a simple one-to-one Langmuir binding model in ProteOn Manager v3.1 software by simultaneously fitting the association and dissociation sensorgrams. The equilibrium dissociation constant (KD) was calculated as the ratio koff/kon. A summary of the kinetic and thermodynamic data is shown in Table 60. The dissociation constant of all affinity-matured clones was improved compared to their parental clone 8B8.









TABLE 60







Summary of the kinetic and thermodynamic data for the interaction


between anti-CD19 huIgG1 and human CD19










clone
ka (1/Ms)
kd (1/s)
KD (M)





Parental 8B8
5.66E+4
1.34E−4
2.36E−9 


5H09
7.91E+4
1.50E−5
1.89E−10


7H07
7.45E+4
5.57E−5
7.47E−10


2B03
6.02E+4
5.00E−5
8.31E−10


2B11
6.34E+4
3.14E−5
4.95E−10


5A07
6.98E+4
3.07E−5
4.40E−10


5B08
6.81E+4
5.26E−5
7.72E−10


5D08
8.88E+4
8.44E−5
9.51E−10









7.2.2.3 Preparation and Purification of Anti-CD19 IgG1 P329G LALA


The selected anti-CD19 antibodies were produced by co-transfecting HEK293-EBNA cells with the mammalian expression vectors using polyethylenimine. The cells were transfected with the corresponding expression vectors in a 1:1 ratio (“vector heavy chain”: “vector light chain”).


For the production in 500 mL shake flasks, 400 million HEK293 EBNA cells were seeded 24 hours before transfection. Before the transfection, cells were centrifuged for 5 minutes at 210× g, and the supernatant was replaced by pre-warmed CD CHO medium. Expression vectors (200 μg of total DNA) were mixed in 20 mL CD CHO medium. After addition of 540 μL PEI, the solution was vortexed for 15 seconds and incubated for 10 minutes at room temperature. Afterwards, cells were mixed with the DNA/PEI solution, transferred to a 500 mL shake flask and incubated for 3 hours at 37° C. in an incubator with a 5% CO2 atmosphere. After the incubation, 160 mL of F17 medium was added and cells were cultured for 24 hours. One day after transfection 1 mM valproic acid and 7% Feed with supplements were added. After culturing for 7 days, the supernatant was collected by centrifugation for 15 minutes at 210× g. The solution was sterile filtered (0.22 μm filter), supplemented with sodium azide to a final concentration of 0.01% (w/v), and kept at 4° C.


Purification of antibody molecules from cell culture supernatants was carried out by affinity chromatography using Protein A as described above for purification of antigen Fc fusions. The protein was concentrated and filtered prior to loading on a HILOAD® Superdex 200 column (GE Healthcare) equilibrated with 20 mM Histidine, 140 mM NaCl solution of pH 6.0.


The protein concentration of purified antibodies was determined by measuring the OD at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the antibodies were analyzed by CE-SDS in the presence and absence of a reducing agent (Invitrogen, USA) using a LabChipGXII (Caliper). The aggregate content of antibody samples was analyzed using a TSKGEL® G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in a 25 mM K2HPO4, 125 mM NaCl, 200 mM L-Arginine Monohydrocloride, 0.02% (w/v) NaN3, pH 6.7 running buffer at 25° C. (Table 61).









TABLE 61







Biochemical analysis of anti-CD19 P329G LALA IgG1 clones











Yield
Monomer
CE-SDS


Clone
[mg/l]
[%]
(non red)













Parental 8B8
25.3
100
99.1


2B11
35.4
100
98.4


7H07
89.8
100
99.4


2B03
182
100
100


5A07
90.2
100
99.4


5D08
90.2
100
99.3


5B08
24.1
99.6
100


5H09
29.9
100
98.1









For the preparation of bispecific constructs clone 2B11 was chosen because it lacks the three deamidation hotspots.


The DNA sequence encoding part of the ectodomain (amino acid 71-254 and 71-248) of human 4-1BB ligand was synthetized according to the P41273 sequence of Uniprot database.


7.2.3 Preparation of Monovalent CD19 (8B8-2B11) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 4.1)


The construct 4.1 was prepared as described for construct 3.1 (FIG. 30A), but using the variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-2B11.


Table 62 shows the cDNA and amino acid sequences of the monovalent CD19(8B8-2B11) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule with crossed CH-CL and charged residues (construct 4.1).









TABLE 62







cDNA and amino acid sequences of monovalent CD19(8B8-2B11)


targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion


containing CH-CL cross with charged residues (construct 4.1). 









SEQ ID




NO:
Description
Sequence





129
Nucleotide
see Table 3



sequence Dimeric




hu 4-1BBL




(71-254)-CL* Fc




knob chain






130
Nucleotide
see Table 3



sequence




Monomeric hu




4-1BBL (71-254)-




CH1*






305
Nucleotide
CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAA



sequence anti-
ACCGGGCGCTTCCGTTAAAGTGAGCTGCAAAGCATCTGG



CD19(8B8-2B11)
TTACACCTTCACTGACTATATCATGCACTGGGTTCGTCA



Fc hole chain
GGCCCCGGGCCAGGGTCTGGAGTGGATGGGCTACATTA




ACCCATACAACGACGGTTCCAAATATACCGAGAAATTC




CAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCC




ACCGCGTACATGGAACTGTCTAGACTGCGTTCTGACGAC




ACCGCTGTTTACTATTGTGCACGCGGTACCTACTACTAC




GGTCCACAGCTGTTTGATTACTGGGGCCAAGGTACCACG




GTGACCGTAAGCTCTGCTAGCACCAAGGGCCCCTCCGTG




TTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGG




CACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACTTCCC




CGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGA




CCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGTT




CTGGCCTGTATAGCCTGAGCAGCGTGGTCACCGTGCCTT




CTAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTG




AACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGT




GGAGCCCAAGAGCTGCGACAAAACTCACACATGCCCAC




CGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCAGTC




TTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATC




TCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTG




AGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGT




GGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGC




GGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGC




GTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAG




GAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGC




CCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGC




CCCGAGAACCACAGGTGTGCACCCTGCCCCCATCCCGG




GATGAGCTGACCAAGAACCAGGTCAGCCTCTCGTGCGC




AGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTG




GGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC




ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTC




GTGAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCA




GGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCT




GCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCC




GGGTAAA





277
Nucleotide
see Table 59



sequence anti-




CD19(8B8-2B11)




light chain






115
Dimeric hu 4-
see Table 3



1BBL (71-254)-




CL* Fc knob




chain






116
Monomeric hu
see Table 3



4-1BBL (71-254)-




CH1*






306
anti-CD19
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQ



(8B8-2B11) Fc hole
APGQGLEWMGYINPYNDGSKYTEKFQGRVTMTSDTSISTA



chain
YMELSRLRSDDTAVYYCARGTYYYGPQLFDYWGQGTTVT




VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT




VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ




TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG




GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW




YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN




GKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRD




ELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPP




VLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNH




YTQKSLSLSPGK





206
anti-CD19(8B8-2b11)
see Table 59



light chain





*for charged residues






7.2.4 Preparation of Monovalent CD19(8B8-2B11) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains without Charged Residues (Construct 4.2)


The construct 4.2 was prepared as described for construct 3.2 (FIG. 30B), but using the variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-2B11.


Table 63 shows the cDNA and amino acid sequences of the monovalent CD19(8B8-2B11) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule containing crossed CH-CL cross without charged residues (construct 4.2).









TABLE 63







cDNA and amino acid sequences of monovalent CD19(8B8-2B11)


targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion


containing CH-CL cross without charged residues (construct 4.2).









SEQ ID NO:
Description
Sequence





165
Nucleotide sequence dimeric ligand
see Table 22



(71-254) - CL Fc knob chain



166
Nucleotide sequence monomeric hu
see Table 22



4-1BBL (71-254) - CH1



305
Nucleotide sequence anti-
see Table 62



CD19(8B8-2B11) Fc hole chain



277
Nucleotide sequence anti-
see Table 59



CD19(8B8-2B11) light chain



117
Dimeric ligand (71-254) - CL Fc
see Table 22



knob chain



118
Monomeric ligand (71-254) - CH1
see Table 22


306
anti-CD19(8B8-2B11) Fc hole chain
see Table 62


279
anti-CD19(8B8-018) light chain
see Table 59









7.2.5 Preparation of Bivalent CD19(8B8-2B11) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding (Construct 4.3)


The construct 4.3 was prepared as described for construct 3.3 (FIG. 30C), but using the variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-2B11.


Table 64 shows the cDNA and amino acid sequences of the bivalent CD19 (8B8-2B11) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule (construct 4.3).









TABLE 64







cDNA and amino acid sequences of bivalent CD19(8B8-2B11)


targeted split trimeric 4-1BB ligand Fc (kih) PGLALA


fusion (construct 4.3)









SEQ ID




NO:
Description
Sequence





307
Nucleotide
CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAA



sequence anti-
ACCGGGCGCTTCCGTTAAAGTGAGCTGCAAAGCATCTGG



CD19 (8B8-2B11)
TTACACCTTCACTGACTATATCATGCACTGGGTTCGTCA



Fc hole dimeric
GGCCCCGGGCCAGGGTCTGGAGTGGATGGGCTACATTA



ligand chain
ACCCATACAACGACGGTTCCAAATATACCGAGAAATTC




CAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCC




ACCGCGTACATGGAACTGTCTAGACTGCGTTCTGACGAC




ACCGCTGTTTACTATTGTGCACGCGGTACCTACTACTAC




GGTCCACAGCTGTTTGATTACTGGGGCCAAGGTACCACG




GTGACCGTAAGCTCTGCTAGCACCAAGGGCCCCTCCGTGT





TCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCAC






AGCCGCTCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAG






CCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCTCCG






GCGTGCACACCTTCCCCGCCGTGCTGCAGAGTTCTGGCCT






GTATAGCCTGAGCAGCGTGGTCACCGTGCCTTCTAGCAGCC






TGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCC






AGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCT






GCGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAA






GCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACC






CAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACAT






GCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAA






GTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCA






AGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCG






TGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGA






ATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTC






GGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC






AGCCCCGAGAACCACAGGTGTGCACCCTGCCCCCATCCCG






GGATGAGCTGACCAAGAACCAGGTCAGCCTCTCGTGCGCA






GTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGA






GAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT






CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCGTGAGCAA






GCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTC






TTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTA






CACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGAGGCGGC






GGAAGCGGAGGAGGAGGATCCAGAGAGGGCCCTGAGCTG






AGCCCCGATGATCCTGCTGGACTGCTGGACCTGCGGCAGG






GCATGTTTGCTCAGCTGGTGGCCCAGAACGTGCTGCTGATC






GATGGCCCCCTGTCCTGGTACAGCGATCCTGGACTGGCTG






GCGTGTCACTGACAGGCGGCCTGAGCTACAAAGAGGACAC






CAAAGAACTGGTGGTGGCCAAGGCCGGCGTGTACTACGTG






TTCTTTCAGCTGGAACTGCGGAGAGTGGTGGCCGGCGAAG






GATCTGGCTCTGTGTCTCTGGCCCTGCATCTGCAGCCTCTG






AGAAGCGCTGCTGGCGCTGCAGCTCTGGCACTGACAGTGG






ATCTGCCTCCTGCCAGCTCCGAGGCCCGGAATAGCGCATTT






GGGTTTCAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGA






GGCTGGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACA






CGCCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG






TTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCTCC






AAGAAGCGAAGGCGGAGGCGGATCTGGCGGCGGAGGATC






TAGAGAGGGACCCGAACTGTCCCCTGACGATCCAGCCGGG






CTGCTGGATCTGAGACAGGGAATGTTCGCCCAGCTGGTGG






CTCAGAATGTGCTGCTGATTGACGGACCTCTGAGCTGGTAC






TCCGACCCAGGGCTGGCAGGGGTGTCCCTGACTGGGGGAC






TGTCCTACAAAGAAGATACAAAAGAACTGGTGGTGGCTAAA






GCTGGGGTGTACTATGTGTTTTTTCAGCTGGAACTGAGGCG






GGTGGTGGCTGGGGAGGGCTCAGGATCTGTGTCCCTGGCT






CTGCATCTGCAGCCACTGCGCTCTGCTGCTGGCGCAGCTG






CACTGGCTCTGACTGTGGACCTGCCACCAGCCTCTAGCGAG






GCCAGAAACAGCGCCTTCGGGTTCCAAGGACGCCTGCTGC






ATCTGAGCGCCGGACAGCGCCTGGGAGTGCATCTGCATAC






TGAAGCCAGAGCCCGGCATGCTTGGCAGCTGACTCAGGGG






GCAACTGTGCTGGGACTGTTTCGCGTGACACCTGAGATCCC






TGCCGGACTGCCAAGCCCTAGATCAGAA






308
Nucleotide
CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAA



sequence anti-
ACCGGGCGCTTCCGTTAAAGTGAGCTGCAAAGCATCTGG



CD19(8B8-2B11)
TTACACCTTCACTGACTATATCATGCACTGGGTTCGTCA



Fc knob
GGCCCCGGGCCAGGGTCTGGAGTGGATGGGCTACATTA



monomeric ligand
ACCCATACAACGACGGTTCCAAATATACCGAGAAATTC




CAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCC




ACCGCGTACATGGAACTGTCTAGACTGCGTTCTGACGAC




ACCGCTGTTTACTATTGTGCACGCGGTACCTACTACTAC




GGTCCACAGCTGTTTGATTACTGGGGCCAAGGTACCACG




GTGACCGTAAGCTCTGCTAGCACCAAGGGCCCATCGGTCT





TCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCAC






AGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA






CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCG






GCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTC






TACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTT






GGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCA






GCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGT






GACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGC






TGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCA






AGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC






GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGT






TCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAA






GACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGT






GTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGA






ATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTC






GGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC






AGCCCCGAGAACCACAGGTGTACACCCTGCCCCCCTGCAG






AGATGAGCTGACCAAGAACCAGGTGTCCCTGTGGTGTCTGG






TCAAGGGCTTCTACCCCAGCGATATCGCCGTGGAGTGGGA






GAGCAACGGCCAGCCTGAGAACAACTACAAGACCACCCCC






CCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACTCCAA






ACTGACCGTGGACAAGAGCCGGTGGCAGCAGGGCAACGTG






TTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTA






CACCCAGAAGTCCCTGAGCCTGAGCCCCGGCGGAGGCGG






CGGAAGCGGAGGAGGAGGATCCAGAGAGGGCCCTGAGCT






GAGCCCCGATGATCCTGCTGGACTGCTGGACCTGCGGCAG






GGCATGTTTGCTCAGCTGGTGGCCCAGAACGTGCTGCTGAT






CGATGGCCCCCTGTCCTGGTACAGCGATCCTGGACTGGCT






GGCGTGTCACTGACAGGCGGCCTGAGCTACAAAGAGGACA






CCAAAGAACTGGTGGTGGCCAAGGCCGGCGTGTACTACGT






GTTCTTTCAGCTGGAACTGCGGAGAGTGGTGGCCGGCGAA






GGATCTGGCTCTGTGTCTCTGGCCCTGCATCTGCAGCCTCT






GAGAAGCGCTGCTGGCGCTGCAGCTCTGGCACTGACAGTG






GATCTGCCTCCTGCCAGCTCCGAGGCCCGGAATAGCGCATT






TGGGTTTCAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAG






AGGCTGGGAGTGCATCTGCACACAGAGGCCAGGGCTAGAC






ACGCCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCT






GTTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCTC






CAAGAAGCGAA






277
Nucleotide
see Table 59



sequence anti-




CD19(8B8-018)




light chain






309
anti-CD19
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQ



(8B8-2B11) Fc hole
APGQGLEWMGYINPYNDGSKYTEKFQGRVTMTSDTSISTA



dimeric ligand
YMELSRLRSDDTAVYYCARGTYYYGPQLFDYWGQGTTVT



chain
VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW





NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN






HKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPP






KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA






KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALG






APIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFY






PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSR






WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSR






EGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDP






GLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGE






GSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQ






GRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTP






EIPAGLPSPRSEGGGGSGGGGSREGPELSPDDPAGLLDLRQG






MFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKEL






VVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGA






AALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTE






ARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE






310
anti-CD19(8B8-2B11)
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQ



Fc knob
APGQGLEWMGYINPYNDGSKYTEKFQGRVTMTSDTSISTA



monomeric ligand
YMELSRLRSDDTAVYYCARGTYYYGPQLFDYWGQGTTVT




VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW





NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN






HKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPP






KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA






KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALG






APIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGF






YPSDIAVEWESNGQPEN1VYKTTPPVLDSDGSFFLYSKLTVDKS






RWQQGNVFSCSVMHEALH1VHYTQKSLSLSPGGGGGSGGGGS






REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSD






PGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAG






EGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGF






QGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVT






PEIPAGLPSPRSE






279
anti-CD19(8B8-018)
see Table 59



light chain









7.2.6 Preparation of Monovalent CD19(8B8-2B11) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 4.4)


The construct 4.4 was prepared as described for construct 3.4 (FIG. 30D), but using the variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-2B11.


Table 65 shows the cDNA and amino acid sequences of the monovalent CD19(8B8-2B11) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule with crossed CH-CL and charged residues (construct 4.4).









TABLE 65







cDNA and amino acid sequences of monovalent CD19(8B8-2B11)


targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion


containing CH-CL cross with charged residues (construct 4.4).









SEQ ID NO:
Description
Sequence





169
Nucleotide sequence dimeric ligand
see Table 24



(71-248) - CL* Fc knob chain



170
Nucleotide sequence monomeric hu
see Table 24



4-1BBL (71-248) - CH1*



305
Nucleotide sequence anti-
see Table 62



CD19(8B8-2B11) Fc hole chain



277
Nucleotide sequence anti-
see Table 59



CD19(8B8-2B11) light chain



119
Dimeric ligand (71-248) - CL* Fc
see Table 24



knob chain



120
Monomeric ligand (71-248) - CH1*
see Table 24


306
anti-CD19(8B8-2B11) Fc hole chain
see Table 62


279
anti-CD19(8B8-2B11) light chain
see Table 59





*charged residues






7.2.7 Preparation of Monovalent CD19(8B8-2B11) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains without Charged Residues (Construct 4.5)


The construct 4.5 was prepared as described for construct 3.5 (FIG. 30E), but using the variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-2B11.


Table 66 shows the cDNA and amino acid sequences of the monovalent CD19(8B8-2B11) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule containing crossed CH-CL cross without charged residues (construct 4.5).









TABLE 66







cDNA and amino acid sequences of monovalent CD19(8B8-2B11)


targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion


containing CH-CL cross without charged residues (construct 4.5).









SEQ ID NO:
Description
Sequence





171
Nucleotide sequence dimeric ligand
see Table 25



(71-248) - CL Fc knob chain



172
Nucleotide sequence monomeric
see Table 25



ligand (71-248)-CH1



305
Nucleotide sequence anti-
see Table 62



CD19(8B8-2B11) Fc hole chain



277
Nucleotide sequence anti-
see Table 59



CD19(8B8-2B11) light chain



173
Dimeric ligand (71-248) - CL Fc
see Table 25



knob chain



174
Monomeric ligand (71-248) - CH1
see Table 25


306
anti-CD19(8B8-2B11) Fc hole chain
see Table 62


279
anti-CD19(8B8-2B11) light chain
see Table 59









7.2.8 Preparation of Bivalent CD19(8B8-2B11) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding (Construct 4.6)


The construct 4.6 was prepared as described for construct 3.6 (FIG. 30F), but using the variable region of heavy and light chain DNA sequences encoding a binder specific for CD19, clone 8B8-2B11.


Table 67 shows the cDNA and amino acid sequences of the bivalent CD19(8B8-2B11) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule (construct 3.6).









TABLE 67







cDNA and amino acid sequences of bivalent CD19(8B8-2B11)


targeted split trimeric 4-1BB ligand (71-248) Fc (kih)


fusion (construct 4.6)









SEQ ID




NO:
Description
Sequence





311
Nucleotide
CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAA



sequence anti-
ACCGGGCGCTTCCGTTAAAGTGAGCTGCAAAGCATCTGG



CD19(8B8-2B11)
TTACACCTTCACTGACTATATCATGCACTGGGTTCGTCA



Fc hole dimeric
GGCCCCGGGCCAGGGTCTGGAGTGGATGGGCTACATTA



ligand (71-248)
ACCCATACAACGACGGTTCCAAATATACCGAGAAATTC



chain
CAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCC




ACCGCGTACATGGAACTGTCTAGACTGCGTTCTGACGAC




ACCGCTGTTTACTATTGTGCACGCGGTACCTACTACTAC




GGTCCACAGCTGTTTGATTACTGGGGCCAAGGTACCACG




GTGACCGTAAGCTCTGCTAGCACCAAGGGCCCCTCCGTGT





TCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCAC






AGCCGCTCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAG






CCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCTCCG






GCGTGCACACCTTCCCCGCCGTGCTGCAGAGTTCTGGCCT






GTATAGCCTGAGCAGCGTGGTCACCGTGCCTTCTAGCAGCC






TGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCC






AGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCT






GCGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAA






GCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACC






CAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACAT






GCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAA






GTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCA






AGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCG






TGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGA






ATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTC






GGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC






AGCCCCGAGAACCACAGGTGTGCACCCTGCCCCCATCCCG






GGATGAGCTGACCAAGAACCAGGTCAGCCTCTCGTGCGCA






GTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGA






GAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT






CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCGTGAGCAA






GCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTC






TTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTA






CACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGAGGCGGC






GGAAGCGGAGGAGGAGGATCCAGAGAGGGCCCTGAGCTG






AGCCCTGATGATCCTGCCGGACTGCTGGACCTGCGGCAGG






GAATGTTTGCCCAGCTGGTGGCCCAGAACGTGCTGCTGATC






GATGGCCCCCTGTCCTGGTACAGCGATCCTGGACTGGCTG






GCGTGTCACTGACAGGCGGCCTGAGCTACAAAGAGGACAC






CAAAGAACTGGTGGTGGCCAAGGCCGGCGTGTACTACGTG






TTCTTTCAGCTGGAACTGCGGAGAGTGGTGGCCGGCGAAG






GATCTGGCTCTGTGTCTCTGGCCCTGCATCTGCAGCCTCTG






AGATCTGCTGCTGGCGCCGCTGCTCTGGCACTGACAGTGG






ATCTGCCTCCTGCCAGCAGCGAGGCCCGGAATAGCGCATTT






GGGTTTCAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGA






GGCTGGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACA






CGCCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG






TTCAGAGTGACCCCCGAGATTCCAGCAGGCCTGGGAGGCG






GCGGATCTGGCGGCGGAGGATCTAGAGAAGGACCCGAGCT






GTCCCCCGACGATCCCGCTGGGCTGCTGGATCTGAGACAG






GGCATGTTCGCTCAGCTGGTGGCTCAGAATGTGCTGCTGAT






TGACGGACCTCTGAGCTGGTACTCCGACCCAGGGCTGGCA






GGGGTGTCCCTGACTGGGGGACTGTCCTACAAAGAAGATAC






AAAAGAACTGGTGGTGGCTAAAGCTGGGGTGTACTATGTGT






TTTTTCAGCTGGAACTGAGGCGGGTGGTGGCTGGGGAGGG






CTCAGGATCTGTGTCCCTGGCTCTGCATCTGCAGCCACTGC






GCTCTGCAGCAGGGGCTGCAGCACTGGCCCTGACTGTGGA






CCTGCCCCCAGCTTCTTCCGAGGCCAGAAACAGCGCCTTCG






GGTTCCAAGGACGCCTGCTGCATCTGAGCGCCGGACAGCG






CCTGGGAGTGCATCTGCATACTGAAGCCAGAGCCCGGCAT






GCTTGGCAGCTGACTCAGGGGGCAACTGTGCTGGGACTGT






TTCGCGTGACACCTGAGATCCCAGCCGGGCTC






312
Nucleotide
CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAA



sequence anti-
ACCGGGCGCTTCCGTTAAAGTGAGCTGCAAAGCATCTGG



CD19(8B8-2B11)
TTACACCTTCACTGACTATATCATGCACTGGGTTCGTCA



Fc knob
GGCCCCGGGCCAGGGTCTGGAGTGGATGGGCTACATTA



monomeric
ACCCATACAACGACGGTTCCAAATATACCGAGAAATTC



(71-248) ligand
CAGGGCCGCGTCACGATGACCAGCGACACTTCTATCTCC




ACCGCGTACATGGAACTGTCTAGACTGCGTTCTGACGAC




ACCGCTGTTTACTATTGTGCACGCGGTACCTACTACTAC




GGTCCACAGCTGTTTGATTACTGGGGCCAAGGTACCACG




GTGACCGTAAGCTCTGCTAGCACCAAGGGCCCATCGGTCT





TCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCAC






AGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA






CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCG






GCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTC






TACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTT






GGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCA






GCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGT






GACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGC






TGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCA






AGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC






GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGT






TCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAA






GACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGT






GTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGA






ATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTC






GGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC






AGCCCCGAGAACCACAGGTGTACACCCTGCCCCCCTGCAG






AGATGAGCTGACCAAGAACCAGGTGTCCCTGTGGTGTCTGG






TCAAGGGCTTCTACCCCAGCGATATCGCCGTGGAGTGGGA






GAGCAACGGCCAGCCTGAGAACAACTACAAGACCACCCCC






CCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACTCCAA






ACTGACCGTGGACAAGAGCCGGTGGCAGCAGGGCAACGTG






TTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTA






CACCCAGAAGTCCCTGAGCCTGAGCCCCGGCGGAGGCGG






CGGAAGCGGAGGAGGAGGATCCAGAGAGGGCCCTGAGCT






GAGCCCTGATGATCCTGCCGGACTGCTGGACCTGCGGCAG






GGAATGTTTGCCCAGCTGGTGGCCCAGAACGTGCTGCTGAT






CGATGGCCCCCTGTCCTGGTACAGCGATCCTGGACTGGCT






GGCGTGTCACTGACAGGCGGCCTGAGCTACAAAGAGGACA






CCAAAGAACTGGTGGTGGCCAAGGCCGGCGTGTACTACGT






GTTCTTTCAGCTGGAACTGCGGAGAGTGGTGGCCGGCGAA






GGATCTGGCTCTGTGTCTCTGGCCCTGCATCTGCAGCCTCT






GAGATCTGCTGCTGGCGCCGCTGCTCTGGCACTGACAGTG






GATCTGCCTCCTGCCAGCAGCGAGGCCCGGAATAGCGCAT






TTGGGTTTCAAGGCAGGCTGCTGCACCTGTCTGCCGGCCA






GAGGCTGGGAGTGCATCTGCACACAGAGGCCAGGGCTAGA






CACGCCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCC






TGTTCAGAGTGACCCCCGAGATTCCTGCCGGGCTC






277
Nucleotide
see Table 59



sequence anti-




CD19(8B8-2B11)




light chain






313
anti-CD19(8B8-2B11)
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQ



Fc hole
APGQGLEWMGYINPYNDGSKYTEKFQGRVTMTSDTSISTA



dimeric ligand
YMELSRLRSDDTAVYYCARGTYYYGPQLFDYWGQGTTVT



(71-248) chain
VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW





NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN






HKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPP






KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA






KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALG






APIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFY






PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSR






WQQGNVFSCS1MHEALH1VHYTQKSLSLSPGGGGGSGGGGSR






EGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDP






GLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGE






GSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQ






GRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTP






EIPAGLGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQL






VAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKA






GVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALT






VDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHA






WQLTQGATVLGLFRVTPEIPAGL






314
anti-CD19(8B8-2B11)
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQ



Fc knob
APGQGLEWMGYINPYNDGSKYTEKFQGRVTMTSDTSISTA



monomeric
YMELSRLRSDDTAVYYCARGTYYYGPQLFDYWGQGTTVT



(71-248) ligand
VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW





NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN






HKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPP






KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA






KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALG






APIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGF






YPSDIAVEWESNGQPEN1VYKTTPPVLDSDGSFFLYSKLTVDKS






RWQQGNVFSCSVMHEALH1VHYTQKSLSLSPGGGGGSGGGGS






REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSD






PGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAG






EGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGF






QGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVT






PEIPAGL






279
anti-CD19(8B8-018)
see Table 59



light chain









7.3 Preparation of Untargeted Split Trimeric 4-1BB Ligand Fc Fusion and Human IgG as Control Molecules


7.3.1 Preparation of Untargeted Human 4-1BB ligand Trimer-Containing Fc Fusion Antigen Binding Molecules (Control Molecules)


These control molecules were prepared as described above for the CD19 targeted construct 3.1 (termed control B), 3.3 (termed control C), 3.4 (termed control D) and 3.5 (termed control E) with the only difference that the anti-CD19 binder (VH-VL) was replaced by a germline control, termed DP47, not binding to the antigen (see FIGS. 30A-F).


Table 68 shows, respectively, the cDNA and amino acid sequences of the monovalent DP47-untargeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion containing crossed CH-CL with charged residues, control B.


Table 69 shows, respectively, the cDNA and amino acid sequences of the bivalent DP47-untargeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion, control C.


Table 70 shows, respectively, the cDNA and amino acid sequences of the monovalent DP47-untargeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion containing CH-CL cross with charged residues, control D.


Table 71 shows, respectively, the cDNA and amino acid sequences of the monovalent DP47-untargeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion without charged residues in the CH-CL cross, control E.









TABLE 68







cDNA and amino acid sequences of monovalent DP47 untargeted


split trimeric human 4-1BB ligand (71-254) Fc (kih) fusion with


CH-CL cross and with charged residues (control B).









SEQ ID NO:
Description
Sequence





96
nucleotide sequence dimeric hu
see Table 3



4-1BBL (71-254) - CL* Fc knob




chain



97
nucleotide sequence monomeric hu
see Table 3



4-1BBL (71-254) CH1*



79
nucleotide sequence DP47 Fc hole
see Table 18



chain



80
nucleotide sequence DP47 light
see Table 18



chain



98
Dimeric hu 4-1BBL (71-254) -
see Table 3



CL* Fc knob chain



99
Monomeric hu
see Table 3



4-1BBL (71-254) - CH1*



81
DP47 Fc hole chain
see Table 18


82
DP47 light chain
see Table 18





* charges residues













TABLE 69







cDNA and amino acid sequences of bivalent DP47 untargeted


split trimeric human 4-1BB ligand (71-254) Fc (kih) fusion (control C).









SEQ ID NO:
Description
Sequence












177
nucleotide sequence DP47 Fc hole
see Table 27



chain fused to dimeric hu 4-1BBL




(71-254)



178
nucleotide sequence DP47 Fc knob
see Table 27



chain fused to monomeric hu 4-1BBL




(71-254)



80
nucleotide sequence DP47 light chain
see Table 18


179
DP47 Fc hole chain fused to dimeric
see Table 27



hu 4-1BBL (71-254)



180
DP47 Fc knob chain fused to monomeric
see Table 27



hu 4-1BBL (71-254)



82
DP47 light chain
see Table 18
















TABLE 70







cDNA and amino acid sequences of monovalent DP47 untargeted


split trimeric human 4-1BB ligand (71-248) Fc (kih) fusion with


CH-CL cross and with charged residues (control D).









SEQ ID NO:
Description
Sequence












169
nucleotide sequence dimeric hu
see Table 24



4-1BBL (71-248) - CL* Fc knob




chain



170
nucleotide sequence monomeric hu
see Table 24



4-1BBL (71-248) - CH1*



79
nucleotide sequence DP47 Fc hole
see Table 18



chain



80
nucleotide sequence DP47 light chain
see Table 18


119
Dimeric hu 4-1BBL (71-254) - CL*
see Table 24



Fc knob chain



120
Monomeric hu 4-1BBL (71-254) -
see Table 24



CH1*



81
DP47 Fc hole chain
see Table 18


82
DP47 light chain
see Table 18





*charged residues













TABLE 71







cDNA and amino acid sequences of monovalent DP47 untargeted


split trimeric human 4-1BB ligand (71-248) Fc (kih) fusion with


CH-CL cross and without charged residues (control E).









SEQ ID NO:
Description
Sequence












171
nucleotide sequence dimeric hu
see Table 25



4-1BBL (71-248) - CL Fc knob




chain



172
nucleotide sequence monomeric hu
see Table 25



4-1BBL (71-248) - CH1



79
nucleotide sequence DP47 Fc hole
see Table 18



chain



80
nucleotide sequence DP47 light
see Table 18



chain



173
Dimeric hu 4-1BBL (71-248) -
see Table 25



CL Fc knob chain



174
Monomeric hu 4-1BBL (71-248) -
see Table 25



CH1



81
DP47 Fc hole chain
see Table 18


82
DP47 light chain
see Table 18









7.3.2 Antibodies as Control Molecules


Two control human IgG1 containing PGLALA were prepared.


Table 72 shows the cDNA and amino acid sequences of the anti-CD19 huIgG1 PGLALA (clone 8B8-018), i.e. control G.


Table 73 shows the cDNA and amino acid sequences of germline control DP47 huIgG1 PGLALA (control F).









TABLE 72







cDNA and amino acid sequences of anti-CD19(8B8-018) huIgG1


PGLALA (control G)









SEQ ID




NO:
Description
Sequence





315
nucleotide sequence
CAGGTCCAGCTGGTGCAGTCCGGCGCCGAGGT



CD19(8B8-018) heavy
CAAGAAACCCGGGGCTTCTGTGAAGGTTTCAT



chain (huIgG1 PGLALA)
GCAAGGCAAGCGGATACACCTTCACCGACTAT




ATCATGCATTGGGTCAGGCAGGCCCCTGGCCA




AGGTCTCGAATGGATGGGCTACATTAACCCAT




ATAATGATGGCTCCAAATACACCGAGAAGTTT




CAGGGAAGAGTCACTATGACATCTGACACCAG




TATCAGCACTGCTTACATGGAGCTGTCCCGCC




TTCGGTCTGATGACACCGCAGTGTATTACTGT




GCCAGGGGCACATATTACTACGGCTCAGCTCT




GTTCGACTATTGGGGGCAGGGAACCACAGTAA




CCGTGAGCTCCGCAAGTACTAAGGGCCCATCG




GTCTTCCCCCTGGCACCCTCCTCCAAGAGCAC




CTCTGGGGGCACAGCGGCCCTGGGCTGCCTGG




TCAAGGACTACTTCCCCGAACCGGTGACGGTG




TCGTGGAACTCAGGCGCCCTGACCAGCGGCGT




GCACACCTTCCCGGCTGTCCTACAGTCCTCAG




GACTCTACTCCCTCAGCAGCGTGGTGACCGTG




CCCTCCAGCAGCTTGGGCACCCAGACCTACAT




CTGCAACGTGAATCACAAGCCCAGCAACACCA




AGGTGGACAAGAAAGTTGAGCCCAAATCTTGT




GACAAAACTCACACATGCCCACCGTGCCCAGC




ACCTGAAGCAGCTGGGGGACCGTCAGTCTTCC




TCTTCCCCCCAAAACCCAAGGACACCCTCATG




ATCTCCCGGACCCCTGAGGTCACATGCGTGGT




GGTGGACGTGAGCCACGAAGACCCTGAGGTC




AAGTTCAACTGGTACGTGGACGGCGTGGAGGT




GCATAATGCCAAGACAAAGCCGCGGGAGGAG




CAGTACAACAGCACGTACCGTGTGGTCAGCGT




CCTCACCGTCCTGCACCAGGACTGGCTGAATG




GCAAGGAGTACAAGTGCAAGGTCTCCAACAA




AGCCCTCGGAGCCCCCATCGAGAAAACCATCT




CCAAAGCCAAAGGGCAGCCCCGAGAACCACA




GGTGTACACCCTGCCCCCATCCCGGGATGAGC




TGACCAAGAACCAGGTCAGCCTGACCTGCCTG




GTCAAAGGCTTCTATCCCAGCGACATCGCCGT




GGAGTGGGAGAGCAATGGGCAGCCGGAGAAC




AACTACAAGACCACGCCTCCCGTGCTGGACTC




CGACGGCTCCTTCTTCCTCTACAGCAAGCTCAC




CGTGGACAAGAGCAGGTGGCAGCAGGGGAAC




GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG




CACAACCACTACACGCAGAAGAGCCTCTCCCT




GTCCCCGGGCAAA





204
nucleotide sequence
see Table 47



CD19(8B8-018) light




chain






316
CD19(8B8-018) heavy
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYI



chain (huIgG1 PGLALA)
MHWVRQAPGQGLEWMGYINPYNDGSKYTEKF




QGRVTMTSDTSISTAYMELSRLRSDDTAVYYCA




RGTYYYGSALFDYWGQGTTVTVSSASTKGPSVF




PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS




GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG




TQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP




PCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCV




VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE




QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK




ALGAPIEKTISKAKGQPREPQVYTLPPSRDELTK




NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT




TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS




VMHEALHNHYTQKSLSLSPGK





206
CD19(8B8-018) light
see Table 47



chain
















TABLE 73







cDNA and amino acid sequences of germline control


DP47 huIgG1 PGLALA (control F)









SEQ ID NO:
Description
Sequence












181
nucleotide sequence DP47 heavy chain
see Table 29



(hu IgG1 PGLALA)



80
DP47 light chain
see Table 18


182
DP47 heavy chain (hu IgG1 PGLALA)
see Table 29


82
DP47 light chain
see Table 18









7.4 Production of CD19-Targeted Split Trimeric 4-1BB Ligand Fc Fusion Antigen Binding Molecules and their Control Molecules


The targeted and untargeted split trimeric 4-1BB ligand Fc (kih) fusion antigen binding molecule encoding sequences were cloned into a plasmid vector, which drives expression of the insert from an MPSV promoter and contains a synthetic polyA sequence located at the 3′ end of the CDS. In addition, the vector contains an EBV OriP sequence for episomal maintenance of the plasmid.


The split trimeric 4-1BB ligand Fc (kih) fusion antigen binding molecule was produced by co-transfecting HEK293-EBNA cells with the mammalian expression vectors using polyethylenimine. The cells were transfected with the corresponding expression vectors. For variants 1,2,4,5 and it's control B, D and E, at a 1:1:1:1 ratio (“vector dimeric ligand-CL- knob chain”: “vector monomeric ligand fusion-CH1”: “vector anti-CD19 Fab-hole chain”: “vector anti-CD19 light chain”). For variant 3, 6 and it's control C, at a 1:1:1 ratio (“vector huIgG1 Fc hole dimeric ligand chain”: “vector huIgG1 Fc knob monomeric ligand chain”: “vector anti-CD19 light chain”). Human IgGs, used as control in the assay, were produced as for the bispecific construct (for transfection only a vector for light and a vector for heavy chain were used at a 1:1 ratio).


For production in 500 mL shake flasks, 300 million HEK293 EBNA cells were seeded 24 hours before transfection. For transfection cells were centrifuged for 10 minutes at 210× g, and the supernatant was replaced by 20 mL pre-warmed CD CHO medium. Expression vectors (200 μg of total DNA) were mixed in 20 mL CD CHO medium. After addition of 540 μL PEI, the solution was vortexed for 15 seconds and incubated for 10 minutes at room temperature. Afterwards, cells were mixed with the DNA/PEI solution, transferred to a 500 mL shake flask and incubated for 3 hours at 37° C. in an incubator with a 5% CO2 atmosphere. After the incubation, 160 mL of Excell medium supplemented with 6 mM L-Glutamine, 5 g/L PEPSOY and 1.2 mM valproic acid was added and cells were cultured for 24 hours. One day after transfection 12% Feed (amino acid and glucose) were added. After culturing for 7 days, the supernatant was collected by centrifugation for 30-40 minutes at least 400× g. The solution was sterile filtered (0.22 μm filter), supplemented with sodium azide to a final concentration of 0.01% (w/v), and kept at 4° C.


The split trimeric 4-1BB ligand Fc (kih) fusion antigen binding molecule, as well as the IgG, was purified from cell culture supernatants by affinity chromatography using Protein A, followed by size exclusion chromatography. For affinity chromatography, the supernatant was loaded on a MABSELECT SURE® column (CV=5-15 mL, resin from GE Healthcare) equilibrated with sodium phosphate (20 mM), sodium sitrate (20 mM) buffer (pH 7.5). Unbound protein was removed by washing with at least 6 column volumes of the same buffer. The bound protein was eluted using either a linear gradient (20 CV) or a step elution (8 CV) with 20 mM sodium citrate, 100 mM sodium chloride, 100 mM glycine buffer (pH 3.0). For the linear gradient an additional 4 column volumes step elution was applied.


The pH of collected fractions was adjusted by adding 1/10 (v/v) of 0.5M sodium phosphate, pH8.0. The protein was concentrated prior to loading on a HILOAD® Superdex 200 column (GE Healthcare) equilibrated with 20 mM histidine, 140 mM sodium chloride, 0.01% (v/v) TWEEN® 20 (polysorbate 20) solution of pH 6.0.


The protein concentration was determined by measuring the optical density (OD) at 280 nm, using a molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the targeted trimeric 4-1BB ligand Fc (kih) fusion was analyzed by SDS-PAGE in the presence and absence of a reducing agent (5 mM 1,4-dithiotreitol) and staining with Coomassie SIMPLYBLUE™ SafeStain (Invitrogen USA). The aggregate content of samples was analyzed using a TSKGEL® G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in 25 mM K2HPO4, 125 mM NaCl, 200 mM L-arginine monohydrochloride, 0.02% (w/v) NaN3, pH 6.7 running buffer at 25° C.


Table 74 summarizes the yield and final monomer content of the CD19 targeted split trimeric 4-1BB ligand Fc (kih) fusion antigen molecules.









TABLE 74







Biochemical analysis of CD19 targeted split trimeric


4-1BB ligand Fc (kih) fusion antigen binding molecules










Monomer




[%]
Yield


Construct
(SEC)
[mg/l]












monovalent CD19(8B8-018) targeted split trimeric
98
8.6


4-1BB ligand (71-254) Fc fusion anitgcontaining




CH-CL cross with charged residues




(construct 3.1)




bivalent CD19(8B8-018) targeted split trimeric
100
11.3


4-1BB ligand (71-254) Fc fusion




(construct 3.3)




monovalent CD19(8B8-018) targeted split trimeric
99
11.5


4-1BB ligand (71-248) Fc fusion containing




CH-CL cross with charged residues




(construct 3.4)




monovalent CD19(8B8-018) targeted split trimeric
97
13.3


4-1BB ligand (71-248) Fc fusion containing




CH-CL cross without charged residues




(construct 3.5)




bivalent CD19(8B8-018) targeted split trimeric
96
19.9


4-1BB ligand (71-248) Fc fusion




(construct 3.6)




monovalent CD19(8B8-2B11) targeted split trimeric
99.2
21.2


4-1BB ligand (71-248) Fc fusion containing CH-CL




cross withcharged residues




(construct 4.4)









Table 75 summarizes the yield and final monomer content of the DP47 untargeted split trimeric 4-1BB ligand Fc (kih) fusion, both monovalent (control B, D and E) and bivalent (control C).









TABLE 75







Biochemical analysis of DP47 untargeted split trimeric


4-1BB ligand Fc (kih) fusion










Monomer




[%]
Yield


Construct
(SEC)
[mg/l]












monovalent DP47-untargeted split trimeric human
99
15.4


4-1BB ligand (71-254) Fc (kih) fusion




(control B)




bivalent DP47 untargeted split trimeric human
98
12.6


4-1BB ligand (71-254) Fc (kih) fusion




(control C)




monovalent DP47-untargeted split trimeric human
99.5
25.9


4-1BB ligand (71-254) Fc (kih) fusion




(control D)




monovalent DP47-untargeted split trimeric human
93.3
4.1


4-1BB ligand (71-254) Fc (kih) fusion




(control E)









Table 76 summarizes the yield and final monomer content of anti-CD19 (8B8-018) and germline DP47 human IgG1 PGLALA (control F).









TABLR 76







Biochemical analysis of control human IgG1 PGLALA










Monomer




[%]
Yield


Construct
(SEC)
[mg/l]












anti-CD19(8B8-018) huIgG1 PGLALA
100
36.6


germline DP47 human IgG1 PGLALA
100
50









Example 8
Functional Characterization of the CD19 Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

8.1. Surface Plasmon Resonance (Affinity)


Binding of CD19 targeted split trimeric 4-1BB ligand Fc fusion antigen binding molecules (constructs 3.4 and 3.6) to the recombinant 4-1BB Fc(kih) and CD19 was assessed by surface plasmon resonance (SPR). All SPR experiments were performed on a BIACORE® T200 instrument at 25° C. with HBS-EP as running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20, Biacore, Freiburg/Germany).


Interaction with Human and Cynomolgus 4-1BB


Anti-human Fab antibody (Biacore, Freiburg/Germany) was directly coupled on a CM5 chip at pH 5.0 using the standard amine coupling kit (Biacore, Freiburg/Germany). The immobilization level was approximately 8000 RU. The CD19 targeted split trimeric 4-1BB ligand Fc fusions were captured for 60 seconds at 2 and 5 nM (control D was also injected). Recombinant human or cynomolgus 4-1BB avi His was passed at a concentration range from 2.7 to 2000 nM (3-fold dilution) with a flow of 30 μL/minutes through the flow cells over 120 seconds. The dissociation was monitored for 180 seconds. Bulk refractive index differences were corrected for by subtracting the response obtained on reference flow cell. Here, the antigens were flown over a surface with immobilized anti-human Fab antibody but on which HBS-EP has been injected rather than the antibodies.


Interaction with Human CD19


Anti-human Fab antibody (Biacore, Freiburg/Germany) was directly coupled on a CM5 chip at pH 5.0 using the standard amine coupling kit (Biacore, Freiburg/Germany). The immobilization level was approximately 8000 RU. The CD19 targeted split trimeric 4-1BB ligand Fc fusions, or the control antibody (anti-CD19(8B8-018) huIgG1 PGLALA) were captured for 60 seconds at 20 nM. Recombinant human CD19-Fc(kih) was passed at a concentration range from 7.8 to 500 nM (2-fold dilution) with a flow of 30 μL/minutes through the flow cells over 120 seconds. The dissociation was monitored for 120/1800 seconds. Bulk refractive index differences were corrected for by subtracting the response obtained on reference flow cell. Here, the antigens were flown over a surface with immobilized anti-human Fab antibody but on which HBS-EP has been injected rather than the antibodies.


Kinetic constants were derived using the Biacore T200 Evaluation Software (vAA, Biacore AB, Uppsala/Sweden), to fit rate equations for 1:1 Langmuir binding by numerical integration.


The bispecific constructs 3.4, 3.6 and control D bind similarly to 4-1BB. Table 77 shows the average with standard deviation (in parenthesis) from the two experiments (using the construct capture solution either at 2 nM or 5 nM). The bispecific constructs 3.4 and 3.6 bind human CD19 with a similar affinity as the IgG. Affinity constants for the interaction were determined by fitting to a 1:1 Langmuir binding. For measurements with hu4-1BB and cy4-1BB, average and standard deviation (in parenthesis) are shown (two experiments with 2 or 5 nM capture solution).









TABLE 77







Binding of CD19 targeted split trimeric 4-1BB ligand Fc fusion to recombinant


human (hu) 4-1BB, cynomolgus (cy) 4-1BB and human (hu) CD19.












Antigen
ka (1/Ms)
kd (1/s)
KD (M)














monovalent CD19(8B8-
hu 4-
7.2E+04
2.5E−02
3.4E−07


018) targeted split trimeric
1BB
(5.9E+03)
(1.0E−05)
(2.8E−08)


4-1BB ligand (71-248) Fc
cy 4-
1.2E+05
1.3E−02
1.1E−07


(kih) fusion containing CH-
1BB
(8.6E+03)
(1.8E−04)
(9.9E−09)


CL cross with charged
hu CD19
2.77E+04
2.67E−04
9.64E−09


residues






(construct 3.4)






bivalent CD19(8B8-018)
hu 4-
6.9E+04
2.4E−02
3.5E−07


targeted split trimeric 4-
1BB
(1.7E+03)
(1.5E−04)
(1.1E−08)


1BB ligand (71-248) Fc
cy 4-
1.1E+05
1.4E−02
1.3E−07


(kih) fusion
1BB
(7.7E+03)
(3.1E−04)
(1.3E−08)


(construct 3.6)
hu CD19
2.55E+04
2.69E−04
1.06E−08


monovalent DP47
hu 4-
7.3E+04
2.6E−02
3.5E−07


untargeted split trimeric
1BB
(3.9E+03)
(6.3E−04)
(1.0E−08)


human 4-1BB ligand (71-
cy 4-
1.2E+05
1.4E−02
1.2E−07


248) Fc (kih) fusion with
1BB
(1.9E+03)
(1.0E−04)
(2.9E−09)


CH-CL cross and with






charged residues






(control D)






anti-CD19(8B8-018)
hu CD19
2.12E+04
2.61E−04
1.23E−08


huIgG1 PGLALA






,









8.2. Surface Plasmon Resonance (Simultaneous Binding)


The capacity of binding simultaneously human 4-1BB Fc(kih) and human CD19 was assessed by surface plasmon resonance (SPR). All SPR experiments were performed on a BIACORE® T200 instrument at 25° C. with HBS-EP as running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20, Biacore, Freiburg/Germany). Biotinylated human 4-1BB Fc(kih) was directly coupled to a flow cell of a streptavidin (SA) sensor chip. Immobilization levels up to 250 resonance units (RU) were used.


The CD19 targeted trimeric split 4-1BBL constructs (constructs 3.1, 3.3, 3.4, 3.5, 3.6, 4.4) were passed at a concentration range of 200 nM with a flow of 30 μL/minute through the flow cells over 90 seconds and dissociation was set to zero sec. Human CD19 was injected as second analyte with a flow of 30 μL/minute through the flow cells over 90 seconds at a concentration of 500 nM (FIG. 34). The dissociation was monitored for 120 sec. Bulk refractive index differences were corrected for by subtracting the response obtained in a reference flow cell, where no protein was immobilized.


As can be seen in the graphs of FIGS. 35A to 35F, all bispecific constructs could bind simultaneously human 4-1BB and human CD19.


Example 9
Functional Characterization of the CD-19 Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

9.1. Binding on Activated Human PMBCs of the CD19-Targeted 4-1BB Ligand Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecules


To determine binding of 4-1BBL trimer-containing Fc fusion antigen binding molecules to human PBMCs, different titrated concentrations of the CD19-targeted 4-1BBL trimer-containing Fc fusion antigen binding molecules were used in the assay as described in Example 5.2.



FIGS. 36A-1 to 36A-3 and 36B-1 to 36B-3 show the binding of Constructs 3.1, 3.3, 3.4, 3.5 and 3.6 as prepared in Example 7 on activated 4-1BB-expressing CD4+ T cells and CD8+ T cells, respectively. Gates were set on living CD45+CD3+CD4+ or CD45+CD3+CD8+ T cells and MFI of PE-conjugated AffiniPure anti-human IgG IgG Fcγ-fragment-specific goat F(ab′)2 fragment were blotted against the titrated concentration of targeted split trimeric 4-1BB ligand Fc fusion variants. Table 78 shows the EC50 values as measured for Constructs 3.1, 3.3. 3.4, 3.5 and 3.6 and control molecules.









TABLE 78







Binding on activated 4-1BB-expressing CD4+ T cells and CD8 +T cells










EC50[nM]
EC50[nM]


Construct
4-1BB+CD8+
4-1BB+CD4+












Control B
0.05
0.26


Control C
0.02
0.30


Control D
0.04
0.28


Control E
0.13
1.22


3.1
0.03
0.28


3.3
0.01
0.29


3.4
0.15
2.04


3.5
0.04
1.03


3.6
0.05
0.21









9.2 Binding to CD19-Expressing Tumor Cells


For binding assays on CD19-expressing tumor cells, the following human CD19-expressing lymphoma cell lines were used: diffuse large non-Hodgkin B cell lymphoma (B-NHL) cell line SU-DHL-8 (DSMZ ACC573), acute B cell precursor lymphoid leukemia cell line Nalm6 (DSMZ ACC-128), diffuse large cell lymphoblast lymphoma cell line Toledo (ATCC CRL-2631) and diffuse large B cell lymphoma cell line OCI-Ly18 (DSMZ ACC-699). The assays were preformed as described for the FAP-expressing MV-3 and WM-266-4 tumor cell lines in Example 5.3.


Gates were set on living tumor cells and MFI of PE-conjugated AffiniPure anti-human IgG IgG Fcγ-fragment-specific goat F(ab′)2 fragment were blotted against the titrated concentration of targeted split trimeric 4-1BB ligand Fc fusion constructs.



FIGS. 37A-1 to 37A-3 show the binding of Constructs 3.1, 3.3, 3.4, 3.5 and 3.6 as prepared in Example 7.1 to diffuse large non-Hodgkin B cell lymphoma (B-NHL) cell line SU-DHL-8 and in FIGS. 37B-1 to 37B-3 the binding of Constructs 3.1, 3.3, 3.4, 3.5 and 3.6 to acute B cell precursor lymphoid leukemia cell line Nalm6 is presented. FIGS. 37C-1 to 37C-3 show the binding of Constructs 3.1, 3.3, 3.4, 3.5 and 3.6 to diffuse large cell lymphoblast lymphoma cell line Toledo and FIGS. 37D-1 to 37D-3 show the binding of Constructs 3.1, 3.3, 3.4, 3.5 and 3.6 to diffuse large B cell lymphoma cell line OCI-Ly18. Table 79 shows the EC50 values as measured for Constructs 3.1, 3.3, 3.4, 3.5 and 3.6 and control molecules.









TABLE 79







Binding to CD19-expressing tumor cells














EC50[nM]
EC50[nM]
EC50[nM]
EC50[nM]



Construct
SU-DHL-8
Nalm6
Toledo
OCI-Ly18

















3.1
0.64
0.43
0.29
0.29



3.3
0.15
0.14
0.10
0.09



3.4
0.31
0.39
0.29
0.26



3.5
0.54
0.43
0.27
0.31



3.6
0.14
0.12
0.09
0.10



control G
0.09
0.10
0.06
0.07










Example 10
Biological Activity of the CD19-Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

10.1. NF-κB Activation in HeLa Cells Expressing Human 4-1BB


HeLa cells expressing human 4-1BB and NF-κB-luciferase were generated as described in Example 6.1.


NF-κB Activation in Hela Cells Expressing Human 4-1BB Co-Cultured with CD19-Expressing Tumor Cells


NF-κB-luciferase human-4-1BB HeLa cells were harvested and resuspended in DMEM medium supplied with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I to a concentration of 0.2×106 cells/ml. 100 μl (2×104 cells) of this cell suspension were transferred to each well of a sterile white 96-well flat bottom tissue culture plate with lid (greiner bio-one, Cat. No. 655083) and the plate were incubated at 37° C. and 5% CO2 overnight. The next day 50 μL of medium containing titrated concentrations of CD19-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules (CD19 split 4-1BBL trimer) or DP47-untargeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules (DP47 split 4-1BBL trimer) were added. CD19-expressing B cell lymphoma cell lines (diffuse large non-Hodgkin B cell lymphoma (B-NHL) cell line SU-DHL-8 (DSMZ ACC573) and human non-Hodgkin's B cell lymphoma cell line Pfeiffer (ATCC CRL-2632)) were resuspended in DMEM medium supplied with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I to a concentration of 2×106 cells/ml.


Suspension of CD19-expressing B cell lymphoma cell (50 final ratio 1:5) or only medium were added to each well and plates were incubated for 6 hours at 37° C. and 5% CO2. Cells were washed two times with 200 μL/well DPBS. 40 μl freshly prepared Reporter Lysis Buffer (Promega, Cat-No: E3971) were added to each well and the plate were stored over night at −20° C. The next day frozen cell plate and Detection Buffer (Luciferase 1000 Assay System, Promega, Cat. No. E4550) were thawed at room temperature. 100 μL of detection buffer were added to each well and luciferase activity was measured as fast as possible using a SpectraMax M5/M5e microplate reader and a SoftMax Pro Software (Molecular Devices) counting light emission in URL (units of released light for 0.5s/well) or Victor3 1420 multilabel counter plate reader (Perkin Elmer) and the Perkin Elmer 2030 Manager Software counting light emission as counts per seconds (CPS) and blotted against the concentration of tested constructs.


CD19-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules Constructs 3.1 and 3.3 triggered activation of the NF-kB signaling pathway in the reporter cell line in the presence of CD19-expressing B cell lymphoma cells. In contrast, the untargeted control molecules failed to trigger such an effect at any of the tested concentrations (FIGS. 38A to 38C).


Example 11

11.1 Preparation of CEA (T84.66-LCHA) Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules


11.1.1 Humanization of Anti-CEA Clone T84.66


Novel humanized variants of the murine antibody T84.66 (Wagener et al., J Immunol 130, 2308 (1983), Neumaier et al., J Immunol 135, 3604 (1985)) were developed by grafting of the CDRs onto human germline framework acceptor sequences.


Humanization of an antibody from non-human origin consists essentially of transplanting the CDR residues from the non-human antibody (donor) onto the framework of a human (acceptor) antibody. Normally the acceptor framework is selected by aligning the sequence of the donor to a collection of potential acceptor sequences and choosing one that has either reasonable homology to the donor, or shows similar amino acids at some positions critical for structure and activity. In the present case, the search for the antibody acceptor framework was performed by aligning the mouse T84.66 protein (NCBI Acc No: CAA36980 for the heavy chain (SEQ ID NO:317), and CAA36979 (SEQ ID NO:318) for the light chain) sequence to a collection of human germ-line sequences and picking that human sequence that showed high sequence identity. Here, the sequence IGHV1-69*08 from the IMGT database was chosen as the heavy chain framework acceptor sequence (IMGT Acc No. Z14309, SEQ ID NO:319), and the IGKV3-11*01 sequence (IMGT Acc No. X01668, SEQ ID NO:320) was chosen to be the framework acceptor for the light chain. Onto these two acceptor frameworks, the three complementary determining regions (CDRs) of the mouse heavy and light variable domains were grafted. Since the framework 4 (FR4) region is not part of the variable region of the germ line V gene, the alignment for that position was done individually. The JH4 sequence was chosen for the heavy chain, and the JK2 sequence was chosen for the light chain.


11.1.2 Binding of Different Humanized Variants of T84.66 IgG to Cells


The binding of different humanized variants of T84.66 IgG was tested on CEA-expressing human gastric adenocarcinoma cells (MKN45, DSMZ ACC 409).


Cells were harvested, counted, checked for viability and re-suspended at 2×106 cells/ml in FACS buffer (100 μl PBS 0.1% BSA). 100 μl of cell suspension (containing 0.2×106 cells) were incubated in round-bottom 96-well plate for 30 min at 4° C. with increasing concentrations of the CEA IgG (4 ng/ml-60 μg/ml), washed twice with cold PBS 0.1% BSA, re-incubated for further 30 min at 4° C. with the PE-conjugated AffiniPure F(ab′)2 Fragment goat anti-human IgG Fcg Fragment Specific secondary antibody (Jackson Immuno Research Lab PE #109-116-170), washed twice with cold PBS 0.1% BSA and immediately analyzed by FACS using a FACS CantoII (Software FACS Diva). Binding curves and EC50 values were obtained and calculated using GraphPadPrism5.



FIG. 39 shows the different binding pattern of selected humanized variants of the T84.66 IgG to human CEA, expressed on MKN45 cells. Based on the calculated EC50 binding values (Table 80), the humanized variant 1 was selected for further evaluation.









TABLE 80







Binding of different humanized variants of T84.66 IgGs to cells


(EC50 values, based on binding curves shown in FIG. 39,


calculated by Graph Pad Prism).











EC50 (μg/m1)














Parental chimeric T84.66
0.99



Humanized variant 1
1.5



Humanized variant 2
8.6



Humanized variant 3
1.4



Humanized variant 4
3.1



Humanized variant 5




Humanized variant 6











Humanized variant 1 is termed in the following T84.66-LCHA. The amino acid sequences of its CDRs and of the VH and VL as well as the aminoacid sequences of the VH and VL domain of the parental chimeric T84.66 clone are shown in Table 81.









TABLE 81







Amino acid sequences of the variable domains of CEA


clone T84.66-LCHA and its parental antibody T84.66











SEQ ID


Description
Sequence
NO:





CEA CDR-H1
DTYMH
321





CEA CDR-H2
RIDPANGNSKYVPKFQG
322





CEA CDR-H3
FGYYVSDYAMAY
323





CEA CDR-L1
RAGESVDIFGVGFLH
324





CEA CDR-L2
RASNRAT
325





CEA CDR-L3
QQTNEDPYT
326





Parental CEA
EVQLQQSGAELVEPGASVKLSCTASGFNIKDTYMHWVKQRPEQ
327


binder VH
GLEWIGRIDPANGNSKYVPKFQGKATITADTSSNTAYLQLTSLTS




EDTAVYYCAPFGYYVSDYAMAYWGQGTSVTVSS






Parental CEA
DIVLTQSPASLAVSLGQRATMSCRAGESVDIFGVGFLHWYQQKP
328


binder VL
GQPPKLLIYRASNLESGIPVRFSGTGSRTDFTLIIDPVEADDVATY




YCQQTNEDPYTFGGGTKLEIK






Humanized
QVQLVQSGAEVKKPGSSVKVSCKASGFNIKDTYMHWVRQAPGQ
329


CEA binder
GLEWMGRIDPANGNSKYVPKFQGRVTITADTSTSTAYMELSSLR



CEA (T84.66-
SEDTAVYYCAPFGYYVSDYAMAYWGQGTLVTVSS



LCHA) VH







Humanized
EIVLTQSPATLSLSPGERATLSCRAGESVDIFGVGFLHWYQQKPG
330


CEA binder
QAPRLLIYRASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYY



CEA (T84.66-
CQQTNEDPYTFGQGTKLEIK



LCHA) VL









11.2 Preparation of CEA (T84.66-LCHA) Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules


Different fragments of the DNA sequence encoding part of the ectodomain (amino acid 71-254 and 71-248) of human 4-1BB ligand were synthetized according to the P41273 sequence of Uniprot database (SEQ ID NO:42).


11.2.1 Preparation of Monovalent CEA (T84.66-LCHA) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 5.1)


A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G4S)2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned as depicted in FIG. 29A: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the human IgG1-CH domain, was cloned as described in FIG. 29B: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CH.


To improve correct pairing the following mutations have been introduced in the crossed CH-CL. In the dimeric 4-1BB ligand fused to human CL, E123R and Q124K. In the monomeric 4-1BB ligand fused to human CH1, K147E and K213E.


The variable region of heavy and light chain DNA sequences encoding a binder specific for CEA, clone T84.66-LCHA, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831.


Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CEA-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CEA light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CEA binding Fab (FIG. 40A, Construct 5.1).


Table 82 shows the cDNA and amino acid sequences of the monovalent CEA (T84.66-LCHA) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule with crossed CH-CL and charged residues (construct 5.1).









TABLE 82







cDNA and amino acid sequences of monovalent CEA(T84.66-LCHA)


targeted split trimeric 4-1BB ligand (71-254) Fc (kih)


fusion containing CH-CL cross with charged residues


(construct 5.1). 









SEQ ID




NO:
Description
Sequence





129
Nucleotide
see Table 3



sequence Dimeric




hu 4-1BBL




(71-254) - CL* Fc




knob chain






130
Nucleotide
see Table 3



sequence




Monomeric hu




4-1BBL (71-254) -




CH1*






331
Nucleotide
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAAGTGAAGAA



sequence anti-
ACCCGGCAGCAGCGTGAAGGTGTCCTGCAAGGCCAGCG



CEA(T84.66-
GCTTCAACATCAAGGACACCTACATGCACTGGGTGCGCC



LCHA) Fc hole
AGGCCCCTGGACAGGGACTGGAATGGATGGGCAGAATC



chain
GACCCCGCCAACGGCAACAGCAAATACGTGCCCAAGTT




CCAGGGCAGAGTGACCATCACCGCCGACACCAGCACCT




CCACCGCCTACATGGAACTGAGCAGCCTGCGGAGCGAG




GACACCGCCGTGTACTACTGTGCCCCCTTCGGCTACTAC




GTGTCCGACTACGCCATGGCCTATTGGGGCCAGGGCAC




ACTCGTGACCGTGTCCTCTGCTAGCACCAAGGGCCCCTC




CGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCG




GCGGCACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACT




TCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCC




CTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAG




AGTTCTGGCCTGTATAGCCTGAGCAGCGTGGTCACCGTG




CCTTCTAGCAGCCTGGGCACCCAGACCTACATCTGCAAC




GTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAA




GGTGGAGCCCAAGAGCTGCGACAAAACTCACACATGCC




CACCGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCA




GTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATG




ATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGAC




GTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTA




CGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC




CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC




AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGC




AAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGG




CGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC




AGCCCCGAGAACCACAGGTGTGCACCCTGCCCCCATCCC




GGGATGAGCTGACCAAGAACCAGGTCAGCCTCTCGTGC




GCAGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGA




GTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGA




CCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCC




TCGTGAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAG




CAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCT




CTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT




CCGGGTAAA





332
Nucleotide
GAGATCGTGCTGACCCAGAGCCCTGCCACCCTGTCACTG



sequence anti-
TCTCCAGGCGAGAGAGCCACCCTGAGCTGTAGAGCCGG



CEA(T84.66-
CGAGAGCGTGGACATCTTCGGCGTGGGATTTCTGCACTG



LCHA) light
GTATCAGCAGAAGCCCGGCCAGGCCCCCAGACTGCTGA



chain
TCTACAGAGCCAGCAACCGGGCCACAGGCATCCCCGCC




AGATTTTCTGGCTCTGGCAGCGGCACCGACTTCACCCTG




ACAATCAGCAGCCTGGAACCCGAGGACTTCGCCGTGTA




CTACTGCCAGCAGACCAACGAGGACCCCTACACCTTTGG




CCAGGGCACCAAGCTGGAAATCAAGCGTACGGTGGCTG




CACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTT




GAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAA




CTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGG




ATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTC




ACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAG




CAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAAC




ACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTG




AGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTG




T





115
Dimeric hu
see Table 3



4-1BBL (71-254) -




CL* Fe knob




chain






116
Monomeric hu
see Table 3



4-1BBL (71-254) -




CH1*






333
anti-CEA
QVQLVQSGAEVKKPGSSVKVSCKASGFNIKDTYMHWVRQ



(T84.66-LCHA)
APGQGLEWMGRIDPANGNSKYVPKFQGRVTITADTSTSTA



Fe hole chain
YMELSSLRSEDTAVYYCAPFGYYVSDYAMAYWGQGTLV




TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV




TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT




QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAA




GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN




W




YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN




GKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRD




ELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPP




VLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNH




YTQKSLSLSPGK





334
anti-CEA
EIVLTQSPATLSLSPGERATLSCRAGESVDIFGVGFLHWYQ



(T84.66-LCHA)
QKPGQAPRLLIYRASNRATGIPARFSGSGSGTDFTLTISSLEP



light chain
EDFAVYYCQQTNEDPYTFGQGTKLEIKRTVAAPSVFIFPPS




DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ




ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG




LSSPVTKSFNRGEC





*for charged residues






11.2.2 Preparation of Monovalent CEA (T84.66-LCHA) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains without Charged Residues (Construct 5.2)


A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G4S)2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned in analogy as depicted in FIG. 29A, but without amino acid mutations in the CL domain: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the human IgG1-CH1 domain, was cloned in analogy as depicted in FIG. 29B, but without amino acid mutations in the CH1 domain: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CH1.


The variable region of heavy and light chain DNA sequences encoding a binder specific for CEA, clone T84.66-LCHA, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1.


The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CEA-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CEA light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CEA-binding Fab (FIG. 40B, Construct 5.2).


Table 83 shows the cDNA and amino acid sequences of the monovalent CEA (T84.66-LCHA) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule containing crossed CH-CL cross without charged residues (construct 5.2).









TABLE 83







cDNA and amino acid sequences of monovalent CEA (T84.66-LCHA) targeted split


trimeric 4-1BB ligand (71-254) Fc (kih) fusion containing CH-CL cross without charged


residues (construct 5.2)









SEQ ID




NO:
Description
Sequence












165
Nucleotide sequence dimeric
see Table 22



ligand (71-254)-CL Fc knob




chain



166
Nucleotide sequence monomeric
see Table 22



hu 4-1BBL (71-254)-CH1



331
Nucleotide sequence anti- CEA
see Table 82



(T84.66-LCHA) Fc hole chain



332
Nucleotide sequence anti- CEA
see Table 82



(T84.66-LCHA) light chain



117
Dimeric ligand (71-254) - CL Fc
see Table 22



knob chain



118
Monomeric ligand (71-254) -CH1
see Table 22


333
anti- CEA (T84.66-LCHA) Fc
see Table 82



hole chain



334
anti- CEA (T84.66-LCHA) light
see Table 82



chain









11.2.3 Preparation of Bivalent CEA(T84.66-LCHA) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding (Construct 5.3)


A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G4S)2 (SEQ ID NO:13) linkers was fused to the C-terminus of human IgG1 Fc hole chain, as depicted in FIG. 29C: human IgG1 Fc hole, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the C-terminus of human IgG1 Fc knob chain as described in FIG. 29D: human IgG1 Fc knob, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand.


The variable region of heavy and light chain DNA sequences encoding a binder specific for CEA, clone T84.66-LCHA, were subcloned in frame with either the constant heavy chain of the hole, the knob or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the anti-CEA huIgG1 hole dimeric ligand chain containing the Y349C/T366S/L368A/Y407V mutations, the anti-CEA huIgG1 knob monomeric ligand chain containing the S354C/T366W mutations and the anti-CEA light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and two CEA binding Fabs (FIG. 40C, construct 5.3).


Table 84 shows the cDNA and amino acid sequences of the bivalent CEA(T84.66-LCHA) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule (construct 5.3).









TABLE 84







cDNA and amino acid sequences of bivalent CEA(T84.66-LCHA)


targeted split trimeric 4-1BB ligand (71-254) Fc (kih)


PGLALA fusion (construct 5.3)









SEQ ID




NO:
Description
Sequence





335
Nucleotide
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAAGTGAAGAA



sequence anti-
ACCCGGCAGCAGCGTGAAGGTGTCCTGCAAGGCCAGCG



CEA(T84. 66-
GCTTCAACATCAAGGACACCTACATGCACTGGGTGCGCC



LCHA) Fc hole
AGGCCCCTGGACAGGGACTGGAATGGATGGGCAGAATC



dimeric 4-1BBL
GACCCCGCCAACGGCAACAGCAAATACGTGCCCAAGTT



(71-254) chain
CCAGGGCAGAGTGACCATCACCGCCGACACCAGCACCT




CCACCGCCTACATGGAACTGAGCAGCCTGCGGAGCGAG




GACACCGCCGTGTACTACTGTGCCCCCTTCGGCTACTAC




GTGTCCGACTACGCCATGGCCTATTGGGGCCAGGGCAC




ACTCGTGACCGTGTCCTCTGCTAGCACCAAGGGCCCCTCC





GTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCG






GCACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACTTCCC






CGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACC






TCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGTTCTG






GCCTGTATAGCCTGAGCAGCGTGGTCACCGTGCCTTCTAGC






AGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAA






GCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAG






AGCTGCGACAAAACTCACACATGCCCACCGTGCCCAGCACC






TGAAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAA






AACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTC






ACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGG






TCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAAT






GCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGT






ACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTG






GCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAG






CCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAA






GGGCAGCCCCGAGAACCACAGGTGTGCACCCTGCCCCCAT






CCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTCTCGTG






CGCAGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGT






GGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCAC






GCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCGTGA






GCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAA






CGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACC






ACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGAGG






CGGCGGAAGCGGAGGAGGAGGATCCAGAGAGGGCCCTGA






GCTGAGCCCCGATGATCCTGCTGGACTGCTGGACCTGCGG






CAGGGCATGTTTGCTCAGCTGGTGGCCCAGAACGTGCTGCT






GATCGATGGCCCCCTGTCCTGGTACAGCGATCCTGGACTG






GCTGGCGTGTCACTGACAGGCGGCCTGAGCTACAAAGAGG






ACACCAAAGAACTGGTGGTGGCCAAGGCCGGCGTGTACTA






CGTGTTCTTTCAGCTGGAACTGCGGAGAGTGGTGGCCGGC






GAAGGATCTGGCTCTGTGTCTCTGGCCCTGCATCTGCAGCC






TCTGAGAAGCGCTGCTGGCGCTGCAGCTCTGGCACTGACA






GTGGATCTGCCTCCTGCCAGCTCCGAGGCCCGGAATAGCG






CATTTGGGTTTCAAGGCAGGCTGCTGCACCTGTCTGCCGGC






CAGAGGCTGGGAGTGCATCTGCACACAGAGGCCAGGGCTA






GACACGCCTGGCAGCTGACACAGGGCGCTACAGTGCTGGG






CCTGTTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTT






CTCCAAGAAGCGAAGGCGGAGGCGGATCTGGCGGCGGAG






GATCTAGAGAGGGACCCGAACTGTCCCCTGACGATCCAGC






CGGGCTGCTGGATCTGAGACAGGGAATGTTCGCCCAGCTG






GTGGCTCAGAATGTGCTGCTGATTGACGGACCTCTGAGCTG






GTACTCCGACCCAGGGCTGGCAGGGGTGTCCCTGACTGGG






GGACTGTCCTACAAAGAAGATACAAAAGAACTGGTGGTGGC






TAAAGCTGGGGTGTACTATGTGTTTTTTCAGCTGGAACTGAG






GCGGGTGGTGGCTGGGGAGGGCTCAGGATCTGTGTCCCTG






GCTCTGCATCTGCAGCCACTGCGCTCTGCTGCTGGCGCAG






CTGCACTGGCTCTGACTGTGGACCTGCCACCAGCCTCTAGC






GAGGCCAGAAACAGCGCCTTCGGGTTCCAAGGACGCCTGC






TGCATCTGAGCGCCGGACAGCGCCTGGGAGTGCATCTGCA






TACTGAAGCCAGAGCCCGGCATGCTTGGCAGCTGACTCAG






GGGGCAACTGTGCTGGGACTGTTTCGCGTGACACCTGAGAT






CCCTGCCGGACTGCCAAGCCCTAGATCAGAA






336
Nucleotide
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAAGTGAAGAA



sequence anti-
ACCCGGCAGCAGCGTGAAGGTGTCCTGCAAGGCCAGCG



CEA(T84.66-
GCTTCAACATCAAGGACACCTACATGCACTGGGTGCGCC



LCHA) Fc knob
AGGCCCCTGGACAGGGACTGGAATGGATGGGCAGAATC



monomeric 41-
GACCCCGCCAACGGCAACAGCAAATACGTGCCCAAGTT



BBL (71-254)
CCAGGGCAGAGTGACCATCACCGCCGACACCAGCACCT




CCACCGCCTACATGGAACTGAGCAGCCTGCGGAGCGAG




GACACCGCCGTGTACTACTGTGCCCCCTTCGGCTACTAC




GTGTCCGACTACGCCATGGCCTATTGGGGCCAGGGCAC




ACTCGTGACCGTGTCCTCTGCTAGCACCAAGGGCCCATCG





GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGG






GCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCC






CGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACC






AGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAG






GACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGC






AGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAA






GCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAAT






CTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCT






GAAGCTGCAGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAA






ACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCA






CATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGT






CAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATG






CCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTA






CCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGG






CTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGC






CCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAG






GGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCCTG






CAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGTGGTGTC






TGGTCAAGGGCTTCTACCCCAGCGATATCGCCGTGGAGTG






GGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCACC






CCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACTC






CAAACTGACCGTGGACAAGAGCCGGTGGCAGCAGGGCAAC






GTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACC






ACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGCGGAGG






CGGCGGAAGCGGAGGAGGAGGATCCAGAGAGGGCCCTGA






GCTGAGCCCCGATGATCCTGCTGGACTGCTGGACCTGCGG






CAGGGCATGTTTGCTCAGCTGGTGGCCCAGAACGTGCTGCT






GATCGATGGCCCCCTGTCCTGGTACAGCGATCCTGGACTG






GCTGGCGTGTCACTGACAGGCGGCCTGAGCTACAAAGAGG






ACACCAAAGAACTGGTGGTGGCCAAGGCCGGCGTGTACTA






CGTGTTCTTTCAGCTGGAACTGCGGAGAGTGGTGGCCGGC






GAAGGATCTGGCTCTGTGTCTCTGGCCCTGCATCTGCAGCC






TCTGAGAAGCGCTGCTGGCGCTGCAGCTCTGGCACTGACA






GTGGATCTGCCTCCTGCCAGCTCCGAGGCCCGGAATAGCG






CATTTGGGTTTCAAGGCAGGCTGCTGCACCTGTCTGCCGGC






CAGAGGCTGGGAGTGCATCTGCACACAGAGGCCAGGGCTA






GACACGCCTGGCAGCTGACACAGGGCGCTACAGTGCTGGG






CCTGTTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTT






CTCCAAGAAGCGAA






332
Nucleotide
see Table 82



sequence anti-




CEA(T84.66-




LCHA) light




chain






337
anti-
QVQLVQSGAEVKKPGSSVKVSCKASGFNIKDTYMHWVRQ



CEA(T84.66-
APGQGLEWMGRIDPANGNSKYVPKFQGRVTITADTSTSTA



LCHA) Fc hole
YMELSSLRSEDTAVYYCAPFGYYVSDYAMAYWGQGTLV



dimeric 41-BBL
TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS



(71-254) chain

WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV






NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFP






PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN






AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL






GAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKG






FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDK






SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGG






SREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYS






DPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVA






GEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFG






FQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRV






TPEIPAGLPSPRSEGGGGSGGGGSREGPELSPDDPAGLLDLR






QGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDT






KELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSA






AGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHL






HTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE






338
anti-
QVQLVQSGAEVKKPGSSVKVSCKASGFNIKDTYMHWVRQ



CEA(T84.66-
APGQGLEWMGRIDPANGNSKYVPKFQGRVTITADTSTSTA



LCHA) Fc knob
YMELSSLRSEDTAVYYCAPFGYYVSDYAMAYWGQGTLV



monomeric
TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS



4-1BBL (71-254)

WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV




chain

NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFP






PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN






AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL






GAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKG






FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK






SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGG






SREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYS






DPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVA






GEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFG






FQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRV






TPEIPAGLPSPRSE






334
anti-
see Table 82



CEA(T84.66-




LCHA) light




chain









11.2.4 Preparation of Monovalent CEA(T84.66-LCHA) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 5.4)


A polypeptide containing two ectodomains of 4-1BB ligand (71-248), separated by (G4S)2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned in analogy to the one depicted in FIG. 29A: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-248) and fused to the human IgG1-CH domain, was cloned in analogy to the one described in FIG. 29B: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CH.


The polypeptide encoding the dimeric 4-1BB ligand fused to human CL domain was subcloned in frame with the human IgG1 heavy chain CH2 and CH3 domains on the knob (Merchant, Zhu et al. 1998). To improve correct pairing the following mutations have been introduced in the crossed CH-CL. In the dimeric 4-1BB ligand fused to human CL, E123R and Q124K. In the monomeric 4-1BB ligand fused to human CH1, K147E and K213E.


The variable region of heavy and light chain DNA sequences encoding a binder specific for CEA, clone T84.66-LCHA, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831.Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CD19-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CD19 light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CEA binding Fab (FIG. 40D, construct 5.4).


Table 85 shows the cDNA and amino acid sequences of the monovalent CEA(T84.66-LCHA) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule with crossed CH-CL and charged residues (construct 5.4).









TABLE 85







cDNA and amino acid sequences of monovalent CEA(T84.66-LCHA) targeted split


trimeric 4-1BB ligand (71-248) Fc (kih) fusion containing CH-CL cross with charged residues


(construct 5.4). * charged residues









SEQ ID




NO:
Description
Sequence












169
Nucleotide sequence dimeric ligand
see Table 24



(71-248)-CL* Fc knob chain



170
Nucleotide sequence monomeric hu
see Table 24



4-1BBL (71-248)-CH1*



331
Nucleotide sequence anti-
see Table 82



CEA(T84.66-LCHA) Fc hole chain



332
Nucleotide sequence anti-
see Table 82



CEA(T84.66-LCHA) light chain



119
Dimeric ligand (71-248)-CL* Fc
see Table 24



knob chain



120
Monomeric ligand (71-248)-CH1*
see Table 24


333
anti- CEA(T84.66-LCHA) Fc hole
see Table 62



chain



334
anti- CEA(T84.66-LCHA) light chain
see Table 59









11.2.5 Preparation of Monovalent CEA(T84.66-LCHA) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains without Charged Residues (Construct 5.5)


A polypeptide containing two ectodomains of 4-1BB ligand (71-248), separated by (G4S)2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned in analogy as depicted in FIG. 29A, but without amino acid mutations in the CL domain: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-248) and fused to the human IgG1-CH1 domain, was cloned in analogy as depicted in FIG. 29B, but without amino acid mutations in the CH1 domain: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CH1.


The variable region of heavy and light chain DNA sequences encoding a binder specific for CEA, clone T84.66-LCHA, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CEA-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CEA light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CD19-binding Fab (FIG. 40E, Construct 5.5).


Table 86 shows the cDNA and amino acid sequences of the monovalent CEA(T84.66-LCHA) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule containing crossed CH-CL cross without charged residues (construct 5.5).









TABLE 86







cDNA and amino acid sequences of monovalent CEA(T84.66-LCHA) targeted split


trimeric 4-1BB ligand (71-248) Fc (kih) fusion containing CH-CL cross without charged


residues (construct 5.5).









SEQ ID




NO:
Description
Sequence












171
Nucleotide sequence dimeric
see Table 25



ligand (71-248)-CL Fc knob




chain



172
Nucleotide sequence
see Table 25



monomeric ligand (71-248)-




CH1



331
Nucleotide sequence anti-
see Table 82



CEA(T84.66-LCHA) Fc hole




chain



332
Nucleotide sequence anti-
see Table 82



CEA(T84.66-LCHA) light




chain



173
Dimeric ligand (71-248)-CL
see Table 25



Fc knob chain



174
Monomeric ligand (71-248)-
see Table 25



CH1



333
anti-CEA(T84.66-LCHA) Fc
see Table 82



hole chain



334
anti-CEA(T84.66-LCHA) light
see Table 82



chain










11.2.6 Preparation of Bivalent CEA(T84.66-LCHA) Targeted 4-1BB Ligand (71-248) Trimer-Containing Fc (Kih) Fusion Antigen Binding (Construct 5.6)


A polypeptide containing two ectodomains of 4-1BB ligand (71-248), separated by (G4S)2 (SEQ ID NO:13) linkers was fused to the C-terminus of human IgG1 Fc hole chain, as depicted in FIG. 29C: human IgG1 Fc hole, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the C-terminus of human IgG1 Fc knob chain as described in FIG. 29D: human IgG1 Fc knob, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand.


The variable region of heavy and light chain DNA sequences encoding a binder specific for CEA, clone T84.66-LCHA, were subcloned in frame with either the constant heavy chain of the hole, the knob or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the anti-CEA huIgG1 hole dimeric ligand chain containing the Y349C/T366S/L368A/Y407V mutations, the anti-CEA huIgG1 knob monomeric ligand chain containing the S354C/T366W mutations and the anti-CEA light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and two CEA binding Fabs (FIG. 40F, construct 5.6).


Table 87 shows the cDNA and amino acid sequences of the bivalent CEA(T84.66-LCHA) targeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion antigen binding molecule (construct 5.6).









TABLE 87







cDNA and amino acid sequences of bivalent CEA (T84.66-LCHA)


targeted split trimeric 4-1BB ligand (71-248) Fc (kih)


fusion (construct 5.6)









SEQ ID




NO:
Description
Sequence





339
Nucleotide
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAAGTGAAGAA



sequence anti-
ACCCGGCAGCAGCGTGAAGGTGTCCTGCAAGGCCAGCG



CEA (T84.66-
GCTTCAACATCAAGGACACCTACATGCACTGGGTGCGCC



LCHA) Fc hole
AGGCCCCTGGACAGGGACTGGAATGGATGGGCAGAATC



dimeric 4-1BBL
GACCCCGCCAACGGCAACAGCAAATACGTGCCCAAGTT



(71-248) chain
CCAGGGCAGAGTGACCATCACCGCCGACACCAGCACCT




CCACCGCCTACATGGAACTGAGCAGCCTGCGGAGCGAG




GACACCGCCGTGTACTACTGTGCCCCCTTCGGCTACTAC




GTGTCCGACTACGCCATGGCCTATTGGGGCCAGGGCAC




ACTCGTGACCGTGTCCTCTGCTAGCACCAAGGGCCCCTC




CGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCG




GCGGCACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACT




TCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCC




CTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAG




AGTTCTGGCCTGTATAGCCTGAGCAGCGTGGTCACCGTG




CCTTCTAGCAGCCTGGGCACCCAGACCTACATCTGCAAC




GTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAA




GGTGGAGCCCAAGAGCTGCGACAAAACTCACACATGCC




CACCGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCA




GTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATG




ATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGAC




GTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTA




CGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC




CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC




AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGC




AAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGG




CGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC




AGCCCCGAGAACCACAGGTGTGCACCCTGCCCCCATCCC




GGGATGAGCTGACCAAGAACCAGGTCAGCCTCTCGTGC




GCAGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGA




GTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGA




CCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCC




TCGTGAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAG




CAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCT




CTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT




CCGGGTGGAGGCGGCGGAAGCGGAGGAGGAGGATCCA




GAGAGGGCCCTGAGCTGAGCCCTGATGATCCTGCCGGA




CTGCTGGACCTGCGGCAGGGAATGTTTGCCCAGCTGGTG




GCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTGG




TACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGGC




GGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGGT




GGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGGA




ACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCTG




TGTCTCTGGCCCTGCATCTGCAGCCTCTGAGATCTGCTG




CTGGCGCCGCTGCTCTGGCACTGACAGTGGATCTGCCTC




CTGCCAGCAGCGAGGCCCGGAATAGCGCATTTGGGTTTC




AAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCTG




GGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACGC




CTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTGTT




CAGAGTGACCCCCGAGATTCCAGCAGGCCTGGGAGGCG




GCGGATCTGGCGGCGGAGGATCTAGAGAAGGACCCGAG




CTGTCCCCCGACGATCCCGCTGGGCTGCTGGATCTGAGA




CAGGGCATGTTCGCTCAGCTGGTGGCTCAGAATGTGCTG




CTGATTGACGGACCTCTGAGCTGGTACTCCGACCCAGGG




CTGGCAGGGGTGTCCCTGACTGGGGGACTGTCCTACAAA




GAAGATACAAAAGAACTGGTGGTGGCTAAAGCTGGGGT




GTACTATGTGTTTTTTCAGCTGGAACTGAGGCGGGTGGT




GGCTGGGGAGGGCTCAGGATCTGTGTCCCTGGCTCTGCA




TCTGCAGCCACTGCGCTCTGCAGCAGGGGCTGCAGCACT




GGCCCTGACTGTGGACCTGCCCCCAGCTTCTTCCGAGGC




CAGAAACAGCGCCTTCGGGTTCCAAGGACGCCTGCTGC




ATCTGAGCGCCGGACAGCGCCTGGGAGTGCATCTGCAT




ACTGAAGCCAGAGCCCGGCATGCTTGGCAGCTGACTCA




GGGGGCAACTGTGCTGGGACTGTTTCGCGTGACACCTGA




GATCCCAGCCGGGCTC





340
Nucleotide
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAAGTGAAGAA



sequence anti-
ACCCGGCAGCAGCGTGAAGGTGTCCTGCAAGGCCAGCG



CEA (T84.66-
GCTTCAACATCAAGGACACCTACATGCACTGGGTGCGCC



LCHA) Fc knob
AGGCCCCTGGACAGGGACTGGAATGGATGGGCAGAATC



monomeric
GACCCCGCCAACGGCAACAGCAAATACGTGCCCAAGTT



(71-248) 4-1BBL
CCAGGGCAGAGTGACCATCACCGCCGACACCAGCACCT



chain
CCACCGCCTACATGGAACTGAGCAGCCTGCGGAGCGAG




GACACCGCCGTGTACTACTGTGCCCCCTTCGGCTACTAC




GTGTCCGACTACGCCATGGCCTATTGGGGCCAGGGCAC




ACTCGTGACCGTGTCCTCTGCTAGCACCAAGGGCCCATC




GGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGG




GGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACT




TCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCC




CTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAG




TCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTG




CCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAAC




GTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAA




AGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCC




ACCGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCAG




TCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGA




TCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACG




TGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC




GTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCC




GCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCA




GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCA




AGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGC




GCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA




GCCCCGAGAACCACAGGTGTACACCCTGCCCCCCTGCA




GAGATGAGCTGACCAAGAACCAGGTGTCCCTGTGGTGT




CTGGTCAAGGGCTTCTACCCCAGCGATATCGCCGTGGAG




TGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGAC




CACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCT




GTACTCCAAACTGACCGTGGACAAGAGCCGGTGGCAGC




AGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCC




CTGCACAACCACTACACCCAGAAGTCCCTGAGCCTGAG




CCCCGGCGGAGGCGGCGGAAGCGGAGGAGGAGGATCC




AGAGAGGGCCCTGAGCTGAGCCCTGATGATCCTGCCGG




ACTGCTGGACCTGCGGCAGGGAATGTTTGCCCAGCTGGT




GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG




GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG




CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG




TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG




AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT




GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGATCTGCT




GCTGGCGCCGCTGCTCTGGCACTGACAGTGGATCTGCCT




CCTGCCAGCAGCGAGGCCCGGAATAGCGCATTTGGGTTT




CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT




GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG




CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG




TTCAGAGTGACCCCCGAGATTCCTGCCGGGCTC





332
Nucleotide
see Table 82



sequence anti-




CEA (T84.66-




LCHA) light




chain






341
anti-CEA
QVQLVQSGAEVKKPGSSVKVSCKASGFNIKDTYMHWVRQ



(T84.66-LCHA)
APGQGLEWMGRIDPANGNSKYVPKFQGRVTITADTSTSTA



Fe hole dimeric
YMELSSLRSEDTAVYYCAPFGYYVSDYAMAYWGQGTLV



4-1BBL (71-248)
TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV



chain
TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT




QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAA




GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN




WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL




NGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSR




DELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTP




PVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHN




HYTQKSLSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLR




QGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKE




DTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHL




QPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLS




AGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPA




GLGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQLVA




QNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAK




AGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAA




ALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLH




TEARARHAWQLTQGATVLGLFRVTPEIPAGL





342
anti-CEA
QVQLVQSGAEVKKPGSSVKVSCKASGFNIKDTYMHWVRQ



(T84.66-LCHA)
APGQGLEWMGRIDPANGNSKYVPKFQGRVTITADTSTSTA



Fc knob
YMELSSLRSEDTAVYYCAPFGYYVSDYAMAYWGQGTLV



monomeric
TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV



(71-248) 4-1BBL
TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT



chain
QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAA




GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN




WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL




NGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCR




DELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTP




PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN




HYTQKSLSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLR




QGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKE




DTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHL




QPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLS




AGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPA




GL





334
anti-CD19
see Table 82



(8B8-018)




light chain









11.2.7 Preparation of Monovalent CEA(T84.66) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule with Crossed CH1-CL Domains with Charged Residues (Construct 5.7)


A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G4S)2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned as depicted in FIG. 29A: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CL. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the human IgG1-CH domain, was cloned as described in FIG. 29B: human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human CH.


To improve correct pairing the following mutations have been introduced in the crossed CH-CL. In the dimeric 4-1BB ligand fused to human CL, E123R and Q124K. In the monomeric 4-1BB ligand fused to human CH1, K147E and K213E.


The variable region of heavy and light chain DNA sequences encoding a binder specific for CEA, clone T84.66, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831.


Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-CD19-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-CD19 light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and a CEA binding Fab. Construct 5.7 corresponds to Construct 5.1 as shown in FIG. 40A.


Table 88 shows the cDNA and amino acid sequences of the monovalent CEA(T84.66) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule with crossed CH-CL and charged residues (construct 5.7).









TABLE 88







cDNA and amino acid sequences of monovalent CEA(T84.66) targeted


split trimeric 4-1BB ligand (71-254) Fc (kih) fusion containing


crossed CH-CL with charged residues (construct 5.7).









SEQ ID




NO:
Description
Sequence





129
Nucleotide
see Table 3



sequence Dimeric




hu 4-1BBL




(71-254) - CL* Fc




knob chain






130
Nucleotide
see Table 3



sequence




Monomeric hu




4-1BBL (71-254) -




CH1*






343
Nucleotide
GAGGTGCAGCTGCAGCAGTCTGGCGCCGAACTGGTGGA



sequence anti-
ACCTGGCGCCTCTGTGAAGCTGAGCTGTACCGCCAGCGG



CEA(T84. 66) Fc
CTTCAACATCAAGGACACCTACATGCACTGGGTCAAGC



hole chain
AGCGGCCTGAGCAGGGCCTGGAATGGATCGGCAGAATC




GACCCCGCCAACGGCAACAGCAAATACGTGCCCAAGTT




CCAGGGCAAGGCCACCATCACCGCCGACACCAGCAGCA




ACACAGCCTACCTGCAGCTGACCAGCCTGACCTCCGAG




GACACCGCCGTGTACTACTGCGCCCCCTTCGGCTACTAC




GTGTCCGACTACGCCATGGCCTATTGGGGCCAGGGCAC




AAGCGTGACCGTGTCCTCTGCTAGCACCAAGGGCCCCTC




CGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCG




GCGGCACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACT




TCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCC




CTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAG




AGTTCTGGCCTGTATAGCCTGAGCAGCGTGGTCACCGTG




CCTTCTAGCAGCCTGGGCACCCAGACCTACATCTGCAAC




GTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAA




GGTGGAGCCCAAGAGCTGCGACAAAACTCACACATGCC




CACCGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCA




GTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATG




ATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGAC




GTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTA




CGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC




CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC




AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGC




AAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGG




CGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC




AGCCCCGAGAACCACAGGTGTGCACCCTGCCCCCATCCC




GGGATGAGCTGACCAAGAACCAGGTCAGCCTCTCGTGC




GCAGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGA




GTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGA




CCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCC




TCGTGAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAG




CAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCT




CTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT




CCGGGTAAA





344
Nucleotide
GACATCGTGCTGACCCAGAGCCCTGCCTCTCTGGCCGTG



sequence anti-
TCTCTGGGACAGAGGGCCACCATGTCTTGCAGAGCCGG



CEA(T84.66)
CGAGAGCGTGGACATCTTCGGCGTGGGATTTCTGCACTG



light chain
GTATCAGCAGAAGCCCGGCCAGCCCCCCAAGCTGCTGA




TCTACAGAGCCAGCAACCTGGAAAGCGGCATCCCCGTG




CGGTTTAGCGGCACCGGCAGCAGAACCGACTTCACCCT




GATCATCGACCCCGTGGAAGCCGACGACGTGGCCACCT




ACTACTGCCAGCAGACCAACGAGGACCCCTACACCTTTG




GCGGAGGCACCAAGCTGGAAATCAAGCGTACGGTGGCT




GCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAG




TTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT




AACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGT




GGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTG




TCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTC




AGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAA




ACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC




TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAG




TGT





115
Dimeric hu
see Table 3



4-1BBL (71-254) -




CL* Fc knob




chain






116
Monomeric hu
see Table 3



4-1BBL (71-254) -




CH1*






345
anti-CEA
EVQLQQSGAELVEPGASVKLSCTASGFNIKDTYMHWVKQ



(T84.66) Fc hole
RPEQGLEWIGRIDPANGNSKYVPKFQGKATITADTSSNTAY



chain
LQLTSLTSEDTAVYYCAPFGYYVSDYAMAYWGQGTSVTV




SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV




SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT




YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG




PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY




VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG




KEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDE




LTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPV




LDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHY




TQKSLSLSPGK





346
anti-CEA
DIVLTQSPASLAVSLGQRATMSCRAGESVDIFGVGFLHWY



(T84.66) light
QQKPGQPPKLLIYRASNLESGIPVRFSGTGSRTDFTLIIDPVE



chain
ADDVATYYCQQTNEDPYTFGGGTKLEIKRTVAAPSVFIFPP




SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS




QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ




GLSSPVTKSFNRGEC





*for charged residues






11.2.8 Preparation of Bivalent CEA(T84.66) Targeted 4-1BB Ligand (71-254) Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecule (Construct 5.8)


A polypeptide containing two ectodomains of 4-1BB ligand (71-254), separated by (G4S)2 (SEQ ID NO:13) linkers was fused to the C-terminus of human IgG1 Fc hole chain, as depicted in FIG. 29C: human IgG1 Fc hole, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand. A polypeptide containing one ectodomain of 4-1BB ligand (71-254) and fused to the C-terminus of human IgG1 Fc knob chain as described in FIG. 29D: human IgG1 Fc knob, (G4S)2 (SEQ ID NO:13) connector, human 4-1BB ligand.


The variable region of heavy and light chain DNA sequences encoding a binder specific for CEA, clone T84.66, were subcloned in frame with either the constant heavy chain of the hole, the knob or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831. Combination of the anti-CEA huIgG1 hole dimeric ligand chain containing the Y349C/T366S/L368A/Y407V mutations, the anti-CEA huIgG1 knob monomeric ligand chain containing the S354C/T366W mutations and the anti-CEA light chain allows generation of a heterodimer, which includes an assembled trimeric 4-1BB ligand and two CEA binding Fabs. Construct 5.8 corresponds to Construct 5.3 as shown in FIG. 40C.


Table 89 shows the cDNA and amino acid sequences of the bivalent CEA(T84.66) targeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion antigen binding molecule (construct 5.8).









TABLE 89







cDNA and amino acid sequences of bivalent CEA(T84.66)


targeted split trimeric 4-1BB ligand (71-254) Fc (kih)


PGLALA fusion (construct 5.8)









SEQ ID




NO:
Description
Sequence





347
Nucleotide
GAGGTGCAGCTGCAGCAGTCTGGCGCCGAACTGGTGGA



sequence anti-
ACCTGGCGCCTCTGTGAAGCTGAGCTGTACCGCCAGCGG



CEA(T84.66) Fc
CTTCAACATCAAGGACACCTACATGCACTGGGTCAAGC



hole dimeric
AGCGGCCTGAGCAGGGCCTGGAATGGATCGGCAGAATC



4-1BBL (71-254)
GACCCCGCCAACGGCAACAGCAAATACGTGCCCAAGTT



chain
CCAGGGCAAGGCCACCATCACCGCCGACACCAGCAGCA




ACACAGCCTACCTGCAGCTGACCAGCCTGACCTCCGAG




GACACCGCCGTGTACTACTGCGCCCCCTTCGGCTACTAC




GTGTCCGACTACGCCATGGCCTATTGGGGCCAGGGCAC




AAGCGTGACCGTGTCCTCTGCTAGCACCAAGGGCCCCTC




CGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCG




GCGGCACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACT




TCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCC




CTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAG




AGTTCTGGCCTGTATAGCCTGAGCAGCGTGGTCACCGTG




CCTTCTAGCAGCCTGGGCACCCAGACCTACATCTGCAAC




GTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAA




GGTGGAGCCCAAGAGCTGCGACAAAACTCACACATGCC




CACCGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCA




GTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATG




ATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGAC




GTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTA




CGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC




CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC




AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGC




AAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGG




CGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC




AGCCCCGAGAACCACAGGTGTGCACCCTGCCCCCATCCC




GGGATGAGCTGACCAAGAACCAGGTCAGCCTCTCGTGC




GCAGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGA




GTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGA




CCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCC




TCGTGAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAG




CAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCT




CTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT




CCGGGTGGAGGCGGCGGAAGCGGAGGAGGAGGATCCA




GAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGGA




CTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGTG




GCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTGG




TACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGGC




GGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGGT




GGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGGA




ACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCTG




TGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCTG




CTGGCGCTGCAGCTCTGGCACTGACAGTGGATCTGCCTC




CTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTTC




AAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCTG




GGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACGC




CTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTGTT




CAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCTCC




AAGAAGCGAAGGCGGAGGCGGATCTGGCGGCGGAGGA




TCTAGAGAGGGACCCGAACTGTCCCCTGACGATCCAGC




CGGGCTGCTGGATCTGAGACAGGGAATGTTCGCCCAGCT




GGTGGCTCAGAATGTGCTGCTGATTGACGGACCTCTGAG




CTGGTACTCCGACCCAGGGCTGGCAGGGGTGTCCCTGAC




TGGGGGACTGTCCTACAAAGAAGATACAAAAGAACTGG




TGGTGGCTAAAGCTGGGGTGTACTATGTGTTTTTTCAGC




TGGAACTGAGGCGGGTGGTGGCTGGGGAGGGCTCAGGA




TCTGTGTCCCTGGCTCTGCATCTGCAGCCACTGCGCTCT




GCTGCTGGCGCAGCTGCACTGGCTCTGACTGTGGACCTG




CCACCAGCCTCTAGCGAGGCCAGAAACAGCGCCTTCGG




GTTCCAAGGACGCCTGCTGCATCTGAGCGCCGGACAGC




GCCTGGGAGTGCATCTGCATACTGAAGCCAGAGCCCGG




CATGCTTGGCAGCTGACTCAGGGGGCAACTGTGCTGGG




ACTGTTTCGCGTGACACCTGAGATCCCTGCCGGACTGCC




AAGCCCTAGATCAGAA





348
Nucleotide
GAGGTGCAGCTGCAGCAGTCTGGCGCCGAACTGGTGGA



sequence anti-
ACCTGGCGCCTCTGTGAAGCTGAGCTGTACCGCCAGCGG



CEA(T84.66) Fc
CTTCAACATCAAGGACACCTACATGCACTGGGTCAAGC



knob monomeric
AGCGGCCTGAGCAGGGCCTGGAATGGATCGGCAGAATC



4-1BBL (72-254)
GACCCCGCCAACGGCAACAGCAAATACGTGCCCAAGTT



chain
CCAGGGCAAGGCCACCATCACCGCCGACACCAGCAGCA




ACACAGCCTACCTGCAGCTGACCAGCCTGACCTCCGAG




GACACCGCCGTGTACTACTGCGCCCCCTTCGGCTACTAC




GTGTCCGACTACGCCATGGCCTATTGGGGCCAGGGCAC




AAGCGTGACCGTGTCCTCTGCTAGCACCAAGGGCCCATC




GGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGG




GGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACT




TCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCC




CTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAG




TCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTG




CCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAAC




GTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAA




AGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCC




ACCGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCAG




TCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGA




TCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACG




TGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC




GTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCC




GCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCA




GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCA




AGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGC




GCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA




GCCCCGAGAACCACAGGTGTACACCCTGCCCCCCTGCA




GAGATGAGCTGACCAAGAACCAGGTGTCCCTGTGGTGT




CTGGTCAAGGGCTTCTACCCCAGCGATATCGCCGTGGAG




TGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGAC




CACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCT




GTACTCCAAACTGACCGTGGACAAGAGCCGGTGGCAGC




AGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCC




CTGCACAACCACTACACCCAGAAGTCCCTGAGCCTGAG




CCCCGGCGGAGGCGGCGGAAGCGGAGGAGGAGGATCC




AGAGAGGGCCCTGAGCTGAGCCCCGATGATCCTGCTGG




ACTGCTGGACCTGCGGCAGGGCATGTTTGCTCAGCTGGT




GGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGTCCTG




GTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGG




CGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGG




TGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGG




AACTGCGGAGAGTGGTGGCCGGCGAAGGATCTGGCTCT




GTGTCTCTGGCCCTGCATCTGCAGCCTCTGAGAAGCGCT




GCTGGCGCTGCAGCTCTGGCACTGACAGTGGATCTGCCT




CCTGCCAGCTCCGAGGCCCGGAATAGCGCATTTGGGTTT




CAAGGCAGGCTGCTGCACCTGTCTGCCGGCCAGAGGCT




GGGAGTGCATCTGCACACAGAGGCCAGGGCTAGACACG




CCTGGCAGCTGACACAGGGCGCTACAGTGCTGGGCCTG




TTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTTCT




CCAAGAAGCGAA





344
Nucleotide
see Table 88



sequence anti-




CEA(T84.66)




light chain






349
anti-
EVQLQQSGAELVEPGASVKLSCTASGFNIKDTYMHWVKQ



CEA(T84.66) Fc
RPEQGLEWIGRIDPANGNSKYVPKFQGKATITADTSSNTAY



hole dimeric
LQLTSLTSEDTAVYYCAPFGYYVSDYAMAYWGQGTSVTV



4-1BBL (71-254)
SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV



chain
SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT




YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG




PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY




VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG




KEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDE




LTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPV




LDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHY




TQKSLSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQG




MFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDT




KELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPL




RSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQ




RLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPS




PRSEGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQLV




AQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVA




KAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGA




AALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHL




HTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE





350
anti-
EVQLQQSGAELVEPGASVKLSCTASGFNIKDTYMHWVKQ



CEA(T84.66) Fc
RPEQGLEWIGRIDPANGNSKYVPKFQGKATITADTSSNTAY



knob monomeric
LQLTSLTSEDTAVYYCAPFGYYVSDYAMAYWGQGTSVTV



4-1BBL (71-254)
SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV



chain
SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT




YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG




PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY




VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG




KEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDE




LTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPV




LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY




TQKSLSLSPGGGGGSGGGGSREGPELSPDDPAGLLDLRQG




MFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDT




KELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPL




RSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQ




RLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPS




PRSE





346
anti-
see Table 88



CEA(T84.66)




light chain









11.3 Preparation of Untargeted Split Trimeric 4-1BB Ligand Fc Fusion Molecules and Human IgG as Control Molecules


11.3.1 Preparation of Untargeted Human 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules (Control Molecules)


These control molecules were prepared as described above for the CEA targeted construct 3.1 (termed control B), 3.3 (termed control C), 3.4 (termed control D) and 3.5 (termed control E) with the only difference that the anti-CD19 binder (VH-VL) was replaced by a germline control, termed DP47, not binding to the antigen (see FIGS. 40A to 40F). The cDNA and amino acid sequences of control B, the monovalent DP47-untargeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion containing crossed CH-CL with charged residues, are shown in Table 68 above (see Example 7.3.1). Table 69 shows the cDNA and amino acid sequences of the bivalent DP47-untargeted split trimeric 4-1BB ligand (71-254) Fc (kih) fusion, control C. Table 70 shows the cDNA and amino acid sequences of the monovalent DP47-untargeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion containing CH-CL cross with charged residues, control D. Table 71 shows the cDNA and amino acid sequences of the monovalent DP47-untargeted split trimeric 4-1BB ligand (71-248) Fc (kih) fusion without charged residues in the CH-CL cross, control E.


11.3.2 Antibodies as Control Molecules


An additional control used in the assays, termed control F, was an untargeted DP47, germline control, human IgG1, containing the Pro329Gly, Leu234Ala and Leu235Ala mutations, to abrogate binding to Fc gamma receptors. The cDNA and amino acid sequences of control F can be found in Table 73 above.


11.4 Production of CEA-Targeted Split Trimeric 4-1BB Ligand Fc Fusion Antigen Binding Molecules and their Control Molecules


The targeted and untargeted split trimeric 4-1BB ligand Fc (kih) fusion antigen binding molecule encoding sequences were cloned into a plasmid vector, which drives expression of the insert from an MPSV promoter and contains a synthetic polyA sequence located at the 3′ end of the CDS. In addition, the vector contains an EBV OriP sequence for episomal maintenance of the plasmid.


The split trimeric 4-1BB ligand Fc (kih) fusion was produced by co-transfecting HEK293-EBNA cells with the mammalian expression vectors using polyethylenimine. The cells were transfected with the corresponding expression vectors. For variants 1,2,4,5 and it's control B, D and E, at a 1:1:1:1 ratio (“vector dimeric ligand-CL- knob chain”: “vector monomeric ligand fusion-CH1”: “vector anti-CEA Fab-hole chain”: “vector anti-CEA light chain”). For variant 3, 6 and it's control C, at a 1:1:1 ratio (“vector huIgG1 Fc hole dimeric ligand chain”: “vector huIgG1 Fc knob monomeric ligand chain”: “vector anti-CEA light chain”). Human IgGs, used as control in the assay, were produced as for the bispecific construct (for transfection only a vector for light and a vector for heavy chain were used at a 1:1 ratio).


For production in 500 mL shake flasks, 300 million HEK293 EBNA cells were seeded 24 hours before transfection. For transfection cells were centrifuged for 10 minutes at 210× g, and the supernatant was replaced by 20 mL pre-warmed CD CHO medium. Expression vectors (200 μg of total DNA) were mixed in 20 mL CD CHO medium. After addition of 540 μL PEI, the solution was vortexed for 15 seconds and incubated for 10 minutes at room temperature. Afterwards, cells were mixed with the DNA/PEI solution, transferred to a 500 mL shake flask and incubated for 3 hours at 37° C. in an incubator with a 5% CO2 atmosphere. After the incubation, 160 mL of Excell medium supplemented with 6 mM L-Glutamine, 5 g/L PEPSOY and 1.2 mM valproic acid was added and cells were cultured for 24 hours. One day after transfection 12% Feed (amino acid and glucose) were added. After culturing for 7 days, the supernatant was collected by centrifugation for 30-40 minutes at least 400× g. The solution was sterile filtered (0.22 μm filter), supplemented with sodium azide to a final concentration of 0.01% (w/v), and kept at 4° C.


The split trimeric 4-1BB ligand Fc (kih) fusion, as well as the IgG, was purified from cell culture supernatants by affinity chromatography using Protein A, followed by size exclusion chromatography. For affinity chromatography, the supernatant was loaded on a MABSELECT SURE® column (CV=5-15 mL, resin from GE Healthcare) equilibrated with Sodium Phosphate (20 mM), Sodium Citrate (20 mM) buffer (pH 7.5). Unbound protein was removed by washing with at least 6 column volumes of the same buffer. The bound protein was eluted using either a linear gradient (20 CV) or a step elution (8 CV) with 20 mM sodium citrate, 100 mM Sodium chloride, 100 mM Glycine buffer (pH 3.0). For the linear gradient an additional 4 column volumes step elution was applied.


The pH of collected fractions was adjusted by adding 1/10 (v/v) of 0.5M sodium phosphate, pH8.0. The protein was concentrated prior to loading on a HILOAD® Superdex 200 column (GE Healthcare) equilibrated with 20 mM Histidine, 140 mM sodium chloride, 0.01% (v/v) TWEEN® 20 (polysorbate 20) solution of pH 6.0.


The protein concentration was determined by measuring the optical density (OD) at 280 nm, using a molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the targeted trimeric 4-1BB ligand Fc (kih) fusion antigen binding molecule was analyzed by SDS-PAGE in the presence and absence of a reducing agent (5 mM 1,4-dithiotreitol) and staining with Coomassie SIMPLYBLUE™ SafeStain (Invitrogen USA) or CE-SDS using Caliper LabChip GXII (Perkin Elmer). The aggregate content of samples was analyzed using a TSKGEL® G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in 25 mM K2HPO4, 125 mM NaCl, 200 mM L-Arginine Monohydrocloride, 0.02% (w/v) NaN3, pH 6.7 running buffer at 25° C.


Table 90 summarizes the yield and final monomer content of the CEA targeted split trimeric 4-1BB ligand Fc (kih) fusion antigen binding molecules.









TABLE 90







Biochemical analysis of CEA targeted split


trimeric 4-1BB ligand Fc (kih) fusion.












Monomer





[%]
Yield



Construct
(SEC)
[mg/l]















monovalent CEA(T84.66-LCHA)
98
1.4



targeted split trimeric 4-





1BB ligand (71-248) Fc fusion





containing CH-CL cross with





charged residues (construct 5.4)





bivalent CEA(T84.66-LCHA)
98
0.4



targeted split trimeric 4-1BB





ligand (71-248) Fc fusion (construct 5.6)





monovalent CEA(T84.66) targeted
97
15



split trimeric 4-1BB ligand





(71-254) Fc fusion containing CH-CL





cross with charged





residues (construct 5.7)





bivalent CEA(T84.66) targeted
96
2



split trimeric 4-1BB ligand





(71-254) Fc fusion (construct 5.8)










Table 91 summarizes the yield and final monomer content of the DP47 untargeted split trimeric 4-1BB ligand Fc (kih) fusion molecules, both monovalent (control B, D and E) and bivalent (control C), and of the germline DP47 human IgG1 PGLALA (control F).









TABLE 91







Biochemical analysis of DP47 untargeted split


trimeric 4-1BB ligand Fc (kih) fusion












Monomer





[%]
Yield



Construct
(SEC)
[mg/l]















monovalent DP47-untargeted split trimeric
99
15.4



human 4-1BB ligand (71-254) Fc (kih)





fusion (control B)





bivalent DP47 untargeted split trimeric
98
12.6



human 4-1BB ligand (71-254) Fc (kih)





fusion (control C)





monovalent DP47-untargeted split trimeric
99.5
25.9



human 4-1BB ligand (71-254) Fc (kih)





fusion (control D)





monovalent DP47-untargeted split
93.3
4.1



trimeric human 4-1BB





ligand (71-254) Fc (kih) fusion (control E)





germline DP47 human IgG1 PGLALA
100
50










Example 12
Functional Characterization of the CEA Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

12.1 Surface Plasmon Resonance (Simultaneous Binding)


Production of Hu NA3B3A2 as Antigen for CEA Targeted Trimeric Split 4-1BBL Constructs

The antigen used to assess binding by SPR to CEA was a hybrid molecule composed of A3 and B3 domains from human CEACAM5 (CEA) and N and A2 domains from human CEACAM1 (BGP1) similarly to what has been described for NABA (Durbin H. et al, Proc Natl Acad Sci USA. 1994 May 10; 91(10):4313-7). The antigen is termed here NA3B3A2 and a schematic description can be found in FIG. 41A.


Table 92 shows the nucleotide and amino acid sequences of hu NA3B3A2-avi-His.









TABLE 92







Nucleotide and amino acid sequences of hu NA3B3A2-avi-His









SEQ ID




NO:
Antigen
Sequence





351
nucleotide
CAGCTGACCACCGAGTCCATGCCCTTCAACGTGGCCG



sequence hu
AGGGCAAAGAGGTGCTGCTGCTGGTCCACAACCTGCC



NA3B3A2-avi
CCAGCAGCTGTTCGGCTACAGCTGGTACAAGGGCGAG



His
CGGGTGGACGGCAACCGGCAGATCGTGGGCTACGCCA




TCGGCACCCAGCAGGCCACACCCGGCCCTGCCAATAG




CGGCAGAGAGACAATCTACCCCAACGCCAGCCTGCTG




ATCCAGAACGTGACCCAGAACGACACCGGCTTCTACA




CACTCCAAGTCATCAAGAGCGACCTGGTCAACGAGGA




AGCCACCGGCCAGTTCCACGTGTACCCCGAGCTGCCC




AAGCCCAGCATCAGCAGCAACAACAGCAAGCCCGTGG




AAGATAAGGACGCCGTGGCCTTTACCTGCGAGCCCGA




GGCCCAGAACACCACCTACCTGTGGTGGGTCAACGGC




CAGAGCCTGCCCGTGTCCCCCAGACTCCAGCTGAGCA




ACGGCAACAGAACCCTGACCCTGTTCAACGTGACCCG




GAATGACGCCAGAGCCTACGTGTGCGGCATCCAGAAC




AGCGTGTCCGCCAACCGCAGCGACCCCGTGACCCTGG




ATGTGCTGTACGGCCCCGACACCCCCATCATCAGCCCC




CCTGACAGCAGCTACCTGAGCGGCGCCAACCTGAACC




TGAGCTGCCACAGCGCCAGCAACCCCAGCCCTCAGTA




CAGCTGGCGGATCAACGGCATCCCCCAGCAGCACACC




CAGGTGCTGTTTATCGCCAAGATCACCCCCAACAACA




ACGGCACCTACGCCTGCTTCGTGTCCAACCTGGCCACC




GGCCGGAACAACAGCATCGTGAAGTCCATCACCGTGT




CCGCCTCCCTGAGCCCCGTGGTGGCCAAGCCTCAGAT




CAAGGCCAGCAAGACCACCGTGACCGGCGACAAGGA




CAGCGTGAACCTGACCTGCTCCACCAACGATACCGGC




ATCAGCATCCGGTGGTTCTTCAAGAATCAGTCCCTGCC




CAGCAGCGAGCGGATGAAGCTGAGCCAGGGCAACAT




CACCCTGTCCATCAACCCCGTGAAAAGAGAGGACGCC




GGCACCTATTGGTGCGAGGTGTTCAACCCCATCAGCA




AGAACCAGAGCGACCCCATCATGCTGAACGTGAACTA




CAACGCCCTGCCCCAAGAAAACCTGATCAATGTTGAT




CTGGAAGTGCTGTTCCAGGGCCCAGGCAGCGGCCTGA




ACGACATCTTCGAAGCCCAGAAAATCGAGTGGCACGA




GGCCAGAGCCCACCACCACCATCACCAC





352
human
QLTTESMPFNVAEGKEVLLLVHNLPQQLFGYSWYKGER



NA3B3A2-avi-
VDGNRQIVGYAIGTQQATPGPANSGRETIYPNASLLIQNV



His
TQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSISSN




NSKPVEDKDAVAFTCEPEAQNTTYLWWVNGQSLPVSPR




LQLSNGNRTLTLFNVTRNDARAYVCGIQNSVSANRSDPV




TLDVLYGPDTPIISPPDSSYLSGANLNLSCHSASNPSPQYS




WRINGIPQQHTQVLFIAKITPNNNGTYACFVSNLATGRN




NSIVKSITVSASLSPVVAKPQIKASKTTVTGDKDSVNLTC




STNDTGISIRWFFKNQSLPSSERMKLSQGNITLSINPVKRE




DAGTYWCEVFNPISKNQSDPIMLNVNYNALPQENLINVD




LEVLFQGPGSGLNDIFEAQKIEWHEARAHHHHHH









Protein production was performed as described above for the Fc-fusion protein (Example 7.1.1). Secreted proteins were purified from cell culture supernatants by chelating chromatography, followed by size exclusion chromatography. The first chromatographic step was performed on a Ni-NTA SUPERFLOW′ Cartridge (5 ml, Qiagen) equilibrated in 20 mM sodium phosphate, 500 nM sodium chloride, pH7.4. Elution was performed by applying a gradient over 12 column volume from 5% to 45% of elution buffer (20 mM sodium phosphate, 500 nM sodium chloride, 500 mM Imidazole, pH7.4).


The protein was concentrated and filtered prior to loading on a HILOAD® Superdex 75 column (GE Healthcare) equilibrated with 20 mM Histidine, 140 mM NaCl, 0.01% TWEEN® 20 (polysorbate 20) pH 6.0. Table 93 summarizes the yield and final monomer content of human NA3B3A2-avi-His.









TABLE 93







Biochemical analysis of human NA3B3A2-avi-His










Monomer [%]
Yield


Construct
(SEC)
[mg/l]












human NA3B3A2-avi-
88
14.1


His











The capacity of binding simultaneously human 4-1BB Fc (kih) and human NA3B3A2 was assessed by surface plasmon resonance (SPR). All SPR experiments were performed on a BIACORE® T200 instrument at 25° C. with HBS-EP as running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20, Biacore, Freiburg/Germany). Biotinylated human 4-1BB Fc (kih) was directly coupled to a flow cell of a streptavidin (SA) sensor chip. Immobilization levels up to 250 resonance units (RU) were used.


The CEA targeted trimeric split 4-1BBL constructs (constructs 5.4, 5.6, 5.7 and 5.8) were passed at a concentration range of 200 nM with a flow of 30 μL/minute through the flow cells over 90 seconds and dissociation was set to zero seconds. Human NA3B3A2 was injected as second analyte with a flow of 30 μL/minute through the flow cells over 90 seconds at a concentration of 500 nM (FIG. 41B). The dissociation was monitored for 120 seconds. Bulk refractive index differences were corrected for by subtracting the response obtained in a reference flow cell, where no protein was immobilized.


As can be seen in the graphs of FIGS. 42A to 42D, all bispecific constructs could bind simultaneously human 4-1BB and human NA3B3A2.


12.2. Binding on Activated Human PMBCs of the CEA-Targeted 4-1BB Ligand Trimer-Containing Fc (Kih) Fusion Antigen Binding Molecules


To determine binding of 4-1BBL trimer-containing Fc fusion antigen binding molecules to human PBMCs, different titrated concentrations of the CEA-targeted 4-1BBL trimer-containing Fc fusion antigen binding molecules were used in the assay as described in Example 5.2.



FIGS. 43A to 43D show the binding of Constructs 5.4, 5.6, 5.7 and 5.8 as prepared in Example 11 on activated 4-1BB-expressing CD4+ T cells and CD8+ T cells, respectively. Gates were set on living CD45+CD3+CD4+ or CD45+CD3+CD8+ T cells and MFI of PE-conjugated AffiniPure anti-human IgG IgG Fcγ-fragment-specific goat F(ab′) 2 fragment were blotted against the titrated concentration of targeted split trimeric 4-1BB ligand Fc fusion variants. Table 94 shows the EC50 values as measured for Constructs 5.4, 5.6, 5.7 and 5.8 and control molecules.









TABLE 94







Binding on activated 4-1BB-expressing CD4 + T cells and CD8 + T cells










EC50 [nM]
EC50 [nM]


Construct
4-1BB+CD8+
4-1BB+CD4+












Control B
0.05
0.26


Control C
0.02
0.30


Control D
0.04
0.28


Control E
0.13
1.22


5.4
0.13
0.35


5.6
0.06
0.34


5.7
0.0004
0.36


5.8
0.17
0.38









12.2 Binding to CEA-Expressing Tumor Cells


For binding assays on CEA-expressing tumor cells, the following human CEA-expressing lymphoma cell lines were used: CEA-expressing tumor cell lines human gastric cancer cell line MKN-45 (ATCC TCP-1008) and human colorectal adenocarcinoma cell line LS180 (ATCC CL-187). The assays were preformed as described for the FAP-expressing MV-3 and WM-266-4 tumor cell lines in Example 5.3.


Gates were set on living tumor cells and MFI of PE-conjugated AffiniPure anti-human IgG IgG Fcγ-fragment-specific goat F(ab′)2 fragment were blotted against the titrated concentration of targeted split trimeric 4-1BB ligand Fc fusion constructs.



FIGS. 44A and 44B shows the binding of Constructs 5.7 as prepared in Example 11.2.7 to human-CEA expressing human gastric cell line MKN-45 (44A) and human colorectal adenocarcinoma cells line LS180 (44B). Table 95 shows the EC50 values as measured for human-CEA expressing human gastric cell line MKN-45.









TABLE 95







Binding to CEA-expressing tumor cells










EC50 [nM]
EC50 [nM]


Construct
MKN45-8
LS180












5.7
11.6
14.4









Example 13
Biological Activity of the CEA-Targeted 4-1BB Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules

13.1. NF-κB Activation in HeLa Cells Expressing Human 4-1BB


HeLa cells expressing human 4-1BB and NF-κB-luciferase were generated as described in Example 6.1.


NF-κB Activation in Hela Cells Expressing Human 4-1BB Co-Cultured with Human CEA-Expressing Tumor Cells


NF-κB-luciferase human-4-1BB HeLa cells were harvested and resuspended in DMEM medium supplied with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I to a concentration of 0.2×106 cells/ml. 100 μl (2×104 cells) of this cell suspension were transferred to each well of a sterile white 96-well flat bottom tissue culture plate with lid (greiner bio-one, Cat. No. 655083) and the plate were incubated at 37° C. and 5% CO2 overnight. The next day 50 μL of medium containing titrated concentrations of CEA-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules (CEA split 4-1BBL trimer) or DP47-untargeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules (DP47 split 4-1BBL trimer) were added. CEA-expressing tumor cell lines human gastric cancer cell line MKN-45 (ATCC TCP-1008) was resuspended in DMEM medium supplied with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I to a concentration of 2×106 cells/ml.


Suspension of CEA-expressing B cell lymphoma cell (50 final ratio 1:5) or only medium were added to each well and plates were incubated for 6 hours at 37° C. and 5% CO2. Cells were washed two times with 200 μL/well DPBS. 40 μl freshly prepared Reporter Lysis Buffer (Promega, Cat-No: E3971) were added to each well and the plate were stored over night at −20° C. The next day frozen cell plate and Detection Buffer (Luciferase 1000 Assay System, Promega, Cat. No. E4550) were thawed at room temperature. 100 μL of detection buffer were added to each well and luciferase activity was measured as fast as possible using a SpectraMax M5/M5e microplate reader and a SoftMax Pro Software (Molecular Devices) counting light emission in URL (units of released light for 0.5s/well) or Victor3 1420 multilabel counter plate reader (Perkin Elmer) and the Perkin Elmer 2030 Manager Software counting light emission as counts per seconds (CPS) and blotted against the concentration of tested constructs.


CEA-targeted 4-1BB ligand trimer-containing Fc fusion antigen binding molecules Constructs 5.7 and 5.8 triggered activation of the NF-kB signaling pathway in the reporter cell line in the presence of human gastric cancer cell line MKN-45 cells. In contrast, the untargeted control molecules failed to trigger such an effect at any of the tested concentrations (FIGS. 45A to 45D). Table 96 shows the corresponding EC50 values.









TABLE 96







Binding to CEA-expressing tumor cells










EC50 [nM]




MKN-45
EC50 [nM]


Construct
no tumor cells
MKN4 5












5.4
3.1
0.34


5.6
2.05
0.21


5.7
0.85
0.05


5.8
1.52
0.45









Example 14

14.1 Preparation of FAP Targeted OX40 Ligand Trimer-Containing Fc Fusion Antigen Binding Molecules


The DNA sequence encoding part of the ectodomain (amino acids 51-183) of human OX40 ligand was synthetized according to the P23510 sequence of Uniprot database. To decrease heterogeneity of human OX40 ligand due to glycosylation asparagine residues at position 90 and 114 were mutated to aspartic acid by site-directed mutagenesis (according to Compaan D. M., Hymowitz S. G., Structure (2006) 14(8), 1321-30).


A polypeptide containing two ectodomains of OX40 ligand, separated by (G4S)2 (SEQ ID NO:13) linkers, and fused to the human IgG1-CL domain, was cloned as depicted in FIG. 46A: human OX40 ligand, (G4S)2 (SEQ ID NO:13) connector, human OX40 ligand, (G4S)2 (SEQ ID NO:13) connector, human CL.


A polypeptide containing one ectodomain of OX40 ligand and fused to the human IgG1-CH domain, was cloned as described in FIG. 46B: human OX40 ligand, (G4S)2 (SEQ ID NO:13) connector, human CH.


To improve correct pairing the following mutations have been introduced in the crossed CH-CL. In the dimeric 4-1BB ligand fused to human CL, E123R and Q124K. In the monomeric 4-1BB ligand fused to human CH1, K147E and K213E.


The generation and preparation of the FAP binders is described in WO 2012/020006 A2, which is incorporated herein by reference.


The variable region of heavy and light chain DNA sequences encoding a binder specific for FAP, clone 28H11, were subcloned in frame with either the constant heavy chain of the hole or the constant light chain of human IgG1. The Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the knob and hole heavy chains to abrogate binding to Fc gamma receptors according to the method described in WO 2012/130831.


Combination of the dimeric ligand-Fc knob chain containing the S354C/T366W mutations, the monomeric CH1 fusion, the targeted anti-FAP-Fc hole chain containing the Y349C/T366S/L368A/Y407V mutations and the anti-FAP light chain allows generation of a heterodimer, which includes an assembled trimeric OX40 ligand and a FAP binding Fab (FIG. 46C, Construct 6.1).


Table 97 shows the cDNA and amino acid sequences of the monovalent CEA (T84.66-LCHA) targeted split trimeric OX40 ligand (51-183) Fc (kih) fusion antigen binding molecule with crossed CH-CL and charged residues (construct 6.1).









TABLE 97







cDNA and amino acid sequences of monovalent FAP(28H1) targeted


split trimeric OX40 ligand Fc (kih) fusion containing CH-CL


cross with charged residues (construct 6.1).









SEQ ID




NO:
Description
Sequence












353
Nucleotide
CAGGTGTCCCACAGATACCCCAGAATCCAGAGCATCAA



sequence Dimeric
GGTGCAGTTCACCGAGTACAAGAAAGAGAAGGGCTTCA



hu OX40L
TCCTGACCAGCCAGAAAGAGGACGAGATCATGAAGGTG



(51-183) CL* Fc
CAGGACAACAGCGTGATCATCAACTGCGACGGCTTCTA



knob chain
CCTGATCAGCCTGAAGGGCTACTTCAGCCAGGAAGTGG




ACATCAGCCTGCACTACCAGAAGGACGAGGAACCCCTG




TTCCAGCTGAAGAAAGTGCGGAGCGTGAACAGCCTGAT




GGTGGCCAGCCTGACCTACAAGGACAAGGTGTACCTGA




ACGTGACCACCGACAACACCAGCCTGGACGACTTCCAC




GTGAACGGCGGCGAGCTGATCCTGATTCACCAGAACCC




CGGCGAGTTCTGCGTGCTGGGAGGCGGAGGATCTGGCG




GAGGCGGATCTCAGGTGTCACACCGCTACCCCCGGATTC




AGTCCATTAAGGTGCAGTTTACAGAGTATAAGAAAGAA




AAAGGCTTTATTCTGACTTCCCAGAAAGAAGATGAGATT




ATGAAGGTGCAGGATAATTCTGTGATCATCAATTGTGAC




GGCTTCTACCTGATCAGCCTGAAGGGCTACTTCAGCCAG




GAAGTGGACATCAGCCTGCACTACCAGAAGGACGAGGA




ACCCCTGTTCCAGCTGAAGAAAGTGCGGAGCGTGAACA




GCCTGATGGTGGCCAGCCTGACCTACAAGGACAAGGTG




TACCTGAACGTGACCACCGACAACACCAGCCTGGACGA




CTTCCACGTGAACGGCGGCGAGCTGATCCTGATCCACCA




GAACCCTGGCGAGTTCTGCGTGCTGGGAGGCGGAGGCT




CCGGAGGGGGAGGATCTCGTACGGTGGCTGCACCATCT




GTCTTTATCTTCCCACCCAGCGACCGGAAGCTGAAGTCT




GGCACAGCCAGCGTCGTGTGCCTGCTGAATAACTTCTAC




CCCCGCGAGGCCAAGGTGCAGTGGAAGGTGGACAATGC




CCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGC




AGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACC




CTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGT




GTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCC




CGTGACCAAGAGCTTCAACCGGGGCGAGTGCGACAAGA




CCCACACCTGTCCTCCATGCCCTGCCCCTGAAGCTGCTG




GCGGCCCTAGCGTGTTCCTGTTCCCCCCAAAGCCCAAGG




ACACCCTGATGATCAGCCGGACCCCTGAAGTGACCTGC




GTGGTGGTGGATGTGTCCCACGAGGACCCTGAAGTGAA




GTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAATG




CCAAGACCAAGCCGCGGGAGGAGCAGTACAACAGCACG




TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGAC




TGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAA




CAAAGCCCTCGGCGCCCCCATCGAGAAAACCATCTCCA




AAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACC




CTGCCCCCATGCCGGGATGAGCTGACCAAGAACCAGGT




CAGCCTGTGGTGCCTGGTCAAAGGCTTCTATCCCAGCGA




CATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGA




ACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC




GGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAG




AGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTG




ATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAG




CCTCTCCCTGTCTCCGGGTAAA





354
Nucleotide
CAGGTGTCCCACAGATACCCCAGAATCCAGAGCATCAA



sequence
GGTGCAGTTCACCGAGTACAAGAAAGAGAAGGGCTTCA



Monomeric hu
TCCTGACCAGCCAGAAAGAGGACGAGATCATGAAGGTG



OX40L (51-183) -
CAGGACAACAGCGTGATCATCAACTGCGACGGCTTCTA



CH1*
CCTGATCAGCCTGAAGGGCTACTTCAGCCAGGAAGTGG




ACATCAGCCTGCACTACCAGAAGGACGAGGAACCCCTG




TTCCAGCTGAAGAAAGTGCGGAGCGTGAACAGCCTGAT




GGTGGCCAGCCTGACCTACAAGGACAAGGTGTACCTGA




ACGTGACCACCGACAACACCAGCCTGGACGACTTCCAC




GTGAACGGCGGCGAGCTGATCCTGATTCACCAGAACCC




CGGCGAGTTCTGCGTGCTGGGAGGCGGAGGTTCCGGAG




GCGGAGGATCTGCTAGCACAAAGGGCCCCAGCGTGTTC




CCTCTGGCCCCTAGCAGCAAGAGCACATCTGGCGGAAC




AGCCGCCCTGGGCTGCCTGGTGGAAGATTACTTCCCCGA




GCCCGTGACCGTGTCCTGGAATTCTGGCGCCCTGACAAG




CGGCGTGCACACCTTTCCAGCCGTGCTGCAGAGCAGCG




GCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCA




GCTCTCTGGGCACCCAGACCTACATCTGCAACGTGAACC




ACAAGCCCAGCAACACCAAGGTGGACGAGAAGGTGGA




ACCCAAGTCCTGC





68
Nucleotide
see Table 2



sequence anti-




FAP(28H1) Fc




hole chain






69
Nucleotide
see Table 2



sequence anti-




FAP(28H1) light




chain






355
Dimeric hu
QVSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKVQDN



OX40L (51-183) -
SVIINCDGFYLISLKGYFSQEVDISLHYQKDEEPLFQLKKVR



CL* Fc knob
SVNSLMVASLTYKDKVYLNVTTDNTSLDDFHVNGGELILI



chain
HQNPGEFCVLGGGGSGGGGSQVSHRYPRIQSIKVQFTEYK




KEKGFILTSQKEDEIMKVQDNSVIINCDGFYLISLKGYFSQE




VDISLHYQKDEEPLFQLKKVRSVNSLMVASLTYKDKVYLN




VTTDNTSLDDFHVNGGELILIHQNPGEFCVLGGGGSGGGG




SRTVAAPSVFIFPPSDRKLKSGTASVVCLLNNFYPREAKVQ




WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYE




KHKVYACEVTHQGLSSPVTKSFNRGECDKTHTCPPCPAPE




AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK




FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD




WLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLP




PCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYK




TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL




HNHYTQKSLSLSPGK





356
Monomeric hu
QVSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKVQDN



OX40L (51-183) -
SVIINCDGFYLISLKGYFSQEVDISLHYQKDEEPLFQLKKVR



CH1*
SVNSLMVASLTYKDKVYLNVTTDNTSLDDFHVNGGELILI




HQNPGEFCVLGGGGSGGGGSASTKGPSVFPLAPSSKSTSGG




TAALGCLVEDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG




LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDEKVEPKS




C





18
anti-FAP(28H1)
see Table 2



Fe hole chain






19
anti-FAP(28H1)
see Table 2



light chain





*for charged residues






14.2 Preparation of Untargeted Human IgG1 as Control F


A control molecule used in the assays, termed control F (FIG. 46D), was an untargeted DP47, germline control, human IgG1, containing the Pro329Gly, Leu234Ala and Leu235Ala mutations, to abrogate binding to Fc gamma receptors according to the method described in International Patent Appl. Publ. No. WO 2012/130831). Its preparation is described in Example 2.3, Table 29 shows the cDNA and amino acid sequences of the cDNA and amino acid sequences of the untargeted DP47 huIgG1 PGLALA (Control F).


14.3 Production of FAP-Targeted Split Trimeric OX40 Ligand Fc Fusion Antigen Binding Molecules and their Control Molecules


The targeted and untargeted split trimeric OX40 ligand Fc (kih) fusion encoding sequences were cloned into a plasmid vector, which drives expression of the insert from an MPSV promoter and contains a synthetic polyA sequence located at the 3′ end of the CDS. In addition, the vector contains an EBV OriP sequence for episomal maintenance of the plasmid.


The split trimeric OX40 ligand Fc (kih) fusion was produced by co-transfecting HEK293-EBNA cells with the mammalian expression vectors using polyethylenimine. The cells were transfected with the corresponding expression vectors. For variants 1,2,4,5 and it's control B, D and E, at a 1:1:1:1 ratio (“vector dimeric ligand-CL- knob chain”: “vector monomeric ligand fusion-CH1”: “vector anti-FAP Fab-hole chain”: “vector anti-FAP light chain”). For variant 3, 6 and it's control C, at a 1:1:1 ratio (“vector huIgG1 Fc hole dimeric ligand chain”: “vector huIgG1 Fc knob monomeric ligand chain”: “vector anti-FAP light chain”). Human IgGs, used as control in the assay, were produced as for the bispecific construct (for transfection only a vector for light and a vector for heavy chain were used at a 1:1 ratio).


For production in 500 mL shake flasks, 300 million HEK293 EBNA cells were seeded 24 hours before transfection. For transfection cells were centrifuged for 10 minutes at 210× g, and the supernatant was replaced by 20 mL pre-warmed CD CHO medium. Expression vectors (200 μg of total DNA) were mixed in 20 mL CD CHO medium. After addition of 540 μL PEI, the solution was vortexed for 15 seconds and incubated for 10 minutes at room temperature. Afterwards, cells were mixed with the DNA/PEI solution, transferred to a 500 mL shake flask and incubated for 3 hours at 37° C. in an incubator with a 5% CO2 atmosphere. After the incubation, 160 mL of Excell medium supplemented with 6 mM L-Glutamine, 5 g/L PEPSOY and 1.2 mM valproic acid was added and cells were cultured for 24 hours. One day after transfection 12% Feed (amino acid and glucose) were added. After culturing for 7 days, the supernatant was collected by centrifugation for 30-40 minutes at least 400× g. The solution was sterile filtered (0.22 μm filter), supplemented with sodium azide to a final concentration of 0.01% (w/v), and kept at 4° C.


The split trimeric OX40 ligand Fc (kih) fusion antigen binding molecule, as well as the IgG, was purified from cell culture supernatants by affinity chromatography using Protein A, followed by size exclusion chromatography. For affinity chromatography, the supernatant was loaded on a MABSELECT SURE® column (CV=5-15 mL, resin from GE Healthcare) equilibrated with Sodium Phosphate (20 mM), Sodium Citrate (20 mM) buffer (pH 7.5). Unbound protein was removed by washing with at least 6 column volumes of the same buffer. The bound protein was eluted using either a linear gradient (20 CV) or a step elution (8 CV) with 20 mM sodium citrate, 100 mM Sodium chloride, 100 mM Glycine buffer (pH 3.0). For the linear gradient an additional 4 column volumes step elution was applied.


The pH of collected fractions was adjusted by adding 1/10 (v/v) of 0.5M sodium phosphate, pH8.0. The protein was concentrated prior to loading on a HILOAD® Superdex 200 column (GE Healthcare) equilibrated with 20 mM Histidine, 140 mM sodium chloride, 0.01% (v/v) TWEEN® 20 (polysorbate 20) solution of pH 6.0.


The protein concentration was determined by measuring the optical density (OD) at 280 nm, using a molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the targeted trimeric 4-1BB ligand Fc (kih) fusion was analyzed by SDS-PAGE in the presence and absence of a reducing agent (5 mM 1,4-dithiotreitol) and staining with Coomassie SIMPLYBLUE™ SafeStain (Invitrogen USA) or CE-SDS using Caliper LabChip GXII (Perkin Elmer). The aggregate content of samples was analyzed using a TSKGEL® G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in 25 mM K2HPO4, 125 mM NaCl, 200 mM L-Arginine Monohydrocloride, 0.02% (w/v) NaN3, pH 6.7 running buffer at 25° C.


Table 98 summarizes the yield and final monomer content of the FAP targeted split trimeric OX40 ligand Fc (kih) fusion antigen binding molecule, and of the germline DP47 human IgG1 PGLALA (control F).









TABLE 98







Biochemical analysis of 0X40 targeted .


split trimeric 4-1BB ligand Fc (kih) fusion












Monomer





[%]
Yield



Construct
(SEC)
[mg/l]















monovalent FAP(28H1) targeted split
93.8
19.7



trimeric 0X40 ligand Fc fusion containing





CH-CL cross with charged residues





(construct 6.1)





germline DP47 human IgG1 PGLALA
100
50










Example 15
Functional Characterization of the Targeted OX40 Ligand Trimer-Containing Fc Fusion Antigen Binding Molecule

15.1 Binding to Human FAP-Expressing Tumor Cells


The binding to cell surface FAP was tested using WM-266-4 cells (ATCC CRL-1676). 0.5×105 WM-266-4 cells were added to each well of a round-bottom suspension cell 96-well plates (greiner bio-one, cellstar, Cat. No. 650185). Cells were stained for 120 minutes at 4° C. in the dark in 50 μL/well 4° C. cold FACS buffer (DPBS (Gibco by Life Technologies, Cat. No. 14190 326) w/BSA (0.1% v/w, Sigma-Aldrich, Cat. No. A9418) containing titrated anti-OX40 antibody construct. After three times washing with excess FACS buffer, cells were stained for 45 minutes at 4° C. in the dark in 25 μL/well 4° C. cold FACS buffer containing Fluorescein isothiocyanate (FITC)-conjugated AffiniPure anti-human IgG Fcγ-fragment-specific goat IgG F(ab′)2 fragment (Jackson ImmunoResearch, Cat. No. 109 096 098).


Plates were finally resuspended in 90 μL/well FACS-buffer containing 0.2 μg/mL DAPI (Santa Cruz Biotec, Cat. No. Sc-3598) and acquired the same day using 5-laser LSR-FORTESSA® (BD Bioscience with DIVA software).


As shown in FIG. 47A, the monovalent FAP(28H1) targeted split trimeric OX40 ligand Fc (kih) fusion antigen binding molecule (FAP-OX40L) but not the negative control F efficiently bound to human FAP-expressing target cells. EC50 values of binding to FAP positive WM-266-4 was [6.9 nM].


15.2 Binding to OX40 and FAP Negative Tumor Cells


The lack of binding to OX40 negative FAP negative tumor cells was tested using A549 NucLight™ Red Cells (Essenbioscience, Cat. No. 4491) expressing the NucLight™ Red fluorescent protein restricted to the nucleus to allow separation from unlabeled human FAP positive WM266-4 cells. Parental A549 (ATCC CCL-185) were transduced with the Essen CellPlayer NucLight™ Red Lentivirus (Essenbioscience, Cat. No. 4476; EF1a, puromycin) at an MOI of 3 (TU/cell) in the presence of 8 μg/ml polybrene following the standard Essen protocol.


A mixture of 5×104 unlabeled WM266-4 cells and unlabeled A549 NucLight™ Red Cells in FACS buffer were added to each well of a round-bottom suspension cell 96-well plates and binding assay was performed as described in section 15.1.


As shown in FIG. 47B, FAP-OX40L did not bind to OX40 negative FAP negative human tumor cells.


15.3 Binding to Human OX40 Expressing Cells: Naïve and Activated Human Peripheral Mononuclear Blood Leukocytes (PBMCs)


Buffy coats were obtained from the Zurich blood donation center. To isolate fresh peripheral blood mononuclear cells (PBMCs) the buffy coat was diluted with the same volume of DPBS (Gibco by Life Technologies, Cat. No. 14190 326). 50 mL polypropylene centrifuge tubes (TPP, Cat.-No. 91050) were supplied with 15 mL HISTOPAQUE® reagent 1077 (SIGMA Life Science, Cat.-No. 10771, polysucrose and sodium diatrizoate, adjusted to a density of 1.077 g/mL) and the buffy coat solution was layered above the HISTOPAQUE® reagent 1077. The tubes were centrifuged for 30 min at 400× g, room temperature and with low acceleration and no break. Afterwards the PBMCs were collected from the interface, washed three times with DPBS and resuspended in T cell medium consisting of RPMI 1640 medium (Gibco by Life Technology, Cat. No. 42401-042) supplied with 10% Fetal Bovine Serum (FBS, Gibco by Life Technology, Cat. No. 16000-044, Lot 941273, gamma-irradiated, mycoplasma-free and heat inactivated at 56° C. for 35 min), 1% (v/v) GlutaMAX I (GIBCO by Life Technologies, Cat. No. 35050 038), 1 mM Sodium-Pyruvat (SIGMA, Cat. No. S8636), 1% (v/v) MEM non-essential amino acids (SIGMA, Cat.-No. M7145) and 50 μM β-Mercaptoethanol (SIGMA, M3148).


PBMCs were used directly after isolation (binding on resting human PBMCs) or they were stimulated to receive a strong human OX40 expression on the cell surface of T cells (binding on activated human PBMCs). Therefore naïve PBMCs were cultured for four days in T cell medium supplied with 200 U/mL Proleukin (Novartis) and 2 ug/mL PHA-L (Sigma-Aldrich, L2769-10) in 6-well tissue culture plate and then over night on pre-coated 6-well tissue culture plates [4 ug/mL] anti-human CD3 (clone OKT3, eBioscience, Ca.No. 16-0037-85) and [2 ug/mL] anti-human CD28 (clone CD28.2, eBioscience, Cat No. 16-0289-85] in T cell medium supplied with 200 U/mL Proleukin at 37° C. and 5% CO2.


For detection of OX40 naïve human PBMC and activated human PBMC were mixed. To enable distinction of naïve from activated human PBMC naïve cells were labeled prior to the binding assay using the EFLUOR® 670 cell proliferation dye (eBioscience, Cat.-No. 65-0840-85).


For labeling cells were harvested, washed with pre-warmed (37° C.) DPBS and adjusted to a cell density of 1×107 cells/mL in DPBS. EFLUOR® 670 cell proliferation dye (eBioscience, Cat.-No. 65-0840-85) was added to the suspension of naïve human PBMC at a final concentration of 2.5 mM and a final cell density of 0.5×107 cells/mL in DPBS. Cells were then incubated for 10 min at room temperature in the dark. To stop labeling reaction 4 mL heat inactivated FBS were added and cells were washed three times with T cell medium. A two to one mixture of 1×105 resting EFLUOR®670 labeled human PBMC and 0.5×105 unlabeled activated human PBMC were then added to each well of a round-bottom suspension cell 96-well plates (greiner bio-one, cellstar, Cat. No. 650185).


Cells were stained for 120 minutes at 4° C. in the dark in 50 μL/well 4° C. cold FACS buffer containing titrated anti-OX40 constructs. After three times washing with excess FACS buffer, cells were stained for 45 minutes at 4° C. in the dark in 25 μL/well 4° C. cold FACS buffer containing a mixture of fluorescently labeled anti-human CD4 (clone RPA-T4, mouse IgG1 k, BioLegend, Cat.-No. 300532), anti-human CD8 (clone RPa-T8, mouse IgG1k, BioLegend, Cat.-No. 3010441) and Fluorescein isothiocyanate (FITC)-conjugated AffiniPure anti-human IgG Fcγ-fragment-specific goat IgG F(ab′) 2 fragment (Jackson ImmunoResearch, Cat.-No. 109-096-098).


Plates were finally resuspended in 90 μL/well FACS-buffer containing 0.2 μg/mL DAPI (Santa Cruz Biotec, Cat. No. Sc-3598) and acquired the same day using 5-laser LSR-FORTESSA® (BD Bioscience with DIVA software).


As shown in FIGS. 48A-1 and 48A-2 and 48B-1 to 48B-2, FAP-OX40L did not bind to resting human CD4+ T-cells or CD8+ T-cells, which are negative for OX40. In contrast, FAP-OX40L bound to activated CD8+ or CD4+ T-cells, which do express OX40. Binding to CD4+ T-cells was much stronger than that to CD8+ T cells. Activated human CD8+ T cells do express only a fraction of the OX40 levels detected on activated CD4+ T cells. Expression levels for OX40 are depending on kinetic and strength of stimulation and conditions were here optimized for OX40 expression on CD4+ T cells but not for CD8+ T cells. Thus, only little OX40 expression was induced on CD8 T cells. The EC 50 value of binding to OX40 positive CD4+ or CD8+ T cells was [0.15 nM].


15.4 NFκB Activation in HeLa Cells Expressing Human OX40 and Reporter Gene NFκB-Luciferase


Agonistic binding of OX40 to its ligand induces downstream signaling via activation of nuclear factor kappa B (NFκB) (A. D. Weinberg et al., J. Leukoc. Biol. 2004, 75(6), 962-972). The recombinant reporter cell line HeLa_hOx40_NFkB_Luc1 was generated to express human OX40 on its surface. Additionally, it harbors a reporter plasmid containing the luciferase gene under the control of an NFκB-sensitive enhancer segment. OX40 triggering induces dose-dependent activation of NFκB, which translocates in the nucleus, where it binds on the NFκB sensitive enhancer of the reporter plasmid to increase expression of the luciferase protein. Luciferase catalyzes luciferin-oxidation resulting in oxyluciferin which emits light. This can be quantified by a luminometer. Thus, the capacity of the various anti-OX40 molecules to induce NFκB activation in HeLa_hOx40_NFkB_Luc1 reporter cells was analyzed as a measure for bioactivity.


Adherent HeLa_hOx40_NFkB_Luc1 cells were harvested using cell dissociation buffer (Invitrogen, Cat.-No. 13151-014) for 10 minutes at 37° C. Cells were washed once with DPBS and were adjusted to a cell density of 1.33×105 in assay media comprising of MEM (Invitrogen, Cat.-No. 22561-021), 10% (v/v) heat-inactivated FBS, 1 mM Sodium-Pyruvat and 1% (v/v) non-essential amino acids. Cells were seeded in a density of 0.2*105 cells per well in a sterile white 96-well flat bottom tissue culture plate with lid (greiner bio-one, Cat. No. 655083) and kept over night at 37° C. and 5% CO2 in an incubator (Hera Cell 150).


The next day, HeLa_hOx40_NFkB_Luc1 were stimulated for 5 hours by adding assay medium containing titrated FAP-OX40L or negative control F. For testing the effect of hyper-crosslinking on anti-OX40 antibodies, 25 μL/well of medium containing secondary antibody anti-human IgG Fcγ-fragment-specific goat IgG F(ab′) 2 fragment (Jackson ImmunoResearch, 109-006-098) were added in a 1:2 ratio (2 times more secondary antibody than the primary antibody). After incubation, supernatant was aspirated and plates washed two times with DPBS. Quantification of light emission was done using the luciferase 100 assay system and the reporter lysis buffer (both Promega, Cat.-No. E4550 and Cat-No: E3971) according to manufacturer instructions. Briefly, cells were lysed for 10 minutes at −20° C. by addition of 30 uL per well 1× lysis buffer. Cells were thawed for 20 minutes at 37° C. before 90 uL per well provided luciferase assay reagent was added. Light emission was quantified immediately with a SpectraMax M5/M5e microplate reader (Molecular Devices, USA) using 500 ms integration time, without any filter to collect all wavelengths. Emitted relative light units (URL) were corrected by basal luminescence of HeLa_hOx40_NFkB_Luc1 cells and were blotted against the logarithmic primary antibody concentration using Prism4 (GraphPad Software, USA). Curves were fitted using the inbuilt sigmoidal dose response.


As shown in FIGS. 49A and 49B, a limited, dose dependent NFkB activation was induced already by addition of FAP-OX40L (49A) to the reporter cell line. Hyper-crosslinking of FAP-OX40L by anti-human IgG specific secondary antibodies increased the induction of NFκB-mediated luciferase-activation in a concentration-dependent manner (49B).


Consequently, we tested the NFkB activating capacity of FAP-OX40L with hyper-crosslinking of the constructs by FAP+ tumor cell lines.


Tested tumor cell line was NIH/3T3-huFAP clone 39. NIH/3T3-huFAP clone 39 was generated by the transfection of the mouse embryonic fibroblast NIH/3T3 cell line (ATCC CRL-1658) with the expression vector pETR4921 to express huFAP under 1.5 μg/mL Puromycin selection. The surface expression of FAP was quantified using the Quifikit (Dako Cat. No. K0078) according to manufactures instructions. The primary antibody used to detect cell surface FAP expression was the human/mouse crossreactive clone F11-24 (mouse IgG1, Calbiochem, Ca. No. OP188). The surface expression on NIH/3T3-huFAP clone 39 was app. 90000 huFAP per cell.


As described herein before, adherent HeLa_hOx40_NFkB_Luc1 cells were cultured over night at a cell density of 0.2*105 cells per well and were stimulated for 5 hours with assay medium containing titrated FAP-OX40L. To test the effect of hyper-crosslinking by cell surface FAP binding 25 μL/well of medium containing FAP+ tumor cells NIH/3T3-huFAP clone 39 were co-cultured in a 3 to 1 ratio (three times as much FAP+ tumor cells than reporter cells per well). Activated NFκB was quantified by measuring light emission using luciferase 100 assay system and the reporter lysis buffer (both Promega, Cat.-No. E4550 and Cat-No: E3971.


As shown in FIG. 50A, the presence of FAP-expressing tumor cells strongly increased induction of NFκB-mediated luciferase-activation when FAP-OX40L was added. Area under the curve of the respective blotted dose-response curves was quantified as a marker for the agonistic capacity of each construct. As shown in FIG. 50B, the presence of cell surface presented FAP ensured higher cross-linking and thus a better agonistic effect of FAP-OX40L then addition of an Fc specific secondary antibody.


15.5 OX40 Mediated Costimulation of Suboptimally TCR Triggered Resting Human PBMC and Hypercrosslinking by Cell Surface FAP


It was shown in Example 15.4 that addition of FAP+ tumor cells can strongly increase the NFkB activity induced by FAP targeted OX40L in a human OX40 positive reporter cell lines by providing strong oligomerization of OX40 receptors. Likewise, we tested FAP-OX40L constructs in the presence of NIH/3T3-huFAP clone 39 cells for their ability to rescue suboptimal TCR stimulation of resting human PBMC cells.


Human PBMC preparations contain (1) resting OX40 negative CD4+ and CD8+ T cells and (2) antigen presenting cells with various Fc-γ receptor molecules on their cell surface e.g. B cells and monocytes. Anti-human CD3 antibody of human IgG1 isotype can bind with its Fc part to the present Fc-γ receptor molecules and mediate a prolonged TCR activation on resting OX40 negative CD4+ and CD8+ T cells. These cells then start to express OX40 within several hours. Functional agonistic compounds against OX40 can signal via the OX40 receptor present on activated CD8+ and CD4+ T cells and support TCR-mediated stimulation.


Resting CFSE-labeled human PBMC were stimulated for five days with a suboptimal concentration of anti-CD3 antibody in the presence of irradiated FAP+ NIH/3T3-huFAP clone 39 cells and titrated FAP-OX40L. Effects on T-cell survival and proliferation were analyzed through monitoring of total cell counts and CFSE dilution in living cells by flow cytometry.


Mouse embryonic fibroblast NIH/3T3-huFAP clone 39 cells (see Example 15.4) were harvested using cell dissociation buffer (Invitrogen, Cat.-No. 13151-014) for 10 minutes at 37° C. Cells were washed once with DPBS. NIH/3T3-huFAP clone 39 cells were cultured at a density of 0.2*105 cells per well in T cell media in a sterile 96-well round bottom adhesion tissue culture plate (TPP, Cat. No. 92097) over night at 37° C. and 5% CO2 in an incubator (Hera Cell 150). The next day they were irradiated in an xRay irradiator using a dose of 4500 RAD to prevent later overgrowth of human PBMC by the tumor cell line.


Human PBMCs were isolated by ficoll density centrifugation as described in Example 15.3. Cells were then labeled with CFSE at a cell density of 1×106 cells/mL with CFDA-SE (Sigma-Aldrich, Cat.-No. 2188) at a final concentration of [50 nM] for 10 minutes at 37° C. Thereafter, cells were washed twice with excess DPBS containing FBS (10% v/v). Labeled cells were rested in T-cell media at 37° C. for 30 minutes. Thereafter, non-converted CFDA-SE was removed by two additional washing steps with DPBS.CFSE labeled resting human PBMC were added to each well at a density of 0.5*105 cells per well. Anti-human CD3 antibody (clone V9, human IgG1, described in Rodrigues et al., Int 0.1 Cancer Suppl 7, 45-50 (1992) and U.S. Pat. No. 6,054,297) at a final concentration of [20 nM] and FAP-OX40L were added at the indicated concentrations. Cells were activated for five days at 37° C. and 5% CO2 in an incubator (Hera Cell 150). Then, Cells were surface-stained with fluorescent dye-conjugated antibodies anti-human CD4 (clone RPA-T4, BioLegend, Cat.-No. 300532) and CD8 (clone RPa-T8, BioLegend, Cat.-No. 3010441) for 20 min at 4° C. After a washing step with FACS buffer, cells were resuspended in 85 μL/well FACS buffer and acquired using a 5-laser FORTESSA® flow cytometer (BD Bioscience with DIVA software).


As shown in FIGS. 51A to 51D, hyper-crosslinking of FAP-OX40L constructs by the present NIH/3T3-huFAP clone 39 cells strongly promoted proliferation (see “Events” graphs, 51A and 51B) and survival (see “proliferation” graphs, 51C and 51D) in TCR stimulated human CD4 and CD8 T cells. In line with a lower expression of OX40 on human CD8+ T cells the agonistic effect of FAP-OX40L was less strong on CD8+ T cells than on CD4+ T cells.


CITATIONS



  • Ascierto, P. A., E. Simeone, M. Sznol, Y. X. Fu, and I. Melero (2010), Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 37:508-516.

  • Aggarwal B. B. (2003), Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3(9), 745-56.

  • Banner D. et al (1993), Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 73, 431-445.

  • Bodmer J., Schneider P. and Tschopp, J. (2002), The molecular architecture of the TNF superfamily. Trends in Biochemical Sciences 27(1), 19-26.

  • Broll, K., Richter, G., Pauly, S., Hofstaedter, F., and Schwarz, H. (2001). CD137 expression in tumor vessel walls. High correlation with malignant tumors. Am J Clin Pathol 115, 543-549.

  • Buechele, C., Baessler, T., Schmiedel, B. J., Schumacher, C. E., Grosse-Hovest, L., Rittig, K., and Salih, H. R. (2012). 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia. Eur J Immunol 42, 737-748.

  • Choi, B. K., Kim, Y. H., Kwon, P. M., Lee, S. C., Kang, S. W., Kim, M. S., Lee, M. J., and Kwon, B. S. (2009). 4-1BB functions as a survival factor in dendritic cells. J Immunol 182, 4107-4115.

  • Cuadros, C., Dominguez, A. L., Lollini, P. L., Croft, M., Mittler, R. S., Borgstrom, P., and Lustgarten, J. (2005). Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int J Cancer 116, 934-943.

  • Curran, M. A., Kim, M., Montalvo, W., A1-Shamkhani, A., and Allison, J. P. (2011). Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 6, e19499.

  • Diehl, L., van Mierlo, G. J., den Boer, A. T., van der Voort, E., Fransen, M., van Bostelen, L., Krimpenfort, P., Melief, C. J., Mittler, R., Toes, R. E., and Offringa, R. (2002). In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway. J Immunol 168, 3755-3762.

  • Dubrot, J., Milheiro, F., Alfaro, C., Palazon, A., Martinez-Forero, I., Perez-Gracia, J. L., Morales-Kastresana, A., Romero-Trevejo, J. L., Ochoa, M. C., Hervas-Stubbs, S., et al. (2010). Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother 59, 1223-1233.

  • Futagawa, T., Akiba, H., Kodama, T., Takeda, K., Hosoda, Y., Yagita, H., and Okumura, K. (2002). Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 14, 275-286.

  • Guo, Z., Cheng, D., Xia, Z., Luan, M., Wu, L., Wang, G., and Zhang, S. (2013). Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med 11, 215.

  • Heinisch, I. V., Daigle, I., Knopfli, B., and Simon, H. U. (2000). CD137 activation abrogates granulocyte-macrophage colony-stimulating factor-mediated anti-apoptosis in neutrophils. Eur J Immunol 30, 3441-3446.

  • Hornig, N., Kermer, V., Frey, K., Diebolder, P., Kontermann, R. E., Mueller, D. (2012), Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. J. Immunother. 35, 418-429.

  • Ju, S. A., Cheon, S. H., Park, S. M., Tam, N. Q., Kim, Y. M., An, W. G., and Kim, B. S. (2008). Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice. Int J Cancer 122, 2784-2790.

  • Kienzle, G., and von Kempis, J. (2000). CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes. Int Immunol 12, 73-82.

  • Kim, D. H., Chang, W. S., Lee, Y. S., Lee, K. A., Kim, Y. K., Kwon, B. S., and Kang, C. Y. (2008). 4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation. J Immunol 180, 2062-2068.

  • Kim, Y. H., Choi, B. K., Oh, H. S., Kang, W. J., Mittler, R. S., and Kwon, B. S. (2009). Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy. Mol Cancer Ther 8, 469-478.

  • Kwon, B. S., and Weissman, S. M. (1989). cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci USA 86, 1963-1967.

  • Lee, H., Park, H. J., Sohn, H. J., Kim, J. M., and Kim, S. J. (2011). Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal. J Surg Res 169, e43-50.

  • Levitsky, V., de Campos-Lima, P. O., Frisan, T., and Masucci, M. G. (1998). The clonal composition of a peptide-specific oligoclonal CTL repertoire selected in response to persistent EBV infection is stable over time. J Immunol 161, 594-601.

  • Li, F., and Ravetch, J. V. (2011). Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333, 1030-1034.

  • Lin, W., Voskens, C. J., Zhang, X., Schindler, D. G., Wood, A., Burch, E., Wei, Y., Chen, L., Tian, G., Tamada, K., et al. (2008). Fc-dependent expression of CD137 on human NK cells: insights into “agonistic” effects of anti-CD137 monoclonal antibodies. Blood 112, 699-707.

  • Melero, I., Johnston, J. V., Shufford, W. W., Mittler, R. S., and Chen, L. (1998). NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 190, 167-172.

  • Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellstrom, K. E., Mittler, R. S., and Chen, L. (1997). Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3, 682-685.

  • Merchant, A. M., Zhu, Z., Yuan, J. Q., Goddard, A., Adams, C. W., Presta, L. G., and Carter, P. (1998). An efficient route to human bispecific IgG. Nat Biotechnol 16, 677-681.

  • Morales-Kastresana, A., Sanmamed, M. F., Rodriguez, I., Palazon, A., Martinez-Forero, I., Labiano, S., Hervas-Stubbs, S., Sangro, B., Ochoa, C., Rouzaut, A., et al. (2013). Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res 19, 6151-6162.

  • Mueller, D., Frey, K., Kontermann, R. E. (2008), A novel antibody-4-1BB1 fusion protein for targeted costimulation in cancer immunotherapy, J. Immunother. 31, 714-722.

  • Murillo, O., Dubrot, J., Palazon, A., Arina, A., Azpilikueta, A., Alfaro, C., Solano, S., Ochoa, M. C., Berasain, C., Gabari, I., et al. (2009). In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol 39, 2424-2436.

  • Narazaki, H., Zhu, Y., Luo, L., Zhu, G., and Chen, L. (2010). CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. Blood 115, 1941-1948.

  • Nishimoto, H., Lee, S. W., Hong, H., Potter, K. G., Maeda-Yamamoto, M., Kinoshita, T., Kawakami, Y., Mittler, R. S., Kwon, B. S., Ware, C. F., et al. (2005). Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor. Blood 106, 4241-4248.

  • Olofsson, P. S., Soderstrom, L. A., Wagsater, D., Sheikine, Y., Ocaya, P., Lang, F., Rabu, C., Chen, L., Rudling, M., Aukrust, P., et al. (2008). CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 117, 1292-1301.

  • Palazon, A., Teijeira, A., Martinez-Forero, I., Hervas-Stubbs, S., Roncal, C., Penuelas, I., Dubrot, J., Morales-Kastresana, A., Perez-Gracia, J. L., Ochoa, M. C., et al. (2011). Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res 71, 801-811.

  • Schwarz, H., Valbracht, J., Tuckwell, J., von Kempis, J., and Lotz, M. (1995). ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood 85, 1043-1052.

  • Shao, Z., and Schwarz, H. (2011). CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. J Leukoc Biol 89, 21-29.

  • Shi, W., and Siemann, D. W. (2006). Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer Res 26, 3445-3453.

  • Simeone, E., and Ascierto, P. A. (2012). Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J Immunotoxicol 9, 241-247.

  • Snell, L. M., Lin, G. H., McPherson, A. J., Moraes, T. J., and Watts, T. H. (2011). T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol Rev 244, 197-217.

  • Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., and Smyth, M. J. (2011). Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 108, 7142-7147.

  • Teng, M. W., Sharkey, J., McLaughlin, N. M., Exley, M. A., and Smyth, M. J. (2009). CD1d-based combination therapy eradicates established tumors in mice. J Immunol 183, 1911-1920.

  • von Kempis, J., Schwarz, H., and Lotz, M. (1997). Differentiation-dependent and stimulus-specific expression of ILA, the human 4-1BB-homologue, in cells of mesenchymal origin. Osteoarthritis Cartilage 5, 394-406.

  • Wei, H., Zhao, L., Li, W., Fan, K., Qian, W., Hou, S., Wang, H., Dai, M., Hellstrom, I., Hellstrom, K. E., and Guo, Y. (2013). Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One 8, e84927.

  • Wilcox, R. A., Chapoval, A. I., Gorski, K. S., Otsuji, M., Shin, T., Flies, D. B., Tamada, K., Mittler, R. S., Tsuchiya, H., Pardoll, D. M., and Chen, L. (2002). Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol 168, 4262-4267.

  • Wilcox, R. A., Tamada, K., Flies, D. B., Zhu, G., Chapoval, A. I., Blazar, B. R., Kast, W. M., and Chen, L. (2004). Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood 103, 177-184.

  • Zhang, N., Sadun, R. E., Arias, R. S., Flanagan, M. L., Sachsman, S. M., Nien, Y, Khawli, L. A., Hu, P., Epstein, A. L. (2007). Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin. Cancer Res. 13, 2758-2767.

  • Zhang, X., Voskens, C. J., Sallin, M., Maniar, A., Montes, C. L., Zhang, Y., Lin, W., Li, G., Burch, E., Tan, M., et al. (2010). CD137 promotes proliferation and survival of human B cells. J Immunol 184, 787-795.


Claims
  • 1-55. (canceled)
  • 56. A method of treating cancer in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising a tumor necrosis factor (TNF) family ligand trimer-containing antigen binding molecule in a pharmaceutically acceptable form, wherein the TNF family ligand trimer-containing antigen-binding molecule comprises: (a) at least one antigen-binding domain comprising an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH) capable of specific binding to a target cell antigen, wherein the target cell antigen is CD19, and(b) a first polypeptide and a second polypeptide that are linked to each other by a disulfide bond, wherein the first polypeptide comprises two ectodomains of a TNF family ligand or fragments thereof that are connected to each other by a peptide linker and the second polypeptide comprises only one ectodomain of the TNF family ligand or fragment thereof,wherein the TNF family ligand is 4-1BBL.
  • 57. The method of claim 56, further comprising: (c) an Fc domain composed of a first subunit and a second subunit, wherein the first subunit and the second subunit are capable of stable association with each other.
  • 58. The method of claim 56, wherein: (i) the first polypeptide comprises an antibody heavy chain constant 1 (CH1) domain or an antibody light chain constant (CL) domain and the second polypeptide comprises a CL domain or a CH1 domain, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 domain and the CL domain, wherein the first polypeptide comprises two ectodomains of the TNF family ligand or fragments thereof that are connected to each other and to the CH1 domain or the CL domain of the first polypeptide by a peptide linker, and wherein the second polypeptide comprises only one ectodomain of the TNF family ligand or fragment thereof connected to the CL domain or the CH1 domain of the second polypeptide by a peptide linker, or(ii) the first polypeptide comprises an antibody heavy chain constant 3 (CH3) domain and the second polypeptide comprises a CH3 domain, wherein the first polypeptide comprises two ectodomains of the TNF family ligand or fragments thereof that are connected to each other and to the C-terminus of the CH3 domain of the first polypeptide by a peptide linker, and wherein the second polypeptide comprises only one ectodomain of the TNF family ligand or fragment thereof connected to C-terminus of the CH3 domain of the second polypeptide by a peptide linker, or(iii) the first polypeptide comprises an antibody heavy chain variable region-light chain constant domain (VH-CL) or an antibody light chain variable region-heavy chain constant 1 domain (VL-CH1) and the second polypeptide comprises a VL-CH1 domain or a VH-CL domain, wherein the second polypeptide is linked to the first polypeptide by a disulfide bond between the CH1 domain and the CL domain, wherein the first polypeptide comprises two ectodomains of the TNF family ligand or fragments thereof that are connected to each other and to the VH or the VL of the first polypeptide by a peptide linker, and wherein the second polypeptide comprises only one ectodomain of the TNF family ligand or fragment thereof connected to the VL or the VH of the second polypeptide by a peptide linker.
  • 59. The method of claim 56, wherein the TNF family ligand costimulates human T-cell activation.
  • 60. The method of claim 56, wherein the ectodomain of the TNF family ligand or fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:96, SEQ ID NO: 373, SEQ ID NO:374, and SEQ ID NO:375.
  • 61. The method of claim 56, wherein the ectodomain of the TNF family ligand or fragment thereof comprises the amino acid sequence of SEQ ID NO:96.
  • 62. The method of claim 56, wherein the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98, and SEQ ID NO:99 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3, and SEQ ID NO:4.
  • 63. The method of claim 56, wherein the antigen-binding domain capable of specific binding to CD19 is selected from the group consisting of an antibody fragment, a Fab molecule, a crossover Fab molecule, a single chain Fab molecule, a Fv molecule, a scFv molecule, a single domain antibody, a VH, and a scaffold antigen-binding protein.
  • 64. The method of claim 56, wherein the molecule comprises one antigen-binding domain capable of specific binding to CD19.
  • 65. The method of claim 56, wherein the antigen-binding domain capable of specific binding to CD19 is a Fab molecule.
  • 66. The method of claim 57, wherein the Fc domain is an IgG domain.
  • 67. The method of claim 57, wherein the Fc domain is an IgG1 Fc domain comprising amino acid substitutions at positions 234 and 235 (EU numbering) and/or 329 (EU numbering) of the IgG heavy chain.
  • 68. A method of treating cancer in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising a tumor necrosis factor (TNF) family ligand trimer-containing antigen binding molecule in a pharmaceutically acceptable form, wherein the TNF family ligand trimer-containing antigen-binding molecule comprises: (a) a first heavy chain and a first light chain, wherein the first heavy chain and the first light chain taken together comprise a Fab molecule capable of specific binding to a target cell antigen, wherein the target cell antigen is CD19, and a first polypeptide comprising two ectodomains of a TNF family ligand or fragments thereof connected to each other by a first peptide linker and fused at its C-terminus by a second peptide linker to a second heavy chain, and a second polypeptide comprising only one ectodomain of the TNF family ligand or fragment thereof fused at its C-terminus by a third peptide linker to a second light chain, wherein the TNF family ligand is 4-1BBL, or(b) a first heavy chain and a first light chain, wherein the first heavy chain and the first light chain taken together comprise a Fab molecule capable of specific binding to a target cell antigen, wherein the target cell antigen is CD19, and a first polypeptide comprising two ectodomains of a TNF family ligand or fragments thereof connected to each other by a first peptide linker and fused at its C-terminus by a second peptide linker to a second light chain, and a second polypeptide comprising only one ectodomain of the TNF family ligand or fragment thereof fused at its C-terminus by a third peptide linker to a second heavy chain, wherein the TNF family ligand is 4-1BBL.
  • 69. The method of claim 68, wherein the first polypeptide comprising two ectodomains of the TNF family ligand or fragments thereof connected to each other by the first peptide linker is fused at its C-terminus by the second peptide linker to a CH1 domain that is part of a heavy chain, and the second polypeptide comprising only one ectodomain of the TNF family ligand or fragment thereof is fused at its C-terminus by the third peptide linker to a CL domain that is part of a light chain.
  • 70. The method of claim 68, wherein the first polypeptide comprising two ectodomains of the TNF family ligand or fragments thereof connected to each other by the first peptide linker is fused at its C-terminus by the second peptide linker to a CL domain that is part of a heavy chain, and the second polypeptide comprising only one ectodomain of the TNF family ligand or fragment thereof is fused at its C-terminus by the third peptide linker to a CH1 domain that is part of a light chain.
  • 71. The method of claim 68, wherein the first polypeptide comprising two ectodomains of the TNF family ligand or fragments thereof connected to each other by the first peptide linker is fused at its C-terminus by the second peptide linker to a VH that is part of a heavy chain, and the second polypeptide comprising only one ectodomain of the TNF family ligand or fragment thereof is fused at its C-terminus by the third peptide linker to a VL that is part of a light chain.
  • 72. The method of claim 70, wherein in the CL domain connected to the first polypeptide comprising two ectodomains of the TNF family ligand or fragments thereof, the amino acid at position 123 (light chain EU numbering) has been substituted by arginine (R) and the amino acid at position 124 (light chain EU numbering) has been substituted by lysine (K), and wherein in the CH1 domain connected to the second polypeptide comprising only ectodomain of the TNF family ligand or fragment thereof, the amino acids at position 147 (heavy chain EU numbering) and at position 213 (heavy chain EU numbering) have been substituted by glutamic acid (E).
  • 73. A method of treating cancer in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising a tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecule in a pharmaceutically acceptable form, wherein the TNF family ligand trimer-containing antigen-binding molecule comprises: (a) a first heavy chain and a first light chain, wherein the first heavy chain and the first light chain taken together comprise a Fab molecule capable of specific binding to a target cell antigen, wherein the target cell antigen is CD19,(b) a second heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98, and SEQ ID NO:99, and(c) a second light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3, and SEQ ID NO:4.
  • 74. The method of claim 56, wherein the first polypeptide comprises a CH3 domain and the second polypeptide comprises a CH3 domain, wherein the first polypeptide comprises two ectodomains of the TNF family ligand or fragments thereof that are connected to each other and to the C-terminus of the CH3 domain by a peptide linker, and wherein the second polypeptide comprises only one ectodomain of the TNF family ligand or fragment thereof connected to the C-terminus of the CH3 domain of the second polypeptide by a peptide linker.
  • 75. The method of claim 74, comprising two antigen-binding domains capable of specific binding to CD19.
  • 76. The method of claim 56, wherein the VH comprises (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:195 or SEQ ID NO:252, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:196 or SEQ ID NO:253, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:197 or SEQ ID NO:254, and the VL comprises (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:198 or SEQ ID NO:249, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:199 or SEQ ID NO:250, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:200 or SEQ ID NO:251.
  • 77. The method of claim 56, wherein the VH comprises the amino acid sequence of SEQ ID NO:201 and the VL comprises the amino acid sequence of SEQ ID NO:202 or wherein the VH comprises the amino acid sequence of SEQ ID NO:357 and the VL comprises the amino acid sequence of SEQ ID NO:358.
  • 78. A method of treating cancer in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising a tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecule in a pharmaceutically acceptable form, wherein the TNF family ligand trimer-containing antigen-binding molecule is capable of specific binding to a target cell antigen, wherein the target cell antigen is CD19, and comprises: (a) a first heavy chain comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:201 and a first light chain comprising a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:202 or a first heavy chain comprising a VH comprising the amino acid sequence of SEQ ID NO:357 and a first light chain comprising a VL comprising the amino acid sequence of SEQ ID NO:358,(b) a second heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:108, SEQ ID NO:111, and SEQ ID NO:113, and(c) a second light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:15, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:112, and SEQ ID NO:114.
  • 79. A method of treating cancer in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising a tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecule in a pharmaceutically acceptable form, wherein the TNF family ligand trimer-containing antigen-binding molecule is capable of specific binding to a target cell antigen, wherein the target cell antigen is CD19, and comprises: (a) a first heavy chain comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:201 and a first light chain comprising a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:202 or a first heavy chain comprising a VH comprising the amino acid sequence of SEQ ID NO:357 and a first light chain comprising a VL comprising the amino acid sequence of SEQ ID NO:358,(b) a second heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119, and SEQ ID NO:173, and(c) a second light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120, and SEQ ID NO:174.
  • 80. A method of treating cancer in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising a tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecule in a pharmaceutically acceptable form, wherein the TNF family ligand trimer-containing antigen-binding molecule is capable of specific binding to a target cell antigen, wherein the target cell antigen is CD19, and comprises: (a) a first heavy chain comprising the amino acid sequence of SEQ ID NO:209, a second heavy chain comprising the amino acid sequence of SEQ ID NO:210, and two light chains each comprising the amino acid sequence of SEQ ID NO:206, or(b) a first heavy chain comprising the amino acid sequence of SEQ ID NO:213, a second heavy chain comprising the amino acid sequence of SEQ ID NO:214, and two light chains each comprising the amino acid sequence of SEQ ID NO:206, or(c) a first heavy chain comprising the amino acid sequence of SEQ ID NO:309, a second heavy chain comprising the amino acid sequence of SEQ ID NO:310, and two light chains each comprising the amino acid sequence of SEQ ID NO:279, or(d) a first heavy chain comprising the amino acid sequence of SEQ ID NO:313, a second heavy chain comprising the amino acid sequence of SEQ ID NO:314, and two light chains each comprising the amino acid sequence of SEQ ID NO:279.
  • 81. A method of treating cancer in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising a tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecule in a pharmaceutically acceptable form, wherein the TNF family ligand trimer-containing antigen-binding molecule comprises: (a) an antigen-binding domain capable of specific binding to CD19, comprising an antibody heavy chain variable region (VH) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:195 or SEQ ID NO:252, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:196 or SEQ ID NO:253, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:197 or SEQ ID NO:254, and an antibody light chain variable region (VL) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:198 or SEQ ID NO:249, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:199 or SEQ ID NO:250, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:200 or SEQ ID NO:251, and(b) a first polypeptide and a second polypeptide that are linked to each other by a disulfide bond, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO:97, and the second polypeptide comprises the amino acid sequence of SEQ ID NO:96.
  • 82. The method of claim 81, further comprising: (c) an Fc domain composed of a first subunit and a second subunit, wherein the first subunit and the second subunit are capable of stable association with each other.
  • 83. The method of claim 82, wherein the Fc domain is an IgG1 Fc domain comprising amino acid substitutions at positions 234 and 235 (EU numbering) and/or 329 (EU numbering) of the IgG heavy chain.
  • 84. A method of treating cancer in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising a tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecule in a pharmaceutically acceptable form, wherein the TNF family ligand trimer-containing antigen-binding molecule comprises: (a) an antigen-binding domain capable of specific binding to CD19 comprising a first heavy chain comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:20 and a first light chain comprising an antibody light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:202, or an antigen-binding domain capable of specific binding to CD19 comprising a first heavy chain comprising an antibody heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:357, and a first light chain comprising an antibody light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:358,(b) a second heavy chain comprising the amino acid sequence of SEQ ID NO:97, and(c) a second light chain comprising the amino acid sequence of SEQ ID NO:96.
  • 85. The method of claim 84, further comprising: (d) an Fc domain composed of a first subunit and a second subunit, wherein the first subunit and the second subunit are capable of stable association with each other.
  • 86. The method of claim 85, wherein the Fc domain is an IgG1 Fc domain comprising amino acid substitutions at positions 234 and 235 (EU numbering) and/or 329 (EU numbering) of the IgG heavy chain.
  • 87. A method of treating cancer in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising a tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecule in a pharmaceutically acceptable form, wherein the TNF family ligand trimer-containing antigen-binding molecule comprises: (a) an antigen-binding domain capable of specific binding to CD19 comprising a first heavy chain comprising an antibody heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:201 and a first light chain comprising an antibody light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:202, or an antigen-binding domain capable of specific binding to CD19 comprising a first heavy chain comprising an antibody heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:357 and a first light chain comprising an antibody light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:358,(b) a second heavy chain comprising the amino acid sequence of SEQ ID NO:119, and(c) a second light chain comprising the amino acid sequence of SEQ ID NO:120.
  • 88. The method of claim 87, further comprising: (d) an Fc domain composed of a first subunit and a second subunit, wherein the first subunit and the second subunit are capable of stable association with each other.
  • 89. The method of claim 88, wherein the Fc domain is an IgG1 Fc domain comprising amino acid substitutions at positions 234 and 235 (EU numbering) and/or 329 (EU numbering) of the IgG heavy chain.
  • 90. The method of claim 87, wherein in the CL domain of the second heavy chain, the amino acid at position 123 (light chain EU numbering) has been substituted by arginine (R) and the amino acid at position 124 (light chain EU numbering) has been substituted by lysine (K), and wherein in the CH1 domain of the second light chain, the amino acids at position 147 (heavy chain EU numbering) and at position 213 (heavy chain EU numbering) have been substituted by glutamic acid (E).
  • 91. A method of treating cancer in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising a tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecule in a pharmaceutically acceptable form, wherein the TNF family ligand trimer-containing antigen-binding molecule is capable of specific binding to CD19, and is selected from the group consisting of: (a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:306, a first light chain comprising the amino acid sequence of SEQ ID NO:279, a second heavy chain comprising the amino acid sequence of SEQ ID NO:115, and a second light chain comprising the amino acid sequence of SEQ ID NO:116,(b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:306, a first light chain comprising the amino acid sequence of SEQ ID NO:279, a second heavy chain comprising the amino acid sequence of SEQ ID NO:117, and a second light chain comprising the amino acid sequence of SEQ ID NO:118,(c) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:306, a first light chain comprising the amino acid sequence of SEQ ID NO:279, a second heavy chain comprising the amino acid sequence of SEQ ID NO:119, and a second light chain comprising the amino acid sequence of SEQ ID NO:120,(d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:306, a first light chain comprising the amino acid sequence of SEQ ID NO:279, a second heavy chain comprising the amino acid sequence of SEQ ID NO:173, and a second light chain comprising the amino acid sequence of SEQ ID NO:174,(e) a molecule comprising two light chains each comprising the amino acid sequence of SEQ ID NO:279, a first heavy chain comprising the amino acid sequence of SEQ ID NO:309, and a second heavy chain comprising the amino acid sequence of SEQ ID NO:310, and(f) a molecule comprising two light chains each comprising the amino acid sequence of SEQ ID NO:279, a first heavy chain comprising the amino acid sequence of SEQ ID NO:313, and a second heavy chain comprising the amino acid sequence of SEQ ID NO:314.
  • 92. A method of treating cancer in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising a tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecule in a pharmaceutically acceptable form, wherein the TNF family ligand trimer-containing antigen-binding molecule is capable of specific binding to CD19, and comprises: a first heavy chain comprising the amino acid sequence of SEQ ID NO:306,a first light chain comprising the amino acid sequence of SEQ ID NO:279,a second heavy chain comprising the amino acid sequence of SEQ ID NO:119, anda second light chain comprising the amino acid sequence of SEQ ID NO:120.
  • 93. The method of claim 56, wherein the ectodomain of the TNF family ligand or fragment thereof comprises the amino acid sequence of SEQ ID NO:1.
  • 94. A method of treating cancer in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising a tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecule in a pharmaceutically acceptable form, wherein the TNF family ligand trimer-containing antigen-binding molecule is capable of specific binding to CD19, and is selected from the group consisting of: (a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:306, a first light chain comprising the amino acid sequence of SEQ ID NO:279, a second heavy chain comprising the amino acid sequence of SEQ ID NO:14, and a second light chain comprising the amino acid sequence of SEQ ID NO:15,(b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:306, a first light chain comprising the amino acid sequence of SEQ ID NO:279, a second heavy chain comprising the amino acid sequence of SEQ ID NO:108, and a second light chain comprising the amino acid sequence of SEQ ID NO:109,(c) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:306, a first light chain comprising the amino acid sequence of SEQ ID NO:279, a second heavy chain comprising the amino acid sequence of SEQ ID NO:108, and a second light chain comprising the amino acid sequence of SEQ ID NO:110,(d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:306, a first light chain comprising the amino acid sequence of SEQ ID NO:279, a second heavy chain comprising the amino acid sequence of SEQ ID NO:111, and a second light chain comprising the amino acid sequence of SEQ ID NO:112, and(e) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:306, a first light chain comprising the amino acid sequence of SEQ ID NO:279, a second heavy chain comprising the amino acid sequence of SEQ ID NO:113, and a second light chain comprising the amino acid sequence of SEQ ID NO:114.
  • 95. The method of claim 57, wherein the Fc domain is an IgG1 Fc domain or an IgG4 Fc domain.
  • 96. The method of claim 69, wherein in the CL domain connected to the second polypeptide comprising only one ectodomain of the TNF family ligand or fragment thereof, the amino acid at position 123 (light chain EU numbering) has been substituted by arginine (R) and the amino acid at position 124 (light chain EU numbering) has been substituted by lysine (K), and wherein in the CH1 domain connected to the first polypeptide comprising two ectodomains of the TNF family ligand or fragments thereof, the amino acids at position 147 (heavy chain EU numbering) and at position 213 (heavy chain EU numbering) have been substituted by glutamic acid (E).
  • 97. The method of claim 56, wherein the antigen-binding molecule activates the NFκB signaling pathway.
  • 98. The method of claim 68, wherein the antigen-binding molecule activates the NFκB signaling pathway.
  • 99. The method of claim 56, wherein the VH comprises (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:252, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:253, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:254, and the VL comprises (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:249, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:250, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:251.
  • 100. The method of claim 81, wherein the VH comprises (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:252, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:253, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:254, and the VL comprises (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:249, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:250, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:251.
Priority Claims (3)
Number Date Country Kind
14193260.8 Nov 2014 EP regional
15183736.6 Sep 2015 EP regional
15188142.2 Oct 2015 EP regional
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of U.S. patent application Ser. No. 16/522,412, filed Jul. 25, 2019, which is a divisional application of U.S. patent application Ser. No. 15/067,024, filed Mar. 10, 2016, now U.S. Pat. No. 10,392,445, which is a continuation of International Patent Application No. PCT/EP2015/076528, filed Nov. 13, 2015, which claims the benefit of and priority to European Patent Application No. 14193260.8, now withdrawn, filed Nov. 14, 2014, European Patent Application No. 15183736.6, now abandoned, filed Sep. 3, 2015, and European Patent Application No. 15188142.2, now abandoned, filed Oct. 2, 2015, each of which are incorporated herein by reference in its entirety.

Divisions (2)
Number Date Country
Parent 16522412 Jul 2019 US
Child 17580980 US
Parent 15067024 Mar 2016 US
Child 16522412 US
Continuations (1)
Number Date Country
Parent PCT/EP2015/076528 Nov 2015 US
Child 15067024 US